FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Barnes, DE Yaffe, K Byers, AL McCormick, M Schaefer, C Whitmer, RA AF Barnes, Deborah E. Yaffe, Kristine Byers, Amy L. McCormick, Mark Schaefer, Catherine Whitmer, Rachel A. TI Midlife vs Late-Life Depressive Symptoms and Risk of Dementia Differential Effects for Alzheimer Disease and Vascular Dementia SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID WHITE-MATTER HYPERINTENSITIES; MILD COGNITIVE IMPAIRMENT; TEMPORAL RELATIONSHIP; PREVALENCE; POPULATION; METAANALYSIS; ASSOCIATION; HYPOTHESIS; DECLINE AB Context: Depression and dementia are common in older adults and often co-occur, but it is unclear whether depression is an etiologic risk factor for dementia. Objective: To clarify the timing and nature of the association between depression and dementia. Design: We examined depressive symptoms assessed in midlife (1964-1973) and late life (1994-2000) and the risks of dementia, Alzheimer disease (AD), and vascular dementia (VaD) (2003-2009) in a retrospective cohort study. Depressive symptoms were categorized as none, midlife only, late life only, or both. Cox proportional hazards models (age as timescale) adjusted for demographics and medical comorbidities were used to examine depressive symptom category and risk of dementia, AD, or VaD. Setting: Kaiser Permanente Medical Care Program of Northern California. Participants: Thirteen thousand five hundred thirty-five long-term Kaiser Permanente members. Main Outcome Measure: Any medical record diagnosis of dementia or neurology clinic diagnosis of AD or VaD. Results: Subjects had a mean (SD) age of 81.1 (4.5) years in 2003, 57.9% were women, and 24.2% were non-white. Depressive symptoms were present in 14.1% of subjects in midlife only, 9.2% in late life only, and 4.2% in both. During 6 years of follow-up, 22.5% were diagnosed with dementia (5.5% with AD and 2.3% with VaD). The adjusted hazard of dementia was increased by approximately 20% for midlife depressive symptoms only (hazard ratio, 1.19 [95% CI, 1.07-1.32]), 70% for latelife symptoms only (1.72 [1.54-1.92]), and 80% for both (1.77 [1.52-2.06]). When we examined AD and VaD separately, subjects with late-life depressive symptoms only had a 2-fold increase in AD risk (hazard ratio, 2.06 [95% CI, 1.67-2.55]), whereas subjects with midlife and latelife symptoms had more than a 3-fold increase in VaD risk (3.51 [2.44-5.05]). Conclusions: Depressive symptoms in midlife or in late life are associated with an increased risk of developing dementia. Depression that begins in late life may be part of the AD prodrome, while recurrent depression may be etiologically associated with increased risk of VaD. C1 [Barnes, Deborah E.; Yaffe, Kristine; Byers, Amy L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Barnes, Deborah E.; Yaffe, Kristine; Byers, Amy L.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [McCormick, Mark; Schaefer, Catherine; Whitmer, Rachel A.] Kaiser Div Res, Oakland, CA USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM deborah.barnes@ucsf.edu FU Brain and Behavior Research Foundation; National Institutes of Health [K24 AG031155, R01 MH086498]; Kaiser Permanente Community Benefits FX This study was supported by the Brain and Behavior Research Foundation (formerly the National Alliance for Research on Schizophrenia and Depression) (Dr Barnes), grants K24 AG031155 and R01 MH086498 from the National Institutes of Health (Dr Yaffe), and Kaiser Permanente Community Benefits (Dr Whitmer). NR 38 TC 88 Z9 93 U1 5 U2 26 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD MAY PY 2012 VL 69 IS 5 BP 493 EP 498 PG 6 WC Psychiatry SC Psychiatry GA 937QB UT WOS:000303672000008 PM 22566581 ER PT J AU Ix, JH Katz, R de Boer, IH Kestenbaurn, BR Peralta, CA Jenny, NS Budoff, M Allison, MA Criqui, MH Siscovick, D Shlipak, MG AF Ix, Joachim H. Katz, Ronit de Boer, Ian H. Kestenbaurn, Bryan R. Peralta, Carmen A. Jenny, Nancy S. Budoff, Matthew Allison, Matthew A. Criqui, Michael H. Siscovick, David Shlipak, Michael G. TI Fetuin-A Is Inversely Associated with Coronary Artery Calcification in Community-Living Persons: The Multi-Ethnic Study of Atherosclerosis SO CLINICAL CHEMISTRY LA English DT Article ID ALPHA(2)-HEREMANS-SCHMID GLYCOPROTEIN/FETUIN-A; SUBCLINICAL CARDIOVASCULAR-DISEASE; MAINTENANCE HEMODIALYSIS-PATIENTS; ELEVATION MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; TYROSINE KINASE; VASCULAR CALCIFICATION; KIDNEY-FUNCTION; OLDER PERSONS; SERUM AB BACKGROUND: Fetuin-A is a hepatic secretory protein that inhibits arterial calcification in vitro. The association of fetuin-A with coronary arterial calcification (CAC) in the general population is uncertain. METHODS: Among 2457 community-living individuals without cardiovascular disease (CVD), we measured serum fetuin-A concentrations by ELISA and evaluated the cross-sectional association of fetuin-A with CAC prevalence (any vs none) and severity; on follow-up 3.2 years (median) later, we evaluated the association of fetuin-A with CAC incidence and progression. RESULTS: The mean age was 62 (SD 10) years, and the mean fetuin-A concentration was 0.48 (0.10) g/L. At baseline, 1200 individuals (49%) had CAC, and 272 individuals developed CAC during follow-up. At baseline, there was a threshold effect at the lowest fetuin-A quartile with CAC prevalence. In models adjusted for demographics, traditional cardiovascular disease (CVD) risk factors and kidney function, the lowest fetuin-A quartile had 7% (95% CI 1%-13%; P = 0.04) greater CAC prevalence compared with quartiles 2-4. Similar associations were observed with CAC severity at baseline, but the association was more linear. Each SD (0.10 g/L) lower fetuin-A was associated with a 12% (95% CI 3%-21%; P = 0.01) greater CAC severity in adjusted models. There was no significant association of fetuin-A with CAC incidence or progression. CONCLUSIONS: Fetuin-A is inversely associated with CAC severity among community-living individuals without CVD. Whether fetuin-A concentrations are associated with incident CVD event in the general population requires future study. (C) 2012 American Association for Clinical Chemistry C1 [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, San Diego, CA 92161 USA. [Criqui, Michael H.] Univ Calif San Diego, Div Cardiol, Dept Med, San Diego, CA 92161 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Ix, Joachim H.; Allison, Matthew A.; Criqui, Michael H.] Univ Calif San Diego, Div Prevent Med, Dept Family & Prevent Med, San Diego, CA 92161 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [de Boer, Ian H.; Kestenbaurn, Bryan R.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.; Kestenbaurn, Bryan R.] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Peralta, Carmen A.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92161 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Jenny, Nancy S.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Div Cardiol, Dept Med, Los Angeles BioMed Res Inst, Torrance, CA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Med Sect, San Francisco, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu OI Allison, Matthew/0000-0003-0777-8272 FU National Heart, Lung, and Blood Institute (NHLBI) [R21HL091217, N01-HC-95159, N01-HC-95169]; VA San Diego Healthcare System FX J.H. Ix (principal investigator), National Heart, Lung, and Blood Institute (NHLBI) grants R21HL091217 and contracts N01-HC-95159 through N01-HC-95169 with the NHLBI, to the VA San Diego Healthcare System; R. Katz, NHLBI grants R21HL091217 and contracts N01-HC-95159 through N01-HC-95169 with the NHLBI; D. Sisovick, NHLBI grants R21HL091217 and contracts N01-HC-95159 through N01-HC-95169 with the NHLBI; M. Shlipak, NHLBI grants R21HL091217 and contracts N01-HC-95159 through N01-HC-95169 with the NHLBI.; The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. This material is the result of work supported with resources of the VA San Diego Healthcare System. We thank Clydene Nee for administrative review and assistance with this manuscript. NR 43 TC 21 Z9 23 U1 3 U2 7 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD MAY PY 2012 VL 58 IS 5 BP 887 EP 895 DI 10.1373/clinchem.2011.177725 PG 9 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 937YZ UT WOS:000303701400017 PM 22377528 ER PT J AU Akber, A Portale, AA Johansen, KL AF Akber, Aalia Portale, Anthony A. Johansen, Kirsten L. TI Pedometer-Assessed Physical Activity in Children and Young Adults with CKD SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; QUALITY-OF-LIFE; EXERCISE CAPACITY; ACTIVITY RECOMMENDATIONS; ADOLESCENTS; HEMODIALYSIS; OVERWEIGHT; PATTERNS; DIALYSIS; PREVALENCE AB Background and objectives Data on physical activity are limited in children with CKD. The objectives of this study were to measure the level and correlates of physical activity in children and young adults with CKD and to determine the association of physical activity with physical performance and physical functioning. Design, setting, participants, & measurements Physical activity was measured for 7 days using pedometers; physical performance was measured by the 6-minute walk distance (6MWD) and physical functioning with the PedsQL 4.0. Results Study participants were 44 patients 7-20 years of age who had CKD stage 1-4 (n=12), had ESRD and were undergoing dialysis (n=7), or had undergone kidney transplantation (n=25). Participants were very sedentary; they walked 6218 (interquartile range, 3637, 9829) steps per day, considerably less than recommended. Physical activity did not differ among participants in the CKD stage 1-4, ESRD, and transplant groups. Females were less active than males (P < 0.01), and physical activity was 44% lower among young adults (18-20 years) than younger participants (P < 0.05). Physical activity was associated positively with maternal education and hemoglobin concentration and inversely with body mass index. Respective 6MWD in males and females was 2 and approximately 4 SDs below expected. Low levels of physical activity were associated with poor physical performance and physical functioning, after adjustment for age, sex, and body mass index. Conclusions In most participants with CKD, physical activity was considerably below recommended levels. Future studies are needed to determine whether increasing physical activity can improve physical performance and physical functioning. Clin J Ant Soc Nephrol 7: 720-726, 2012. doi: 10.2215/CJN.06330611 C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Akber, Aalia; Portale, Anthony A.] Univ Calif San Francisco, Dept Pediat, Div Pediat Nephrol, San Francisco, CA USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect 111J, 4150 Clement St, San Francisco, CA 94121 USA. EM Kirsten.johansen@Ucsf.edu FU University of California, San Francisco, Nephrology Division [K24DK085153]; National Institutes of Health/National Center for Research Resources University of California, San Francisco-Clinical & Translational Science Institute [UL1 RR024131]; Amgen, Inc.; Abbott Laboratories; Genzyme Corp. FX This project was supported by the University of California, San Francisco, Nephrology Division T32 fellowship training grants (A.A.) and grant K24DK085153 (K.L.J.). This project was also supported by National Institutes of Health/National Center for Research Resources University of California, San Francisco-Clinical & Translational Science Institute grant UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.; K.L.J. also receives research support from Amgen, Inc., and Abbott Laboratories and serves on the National Nephrology Advisory Board of Amgen. A.A.P. receives research support from Genzyme Corp. and Abbott Laboratories. NR 40 TC 15 Z9 16 U1 1 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAY PY 2012 VL 7 IS 5 BP 720 EP 726 DI 10.2215/CJN.06330611 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 937AZ UT WOS:000303632700006 PM 22422539 ER PT J AU Molitoris, BA Okusa, MD Palevsky, PM Kimmel, PL Star, RA AF Molitoris, Bruce A. Okusa, Mark D. Palevsky, Paul M. Kimmel, Paul L. Star, Robert A. TI Designing Clinical Trials in Acute Kidney Injury SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID ACUTE-RENAL-FAILURE; MORTALITY C1 [Kimmel, Paul L.; Star, Robert A.] NIDDK, Div Kidney Urol & Hematol Dis, NIH, Bethesda, MD 20892 USA. [Molitoris, Bruce A.] Indiana Univ, Dept Med, Indianapolis, IN USA. [Molitoris, Bruce A.] Roudebush VA Med Ctr, Indianapolis, IN USA. [Okusa, Mark D.] Univ Virginia Hlth Syst, Div Nephrol, Charlottesville, VA USA. [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Kimmel, PL (reprint author), NIDDK, Div Kidney Urol & Hematol Dis, NIH, 6707 Democracy Blvd, Bethesda, MD 20892 USA. EM KimmelP@extra.niddk.nih.gov OI Palevsky, Paul/0000-0002-7334-5400 NR 10 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAY PY 2012 VL 7 IS 5 BP 842 EP 843 DI 10.2215/CJN.12801211 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 937AZ UT WOS:000303632700021 PM 22442185 ER PT J AU Chen, DD Dong, YG Yuan, H Chen, AF AF Chen, Dan-Dan Dong, Yu-Gang Yuan, Hong Chen, Alex F. TI Endothelin 1 Activation of Endothelin A Receptor/NADPH Oxidase Pathway and Diminished Antioxidants Critically Contribute to Endothelial Progenitor Cell Reduction and Dysfunction in Salt-Sensitive Hypertension SO HYPERTENSION LA English DT Article DE endothelin 1; oxidative stress; NADPH oxidase; endothelial progenitor cell; hypertension ID MANGANESE SUPEROXIDE-DISMUTASE; CORONARY-ARTERY-DISEASE; OXIDATIVE STRESS; MINERALOCORTICOID HYPERTENSION; CARDIOVASCULAR DISORDERS; ETA-RECEPTOR; PROTEIN; RATS; SENESCENCE; EXPRESSION AB Circulating endothelial progenitor cells (EPCs) are reduced in hypertension, which inversely correlates with its mortality. Deoxycorticosterone acetate (DOCA)-salt hypertension features elevated endothelin (ET) 1 and oxidative stress. We tested the hypothesis that ET-1 induces EPC dysfunction by elevating oxidative stress through the ETA/NADPH oxidase pathway in salt-sensitive hypertension. Both ETA and ETB receptors were expressed in EPCs, but only ETA receptors were significantly increased in EPCs of DOCA-salt rats. EPC number and function were reduced in DOCA-salt rats compared with sham controls, and both were reversed by in vivo blockade of ETA receptors or NADPH oxidase. The enzymatic activities of NAPDH oxidase and its subunits gp91(phox), p22(phox), and Rac1 were augmented in EPCs of DOCA-salt rats, with concomitantly decreased antioxidant enzymes manganese superoxide dismutase, copper-zinc superoxide dismutase, and glutathione peroxidase 1. Reactive oxygen species level was elevated in EPCs from DOCA-salt rats, accompanied by increased EPC telomerase inactivation, senescence, and apoptosis, which were rescued by ETA or NADPH oxidase blockade. Cell therapy of normal or treated DOCA EPCs, but not untreated DOCA EPCs, significantly increased capillary density and blood perfusion in ischemic hindlimbs of DOCA-salt rats. p53 and Bax/Bcl-2 ratios were increased in EPCs of DOCA-salt rats, which were reversed by ETA antagonist, NADPH oxidase inhibitor, or polyethylene glycol-superoxide dismutase, Finally, in ETB-deficient rats, plasma ET-1 was elevated, and EPC number and telomerase activity were diminished. These results demonstrate, for the first time, that both ET-1 activation of ETA/NADPH oxidase pathway and diminished antioxidants critically contribute to EPC reduction and dysfunction via increased oxidative stress in salt-sensitive hypertension. (Hypertension. 2012;59:1037-1043.) circle Online Data Supplement C1 [Yuan, Hong; Chen, Alex F.] Cent S Univ, Xiangya Hosp 3, Dept Cardiol, Changsha 410013, Hunan, Peoples R China. [Yuan, Hong; Chen, Alex F.] Cent S Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha, Hunan, Peoples R China. [Chen, Dan-Dan; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Chen, Dan-Dan; Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Chen, Dan-Dan; Dong, Yu-Gang] Sun Yat Sen Univ, Dept Cardiol, Affiliated Hosp 1, Guangzhou, Peoples R China. RP Chen, AF (reprint author), Cent S Univ, Xiangya Hosp 3, Dept Cardiol, 138 Tong Zi Bo Rd, Changsha 410013, Hunan, Peoples R China. EM afychen@yahoo.com FU National Institutes of Health [R01 GM077352]; American Heart Association [0855601G, 0720114Z]; National Science Foundation of China [30900519] FX This work was supported by National Institutes of Health grant R01 GM077352 and the American Heart Association Grant-in-Aid 0855601G (to A.F.C.). D.-D.C. is the receipt of the American Heart Association postdoctoral fellowship 0720114Z and the National Science Foundation of China grant 30900519. NR 42 TC 29 Z9 30 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD MAY PY 2012 VL 59 IS 5 BP 1037 EP + DI 10.1161/HYPERTENSIONAHA.111.183368 PG 27 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 938VH UT WOS:000303760900035 PM 22431579 ER PT J AU Smith, RJ McCannel, CA Gordon, LK Hollander, DA Giaconi, JA Stelzner, SK Devgan, U Bartlett, J Mondino, BJ AF Smith, Ronald J. McCannel, Colin A. Gordon, Lynn K. Hollander, David A. Giaconi, JoAnn A. Stelzner, Sadiqa K. Devgan, Uday Bartlett, John Mondino, Bartly J. TI Evaluating teaching methods of cataract surgery: Validation of an evaluation tool for assessing surgical technique of capsulorhexis SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY LA English DT Article AB PURPOSE: To develop and assess the validity of an evaluation tool to quantitatively assess the capsulorhexis portion of cataract surgery performed by residents. SETTING: University of California at Los Angeles (UCLA), Department of Ophthalmology, Jules Stein Eye Institute, Los Angeles, California, USA. DESIGN: Masked prospective case series. METHODS: Ophthalmology faculty members at UCLA were surveyed and literature was reviewed to develop a grading tool comprising 12 questions to evaluate surgical technique, including 4 from the Global Rating Assessment of Skills in Intraocular Surgery and 2 from the International Council of Ophthalmology's Ophthalmology Surgical Competency Assessment Rubric. Video clips of continuous curvilinear capsulorhexis (CCC) performed by 2 postgraduate year (PGY) 3 residents, 2 PGY 4 residents, and 2 advanced surgeons were independently graded in a masked fashion by a 7-member faculty panel. RESULTS: Four questions had low interobserver variability and a significant correlation with surgical skill level (intraclass correlation coefficient >0.75; P<.05, analysis of variance; 42 observations). The 4 questions were visual Likert-scale questions grading flow of operation, set up for regrasp, commencement of flap and formation, and circular completion of the CCC. CONCLUSIONS: Surgical performance can be validly measured using an evaluation tool. However, not all evaluation questions produced reliable results. The reliability and accuracy of the measurements appear to depend on the form and content of the question. Studies to optimize assessment tools identifying the best questions for evaluating each step of cataract surgery may help ophthalmic educators more precisely measure outcomes for improving teaching interventions. C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90024 USA. Vet Adm Greater Los Angeles, Los Angeles, CA USA. RP Smith, RJ (reprint author), 7320 Hawthorn Ave,207, Los Angeles, CA 90046 USA. EM lasik@pacbell.net OI McCannel, Colin/0000-0003-0774-6414 FU American Society of Cataract and Refractive Surgery Foundation, Fairfax, Virginia, USA FX Supported by a grant from the American Society of Cataract and Refractive Surgery Foundation, Fairfax, Virginia, USA. NR 13 TC 7 Z9 7 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0886-3350 J9 J CATARACT REFR SURG JI J. Cataract. Refract. Surg. PD MAY PY 2012 VL 38 IS 5 BP 799 EP 806 DI 10.1016/j.jcrs.2011.11.046 PG 8 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 939VD UT WOS:000303846300012 PM 22520304 ER PT J AU Smith, ZA Yang, I Gorgulho, A Raphael, D De Salles, AAF Khoo, LT AF Smith, Zachary A. Yang, Isaac Gorgulho, Alessandra Raphael, Dan De Salles, Antonio A. F. Khoo, Larry T. TI Emerging techniques in the minimally invasive treatment and management of thoracic spine tumors SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Vertebroplasty; Minimally invasive spine; Spine surgery; Spinal radiosurgery; Lateral extracavitary; Lateral interbody ID LATERAL EXTRACAVITARY APPROACH; CORD COMPRESSION; LUMBAR SPINE; PERCUTANEOUS VERTEBROPLASTY; RADIATION TOLERANCE; RANDOMIZED-TRIAL; STEREOTACTIC RADIOSURGERY; ANTERIOR DECOMPRESSION; NONOPERATIVE TREATMENT; THORACOSCOPIC APPROACH AB Over the past decade, the development and refinement of minimally invasive spine surgery techniques has lead to procedures with the potential to minimize iatrogenic and post-operative sequelae that may occur during the surgical treatment of various pathologies. In a similar manner, parallel advances in other current treatment technologies have led to the development of other minimally invasive treatments of spinal malignancies. These advances include percutaneous techniques for vertebral reconstruction, including vertebroplasty and kyphoplasty, the development of safe and effective spinal radiosurgery, and minimal-access spinal surgical procedures that allow surgeons to safely decompress and reconstruct the anterior spinal column. The advent of these new techniques has given modern practitioners treatment options in situations where they previously were limited by the potentially significant morbidities of the available techniques. Here, the authors discuss the application of current minimally invasive technologies in the treatment of malignancies of the thoracic spine, focusing on vertebral kyphoplasty, spinal radiosurgery, and minimally invasive spinal decompression techniques. The author's describe how these emerging treatment options are significantly expanding the options open to clinicians in the treatment of thoracic spinal column malignancies. Specific illustrative case examples are provided. The development of these techniques has the potential to improve clinical outcomes, limit surgical morbidity, and also improve the safety and efficiency of treatment pathways. C1 [Smith, Zachary A.; Raphael, Dan; Khoo, Larry T.] Univ So Calif, Hosp Good Samaritan, Spine Clin Los Angeles, Los Angeles, CA 90017 USA. [Smith, Zachary A.] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60601 USA. [Yang, Isaac; Gorgulho, Alessandra; De Salles, Antonio A. F.] David Geffen UCLA Sch Med, Ronald Reagan UCLA Med Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA. [De Salles, Antonio A. F.] W Los Angeles Vet Adm Hosp, Dept Neurosurg, Los Angeles, CA 90095 USA. RP Khoo, LT (reprint author), Univ So Calif, Hosp Good Samaritan, Spine Clin Los Angeles, 1245 Wilshire Ave,717, Los Angeles, CA 90017 USA. EM lkhoo@laspineclinic.com FU UCLA; AANS/CNS; CNS FX Dr. Isaac Yang, the second author, was partially support by a UCLA Stein Oppenheimer Grant. Dr. Larry T. Khoo is a consultant and member of the medical speaker's board for Globus Medical Inc.; Audubon, PA; Drs. Antonio A. F. De Salles and Alessandra Gorgulho have received honorarium from Brainlab Inc. for speaking engagements. Dr. Zachary A. Smith acknowledges the support of both the AANS/CNS Spine Section Apfelbaum Award as well as the CNS Spine Fellowship in aiding the production of this work. The other authors in this manuscript do not have disclosures. NR 90 TC 8 Z9 8 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD MAY PY 2012 VL 107 IS 3 BP 443 EP 455 DI 10.1007/s11060-011-0755-6 PG 13 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 934TK UT WOS:000303469400001 PM 22094716 ER PT J AU Wu, Y Zhao, JB Zhao, WD Pan, JP Bauman, WA Cardozo, CP AF Wu, Yong Zhao, Jingbo Zhao, Weidong Pan, Jiangping Bauman, William A. Cardozo, Christopher P. TI Nandrolone Normalizes Determinants of Muscle Mass and Fiber Type after Spinal Cord Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE muscle atrophy; nandrolone; oxidative metabolism; PGC-1 alpha; slow twitch muscle; spinal cord injury ID FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; GENE-EXPRESSION; DENERVATION ATROPHY; SIGNALING PATHWAYS; TESTOSTERONE REPLACEMENT; UBIQUITIN LIGASES; OLDER MEN; STIMULATION; TIME AB Spinal cord injury (SCI) results in atrophy of skeletal muscle and changes from slow oxidative to fast glycolytic fibers, which may reflect reduced levels of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), increased myostatin signaling, or both. In animals, testosterone reduces loss of muscle fiber cross-sectional area and activity of enzymes of energy metabolism. To identify the molecular mechanisms behind the benefits of androgens on paralyzed muscle, male rats were spinal cord transected and treated for 8 weeks with vehicle, testosterone at a physiological replacement dose, or testosterone plus nandrolone, an anabolic steroid. Treatments were initiated immediately after SCI and continued until the day animals were euthanized. In the SCI animals, gastrocnemius muscle mass was significantly increased by testosterone plus nandrolone, but not by testosterone alone. Both treatments significantly reduced nuclear content of Smad2/3 and mRNA levels of activin receptor IIB and follistatin-like 3. Testosterone alone or with nandrolone reversed SCI-induced declines in cellular and nuclear levels of PGC-1 alpha protein and PGC-1 alpha mRNA levels. For PGC-1 alpha target genes, testosterone plus nandrolone partially reversed SCI-induced decreases in levels of proteins without corresponding increases in their mRNA levels. Thus, the findings demonstrate that following SCI, signaling through activin receptors and Smad2/3 is increased, and that androgens suppress activation of this signaling pathway. The findings also indicate that androgens upregulate PGC-1 alpha in paralyzed muscle and promote its nuclear localization, but that these effects are insufficient to fully activate transcription of PGC-1 alpha target genes. Furthermore, the transcription of these genes is not tightly coupled with their translation. C1 [Wu, Yong; Zhao, Jingbo; Zhao, Weidong; Pan, Jiangping; Bauman, William A.; Cardozo, Christopher P.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Chris.cardozo@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, B4616R, B3347K] FX This work was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (B4162C, B4616R, and B3347K). NR 49 TC 12 Z9 13 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAY PY 2012 VL 29 IS 8 BP 1663 EP 1675 DI 10.1089/neu.2011.2203 PG 13 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 939NJ UT WOS:000303818000012 PM 22208735 ER PT J AU Friedlander, AH Tajima, T Garrett, NR AF Friedlander, Arthur H. Tajima, Tracey Garrett, Neal R. TI Panoramic Radiographs of Head and Neck Cancer Patients Are Often Evidence of Carotid Artery Atherosclerotic Lesions: A Sign of High-Risk Comorbid Illness SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Review ID ALCOHOL-CONSUMPTION; CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; DENSITY-LIPOPROTEINS; TOBACCO-SMOKE; HYPERTENSION; PROGRESSION; COMPLICATIONS; POPULATION; COMMUNITIES AB Purpose: The purpose of this study was to estimate the prevalence and identify the risk factors for calcified carotid artery plaque (CCAP) in patients with squamous cell carcinoma of the head and neck. Materials and Methods: Radiographs of 48 consecutive patients were evaluated for CCAP and their medical histories reviewed for the anatomic extent of cancer (staging) and atherogenic risk factors (age, extent of alcohol and tobacco use, body mass index, hypertension, dyslipidemia, and diabetes mellitus). Results: Unilateral or bilateral CCAPs were found in 52.1% of subjects (mean age, 61.5 years). Hypertension was seen in a larger percentage (60%; P = .049) of subjects with CCAP on their radiographs compared with those without CCAP (30.4%). No other atheroma risk factors or stage of cancer differed significantly between those with and those without CCAP. Conclusion: Panoramic radiographs of patients with squamous cell carcinoma of the head and neck show a very high rate of CCAP, a marker of comorbid vascular diseases that may cause treatment complications and affect overall survival. This is a US government work. There are no restrictions on its use. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg 70: 1096-1101, 2012 C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. [Tajima, Tracey] Univ Calif Los Angeles, Sch Dent, Oral Med & Orofacial Pain Div, Los Angeles, CA 90024 USA. [Tajima, Tracey] VA Greater Los Angeles Healthcare Syst, Gen Practice Dent Residency, Los Angeles, CA 90073 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA. [Garrett, Neal R.] VA Greater Los Angeles Healthcare Syst, Oral Biol Res Lab, Los Angeles, CA 90073 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Grad Med Educ, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthurfriedlander@med.va.gov FU Department of Veterans Affairs; University of California; National Center for Research Resources, National Institutes of Health [CO6 RR-14529-01] FX The financial support of this project was limited to the full-time salaries paid to the authors by the Department of Veterans Affairs and the University of California. Elements of this investigation were conducted in a facility constructed with support from Research Facilities Improvement Program Grant CO6 RR-14529-01 from the National Center for Research Resources, National Institutes of Health. NR 46 TC 4 Z9 4 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAY PY 2012 VL 70 IS 5 BP 1096 EP 1101 DI 10.1016/j.joms.2011.05.020 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 938IF UT WOS:000303726500023 PM 21855199 ER PT J AU Friedlander, AH Rosenbluth, SC Rubin, RT AF Friedlander, Arthur H. Rosenbluth, Susan C. Rubin, Robert T. TI The Adult Suicide-Prone Patient: A Review of the Medical Literature and Implications for Oral and Maxillofacial Surgeons SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; NESTED CASE-CONTROL; RISK-FACTORS; PSYCHIATRIC-DISORDERS; CANCER-PATIENTS; IDEATION; FREUD,SIGMUND; DEPRESSION; BEHAVIOR; ILLNESS AB Purpose: Suicide is the 11th most common cause of death among American adults. Some individuals who commit suicide may have been treated by oral and maxillofacial surgeons in the days preceding the event. Because suicide often is preventable, in this report we review methods that are useful in identifying individuals at risk of imminent suicide and give suggestions for obtaining interventional assistance. Methods: A Medline search using the key terms "suicide," "adult," and "oral surgery" was conducted. Articles selected were published in peer-reviewed journals. Results: Individuals who have told their surgeon they have no further reason to live, have developed a suicide plan, have secured a lethal device, and have previously made such an attempt are at extreme risk and require immediate intervention. Additional risk factors include being white, aged older than 45 years, and unemployed; living alone, with poor social supports; having a current mental illness or history of mental illness, including substance abuse; and having a family history of suicide. Specialty-specific patients at highest risk are those treated for oral cancer and cosmetic issues and those with adverse surgical outcomes. With regard to assessment of these individuals, the modified SAD PERSONS acronym can assist surgeons in documenting the presence of major risk factors associated with adult suicide and in facilitating communication with emergency personnel. Conclusions: Suicide is a potentially preventable public health problem. Oral and maxillofacial surgeons can be key in elucidating clinically significant suicide potential in their patients and referring them for timely intervention. This is a US government work. There are no restrictions on its use. Published by Elsevier Inc on behalf of the American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg 70:1253-1260, 2012 C1 [Friedlander, Arthur H.; Rosenbluth, Susan C.] VA Greater Los Angeles Healthcare Syst, Mental Hlth Outpatient Addict Treatment Programs, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Rosenbluth, Susan C.; Rubin, Robert T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Mental Hlth Outpatient Addict Treatment Programs, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov RI Price, Katie/H-1931-2012 NR 72 TC 1 Z9 1 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAY PY 2012 VL 70 IS 5 BP 1253 EP 1260 DI 10.1016/j.joms.2011.02.024 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 938IF UT WOS:000303726500048 PM 21741743 ER PT J AU Merkow, RP Hall, BL Cohen, ME Dimick, JB Wang, E Chow, WB Ko, CY Bilimoria, KY AF Merkow, Ryan P. Hall, Bruce L. Cohen, Mark E. Dimick, Justin B. Wang, Edward Chow, Warren B. Ko, Clifford Y. Bilimoria, Karl Y. TI Relevance of the C-Statistic When Evaluating Risk-Adjustment Models in Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID PREDICTION MODELS; FRAMEWORK; MORTALITY; CURVE AB BACKGROUND: The measurement of hospital quality based on outcomes requires risk adjustment. The c-statistic is a popular tool used to judge model performance, but can be limited, particularly when evaluating specific operations in focused populations. Our objectives were to examine the interpretation and relevance of the c-statistic when used in models with increasingly similar case mix and to consider an alternative perspective on model calibration based on a graphical depiction of model fit. STUDY DESIGN: From the American College of Surgeons National Surgical Quality Improvement Program (2008-2009), patients were identified who underwent a general surgery procedure, and procedure groups were increasingly restricted: colorectal-all, colorectal-elective cases only, and colorectal-elective cancer cases only. Mortality and serious morbidity outcomes were evaluated using logistic regression-based risk adjustment, and model c-statistics and calibration curves were used to compare model performance. RESULTS: During the study period, 323,427 general, 47,605 colorectal-all, 39,860 colorectal-elective, and 21,680 colorectal cancer patients were studied. Mortality ranged from 1.0% in general surgery to 4.1% in the colorectal-all group, and serious morbidity ranged from 3.9% in general surgery to 12.4% in the colorectal-all procedural group. As case mix was restricted, c-statistics progressively declined from the general to the colorectal cancer surgery cohorts for both mortality and serious morbidity (mortality: 0.949 to 0.866; serious morbidity: 0.861 to 0.668). Calibration was evaluated graphically by examining predicted vs observed number of events over risk deciles. For both mortality and serious morbidity, there was no qualitative difference in calibration identified between the procedure groups. CONCLUSIONS: In the present study, we demonstrate how the c-statistic can become less informative and, in certain circumstances, can lead to incorrect model-based conclusions, as case mix is restricted and patients become more homogenous. Although it remains an important tool, caution is advised when the c-statistic is advanced as the sole measure of a model performance. (J Am Coll Surg 2012; 214: 822-830. (C) 2012 by the American College of Surgeons) C1 [Merkow, Ryan P.; Hall, Bruce L.; Cohen, Mark E.; Chow, Warren B.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Wang, Edward; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] John Cochran St Louis VA Med Ctr, Dept Surg, St Louis, MO USA. [Dimick, Justin B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Chow, Warren B.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Chow, Warren B.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM RMerkow@facs.org FU American College of Surgeons, Chicago, IL FX Drs Merkow and Chow are supported by the American College of Surgeons Clinical Scholars in Residence Program, Chicago, IL. Drs Hall and Bilimoria are consultants to the Division of Research and Optimal Patient Care, American College of Surgeons. NR 14 TC 37 Z9 37 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAY PY 2012 VL 214 IS 5 BP 822 EP 830 DI 10.1016/j.jamcollsurg.2011.12.041 PG 9 WC Surgery SC Surgery GA 938HI UT WOS:000303724200013 PM 22440055 ER PT J AU Boyce, RD Hanlon, JT Karp, JF Kloke, J Saleh, A Handler, SM AF Boyce, Richard D. Hanlon, Joseph T. Karp, Jordan F. Kloke, John Saleh, Ahlam Handler, Steven M. TI A Review of the Effectiveness of Antidepressant Medications for Depressed Nursing Home Residents SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Review DE Antidepressants; nursing homes; depression; effectiveness ID LONG-TERM-CARE; GERIATRIC DEPRESSION; ALZHEIMERS-DISEASE; MAJOR DEPRESSION; ELDERLY-PATIENTS; CLINICAL-TRIAL; CORNELL SCALE; HEALTH-CARE; LATE-LIFE; SERTRALINE AB Background: Antidepressant medications are the most common psychopharmacologic therapy used to treat depressed nursing home(NH) residents. Despite a significant increase in the rate of antidepressant prescribing over the past several decades, little is known about the effectiveness of these agents in the NH population. Objective: To conduct a systematic review of the literature to examine and compare the effectiveness of antidepressant medications for treating major depressive symptoms in elderly NH residents. Methods: The following databases were searched with searches completed prior to January 2011 and no language restriction: MEDLINE, Embase, PsycINFO, CINHAL, CENTRAL, LILACS, ClinicalTrials. gov, International Standard Randomized Controlled Trial Number Register, and the WHO International Clinical Trial Registry Platform. Additional studies were identified from citations in evidence-based guidelines and reviews as well as book chapters on geriatric depression and pharmacotherapy from several clinical references. Studies were included if they described a clinical trial that assessed the effectiveness of any currently-marketed antidepressant for adults aged 65 years or older, who resided in the NH, and were diagnosed by DSM criteria and/or standardized validated screening instruments with Major Depressive Disorder, minor depression, dysthymic disorder, or Depression in Alzheimer's disease. Results: A total of eleven studies, including four randomized and seven non-randomized open-label trials, met all inclusion and exclusion criteria. It was not feasible to conduct a meta-analysis because the studies were heterogeneous in terms of study design, operational definitions of depression, participant characteristics, pharmacologic interventions, and outcome measures. Of the four randomized trials, two had a control group and did not demonstrate a statistically-significant benefit for antidepressant pharmacotherapy over placebo. While six of the seven non-randomized studies identified a response to an antidepressant, their results must be interpreted with caution as they lacked a comparison group. Conclusions: The limited amount of evidence from randomized and non-randomized open-label trials suggests that depressed NH residents have a modest response to antidepressant medications. Further research using rigorous study designs are needed to examine the effectiveness and safety of antidepressants in depressed NH residents, and to determine the various facility, provider, andpatient factors associated with response totreatment. Copyright (C) 2012 - American Medical Directors Association, Inc. C1 [Boyce, Richard D.; Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA. [Boyce, Richard D.; Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Geriatr Pharmaceut Outcomes & Geroinformat Res &, Pittsburgh, PA USA. [Hanlon, Joseph T.; Handler, Steven M.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA USA. [Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr GRECC, Pittsburgh, PA USA. [Hanlon, Joseph T.; Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Karp, Jordan F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Karp, Jordan F.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Kloke, John] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Saleh, Ahlam] Univ Pittsburgh, Hlth Sci Lib Syst, Pittsburgh, PA USA. RP Boyce, RD (reprint author), Parkvale Bldg,Suite M-183,200 Meyran Ave, Pittsburgh, PA 15260 USA. EM rdb20@pitt.edu RI Saleh, Ahlam/G-3766-2013 OI Saleh, Ahlam/0000-0002-3492-3140; Handler, Steven/0000-0002-3940-3224; Boyce, Richard/0000-0002-2993-2085 FU Agency for Healthcare Research and Quality [K12HS019461, R01HS017695, 1R01HS018721-01]; National Institute on Aging [K07AG033174, P30AG024827, T32 AG021885, R01AG034056, R56AG027017, 3U01 AG012553, AG033575]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; National Center for Research resources [KL2 RR024154, 3 UL1 R024153-04S4]; VA Health Services Research [IIR-06-062] FX The corresponding author (R.D.B.) was funded by grant K12HS019461 from the Agency for Healthcare Research and Quality. Additional grant support for the coauthors was provided by an Agency for Healthcare Research and Quality grant (R01HS017695 and 1R01HS018721-01), National Institute on Aging grants (K07AG033174, P30AG024827, T32 AG021885, R01AG034056, R56AG027017, 3U01 AG012553, and AG033575), a National Institute of Mental Health grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), National Center for Research resources grants (KL2 RR024154, 3 UL1 R024153-04S4), and a VA Health Services Research grant (IIR-06-062). The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality or any of the other funding sources. NR 52 TC 19 Z9 19 U1 2 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAY PY 2012 VL 13 IS 4 BP 326 EP 331 DI 10.1016/j.jamda.2011.08.009 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 935OA UT WOS:000303527300005 PM 22019084 ER PT J AU El-Shewy, HM Sohn, M Wilson, P Lee, MH Hammad, SM Luttrell, LM Jaffa, AA AF El-Shewy, Hesham M. Sohn, Mimi Wilson, Parker Lee, Mi Hye Hammad, Samar M. Luttrell, Louis M. Jaffa, Ayad A. TI Low-Density Lipoprotein Induced Expression of Connective Tissue Growth Factor via Transactivation of Sphingosine 1-Phosphate Receptors in Mesangial Cells SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID GLYCOSYLATION END-PRODUCTS; PROTEIN-RELATED PROTEIN-2; SMAD SIGNALING CASCADE; P38 MAP KINASE; ENDOTHELIAL-CELLS; DIABETIC-NEPHROPATHY; SPHINGOSINE-1-PHOSPHATE RECEPTORS; ATHEROSCLEROTIC LESIONS; LYSOPHOSPHATIDIC ACID; RENAL-DISEASE AB The pro-fibrotic connective tissue growth factor (CTGF) has been linked to the development and progression of diabetic vascular and renal disease. We recently reported that low-density lipoproteins (LDL) induced expression of CTGF in aortic endothelial cells. However, the molecular mechanisms are not fully defined. Here, we have studied the mechanism by which LDL regulates CTGF expression in renal mesangial cells. In these cells, treatment with pertussis toxin abolished LDL-stimulated activation of ERK1/2 and c-Jun N-terminal kinase (JNK), indicating the involvement of heterotrimeric G proteins in LDL signaling. Treatment with LDL promoted activation and translocation of endogenous sphingosine kinase 1 (SK1) from the cytosol to the plasma membrane concomitant with production of sphingosine-1-phosphate (S1P). Pretreating cells with SK inhibitor, dimethylsphinogsine or down-regulation of SK1 and SK2 revealed that LDL-dependent activation of ERK1/2 and JNK is mediated by SK1. Using a green fluorescent protein-tagged S1P(1) receptor as a biological sensor for the generation of physiologically relevant S1P levels, we found that LDL induced S1P receptor activation. Pretreating cells with S1P(1)/S1P(3) receptor antagonist VPC23019 significantly inhibited activation of ERK1/2 and JNK by LDL, suggesting that LDL elicits G protein-dependent activation of ERK1/2 and JNK by stimulating SK1-dependent transactivation of S1P receptors. Furthermore, S1P stimulation induced expression of CTGF in a dose-dependent manner that was markedly inhibited by blocking the ERK1/2 and JNK signaling pathways. LDL-induced CTGF expression was pertussis toxin sensitive and inhibited by dimethylsphinogsine down-regulation of SK1 and VPC23019 treatment. Our data suggest that SK1-dependent S1P receptor transactivation is upstream of ERK1/2 and JNK and that all three steps are required for LDL-regulated expression of CTGF in mesangial cells. (Molecular Endocrinology 26: 833-845, 2012) C1 [Jaffa, Ayad A.] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon. [El-Shewy, Hesham M.; Sohn, Mimi; Wilson, Parker; Lee, Mi Hye; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Jaffa, AA (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Riad El Solh St, Beirut, Lebanon. EM aj24@aub.edu.lb FU NIH [HL077192, HL087986, DK55524]; South Carolina COBRE in Lipidomics and Pathobiology [P2 RR17677]; Research Service of the Ralph H. Johnson Veterans Affairs Medical Center FX This work was supported by NIH Grants HL077192, HL087986 (to A.A.J.), DK55524 (to L.M.L.), the South Carolina COBRE in Lipidomics and Pathobiology (P2 RR17677) (to H.M.E.), and Research Service of the Ralph H. Johnson Veterans Affairs Medical Center (to L.M.L.). NR 62 TC 13 Z9 13 U1 0 U2 6 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD MAY PY 2012 VL 26 IS 5 BP 833 EP 845 DI 10.1210/me.2011-1261 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 940BL UT WOS:000303864900012 PM 22422617 ER PT J AU Cummings, DE AF Cummings, David E. TI Metabolic surgery for type 2 diabetes SO NATURE MEDICINE LA English DT Editorial Material ID BARIATRIC SURGERY; GASTROINTESTINAL SURGERY; LIFE-STYLE; MECHANISMS; MORTALITY; RISK AB Clinicians note that bariatric operations can dramatically resolve type 2 diabetes, often before and out of proportion to postoperative weight loss. Now two randomized controlled trials formally show superior results from surgical compared with medical diabetes care, including among only mildly obese patients. The concept of 'metabolic surgery' to treat diabetes has taken a big step forward. C1 [Cummings, David E.] Univ Washington, Seattle, WA 98195 USA. [Cummings, David E.] VA Puget Sound Hlth Care Syst, Diabet & Obes Ctr Excellence, Seattle, WA USA. RP Cummings, DE (reprint author), Univ Washington, Seattle, WA 98195 USA. EM davidec@u.washington.edu NR 16 TC 20 Z9 21 U1 2 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAY PY 2012 VL 18 IS 5 BP 656 EP 658 DI 10.1038/nm.2773 PG 4 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 938WE UT WOS:000303763500026 PM 22561818 ER PT J AU Barral, S Bird, T Goate, A Farlow, MR Diaz-Arrastia, R Bennett, DA Graff-Radford, N Boeve, BF Sweet, RA Stern, Y Wilson, RS Foroud, T Ott, J Mayeux, R AF Barral, S. Bird, T. Goate, A. Farlow, M. R. Diaz-Arrastia, R. Bennett, D. A. Graff-Radford, N. Boeve, B. F. Sweet, R. A. Stern, Y. Wilson, R. S. Foroud, T. Ott, J. Mayeux, R. CA Natl Inst Aging Late-Onset Alzheim TI Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory SO NEUROLOGY LA English DT Article ID ONSET ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; COGNITIVE DECLINE; APOLIPOPROTEIN-E; IDENTIFIES VARIANTS; EPSILON-4 ALLELE; AGE; FAMILY; METABOLISM; HEALTH AB Objective: Several genome-wide association studies (GWAS) have associated variants in late-onset Alzheimer disease (LOAD) susceptibility genes; however, these single nucleotide polymorphisms (SNPs) have very modest effects, suggesting that single SNP approaches may be inadequate to identify genetic risks. An alternative approach is the use of multilocus genotype patterns (MLGPs) that combine SNPs at different susceptibility genes. Methods: Using data from 1,365 subjects in the National Institute on Aging Late-Onset Alzheimer's Disease Family Study, we conducted a family-based association study in which we tabulated MLGPs for SNPs at CR1, BIN1, CLU, PICALM, and APOE. We used generalized estimating equations to model episodic memory as the dependent endophenotype of LOAD and the MLGPs as predictors while adjusting for sex, age, and education. Results: Several genotype patterns influenced episodic memory performance. A pattern that included PICALM and CLU was the strongest genotypic profile for lower memory performance (beta = -0.32, SE = 0.19, p = 0.021). The effect was stronger after addition of APOE (p = 0.016). Two additional patterns involving PICALM, CR1, and APOE and another pattern involving PICALM, BIN1, and APOE were also associated with significantly poorer memory performance (beta = -0.44, SE = 0.09, p = 0.009 and beta = -0.29, SE = 0.07, p = 0.012) even after exclusion of patients with LOAD. We also identified genotype pattern involving variants in PICALM, CLU, and APOE as a predictor of better memory performance (beta = 0.26, SE = 0.10, p = 0.010). Conclusions: MLGPs provide an alternative analytical approach to predict an individual's genetic risk for episodic memory performance, a surrogate indicator of LOAD. Identifying genotypic patterns contributing to the decline of an individual's cognitive performance may be a critical step along the road to preclinical detection of Alzheimer disease. Neurology (R) 2012;78:1464-1471 C1 [Barral, S.; Stern, Y.; Mayeux, R.] Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA. [Barral, S.; Stern, Y.; Mayeux, R.] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Bird, T.] Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA. [Bird, T.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Goate, A.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Farlow, M. R.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA. [Foroud, T.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA. [Diaz-Arrastia, R.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA. [Bennett, D. A.; Wilson, R. S.] Rush Univ, Rush Alzheimers Dis Ctr, Med Ctr, Chicago, IL 60612 USA. [Graff-Radford, N.] Mayo Clin, Dept Neurol, Coll Med, Jacksonville, FL 32224 USA. [Boeve, B. F.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Sweet, R. A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Ott, J.] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China. RP Mayeux, R (reprint author), Columbia Univ Coll Phys & Surg, Gertrude H Sergievsky Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, 630 W 168th St, New York, NY 10032 USA. EM rpm2@columbia.edu RI Kowall, Neil/G-6364-2012 OI Kowall, Neil/0000-0002-6624-0213 FU NIH [HHSN268200782096C]; NIA [U24AG26396, U24AG021886, R01AG17917, P50AG8702, P30AG10161, P30AG013846, P30AG028377, P30AG010133, P50AG05134, P50AG016574]; NSFC from the Chinese Government [30730057]; Alzheimer Disease Genetic Consortium; Athena Diagnostics, Inc.; AstraZeneca; Genetech; Pfizer; Danone Research; Elan Pharma; Eli Lilly; Novartis; OctaPharma; sanofi-aventis; Sonexa Therapeutics; Eisai; Medivation; Janssen; Allon; Forest; Cephalon Inc.; Allon Pharmaceuticals; Mangurian Foundation; Alzheimer Association; Behavioral Neurology of Dementia; Rush University Medical Center; Natural Science Foundation of China; N I A [P50AG05138, P30AG013854, P30AG08017, P50AG016582, P50AG016570, P30AG028383, P30AG010124, P50AG005133, R01AG027224, P50AG05142, P30AG012300, P50AG05136, P50AG05681] FX Supported by NIH and NIA grants U24AG26396, U24AG021886, R01AG17917, P50AG8702, P30AG10161, P30AG013846, P30AG028377, P30AG010133, P50AG05134, P50AG016574, P50AG05138, P30AG013854, P30AG08017, P50AG016582, P50AG016570, P30AG028383, P30AG010124, P50AG005133, R01AG027224, P50AG05142, P30AG012300, P50AG05136, and P50AG05681 and NSFC grant 30730057 from the Chinese Government to J. Ott. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the NIH to The Johns Hopkins University (contract HHSN268200782096C). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, but did review the manuscript before submission.; Dr. Barral receives research support from Alzheimer Disease Genetic Consortium. Dr. Bird receives research support from Athena Diagnostics, Inc. Dr. Goate serves as consultant for AstraZeneca; serves as an expert testimony for Howrey & Associates; receives research support from AstraZeneca, Genetech, Pfizer, and NIA; and holds patent royalties from Taconic (Tau mutation patent). Dr. Farlow serves as a board member for Medivation, Merck, and INC Res/Toyama; serves as a consultant for Accera, Astellas, Baxter, Bristol Meyers Squibb, GE Healthcare, Novartis, Pfizer, Prana, and sanofi-aventis; serves as an expert testimony for Pfizer; receives research support from Danone Research, Elan Pharma, Eli Lilly, Novartis, Genetech, OctaPharma, Pfizer, sanofi-aventis, Sonexa Therapeutics, Eisai, and NIA; holds a patent from Elan and patent royalties from UpTo-Date; and holds stock options from QR Pharm and MedAvante. Dr. Diaz-Arrastia receives research support from NIH. Dr. Bennett receives research support from NIH. Dr. Graff-Radford serves as board member of The Neurologist; serves as a consultant for Codman; and receives research support from Medivation, Janssen, Allon, Forest, and NIA. Dr. Boeve receives research support from Cephalon Inc., Allon Pharmaceuticals, Mangurian Foundation, Alzheimer Association, and NIH; receives royalties as a co-editor of Behavioral Neurology of Dementia; and receives support for development of educational presentations from the American Academy of Neurology. Dr. Sweet receives research support from NIH. Dr. Stern serves as consultant for Allergan Inc., Cephalon Inc., Elan Corporation, Eisai Inc., Pfizer, Ortho-McNeil Neurologics, Merck Serono, GlaxoSmithKline, Eli Lilly, Janssen, and NIH. Dr. Wilson receives research support from a grant from Rush University Medical Center. Dr. Foroud receives research support from NIH. Dr. Ott receives research support from Natural Science Foundation of China. Dr. Mayeux receives research support from NIH. Go to Neurology. org for full disclosures. NR 37 TC 40 Z9 40 U1 1 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD MAY PY 2012 VL 78 IS 19 BP 1464 EP 1471 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 939AW UT WOS:000303776900007 PM 22539578 ER PT J AU Perkins, HS Cortez, JD Hazuda, HP AF Perkins, Henry S. Cortez, Josie D. Hazuda, Helen P. TI Diversity of Patients' Beliefs about the Soul after Death and Their Importance in End-of-Life Care SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE attitude toward death; cross-cultural comparison; end of life; palliative care; terminal care ID SPIRITUAL CARE; DYING PATIENTS; DECISION-MAKING; CANCER-PATIENTS; TREATMENT PREFERENCES; AFRICAN-AMERICANS; MEDICAL-PRACTICE; CULTURAL ISSUES; PALLIATIVE CARE; FAMILY-MEMBERS AB Background: Because beliefs about the soul after death affect the dying experience, patients and survivors may want to discuss those beliefs with their healthcare provider; however, almost no medical research describes such beliefs, leaving healthcare professionals ill prepared to respond. This exploratory study begins the descriptive process. Methods: Assuming that culture is key, we asked older adult Mexican American (MA), European American (EA), and African American (AA) inpatients their beliefs about whether the soul lives on after physical death; if so, where; and what the "afterlife" is like. Results: Some beliefs varied little across the sample. For example, most participants said that the soul lives on after physical death, leaves the body immediately at death, and eventually reaches heaven. Many participants also said death ends physical suffering; however, other beliefs varied distinctly by ethnic group or sex. More AAs than MAs or EAs said that they believed that the soul after physical death exists in the world (57% vs 35% and 33%) or interacts with the living (43% vs 31% and 28%). Furthermore, in every ethnic group more women than men said they believed that the soul exists in the world (42% vs 29% for MAs, 45% vs 14% for EAs, and 71% vs 43% for AAs). Conclusions: As death nears, patients or survivors may want to discuss beliefs about the soul after death with their healthcare provider. This preliminary study characterizes some of those beliefs. By suggesting questions to ask and responses to give, the study provides healthcare professionals a supportive, knowledgeable way to participate in such discussions. C1 Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. Intercultural Dev Res Assoc, San Antonio, TX USA. Audie L Murphy Med Ctr, Dept Vet Affairs, San Antonio, TX USA. RP Perkins, HS (reprint author), POB 1696, Dearborn, MI 48121 USA. EM perkins@uthscsa.edu FU John A. Hartford Foundation; American Federation on Aging Research; US Department of Veterans Affairs; Medical Dean's Office at the University of Texas Health Science Center at San Antonio FX Support for the research was provided by the John A. Hartford Foundation, the American Federation on Aging Research, the US Department of Veterans Affairs, and the Medical Dean's Office at the University of Texas Health Science Center at San Antonio. NR 67 TC 2 Z9 2 U1 2 U2 21 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD MAY PY 2012 VL 105 IS 5 BP 266 EP 272 DI 10.1097/SMJ.0b013e3182549eda PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 937SM UT WOS:000303678900006 PM 22561539 ER PT J AU Boninger, ML Brienza, D Charlifue, S Chen, YY Curley, KC Graves, DE Groah, S Heinemann, AW Hudson, LM Jackson, AB Johnson, KL Kalpakjian, CZ Kusiak, A Larson, KE Agustin, TS Sherwood, AM Shinowara, N Stripling, T Tate, D AF Boninger, M. L. Brienza, D. Charlifue, S. Chen, Y-Y Curley, K. C. Graves, D. E. Groah, S. Heinemann, A. W. Hudson, L. M. Jackson, A. B. Johnson, K. L. Kalpakjian, C. Z. Kusiak, A. Larson, K. E. Agustin, T. S. Sherwood, A. M. Shinowara, N. Stripling, T. Tate, D. TI State of the Science Conference in Spinal Cord Injury Rehabilitation 2011: introduction SO SPINAL CORD LA English DT Editorial Material DE spinal cord injury; rehabilitation; research funding ID MODEL SYSTEMS C1 [Heinemann, A. W.] Northwestern Univ, Dept Phys Med & Rehabil, Ctr Rehabil Outcomes Res, Feinberg Sch Med,Rehabil Inst Chicago, Chicago, IL 60611 USA. [Boninger, M. L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, M. L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Brienza, D.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Rehabil Engn Res Ctr Spinal Cord Injury, Pittsburgh, PA USA. [Charlifue, S.] Craig Hosp, SCI Model Syst, Englewood, CO USA. [Chen, Y-Y] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Curley, K. C.] USA, Telemed & Adv Technol Res Ctr, Med Res & Mat Command, ATTN MCMR RTC, Ft Detrick, MD USA. [Curley, K. C.] Ctr Disaster & Humanitarian Assistance Med, Dept Sci & Med, Bethesda, MD USA. [Curley, K. C.] Uniformed Serv Univ Hlth Sci, Dept Biomed Informat, Bethesda, MD 20814 USA. [Curley, K. C.] Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Bethesda, MD 20814 USA. [Graves, D. E.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Groah, S.] Natl Rehabil Hosp, Washington, DC USA. [Hudson, L. M.] Shepherd Ctr, SE Reg SCI Model Syst, Atlanta, GA USA. [Jackson, A. B.] Univ Alabama Birmingham, Sch Med, Dept PM&R, Birmingham, AL USA. [Johnson, K. L.] Univ Washington, Sch Med, Dept Rehabil Med, Div Rehabil Counseling, Seattle, WA 98195 USA. [Kalpakjian, C. Z.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. [Kusiak, A.] US EPA, Off Res & Dev, Dept Vet Affairs, Washington, DC 20460 USA. [Larson, K. E.] NSCIA, Elmhurst, NY USA. [Agustin, T. S.] Natl Inst Disabil & Rehabil Res, OSERS US Dept Educ, Washington, DC USA. [Sherwood, A. M.] Baylor Coll Med, Washington, DC USA. [Shinowara, N.] NICHD, Natl Ctr Med Rehabil Res, NIH, Bethesda, MD USA. [Stripling, T.] Larkview Court, Fairfax Stn, VA USA. [Tate, D.] Univ Michigan, Michigan Burlington Off Ctr, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. RP Heinemann, AW (reprint author), Northwestern Univ, Dept Phys Med & Rehabil, Ctr Rehabil Outcomes Res, Feinberg Sch Med,Rehabil Inst Chicago, 345 E Super St, Chicago, IL 60611 USA. EM a-heinemann@northwestern.edu RI Heinemann, Allen /K-6283-2012 OI Heinemann, Allen /0000-0003-2782-7326; Sherwood, Arthur/0000-0002-0110-4317; Boninger, Michael/0000-0001-6966-919X FU NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [UL1 RR024153] NR 2 TC 2 Z9 2 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAY PY 2012 VL 50 IS 5 SI SI BP 342 EP 343 DI 10.1038/sc.2012.13 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 938ZF UT WOS:000303771700002 PM 22450887 ER PT J AU Boninger, M French, J Abbas, J Nagy, L Ferguson-Pell, M Taylor, SJ Rodgers, M Saunders, N Peckham, H Marshall, R Sherwood, A AF Boninger, M. French, J. Abbas, J. Nagy, L. Ferguson-Pell, M. Taylor, S. J. Rodgers, M. Saunders, N. Peckham, H. Marshall, R. Sherwood, A. TI Technology for mobility in SCI 10 years from now SO SPINAL CORD LA English DT Article DE spinal cord injury; mobility; assistive technology; International Classification of Function ID SPINAL-CORD-INJURY; VIRTUAL-REALITY; REHABILITATION; WALKING; DESIGN; EXOSKELETONS; MULTICENTER; INTERFACE; MEDICINE; THERAPY AB Objectives: To identify technological advances and that are likely to have a great impact on the quality of life and participation in individuals with spinal cord injury (SCI). Methods: In this paper we use the International Classification of Function to frame a discussion on how technology is likely to impact SCI in 10 years. In addition, we discuss the implication of technological advances on future research. Results/Conclusion: Although technology advances are exciting, a large challenge for the research community will be how to effectively apply and deploy this technology. Advances occurring in the next 10 years that reduce cost of technology may be more important to the population with SCI than brand new technologies. Social context is everything. As a research community we must advocate for better systems of care. Advocating now for better care will lead to a world in 2020 that is ready to adopt new technologies that are truly transformative. Spinal Cord (2012) 50, 358-363; doi:10.1038/sc.2011.165; published online 17 January 2012 C1 [Boninger, M.] UPMC Rehabil Inst, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Boninger, M.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [French, J.] Neurotech Network, Tampa, FL USA. [Abbas, J.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Ctr Adapt Neural Syst, Tempe, AZ USA. [Nagy, L.] MetroHlth Rehabil Inst Ohio, Community Advisory Board, Cleveland, OH USA. [Ferguson-Pell, M.] Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada. [Taylor, S. J.] Rehabil Inst Chicago, Chicago, IL 60611 USA. [Rodgers, M.] Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA. [Rodgers, M.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA. [Saunders, N.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3052, Australia. [Peckham, H.] Case Western Reserve Univ, Dept Biomed Engn, Sch Med, Cleveland, OH 44106 USA. [Peckham, H.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Marshall, R.] Univ Adelaide, Fac Hlth Sci, Sch Med, Adelaide, SA, Australia. [Sherwood, A.] Natl Inst Disabil & Rehabil Res, US Dept Educ, Washington, DC USA. RP Boninger, M (reprint author), UPMC Rehabil Inst, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA. EM boninger@pitt.edu OI Sherwood, Arthur/0000-0002-0110-4317; Boninger, Michael/0000-0001-6966-919X; Abbas, James/0000-0002-3647-7041; Saunders, Norman/0000-0001-6660-7639 NR 36 TC 3 Z9 3 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAY PY 2012 VL 50 IS 5 SI SI BP 358 EP 363 DI 10.1038/sc.2011.165 PG 6 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 938ZF UT WOS:000303771700005 PM 22249329 ER PT J AU Heinemann, AW Steeves, JD Boninger, M Groah, S Sherwood, AM AF Heinemann, A. W. Steeves, J. D. Boninger, M. Groah, S. Sherwood, A. M. TI State of the science in spinal cord injury rehabilitation 2011: informing a new research agenda SO SPINAL CORD LA English DT Article DE spinal cord injury; rehabilitation; research funding AB Study design: This manuscript summarizes recommendations from the State of the Science Conference in Spinal Cord Injury Rehabilitation 2011. Objectives: To develop an agenda for spinal cord injury (SCI) rehabilitation research in the next decade. Setting: Participants scheduled planning meetings and then gathered at the 2011 joint meeting of the American Spinal Injury Association and International Spinal Cord Society in Washington DC. Methods: Recommendations were made by an international, multidisciplinary team that met in large plenary sessions and breakout groups during the meeting. Results: Recommendations are organized by conference track, including neurological and functional recovery; technology issues; aging with spinal cord injury; and employment, psychosocial and quality of life issues. Conclusion: A number of themes emerged across the conference tracks, including the need for improved measures of process and outcome constructs, application of qualitative and quantitative research designs, and use of contemporary statistical analytic approaches. Participants emphasized the value of collaborative research that uses the latest methods, techniques and information. Spinal Cord (2012) 50, 390-397; doi:10.1038/sc.2012.12; published online 20 March 2012 C1 [Heinemann, A. W.] Northwestern Univ, Ctr Rehabil Outcomes Res, Feinberg Sch Med, Rehabil Inst Chicago, Chicago, IL 60611 USA. [Heinemann, A. W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA. [Steeves, J. D.] Blusson Spinal Cord Ctr, ICORD, UBC, Vancouver, BC, Canada. [Boninger, M.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, M.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Groah, S.] Georgetown Univ, Washington, DC USA. [Groah, S.] Natl Rehabil Hosp, SCI Res, Washington, DC USA. [Sherwood, A. M.] Natl Inst Disabil & Rehabil Res, US Dept Educ, Washington, DC USA. RP Heinemann, AW (reprint author), Northwestern Univ, Ctr Rehabil Outcomes Res, Feinberg Sch Med, Rehabil Inst Chicago, 345 E Super St, Chicago, IL 60611 USA. EM a-heinemann@northwestern.edu RI Heinemann, Allen /K-6283-2012 OI Heinemann, Allen /0000-0003-2782-7326; Sherwood, Arthur/0000-0002-0110-4317; Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research (NIDRR); US Army Medical Research and Materiel Command; University of Pittsburgh Rehabilitation Engineering Research Center on SCI; Craig H Neilsen Foundation; Christopher and Dana Reeve Foundation; Ontario Neurotrauma Foundation; Miami Project to Cure Paralysis; International Spinal Cord Society; National Institute of Biomedical Imaging and Bioengineering; US Department of Veterans Affairs FX The authors acknowledge the contributions of individuals who served as scribe and facilitators of the break-out sessions, including Charles Bombardier, Barbara Bregman, David Brennan, David Brienza, Pat Brown, Tom Bryce, Dave Chen, Jennifer Collinger, Marcel Dijkers, Bill Donovan, Martin Forchheimer, Jeanne Hoffman, Sarah Huey, Amie Jackson, Susan Knoblach, John 'Kip' Kramer, Audrey Kusiak, Dan Lammertse, Eric Larson, Alex Libin, Inger Ljungberg, Ralph Marino, Greg Nemunaitis, Michelle Oyster, Miriam I Philmon, Jason Plemel, Scott Richards, Jennifer Stevenson, Thomas Stripling, Nancy Shinowara, Norman Saunders, Denise Tate, and Gale Whiteneck. Their contributions were critical to the success of the conference. The authors also acknowledge the support of the National Institute on Disability and Rehabilitation Research (NIDRR), the NIDRR Spinal Cord Injury Model System Program, the US Army Medical Research and Materiel Command, the University of Pittsburgh Rehabilitation Engineering Research Center on SCI, the Craig H Neilsen Foundation, the Christopher and Dana Reeve Foundation, the Ontario Neurotrauma Foundation, The Miami Project to Cure Paralysis, the International Spinal Cord Society, the National Institute of Biomedical Imaging and Bioengineering, and the US Department of Veterans Affairs. Finally, the authors acknowledge the efforts of the Steering Committee, and the input of the meeting participants. NR 12 TC 7 Z9 8 U1 2 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD MAY PY 2012 VL 50 IS 5 SI SI BP 390 EP 397 DI 10.1038/sc.2012.12 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 938ZF UT WOS:000303771700011 PM 22430512 ER PT J AU Zhang, F Wang, SP Zhang, MJ Weng, ZF Li, PY Gan, Y Zhang, LL Cao, GD Gao, YQ Leak, RK Sporn, MB Chen, J AF Zhang, Feng Wang, Suping Zhang, Meijuan Weng, Zhongfang Li, Peiying Gan, Yu Zhang, Lili Cao, Guodong Gao, Yanqin Leak, Rehana K. Sporn, Michael B. Chen, Jun TI Pharmacological Induction of Heme Oxygenase-1 by a Triterpenoid Protects Neurons Against Ischemic Injury SO STROKE LA English DT Article DE CDDO; cytoprotective; Nrf2; stroke ID CEREBRAL-ARTERY OCCLUSION; NITRIC-OXIDE PRODUCTION; SYNTHETIC TRITERPENOIDS; CDDO-IMIDAZOLIDE; POTENT INDUCERS; MOUSE MODEL; IN-VIVO; NRF2; PATHWAY; INHIBITION AB Background and Purpose-Heme oxygenase-1 (HO-1) is an inducible Phase 2 enzyme that degrades toxic heme; its role in cerebral ischemia is not fully understood. We hypothesize that chemically induced HO-1 upregulation with the novel triterpenoid CDDO-Im (2-cyano-3,12 dioxooleana-1,9 dien-28-oyl imidazoline), a robust inducer of Phase 2 genes, protects neurons against ischemic injury. Methods-Using 3 different models of ischemia, including oxygen-glucose deprivation in neuronal cultures, global ischemia in rats, and focal ischemia in mice, we determined (1) whether CDDO-Im induces HO-1 expression and protects against ischemic injury; and (2) whether HO-1 inhibition disrupts the neuroprotective effect of CDDO-Im. Results-CDDO-Im treatment (50-300 nmol/L) resulted in 8-fold HO-1 upregulation in cultured neurons and protected against oxygen-glucose deprivation. The protection was abolished when the cultures were transfected with nuclear factor (erythroid-derived 2) like-2-shRNA or coincubated with tin protoporphyrin IX, a specific HO-1 inhibitor. In the rat model of global ischemia, intracerebroventricular infusion of CDDO-Im (0.5-1.5 mu g) augmented HO-1 expression in hippocampal neurons and resulted in significant increases in CA1 neuronal survival after global ischemia. To further strengthen the clinical relevance of the CDDO-Im treatment, we tested its effects in the mouse model of temporary focal ischemia (60 minutes). Postischemic intraperitoneal injection of CDDO-Im (10-100 mu g) enhanced HO-1 expression and significantly reduced neurological dysfunction and infarct volume. Intracerebroventricular infusion of tin protoporphyrin IX reduced the neuroprotective effect of CDDO-Im against global and focal ischemia. Conclusions-CDDO-Im confers neuroprotection against ischemic injury by upregulating HO-1, suggesting that enhance of HO-1 expression may be a legitimate strategy for therapeutic intervention of stroke. (Stroke. 2012;43:1390-1397.) C1 [Zhang, Feng; Wang, Suping; Zhang, Meijuan; Weng, Zhongfang; Li, Peiying; Gan, Yu; Zhang, Lili; Cao, Guodong; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Ctr Cerebrovasc Dis, Pittsburgh, PA 15213 USA. [Zhang, Feng; Wang, Suping; Weng, Zhongfang; Li, Peiying; Gan, Yu; Zhang, Lili; Cao, Guodong; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Mylan Sch Pharm, Pittsburgh, PA 15219 USA. [Sporn, Michael B.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol, Hanover, NH 03756 USA. [Sporn, Michael B.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA. [Zhang, Feng; Wang, Suping; Weng, Zhongfang; Zhang, Lili; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. EM zhanfx2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Zhang, Meijuan/0000-0002-5375-5349; Zhang, Feng/0000-0001-7275-9989 FU National Institutes of Health [NS36736, NS43802, NS45048]; VA Merit Review Grant; American Heart Association [10SDG2560122] FX This work was supported by funds from the National Institutes of Health (NS36736, NS43802, and NS45048 to J.C.), the VA Merit Review Grant to J.C., and the American Heart Association (10SDG2560122 to F.Z.). NR 36 TC 39 Z9 40 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAY PY 2012 VL 43 IS 5 BP 1390 EP + DI 10.1161/STROKEAHA.111.647420 PG 13 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 936PO UT WOS:000303602700043 PM 22461332 ER PT J AU Ellis, C Simpson, AN Bonilha, H Mauldin, PD Simpson, KN AF Ellis, Charles Simpson, Annie N. Bonilha, Heather Mauldin, Patrick D. Simpson, Kit N. TI The One-Year Attributable Cost of Poststroke Aphasia SO STROKE LA English DT Article DE aphasia; costs ID ISCHEMIC-STROKE; REHABILITATION; EPIDEMIOLOGY; CARE AB Background and Purpose-Little is known about the contribution of aphasia to the cost of care for patients who experience stroke. Methods-We retrospectively examined a cohort of South Carolina Medicare beneficiaries who experienced ischemic stroke in 2004 to determine the attributable cost of aphasia. Univariate analyses were used to compare demographic, comorbidity, and severity differences between individuals with poststroke aphasia and those without aphasia. Differences in payments by Medicare because of stroke were examined using a gamma-distributed generalized linear multivariate model. Results-Three thousand, two hundred Medicare beneficiaries experienced ischemic stroke in South Carolina in 2004, and 398 beneficiaries had poststroke aphasia. Patients with aphasia experienced longer length of stays, greater morbidity, and greater mortality than did those without aphasia. In adjusted models that controlled for relevant covariates, the attributable 1-year cost of aphasia was estimated at $1703. Conclusions-Aphasia adds to the cost of stroke-related care, above the cost of stroke alone. (Stroke. 2012;43:1429-1431.) C1 [Ellis, Charles; Simpson, Annie N.; Bonilha, Heather; Simpson, Kit N.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Ellis, Charles] Ralph H Johnson VA Med Ctr, VA Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA. [Simpson, Annie N.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Med Univ S Carolina, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA. [Simpson, Kit N.] Med Univ S Carolina, Dept Hlth Adm & Policy, Charleston, SC 29425 USA. RP Ellis, C (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM ellisc@musc.edu FU Veterans Health Administration Health Services [07-012-3]; NIH/NCRR [UL1 RR029880] FX C.E. is supported by a career development award (CDA# 07-012-3) from the Veterans Health Administration Health Services Research and Development program.; H. B. is supported by NIH/NCRR grant #UL1 RR029880. NR 15 TC 36 Z9 37 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAY PY 2012 VL 43 IS 5 BP 1429 EP + DI 10.1161/STROKEAHA.111.647339 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 936PO UT WOS:000303602700053 PM 22343643 ER PT J AU Hirsh, D Gaufberg, E Ogur, B Cohen, P Krupat, E Cox, M Pelletier, S Bor, D AF Hirsh, David Gaufberg, Elizabeth Ogur, Barbara Cohen, Pieter Krupat, Edward Cox, Malcolm Pelletier, Stephen Bor, David TI Educational Outcomes of the Harvard Medical School-Cambridge Integrated Clerkship: A Way Forward for Medical Education SO ACADEMIC MEDICINE LA English DT Article ID CLINICAL EDUCATION; HIDDEN CURRICULUM; PATIENT-CENTEREDNESS; STUDENTS; CONTINUITY; COMMUNITY; PROGRAM; REFORM; MODEL; CARE AB Purpose The authors report data from the Harvard Medical School-Cambridge Integrated Clerkship (CIC), a model of medical education in which students' entire third year consists of a longitudinal, integrated curriculum. The authors compare the knowledge, skills, and attitudes of students completing the CIC with those of students completing traditional third-year clerkships. Method The authors compared 27 students completing the first three years of the CIC (2004-2007) with 45 students completing clerkships at other Harvard teaching hospitals during the same period. At baseline, no significant between-group differences existed (Medical College Admission Test and Step 1 scores, second-year objective structured clinical examination [OSCE] performance, attitudes toward patient-centered care, and plans for future practice) in any year. The authors compared students' National Board of Medical Examiners Subject and Step 2 Clinical Knowledge scores, OSCE performance, perceptions of the learning environment, and attitudes toward patient-centeredness. Results CIC students performed as well as or better than their traditionally trained peers on measures of content knowledge and clinical skills. CIC students expressed higher satisfaction with the learning environment, more confidence in dealing with numerous domains of patient care, and a stronger sense of patient-centeredness. Conclusions CIC students are at least as well as and in several ways better prepared than their peers. CIC students also demonstrate richer perspectives on the course of illness, more insight into social determinants of illness and recovery, and increased commitment to patients. These data suggest that longitudinal integrated clerkships offer students important intellectual, professional, and personal benefits. C1 [Hirsh, David; Gaufberg, Elizabeth; Ogur, Barbara; Cohen, Pieter; Bor, David] Cambridge Hlth Alliance, Cambridge, MA 02139 USA. [Hirsh, David; Gaufberg, Elizabeth; Ogur, Barbara; Cohen, Pieter; Bor, David] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. [Gaufberg, Elizabeth] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Krupat, Edward] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Krupat, Edward; Pelletier, Stephen] Harvard Univ, Sch Med, Ctr Evaluat, Boston, MA USA. [Cox, Malcolm] Univ Penn, Dept Med, Sch Med, Washington, DC USA. [Cox, Malcolm] US Dept Vet Affairs, Washington, DC USA. RP Hirsh, D (reprint author), Cambridge Hlth Alliance, 1493 Cambridge St, Cambridge, MA 02139 USA. EM david_hirsh@hms.harvard.edu FU Cambridge Health Alliance; Harvard Medical School Academy of Educators; Association of American Medical Colleges, New York Academy of Medicine, Macy Foundation [281918] FX The authors wish to thank the following individuals for their wise teaching and advice, their outstanding work in creating and advancing the CIC, and for inspiration that led to this report: Ronald Arky, MD, Elizabeth Armstrong, PhD, Kirsten Austad, Jeremiah Barondess, MD, Maren Batalden, MD, MPH, Carolyn Bernstein, MD, Jack Burke, Jr, MD, MPH, Jeanette Callahan, MD, Steve Carter, MBA, Allison Cook, EdM, MA, Molly Cooke, MD, Jules Dienstag, MD, Jeffrey Flier, MD, Martha Garcia, MD, Arundhati Ghosh, MD, James Gordon, MD, Wendy Gutterson, MS, Frederic Hafferty, PhD, Kathleen Harney, MD, Carol Hulka, MD, David Irby, PhD, Dennis Keefe, MBA, Robert Kegan, PhD, Judy Klickstein, MS, Kathy Kosinski, MD, David Link, MD, Bridget O'Brien, PhD, Joseph Martin, MD, PhD, Robert Meyer, MD, Stephen Schwaitzberg, MD, Gary Setnick, MD, Kitt Shaffer, MD, PhD, Derri Shtasel, MD, MPH, William Silen, MD, Art Spector, MD, George Thibault, MD, Todd Thompson, MD, Joseph Velletri, Ronald Weintraub, MD, and Michael Whitcomb, MD. Indeed, the authors thank all the students, faculty, and administrators of the CIC. The authors also thank the Cambridge Health Alliance and the Harvard Medical School Academy of Educators for their financial support.; Association of American Medical Colleges, New York Academy of Medicine, Macy Foundation Grant (#281918) from 2004 to 2006. NR 57 TC 62 Z9 64 U1 4 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD MAY PY 2012 VL 87 IS 5 BP 643 EP 650 DI 10.1097/ACM.0b013e31824d9821 PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 933TD UT WOS:000303384700027 PM 22450189 ER PT J AU Yang, SZ Mulvey, EP AF Yang, Suzanne Mulvey, Edward P. TI Violence risk: Re-defining variables from the first-person perspective SO AGGRESSION AND VIOLENT BEHAVIOR LA English DT Article DE Mentally ill offenders; Prevention; Structured clinical judgment; Subjective experience; Violence risk assessment ID MENTALIZATION-BASED TREATMENT; SELF-APPRAISAL QUESTIONNAIRE; INTIMATE PARTNER VIOLENCE; SHORT-TERM ASSESSMENT; ATTRIBUTIONAL STYLE; PSYCHIATRIC-PATIENTS; AGGRESSIVE-BEHAVIOR; BORDERLINE PERSONALITY; PREDICTIVE-VALIDITY; PREMEDITATED AGGRESSION AB Over the past 25 years, there have been notable advances in violence risk assessment of mentally ill individuals using actuarial methods to define high versus low risk groups. A focus on readily observable risk factors, however, has led to a relative neglect of how the offender's subjective states may be valuable to consider in research on the ongoing assessment and prevention of violence. We argue for the relevance of considering idiographic features of subjective experience in the development of structured assessment methods. We then identify three heuristic groups of existing constructs related to aggressive and illegal behavior that may capture modifiable, time-varying aspects of mental functioning leading up to involvement in an act of violence. These hypothesized domains are: (i) construal of intent and cause; (ii) normative reference points; and (iii) emotion recognition and regulation. We suggest that risk state for violence can be studied in a parsimonious and direct manner through systematic research on coded speech samples. The coding method for such an assessment procedure would be almost identical to existing structured clinical judgment instruments with the difference that variables be defined from a first-person point of view. Some implications of this approach for the tertiary prevention of violence in high-risk individuals are described. Published by Elsevier Ltd. C1 [Yang, Suzanne] Vet Affairs Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Yang, Suzanne; Mulvey, Edward P.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA. RP Yang, SZ (reprint author), VISN4 VA Pittsburgh Healthcare Syst, MIRECC, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM yangs@upmc.edu FU NIMH NIH HHS [T32 MH016804, T32 MH016804-30] NR 153 TC 4 Z9 5 U1 4 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-1789 EI 1873-6335 J9 AGGRESS VIOLENT BEH JI Aggress. Violent Behav. PD MAY-JUN PY 2012 VL 17 IS 3 BP 198 EP 207 DI 10.1016/j.avb.2012.02.001 PG 10 WC Criminology & Penology; Psychology, Multidisciplinary SC Criminology & Penology; Psychology GA 934ZU UT WOS:000303487400004 PM 23878518 ER PT J AU Bottonari, KA Tripathi, SP Fortney, JC Curran, G Rimland, D Rodriguez-Barradas, M Gifford, AL Pyne, JM AF Bottonari, Kathryn A. Tripathi, Shanti P. Fortney, John C. Curran, Geoff Rimland, David Rodriguez-Barradas, Maria Gifford, Allen L. Pyne, Jeffrey M. TI Correlates of Antiretroviral and Antidepressant Adherence Among Depressed HIV-Infected Patients SO AIDS PATIENT CARE AND STDS LA English DT Article ID NEUROPSYCHIATRIC INTERVIEW MINI; SELF-REPORTED ADHERENCE; MEDICATION ADHERENCE; COLLABORATIVE CARE; INHIBITOR THERAPY; VALIDITY; RECOMMENDATIONS; NONADHERENCE; RELIABILITY; SUPPRESSION AB Although crucial for efficacy of pharmacotherapy, adherence to prescribed medication regimens for both antiretrovirals and antidepressants is often suboptimal. As many depressed HIV-infected individuals are prescribed both antiretrovirals and antidepressants, it is important to know whether correlates of nonadherence are similar or different across type of regimen. The HIV Translating Initiatives for Depression into Effective Solutions (HI-TIDES) study was a single-blinded, longitudinal, randomized controlled effectiveness trial comparing collaborative care to usual depression care at three Veterans Affairs HIV clinics. The current investigation utilized self-report baseline interview and chart-abstracted data. Participants were 225 depressed HIV-infected patients who were prescribed an antidepressant (n = 146), an antiretroviral (n = 192), or both (n = 113). Treatment adherence over the last 4 days was dichotomized as "less than 90% adherence'' or "90% or greater adherence.'' After identifying potential correlates of nonadherence, we used a seemingly unrelated regression (SUR) bivariate probit model, in which the probability of adherence to HIV medications and the probability of adherence to antidepressant medications are modeled jointly. Results indicated that 75.5% (n = 146) of those prescribed antiretrovirals reported 90%-plus adherence to their antiretroviral prescription and 76.7% (n = 112) of those prescribed antidepressants reported 90%-plus adherence to their antidepressant prescription, while 67% of those prescribed both (n = 113) reported more than 90% adherence to both regimens. SUR results indicated that education, age, and HIV symptom severity were significant correlates of antiretroviral medication adherence while gender and generalized anxiety disorder diagnosis were significant correlates of adherence to antidepressant medications. In addition, antiretroviral adherence did not predict antidepressant adherence (beta = 1.62, p = 0.17), however, antidepressant adherence did predict antiretroviral adherence (beta = 2.30, p < 0.05). C1 [Bottonari, Kathryn A.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Tripathi, Shanti P.; Fortney, John C.; Curran, Geoff; Pyne, Jeffrey M.] Cent Arkansas Vet Healthcare Syst, N Little Rock, AR USA. [Tripathi, Shanti P.; Fortney, John C.; Curran, Geoff; Pyne, Jeffrey M.] Univ Arkansas Med Sci, Coll Med, UAMS Psychiat Res Inst, Div Hlth Serv Res, Little Rock, AR 72205 USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, Maria] VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA. [Gifford, Allen L.] Edith Nourse VA Med Ctr, HSRD Ctr Excellence, Ctr Hlth Qual Outcomes & Econ Res CHQOER, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Bottonari, KA (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM Kathryn.Bottonari@va.gov NR 45 TC 14 Z9 14 U1 4 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD MAY PY 2012 VL 26 IS 5 BP 265 EP 273 DI 10.1089/apc.2011.0218 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 934HU UT WOS:000303435800004 PM 22536930 ER PT J AU Verplaetse, TL Rasmussen, DD Froehlich, JC Czachowski, CL AF Verplaetse, Terril L. Rasmussen, Dennis D. Froehlich, Janice C. Czachowski, Cristine L. TI Effects of Prazosin, an alpha(1)-Adrenergic Receptor Antagonist, on the Seeking and Intake of Alcohol and Sucrose in Alcohol-Preferring (P) Rats SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Prazosin; Alcohol; P Rats; Sipper Tube; Noradrenergic ID CHRONIC DAILY ETHANOL; WITHDRAWAL; DEPENDENCE; ACAMPROSATE; ABSTINENCE; DISORDERS; DRINKING; BRAIN; LINES AB Background: Previous studies show that prazosin, an alpha 1-adrenergic receptor antagonist, decreases alcohol drinking in animal models of alcohol use and dependence [Rasmussen et similar to al. (2009) Alcohol Clin Exp Res 3:264272; Walker et similar to al. (2008) Alcohol 42:9197] and in alcohol-dependent men [Simpson et similar to al. (2009) Alcohol Clin Exp Res 33:255263]. This study extended these findings by using a paradigm that allows for separate assessment of prazosin on motivation to seek versus consume alcohol or sucrose in selectively bred rats. Methods: Alcohol-preferring (P) rats were trained to complete an operant response that resulted in access to either 2% sucrose or 10% alcohol. A 4-week Seeking Test Phase examined responding in single, weekly extinction sessions when no reinforcer could be obtained. A 4-week Drinking Test Phase consisted of rats lever-pressing to pay a specified amount up front to gain access to unlimited alcohol (or sucrose) for a 20-minute period. On Seeking and Drinking test days, prazosin (0.0, 0.5, 1.0, and 1.5 mg/kg) was administered intraperitoneally 30 minutes prior to behavioral sessions. Results: Rats were self-administering an average of 0.9 (+/-0.09) g/kg alcohol on vehicle test day and had pharmacologically relevant blood ethanol concentrations. Prazosin significantly decreased alcohol seeking at all doses tested. The highest dose of prazosin also increased the latency to first response for alcohol and decreased alcohol intake. While sucrose-seeking and intake were similarly affected by prazosin, the high dose of prazosin did not increase response latency. Conclusions: These findings are consistent with and extend previous research and suggest that prazosin decreases motivation to initiate and engage in alcohol consumption. The specificity of prazosin in attenuating the initiation of alcohol- but not sucrose-seeking suggests that this effect is not because of prazosin-induced motor-impairment or malaise. Together with previous findings, these data suggest that prazosin may be an effective pharmacotherapy, with specific application in people that drink excessively or have a genetic predisposition to alcohol abuse. C1 [Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA. [Rasmussen, Dennis D.] Univ Washington, Seattle, WA 98195 USA. [Froehlich, Janice C.] Indiana Univ, Dept Med, Indianapolis, IN USA. [Czachowski, Cristine L.] Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA. [Verplaetse, Terril L.; Czachowski, Cristine L.] Indiana Univ, Dept Psychol, Indianapolis, IN 46204 USA. RP Czachowski, CL (reprint author), Indiana Univ Sch Med, Inst Psychiat Res, 791 Union Dr, Indianapolis, IN 46202 USA. EM cczachow@iupui.edu FU National Institute on Alcohol Abuse and Alcoholism [R01AA018604, P60AA007611, R01AA016101]; Department of Veterans Affairs [P20AA017839] FX This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism R01AA018604 (JCF and DDR); P60AA007611 (JCF and CLC); R01AA016101 (CLC); Department of Veterans Affairs and P20AA017839 (DDR). NR 24 TC 18 Z9 18 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAY PY 2012 VL 36 IS 5 BP 881 EP 886 DI 10.1111/j.1530-0277.2011.01653.x PG 6 WC Substance Abuse SC Substance Abuse GA 933UJ UT WOS:000303388500016 PM 21981346 ER PT J AU Vagin, O Dada, LA Tokhtaeva, E Sachs, G AF Vagin, Olga Dada, Laura A. Tokhtaeva, Elmira Sachs, George TI The Na-K-ATPase alpha(1)beta(1) heterodimer as a cell adhesion molecule in epithelia SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Review DE Na-K-ATPase beta(1) subunit; epithelial junctions; trans-dimerization ID NA,K-ATPASE BETA-SUBUNIT; NECTIN-LIKE MOLECULES; TIGHT-JUNCTION; E-CADHERIN; GLYCOSYLATION AFFECTS; ADHERENS JUNCTIONS; CANCER PROGRESSION; FUNCTIONAL ROLES; ANKYRIN-BINDING; TRANSPORT AB Vagin O, Dada LA, Tokhtaeva E, Sachs G. The Na-K-ATPase alpha(1)beta(1) heterodimer as a cell adhesion molecule in epithelia. Am J Physiol Cell Physiol 302: C1271-C1281, 2012. First published January 25, 2012; doi:10.1152/ajpcell.00456.2011.-The ion gradients generated by the Na-K-ATPase play a critical role in epithelia by driving transepithelial transport of various solutes. The efficiency of this Na-K-ATPase-driven vectorial transport depends on the integrity of epithelial junctions that maintain polar distribution of membrane transporters, including the basolateral sodium pump, and restrict paracellular diffusion of solutes. The review summarizes the data showing that, in addition to pumping ions, the Na-K-ATPase located at the sites of cell-cell junction acts as a cell adhesion molecule by interacting with the Na-K-ATPase of the adjacent cell in the intercellular space accompanied by anchoring to the cytoskeleton in the cytoplasm. The review also discusses the experimental evidence on the importance of a specific amino acid region in the extracellular domain of the Na-K-ATPase beta(1) subunit for the Na-K-ATPase trans-dimerization and intercellular adhesion. Furthermore, a possible role of N-glycans linked to the Na-K-ATPase beta(1) subunit in regulation of epithelial junctions by modulating beta(1)-beta(1) interactions is discussed. C1 [Vagin, Olga; Tokhtaeva, Elmira; Sachs, George] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. [Vagin, Olga; Tokhtaeva, Elmira; Sachs, George] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Dada, Laura A.] Northwestern Univ, Div Pulm & Crit Care Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Vagin, O (reprint author), VAGLAHS W LA, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU National Institutes of Health [DK-077149, R37-HL-48129] FX The work was supported by National Institutes of Health Grants DK-077149 and R37-HL-48129. NR 91 TC 31 Z9 32 U1 2 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD MAY PY 2012 VL 302 IS 9 BP C1271 EP C1281 DI 10.1152/ajpcell.00456.2011 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 937MV UT WOS:000303663500002 PM 22277755 ER PT J AU Mullen, TD Obeid, LM AF Mullen, Thomas D. Obeid, Lina M. TI Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY LA English DT Article DE Apoptosis; Ceramide; Ceramide synthase; De novo sphingolipid synthesis; Programmed cell death; Salvage pathway; Serine palmitoyl transferase; Sphingomyelinase ID PROTEIN-KINASE-C; RADIATION-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; NECROSIS-FACTOR-ALPHA; HUMAN GLIOMA-CELLS; MAMMALIAN SERINE-PALMITOYLTRANSFERASE; CANNABINOID-INDUCED APOPTOSIS; INOSTAMYCIN-INDUCED APOPTOSIS; PERMEABILITY TRANSITION PORE; LONGEVITY ASSURANCE GENE-1 AB Programmed cell death, or apoptosis, is a complex process whereby eukaryotic cells react to physiologic or pathophysiologic stimuli by undergoing genetically programmed suicide. Programmed cell death involves many well-characterized signaling pathways including permeabilization of the mitochondrial outer membrane and activation of caspases. Other pathways, such as pro-apoptotic lipid signaling, are less understood despite many years of study. The sphingolipid ceramide has received considerable attention as a key regulator of programmed cell death, yet the mechanisms of its up-regulation and ability to control cell fate remain ill-defined. In this review, we will examine the connections between sphingolipid metabolism and programmed cell death with a focus on the role of de novo sphingolipid synthesis and sphingosine salvage in producing pro-apoptotic ceramide. We will also highlight the evidence supporting an increasingly complex role for ceramide in regulating apoptosis and provide a framework in which to ask new questions about the functions of this enigmatic lipid. C1 [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), 114 Doughty St,Room 603 STRB,MSC 779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU MUSC (NIH/NIEHS) [5T32ES012878]; NIH/NIEHS [1 F30 ES016975-01]; Office of Research and Development, Dept. of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC; NIH/NIGMS [R01 GM062887]; NIH/NIA [R01 AG016583]; NIH/NCCR [P20 RR17677] FX Support for this work was provided by MUSC Department of Pharmaceutical Sciences Training Program in Environmental Stress Signaling (NIH/NIEHS 5T32ES012878) and Ruth L. Kirschstein National Research Service Award (NIH/NIEHS 1 F30 ES016975-01) for T.D.M. Work was supported in part by a MERIT Award (to L.M.O.) by the Office of Research and Development, Dept. of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC. NIH/NIGMS R01 GM062887, NIH/NIA R01 AG016583, and NIH/NCCR P20 RR17677 (to L.M.O.). We also would like to thank Jillian Michaud-King for her assistance in editing this manuscript. NR 269 TC 53 Z9 54 U1 6 U2 28 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1871-5206 J9 ANTI-CANCER AGENT ME JI Anti-Cancer Agents Med. Chem. PD MAY PY 2012 VL 12 IS 4 BP 340 EP 363 PG 24 WC Oncology; Chemistry, Medicinal SC Oncology; Pharmacology & Pharmacy GA 936UA UT WOS:000303614300006 PM 21707511 ER PT J AU Gaffo, AL Schumacher, HR Saag, KG Taylor, WJ Dinnella, J Outman, R Chen, L Dalbeth, N Sivera, F Vazquez-Mellado, J Chou, CT Zeng, XJ Perez-Ruiz, F Kowalski, SC Goldenstein-Schainberg, C Chen, L Bardin, T Singh, JA AF Gaffo, Angelo L. Schumacher, H. Ralph Saag, Kenneth G. Taylor, William J. Dinnella, Janet Outman, Ryan Chen, Lang Dalbeth, Nicola Sivera, Francisca Vazquez-Mellado, Janitzia Chou, Chung-Tei Zeng, Xuejun Perez-Ruiz, Fernando Kowalski, Sergio C. Goldenstein-Schainberg, Claudia Chen, Lan Bardin, Thomas Singh, Jasvinder A. TI Developing a provisional definition of flare in patients with established gout SO ARTHRITIS AND RHEUMATISM LA English DT Article ID RHEUMATOLOGY 1990 CRITERIA; HEALTH-ASSESSMENT QUESTIONNAIRE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HENOCH-SCHONLEIN PURPURA; WEGENER GRANULOMATOSIS; PROSPECTIVE VALIDATION; POLYARTERITIS-NODOSA; PSORIATIC-ARTHRITIS; TAKAYASU ARTERITIS; DISEASE-ACTIVITY AB Objective Various nonvalidated criteria for disease flare have been used in studies of gout. Our objective was to develop empirical definitions for a gout flare from patient-reported features. Methods Possible elements for flare criteria were previously reported. Data were collected from 210 gout patients at 8 international sites to evaluate potential gout flare criteria against the gold standard of an expert rheumatologist definition. Flare definitions based on the presence of the number of criteria independently associated with the flare and classification and regression tree approaches were developed. Results The mean +/- SD age of the study participants was 56.2 +/- 15 years, 207 of them (98%) were men, and 54 of them (26%) had flares of gout. The presence of any patient-reported warm joint, any patient-reported swollen joint, patient-reported pain at rest score of >3 (010 scale), and patient-reported flare were independently associated with the study gold standard. The greatest discriminating power was noted for the presence of 3 or more of the above 4 criteria (sensitivity 91% and specificity 82%). Requiring all 4 criteria provided the highest specificity (96%) and positive predictive value (85%). A classification tree identified pain at rest with a score of >3, followed by patient self-reported flare, as the rule associated with the gold standard (sensitivity 83% and specificity 90%). Conclusion We propose definitions for a disease flare based on self-reported items in patients previously diagnosed as having gout. Patient-reported flare, joint pain at rest, warm joints, and swollen joints were most strongly associated with presence of a gout flare. These provisional definitions will next be validated in clinical trials. C1 [Gaffo, Angelo L.; Saag, Kenneth G.; Outman, Ryan; Chen, Lang; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Schumacher, H. Ralph] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Schumacher, H. Ralph; Dinnella, Janet] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Taylor, William J.] Univ Otago, Wellington, New Zealand. [Dalbeth, Nicola] Univ Auckland, Sch Med, Auckland, New Zealand. [Sivera, Francisca] Gen Hosp Univ Alicante, E-03080 Alicante, Spain. [Sivera, Francisca] Univ Miguel Hernandez, Alicante, Spain. [Vazquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Vazquez-Mellado, Janitzia] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico. [Chou, Chung-Tei] Vet Gen Hosp, Taipei, Taiwan. [Zeng, Xuejun] Beijing Union Med Coll Hosp, Beijing, Peoples R China. [Zeng, Xuejun] Chinese Acad Med Sci, Beijing, Peoples R China. [Perez-Ruiz, Fernando] Hosp Cruces, Baracaldo, Pais Vasco, Spain. [Kowalski, Sergio C.; Goldenstein-Schainberg, Claudia] Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil. [Chen, Lan] Penn Presbyterian Med Ctr, Philadelphia, PA USA. [Bardin, Thomas] Hop Lariboisiere, AP HP, F-75475 Paris, France. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com RI PEREZ-RUIZ, FERNANDO/E-4844-2012; , Ivan/D-6804-2012 OI , Ivan/0000-0002-3108-058X; singh, jasvinder/0000-0003-3485-0006; Perez-Ruiz, Fernando/0000-0002-5268-1894 FU American College of Rheumatology; European League Against Rheumatism; Novartis; Ardea Biosciences; Savient; Takeda; Menarini; Ipsen; Roche FX Supported in part by a grant from the American College of Rheumatology and the European League Against Rheumatism.; Dr. Saag has received consulting fees from Novartis, Ardea Biosciences, and Savient (less than $10,000 each) and has received research funding from Takeda. Dr. Perez-Ruiz has received consulting fees and/or speaking fees from Novartis, Ardea Biosciences, Menarini, and Savient (less than $10,000 each). Dr. Bardin has received consulting fees and/or speaking fees from Ipsen, Menarini, Novartis, Roche, and Ardea Biosciences (less than $10,000 each). NR 34 TC 19 Z9 20 U1 4 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAY PY 2012 VL 64 IS 5 BP 1508 EP 1517 DI 10.1002/art.33483 PG 10 WC Rheumatology SC Rheumatology GA 931SG UT WOS:000303239000027 PM 22083456 ER PT J AU Jarrett, RB Minhajuddin, A Borman, PD Dunlap, L Segal, ZV Kidner, CL Friedman, ES Thase, ME AF Jarrett, Robin B. Minhajuddin, Abu Borman, Patricia D. Dunlap, Lauren Segal, Zindel V. Kidner, Cindy L. Friedman, Edward S. Thase, Michael E. TI Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Depression; Cognitive therapy; Cognitive reactivity; Mood induction; Dysfunctional attitudes ID FOLLOW-UP; EMOTIONAL REACTIVITY; UNIPOLAR DEPRESSION; RATING-SCALE; SAD MOOD; DISORDERS; VALIDITY; VULNERABILITY; SYMPTOMS; ANXIETY AB Dysfunctional attitudes can foreshadow depressive relapse/recurrence. Priming mood, through induction paradigms, is hypothesized to activate dysfunctional attitudes. Cognitive reactivity (CR) refers to mood-linked increases in dysfunctional attitudes after priming. Here we explored the extent to which CR as well as residual, unprimed, dysfunctional attitudes predicted depressive relapse/recurrence among depressed patients who responded to acute phase cognitive therapy (CT). Consenting adults, aged 18-70, with recurrent major depressive disorder (n = 523) participated in a two-site randomized controlled trial examining the durability of continuation phase treatments. Patients received 16-20 sessions of CT. Among the 245 incompletely remitted responders, 213 agreed to undergo a mood induction paradigm. After 8 months of continuation phase treatments, participants were followed an additional 24 months. Although the mood induction significantly lowered mood in 80% of responders, the expected CR was not evident. By contrast, higher unprimed dysfunctional attitudes following CT did predict relapse/recurrence over 20 and 32 months post-randomization. The findings of this large longitudinal study of incompletely remitted CT responders challenge the notion that it is necessary to prime mood in order to maximize dysfunctional attitudes' prediction of relapse and/or recurrence. While findings cannot be generalized beyond CT responders, they emphasize the clinical importance of reducing dysfunctional attitudes in preventing depression. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Jarrett, Robin B.; Borman, Patricia D.; Dunlap, Lauren; Kidner, Cindy L.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Segal, Zindel V.] Univ Toronto, Dept Psychiat, Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada. [Friedman, Edward S.; Thase, Michael E.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Thase, Michael E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19102 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM Robin.Jarrett@UTSouthwestern.edu; Abu.Minhajuddin@UTSouthwestern.edu; TrishBormanPhD@gmail.com; Lauren.Dunlap@UTSouthwestern.edu; Zindel_Segal@camh.net; Cindy.Kidner@alumni.UTSouthwestern.edu; Friedmane@upmc.edu; Thase@mail.med.upenn.edu RI Segal, Zindel/F-8008-2014 FU NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [UL1 RR024153]; NIMH NIH HHS [K24 MH001571, K24 MH001571-10, R01 MH058356, R01 MH058356-11, R01 MH058397, R01 MH058397-11, R01 MH069618, R01 MH069618-04, R01 MH069619, R01 MH069619-05] NR 53 TC 21 Z9 21 U1 6 U2 36 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 J9 BEHAV RES THER JI Behav. Res. Ther. PD MAY PY 2012 VL 50 IS 5 BP 280 EP 286 DI 10.1016/j.brat.2012.01.008 PG 7 WC Psychology, Clinical SC Psychology GA 937CS UT WOS:000303637200002 PM 22445946 ER PT J AU Jahshan, C Wynn, JK Mathis, KI Altshuler, LL Glahn, DC Green, MF AF Jahshan, Carol Wynn, Jonathan K. Mathis, Kristopher I. Altshuler, Lori L. Glahn, David C. Green, Michael F. TI Cross-diagnostic comparison of duration mismatch negativity and P3a in bipolar disorder and schizophrenia SO BIPOLAR DISORDERS LA English DT Article DE auditory processing; bipolar disorder; mismatch negativity; P3a; schizophrenia ID EVENT-RELATED POTENTIALS; AUDITORY SENSORY MEMORY; ELECTROPHYSIOLOGICAL INDEXES; SPECTRUM DISORDERS; DEVIANCE DETECTION; NMDA ANTAGONIST; MESSENGER-RNA; TEMPORAL-LOBE; RATING-SCALE; DEFICITS AB Jahshan C, Wynn JK, Mathis KI, Altshuler LL, Glahn DC, Green MF. Cross-diagnostic comparison of duration mismatch negativity and P3a in bipolar disorder and schizophrenia. ?Bipolar Disord 2012: 14: 239248. (C) 2012 The Authors. Journal compilation (C) 2012 John Wiley & Sons A/S. Objectives: Bipolar disorder and schizophrenia share common pathophysiological processes and may have similar perceptual abnormalities. Mismatch negativity (MMN) and P3a event-related potentials associated with auditory preattentional processing have been extensively studied in schizophrenia, but rarely in bipolar disorder. Furthermore, MMN and P3a have not been examined between diagnostic subgroups of patients with bipolar disorder. We evaluated MMN and P3a in patients with bipolar disorder compared to patients with schizophrenia and healthy controls. Methods: MMN and P3a were assessed in 52 bipolar disorder patients, 30 schizophrenia patients, and 27 healthy control subjects during a duration-deviant auditory oddball paradigm. Results: Significant MMN and P3a amplitude reductions were present in patients with bipolar disorder and schizophrenia relative to controls. The MMN reduction was more prominent in patients with schizophrenia than bipolar disorder, at a trend level. P3a did not differ significantly between patient groups. There were no MMN or P3a differences between patients with bipolar I (n = 34) and bipolar II (n = 18) disorder. Patients with bipolar I disorder failed to show lateralized MMN, in contrast to the other groups. No MMN or P3a differences were found between patients with bipolar disorder taking (n = 12) and not taking (n = 40) lithium, as well as between those taking (n = 30) and not taking (n = 22) antipsychotic medications. Conclusions: Patients with bipolar disorder showed deficits in preattentive auditory processing, including MMN deficits that are less severe and P3a deficits that are slightly more pronounced, than those seen in schizophrenia. C1 [Jahshan, Carol; Wynn, Jonathan K.; Mathis, Kristopher I.; Altshuler, Lori L.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Los Angeles, CA 90073 USA. [Wynn, Jonathan K.; Altshuler, Lori L.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Glahn, David C.] Yale Univ, Sch Med, Olin Neuropsychiat Res Ctr, Inst Living, New Haven, CT USA. [Glahn, David C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Jahshan, C (reprint author), VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Bldg 210,Room 106,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM caroljahshan@hotmail.com RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU National Institute of Mental Health [MH089634] FX This work was supported by a grant from the National Institute of Mental Health (MH089634 to MFG). The authors wish to thank Crystal Gibson, Cory Tripp, Katie Weiner, Mark McGee, Christen Waldon, and Amanda Bender for their assistance with recruitment and testing. NR 67 TC 27 Z9 27 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD MAY PY 2012 VL 14 IS 3 BP 239 EP 248 DI 10.1111/j.1399-5618.2012.01008.x PG 10 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 934IO UT WOS:000303438000003 PM 22548897 ER PT J AU Greenstein, RJ Cameron, DW Brown, ST AF Greenstein, Robert J. Cameron, D. William Brown, Sheldon T. TI On the zoonosis of M. avium subspecies paratuberculosis (MAP) SO JOURNAL OF CROHNS & COLITIS LA English DT Letter ID CROHNS-DISEASE C1 [Greenstein, Robert J.] James J Peters VAMC, Dept Surg, Bronx, NY USA. [Cameron, D. William] Ottawa Hosp, Res Inst, Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada. RP Greenstein, RJ (reprint author), James J Peters VAMC, Dept Surg, Bronx, NY USA. EM BGAxis@aol.com OI Cameron, Bill/0000-0002-0090-3539 NR 6 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1873-9946 J9 J CROHNS COLITIS JI J. Crohns Colitis PD MAY PY 2012 VL 6 IS 4 BP 504 EP 504 DI 10.1016/j.crohns.2012.01.006 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 937DM UT WOS:000303639200016 PM 22398086 ER PT J AU Raitt, MH Kusumoto, W AF Raitt, Merritt H. Kusumoto, Walter TI Correlations among the frequencies of atrial activity on the surface electrocardiogram, intracardiac atrial electrograms, and the atrial effective refractory period in patients with atrial fibrillation SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article ID CYCLE LENGTH; PROCAINAMIDE; TERMINATION; IBUTILIDE AB Background: The frequency of surface atrial electrocardiogram (ECG) depolarization has been postulated to reflect the atrial effective refractory period (AERP). Methods: Frequency analysis of surface ECGs after QRST subtraction and of electrograms from 4 right atrium and 4 coronary sinus electrode pairs was performed in 38 patients in atrial fibrillation. The AERP was measured in the right atrium and coronary sinus 10 minutes after cardioversion. Results: The correlation between the dominant frequencies of intracardiac electrograms and atrial activity in leads I, II, and V-1 were 0.89, 0.85, and 0.88, respectively (all P < .001). The correlation between the average AERP and the frequency of atrial activity in the surface leads was 0.50, 0.45, and 0.47 (all P < .005). Conclusion: In atrial fibrillation, the frequency of atrial depolarization measured from the surface ECG is highly correlated with intracardiac atrial frequency. However, the correlation between the frequency of surface atrial activity and atrial refractoriness, although significant, is not strong. Published by Elsevier Inc. C1 [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR 97239 USA. [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kusumoto, Walter] Arrhythmia Ctr No Calif, Chico, CA USA. RP Raitt, MH (reprint author), Portland VA Med Ctr, P-3 CARD, Portland, OR 97239 USA. EM merritt.raitt@va.gov FU Department of Veterans Affairs FX Supported by the Department of Veterans Affairs Merit Review Entry Program. NR 16 TC 1 Z9 1 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD MAY-JUN PY 2012 VL 45 IS 3 BP 296 EP 303 DI 10.1016/j.jlectrocard.2011.12.006 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 935VF UT WOS:000303549600025 PM 22280798 ER PT J AU Strehlow, AJ Robertson, MJ Zerger, S Rongey, C Arangua, L Farrell, E O'Sullivan, A Gelberg, L AF Strehlow, Aaron J. Robertson, Marjorie J. Zerger, Suzanne Rongey, Catherine Arangua, Lisa Farrell, Ed O'Sullivan, Adele Gelberg, Lillian TI Hepatitis C among Clients of Health Care for the Homeless Primary Care Clinics SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Homeless; hepatitis C; Health Care for the Homeless; tattoos; injection drug use; prison; risk factors; primary care clinics; blood borne disease; infectious disease; sexual risk ID VIRUS-INFECTION; UNITED-STATES; SAN-FRANCISCO; PREVALENCE; MANAGEMENT; RISK; POPULATION; PRISONS; ADULTS; SEROPREVALENCE AB Objectives. To describe the prevalence, distribution and risk factors for hepatitis C virus (HCV) infection among homeless adults using eight Health Care for the Homeless (HCH) clinics nationally. Methods. Data were collected for 387 participants through blood draws, structured interviews, chart reviews. Results. Overall prevalence of HCV-antibody positivity was 31.0%, including 70.0% among injection drug users and 15.5% among reported non-injectors. Much HCV infection was hidden as the majority (53.3%) of HCV-antibody positive participants was unaware of their status. Independent risk factors for HCV among the total sample included injection drug use, prison, and tattoos; among injectors, risk factors included prison and three or more years of injection drug use; among reported non-injectors, risk factors included tattoos and prison. Conclusion. These HCH clinics serve high concentrations of HCV-infected injectors, making these and similar clinics priority intervention sites for aggressive screening, education, testing, and treatment for HCV and other blood-borne diseases. C1 [Rongey, Catherine] San Francisco VA Med Ctr, San Francisco, CA USA. [Rongey, Catherine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Arangua, Lisa] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Farrell, Ed] Clin Family Hlth Serv, Thornton, CO USA. [O'Sullivan, Adele] Circle City, Phoenix, AZ USA. [Gelberg, Lillian] UCLA David Geffen Sch Med, Los Angeles, CA USA. RP Strehlow, AJ (reprint author), 1228 N La Cienega Blvd 102, W Hollywood, CA 90069 USA. EM astrehlo@ucla.edu FU NIDA NIH HHS [R01-DA14294,, R01 DA014294] NR 45 TC 14 Z9 14 U1 0 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD MAY PY 2012 VL 23 IS 2 BP 811 EP 833 PG 23 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 934EY UT WOS:000303427600027 PM 22643626 ER PT J AU Viola, GM Awan, LL Ostrosky-Zeichner, L Chan, WY Darouiche, RO AF Viola, George M. Awan, Leah L. Ostrosky-Zeichner, Luis Chan, Wenyaw Darouiche, Rabih O. TI Infections of Cardiac Implantable Electronic Devices A Retrospective Multicenter Observational Study SO MEDICINE LA English DT Article ID CARDIOVERTER-DEFIBRILLATORS; RISK-FACTORS; PERMANENT PACEMAKER; CONSECUTIVE PATIENTS; UNITED-STATES; MANAGEMENT; ENDOCARDITIS; DIAGNOSIS; RATES; BACTEREMIA AB Infections of cardiac implantable electronic devices (CIED) can cause significant morbidity, mortality, and financial burden. Although staphylococcal organisms account for most infections of these cardiac devices, approximately 20% of all CIED-related infections are caused by non-Staphylococcus species. Herein we describe and compare the demographics, clinical presentation, and outcomes of Staphylococcus aureus and non-staphylococcal infections of CIED. We performed a retrospective, multicenter, observational study of patients from 4 academic hospitals in Houston between 2002 and 2009. All 80 identified non-staphylococcal CIED-related infections were matched, at a 1:1 ratio, to S. aureus infections. Although the demographics and general comorbidities in the 2 study groups were relatively similar, the S. aureus group had a higher proportion of patients with coronary artery disease, diabetes mellitus, and end-stage renal disease. Additionally, 81% of S. aureus compared with only 48.5% of the non-staphylococcal CIED-related infections were health care-associated (p < 0.001). Furthermore, when compared to non-staphylococcal infections, the S. aureus group had more indwelling intravascular foreign material (p < 0.001), more rapid clinical progression (p < 0.001), and overall worse clinical presentation (p < 0.001). However, after stratifying by clinical presentation, the mortality rates in the 2 groups were similar (p = 0.45). Since approximately one-fifth of all CIED-related infections are caused by non-staphylococcal organisms, and untimely antibiotic treatment can result in serious complications, it may be prudent to broaden empiric antimicrobial therapy to cover both Gram-positive and -negative bacteria, until the causative organism is identified. C1 [Viola, George M.] Univ Texas MD Anderson Canc Ctr, Dept Internal Med, Div Infect Dis, Houston, TX 77030 USA. [Viola, George M.; Awan, Leah L.; Darouiche, Rabih O.] Univ Texas MD Anderson Canc Ctr, Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Ostrosky-Zeichner, Luis] Univ Texas Houston, Sch Med, Houston, TX USA. [Darouiche, Rabih O.] Univ Texas Hlth Sci Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Chan, Wenyaw] Univ Texas Hlth Ctr, Div Biostat, Houston, TX USA. RP Viola, GM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Internal Med, Div Infect Dis, 1515 Holcombe Blvd,Unit 1460, Houston, TX 77030 USA. EM GMViola@mdanderson.org FU Michael E. DeBakey Veterans Affairs Medical Center; Methodist Hospital; Memorial Hermann Hospital, at Houston, Texas; St. Luke's Episcopal Hospital FX We are thankful for the support provided by the Michael E. DeBakey Veterans Affairs Medical Center, St. Luke's Episcopal Hospital, the Methodist Hospital, and the Memorial Hermann Hospital, at Houston, Texas. NR 32 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7974 J9 MEDICINE JI Medicine (Baltimore) PD MAY PY 2012 VL 91 IS 3 BP 123 EP 130 DI 10.1097/MD.0b013e31825592a7 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 936QK UT WOS:000303604900001 PM 22543626 ER PT J AU Vesco, KK Marshall, LM Nelson, HD Humphrey, L Rizzo, J Pedula, KL Cauley, JA Ensrud, KE Hochberg, MC Antoniucci, D Hillier, TA AF Vesco, Kimberly K. Marshall, Lynn M. Nelson, Heidi D. Humphrey, Linda Rizzo, Joanne Pedula, Kathryn L. Cauley, Jane A. Ensrud, Kristine E. Hochberg, Marc C. Antoniucci, Diana Hillier, Teresa A. CA Study Osteoporotic Fractures TI Surgical menopause and nonvertebral fracture risk among older US women SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Database search terms; Menopause; Fracture; Oophorectomy ID BONE-MINERAL DENSITY; SERVICES TASK-FORCE; RECOMMENDATION STATEMENT; BILATERAL OOPHORECTOMY; OSTEOPOROTIC FRACTURES; PREMATURE MENOPAUSE; HORMONE-THERAPY; UNITED-STATES; HIP FRACTURE; HYSTERECTOMY AB Objective: The aim of this study was to determine whether older postmenopausal women with a history of bilateral oophorectomy before natural menopause (surgical menopause) have a higher risk of nonvertebral postmenopausal fracture than women with natural menopause. Methods: We used 21 years of prospectively collected incident fracture data from the ongoing Study of Osteoporotic Fractures, a cohort study of community-dwelling women without previous bilateral hip fracture who were 65 years or older at enrollment, to determine the risk of hip, wrist, and any nonvertebral fracture. X-2 and t tests were used to compare the two groups on important characteristics. Multivariable Cox proportional hazards regression models stratified by baseline oral estrogen use status were used to estimate the risk of fracture. Results: Baseline characteristics differed significantly among the 6,616 women within the Study of Osteoporotic Fractures who underwent either surgical (1,157) or natural (5,459) menopause, including mean age at menopause (44.3 +/- 7.4 vs 48.9 +/- 4.9 y, P < 0.001) and current use of oral estrogen (30.2% vs 6.5%, P < 0.001). Fracture rates were not significantly increased for surgical versus natural menopause, even among women who had never used oral estrogen (hip fracture: hazard ratio [HR], 0.87; 95% CI, 0.63-1.21; wrist fracture: HR, 1.10; 95% CI, 0.78-1.57; any nonvertebral fracture: HR, 1.11; 95% CI, 0.93-1.32). Conclusions: These data provide some reassurance that the long-term risk of nonvertebral fracture is not substantially increased for postmenopausal women who experienced premenopausal bilateral oophorectomy, compared with postmenopausal women with intact ovaries, even in the absence of postmenopausal estrogen therapy. C1 [Vesco, Kimberly K.] Kaiser Permanente NW, Ctr Hlth Res, Sci Programs Dept, Portland, OR 97227 USA. [Vesco, Kimberly K.; Humphrey, Linda] Portland VA Med Ctr, Portland, OR USA. [Marshall, Lynn M.; Humphrey, Linda] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Nelson, Heidi D.; Humphrey, Linda] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA. [Nelson, Heidi D.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Nelson, Heidi D.] Providence Hlth & Serv, Women & Childrens Hlth Res Ctr, Portland, OR USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. [Hochberg, Marc C.] Univ Maryland, Dept Med, Baltimore, MD 21201 USA. [Hochberg, Marc C.] Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Antoniucci, Diana] Univ Calif San Francisco, Dept Med, Endocrine Res Unit, San Francisco Dept Vet Affairs Med Ctr, San Francisco, CA USA. RP Vesco, KK (reprint author), Kaiser Permanente NW, Ctr Hlth Res, Sci Programs Dept, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Kimberly.k.vesco@kpchr.org OI Cauley, Jane A/0000-0003-0752-4408 FU NIA NIH HHS [R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1, R01 AG005394, R01 AG005407, R01 AG027574, R01 AG027574-27, R01 AG027576]; NIAMS NIH HHS [AR35582, AR35583, AR35584, R01 AR035582, R01 AR035583, R01 AR035584] NR 32 TC 11 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD MAY PY 2012 VL 19 IS 5 BP 510 EP 516 DI 10.1097/gme.0b013e318239caeb PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 934AN UT WOS:000303411200007 PM 22547252 ER PT J AU Gleason, CE Dowling, NM Friedman, E Wharton, W Asthana, S AF Gleason, Carey E. Dowling, N. Maritza Friedman, Elliot Wharton, Whitney Asthana, Sanjay TI Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy? SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Hormone therapy; Healthy user; Cognition; Menopause; Selection bias; Executive functioning ID ESTROGEN REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; CONJUGATED EQUINE ESTROGENS; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; INITIATIVE MEMORY; PLUS PROGESTIN; ALZHEIMER-DISEASE; DETERMINANTS; RISK AB Objective: This study investigated the phenomenon known as the healthy user bias by equating hormone therapy (HT) use (past or current) with healthy user status. Methods: Data from the Survey of Midlife in the United States were used to identify the predictors of HT use. The unique Survey of Midlife in the United States data include psychological, demographic, health-related, and behavioral variables as well as history of HT use. Predictors of HT use were combined to derive propensity scores, describing the likelihood that a woman was an HT user, based on her psychological, demographic, physical, and behavioral profile (ie, likelihood of being a healthy user) as opposed to her actual use of HT. Finally, cognitive performance on an executive function test was examined in women stratified by propensity score. Results: Using a multiple logistic regression model, nine variables emerged as predictors of HT use. The nine variables were used to estimate the propensity or conditional probability of using HT for each subject; resultant propensity scores were ranked and divided into tertiles. Women in the highest tertile demonstrated shorter median response latencies on a test of executive function than did women who did not use HT. Conclusions: From an array of psychological, medical, and behavioral variables, nine emerged as predictors of HT use. If validated, these features may serve as a means of estimating the phenomenon known as healthy user bias. Moreover, these data suggest that the degree to which a woman fits a model of a healthy user may influence cognitive response to HT. C1 [Gleason, Carey E.; Wharton, Whitney; Asthana, Sanjay] Univ Wisconsin, Dept Med, Div Geriatr & Gerontol, Sch Med & Publ Hlth, Madison, WI USA. [Gleason, Carey E.; Wharton, Whitney; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Gleason, Carey E.; Dowling, N. Maritza; Wharton, Whitney; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Friedman, Elliot] Univ Wisconsin, Inst Aging, Madison, WI USA. RP Gleason, CE (reprint author), Madison VA GRECC D4211, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU National Institutes of Health [K23 AG024302, P50 AG033514] FX This research was supported by funding from the National Institutes of Health (K23 AG024302; P50 AG033514). NR 45 TC 5 Z9 5 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD MAY PY 2012 VL 19 IS 5 BP 524 EP 533 DI 10.1097/gme.0b013e318238ff2c PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 934AN UT WOS:000303411200009 PM 22207317 ER PT J AU Sharma, A Mendez, E Yueh, B Lohavanichbutr, P Houck, J Doody, DR Futran, ND Upton, MP Schwartz, SM Chen, C AF Sharma, Arun Mendez, Eduardo Yueh, Bevan Lohavanichbutr, Pawadee Houck, John Doody, David R. Futran, Neal D. Upton, Melissa P. Schwartz, Stephen M. Chen, Chu TI Human Papillomavirus-Positive Oral Cavity and Oropharyngeal Cancer Patients Do Not Have Better Quality-of-Life Trajectories SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT AAO-HNSF Annual Meeting and OTO EXPO CY SEP 10-14, 2011 CL San Francisco, CA SP AAO, HNSF DE head and neck cancer; quality of life; epidemiology/outcomes research; head and neck surgery; human papillomavirus; oropharyngeal squamous cell carcinoma ID NECK-CANCER; HEAD; SURVIVAL; TRENDS; RACE AB Objective. To determine the role of human papillomavirus (HPV) status on quality of life (QOL) in patients with oral cavity and oropharyngeal squamous cell carcinoma (OSCC). Since OSCC that are associated with high-risk HPV have an improved response to treatment and survival, we hypothesized that patients with these tumors would have better QOL trajectories. Study Design. Prospective cohort study. Setting. Tertiary care academic medical center and 2 affiliated hospitals. Subjects and Methods. Head and neck-specific QOL was determined using the University of Washington Quality of Life scale version 4 in patients with newly diagnosed invasive OSSC (N = 228). Results. Pretreatment QOL was higher in patients with high-risk HPV-associated tumors compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .015). Patients with high-risk HPV-associated tumors had larger decreases in QOL from pretreatment to immediate post-treatment compared with patients with HPV-negative or low-risk HPV-associated tumors (P = .041). There was no association between HPV status and 1-year posttreatment QOL. Conclusion. Among OSCC patients, high-risk HPV-associated tumors were associated with higher pretreatment QOL and a larger decrease in QOL from pretreatment to immediate posttreatment, suggesting that treatment intensity in this unique population may adversely affect QOL. C1 [Lohavanichbutr, Pawadee; Houck, John; Doody, David R.; Schwartz, Stephen M.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98109 USA. [Sharma, Arun; Mendez, Eduardo; Futran, Neal D.; Chen, Chu] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Upton, Melissa P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Schwartz, Stephen M.; Chen, Chu] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Chen, C (reprint author), Fred Hutchinson Canc Res Ctr, Program Epidemiol, 1100 Fairview Ave N,Mailstop M5-C-800, Seattle, WA 98109 USA. EM cchen@fhcrc.org OI Yueh, Bevan/0000-0003-1380-1053; Schwartz, Stephen/0000-0001-7499-8502 FU NCI NIH HHS [R01 CA095419, R01CA095419]; NCRR NIH HHS [1K1L2RR025015-01, KL2 RR025015, KL2 RR025015-01] NR 16 TC 24 Z9 24 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD MAY PY 2012 VL 146 IS 5 BP 739 EP 745 DI 10.1177/0194599811434707 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 935YY UT WOS:000303559300012 PM 22275190 ER PT J AU Hudkins, M O'Neill, J Tobias, MC Bartzokis, G London, ED AF Hudkins, Matthew O'Neill, Joseph Tobias, Marc C. Bartzokis, George London, Edythe D. TI Cigarette smoking and white matter microstructure SO PSYCHOPHARMACOLOGY LA English DT Article DE White matter; Diffusion tensor imaging; Nicotine dependence; Magnetic resonance imaging; Fractional anisotropy; Tobacco ID NICOTINIC ACETYLCHOLINE-RECEPTORS; CEREBRAL-BLOOD-FLOW; HUMAN BRAIN; FRACTIONAL ANISOTROPY; ALZHEIMERS-DISEASE; DIFFUSION; SMOKERS; INTEGRITY; DEPENDENCE; EXPOSURE AB Diffusion tensor imaging has been used before in testing associations between cigarette smoking and white matter integrity, with inconsistent results. Published reports indicate higher fractional anisotropy (FA, a measure of linear water diffusion) in some brain regions and lower FA in others in adult smokers compared to nonsmokers. Adolescent smokers exhibited elevated FA at several brain regions and a positive correlation of FA in the genu corpus callosum with exposure to smoking (pack-years). To help resolve prior discrepancies, we studied adults, sampling multiple brain regions, and testing for relationships to clinical features of nicotine dependence and exposure to smoking. Brain MRI scans (1.5 T) were acquired, and FA and apparent diffusion coefficient (ADC, a measure of random diffusion) were assayed in corpus callosum and prefrontal white matter, corona radiata, internal capsule, cingulum bundle, and hippocampal perforant fibers in 18 smokers (33.7 +/- 7.9 years of age) and 18 age- and gender-matched nonsmokers. ADC showed no group difference, but smokers had higher (4.3-21.1%) FA than nonsmokers. The differences were significant in right prefrontal white matter, cingulum, and genu corpus callosum. FA in several regions was negatively correlated with nicotine dependence or cigarettes/day. Combined with earlier findings, these results suggest a model of changing trajectories whereby FA is higher with tobacco exposure during adolescence and declines with continued smoking in adulthood. This notion is supported by the observation that, at multiple sampling sites, participants who had started smoking earlier in life had higher FA than those who had started later. C1 [Hudkins, Matthew; O'Neill, Joseph] UCLA Semel Inst Neurosci & Biobehav Studies, Div Child & Adolescent Psychiat, Los Angeles, CA 90024 USA. [Tobias, Marc C.; London, Edythe D.] UCLA Semel Inst Neurosci & Biobehav Studies, Lab Mol Neuroimaging, Los Angeles, CA 90024 USA. [Bartzokis, George; London, Edythe D.] UCLA Brain Res Inst, Los Angeles, CA USA. [Bartzokis, George] Univ Calif Los Angeles, Dept Neurol, Div Brain Mapping, Lab Neuroimaging, Los Angeles, CA 90024 USA. [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [London, Edythe D.] UCLA Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP O'Neill, J (reprint author), UCLA Semel Inst Neurosci & Biobehav Studies, Div Child & Adolescent Psychiat, 760 Westwood Plaza,58-227A, Los Angeles, CA 90024 USA. EM joneill@mednet.ucla.edu RI Bartzokis, George/K-2409-2013 FU National Institutes of Health [P20DA022539, R01DA020726, R03DA20512, R21DA023192, MOIRR00865]; Katherine K. and Thomas P. Pike Chair in Addiction Studies; Marjorie Green Family Trust; UCLA [20063287]; Philip Morris USA FX This work was supported by grants from the National Institutes of Health [P20DA022539, R01DA020726-EDL; R03DA20512, R21DA023192 -JON; and MOIRR00865 (UCLA General Clinical Research Center)]. Additional funding was provided by endowments from the Katherine K. and Thomas P. Pike Chair in Addiction Studies and the Marjorie Green Family Trust (EDL). Research support for projects other than the one reported here was supplied to Dr. Edythe London under UCLA contract (number 20063287) with Philip Morris USA. NR 50 TC 29 Z9 30 U1 3 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD MAY PY 2012 VL 221 IS 2 BP 285 EP 295 DI 10.1007/s00213-011-2621-9 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 934PT UT WOS:000303457600010 PM 22215225 ER PT J AU Passon, N Puppin, C Lavarone, E Bregant, E Franzoni, A Hershman, JM Fenton, MS D'Agostino, M Durante, C Russo, D Filetti, S Damante, G AF Passon, Nadia Puppin, Cinzia Lavarone, Elisa Bregant, Elisa Franzoni, Alessandra Hershman, Jerome M. Fenton, Mike S. D'Agostino, Maria Durante, Cosimo Russo, Diego Filetti, Sebastiano Damante, Giuseppe TI Cyclic AMP-Response Element Modulator Inhibits the Promoter Activity of the Sodium Iodide Symporter Gene in Thyroid Cancer Cells SO THYROID LA English DT Article ID SODIUM/IODIDE SYMPORTER; TRANSCRIPTIONAL REPRESSION; UPSTREAM ENHANCER; EXPRESSION; BINDING; PROTEIN; DOMAIN; PAX-8; IDENTIFICATION; CARCINOMA AB Background: Comprehension of the regulatory mechanism involved in the sodium iodide symporter (NIS) expression is of great relevance for thyroid cancer. In fact, restoration of NIS expression would be a strategy to treat undifferentiated thyroid cancer. Previous in vitro findings suggest that the cyclic AMP-response element (CRE) modulator (CREM) is involved in control of NIS expression. In this work, we examined the expression of CREM in a series of thyroid cancer tissues and its action on NIS promoter in human thyroid cancer cells. Methods: Expression of mRNA levels for CREM, PAX8 and NIS was measured by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in 6 normal thyroid tissues, 22 papillary, 12 follicular and 4 anaplastic thyroid cancers. The effect of CREM on transcriptional activity of the NIS promoter was investigated by transient transfection of human thyroid cell lines. Results: Compared to normal tissues, NIS and PAX8 mRNA levels were significantly reduced in all types of thyroid cancer. As expected, the maximal decrease was detected in anaplastic thyroid cancer. Conversely, CREM mRNA levels were increased in all types of thyroid cancer, reaching statistical significance for follicular and anaplastic thyroid carcinoma (p = 0.0157 and 0.0045, respectively). Transfection experiments showed an inhibitory effect of CREM on NIS promoter activity in various thyroid cancer cell lines. Conclusions: These data demonstrate that CREM expression is increased in thyroid cancer tissue and may play a role in the downregulation of NIS expression in thyroid cancer acting at the transcriptional level. C1 [Durante, Cosimo; Filetti, Sebastiano] Univ Roma La Sapienza, Dipartimento Med Interna & Specialita Med, I-00161 Rome, Italy. [Passon, Nadia; Puppin, Cinzia; Lavarone, Elisa; Bregant, Elisa; Damante, Giuseppe] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy. [Franzoni, Alessandra; Damante, Giuseppe] St Mary Mercy Univ Hosp, Inst Med Genet, Udine, Italy. [Hershman, Jerome M.; Fenton, Mike S.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [D'Agostino, Maria] Univ Catanzaro, Dept Pharmacobiol Sci, Catanzaro, Italy. RP Filetti, S (reprint author), Univ Roma La Sapienza, Dipartimento Med Interna & Specialita Med, Piazzale Aldo Moro 5, I-00161 Rome, Italy. EM sebastiano.filetti@uniroma1.it RI Lavarone, Elisa/I-4853-2012 FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 10296]; MIUR [20093WAPIK_003]; American Thyroid Association; Umberto Di Mario Foundation; Banca d'Italia FX This work was supported by grants to G.D. from Associazione Italiana per la Ricerca sul Cancro (AIRC) (No. IG 10296) and MIUR (PRIN No. 20093WAPIK_003), to M. F. from the American Thyroid Association, and to S. F. from The Umberto Di Mario Foundation and from the Banca d'Italia. NR 37 TC 1 Z9 2 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD MAY PY 2012 VL 22 IS 5 BP 487 EP 493 DI 10.1089/thy.2011.0360 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 935UI UT WOS:000303546500007 PM 22510021 ER PT J AU Ramsey, SD Zeliadt, SB Blough, DK Fedorenko, CR Fairweather, ME McDermott, CL Penson, DF Van Den Eeden, SK Hamilton, AS Arora, NK AF Ramsey, Scott D. Zeliadt, Steven B. Blough, David K. Fedorenko, Catherine R. Fairweather, Megan E. McDermott, Cara L. Penson, David F. Van Den Eeden, Stephen K. Hamilton, Ann S. Arora, Neeraj K. TI Complementary and Alternative Medicine Use, Patient-reported Outcomes, and Treatment Satisfaction Among Men With Localized Prostate Cancer SO UROLOGY LA English DT Article ID QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; PREVALENCE; THERAPY; CAPSURE; BOTHER AB OBJECTIVE To evaluate the association between complementary and alternative medicine (CAM) use, satisfaction with treatment, and patient-reported outcomes after treatment. METHODS The Prostate CAncer Therapy Selection Study prospectively surveyed patients newly diagnosed with localized prostate cancer about their treatment decision-making process and outcomes. The Prostate CAncer Therapy Selection Study recruited patients from 3 geographic areas through hospital-based urology clinics and community urology practices. RESULTS More than 700 patients completed the baseline and follow-up surveys. More than 50% of respondents reported using CAM; this decreased to 39% if prayer was excluded as a type of CAM. On multivariate analysis, factors related to communication with the treating physician, but not CAM use, were associated with treatment satisfaction. The likelihood of stability or improvement in urinary, bowel, and sexual function at 6 months was related to the choice of primary therapy but was unrelated to CAM use. CONCLUSION In the present prospective observational study, CAM use was highly prevalent but unrelated to treatment satisfaction or changes in functional status. The effect of CAM on these endpoints remains to be established in comparative effectiveness studies. UROLOGY 79: 1034-1041, 2012. (C) 2012 Elsevier Inc. All rights reserved. C1 [Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Sch Pharm, Seattle, WA 98195 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Kaiser Permanente No Calif, Div Res, Oakland, CA USA. Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. Natl Canc Inst, Div Canc Control & Populat Sci, Bethesda, MD USA. RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-B232, Seattle, WA 98109 USA. EM sramsey@fhcrc.org FU National Cancer Institute [HHSN261200900582P, N01-PC-35142, N01-PC-35139, N01-PC-35136]; Cancer Surveillance System of the Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; State of Washington FX This publication was supported by the National Cancer Institute (grants HHSN261200900582P, N01-PC-35142, N01-PC-35139, and N01-PC-35136) and by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, funded by contract N01-PC-35142 from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington. NR 28 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD MAY PY 2012 VL 79 IS 5 BP 1034 EP 1041 DI 10.1016/j.urology.2012.01.023 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 934TW UT WOS:000303470600022 PM 22546381 ER PT J AU Davies, LE Schoch, PH AF Davies, Loren E. Schoch, Patricia H. TI Retrospective Review of PeriProcedures in Warfarin Patients At the Denver Va Medical Center (DVAMC) SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Davies, Loren E.; Schoch, Patricia H.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0361-8609 J9 AM J HEMATOL JI Am. J. Hematol. PD MAY PY 2012 VL 87 SU 1 BP S153 EP S153 PG 1 WC Hematology SC Hematology GA 928RB UT WOS:000302999500046 ER PT J AU Lehavot, K Hoerster, KD Nelson, KM Jakupcak, M Simpson, TL AF Lehavot, Keren Hoerster, Katherine D. Nelson, Karin M. Jakupcak, Matthew Simpson, Tracy L. TI Health Indicators for Military, Veteran, and Civilian Women SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; US MILITARY; MILLENNIUM COHORT; WAR VETERANS; ACTIVE-DUTY; CARE; OBESITY; DISPARITIES AB Background: Women who have served in the military are a rapidly growing population. No previous studies have compared directly their health status to that of civilians. Purpose: To provide estimates of several leading U.S. health indicators by military service status among women. Methods: Data were obtained from the 2010 Behavioral Risk Factor Surveillance Survey, a U.S. population-based study. Health outcomes were compared by military status using multivariable logistic regression among the female participants (274,399 civilians, 4221 veterans, 661 active duty, and 995 National Guard or Reserves [NG/R]). Data were analyzed in August 2011. Results: Veterans reported poorer general health and greater incidence of health risk behaviors, mental health conditions, and chronic health conditions than civilian women. Active duty women reported better access to health care, better physical health, less engagement in health risk behaviors, and greater likelihood of having had a recent Pap than civilian women. Women from the NG/R were comparable to civilians across most health domains, although they had a greater likelihood of being overweight or obese and reporting a depressive and anxiety disorder. Conclusions: Compared with civilian women, NG/R women rated their health and access to health care similarly and active duty women rated theirs better on several domains, but veterans consistently reported poorer health. (Am J Prev Med 2012;42(5):473-480) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Lehavot, Keren; Hoerster, Katherine D.; Nelson, Karin M.; Jakupcak, Matthew; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Lehavot, Keren; Hoerster, Katherine D.; Jakupcak, Matthew; Simpson, Tracy L.] Univ Washington, Seattle Div, Seattle, WA 98195 USA. [Lehavot, Keren; Hoerster, Katherine D.; Jakupcak, Matthew; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116-POC, Seattle, WA 98108 USA. EM klehavot@uw.edu FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. The views expressed in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 46 TC 59 Z9 59 U1 4 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAY PY 2012 VL 42 IS 5 BP 473 EP 480 DI 10.1016/j.amepre.2012.01.006 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 928ED UT WOS:000302963300012 PM 22516487 ER PT J AU Nelson, HD Zakher, B Cantor, A Fu, RW Griffin, J O'Meara, ES Buist, DSM Kerlikowske, K van Ravesteyn, NT Trentham-Dietz, A Mandelblatt, JS Miglioretti, DL AF Nelson, Heidi D. Zakher, Bernadette Cantor, Amy Fu, Rongwei Griffin, Jessica O'Meara, Ellen S. Buist, Diana S. M. Kerlikowske, Karla van Ravesteyn, Nicolien T. Trentham-Dietz, Amy Mandelblatt, Jeanne S. Miglioretti, Diana L. TI Risk Factors for Breast Cancer for Women Aged 40 to 49 Years A Systematic Review and Meta-analysis SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID ORAL-CONTRACEPTIVE USE; AFRICAN-AMERICAN WOMEN; HISPANIC WHITE WOMEN; SERVICES-TASK-FORCE; PHYSICAL-ACTIVITY; BODY-SIZE; MAMMOGRAPHIC DENSITY; UNITED-STATES; REPRODUCTIVE FACTORS; CIGARETTE-SMOKING AB Background: Identifying risk factors for breast cancer specific to women in their 40s could inform screening decisions. Purpose: To determine what factors increase risk for breast cancer in women aged 40 to 49 years and the magnitude of risk for each factor. Data Sources: MEDLINE (January 1996 to the second week of November 2011), Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews (fourth quarter of 2011), Scopus, reference lists of published studies, and the Breast Cancer Surveillance Consortium. Study Selection: English-language studies and systematic reviews of risk factors for breast cancer in women aged 40 to 49 years. Additional inclusion criteria were applied for each risk factor. Data Extraction: Data on participants, study design, analysis, follow-up, and outcomes were abstracted. Study quality was rated by using established criteria, and only studies rated as good or fair were included. Results were summarized by using meta-analysis when sufficient studies were available or from the best evidence based on study quality, size, and applicability when meta-analysis was not possible. Data from the Breast Cancer Surveillance Consortium were analyzed with proportional hazards models by using partly conditional Cox regression. Reference groups for comparisons were set at U. S. population means. Data Synthesis: Sixty-six studies provided data for estimates. Extremely dense breasts on mammography or first-degree relatives with breast cancer were associated with at least a 2-fold increase in risk for breast cancer. Prior breast biopsy, second-degree relatives with breast cancer, or heterogeneously dense breasts were associated with a 1.5- to 2.0-fold increased risk; current use of oral contraceptives, nulliparity, and age 30 years or older at first birth were associated with a 1.0- to 1.5-fold increased risk. Limitations: Studies varied by measures, reference groups, and adjustment for confounders, which could bias combined estimates. Effects of multiple risk factors were not considered. Conclusion: Extremely dense breasts and first-degree relatives with breast cancer were each associated with at least a 2-fold increase in risk for breast cancer in women aged 40 to 49 years. Identification of these risk factors may be useful for personalized mammography screening. C1 [Nelson, Heidi D.] Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA. Providence Canc Ctr, Portland, OR USA. Grp Hlth Res Inst, Seattle, WA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Erasmus MC, Rotterdam, Netherlands. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Lombardi Comprehens Canc Ctr, Washington, DC USA. RP Nelson, HD (reprint author), Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Mail Code BICC,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM nelsonh@ohsu.edu FU National Cancer Institute [U01CA086076-10S1]; BCSC [U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040]; Providence Health Services; Veterans Affairs Fellowship in Health Issues of Women Veterans FX By a National Cancer Institute Activities to Promote Research Collaboration supplement (U01CA086076-10S1). Data collection was supported by the National Cancer Institute-funded BCSC co-operative agreements (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, and U01CA70040). Providence Health & Services provided additional support for Dr. Nelson, and the Veterans Affairs Fellowship in Health Issues of Women Veterans provided support for Dr. Cantor. The collection of BCSC cancer data used in this study was supported in part by several state public health departments and cancer registries throughout the United States. For a full description of these sources, please see www.breastscreening.cancer.gov/work/acknowledgement.html. NR 121 TC 104 Z9 111 U1 8 U2 61 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 1 PY 2012 VL 156 IS 9 BP 635 EP U79 DI 10.7326/0003-4819-156-9-201205010-00006 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA 933YR UT WOS:000303403700004 PM 22547473 ER PT J AU Brooks, RC Hasley, PB Jasti, H Macpherson, D AF Brooks, Robert C. Hasley, Peggy B. Jasti, Harish Macpherson, David TI Update in General Internal Medicine: Evidence Published in 2011 SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID AMBULATORY BLOOD-PRESSURE; VENOUS THROMBOEMBOLISM; PRIMARY-CARE; RISK; THERAPY; HOME C1 Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Vet Integrated Serv Network 4, Pittsburgh, PA USA. RP Macpherson, D (reprint author), 323 N Shore Dr,Suite 400, Pittsburgh, PA 15212 USA. EM David.Macpherson@va.gov NR 16 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 1 PY 2012 VL 156 IS 9 BP 649 EP U85 DI 10.7326/0003-4819-156-9-201205010-00410 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 933YR UT WOS:000303403700005 PM 22517813 ER PT J AU Hosseini, M Ehrhardt, N Weissglas-Volkov, D Lai, CM Mao, HZ Liao, JL Nikkola, E Bensadoun, A Taskinen, MR Doolittle, MH Pajukanta, P Peterfy, M AF Hosseini, Maryam Ehrhardt, Nicole Weissglas-Volkov, Daphna Lai, Ching-Mei Mao, Hui Z. Liao, Jo-Ling Nikkola, Elina Bensadoun, Andre Taskinen, Marja-Riitta Doolittle, Mark H. Pajukanta, Paeivi Peterfy, Miklos TI Transgenic Expression and Genetic Variation of Lmf1 Affect LPL Activity in Mice and Humans SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE hyperlipoproteinemia; lipases; transgenic models; lipoprotein lipase ID FAMILIAL COMBINED HYPERLIPIDEMIA; HUMAN LIPOPROTEIN-LIPASE; LOW-DENSITY LIPOPROTEIN; ADIPOSE-TISSUE; INSULIN-RESISTANCE; HEPATIC LIPASE; SEVERE HYPERTRIGLYCERIDEMIA; ENDOPLASMIC-RETICULUM; ENDOTHELIAL LIPASE; FINNISH FAMILIES AB Objective-Lipoprotein lipase (LPL) is a principal enzyme in lipoprotein metabolism, tissue lipid utilization, and energy metabolism. LPL is synthesized by parenchymal cells in adipose, heart, and muscle tissues followed by secretion to extracellular sites, where lipolyic function is exerted. The catalytic activity of LPL is attained during posttranslational maturation, which involves glycosylation, folding, and subunit assembly within the endoplasmic reticulum. A lipase-chaperone, lipase maturation factor 1 (Lmf1), has recently emerged as a critical factor in this process. Previous studies demonstrated that loss-of-function mutations of Lmf1 result in diminished lipase activity and severe hypertriglyceridemia in mice and human subjects. The objective of this study is to investigate whether, beyond its role as a required factor in lipase maturation, variation in Lmf1 expression is sufficient to modulate LPL activity in vivo. Methods and Results-To assess the effects of Lmf1 overexpression in adipose and muscle tissues, we generated aP2-Lmf1 and Mck-Lmf1 transgenic mice. Characterization of relevant tissues revealed increased LPL activity in both mouse strains. In the omental and subcutaneous adipose depots, Lmf1 overexpression was associated with increased LPL specific activity without changes in LPL mass. In contrast, increased LPL activity was due to elevated LPL protein level in heart and gonadal adipose tissue. To extend these studies to humans, we detected association between LMF1 gene variants and postheparin LPL activity in a dyslipidemic cohort. Conclusion-Our results suggest that variation in Lmf1 expression is a posttranslational determinant of LPL activity. (Arterioscler Thromb Vasc Biol. 2012; 32: 1204-1210.) C1 [Hosseini, Maryam; Ehrhardt, Nicole; Mao, Hui Z.; Liao, Jo-Ling; Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Hosseini, Maryam; Lai, Ching-Mei; Liao, Jo-Ling; Doolittle, Mark H.; Peterfy, Miklos] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hosseini, Maryam; Lai, Ching-Mei; Doolittle, Mark H.; Peterfy, Miklos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Weissglas-Volkov, Daphna; Nikkola, Elina; Pajukanta, Paeivi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Bensadoun, Andre] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [Taskinen, Marja-Riitta] Helsinki Univ Hosp, Dept Med, Helsinki, Finland. RP Peterfy, M (reprint author), Cedars Sinai Med Ctr, Inst Med Genet, Davis 4091,8700 Beverly Blvd, Los Angeles, CA 90048 USA. EM mpeterfy@ucla.edu FU National Institutes of Health [HL095056, HL028481]; Cedars-Sinai Medical Center FX This work was supported by the National Institutes of Health grants HL095056 (to P. P.), HL028481 (to P. P. and M. P.), and the Cedars-Sinai Medical Center. NR 54 TC 6 Z9 8 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAY PY 2012 VL 32 IS 5 BP 1204 EP + DI 10.1161/ATVBAHA.112.245696 PG 28 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 931DL UT WOS:000303195100025 PM 22345169 ER PT J AU O'Donovan, A Neylan, TC Metzler, T Cohen, BE AF O'Donovan, Aoife Neylan, Thomas C. Metzler, Thomas Cohen, Beth E. TI Lifetime exposure to traumatic psychological stress is associated with elevated inflammation in the Heart and Soul Study SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Aging; Cardiovascular disease; C-reactive protein; Immune system; Inflammation; Interleukin-6; Psychological stress; Resistin; Traumatic psychological stress; Tumor necrosis factor-alpha ID C-REACTIVE PROTEIN; NECROSIS-FACTOR-ALPHA; PRIMARY-CARE PATIENTS; POSTTRAUMATIC-STRESS; CARDIOVASCULAR EVENTS; DEPRESSIVE SYMPTOMS; CIRCULATING INTERLEUKIN-6; MYOCARDIAL-INFARCTION; INDUCIBLE ISCHEMIA; NATIONAL SAMPLE AB Exposure to traumatic psychological stress increases risk for disease events and mortality in patients with cardiovascular disease (CVD). While the biological mechanisms of these effects are not known, inflammation may play a key role as it is both elevated by psychological stress and involved in the development and progression of CVD. In a prospective study of patients with stable CVD (n = 979), we examined if higher lifetime trauma exposure was associated with elevated levels of inflammation at baseline and at five-year follow-up, and with greater increases in inflammation over time. Inflammation was indexed by a composite score incorporating the inflammatory markers interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP) and resistin. In follow-up analyses, we adjusted for sociodemographic factors, psychiatric disorders and health behaviors that were significantly associated with trauma exposure. Higher trauma exposure was associated with elevated inflammation at baseline (beta = .09, p = .01) and at five-year follow-up (beta = .09, p = .03). While levels of inflammation increased from baseline to follow-up in the sample, there was no significant association between trauma exposure and rate of change in inflammation. Findings were robust to adjustments for sociodemographic factors and psychiatric disorders, but health behaviors appeared to contribute to the association between trauma and inflammation at follow-up. This is the first large-scale demonstration of an association between lifetime trauma exposure and inflammation. High lifetime exposure to traumatic stress may contribute to an accelerated rate of CVD progression through elevated inflammation. (C) 2012 Elsevier Inc. All rights reserved. C1 [O'Donovan, Aoife; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [O'Donovan, Aoife; Neylan, Thomas C.; Metzler, Thomas; Cohen, Beth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [O'Donovan, Aoife; Neylan, Thomas C.; Metzler, Thomas; Cohen, Beth E.] No Calif Inst Res & Educ, San Francisco, CA USA. [Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP O'Donovan, A (reprint author), Univ Calif San Francisco, Dept Psychiat, 3333 Calif St,Suite 465, San Francisco, CA 94143 USA. EM aoife.odonovan@ucsf.edu FU NIH/NHLBI [K23 HL 094765-01]; Department of Defense/NCIRE [DAMD17-03-1-0532, W81XWH-05-2-0094]; Irene Perstein Foundation; Society in Science: Branco Weiss Fellowship; Department of Veterans Affairs, Washington, DC; National Heart Lung and Blood Institute, Bethesda, MD [R01 HL079235]; American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY; Robert Wood Johnson Foundation, Princeton, NJ; Ischemia Research and Education Foundation, South San Francisco, CA; Nancy Kirwan Heart Research Fund, San Francisco, CA; Department of Defense [W81XWH-10-2-0089]; Mental Illness Research and Education Clinical Center (MIRECC) of the US Veterans Health Administration FX This research was supported in part by NIH/NHLBI Grant K23 HL 094765-01, Department of Defense/NCIRE Grants DAMD17-03-1-0532, W81XWH-05-2-0094, and a Grant from the Irene Perstein Foundation to Dr. Cohen and by a Society in Science: Branco Weiss Fellowship to Dr. O'Donovan. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington, DC, the National Heart Lung and Blood Institute (R01 HL079235), Bethesda, MD, the American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY, the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, NJ, the Ischemia Research and Education Foundation, South San Francisco, CA, and the Nancy Kirwan Heart Research Fund, San Francisco, CA. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Medical Center, San Francisco, CA. Mr. Metzler is supported in part by Grants from the Department of Defense (W81XWH-10-2-0089), the Mental Illness Research and Education Clinical Center (MIRECC) of the US Veterans Health Administration. The funding organizations had no role in the design or conduct of the study; data collection, management, analysis or interpretation of the data; or preparation, review or approval of the manuscript. The authors would like to thank The Heart and Soul Study team for supporting this manuscript, particular Dr. Mary Whooley, Mathilda Regan and Bee Ya Na. NR 74 TC 28 Z9 28 U1 2 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD MAY PY 2012 VL 26 IS 4 BP 642 EP 649 DI 10.1016/j.bbi.2012.02.003 PG 8 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 929PV UT WOS:000303078800018 PM 22366689 ER PT J AU Jin, JF Sundararaj, KP Samuvel, DJ Zhang, XM Li, YC Lu, ZY Lopes-Virella, MF Huang, Y AF Jin, Junfei Sundararaj, Kamala P. Samuvel, Devadoss J. Zhang, Xiaoming Li, Yanchun Lu, Zhongyang Lopes-Virella, Maria F. Huang, Yan TI Different signaling mechanisms regulating IL-6 expression by LPS between gingival fibroblasts and mononuclear cells: seeking the common target SO CLINICAL IMMUNOLOGY LA English DT Article DE Inflammation; LPS; Cytokine; Gene expression; Signal transduction; Transcription ID NF-KAPPA-B; C-REACTIVE PROTEIN; PERIODONTAL-DISEASE; ENDOTHELIAL-CELLS; MMP-1 EXPRESSION; LIPOPOLYSACCHARIDE; INTERLEUKIN-6; ACTIVATION; RECEPTOR; AP-1 AB To reduce connective tissue IL-6 level stimulated by LPS, it is essential to control IL-6 expression in both mononuclear cells and fibroblasts. However, it is unclear whether the regulatory mechanisms for both cells are similar or not. In this study, we found that signaling pathways mediating LPS-stimulated IL-6 in mononuclear U937 cells and fibroblasts were different. Furthermore, our studies showed that while LPS activated AP-1 and NF kappa B in U937 cells, it only activated NF kappa B in fibroblasts. Analysis of nuclear AP-1 subunits showed that LPS stimulated c-Fos, Fra-1 and Jun D activities in U937 cells, but not fibroblasts. The lack of ERK involvement in LPS-stimulated IL-6 in fibroblasts was further supported by the observations that simvastatin, which is known to target ERK-AP-1, failed to inhibit LPS-stimulated IL-6 by fibroblasts. Finally, we showed that targeting NFKB pathway was highly effective in inhibition of LPS-stimulated IL-6 in coculture of U937 cells and fibroblasts. Published by Elsevier Inc. C1 [Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Jin, Junfei; Sundararaj, Kamala P.; Samuvel, Devadoss J.; Zhang, Xiaoming; Li, Yanchun; Lu, Zhongyang; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU Department of Veterans Affairs; NIH [DE16353] FX This work was supported by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs and by NIH grant DE16353 (to Y.H.). NR 38 TC 9 Z9 10 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PD MAY PY 2012 VL 143 IS 2 BP 188 EP 199 DI 10.1016/j.clim.2012.01.019 PG 12 WC Immunology SC Immunology GA 932KV UT WOS:000303290900010 PM 22386866 ER PT J AU Dooley, KE Bliven-Sizemore, EE Weiner, M Lu, Y Nuermberger, EL Hubbard, WC Fuchs, EJ Melia, MT Burman, WJ Dorman, SE AF Dooley, K. E. Bliven-Sizemore, E. E. Weiner, M. Lu, Y. Nuermberger, E. L. Hubbard, W. C. Fuchs, E. J. Melia, M. T. Burman, W. J. Dorman, S. E. TI Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ACQUIRED RIFAMYCIN RESISTANCE; HIV-RELATED TUBERCULOSIS; PLASMA-CONCENTRATIONS; RIFAMPICIN; INDUCTION; MIDAZOLAM; TWICE; MOXIFLOXACIN; RIFABUTIN; REGIMENS AB Rifapentine (RPT) is an antituberculosis drug that may shorten treatment duration when substituted for rifampin (RIF). The maximal tolerated daily dose of RP T and its potential for cytochrome 3A4 induction and autoinduction at clinically relevant doses are unknown. In this phase I, dose-escalation study among healthy volunteers, daily doses as high as a prespecified maximum of 20 mg/kg/day were well tolerated. Steady-state RP T concentrations increased with dose from 5 to 15 mg/kg, but area under the plasma concentration-time curve (AUC(0-24)) and maximum concentration (C-max) were similar in the 15- and 20-mg/kg cohorts. Although RP T pharmacokinetics (PK) appeared to be time-dependent, accumulation occurred with daily dosing. The mean AUC(0-12) of oral midazolam (MDZ), a cytochrome 3A (CYP3A) probe drug, was reduced by 93% with the coadministration of RPT and by 74% with the coadministration of RIF (P < 0.01). Changes in the oral clearance of MDZ did not vary by RP T dose. In conclusion, RP T was tolerated at doses as high as 20 mg/kg/day, its PK were less than dose-proportional, and its CYP3A induction was robust. C1 [Dooley, K. E.; Lu, Y.; Hubbard, W. C.; Fuchs, E. J.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Dooley, K. E.; Nuermberger, E. L.; Melia, M. T.; Dorman, S. E.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Bliven-Sizemore, E. E.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Weiner, M.] Vet Adm Med Ctr, Div Med & Infect Dis, San Antonio, TX USA. [Burman, W. J.] Denver Publ Hlth, Denver, CO USA. RP Dooley, KE (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. EM kdooley1@jhmi.edu FU Centers for Disease Control and Prevention; CDC Foundation; National Institutes of Health National Center for Research Resources [UL1 RR025005]; NIAID [P30 50410, K23AI080842]; Sanofi-Aventis; [1S10 RR 27733] FX The study team is grateful to the individuals who participated in this study. We appreciate the efforts of the research team at the Drug Development Unit at Johns Hopkins, notably Stephanie Everts and Elizabeth Purdy. We acknowledge the contributions of Namandje Bumpus and Teresa Parsons from the Clinical Pharmacology Analytical Laboratory at Johns Hopkins to the development of the RPT and RIF (and metabolite) assays, and we thank Angela Kashuba and Stephanie Malone at the University of North Carolina for quantifying MDZ and its metabolite. We also acknowledge Carla Jeffries of the Centers for Disease Control and Prevention for her assistance with graphics. We appreciate the thoughtful input and comments of Chad Heilig and Andy Vernon from the Centers for Disease Control and Prevention and Theresa Shapiro from Johns Hopkins. This study was sponsored by the Centers for Disease Control and Prevention and the CDC Foundation and was supported by the following grants: Institutional Clinical and Translational Science Award National Institutes of Health National Center for Research Resources UL1 RR025005, NIAID P30 50410 (UNC Center for AIDS Research (MDZ assays)), and K23AI080842 (K. E. D.). The ABI-Sciex API5500 Quadrupole-Linear Ion Trap console used for quantification of rifapentine and rifampin was purchased from Grant 1S10 RR 27733 awarded to W. C. H. The Waters Acquity ultraperformance liquid chromatography interfaced with the API5500 was purchased with funds from Pendleton Enterprises awarded to Craig W. Hendrix. Rifapentine (Priftin; Anagni, Italy) was provided by Sanofi-Aventis. NR 37 TC 24 Z9 25 U1 1 U2 23 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD MAY PY 2012 VL 91 IS 5 BP 881 EP 888 DI 10.1038/clpt.2011.323 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 929FT UT WOS:000303047400022 PM 22472995 ER PT J AU Gopal, RK Yamashita, TE Prochazka, AV AF Gopal, Ravi K. Yamashita, Traci E. Prochazka, Allan V. TI Research without results: Inadequate public reporting of clinical trial results SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Publication bias; Food and Drug Administration; Transparency; Clinical trials; Trial registries ID EFFICACY; BIAS AB Objective: In order to increase transparency in the medical literature, the Food and Drug Administration (FDA) Modernization Act of 1997 and the FDA Amendment Act of 2007 required registration of all "applicable trials" with required "basic results" reporting. We evaluated the rate of compliance with the FDA mandatory results reporting in www.clinicaltrials.gov. Methods: All completed registered interventional studies that may be subject to FDA regulation, one year prior to required results reporting (October 2006 to September 2007, n = 1097) and during the two years after required reporting (October 2007 to September 2008 (07-08), n = 2231 and October 2008 to September 2009 (08-09), n = 2923). Results: Downloading all 99,315 records from clinicaltrials.gov, we excluded all non-applicable studies. Results reporting increased from 6.8% (n = 75) prior to mandatory reporting to 19.1% (n = 427, p<.01) in 07-08 and 10.8% (n = 316, p<.01) in 08-09. The odds ratio for results reporting using the 06-07 time period as the reference was 3.31 (95% Cl 2.54-4.32) for 07-08 and 1.74 (1.33-2.28) for 08-09. Of the 818 trials with results in clinicaltrials.gov, the rate of published articles found decreased from 60% (n = 45) in the year prior to required reporting to 33% (n = 140, p<.001) for 07-08 and 20% (n = 63, p<.001) for 08-09 time period. Conclusion: The majority of studies registered in clinicaltrials.gov are not required to report data. Of studies that may be required to report data, compliance with data reporting has improved. The clinicaltrials.gov website is not yet a comprehensive resource for study results. Published by Elsevier Inc. C1 [Gopal, Ravi K.; Prochazka, Allan V.] Univ Colorado Denver Sch Med, Denver Vet Affairs Hosp, Dept Ambulatory Care, Denver, CO USA. [Yamashita, Traci E.] Univ Colorado Denver Sch Med, Dept Gen Internal Med, Dept Ambulatory Care, Denver, CO USA. RP Gopal, RK (reprint author), Denver VAMC, Box 11B,1055 Clermont St, Denver, CO 80220 USA. EM ravi.gopal@va.gov NR 13 TC 12 Z9 12 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2012 VL 33 IS 3 BP 486 EP 491 DI 10.1016/j.cct.2012.02.001 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 930XM UT WOS:000303178100006 PM 22342449 ER PT J AU Willette, AA Bendlin, BB Colman, RJ Kastman, EK Field, AS Alexander, AL Sridharan, A Allison, DB Anderson, R Voytko, ML Kemnitz, JW Weindruch, RH Johnson, SC AF Willette, Auriel A. Bendlin, Barbara B. Colman, Ricki J. Kastman, Erik K. Field, Aaron S. Alexander, Andrew L. Sridharan, Aadhavi Allison, David B. Anderson, Rozalyn Voytko, Mary-Lou Kemnitz, Joseph W. Weindruch, Richard H. Johnson, Sterling C. TI Calorie Restriction Reduces the Influence of Glucoregulatory Dysfunction on Regional Brain Volume in Aged Rhesus Monkeys SO DIABETES LA English DT Article ID DIETARY RESTRICTION; INSULIN-RESISTANCE; ALZHEIMERS-DISEASE; ENERGY-METABOLISM; GLUCOSE; MECHANISMS; TERM; RAT; PATHOGENESIS; HIPPOCAMPUS AB Insulin signaling dysregulation is related to neural atrophy in hippocampus and other areas affected by neurovascular and neurodegenerative disorders. It is not known if long-term calorie restriction (CR) can ameliorate this relationship through improved insulin signaling or if such an effect might influence task learning and performance. To model this hypothesis, magnetic resonance imaging was conducted on 27 CR and 17 control rhesus monkeys aged 19-31 years from a longitudinal study. Voxel-based regression analyses were used to associate insulin sensitivity with brain volume and microstructure cross-sectionally. Monkey motor assessment panel (mMAP) performance was used as a measure of task performance. CR improved glucoregulation parameters and related indices. Higher insulin sensitivity predicted more gray matter in parietal and frontal cortices across groups. An insulin sensitivity x dietary condition interaction indicated that CR animals had more gray matter in hippocampus and other areas per unit increase relative to controls, suggesting a beneficial effect. Finally, bilateral hippocampal volume adjusted by insulin sensitivity, but not volume itself, was significantly associated with mMAP learning and performance. These results suggest that CR improves glucose regulation and may positively influence specific brain regions and at least motor task performance. Additional studies are warranted to validate these relationships. Diabetes 61:1036-1042, 2012 C1 [Willette, Auriel A.; Bendlin, Barbara B.; Kastman, Erik K.; Sridharan, Aadhavi; Anderson, Rozalyn; Weindruch, Richard H.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Willette, Auriel A.; Alexander, Andrew L.; Johnson, Sterling C.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI USA. [Willette, Auriel A.; Bendlin, Barbara B.; Kastman, Erik K.; Sridharan, Aadhavi; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Colman, Ricki J.; Anderson, Rozalyn; Kemnitz, Joseph W.; Johnson, Sterling C.] Wisconsin Natl Primate Res Ctr, Madison, WI USA. [Field, Aaron S.] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA. [Sridharan, Aadhavi; Johnson, Sterling C.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [Allison, David B.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Voytko, Mary-Lou] Wake Forest Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA. [Kemnitz, Joseph W.] Univ Wisconsin, Dept Cell & Regenerat Biol, Sch Med & Publ Hlth, Madison, WI USA. [Johnson, Sterling C.] Univ Wisconsin, Inst Clin & Translat Res, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. EM scj@medicine.wisc.edu RI Kastman, Erik/N-6645-2016 OI Kastman, Erik/0000-0001-7221-9042; Bendlin, Barbara/0000-0002-0580-9875; Allison, David/0000-0003-3566-9399 FU National Institutes of Health [RR-000167, AG-011915, AG-000213, GM-007507, MH-085051, MH-062015]; William S. Middleton Memorial Veterans Hospital; Research Facilities Improvement Program [RR-15459-01, RR-020141-01] FX This study was supported in part by the National Institutes of Health grants RR-000167, AG-011915, AG-000213, GM-007507, MH-085051, and MH-062015. This study was also supported with resources and facilities at the William S. Middleton Memorial Veterans Hospital. This research was conducted in part at a facility constructed with support from Research Facilities Improvement Program grants RR-15459-01 and RR-020141-01. NR 48 TC 22 Z9 23 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD MAY PY 2012 VL 61 IS 5 BP 1036 EP 1042 DI 10.2337/db11-1187 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 930XW UT WOS:000303179100015 PM 22415875 ER PT J AU Marina, AL Utzschneider, KM Wright, LA Montgomery, BK Marcovina, SM Kahn, SE AF Marina, Anna L. Utzschneider, Kristina M. Wright, Lorena A. Montgomery, Brenda K. Marcovina, Santica M. Kahn, Steven E. TI Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and beta-Cell Function SO DIABETES CARE LA English DT Article ID TYPE-2 DIABETES-MELLITUS; GLYCEMIC CONTROL; BILE-ACIDS; PANCREATIC-SECRETION; DOUBLE-BLIND; CHOLECYSTOKININ; RELEASE; CHOLESTYRAMINE; HYDROCHLORIDE; THERAPY AB OBJECTIVE-To determine the mechanism by which the bile acid sequestrant colesevelam improves glycemic control. RESEARCH DESIGN AND METHODS-We performed a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model analysis and a meal tolerance test (MTT) in 20 subjects with impaired fasting glucose (11 men, 9 women; mean age 60.7 +/- 1.9 years, BM I 29.4 +/- 0.9 kg/m(2)) in a single-blind study after 2 weeks of placebo treatment and 8 weeks of colesevelam 3.75 g daily. From these tests, insulin sensitivity, beta-cell function, and glucose tolerance were determined, along with gastrointestinal peptide levels during the MTT. RESULTS-Fasting plasma glucose and HbA(1c) decreased with colesevelam (from 5.9 +/- 0.1 to 5.7 +/- 0.1 mmol/L, P < 0.05, and from 5.86 +/- 0.06 to 5.76 +/- 0.06%, P = 0.01, respectively), but fasting insulin did not change. Colesevelam had no effect on any FSIGT measures. In contrast, the MTT incremental area under the curve (iAUC) for both glucose (from 249.3 +/- 28.5 to 198.8 +/- 23.6 mmol/L . min, P < 0.01) and insulin (from 20,130 [13,542-35,292] to 13,086 [9,804-21,138] pmol/L . min, P < 0.05) decreased with, colesevelam. However, the ratio of iAUC insulin to iAUC glucose was not changed. iAUC for cholecystokinin (CCK) increased (from 43.2 [0-130.1] to 127.1 [47.2-295.2] pmol/L . min, P < 0.01), while iAUC for fibroblast growth factor 19 decreased (from 11,185 [1,346-17,661] to 2,093 [673-6,707] pg/mL . min, P < 0.01.) with colesevelam. However, iAUC for glucagon, glucose-dependent insulinocropic peptide, and glucagon-like peptide 1 did not change. CONCLUSIONS-Colesevelam improves oral but not intravenous glucose tolerance without changing insulin sensitivity, beta-cell function, or incretins. This effect may be at least partially explained by the colesevelam-induced increase in CCK. C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. EM skahn@u.washington.edu FU U.S. Department of Veterans Affairs, National Institutes of Health [DK-007247, DK-017047]; Daiichi Sankyo FX This study was supported in pan by the U.S. Department of Veterans Affairs, National Institutes of Health Grants DK-007247 and DK-017047.; The study was also supported by an investigator-initiated proposal sponsored by Daiichi Sankyo. No other potential conflicts of interest relevant to this article were reported. NR 30 TC 26 Z9 26 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2012 VL 35 IS 5 BP 1119 EP 1125 DI 10.2337/dc11-2050 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 931KN UT WOS:000303218900033 PM 22446171 ER PT J AU Carmody, TP Delucchi, K Duncan, CL Banys, P Simon, JA Solkowitz, SN Huggins, J Lee, SK Hall, SM AF Carmody, Timothy P. Delucchi, Kevin Duncan, Carol L. Banys, Peter Simon, Joel A. Solkowitz, Sharon N. Huggins, Joy Lee, Sharon K. Hall, Sharon M. TI Intensive intervention for alcohol-dependent smokers in early recovery: A randomized trial SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Smoking cessation; Tobacco use; Alcohol dependence; Concurrent intervention; Early recovery ID ADDICTION SEVERITY INDEX; POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE-ABUSE TREATMENT; MENTAL-HEALTH-CARE; FAGERSTROM TOLERANCE QUESTIONNAIRE; SMOKING-CESSATION INTERVENTIONS; INTEGRATING TOBACCO CESSATION; NATIONAL EPIDEMIOLOGIC SURVEY; NICOTINE DEPENDENCE; CIGARETTE-SMOKING AB Introduction: The purpose of this study was to investigate the efficacy of an intensive tobacco cessation intervention for alcohol-dependent smokers in early recovery. Methods: A total of 162 alcohol-dependent smokers were randomized to either intensive intervention for smoking cessation or usual care. The intensive intervention consisted of 16 sessions of individual cognitive behavior therapy (CBT) and combination nicotine replacement therapy that lasted 26 weeks. Usual care involved referral to a free-standing smoking cessation program that provided smoking cessation counseling of varying duration and guideline-concordant medications. The primary cessation outcome was verified 7-day point prevalence abstinence (PPA) at 12, 26, 38, and 52 weeks. Results: At 12 and 26 weeks, the verified 7-day point-prevalence quit rate was significantly higher for the intensive intervention group than for the usual care group (both p = 0.03). However, the quit rates for the two treatment groups were not significantly different at 38 or 52 weeks. Verified 30-day alcohol abstinence rates were not significantly different for the two treatment groups at any of the follow-up assessments. Conclusions: The intensive smoking cessation intervention yielded a higher short-term smoking quit rate without jeopardizing sobriety. A chronic care model might facilitate maintenance of smoking cessation during the first year of alcohol treatment and perhaps for longer periods of time. It is hoped that studies such as this will inform the development of more effective interventions for concurrent alcohol and tobacco use disorders. Published by Elsevier Ireland Ltd. C1 [Carmody, Timothy P.; Duncan, Carol L.; Banys, Peter; Solkowitz, Sharon N.; Huggins, Joy; Lee, Sharon K.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Carmody, Timothy P.; Delucchi, Kevin; Duncan, Carol L.; Banys, Peter; Simon, Joel A.; Solkowitz, Sharon N.; Huggins, Joy; Lee, Sharon K.; Hall, Sharon M.] Univ Calif San Francisco, Treatment Res Ctr, San Francisco, CA 94143 USA. [Simon, Joel A.] San Francisco VA Med Ctr, Gen Internal Med Sect, Med Serv, San Francisco, CA 94121 USA. [Simon, Joel A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Simon, Joel A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Carmody, TP (reprint author), Vet Affairs Med Ctr, Mental Hlth Serv 116B, 4150 Clement St, San Francisco, CA 94121 USA. EM Timothy.Carmody@va.gov FU NIDA [P50 DA09253] FX This work is a component of the UCSF Treatment Research Center and was supported by NIDA grant P50 DA09253. NIDA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 66 TC 14 Z9 14 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2012 VL 122 IS 3 BP 186 EP 194 DI 10.1016/j.drugalcdep.2011.09.026 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 934GQ UT WOS:000303432200003 PM 22014532 ER PT J AU Oliva, EM Harris, AHS Trafton, JA Gordon, AJ AF Oliva, Elizabeth M. Harris, Alex H. S. Trafton, Jodie A. Gordon, Adam J. TI Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Opioid-related disorders; Buprenorphine; Methadone; United States Department of Veterans Affairs ID OFFICE-BASED TREATMENT; PRIMARY-CARE; OPIATE ADDICTION; BUPRENORPHINE; METHADONE; DEPENDENCE; RETENTION; BARRIERS; NALOXONE; RISK AB Background: Opioid agonist treatment (OAT)-through licensed clinic settings (C-OAT) using methadone or buprenorphine or office-based settings with buprenorphine (O-OAT)-is an evidence-based treatment for opioid dependence. Because of limited availability of on-site C-OAT (n = 28 of 128 facilities) in the Veterans Health Administration (VHA), O-OAT use has been encouraged. This study examined OAT utilization across VHA facilities and the patient and facility factors related to variability in utilization. Method: We examined 12 months of VHA administrative data (fiscal year [FY] 2008, October 2007 through September 2008) for evidence of OAT utilization and substance use disorder program data from an annual VHA survey. Variability in OAT utilization across facilities and patient and facility factors related to OAT utilization were examined using mixed-effects, logistic regression models. Results: Among 128 VHA facilities, 35,240 patients were diagnosed with an opioid use disorder. Of those, 27.3% received OAT: 22.2% received C-OAT and 5.1% received O-OAT with buprenorphine. Substantial facility-level variability in proportions of patients treated with OAT was found, ranging from 0% to 66% with 44% of facilities treating <5%. Significant patient-level predictors of OAT receipt included being male, age >= 56, and without another mental health diagnosis. Significant facility-level predictors included offering any OAT services (C-OAT or O-OAT) and specialty substance abuse treatment services on weekends. Conclusion: In FY2008, prior to the VHA national mandate of access to buprenorphine OAT, substantial variation in the use of OAT existed, partially explained by patient- and facility-level factors. Implementation efforts should focus on increasing access to this evidence-based treatment, especially in facilities at the low end of the distribution. (C) 2011 Published by Elsevier Ireland Ltd. C1 [Gordon, Adam J.] Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr,Ctr Res Hlth Care, Pittsburgh, PA 15206 USA. [Oliva, Elizabeth M.; Harris, Alex H. S.; Trafton, Jodie A.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr,Ctr Res Hlth Care, 7180 Highland Dr,Mailcode 151-C-H, Pittsburgh, PA 15206 USA. EM adam.gordon@va.gov RI Nilsson, Marcus/H-2186-2012 NR 22 TC 10 Z9 10 U1 2 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2012 VL 122 IS 3 BP 241 EP 246 DI 10.1016/j.drugalcdep.2011.10.004 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 934GQ UT WOS:000303432200011 PM 22115887 ER PT J AU Azadani, AN Chitsaz, S Matthews, PB Jaussaud, N Leung, J Wisneski, A Ge, L Tseng, EE AF Azadani, Ali N. Chitsaz, Sam Matthews, Peter B. Jaussaud, Nicolas Leung, James Wisneski, Andrew Ge, Liang Tseng, Elaine E. TI Biomechanical comparison of human pulmonary and aortic roots SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY LA English DT Article DE Biomechanics; Aortic root; Pulmonary root; Ross operation; Stress; Strain ID PORCINE PULMONARY; ASCENDING AORTA; VALVE; ANEURYSM AB Significant dilation of the pulmonary autograft is problematic after the Ross operation and may require reoperation. Pulmonary autograft remodelling occurs in response to the immediate rise in pressure and consequently wall stress. Stress-strain response of the pulmonary root plays an important role in understanding autograft function and remodelling following the Ross procedure. However, limited data are available on mechanical properties of fresh human pulmonary roots. The aim of this study was to compare mechanical properties of fresh human pulmonary and aortic roots prior to the Ross operation. Fresh healthy human hearts (n = 21) were obtained from California Transplant Donor Network (Oakland, CA, USA). Five regions of pulmonary and aortic roots, anterior and posterior artery and three sinuses, were subjected to displacement-controlled equibiaxial stretch testing within 24 h of cross-clamp time. Different regions of pulmonary and aortic roots were compared using a paired-comparison approach based on tissue stiffness at systemic pressure. Furthermore, histologic analysis was performed to compare the fibrous structure of pulmonary and aortic roots. Human pulmonary and aortic roots demonstrated nonlinear response to biaxial loading in both circumferential and longitudinal directions. Pulmonary artery was found to be significantly stiffer than ascending aorta at systemic pressure in the two principal directions (P < 0.001). Similarly, pulmonary sinuses were significantly stiffer than the aortic sinuses at systemic pressure in the two directions (P < 0.001). Histological analysis revealed that aortic roots had tight denser weave of elastin than pulmonary roots. Significant differences were found in the compliance and fibrous structure of human pulmonary and aortic roots. These regional differences may impact pulmonary autograft remodelling and influence late autograft dilation. C1 [Tseng, Elaine E.] Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org RI Chitsaz, Sam/C-4586-2008 FU American Heart Association FX This research was funded by the American Heart Association administered by the Northern California Institute for Research and Education using resources from the San Francisco VA Medical Center. NR 12 TC 19 Z9 19 U1 5 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1010-7940 J9 EUR J CARDIO-THORAC JI Eur. J. Cardio-Thorac. Surg. PD MAY PY 2012 VL 41 IS 5 BP 1111 EP 1116 DI 10.1093/ejcts/ezr163 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 930TA UT WOS:000303161800040 PM 22219450 ER PT J AU Leung, FW AF Leung, Felix W. TI Magnetic endoscope imaging colonoscope: a new modality for hypothesis testing in unsedated colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; PATIENT PAIN; PERFORMANCE; IMPROVEMENT C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Gastroenterol, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Gastroenterol, North Hills, CA USA. NR 10 TC 5 Z9 5 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2012 VL 75 IS 5 BP 1037 EP 1039 DI 10.1016/j.gie.2012.02.058 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 932GC UT WOS:000303277400015 PM 22520878 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Teaching the endoscopic and paraendoscopic skills of gastroenterology SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2012 VL 75 IS 5 BP 1069 EP 1071 DI 10.1016/j.gie.2012.02.014 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 932GC UT WOS:000303277400020 PM 22520879 ER PT J AU Lomonaco, R Ortiz-Lopez, C Orsak, B Webb, A Hardies, J Darland, C Finch, J Gastaldelli, A Harrison, S Tio, F Cusi, K AF Lomonaco, Romina Ortiz-Lopez, Carolina Orsak, Beverly Webb, Amy Hardies, Jean Darland, Celia Finch, Joan Gastaldelli, Amalia Harrison, Stephen Tio, Fermin Cusi, Kenneth TI Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease SO HEPATOLOGY LA English DT Article ID STELLATE CELL ACTIVATION; DEPENDENT DIABETES-MELLITUS; ACID-METABOLISM; PPAR-GAMMA; STEATOHEPATITIS; ADIPONECTIN; GLUCOSE; LIPOTOXICITY; MECHANISMS; SECRETION AB The role of adipose tissue insulin resistance in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains unclear. To evaluate this, we measured in 207 patients with NAFLD (age = 51 +/- 1, body mass index = 34.1 +/- 0.3 kg/m2) and 22 controls without NAFLD (no NAFLD) adipose tissue insulin resistance by means of a validated index (Adipo-IRi = plasma free fatty acids [FFA] x insulin [FPI] concentration) and as the suppression of plasma FFA during an oral glucose tolerance test and by a low-dose insulin infusion. We also explored the relationship between adipose tissue insulin resistance with metabolic and histological parameters by dividing them based on quartiles of adipose tissue insulin resistance (Adipo-IRi quartiles: Q1 = more sensitive; Q4 = more insulin resistant). Hepatic insulin resistance, measured as an index derived from endogenous glucose production x FPI (HIRi), and muscle insulin sensitivity, were assessed during a euglycemic insulin clamp with 3-[3H] glucose. Liver fat was measured by magnetic resonance imaging and spectroscopy, and a liver biopsy was performed to assess liver histology. Compared to patients without steatosis, patients with NAFLD were insulin resistant at the level of adipose tissue, liver, and skeletal muscle and had higher plasma aspartate aminotransferase and alanine aminotransferase, triglycerides, and lower high-density lipoprotein cholesterol and adiponectin levels (all P < 0.01). Metabolic parameters, hepatic insulin resistance, and liver fibrosis (but not necroinflammation) deteriorated as quartiles of adipose tissue insulin resistance worsened (all P < 0.01). Conclusion: Adipose tissue insulin resistance plays a key role in the development of metabolic and histological abnormalities of obese patients with NAFLD. Treatment strategies targeting adipose tissue insulin resistance (e.g., weight loss and thiazolidinediones) may be of value in this population. (HEPATOLOGY 2012) C1 [Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, Audie L Murphy Vet Adm Med Ctr, San Antonio, TX 78229 USA. [Webb, Amy] Univ Texas Hlth Sci Ctr San Antonio, Div Hepatol, San Antonio, TX 78229 USA. [Hardies, Jean] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Tio, Fermin] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Harrison, Stephen] Brooke Army Med Ctr, San Antonio, TX USA. RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, Audie L Murphy Vet Adm Med Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cusi@uthscsa.edu RI Gastaldelli, Amalia/H-3319-2014; webb, andrew/G-9642-2016 OI Gastaldelli, Amalia/0000-0003-2594-1651; webb, andrew/0000-0003-4045-9732 FU Burroughs Wellcome Fund; American Diabetes Association [1-08-CR-08]; Veterans Affairs Merit Award [1 I01 CX000167-01]; Veterans Affairs Medical Research Fund; National Center for Research Resources [UL 1RR025767] FX This work was supported by the Burroughs Wellcome Fund (to K.C.), the American Diabetes Association (1-08-CR-08; to K.C.), and a Veterans Affairs Merit Award (1 I01 CX000167-01; to K.C.), the Veterans Affairs Medical Research Fund, and the National Center for Research Resources (award no.: UL 1RR025767). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources of the National Institutes of Health. NR 47 TC 100 Z9 103 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAY PY 2012 VL 55 IS 5 BP 1389 EP 1397 DI 10.1002/hep.25539 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 929GN UT WOS:000303049400009 PM 22183689 ER PT J AU Singal, AK Bashar, H Anand, BS Jampana, SC Singal, V Kuo, YF AF Singal, Ashwani K. Bashar, Hmoud Anand, Bhupinderjit S. Jampana, Sarat C. Singal, Vineet Kuo, Yong-Fang TI Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: Exploratory analysis from the UNOS database SO HEPATOLOGY LA English DT Article ID DISEASE; SURVIVAL; GRAFT AB Data on liver transplantation for patients with alcoholic hepatitis are limited. Using the United Network for Organ Sharing database (2004-2010), adults undergoing liver transplantation for a listing diagnosis of alcoholic hepatitis were matched for age, gender, ethnicity, and model for endstage disease (MELD) score, donor risk index, and year of transplantation with three patients transplanted for a listing diagnosis of alcoholic cirrhosis. Study outcomes of graft and patient survival on follow-up were also analyzed for cohorts based on the diagnosis of the explant (46 alcoholic hepatitis and 138 alcoholic cirrhosis) and diagnosis at both listing as well as of the explant (11 alcoholic hepatitis and 33 alcoholic cirrhosis). Five-year graft and patient survival of alcoholic hepatitis and alcoholic cirrhosis patients were 75% and 73% (P = 0.97) and 80% and 78% (P = 0.90), respectively. Five-year graft and patient survival rates were also similar for cohorts based on diagnosis of the explant and diagnosis at listing as well as explant. Cox proportional regression analysis adjusting for other variables showed no impact of the etiology of liver disease (alcoholic hepatitis versus alcoholic cirrhosis) on the graft and patient survival. The causes of graft loss and patient mortality were similar in the two groups, and were not alcohol-related in any patient. Conclusion: Compared with alcoholic cirrhosis, patients with alcoholic hepatitis have similar posttransplantation graft and patient survival. Based on these preliminary findings, liver transplantation may be considered in a select group of patients with alcoholic hepatitis who fail to improve with medical therapy. Prospective studies are needed to assess the long-term outcome after liver transplantation in patients with alcoholic hepatitis. (HEPATOLOGY 2012) C1 [Singal, Ashwani K.; Bashar, Hmoud; Jampana, Sarat C.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA. [Singal, Ashwani K.] Univ Texas Med Branch, Dept Gastroenterol, Galveston, TX USA. [Anand, Bhupinderjit S.] Baylor Coll Med, Michael DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singal, Vineet] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA. [Kuo, Yong-Fang] Univ Texas Med Branch, Dept Biostat, Galveston, TX USA. RP Singal, AK (reprint author), Mayo Clin, Dept Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA. EM ashwanisingal.com@gmail.com NR 25 TC 43 Z9 44 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAY PY 2012 VL 55 IS 5 BP 1398 EP 1405 DI 10.1002/hep.25544 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 929GN UT WOS:000303049400010 PM 22213344 ER PT J AU Chavez, LJ Williams, EC Lapham, G Bradley, KA AF Chavez, Laura J. Williams, Emily C. Lapham, Gwen Bradley, Katharine A. TI Association Between Alcohol Screening Scores and Alcohol-Related Risks Among Female Veterans Affairs Patients SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID BEHAVIORAL-COUNSELING INTERVENTIONS; INTIMATE PARTNER VIOLENCE; IDENTIFICATION TEST AUDIT; PRIMARY-CARE; GENDER-DIFFERENCES; EMERGENCY-DEPARTMENT; PREVENTIVE-SERVICES; DRINKING BEHAVIOR; SUBSTANCE-ABUSE; SEXUAL ASSAULT AB Objective: Evidence-based brief interventions for primary care patients with at-risk drinking include personalized feedback on alcohol-related risks, yet little is known about associations between alcohol screening scores and outcomes among women. This study evaluated associations between scores on the three-item Alcohol Use Disorders Identification Test consumption (AUDIT-C) questionnaire and self-reported alcohol-related risks and consequences among veteran women. Method: Female outpatients from an urban Veterans Affairs facility were mailed annual surveys (1998-2000) (response rates: 65% Years 1 and 2, 55% Year 3). Measures were obtained from each respondent's first completed survey and included a gender-specific AUDIT-C (0-12 points), self-reported alcohol-related consequences, problem drinking or other drug use, and health risks. The prevalence of each outcome across AUDIT-C score groups (0, 1-2, 3, 4, 5-7, 8-12) was estimated using logistic regression, adjusting for age, race, and marital status. Results: Among 2,670 respondents, 23.7% screened positive for alcohol misuse (AUDIT-C >= 3). For three out of the five alcohol-related consequences (tolerance, blackouts, felt needed to cut down), adjusted prevalence increased at AUDIT-C scores of 3 or more. The remaining alcohol-related consequences (morning eye openers, family/friends worried) increased at scores of 4 or more, as did self-reported problem drinking or other drug use. Associations between health risks (two or more sexual partners, sexually transmitted diseases, injuries, domestic violence, hepatitis/cirrhosis) and AUDIT-C scores were less consistent, but prevalence generally increased at scores of 5 or more. Conclusions: Increasing scores on the AUDIT-C reflect increasing prevalence of self-reported alcohol-related risks and consequences among women. These results provide clinicians with gender-specific information on alcohol-related risks that could be incorporated into brief interventions. (J. Stud. Alcohol Drugs, 73, 391-400, 2012) C1 [Chavez, Laura J.; Williams, Emily C.; Lapham, Gwen; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Chavez, Laura J.; Williams, Emily C.; Lapham, Gwen; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Chavez, LJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Laura.Chavez2@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [GEN-97-022]; Substance Use Disorders Quality Enhancement Research Initiative FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (GEN-97-022), and Substance Use Disorders Quality Enhancement Research Initiative. Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the University of Washington. NR 59 TC 11 Z9 11 U1 1 U2 4 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2012 VL 73 IS 3 BP 391 EP 400 PG 10 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA 929UQ UT WOS:000303091600006 PM 22456244 ER PT J AU Putterman, DB Valente, M AF Putterman, Daniel B. Valente, Michael TI Difference between the Default Telecoil (T-Coil) and Programmed Microphone Frequency Response in Behind-the-Ear (BTE) Hearing Aids SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Electromagnetic (EM) field; hearing aid; telecoil (t-coil) ID PERFORMANCE; TELEPHONE AB Background: A telecoil (t-coil) is essential for hearing aid users when listening on the telephone because using the hearing aid microphone when communicating on the telephone can cause feedback due to telephone handset proximity to the hearing aid microphone. Clinicians may overlook the role of the t-coil due to a primary concern of matching the microphone frequency response to a valid prescriptive target. Little has been published to support the idea that the t-coil frequency response should match the microphone frequency response to provide "seamless" and perhaps optimal performance on the telephone. If the clinical goal were to match both frequency responses, it would be useful to know the relative differences, if any, that currently exist between these two transducers. Purpose: The primary purpose of this study was to determine if statistically significant differences were present between the mean output (in dB SPL) of the programmed microphone program and the hearing aid manufacturer's default t-coil program as a function of discrete test frequencies. In addition, pilot data are presented on the feasibility of measuring the microphone and t-coil frequency response with real-ear measures using a digital speech-weighted noise. Research Design: A repeated-measures design was utilized for a 2-cc coupler measurement condition. Independent variables were the transducer (microphone, t-coil) and 11 discrete test frequencies (15 discrete frequencies in the real-ear pilot condition). Study Sample: The study sample was comprised of behind-the-ear (BTE) hearing aids from one manufacturer. Fifty-two hearing aids were measured in a coupler condition, 39 of which were measured in the real-ear pilot condition. Hearing aids were previously programmed and verified using real-ear measures to the NAL-NL1 (National Acoustic Laboratories Non-linear 1) prescriptive target by a licensed audiologist. Data Collection and Analysis: Hearing aid output was measured with a Fonix 7000 hearing aid analyzer (Frye Electronics, Inc.) in a HA-2 2-cc coupler condition using a pure-tone sweep at an input level of 60 dB SPL with the hearing aid in the microphone program and 31.6 mA/M in the t-coil program. A digital speech weighted noise input signal presented at additional input levels was used in the real-ear pilot condition. A mixed-model repeated-measures analysis of variance (ANOVA) and the Tukey Honestly Significant Difference (HSD) post hoc test were utilized to determine if significant differences were present in performance across treatment levels. Results: There was no significant difference between mean overall t-coil and microphone output averaged across 11 discrete frequencies (F(1,102) = 0, p < 0.98). A mixed-model repeated-measures ANOVA revealed a significant transducer by frequency interaction (F(10,102) = 13.0, p < 0.0001). Significant differences were present at 200 and 400 Hz where the mean t-coil output was less than the mean microphone output, and at 4000, 5000, and 6300 Hz where the mean t-coil output was greater than the mean microphone output. Conclusions: The mean t-coil output was significantly lower than the mean microphone output at 400 Hz, a frequency that lies within the typical telephone bandwidth of 300-3300 Hz. This difference may partially help to explain why some patients often complain the t-coil fails to provide sufficient loudness for telephone communication. C1 [Putterman, Daniel B.] Washington Univ, Sch Med, Program Audiol & Commun Sci, St Louis, MO USA. [Valente, Michael] Washington Univ, Sch Med, Div Adult Audiol, St Louis, MO USA. RP Putterman, DB (reprint author), Portland VA Med Ctr, NCRAR, Portland, OR 97239 USA. EM Daniel.Putterman@va.gov FU National Center for Research Resources (NCRR) [TL1 RR024995]; National Institutes of Health (NIH); NIH Roadmap for Medical Research FX This publication was made possible by Grant Number TL1 RR024995 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. NR 29 TC 0 Z9 0 U1 0 U2 3 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD MAY PY 2012 VL 23 IS 5 SI SI BP 366 EP 378 DI 10.3766/jaaa.23.5.7 PG 13 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 931LA UT WOS:000303220200007 PM 22533979 ER PT J AU Davis, LL Leon, AC Toscano, R Drebing, CE Ward, LC Parker, PE Kashner, TM Drake, RE AF Davis, Lori L. Leon, Andrew C. Toscano, Richard Drebing, Charles E. Ward, L. Charles Parker, Pamela E. Kashner, T. Michael Drake, Robert E. TI A Randomized Controlled Trial of Supported Employment Among Veterans With Posttraumatic Stress Disorder SO PSYCHIATRIC SERVICES LA English DT Article ID SEVERE MENTAL-ILLNESS; WORK THERAPY; OUTCOMES; DISABILITY; PEOPLE; SCALE; COMPENSATION AB Objective: Posttraumatic stress disorder (PTSD) is a potentially disabling mental illness that can cause occupational dysfunction. Although vocational rehabilitation is often prescribed for patients with PTSD, standard vocational services are far from adequate in helping them obtain and maintain competitive employment. This study is the first to examine the outcome of evidence-based supported employment for veterans with PTSD. Methods: Unemployed veterans with PTSD were randomly assigned to either individual placement and support (IFS) supported employment (N=42) or a Veterans Health Administration Vocational Rehabilitation Program (VRP) treatment as usual (N=43). Employment rates and occupational outcomes were followed for 12 months. Results: During the 12-month study, 76% of the IFS participants gained competitive employment, compared with 28% of the VRP participants (number needed to treat=2.07; chi(2)=19.84, df=1, p<.001). Veterans assigned to IPS also worked substantially more weeks than those assigned to VRP (42% versus 16% of the eligible weeks, respectively; Mann-Whitney z test p<.001) and earned higher 12-month income (meant+/-SD income of $9,264+/-$13,294 for IFS versus $2,601+/-$6,009 for VRP; Mann-Whitney z test p<.001) during the 12-month period. Conclusions: Veterans with PTSD who received IPS were 2.7 times more likely to gain competitive employment than those who received VRP. Because work is central to recovery, these results should assist stakeholders in planning improved services for veterans with PTSD. (Psychiatric Services 63:464-470, 2012; doi:10.1176/appi.ps.201100340) C1 [Davis, Lori L.; Toscano, Richard] Tuscaloosa Vet Affairs Med Ctr VAMC, Res & Dev Serv, Tuscaloosa, AL 35404 USA. [Ward, L. Charles] Tuscaloosa Vet Affairs Med Ctr VAMC, Psychol Serv, Tuscaloosa, AL 35404 USA. [Leon, Andrew C.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Drebing, Charles E.] Boston Univ, Sch Med, Dept Psychiat, Bedford, MA USA. [Drebing, Charles E.] Edith Nourse Rogers Mem Vet Hosp, New England Mental Illness Res Educ & Clin Ctr, Bedford, MA USA. [Parker, Pamela E.] VAMC, Mental Hlth Serv, Birmingham, AL USA. [Kashner, T. Michael] US Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA. [Kashner, T. Michael] Loma Linda Univ, Sch Med, Loma Linda, CA USA. [Drake, Robert E.] Dartmouth Med Sch, Psychiat Res Ctr, Lebanon, NH USA. RP Davis, LL (reprint author), Tuscaloosa Vet Affairs Med Ctr VAMC, Res & Dev Serv, 3701 Loop Rd E, Tuscaloosa, AL 35404 USA. EM lori.davis@va.gov RI Schueter, nicos/A-3625-2014 FU VA Rehabilitation Research and Development grant [D4092i]; Tuscaloosa VAMC's Research and Development Services; AstraZeneca FX This project was funded by VA Rehabilitation Research and Development grant D4092i and is registered at www.ClinicalTrials.gov (identifier number NCT00333801). The authors acknowledge the generous support of the Tuscaloosa VAMC's Research and Development Services and the hard work and devotion of the vocational rehabilitation specialists involved in the study, especially Allen Riley, M.A. The authors acknowledge the consultative expertise of Robert Rosenheck, M.D., and the Tuscaloosa VAMC vocational rehabilitation programmatic support of Thomas McNutt, Ph.D., and James Carr. The authors are grateful for the technical assistance of Catherine M. Blansett, Ph.D., Charles Li, Bonita S. Perry, M.S., Laura E. Blackburn, and Jessie McAlpine.; Dr. Davis has received a speaker honorarium and research funding from AstraZeneca. Dr. Leon served on independent data and safety monitoring boards for AstraZeneca, Sunovion, and Pfizer; served as a consultant-advisor to MedAvante and Roche; and had equity in MedAvante. The other authors report no competing interests. NR 26 TC 22 Z9 22 U1 4 U2 20 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAY PY 2012 VL 63 IS 5 BP 464 EP 470 DI 10.1176/appi.ps.201100340 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 933PE UT WOS:000303373600014 PM 22307881 ER PT J AU Whitford, TJ Ford, JM Mathalon, DH Kubicki, M Shenton, ME AF Whitford, Thomas J. Ford, Judith M. Mathalon, Daniel H. Kubicki, Marek Shenton, Martha E. TI Schizophrenia, Myelination, and Delayed Corollary Discharges: A Hypothesis SO SCHIZOPHRENIA BULLETIN LA English DT Article DE white matter; dopamine; neurodevelopment; salience; self-monitoring; efference copy; myelin ID WHITE-MATTER ABNORMALITIES; RECENT-ONSET SCHIZOPHRENIA; MULTIPLE-SCLEROSIS; SYNAPTIC PLASTICITY; AUDITORY HALLUCINATIONS; PSYCHIATRIC-DISORDERS; NERVOUS-SYSTEM; OPTIC NEURITIS; D-2 RECEPTORS; PSYCHOSIS AB Any etiological theory of schizophrenia must account for at least 3 distinctive features of the disorder, namely its excessive dopamine neurotransmission, its frequent periadolescent onset, and its bizarre, pathognomonic symptoms. In this article, we theorize that each of these features could arise from a single underlying cause-namely abnormal myelination of late-developing frontal white matter fasciculi. Specifically, we suggest that abnormalities in frontal myelination result in conduction delays in the efference copies initiated by willed actions. These conduction delays cause the resulting corollary discharges to be generated too late to suppress the sensory consequences of the willed actions. The resulting ambiguity as to the origins of these actions represents a phenomenologically and neurophysiologically significant prediction error. On a phenomenological level, the perception of salience in a self-generated action leads to confusion as to its origins and, consequently, passivity experiences and auditory hallucinations. On a neurophysiological level, this prediction error leads to the increased activity of dopaminergic neurons in the midbrain. This dopaminergic activity causes previously insignificant events to be perceived as salient, which exacerbates the budding hallucinations and passivity experiences and triggers additional first-rank symptoms such as delusions of reference. The article concludes with a discussion of the implications of the theory and some testable predictions which may form a worthwhile basis for future research. C1 [Whitford, Thomas J.; Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02215 USA. [Whitford, Thomas J.] Univ Melbourne, Melbourne Neuropsychiat Ctr, Dept Psychiat, Melbourne, Vic, Australia. [Whitford, Thomas J.] Melbourne Hlth, Melbourne, Vic, Australia. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Boston Vet Affairs Healthcare Syst, Clin Neurosci Div, Lab Neurosci,Dept Psychiat,Med Sch, Brockton, MA 02401 USA. RP Whitford, TJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Psychiat Neuroimaging Lab,Dept Psychiat, 1249 Boylston St, Boston, MA 02215 USA. EM whitford@bwh.harvard.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU National Health and Medical Research Council of Australia [NHMRC 520627]; National Institutes of Health [R01 MH076989, R01 MH058262, K02 MH067967, R03 MH068464-0, R01 MH 50747, K05 MH 070047, P50 MH 080272]; Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs (VA Schizophrenia Research Center) FX National Health and Medical Research Council of Australia (NHMRC 520627 to T.J.W.); the National Institutes of Health (R01 MH076989 to D. H. M.; R01 MH058262 and K02 MH067967 to J.M.F.; R03 MH068464-0 to M. K.; R01 MH 50747, K05 MH 070047, and P50 MH 080272 to M. E. S.); Harvard Medical School (Milton Award); Department of Veterans Affairs (VA Merit Review to J.M.F., VA Merit Award, VA Research Enhancement Award Program, and VA Schizophrenia Research Center Grant to M.E.S.). NR 91 TC 45 Z9 45 U1 2 U2 24 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAY PY 2012 VL 38 IS 3 BP 486 EP 494 DI 10.1093/schbul/sbq105 PG 9 WC Psychiatry SC Psychiatry GA 930VB UT WOS:000303169000016 PM 20855415 ER PT J AU Hope, MD Urbania, TH Yu, JPJ Chitsaz, S Tseng, E AF Hope, Michael D. Urbania, Thomas H. Yu, John-Paul J. Chitsaz, Sam Tseng, Elaine TI Incidental Aortic Valve Calcification on CT Scans: Significance for Bicuspid and Tricuspid Valve Disease SO ACADEMIC RADIOLOGY LA English DT Article DE Bicuspid aortic valve; aortic stenosis; aortic valve calcification ID CLINICAL-SIGNIFICANCE; STENOSIS; PROGRESSION; TOMOGRAPHY; PREVALENCE; AGE AB Rationale and Objectives: The aim of this study was to evaluate the role of incidental aortic valve calcification on routine computed tomographic scans as a marker for stenosis, as assessed by echocardiography, in patients with bicuspid aortic valve (BAV) and tricuspid aortic valve. Materials and Methods: Computed tomographic and echocardiographic studies were retrospectively reviewed for 182 consecutive, unselected patients and 426 patients identified by a record search for "aortic valve calcification." Location and severity of valve calcification were correlated with aortic valve morphology and stenosis. Differences between subgroups were assessed using chi(2) or Fisher's exact tests. Results: In unselected patients, calcification was present in 25.8% with tricuspid aortic valves (46 of 178) and 75% (three of four) with BAV. In patients selected for valve calcification, the average age of those with tricuspid aortic valves (n = 395) was 14.3 years older than those with BAV (n = 31). Patients with BAV were more likely to have severe calcification (87% vs 50%, P <.001), and if severe, calcification was present, it was more likely to involve only the valve leaflets (41% vs 9%, P < .001) and result in aortic stenosis (85% vs 58%, P = .006). Patients aged < 60 years with severe calcification were more likely to have BAV (56% vs 7%; odds ratio, 7.9; 95% confidence interval, 3.4-18.7). Conclusions: Aortic valve calcification was found 14 years earlier in patients with BAV and was more severe and strongly linked to aortic stenosis. Valve calcification on computed tomographic scans should be considered a marker for BAV if found before the seventh decade. C1 [Hope, Michael D.; Urbania, Thomas H.; Yu, John-Paul J.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Chitsaz, Sam; Tseng, Elaine] San Francisco VA Med Ctr, Dept Cardiothorac Surg, San Francisco, CA USA. RP Hope, MD (reprint author), Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. EM michael.hope@ucsf.edu RI Chitsaz, Sam/C-4586-2008 OI Yu, John-Paul/0000-0003-1878-052X NR 14 TC 3 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD MAY PY 2012 VL 19 IS 5 BP 542 EP 547 DI 10.1016/j.acra.2011.10.012 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 929OR UT WOS:000303075700006 PM 22104287 ER PT J AU Jotwani, V Li, YM Grunfeld, C Choi, AI Shlipak, MG AF Jotwani, Vasantha Li, Yongmei Grunfeld, Carl Choi, Andy I. Shlipak, Michael G. TI Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE End-stage renal disease; human immunodeficiency virus (HIV); chronic kidney disease; risk factors ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; OF-VETERANS-AFFAIRS; CARDIOVASCULAR EVENTS; CYSTATIN C; COHORT; ASSOCIATION; PREVALENCE; NEPHROPATHY AB Background: Despite improvements in survival with human immunodeficiency virus (HIV) infection, kidney disease remains an important complication. Few studies have evaluated risk factors associated with the development of end-stage renal disease (ESRD) in HIV-infected individuals. We sought to identify traditional and HIV-related risk factors for ESRD in HIV-infected individuals and compare ESRD risk by estimated glomerular filtration rate (eGFR) and proteinuria levels. Study Design: Retrospective cohort study. Setting & Participants: 22,156 HIV-infected veterans without pre-existing ESRD receiving health care in the Veterans' Affairs medical system between 1996 and 2004. Predictors: Hypertension, diabetes, cardiovascular disease, hypoalbuminemia (serum albumin <3.5 mg/dL), CD4 lymphocyte count, HIV viral load, hepatitis C virus coinfection, proteinuria, and eGFR were identified using the Veterans' Affairs electronic record system. Outcomes: ESRD was ascertained by the US Renal Data System. Results: 366 cases of ESRD occurred, corresponding to 3 cases/1,000 person-years. Hypertension (HR, 1.9; 95% CI, 1.5-2.4), diabetes (HR, 1.7; 95% CI, 1.3-2.2), and cardiovascular disease (HR, 2.2; 95% CI, 1.7-2.7) were associated independently with ESRD risk in multivariate-adjusted models, as were CD4 lymphocyte count <200 cells/mu L (HR, 1.5; 95% CI, 1.2-2.0), HIV viral load >= 30,000 copies/mL (HR, 2.0; 95% CI, 1.5-2.8), hepatitis C virus coinfection (HR, 1.9; 95% CI, 1.5-2.4), and hypoalbuminemia (HR, 2.1; 95% CI, 1.8-2.5). Compared with persons without chronic kidney disease, defined as eGFR >60 mL/min/1.73 m(2) and no proteinuria, lower eGFR and higher proteinuria categories were associated jointly with exponentially higher ESRD rates, ranging from 6.6 events/1,000 person-years for persons with urine protein excretion of 30-100 mg/dL and eGFR >60 mL/min/1.73 m(2) to 193 events/1,000 person-years for persons with urine protein excretion >= 300 mg/dL and eGFR <30 mL/min/1.73 m(2). Limitations: Results may not be generalizable to female and nonveteran populations. Conclusions: In HIV-infected persons, ESRD risk appears attributable to a combination of traditional and HIV-related risk factors for kidney disease. Combining eGFR and proteinuria for chronic kidney disease staging is most effective for stratifying the risk of ESRD. Am J Kidney Dis. 59(5): 628-635. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, Vet Affairs Med Ctr 111A1, Div Gen Internal Med, San Francisco, CA 94121 USA. [Jotwani, Vasantha; Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Grunfeld, Carl] San Francisco VA Med Ctr, Div Endocrinol, San Francisco, CA USA. [Choi, Andy I.] San Francisco VA Med Ctr, Div Nephrol, San Francisco, CA USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Gen Internal Med Sect, Vet Affairs Med Ctr 111A1, Div Gen Internal Med, 4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU National Institutes of Health [K23DK080645-01A1, 1R03AG034871-01, R01 DK066488-01] FX This study was supported by National Institutes of Health grants K23DK080645-01A1 (A.I.C.), 1R03AG034871-01 (A.I.C.), R01 DK066488-01 (M.G.S.), which were administered by the Northern California Institute for Research and Education, and with resources of the VA Medical Center, San Francisco, CA. These funding sources had no involvement in the design or execution of this study. NR 44 TC 50 Z9 52 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2012 VL 59 IS 5 BP 628 EP 635 DI 10.1053/j.ajkd.2011.10.050 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 926XH UT WOS:000302864700009 PM 22206742 ER PT J AU Mitsani, D Nguyen, MH Shields, RK Toyoda, Y Kwak, EJ Silveira, FP Pilewski, JM Crespo, MM Bermudez, C Bhama, JK Clancy, CJ AF Mitsani, Dimitra Nguyen, M. Hong Shields, Ryan K. Toyoda, Yoshiya Kwak, Eun J. Silveira, Fernanda P. Pilewski, Joseph M. Crespo, Maria M. Bermudez, Christian Bhama, Jay K. Clancy, Cornelius J. TI Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID INVASIVE FUNGAL-INFECTIONS; STEM-CELL TRANSPLANTATION; ADVERSE EVENTS; CANINE LUNG; SAFETY; PHARMACOKINETICS; ASPERGILLOSIS; POPULATION; ABNORMALITIES; DEFINITIONS AB Voriconazole prophylaxis is common following lung transplantation, but the value of therapeutic drug monitoring is unknown. A prospective, observational study of lung transplant recipients (n = 93) receiving voriconazole prophylaxis was performed. Serum voriconazole troughs (n = 331) were measured by high-pressure liquid chromatography. The median initial and subsequent troughs were 1.91 and 1.46 mu g/ml, respectively. The age of the patient directly correlated with initial troughs (P = 0.005). Patients that were >= 60 years old and cystic fibrosis patients were significantly more likely to have higher and lower initial troughs, respectively. In 95% (88/93) of patients,>= 2 troughs were measured. In 28% (25/88) and 32% (28/88) of these patients, all troughs were <= 1.5 mu g/ml or > 1.5 mu g/ml, respectively. Ten percent (10/93) and 27% (25/93) of the patients developed invasive fungal infection (tracheobronchitis) and fungal colonization, respectively. The median troughs at the times of positive and negative fungal cultures were 0.92 and 1.72 mu g/ml (P = 0.07). Invasive fungal infections or colonization were more likely with troughs of <= 1.5 mu g/ml (P = 0.01) and among patients with no trough of > 1.5 mu g/ml (P = 0.007). Other cutoff troughs correlated less strongly with microbiologic outcomes. Troughs correlated directly with aspartate transferase levels (P = 0.003), but not with other liver enzymes. Voriconazole was discontinued due to suspected toxicity in 27% (25/93) of the patients. The troughs did not differ at the times of suspected drug-induced hepatotoxicity, central nervous system (CNS) toxicity, or nausea/vomiting and in the absence of toxicity. Voriconazole prophylaxis was most effective at troughs of > 1.5 mu g/ml. A cutoff for toxicity was not identified, but troughs of > 4 mu g/ml were rare. The data support a target range of > 1.5 to 4 mu g/ml. C1 [Mitsani, Dimitra; Nguyen, M. Hong; Shields, Ryan K.; Kwak, Eun J.; Silveira, Fernanda P.; Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15260 USA. [Pilewski, Joseph M.; Crespo, Maria M.] Univ Pittsburgh, Div Pulm Med, Dept Med, Pittsburgh, PA USA. [Toyoda, Yoshiya; Bermudez, Christian; Bhama, Jay K.] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15260 USA. EM mhn5@pitt.edu FU Pfizer; Merck; Astellas; ViraCor-IBT Laboratories FX Funding for this project was provided through an investigator-initiated research grant from Pfizer to C. J. Clancy. Pfizer had no input into the study design, data interpretation, or conclusions. C. J. Clancy has received grant support for unrelated research projects from Pfizer, Merck, and Astellas. M. H. Nguyen has received grant support for unrelated research projects from Pfizer, Merck, and ViraCor-IBT Laboratories. R. K. Shields has received grant support for unrelated research projects from Merck and Astellas. E. J. Kwak has received grant support for unrelated research projects from Pfizer. NR 41 TC 51 Z9 55 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2012 VL 56 IS 5 BP 2371 EP 2377 DI 10.1128/AAC.05219-11 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 925VQ UT WOS:000302790400023 PM 22330924 ER PT J AU Salanitro, AH Ritchie, CS Hovater, M Roth, DL Sawyer, P Locher, JL Bodner, E Brown, CJ Allman, RM AF Salanitro, Amanda H. Ritchie, Christine S. Hovater, Martha Roth, David L. Sawyer, Patricia Locher, Julie L. Bodner, Eric Brown, Cynthia J. Allman, Richard M. TI Inflammatory biomarkers as predictors of hospitalization and death in community-dwelling older adults SO ARCHIVES OF GERONTOLOGY AND GERIATRICS LA English DT Article DE Inflammation; Hospitalization; Mortality; Community-dwelling older adults ID FUNCTIONAL DECLINE; AFRICAN-AMERICAN; BODY-COMPOSITION; MARKERS; MORTALITY; RISK; HEALTH; ELDERS; ASSOCIATIONS; CHOLESTEROL AB Individuals with multimorbidity may be at increased risk of hospitalization and death. Comorbidity indexes do not capture severity of illness or healthcare utilization; however, inflammation biomarkers that are not disease-specific may predict hospitalization and death in older adults. We sought to predict hospitalization and mortality of older adults using inflammation biomarkers. From a prospective, observational study, 370 community-dwelling adults 65 years or older from central Alabama participated in an in-home assessment and provided fasting blood samples for inflammation biomarker testing in 2004. We calculated an inflammation summary score (range 0-4), one point each for low albumin, high C-reactive protein, low cholesterol, and high interleukin-6. Utilizing Cox proportional hazards models, inflammation summary scores were used to predicted time to hospitalization and death during a 4-year follow up period. The mean age was 73.7 (+/- 5.9 yrs), and 53 (14%) participants had summary scores of 3 or 4. The rates of dying were significantly increased for participants with inflammation summary scores of 2, 3, or 4 (hazard ratio (HR) 2.22, 2.78, and 7.55, respectively; p < 0.05). An inflammation summary score of 4 significantly predicted hospitalization (HR 5.92, p < 0.05). Community-dwelling older adults with biomarkers positive for inflammation had increased rates of being hospitalized or dying during the follow up period. Assessment of the individual contribution of particular inflammation biomarkers in the prediction of health outcomes in older populations and the development of validated summary scores to predict morbidity and mortality are needed. Published by Elsevier Ireland Ltd. C1 [Salanitro, Amanda H.] Vanderbilt Univ, Sect Hosp Med, Nashville, TN 37212 USA. [Salanitro, Amanda H.] Vanderbilt Univ, VA Tennessee Valley Healthcare Geriatr Res Educ C, Nashville, TN 37212 USA. [Ritchie, Christine S.; Sawyer, Patricia; Locher, Julie L.; Bodner, Eric; Brown, Cynthia J.; Allman, Richard M.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Ritchie, Christine S.; Roth, David L.; Brown, Cynthia J.; Allman, Richard M.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Ritchie, Christine S.; Roth, David L.; Brown, Cynthia J.; Allman, Richard M.] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA. [Hovater, Martha; Roth, David L.] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. RP Salanitro, AH (reprint author), Room A-414,1310 24th Ave S, Nashville, TN 37212 USA. EM Amanda.Salanitro@Vanderbilt.Edu FU National Institute on Aging (NIA) [R01-AG015062, P30AG031054, 1K07AG31779]; American Cancer Society; AHRQ; NIH [1UL 1RR025777]; HRSA; Donald W. Reynolds Foundation; UpToDate; Department of Veterans Affairs Health Services Research & Development Service [E6326W]; GCRC from the National Center for Research Resources [M01 RR-00032] FX CJB was a member of the editorial board for JAGS. DLR, JLL, RMA were received the grant funding from National Institute on Aging (NIA). JLL was received the grant funding from American Cancer Society. CSR was employment at UAB, Birmingham VA Medical Center; grants/funds from AHRQ, NIH, HRSA, Donald W. Reynolds Foundation; honoraria from Center to Advance Palliative Care, Macon State College, & American Board of Internal Medicine; consultant for University of Puerto Rico; royalties from UpToDate; member of American Academy of Hospice & Palliative Medicine Board of Directors.; This work was supported by the National Institute on Aging [grant numbers R01-AG015062, P30AG031054] to RMA; the National Institute on Aging [grant number 1K07AG31779] to CSR; and the Department of Veterans Affairs Health Services Research & Development Service, Research Career Development Award [grant number E6326W] to CJB; and the National Institutes of Health grant award 1UL 1RR025777 partially supported RMA. Blood analyses supported by GCRC Grant M01 RR-00032 from the National Center for Research Resources. The funding sources had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; nor in the decision to submit the manuscript for publication. NR 32 TC 11 Z9 11 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-4943 J9 ARCH GERONTOL GERIAT JI Arch. Gerontol. Geriatr. PD MAY-JUN PY 2012 VL 54 IS 3 BP E387 EP E391 DI 10.1016/j.archger.2012.01.006 PG 5 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 928DB UT WOS:000302959400021 PM 22305611 ER PT J AU Perera, MN Ganesan, V Siskind, LJ Szulc, ZM Bielawski, J Alicja, B Bittman, R Colombini, M AF Perera, Meenu N. Ganesan, Vidyaramanan Siskind, Leah J. Szulc, Zdzislaw M. Bielawski, Jacek Alicja, Bielawska Bittman, Robert Colombini, Marco TI Ceramide channels: Influence of molecular structure on channel formation in membranes SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES LA English DT Article DE Ceramide; Analogs; Channels; Mitochondria; Permeabilization; Pore ID MITOCHONDRIAL OUTER-MEMBRANE; TANDEM MASS-SPECTROMETRY; BIOACTIVE SPHINGOLIPIDS; SUBSTRATE-SPECIFICITY; QUANTITATIVE-ANALYSIS; PLANT-MITOCHONDRIA; ESTER PRECURSORS; LIPID-BILAYERS; SPHINGOSINE; PROTEINS AB The sphingolipid, ceramide, self-assembles in the mitochondrial outer membrane (MOM), forming large channels capable of translocating proteins. These channels are believed to be involved in protein release from mitochondria, a key decision-making step in cell death. Synthetic analogs of ceramide, bearing modifications in each of the major structural features of ceramide were used to probe the molecular basis for the stability of ceramide channels. Channel stability and mitochondrial permeabilization were disrupted by methylation of the C1-hydroxyl group whereas modifications of the C3 allylic hydroxyl group were well tolerated. A change in chirality at C2 that would influence the orientation of the C1-hydroxyl group resulted in a strong reduction of channel-forming ability. Similarly, methylation of the amide nitrogen is also detrimental to channel formation. Many changes in the degree, location and nature of the unsaturation of ceramide had little effect on mitochondrial permeabilization. Competition experiments between ceramide and analogs resulted in synergy with structures compatible with the ceramide channel model and antagonism with incompatible structures. The results are consistent with ceramide channels being highly organized structures, stabilized by specific inter-molecular interactions, similar to the interactions responsible for protein folding. (C) 2012 Elsevier B.V. All rights reserved. C1 [Perera, Meenu N.; Ganesan, Vidyaramanan; Colombini, Marco] Univ Maryland, Dept Biol, College Pk, MD 20742 USA. [Siskind, Leah J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Siskind, Leah J.; Szulc, Zdzislaw M.; Bielawski, Jacek; Alicja, Bielawska] Med Univ S Carolina, Charleston, SC 29403 USA. [Bittman, Robert] CUNY Queens Coll, Flushing, NY 11367 USA. RP Colombini, M (reprint author), Univ Maryland, Dept Biol, College Pk, MD 20742 USA. EM colombini@umd.edu RI Colombini, Marco/A-1540-2014; Ganesan, Vidyaramanan/H-3787-2016 OI Ganesan, Vidyaramanan/0000-0002-6160-5594; Szulc, Zdzislaw M./0000-0003-1756-9028 FU National Science Foundation [MCB-1023008]; National Institutes of Health [HL-083187]; Veterans Administration; Veteran's Administration REAP; NCI [IPO1CA097132, P30 CA 138313]; NIH/NCRR [P20 RR017677]; NIH from National Center for Research Resources [C06 RR018823] FX This work was supported by grants from the National Science Foundation [MCB-1023008] to MC and from the National Institutes of Health [HL-083187] to RB. L.J.S is supported by a Career Development Award-2 from the Veterans Administration and pilot project funding from a Veteran's Administration REAP. Synthetic lipids and LC-MS/MS analysis of sphingolipids were provided by the Lipidomics Shared Resource, MUSC, supported by NCI Grants: [IPO1CA097132] and [P30 CA 138313] and NIH/NCRR SC COBRE Grant [P20 RR017677]. Laboratory space for Lipidomics Shared Resource in the CRI building of MUSC was supported by NIH Grant [C06 RR018823] from the Extramural Research Facilities Program of the National Center for Research Resources. NR 45 TC 22 Z9 23 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0005-2736 J9 BBA-BIOMEMBRANES JI Biochim. Biophys. Acta-Biomembr. PD MAY PY 2012 VL 1818 IS 5 BP 1291 EP 1301 DI 10.1016/j.bbamem.2012.02.010 PG 11 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 928GL UT WOS:000302971100021 PM 22365970 ER PT J AU Deatrick, JA Hardie, T AF Deatrick, Janet A. Hardie, Thomas TI Strategies for Selecting Measures for Pediatric and Maternal Child Research SO CLINICAL NURSING RESEARCH LA English DT Editorial Material C1 [Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Hardie, Thomas] Drexel Univ, Philadelphia, PA 19104 USA. RP Deatrick, JA (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Claire M Fagin Hall,418 Curie Blvd,223 2L, Philadelphia, PA 19104 USA. EM deatrick@nursing.upenn.edu RI Hardie, Thomas/J-7776-2012 OI Hardie, Thomas/0000-0002-4547-7991 NR 10 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1054-7738 J9 CLIN NURS RES JI Clin. Nurs. Res. PD MAY PY 2012 VL 21 IS 2 SI SI BP 135 EP 141 DI 10.1177/1054773812439511 PG 7 WC Nursing SC Nursing GA 926TL UT WOS:000302854600001 PM 22508686 ER PT J AU French, SL Floyd, M Wilkins, S Osato, S AF French, Samantha L. Floyd, Mark Wilkins, Stacy Osato, Sheryl TI The Fear of Alzheimer's Disease Scale: a new measure designed to assess anticipatory dementia in older adults SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE anticipatory dementia; fear of developing Alzheimer's disease; Alzheimer's disease threat; anxiety; older adults ID TRAIT ANXIETY INVENTORY; SUBJECTIVE FORGETFULNESS; 1ST-DEGREE RELATIVES; PERSONAL-EXPERIENCE; HELP-SEEKING; POPULATION; PREVALENCE AB Background: As the prevalence of Alzheimer's disease (AD) is rapidly increasing, apprehension about developing the degenerative disease (anticipatory dementia or fear of developing AD) has become a topic of interest. However, most studies of anticipatory dementia have utilized brief, nonvalidated measures to explore older adults' apprehension. As such, there is a significant need for a psychometrically sound instrument to measure this fear. Methods: The current study utilized 101 older adults ages 65 to 91 to develop and validate an important new scale, the Fear of Alzheimer's Disease Scale (FADS). Construct validity of the FADS was assessed with the State-Trait Anxiety Inventory-Form Y (STAI-Y). Results: Analyses revealed a three-factor model for the FADS (i.e., General Fear, Physical Symptoms, and Catastrophic Attitude) and an alpha of 0.94 for the entire measure, indicating good internal consistency. The FADS demonstrated good construct validity, as it was significantly correlated with both the state and trait subscales of the STAI-Y, with the trait subscale yielding the highest correlation. Conclusion: The FADS is a reliable and valid instrument and is the first of its kind available to directly address anticipatory dementia among a general population of older adults. Copyright (C) 2011 John Wiley& Sons, Ltd. C1 [French, Samantha L.] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. [French, Samantha L.; Wilkins, Stacy; Osato, Sheryl] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Floyd, Mark] VA N Texas Healthcare Syst, Bonham, TX USA. [Wilkins, Stacy; Osato, Sheryl] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [French, Samantha L.] VA Loma Linda Healthcare Syst, Loma Linda, CA USA. RP French, SL (reprint author), Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. EM Samantha.French@va.gov NR 35 TC 8 Z9 8 U1 0 U2 20 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD MAY PY 2012 VL 27 IS 5 BP 521 EP 528 DI 10.1002/gps.2747 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 926XL UT WOS:000302865200011 PM 21721044 ER PT J AU Freedland, SJ Walter, LC AF Freedland, Stephen J. Walter, Louise C. TI 80 is the new 60: Implications of Irrational Exuberance Regarding Longevity on Prostate Cancer Treatment Decisions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Freedland, Stephen J.] Duke Univ, Surg Sect, Durham VA Med Ctr, Durham, NC 27706 USA. [Freedland, Stephen J.] Duke Univ, Dept Urol Surg, Duke Prostate Ctr, Duke Canc Inst, Durham, NC 27706 USA. [Freedland, Stephen J.] Duke Univ, Dept Pathol, Duke Prostate Ctr, Duke Canc Inst, Durham, NC 27706 USA. [Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Freedland, SJ (reprint author), Duke Univ, Surg Sect, Durham VA Med Ctr, Durham, NC 27706 USA. EM steve.freedland@duke.edu FU NCI NIH HHS [R01 CA134425] NR 6 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 485 EP 486 DI 10.1007/s11606-012-2006-8 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300002 PM 22328015 ER PT J AU Chamie, K Daskivich, TJ Kwan, L Labo, J Dash, A Greenfield, S Litwin, MS AF Chamie, Karim Daskivich, Timothy J. Kwan, Lorna Labo, Jessica Dash, Atreya Greenfield, Sheldon Litwin, Mark S. TI Comorbidities, Treatment and Ensuing Survival in Men with Prostate Cancer SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE prostatic neoplasms; comorbidity; outcome assessment; survival; treatment mismatch ID PROPORTIONAL HAZARDS MODEL; RADICAL PROSTATECTOMY; INITIAL TREATMENT; OUTCOMES; RADIOTHERAPY; STATISTICS; VALIDATION; RADIATION; THERAPY; TRENDS AB Comorbidity is poorly integrated into prostate cancer decision making. We sought to characterize treatment type and subsequent survival for men with no more than a single comorbid condition. We conducted a retrospective study of 1,031 veterans with non-metastatic prostate cancer diagnosed in 1997-2004 at the Greater Los Angeles and Long Beach Veterans Affairs Medical Centers and followed until 2010. We used multivariate analyses to determine probabilities and relative risks of undergoing treatment for each health state and competing-risks regression analyses to model non-prostate cancer mortality. Compared with subjects without any comorbid conditions, only men with moderate-severe chronic obstructive pulmonary disease were less likely to receive definitive treatment for their prostate cancer (RR 0.74; 95% CI 0.44-0.99). Men with all other individual comorbidities were equally likely as men without comorbidity to receive definitive treatment. Compared with men without any comorbidities, a higher hazard rate for non-prostate cancer mortality was identified among men with diabetes without end-organ damage (HR 2.32; 95% CI 1.32-4.08), peripheral vascular disease (HR 2.77; 95% CI 1.14-6.73), moderate-severe chronic obstructive pulmonary disease (HR 5.46; 95% CI 2.68-11.12), diabetes with end-organ damage (HR 4.27; 95% CI 1.64-11.10), those in need of a mobility device (HR 3.29; 95% CI 1.87-5.80), and men with history of alcoholism (HR 1.77; 95% CI 1.07-2.93). Men with comorbid conditions and health states that portend poor prognoses are nonetheless aggressively treated for their prostate cancer. Advancing age modulates this effect. C1 [Chamie, Karim; Daskivich, Timothy J.; Labo, Jessica; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Hlth Serv Res Grp, Los Angeles, CA 90024 USA. [Chamie, Karim; Kwan, Lorna; Litwin, Mark S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Daskivich, Timothy J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dash, Atreya] Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA. [Dash, Atreya] Univ Calif Irvine, Dept Urol, Irvine, CA USA. [Greenfield, Sheldon] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA. [Greenfield, Sheldon] Univ Calif Irvine, Hlth Policy Res Inst, Irvine, CA USA. [Litwin, Mark S.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Chamie, K (reprint author), Univ Calif Los Angeles, Dept Urol, Hlth Serv Res Grp, 924 Westwood Blvd,Suite 1000, Los Angeles, CA 90024 USA. EM kchamie@mednet.ucla.edu FU American Cancer Society [117496-PF-09-147-01-CPHPS]; Ruth L. Kirschstein National Research Service Award Extramural [1 F32 CA144461-01]; Jonsson Comprehensive Cancer Center; National Institute of Diabetes and Digestive and Kidney Diseases [N01-DK-1-2460] FX This work was supported by the American Cancer Society (117496-PF-09-147-01-CPHPS (Principal Investigator: KC)); Ruth L. Kirschstein National Research Service Award Extramural (1 F32 CA144461-01 (Principal Investigator: KC)); Jonsson Comprehensive Cancer Center Seed Grant (Principal Investigator: MSL)); and National Institute of Diabetes and Digestive and Kidney Diseases (N01-DK-1-2460 (Principal investigator: M.S.L.)) NR 20 TC 9 Z9 9 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 492 EP 499 DI 10.1007/s11606-011-1869-4 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300006 PM 21935751 ER PT J AU Ahluwalia, SC Gross, CP Chaudhry, SI Ning, YM Leo-Summers, L Van Ness, PH Fried, TR AF Ahluwalia, Sangeeta C. Gross, Cary P. Chaudhry, Sarwat I. Ning, Yuming M. Leo-Summers, Linda Van Ness, Peter H. Fried, Terri R. TI Impact of Comorbidity on Mortality Among Older Persons with Advanced Heart Failure SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE heart failure; mortality; comorbidity ID DIFFERENTIAL PROGNOSTIC IMPACT; CHRONIC KIDNEY-DISEASE; POPULATION; HOSPITALIZATIONS; ASSOCIATION; PREVALENCE; CANCER AB Care for patients with advanced heart failure (HF) has traditionally focused on managing HF alone; however, little is known about the prevalence and contribution of comorbidity to mortality among this population. We compared the impact of comorbidity on mortality in older adults with HF with high mortality risk and those with lower mortality risk, as defined by presence or absence of a prior hospitalization for HF, respectively. This was a retrospective cohort study (2002-2006) of 18,322 age-matched and gender-matched Medicare beneficiaries. We used the baseline year of 2002 to ascertain HF hospitalization history, in order to identify beneficiaries at either high or low risk of future HF mortality. We calculated the prevalence of 19 comorbidities and overall comorbidity burden, defined as a count of conditions, among both high and low risk beneficiaries, in 2002. Proportional hazards regressions were used to determine the effect of individual comorbidity and comorbidity burden on mortality between 2002 and 2006 among both groups. Most comorbidities were significantly more prevalent among hospitalized versus non-hospitalized beneficiaries; myocardial infarction, atrial fibrillation, kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and hip fracture were more than twice as prevalent in the hospitalized group. Among hospitalized beneficiaries, myocardial infarction, diabetes, COPD, CKD, dementia, depression, hip fracture, stroke, colorectal cancer and lung cancer were each significantly associated with increased hazard of dying (hazard ratios [HRs]: 1.16-1.93), adjusting for age, gender and race. The mortality risk associated with most comorbidities was higher among non-hospitalized beneficiaries (HRs: 1.32-3.78). Comorbidity confers a significantly increased mortality risk even among older adults with an overall high mortality risk due to HF. Clinicians who routinely care for this population should consider the impact of comorbidity on outcomes in their overall management of HF. Such information may also be useful when considering the risks and benefits of aggressive, high-intensity life-prolonging interventions. C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA. [Gross, Cary P.; Chaudhry, Sarwat I.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Ning, Yuming M.; Leo-Summers, Linda; Van Ness, Peter H.] Yale Univ, Sch Med, Program Aging, New Haven, CT USA. [Van Ness, Peter H.; Fried, Terri R.] Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06510 USA. [Fried, Terri R.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA. RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90064 USA. EM sangeeta.ahluwalia@va.gov OI Walton, Kerry/0000-0003-2272-3878 FU National Institute on Aging [T32AG1934, K24 AG028443, K23AG030986]; Office of Academic Affiliation's VA at the VA Greater Los Angeles HSR&D Center of Excellence; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (NIH/NIA) [2P30AG021342-06] FX Dr. Ahluwalia was supported by a training grant from the National Institute on Aging (T32AG1934) and is currently supported by an Office of Academic Affiliation's VA Associated Health Postdoctoral Fellowship Program at the VA Greater Los Angeles HSR&D Center of Excellence. Dr. Fried is a recipient of a Midcareer Investigator Award in Patient-Oriented Research from the National Institute on Aging (K24 AG028443). Dr. Chaudhry is the recipient of a Paul Beeson/K23 Career Development Award (K23AG030986) from the National Institute on Aging. Supported by the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (#2P30AG021342-06 NIH/NIA). NR 25 TC 32 Z9 32 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 513 EP 519 DI 10.1007/s11606-011-1930-3 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300009 PM 22095572 ER PT J AU Sun, VK Cenzer, IS Kao, HL Ahalt, C Williams, BA AF Sun, Vivien K. Cenzer, Irena Stijacic Kao, Helen Ahalt, Cyrus Williams, Brie A. TI How Safe is Your Neighborhood? Perceived Neighborhood Safety and Functional Decline in Older Adults SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE functional decline; disparities; neighborhood safety; elderly ID RISK-FACTORS; ELDERLY-PEOPLE; MENTAL-HEALTH; FEAR; CRIME; MOBILITY; LIFE; PREDICTION; MORTALITY; ASSOCIATION AB Neighborhood characteristics are associated with health and the perception of safety is particularly important to exercise and health among older adults. Little is known about the relationship between perception of neighborhood safety and functional decline in older adults. To determine the relationship between perceived neighborhood safety and functional decline in older adults. Longitudinal, community-based. 18,043 persons, 50 years or older, who participated in the 1998 and 2008 Health and Retirement Study. The primary outcome was 10-year functional decline (new difficulty or dependence in any Activity of Daily Living, new mobility difficulty, and/or death). The primary predictor was perceived neighborhood safety categorized into three groups: "very safe", "moderately safe", and "unsafe." We evaluated the association between perceived neighborhood safety and 10-year functional decline using a modified Poisson regression to generate unadjusted and adjusted relative risks (ARR). At baseline 11,742 (68.0%) participants perceived their neighborhood to be very safe, 4,477 (23.3%) moderately safe, and 1,824 (8.7%) unsafe. Over 10 years, 10,338 (53.9%) participants experienced functional decline, including 6,266 (50.2%) who had perceived their neighborhood to be very safe, 2,839 (61.2%) moderately safe, and 1,233 (63.6%) unsafe, P < 0.001. For the 11,496 (63.3%) of participants who were functionally independent at baseline, perceived neighborhood safety was associated with 10-year functional decline (moderately safe ARR 1.15 95% CI 1.09-1.20; unsafe ARR 1.21 95% CI: 1.03-1.31 compared to very safe group). The relationship between perceived neighborhood safety and 10-year functional decline was not statistically significant for participants who had baseline functional impairment. Asking older adults about their perceived neighborhood safety may provide important information about their risk of future functional decline. These findings also suggest that future studies might focus on assessing whether interventions that promote physical activity while addressing safety concerns help reduce functional decline in older adults. C1 [Cenzer, Irena Stijacic; Kao, Helen; Ahalt, Cyrus; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Sun, Vivien K.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Cenzer, Irena Stijacic; Williams, Brie A.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, Box 1265,Suite 380,3333 Calif St, San Francisco, CA 94143 USA. EM brie.williams@ucsf.edu FU National Institute of Aging [K23AG033102]; UCSF Hartford Center of Excellence; Jacob and Valeria Langeloth Foundation; UCSF; American Federation for Aging Research FX Dr. Williams is supported by the National Institute of Aging (K23AG033102), The UCSF Hartford Center of Excellence, The Jacob and Valeria Langeloth Foundation, and the UCSF Program for the Aging Century. Vivien Sun received funding from the National Institute on Aging and the American Federation for Aging Research through the Medical Student Training in Aging Research (MSTAR) Program. These funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Dr. Williams is an employee of the Department of Veterans Affairs. The opinions expressed in this manuscript may not represent those of the VA. NR 42 TC 4 Z9 4 U1 5 U2 27 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 541 EP 547 DI 10.1007/s11606-011-1943-y PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300013 PM 22160889 ER PT J AU Lakin, J Baxi, SM Kohlwes, J AF Lakin, Joshua Baxi, Sanjiv M. Kohlwes, Jeff TI Missing the Tree for the Forest: A Case of Secondary Spontaneous Pneumothorax SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE emergency medicine; pulmonary diseases; infectious disease; clinical image C1 [Lakin, Joshua; Baxi, Sanjiv M.] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. [Kohlwes, Jeff] San Francisco Vet Adm Med Ctr, Dept Internal Med, San Francisco, CA USA. RP Lakin, J (reprint author), Univ Calif San Francisco, Dept Internal Med, 505 Parnassus Ave,Room M-987, San Francisco, CA 94143 USA. EM Joshua.lakin@ucsf.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 601 EP 602 DI 10.1007/s11606-011-1954-8 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300022 PM 22215268 ER PT J AU Spassieva, SD Rahmaniyan, M Bielawski, J Clarke, CJ Kraveka, JM Obeid, LM AF Spassieva, Stefka D. Rahmaniyan, Mehrdad Bielawski, Jacek Clarke, Christopher J. Kraveka, Jacqueline M. Obeid, Lina M. TI Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells SO JOURNAL OF LIPID RESEARCH LA English DT Article DE sphingolipid; dihydroceramide; ceramide; cell-cycle arrest ID CERAMIDE SYNTHESIS; MASS-SPECTROMETRY; GROWTH ARREST; METABOLISM; SPHINGOSINE-1-PHOSPHATE; SPHINGOLIPIDS; CANCER; IDENTIFICATION; SPHINGOSINE; INVOLVEMENT AB We applied a metabolic approach to investigate the role of sphingolipids in cell density-induced growth arrest in neuroblastoma cells. Our data revealed that sphingolipid metabolism in neuroblastoma cells significantly differs depending on the cells' population context. At high cell density, cells exhibited G0/G1 cell-cycle arrest and reduced ceramide, monohexosylceramide, and sphingomyelin, whereas dihydroceramide was significantly increased. In addition, our metabolic-labeling experiments showed that neuroblastoma cells at high cell density preferentially synthesized very long chain (VLC) sphingolipids and dramatically decreased synthesis of sphingosine-1-phosphate (S1P). Moreover, densely populated neuroblastoma cells showed increased message levels of both anabolic and catabolic enzymes of the sphingolipid pathway. Notably, our metabolic-labeling experiments indicated reduced dihydroceramide desaturase activity at confluence, which was confirmed by direct measurement of dihydroceramide desaturase activity in situ and in vitro. Importantly, we could reduce dihydroceramide desaturase activity in low-density cells by applying conditional media from high-density cells, as well as by adding reducing agents, such as DTT and L-cysteine to the media.jlr In conclusion, our data suggest a role of the sphingolipid pathway, dihydroceramides desaturase in particular, in confluence-induced growth arrest in neuroblastoma cells.-Spassieva, S. D., M. Rahmaniyan, J. Bielawski, C. J. Clarke, J. M. Kraveka, and L. M. Obeid. Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells. J. Lipid Res. 2012. 53: 918-928. C1 [Spassieva, Stefka D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Rahmaniyan, Mehrdad; Kraveka, Jacqueline M.] Med Univ S Carolina, Div Hematol Oncol, Dept Pediat, Charleston, SC 29425 USA. [Bielawski, Jacek; Clarke, Christopher J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [AG-016583, P20-RR17677, C06-RR-018823]; Office of Research and Development; Department of Veterans Affairs; Ralph H. Johnson VA Medical Center, Charleston, SC; Rally Foundation for Childhood Cancer Research; Monica Kreber Golf Tournament; Chase After a Cure Foundation; Hyundai Hope on Wheels FX This work was supported by National Institutes of Health Grants AG-016583 (to L.M.O.) and P20-RR17677 (to J.M.K.); by a MERIT Award (to L.M.O.) from the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, SC; and by grants from the Rally Foundation for Childhood Cancer Research, the Monica Kreber Golf Tournament, Chase After a Cure Foundation, and Hyundai Hope on Wheels (to J.M.K.). The MUSC Lipidomics facility was constructed with support from National Institutes of Health Grant C06-RR-018823. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 41 TC 8 Z9 8 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD MAY PY 2012 VL 53 IS 5 BP 918 EP 928 DI 10.1194/jlr.M019075 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 925UI UT WOS:000302786800010 PM 22377532 ER PT J AU Furmaga, H Sadhu, M Frazer, A AF Furmaga, Havan Sadhu, Mohona Frazer, Alan TI Comparison of Delta FosB Immunoreactivity Induced by Vagal Nerve Stimulation with That Caused by Pharmacologically Diverse Antidepressants SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID TREATMENT-RESISTANT DEPRESSION; CEREBRAL-BLOOD-FLOW; VAGUS NERVE; C-FOS; RAT-BRAIN; MESSENGER-RNA; LONG-TERM; PERIAQUEDUCTAL GRAY; MEDULLA-OBLONGATA; LOCUS COERULEUS AB Vagal nerve stimulation (VNS) has been approved for treatment of refractory depression. However, there have been few, if any, studies directly comparing the effects produced by VNS in animals with those caused by antidepressants, particularly using clinically relevant stimulation parameters in nonanesthetized animals. In this study, Delta FosB immunohistochemistry was used to evaluate different brain regions activated by long-term administration of VNS. Effects of VNS were compared with those caused by sertraline or desipramine (DMI). Double-labeling of Delta FosB and serotonin was used to determine whether serotonergic neurons in the dorsal raphe nucleus (DRN) were activated by long-term VNS. VNS significantly increased Delta FosB staining in the nucleus tractus solitarius (NTS), parabrachial nucleus (PBN), locus ceruleus (LC), and DRN, as well as in many cortical and limbic areas of brain including those involved in mood and cognition. Most, but not all, of these effects were seen also upon long-term treatments of rats with sertraline or DMI. Some areas where VNS increased Delta FosB (e. g., the NTS, PBN, LC, and peripeduncular nucleus) were not affected significantly by either drug. Sertraline was similar to VNS in causing an increase in the DRN whereas DMI did not. Double-labeling of the DRN with Delta FosB and an antibody for serotonin revealed that only a small percentage of Delta FosB staining in the DRN colocalized with serotonergic neurons. The effects of VNS were somewhat more widespread than those caused by the antidepressants. The increases in Delta FosB produced by VNS were either equivalent to and/or more robust than those seen with antidepressants. C1 [Furmaga, Havan; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Sadhu, Mohona] Univ Texas Austin, Austin, TX 78712 USA. [Frazer, Alan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Frazer, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM frazer@uthscsa.edu FU National Institutes of Health National Institute of Mental Health [MH082933]; Cyberonics Inc. FX This work was supported by the National Institutes of Health National Institute of Mental Health [Grant MH082933]. The electrodes, VNS stimulators, and dummy stimulators were gifts from Cyberonics, Inc. (Houston, TX).; Dr. Frazer has served on advisory boards for Lundbeck and for Takeda in the last 3 years. Previously, Dr. Frazer had received financial compensation as a consultant for Cyberonics Inc. and had also obtained grant support from them for a preclinical study. NR 45 TC 9 Z9 9 U1 0 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD MAY PY 2012 VL 341 IS 2 BP 317 EP 325 DI 10.1124/jpet.111.188953 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 927JM UT WOS:000302903500002 PM 22286499 ER PT J AU Pastor, R Reed, C Meyer, PJ McKinnon, C Ryabinin, AE Phillips, TJ AF Pastor, Raul Reed, Cheryl Meyer, Paul J. McKinnon, Carrie Ryabinin, Andrey E. Phillips, Tamara J. TI Role of Corticotropin-Releasing Factor and Corticosterone in Behavioral Sensitization to Ethanol SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID DBA/2J MICE; FACTOR CRF; RECEPTOR ANTAGONISTS; CROSS-SENSITIZATION; ADDICTION; ALCOHOL; EXPRESSION; STRESS; RATS; MECHANISMS AB Neuroadaptations underlying sensitization to drugs of abuse seem to influence compulsive drug pursuit and relapse associated with addiction. Our previous data support a role for the corticotropin-releasing factor (CRF) type-1 receptor (CRF 1) in ethanol (EtOH)-induced psychomotor sensitization. CRF 1 is endogenously activated by CRF and urocortin-1. Because genetic deletion of urocortin-1 did not affect EtOH sensitization, we hypothesized that CRF is the important ligand underlying EtOH sensitization. To test this hypothesis, we used heterozygous and homozygous knockout (KO) mice, which lack one or both copies of the gene coding for CRF, and their respective wildtype controls. EtOH sensitization was normal in heterozygous, but absent in homozygous, CRF KO mice. Corticosterone (CORT) levels were drastically reduced only in CRF KO mice. Because CRF/CRF1 initiate EtOH-induced activation of the hypothalamic-pituitary-adrenal axis, we investigated CORT effects on EtOH sensitization. The CORT synthesis inhibitor metyrapone prevented the acquisition, but not the expression, of EtOH sensitization. Exogenous CORT administration sensitized the locomotor response to a subsequent EtOH challenge; we observed, however, that the exogenous CORT levels necessary to induce sensitization to EtOH were significantly higher than those produced by EtOH treatment. Therefore, participation of CORT seems to be necessary, but not sufficient, to explain the role of CRF/CRF1 in the acquisition of sensitization to EtOH. Extra-hypothalamic CRF/CRF1 mechanisms are suggested to be involved in the expression of EtOH sensitization. The present results are consistent with current theories proposing a key role for CRF and CRF1 in drug-induced neuroplasticity, dependence, and addictive behavior. C1 [Pastor, Raul; Reed, Cheryl; Meyer, Paul J.; McKinnon, Carrie; Ryabinin, Andrey E.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Pastor, Raul; Reed, Cheryl; Meyer, Paul J.; McKinnon, Carrie; Ryabinin, Andrey E.; Phillips, Tamara J.] Portland Alcohol Res Ctr, Portland, OR USA. [Phillips, Tamara J.] Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. [Pastor, Raul] Univ Jaume 1, Area Psicobiol, Castellon de La Plana, Spain. RP Phillips, TJ (reprint author), Portland VA Med Ctr, Res Serv, R&D32,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM phillipt@ohsu.edu FU Department of Veterans Affairs; National Institutes of Health National Institute on Alcohol Abuse and Alcoholism [R01-AA13331, P60-AA010760, R01-AA013738, R24-AA020245, U01016647] FX This work was supported by the Department of Veterans Affairs and the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism [Grants R01-AA13331, P60-AA010760, R01-AA013738, R24-AA020245, U01016647]. NR 44 TC 10 Z9 10 U1 0 U2 2 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD MAY PY 2012 VL 341 IS 2 BP 455 EP 463 DI 10.1124/jpet.111.190595 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 927JM UT WOS:000302903500015 PM 22333290 ER PT J AU Iwasaki, JK Srivastava, D Moy, RL Lin, HJ Kouba, DJ AF Iwasaki, Julie K. Srivastava, Divya Moy, Ronald L. Lin, Henry J. Kouba, David J. TI The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE carcinoma; basal cell; sonic hedgehog ID NONMELANOMA SKIN-CANCER; HEDGEHOG SIGNALING PATHWAY; CENTRAL-NERVOUS-SYSTEM; SONIC HEDGEHOG; HUMAN HOMOLOG; N-MYC; EXPRESSION; MUTATIONS; PROLIFERATION; INHIBITION AB Mutations in the sonic hedgehog signaling pathway play a key role in the development of basal cell carcinomas. Specifically, mutations in the PTCH1 (also known as PTCH or PTC1) and SMO genes cause tumor formation through constitutive activation of the pathway. Misregulation of the pathway has also been implicated in the nevoid basal cell carcinoma syndrome and other tumors. Understanding the function of the sonic hedgehog pathway has led to novel strategies for treatment. In this review we highlight the role of the pathway in the pathogenesis of basal cell carcinoma and review potential targeted therapies. (J Am Acad Dermatol 2012;66:e167-78.) C1 [Kouba, David J.] Henry Ford Hlth Syst, Dept Dermatol, Div Mohs Microg Surg, Detroit, MI 48202 USA. [Srivastava, Divya] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Moy, Ronald L.; Lin, Henry J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moy, Ronald L.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. [Lin, Henry J.] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA. [Lin, Henry J.] Harbor UCLA Med Ctr, Div Med Genet, Torrance, CA 90509 USA. [Kouba, David J.] Toledo Clin Dermasurg & Laser Ctr, Toledo, OH USA. RP Kouba, DJ (reprint author), Henry Ford Hlth Syst, Dept Dermatol, Div Mohs Microg Surg, 3031 W Grand Blvd,Suite 800, Detroit, MI 48202 USA. EM dkouba1@hfhs.org NR 49 TC 22 Z9 22 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAY PY 2012 VL 66 IS 5 BP E167 EP E178 DI 10.1016/j.jaad.2010.06.054 PG 12 WC Dermatology SC Dermatology GA 926UZ UT WOS:000302858700005 PM 20800318 ER PT J AU Lanham, HJ Leykum, LK McDaniel, RR AF Lanham, Holly Jordan Leykum, Luci K. McDaniel, Reuben R., Jr. TI Same organization, same electronic health records (EHRs) system, different use: exploring the linkage between practice member communication patterns and EHR use patterns in an ambulatory care setting SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID COMPLEX ADAPTIVE SYSTEMS; INFORMATION-SYSTEMS; QUALITY; TECHNOLOGY; IMPACT; STATES; COSTS; TEAMS AB Objective Despite efforts made by ambulatory care organizations to standardize the use of electronic health records (EHRs), practices often incorporate these systems into their work differently from each other. One potential factor contributing to these differences is within-practice communication patterns. The authors explore the linkage between within-practice communication patterns and practice-level EHR use patterns. Design Qualitative study of six practices operating within the same multi-specialty ambulatory care organization using the same EHR system. Semistructured interviews and direct observation were conducted with all physicians, nurses, medical assistants, practice managers, and non-clinical staff from each practice. Measurements An existing model of practice relationships was used to analyze communication patterns within the practices. Practice-level EHR use was defined and analyzed as the ways in which a practice uses an EHR as a collective or a group-including the degree of feature use, level of EHR-enabled communication, and frequency that EHR use changes in a practice. Interview and observation data were analyzed for themes. Based on these themes, within-practice communication patterns were categorized as fragmented or cohesive, and practice-level EHR use patterns were categorized as heterogeneous or homogeneous. Practices where EHR use was uniformly high across all users were further categorized as having standardized EHR use. Communication patterns and EHR use patterns were compared across the six practices. Results Within-practice communication patterns were associated with practice-level EHR use patterns. In practices where communication patterns were fragmented, EHR use was heterogeneous. In practices where communication patterns were cohesive, EHR use was homogeneous. Additional analysis revealed that practices that had achieved standardized EHR use (uniformly high EHR use across all users) exhibited high levels of mindfulness and respectful interaction, whereas practices that were furthest from achieving standardized EHR use exhibited low levels of mindfulness and respectful interaction. Conclusion Within-practice communication patterns provide a unique perspective for exploring the issue of standardization in EHR use. A major fallacy of setting homogeneous EHR use as the goal for practice-level EHR use is that practices with uniformly low EHR use could be considered successful. Achieving uniformly high EHR use across all users in a practice is more consistent with the goals of current EHR adoption and use efforts. It was found that some communication patterns among practice members may enable more standardized EHR use than others. Understanding the linkage between communication patterns and EHR use can inform understanding of the human element in EHR use and may provide key lessons for the implementation of EHRs and other health information technologies. C1 [Lanham, Holly Jordan; Leykum, Luci K.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Lanham, Holly Jordan; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Lanham, Holly Jordan] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [McDaniel, Reuben R., Jr.] McCombs Sch Business, Dept Informat Risk & Operat, Austin, TX USA. RP Lanham, HJ (reprint author), 1 Univ Stn,B6000, Austin, TX 78712 USA. EM lanham@uthscsa.edu FU South Texas Veterans Health Care System, Veterans Evidence Based Research Dissemination and Implementation Center (VERDICT), San Antonio, Texas, United States; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [REA 05-129, CDA 07-022]; LKL; South Texas Veterans Health Care System; IC2 Institute of The University of Texas at Austin FX This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System, Veterans Evidence Based Research Dissemination and Implementation Center (VERDICT), San Antonio, Texas, United States. The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (REA 05-129, CDA 07-022). Investigator salary support for LKL is provided through this funding, and through the South Texas Veterans Health Care System. RRM receives support from the IC2 Institute of The University of Texas at Austin. We would like to express our gratitude to the Chief Information Officer, physician leadership, EHR staff, and the physicians, nurses and other healthcare professionals that participated in this study. We would also like to acknowledge Madhu C Reddy and two anonymous reviewers for their helpful comments on previous versions of this manuscript. NR 57 TC 17 Z9 17 U1 0 U2 16 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAY PY 2012 VL 19 IS 3 BP 382 EP 391 DI 10.1136/amiajnl-2011-000263 PG 10 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 925TE UT WOS:000302783600010 PM 21846780 ER PT J AU Zhong, YF Wu, YW Liu, RJ Deng, YY Mallipattu, SK Klotman, PE Chuang, PY He, JC AF Zhong, Yifei Wu, Yingwei Liu, Ruijie Deng, Yueyi Mallipattu, Sandeep K. Klotman, Paul E. Chuang, Peter Y. He, John C. TI Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure SO KIDNEY INTERNATIONAL LA English DT Article DE collapsing glomerulopathy; glomerular disease; HIV nephropathy; podocyte; signaling ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HIV-1-ASSOCIATED NEPHROPATHY; ANTIRETROVIRAL THERAPY; CAMP PATHWAY; ACID; PODOCYTE; EXPRESSION; CREB; DEDIFFERENTIATION; PHOSPHORYLATION AB Retinoic acid decreases proteinuria and glomerulosclerosis in several animal models of kidney disease by protecting podocytes from injury. Our recent in vitro studies suggest that all-trans retinoic acid induces podocyte differentiation by activating the retinoic acid receptor-alpha (RAR alpha)/cAMP/PKA/CREB pathway. When used in combination with all-trans retinoic acid, an inhibitor of phosphodiesterase 4 further enhanced podocyte differentiation by increasing intracellular cAMP. Additionally, we found that Am580, a specific RAR alpha agonist, has similar renal protective effects as all-trans retinoic acid in a rederived colony of HIV-1 transgenic mice with rapidly progressive renal failure (HIV-Tg) that mimics human HIV-associated nephropathy. Treatment with either the inhibitor of phosphodiesterase 4, roflumilast, or Am580 significantly reduced proteinuria, attenuated kidney injury, and improved podocyte differentiation in these HIV-Tg mice. Additional renal protective effects were found when roflumilast was combined with Am580. Consistent with the in vitro data, glomeruli from HIV-Tg mice treated with both Am580 and roflumilast had more active phosphorylated CREB than with either agent alone. Thus, phosphodiesterase 4 inhibitors could be used in combination with RAR alpha agonists to provide additional renal protection. Kidney International (2012) 81, 856-864; doi:10.1038/ki.2011.467; published online 18 January 2012 C1 [Zhong, Yifei; Liu, Ruijie; Mallipattu, Sandeep K.; Chuang, Peter Y.; He, John C.] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY 10029 USA. [Zhong, Yifei; Deng, Yueyi] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China. [Wu, Yingwei] Tongji Univ, Shanghai E Hosp, Shanghai 200092, Peoples R China. [Klotman, Paul E.] Baylor Coll Med, Houston, TX 77030 USA. [He, John C.] James J Peters VA Med Ctr, Bronx, NY USA. RP He, JC (reprint author), Mt Sinai Sch Med, Div Nephrol, Dept Med, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM cijiang.he@mssm.edu RI Mallipattu , Sandeep/M-7009-2014 FU NIH [1R01DK078897, 1R01DK088541, P01-DK-56492, 5K08DK082760]; VA Merit Award FX JCH is supported by NIH 1R01DK078897, 1R01DK088541, P01-DK-56492, and VA Merit Award; PYC is supported by NIH 5K08DK082760. NR 34 TC 10 Z9 11 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAY PY 2012 VL 81 IS 9 BP 856 EP 864 DI 10.1038/ki.2011.467 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 926XF UT WOS:000302864500009 PM 22258322 ER PT J AU Katon, J Reiber, G Williams, MA Yanez, D Miller, E AF Katon, Jodie Reiber, Gayle Williams, Michelle A. Yanez, David Miller, Edith TI Antenatal haemoglobin A1c and risk of large-for-gestational-age infants in a multi-ethnic cohort of women with gestational diabetes SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE gestational diabetes; Hb A1c; glycaemic control; birthweight ID GLUCOSE-TOLERANCE LEVELS; BIRTH-WEIGHT; FETAL-GROWTH; LATE PREGNANCY; GLYCATED HEMOGLOBIN; METABOLIC SYNDROME; EXPERT COMMITTEE; MATERNAL OBESITY; UNITED-STATES; DCA 2000 AB Gestational diabetes mellitus (GDM) is a risk factor for delivering a large-for-gestational-age (LGA) infant. Haemoglobin A1c (A1C) is an indicator of glycaemic control. The objective of this study was to test whether higher A1C quartile at the time of diagnosis of GDM is associated with increased risk of delivering a LGA or macrosomic infant. Women with singleton pregnancies treated for GDM at a large diabetes and pregnancy programme located in Charlotte, North Carolina, were eligible for inclusion in this retrospective cohort study. Clinical information, including A1C at diagnosis, treatment, prior medical and obstetric history, and birth data were abstracted from medical records. LGA was defined as birthweight > 90th percentile for gestational age and sex and macrosomia as birthweight > 4000 g. Logistic regression was used to analyse the association of A1C at GDM diagnosis with risk of delivering LGA or macrosomic infants. This study included 502 women. Prevalences of LGA and macrosomia were 4% and 6% respectively. After adjustment there was no detectable trend of increased risk for LGA (P for trend = 0.12) or macrosomia (P for trend = 0.20) across increasing quartiles of A1C at GDM diagnosis. A1C at GDM diagnosis may not be linearly associated with LGA or macrosomia, possibly because of the mediating effect of strict glycaemic control in this clinical setting. C1 [Katon, Jodie; Reiber, Gayle; Williams, Michelle A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Yanez, David] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Reiber, Gayle] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Miller, Edith] Carolinas Med Ctr, Diabet & Pregnancy Program, Charlotte, NC 28203 USA. RP Katon, J (reprint author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. EM jkaton@u.washington.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH [T32 HD052462]; Achievement Rewards for College Scientists (ARCS); Samuel and Althea Stroum Foundation; University of Washington Department of Epidemiology FX Jodie Katon was supported by grant number T32 HD052462 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH; Achievement Rewards for College Scientists (ARCS); and the Samuel and Althea Stroum Foundation. This study was also funded by a grant from the University of Washington Department of Epidemiology. The authors would like to thank Misty Morris, RN for data collection. NR 48 TC 8 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-5022 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAY PY 2012 VL 26 IS 3 BP 208 EP 217 DI 10.1111/j.1365-3016.2012.01266.x PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 921IL UT WOS:000302471200005 PM 22471680 ER PT J AU Xiang, M Yuan, YZ Fan, LY Li, YH Li, AJ Yin, LH Scott, MJ Xiao, GZ Billiar, TR Wilson, MA Fan, J AF Xiang, Meng Yuan, Youzhong Fan, Liyan Li, Yuehua Li, Aijun Yin, Lianhua Scott, Melanie J. Xiao, Guozhi Billiar, Timothy R. Wilson, Mark A. Fan, Jie TI ROLE OF MACROPHAGES IN MOBILIZATION OF HEMATOPOIETIC PROGENITOR CELLS FROM BONE MARROW AFTER HEMORRHAGIC SHOCK SO SHOCK LA English DT Article DE G-CSF; HMGB1; RAGE; innate immune; beta-adrenergic receptor ID COLONY-STIMULATING FACTOR; SYMPATHETIC-NERVOUS-SYSTEM; ENHANCED MOBILIZATION; TISSUE-DAMAGE; CUTTING EDGE; G-CSF; INJURY; HMGB1; SITE; ACTIVATION AB The release of hematopoietic progenitor cells (HPCs) from bone marrow (BM) is under tight homeostatic control. Under stress conditions, HPCs migrate from BM and egress into circulation to participate in immune response, wound repair, or tissue regeneration. Hemorrhagic shock with resuscitation (HS/R), resulting from severe trauma and major surgery, promotes HPC mobilization from BM, which, in turn, affects post-HS immune responses. In this study, we investigated the mechanism of HS/R regulation of HPC mobilization from BM. Using a mouse HS/R model, we demonstrate that the endogenous alarmin molecule high-mobility group box 1 mediates HS/R-induced granulocyte colony-stimulating factor secretion from macrophages (M phi in a RAGE [receptor for advanced glycation end products] signaling-dependent manner. Secreted granulocyte colony-stimulating factor, in turn, induces HPC egress from BM. We also show that activation of beta-adrenergic receptors on M phi by catecholamine mediates the HS/R-induced release of high-mobility group box 1. These data indicate that HS/R, a global ischemia-reperfusion stimulus, regulates HPC mobilization through a series of interacting pathways that include neuroendocrine and innate immune systems, in which M phi play a central role. C1 [Xiang, Meng; Yuan, Youzhong; Li, Yuehua; Scott, Melanie J.; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Xiang, Meng; Yin, Lianhua] Fudan Univ, Shanghai Med Coll, Dept Physiol & Pathophysiol, Shanghai 200433, Peoples R China. [Fan, Liyan] Univ Pittsburgh, Sch Arts & Sci, Pittsburgh, PA USA. [Li, Aijun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China. [Xiao, Guozhi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Surg Res, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Surg Res, Bldg 1,Room 2W109,151L U,Univ Dr C, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU National Institutes of Health [R01-HL-079669]; National Institutes of Health Center [P50-GM53789]; VA Merit Award; NSFC [81100047/H0111] FX This work was supported by the National Institutes of Health (grant R01-HL-079669 to J.F. and M. A. W.), National Institutes of Health Center (grant P50-GM53789 to T. R. B. and J.F.), VA Merit Award (to J.F.), and NSFC (grant 81100047/H0111 to M.X). NR 38 TC 9 Z9 9 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1073-2322 EI 1540-0514 J9 SHOCK JI Shock PD MAY PY 2012 VL 37 IS 5 BP 518 EP 523 DI 10.1097/SHK.0b013e318249b81d PG 6 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 928UB UT WOS:000303010000011 PM 22293600 ER PT J AU Saladin, ME Gray, KM Carpenter, MJ LaRowe, SD DeSantis, SM Upadhyaya, HP AF Saladin, Michael E. Gray, Kevin M. Carpenter, Matthew J. LaRowe, Steven D. DeSantis, Stacia M. Upadhyaya, Himanshu P. TI Gender Differences in Craving and Cue Reactivity to Smoking and Negative Affect/Stress Cues SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID NICOTINE REPLACEMENT THERAPY; LUNG-CANCER RISK; SEX-DIFFERENCES; INDIVIDUAL-DIFFERENCES; CIGARETTE AVAILABILITY; MOOD INDUCTION; MENSTRUAL-CYCLE; FEMALE SMOKERS; DRUG-ABUSE; CESSATION AB There is evidence that women may be less successful when attempting to quit smoking than men. One potential contributory cause of this gender difference is differential craving and stress reactivity to smoking- and negative affect/stress-related cues. The present human laboratory study investigated the effects of gender on reactivity to smoking and negative affect/stress cues by exposing nicotine dependent women (n = 37) and men (n = 53) smokers to two active cue types, each with an associated control cue: (1) in vivo smoking cues and in vivo neutral control cues, and (2) imagery-based negative affect/stress script and a neutral/relaxing control script. Both before and after each cue/script, participants provided subjective reports of smoking-related craving and affective reactions. Heart rate (HR) and skin conductance (SC) responses were also measured. Results indicated that participants reported greater craving and SC in response to smoking versus neutral cues and greater subjective stress in response to the negative affect/stress versus neutral/relaxing script. With respect to gender differences, women evidenced greater craving, stress and arousal ratings and lower valence ratings (greater negative emotion) in response to the negative affect/stressful script. While there were no gender differences in responses to smoking cues, women trended towards higher arousal ratings. Implications of the findings for treatment and tobacco-related morbidity and mortality are discussed. ?(Am J Addict 2012;21:210220) C1 [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. [Saladin, Michael E.; Carpenter, Matthew J.; LaRowe, Steven D.; DeSantis, Stacia M.; Upadhyaya, Himanshu P.] Med Univ S Carolina, Clin Neurosci Div, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Gray, Kevin M.] Med Univ S Carolina, Youth Div, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Carpenter, Matthew J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [DeSantis, Stacia M.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Subst Abuse Treatment Ctr, Mental Hlth Serv, Charleston, SC USA. [Upadhyaya, Himanshu P.] Eli Lilly & Co, Indianapolis, IN 46285 USA. RP Saladin, ME (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Room 224,MSC700, Charleston, SC 29425 USA. EM saladinm@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NCATS NIH HHS [UL1 TR000062]; NCRR NIH HHS [TL1 RR029881-02, KL2 RR029880, KL2 RR029880-01, KL2 RR029880-02, KL2 RR029880-03, M01 RR001070, M01 RR01070, TL1 RR029881, TL1 RR029881-01, TL1 RR029881-03, UL1 RR029882, UL1 RR029882-01, UL1 RR029882-02, UL1 RR029882-03]; NIDA NIH HHS [K12 DA000357, K23 DA020482, P50 DA016511, P50 DA016511-01, P50 DA016511-02, P50 DA016511-03, P50 DA016511-04, P50 DA016511-05, P50 DA016511-06, P50 DA016511-07, P50 DA016511-08, P50 DA016511-09, P50 DA016511-10] NR 82 TC 34 Z9 35 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAY-JUN PY 2012 VL 21 IS 3 BP 210 EP 220 DI 10.1111/j.1521-0391.2012.00232.x PG 11 WC Substance Abuse SC Substance Abuse GA 923IL UT WOS:000302612900006 PM 22494223 ER PT J AU Hughes, T Adler, A Merrill, JT Kelly, JA Kaufman, KM Williams, A Langefeld, CD Gilkeson, GS Sanchez, E Martin, J Boackle, SA Stevens, AM Alarcon, GS Niewold, TB Brown, EE Kimberly, RP Edberg, JC Ramsey-Goldman, R Petri, M Reveille, JD Criswell, LA Vila, LM Jacob, CO Gaffney, PM Moser, KL Vyse, TJ Alarcon-Riquelme, ME James, JA Tsao, BP Scofield, RH Harley, JB Richardson, BC Sawalha, AH AF Hughes, Travis Adler, Adam Merrill, Joan T. Kelly, Jennifer A. Kaufman, Kenneth M. Williams, Adrienne Langefeld, Carl D. Gilkeson, Gary S. Sanchez, Elena Martin, Javier Boackle, Susan A. Stevens, Anne M. Alarcon, Graciela S. Niewold, Timothy B. Brown, Elizabeth E. Kimberly, Robert P. Edberg, Jeffrey C. Ramsey-Goldman, Rosalind Petri, Michelle Reveille, John D. Criswell, Lindsey A. Vila, Luis M. Jacob, Chaim O. Gaffney, Patrick M. Moser, Kathy L. Vyse, Timothy J. Alarcon-Riquelme, Marta E. James, Judith A. Tsao, Betty P. Scofield, R. Hal Harley, John B. Richardson, Bruce C. Sawalha, Amr H. CA BIOLUPUS Network TI Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID MULTIFACTOR-DIMENSIONALITY REDUCTION; GENOME-WIDE ASSOCIATION; MULTIPLE-SCLEROSIS; REVISED CRITERIA; SUSCEPTIBILITY; POLYMORPHISMS; CLASSIFICATION; ARCHITECTURE; VARIANTS; DISEASE AB Objectives Systemic lupus erythematosus (SLE) is a sexually dimorphic autoimmune disease which is more common in women, but affected men often experience a more severe disease. The genetic basis of sexual dimorphism in SLE is not clearly defined. A study was undertaken to examine sex-specific genetic effects among SLE susceptibility loci. Methods A total of 18 autosomal genetic susceptibility loci for SLE were genotyped in a large set of patients with SLE and controls of European descent, consisting of 5932 female and 1495 male samples. Sex-specific genetic association analyses were performed. The sex-gene interaction was further validated using parametric and nonparametric methods. Aggregate differences in sex-specific genetic risk were examined by calculating a cumulative genetic risk score for SLE in each individual and comparing the average genetic risk between male and female patients. Results A significantly higher cumulative genetic risk for SLE was observed in men than in women. (P=4.52x10(-8)) A significant sex-gene interaction was seen primarily in the human leucocyte antigen (HLA) region but also in IRF5, whereby men with SLE possess a significantly higher frequency of risk alleles than women. The genetic effect observed in KIAA1542 is specific to women with SLE and does not seem to have a role in men. Conclusions The data indicate that men require a higher cumulative genetic load than women to develop SLE. These observations suggest that sex bias in autoimmunity could be influenced by autosomal genetic susceptibility loci. C1 [Merrill, Joan T.; Kaufman, Kenneth M.; James, Judith A.; Scofield, R. Hal; Sawalha, Amr H.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA. [Hughes, Travis; Adler, Adam; Kelly, Jennifer A.; Kaufman, Kenneth M.; Sanchez, Elena; Gaffney, Patrick M.; Moser, Kathy L.; Alarcon-Riquelme, Marta E.; James, Judith A.; Scofield, R. Hal; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA. [Kaufman, Kenneth M.; Scofield, R. Hal; Sawalha, Amr H.] Med Ctr, US Dept Vet Affairs, Oklahoma City, OK 73104 USA. [Williams, Adrienne; Langefeld, Carl D.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Martin, Javier] Consejo Super Invest Cient, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain. [Boackle, Susan A.] Univ Colorado Denver, Sch Med, Div Rheumatol, Aurora, CO USA. [Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA. [Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA. [Alarcon, Graciela S.; Brown, Elizabeth E.; Kimberly, Robert P.; Edberg, Jeffrey C.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Niewold, Timothy B.] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA. [Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. [Ramsey-Goldman, Rosalind] Northwestern Univ, Dept Med, Chicago, IL 60611 USA. [Petri, Michelle] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Reveille, John D.] Univ Texas Houston Hlth Sci Ctr, Dept Med, Houston, TX USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA 94143 USA. [Vila, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA. [Jacob, Chaim O.] Univ So Calif, Dept Med, Los Angeles, CA USA. [Vyse, Timothy J.] Kings Coll London, Guys Hosp, Div Genet, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Guys Hosp, Div Mol Med, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Guys Hosp, Div Immunol, London WC2R 2LS, England. [Vyse, Timothy J.] Kings Coll London, Guys Hosp, Div Infect & Inflammatory Dis, London WC2R 2LS, England. [Alarcon-Riquelme, Marta E.] Pfizer Univ Granada Junta Andalucia, Ctr Genom & Oncol Res, Granada, Spain. [Tsao, Betty P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH USA. [Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Autoimmune Genom Ctr, Cincinnati, OH USA. [Harley, John B.] Med Ctr, US Dept Vet Affairs, Cincinnati, OH USA. [Richardson, Bruce C.] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Richardson, Bruce C.] Vet Adm Med Ctr, US Dept Vet Affairs, Ann Arbor, MI 48105 USA. RP Sawalha, AH (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu RI D'Alfonso, Sandra/K-7295-2014; Witte, Torsten/B-5783-2016; Martin, Javier/B-8141-2008; Sanchez, Elena/B-4140-2017 OI D'Alfonso, Sandra/0000-0002-3983-9925; Sanchez, Elena/0000-0002-7041-5485; Frostegard, Johan/0000-0002-3569-3367; Silva, Berta/0000-0001-6579-5068; Vasconcelos, Carlos/0000-0002-8073-5028; Kimberly, Robert/0000-0002-5330-3086; Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660 FU Lupus Foundation of America; NIH; Arthritis National Research Foundation; American College of Rheumatology/Research and Education Foundation; Lupus Research Institute; Kirkland Scholar awards; Alliance for Lupus Research; US Department of Veterans Affairs; US Department of Defense [PR094002]; European Science Foundation [07-RNP-083]; Swedish Research Council; Instituto de Salud Carlos III [PS09/00129]; European Union; Consejeria de Salud de Andalucia [PI0012] FX This work was made possible by the Lupus Foundation of America, the NIH (R03AI076729, P20RR020143, P20RR015577, P30AR053483, R01AR042460, R37AI024717, R01AI031584, N01AR62277, P50AR048940, P01AI083194, RC1AR058554, U19AI082714, HHSN266200500026C, P30RR031152, P01AR049084, R01AR043274, R01AI063274, K24AR002138, P602AR30692, UL1RR025741, R01DE018209, R01AR043727, UL1RR025005, R01AR043814, K08AI083790, P30DK42086, L30AI071651, UL1RR024999, R01AR044804, M01RR000079, R21AI070304), Arthritis National Research Foundation, American College of Rheumatology/Research and Education Foundation, Lupus Research Institute, Kirkland Scholar awards, Alliance for Lupus Research, US Department of Veterans Affairs, US Department of Defense PR094002, European Science Foundation to the BIOLUPUS network (07-RNP-083), the Swedish Research Council and the Instituto de Salud Carlos III (PS09/00129), cofinanced partly through FEDER funds of the European Union and grant PI0012 from the Consejeria de Salud de Andalucia. NR 31 TC 22 Z9 23 U1 0 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD MAY PY 2012 VL 71 IS 5 BP 694 EP 699 DI 10.1136/annrheumdis-2011-200385 PG 6 WC Rheumatology SC Rheumatology GA 923QO UT WOS:000302634000012 PM 22110124 ER PT J AU Harmar, AJ Fahrenkrug, J Gozes, I Laburthe, M May, V Pisegna, JR Vaudry, D Vaudry, H Waschek, JA Said, SI AF Harmar, Anthony J. Fahrenkrug, Jan Gozes, Illana Laburthe, Marc May, Victor Pisegna, Joseph R. Vaudry, David Vaudry, Hubert Waschek, James A. Said, Sami I. TI Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1 SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Review DE accessory proteins; agonists and antagonists; class B GPCR; PAC1 receptor; PACAP; signal transduction; splice variant; VIP; VPAC1 receptor; VPAC2 receptor ID CEREBELLAR GRANULE NEURONS; PACAP TYPE-1 RECEPTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROTEIN-COUPLED RECEPTOR; DIFFERENTIAL SIGNAL-TRANSDUCTION; LONG-TERM POTENTIATION; IN-SITU HYBRIDIZATION; RAT ADRENAL-MEDULLA; INDUCED PHASE-SHIFT; MICE LACKING PACAP AB Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are members of a superfamily of structurally related peptide hormones that includes glucagon, glucagon-like peptides, secretin, gastric inhibitory peptide (GIP) and growth hormone-releasing hormone (GHRH). VIP and PACAP exert their actions through three GPCRs PAC1, VPAC1 and VPAC2 belonging to class B (also referred to as class II, or secretin receptor-like GPCRs). This family comprises receptors for all peptides structurally related to VIP and PACAP, and also receptors for parathyroid hormone, corticotropin-releasing factor, calcitonin and related peptides. PAC1 receptors are selective for PACAP, whereas VPAC1 and VPAC2 respond to both VIP and PACAP with high affinity. VIP and PACAP play diverse and important roles in the CNS, with functions in the control of circadian rhythms, learning and memory, anxiety and responses to stress and brain injury. Recent genetic studies also implicate the VPAC2 receptor in susceptibility to schizophrenia and the PAC1 receptor in post-traumatic stress disorder. In the periphery, VIP and PACAP play important roles in the control of immunity and inflammation, the control of pancreatic insulin secretion, the release of catecholamines from the adrenal medulla and as co-transmitters in autonomic and sensory neurons. This article, written by members of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) subcommittee on receptors for VIP and PACAP, confirms the existing nomenclature for these receptors and reviews our current understanding of their structure, pharmacology and functions and their likely physiological roles in health and disease. More detailed information has been incorporated into newly revised pages in the IUPHAR database (). C1 [Harmar, Anthony J.] Univ Edinburgh, Univ BHF Ctr Cardiovasc Sci, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland. [Fahrenkrug, Jan] Univ Copenhagen, Dept Clin Biochem, Copenhagen, Denmark. [Gozes, Illana] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel. [Laburthe, Marc] Univ Paris 07, INSERM U773, Ctr Rech Biomed Bichat Beaujon CRB3, Paris, France. [May, Victor] Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA. [Pisegna, Joseph R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Pisegna, Joseph R.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. [Vaudry, David] Univ Rouen, European Inst Peptide Res IFRMP23, Mont St Aignan, France. [Waschek, James A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Said, Sami I.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Said, Sami I.] SUNY Stony Brook, Grad Program Pharmacol, Stony Brook, NY 11794 USA. RP Harmar, AJ (reprint author), Univ Edinburgh, Univ BHF Ctr Cardiovasc Sci, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland. EM tony.harmar@ed.ac.uk OI Vaudry, David/0000-0003-3567-7452; Harmar, Anthony/0000-0002-3838-9264 FU IUPHAR; British Pharmacological Society; British Heart Foundation [RE/08/001] FX AJH is supported by IUPHAR, the British Pharmacological Society and the British Heart Foundation Centre of Research Excellence Award (RE/08/001). NR 178 TC 113 Z9 115 U1 2 U2 30 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1188 EI 1476-5381 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD MAY PY 2012 VL 166 IS 1 SI SI BP 4 EP 17 DI 10.1111/j.1476-5381.2012.01871.x PG 14 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 923FZ UT WOS:000302606200002 PM 22289055 ER PT J AU Nguyen, MH Wissel, MC Shields, RK Salomoni, MA Hao, BH Press, EG Shields, RM Cheng, SJ Mitsani, D Vadnerkar, A Silveira, FP Kleiboeker, SB Clancy, CJ AF Nguyen, M. Hong Wissel, Mark C. Shields, Ryan K. Salomoni, Martin A. Hao, Binghua Press, Ellen G. Shields, Ryan M. Cheng, Shaoji Mitsani, Dimitra Vadnerkar, Aniket Silveira, Fernanda P. Kleiboeker, Steven B. Clancy, Cornelius J. TI Performance of Candida Real-time Polymerase Chain Reaction, beta-D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID FUNGAL-INFECTIONS; WHOLE-BLOOD; SPECIES IDENTIFICATION; NEUTROPENIC PATIENTS; PCR; SERUM; DNA; MANNOPROTEINEMIA; LEUKEMIA; ALBICANS AB Background. The sensitivity of blood cultures for diagnosing invasive candidiasis (IC) is poor. Methods. We performed a validated Candida real-time polymerase chain reaction (PCR) and the Fungitell 1,3-beta-D-glucan (BDG) assay on blood samples collected from prospectively identified patients with IC (n = 55) and hospitalized controls (n = 73). Patients with IC had candidemia (n = 17), deep-seated candidiasis (n = 33), or both (n = 5). Controls had mucosal candidiasis (n = 5), Candida colonization (n = 48), or no known Candida colonization (n = 20). Results. PCR using plasma or sera was more sensitive than whole blood for diagnosing IC (P = .008). Plasma or sera PCR was more sensitive than BDG in diagnosing IC (80% vs 56%; P = .03), with comparable specificity (70% vs 73%; P = .31). The tests were similar in diagnosing candidemia (59% vs 68%; P = .77), but PCR was more sensitive for deep-seated candidiasis (89% vs 53%; P = .004). PCR and BDG were more sensitive than blood cultures among patients with deep-seated candidiasis (88% and 62% vs 17%; P = .0005 and .003, respectively). PCR and culture identified the same Candida species in 82% of patients. The sensitivity of blood cultures combined with PCR or BDG among patients with IC was 98% and 79%, respectively. Conclusions. Candida PCR and, to a lesser extent, BDG testing significantly enhanced the ability of blood cultures to diagnose IC. C1 [Nguyen, M. Hong; Shields, Ryan K.; Hao, Binghua; Press, Ellen G.; Cheng, Shaoji; Mitsani, Dimitra; Vadnerkar, Aniket; Silveira, Fernanda P.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Wissel, Mark C.; Salomoni, Martin A.; Shields, Ryan M.; Kleiboeker, Steven B.] Viracor IBT Labs, Lees Summit, MO USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, 3550 Terrace St,Suite 871, Pittsburgh, PA 15261 USA. EM mhn5@pitt.edu FU Viracor-IBT Laboratories; Pfizer; Merck; CSL Behring; Biotherapies for Life; AstraZeneca FX This work was supported by an investigator-initiated research grant from Viracor-IBT Laboratories (to M. H. N.).; M. C. W., M. A. S., R. M. S., and S. B. K. are employees of Viracor-IBT Laboratories. M. H. N. has received research funding from Viracor-IBT Laboratories and grant support from Pfizer, Merck, CSL Behring, and Biotherapies for Life. F. P. S. has received research funding from Pfizer and CSL Behring. C. J. C. has received research funding from Pfizer, Merck, and AstraZeneca. R. K. S. has received funding from Pfizer and Merck. All other authors: no conflicts. NR 31 TC 91 Z9 93 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2012 VL 54 IS 9 BP 1240 EP 1248 DI 10.1093/cid/cis200 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 926BG UT WOS:000302805700008 PM 22431804 ER PT J AU Weekley, CC Peralta, CA AF Weekley, Cristin C. Peralta, Carmen A. TI Advances in the use of multimarker panels for renal risk stratification SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE albuminuria; chronic kidney disease; creatinine; cystatin C; multimarker ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; CYSTATIN-C; CARDIOVASCULAR EVENTS; ADVERSE OUTCOMES; SERUM CREATININE; ASSOCIATION; RECLASSIFICATION; PROTEINURIA; CKD AB Purpose of review This review discusses novel studies in the past year that have examined the use of combinations of multiple markers to improve risk prediction in the setting of chronic kidney disease (CKD). We will focus on multimarker panels to: improve prediction of CKD onset; improve classification of CKD and risk stratification of persons with CKD; and develop individual-level risk scores for progression to end-stage renal disease (ESRD). Recent findings One study reported that several novel circulation biomarkers may aid in predicting incident CKD and microalbuminuria. Second, our group has shown that the combination of creatinine, cystatin C, and albuminuria improves detection and risk stratification for death, heart failure, cardiovascular events, and ESRD compared with creatinine alone. Finally, a highly accurate individual risk score was developed to predict progression to ESRD using readily available clinical markers. Summary The combination of multiple markers improves detection and risk stratification in CKD. Future research is needed in understanding the use of a 'renal panel' for detection, classification, and risk stratification in kidney disease in diverse populations. The studies presented here represent the beginning of a paradigm shift to multimarker panels in nephrology. C1 [Weekley, Cristin C.; Peralta, Carmen A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Weekley, Cristin C.; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Institutes of Diabetes and Digestive and Kidney Diseases [1K23SK082793-01]; Robert Wood Johnson Harold Amos award FX C.A.P. is funded by the National Institutes of Diabetes and Digestive and Kidney Diseases (1K23SK082793-01) and a Robert Wood Johnson Harold Amos award. NR 32 TC 3 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD MAY PY 2012 VL 21 IS 3 BP 301 EP 308 DI 10.1097/MNH.0b013e328352132d PG 8 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 925OA UT WOS:000302769500010 PM 22449944 ER PT J AU Truman, JP Al Gadban, MM Smith, KJ Jenkins, RW Mayroo, N Virella, G Lopes-Virella, MF Bielawska, A Hannun, YA Hammad, SM AF Truman, Jean-Philip Al Gadban, Mohammed M. Smith, Kent J. Jenkins, Russell W. Mayroo, Nalini Virella, Gabriel Lopes-Virella, Maria F. Bielawska, Alicja Hannun, Yusuf A. Hammad, Samar M. TI Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release SO IMMUNOLOGY LA English DT Article DE acid sphingomyelinase; HSP70; interleukin-1; oxidized low-density lipoprotein immune complexes ID RECEPTOR-RELATED PROTEIN; RICH MEMBRANE RAFTS; MONOCYTE-DERIVED MACROPHAGES; SECRETORY SPHINGOMYELINASE; CELL-SURFACE; CERAMIDE; DISEASE; GENE; ATHEROGENESIS; CHOLESTEROL AB Oxidized low-density lipoprotein (oxLDL) and oxLDL-containing immune complexes (oxLDL-IC) contribute to the formation of lipid-laden macrophages (foam cells). Fc? receptors mediate uptake of oxLDL-IC, whereas scavenger receptors internalize oxLDL. We have previously reported that oxLDL-IC, but not free oxLDL, activate macrophages and prolong their survival. Sphingomyelin is a major constituent of cell membranes and lipoprotein particles and acid sphingomyelinase (ASMase) hydrolyses sphingomyelin to generate the bioactive lipid ceramide. ASMase exists in two forms: lysosomal (L-ASMase) and secretory (S-ASMase). In this study we examined whether oxLDL and oxLDL-IC regulate ASMase differently, and whether ASMase mediates monocyte/macrophage activation and cytokine release. The oxLDL-IC, but not oxLDL, induced early and consistent release of catalytically active S-ASMase. The oxLDL-IC also consistently stimulated L-ASMase activity, whereas oxLDL induced a rapid transient increase in L-ASMase activity before it steadily declined below baseline. Prolonged exposure to oxLDL increased L-ASMase activity; however, activity remained significantly lower than that induced by oxLDL-IC. Further studies were aimed at defining the function of the activated ASMase. In response to oxLDL-IC, heat-shock protein 70B (HSP70B) was up-regulated and localized with redistributed ASMase in the endosomal compartment outside the lysosome. Treatment with oxLDL-IC induced the formation and release of HSP70-containing and IL-1 beta-containing exosomes via an ASMase-dependent mechanism. Taken together, the results suggest that oxLDL and oxLDL-IC differentially regulate ASMase activity, and the pro-inflammatory responses to oxLDL-IC are mediated by prolonged activation of ASMase. These findings may contribute to increased understanding of mechanisms mediating macrophage involvement in atherosclerosis. C1 [Truman, Jean-Philip; Al Gadban, Mohammed M.; Smith, Kent J.; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Jenkins, Russell W.; Mayroo, Nalini; Bielawska, Alicja; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU National Institutes of Health (NIH) [HL079274, R01 HL079274-04S1]; South Carolina COBRE in Lipidomics and Pathobiology, NCRR [P20 RR17677]; Department of Veterans Affairs; NIH [P20 RR17677]; [P01 HL55782]; [R01 DK081352]; [R01 DK081352-02S1] FX This work was supported by the National Institutes of Health (NIH) grants HL079274, R01 HL079274-04S1 (American Recovery and Investment Act (ARRA)) and the South Carolina COBRE in Lipidomics and Pathobiology (P20 RR17677 from NCRR) to SMH, and P01 HL55782, R01 DK081352, and R01 DK081352-02S1 (ARRA) to MFL-V. This work was also supported by funding from the Department of Veterans Affairs to MFL-V. ASMase KO and ASMase wild-type mice were provided by SC COBRE Animal Pathobiology Core supported by NIH grant P20 RR17677. Special thanks to the Lipidomics Shared Resource facility at MUSC. We thank Dr Richard Kolesnick (Memorial Sloan-Kettering Cancer Center, New York) for anti-ASMase antibodies and Charlyne Chassereau (MUSC) for assistance with lipoprotein isolation. NR 67 TC 19 Z9 20 U1 0 U2 13 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0019-2805 J9 IMMUNOLOGY JI Immunology PD MAY PY 2012 VL 136 IS 1 BP 30 EP 45 DI 10.1111/j.1365-2567.2012.03552.x PG 16 WC Immunology SC Immunology GA 920JA UT WOS:000302399200005 PM 22236141 ER PT J AU Ho, TT Cadena, J Childs, LM Gonzalez-Velez, M Lewis, JS AF Ho, Tony T. Cadena, Jose Childs, Lindsey M. Gonzalez-Velez, Miguel Lewis, James S., II TI Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE vancomycin-intermediate Staphylococcus aureus; VISA; pharmacodynamics; pharmacokinetics ID CEPHALOSPORIN; PATHOGENS AB One of the newest methicillin-resistant Staphylococcus aureus (MRSA) antibiotics to receive FDA approval is ceftaroline fosamil, a member of a new subclass of cephalosporins with unique activity against MRSA. However, ceftaroline is currently only FDA approved for complicated skin/soft tissue infections and community-acquired pneumonia; there are currently no clinical data regarding its use in MRSA bacteraemia and endocarditis. We report a series of six patients in which ceftaroline was utilized as salvage monotherapy in persistent MRSA bacteraemia or endocarditis. Using pharmacy records, 11 ceftaroline-treated patients were identified between January 2011 and November 2011 at University Health System and the South Texas Veterans Health Care System in San Antonio, TX, USA. All cases were reviewed and six patients received ceftaroline therapy for MRSA bacteraemia or endocarditis due to persistent or recurrent bacteraemia while on standard antibiotics (vancomycin or daptomycin). All six patients experienced rapid clearance of their bacteraemia after starting ceftaroline. In the case of endocarditis for which the patient subsequently developed heart failure and required valve replacement, there was no evidence of growth from cultures taken from the excised valve, suggesting sterilization within 13 days of starting ceftaroline. Ceftaroline exhibits potent anti-MRSA activity in both in vitro and animal studies, including rabbit endocarditis models; however, the lack of clinical data has limited its use in bacteraemia and endovascular infections in humans. We hope that this series serves as an initial stepping stone for further evaluation of this compound for more invasive infections due to MRSA. C1 [Lewis, James S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX 78229 USA. [Ho, Tony T.; Cadena, Jose; Gonzalez-Velez, Miguel; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. [Cadena, Jose; Childs, Lindsey M.] Audie L Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Childs, Lindsey M.; Lewis, James S., II] Univ Texas Austin, Coll Pharm, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. RP Lewis, JS (reprint author), Univ Hlth Syst, Dept Pharm, 4502 Med Dr,MS 102, San Antonio, TX 78229 USA. EM james.lewis@uhs-sa.com NR 8 TC 54 Z9 54 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAY PY 2012 VL 67 IS 5 BP 1267 EP 1270 DI 10.1093/jac/dks006 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 921PJ UT WOS:000302489200035 PM 22311935 ER PT J AU Fischer, BL Gunter-Hunt, G Steinhafel, CH Howell, T AF Fischer, Barbara L. Gunter-Hunt, Gail Steinhafel, Courtney Holm Howell, Timothy TI The Identification and Assessment of Late-Life ADHD in Memory Clinics SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE adult ADHD; geriatric; cognition ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; ADULTS AB Objective: Little data exist about ADHD in late life. While evaluating patients' memory problems, the memory clinic staff has periodically identified ADHD in previously undiagnosed older adults. The authors conducted a survey to assess the extent to which other memory clinics view ADHD as a relevant clinical issue. Method: The authors developed and sent a questionnaire to memory clinics in the United States to determine the extent to which they identified patients with ADHD and the extent to which they took it into consideration. Results: Approximately one half of the memory clinics that responded reported seeing ADHD patients, either identifying previously diagnosed cases and/or newly diagnosing ADHD themselves. One fifth of clinics reported screening regularly for ADHD, and few clinics described accessing collateral informants to establish the diagnosis. Conclusion: This article suggests that U.S. memory clinics may not adequately identify and address ADHD in the context of late-life cognitive disorders. (J. of Att. Dis. 2012; 16(4) 333-338) C1 [Fischer, Barbara L.; Gunter-Hunt, Gail; Steinhafel, Courtney Holm; Howell, Timothy] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Howell, Timothy] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Fischer, BL (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM barbara.fischer@va.gov FU William S. Middleton Memorial Veterans Hospital; Geriatric Research, Education, and Clinical Center (GRECC) FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: William S. Middleton Memorial Veterans Hospital, Geriatric Research, Education, and Clinical Center (GRECC). This is GRECC manuscript No. 2008-02. NR 24 TC 2 Z9 2 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 J9 J ATTEN DISORD JI J. Atten. Disord. PD MAY PY 2012 VL 16 IS 4 BP 333 EP 338 DI 10.1177/1087054711398886 PG 6 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA 922UQ UT WOS:000302574300008 PM 22173147 ER PT J AU Conlin, MJ AF Conlin, Michael J. TI EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Conlin, MJ (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. OI Conlin, Michael/0000-0002-3128-3731 NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD MAY PY 2012 VL 187 IS 5 BP 1650 EP 1650 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 925YD UT WOS:000302797500052 PM 22425107 ER PT J AU Wang, L Murphy, NP Stengel, A Goebel-Stengel, M St Pierre, DH Maidment, NT Tache, Y AF Wang, L. Murphy, N. P. Stengel, A. Goebel-Stengel, M. St Pierre, D. H. Maidment, N. T. Tache, Y. TI Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE dopamine; gastric emptying; ghrelin; levodopa; rats ID PARKINSONS-DISEASE; FOS EXPRESSION; IN-VITRO; RESPONSE FLUCTUATIONS; GASTROINTESTINAL MOTILITY; SOLITARY TRACT; FOOD-INTAKE; GUINEA-PIG; C-FOS; SECRETION AB Background Levodopa (l-dopa) is the most commonly used treatment for alleviating symptoms of Parkinsons disease. However, l-dopa delays gastric emptying, which dampens its absorption. We investigated whether ghrelin prevents l-dopa action on gastric emptying and enhances circulating l-dopa in rats. Methods Gastric emptying of non-nutrient methylcellulose/phenol red viscous solution was determined in fasted rats treated with orogastric or intraperitoneal (i.p.) L-dopa, or intravenous (i.v.) ghrelin 10 min before orogastric L-dopa. Plasma L-dopa and dopamine levels were determined by high pressure liquid chromatography. Plasma acyl ghrelin levels were assessed by radioimmunoassay. Fos expression in the brain was immunostained after i. v. ghrelin (30 lg kg(-1)) 10 min before i.p. L-dopa. Key Results Levodopa (5 and 15 mg kg(-1)) decreased significantly gastric emptying by 32% and 62%, respectively, when administered orally, and by 91% and 83% when injected i.p. Ghrelin (30 or 100 lg kg(-1), i. v.) completely prevented L-dopa's (15 mg kg(-1), orogastrically) inhibitory action on gastric emptying and enhanced plasma L-dopa and dopamine levels compared with vehicle 15 min after orogastric L-dopa. Levodopa (5 mg kg(-1)) did not modify plasma acyl ghrelin levels at 30 min, 1, and 2 h after i. v. injection. Levodopa (15 mg kg(-1), i.p.) induced Fos in brain autonomic centers, which was not modified by i. v. ghrelin. Conclusions& Inferences Ghrelin counteracts L-dopa-induced delayed gastric emptying but not Fos induction in the brain and enhances circulating L-dopa levels. Potential therapeutic benefits of ghrelin agonists in Parkinson's disease patients treated with L-dopa remain to be investigated. C1 [Wang, L.; Stengel, A.; Goebel-Stengel, M.; Tache, Y.] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Ctr, Los Angeles, CA 90024 USA. [Wang, L.; Stengel, A.; Goebel-Stengel, M.; Tache, Y.] Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA USA. [Wang, L.; Stengel, A.; Goebel-Stengel, M.; Tache, Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Murphy, N. P.; Maidment, N. T.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Dept Psychol, Los Angeles, CA 90095 USA. [St Pierre, D. H.] Univ Montreal, Montreal, PQ, Canada. RP Wang, L (reprint author), Bldg 115,Rm 117B,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lixinw@ucla.edu FU Michael J. Fox Foundation for Parkinson's Research, NIH Center [DK-41301]; Veterans Administration FX This work was supported by the Michael J. Fox Foundation for Parkinson's Research, NIH Center Grant DK-41301 (Animal Core) and Veterans Administration Research Career Scientist Award (Y.T.). We are grateful to Mrs. Honghui Liang and Ms. Rachel Kelly for excellent technical support and we thank Ms. Eugenia Hu for reviewing the manuscript. NR 72 TC 14 Z9 14 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD MAY PY 2012 VL 24 IS 5 BP e235 EP e245 DI 10.1111/j.1365-2982.2012.01904.x PG 11 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 923IH UT WOS:000302612500002 PM 22443313 ER PT J AU Gellhorn, AC Morgenroth, DC Goldstein, B AF Gellhorn, Alfred C. Morgenroth, David C. Goldstein, Barry TI A NOVEL SONOGRAPHIC METHOD OF MEASURING PATELLAR TENDON LENGTH SO ULTRASOUND IN MEDICINE AND BIOLOGY LA English DT Article DE Tendon; Tendinopathy; Measurement; Ultrasound; Interrater reliability; Patellar; Patella alta; Infera; Baja ID FIELD-OF-VIEW; CRUCIATE LIGAMENT RECONSTRUCTION; ACHILLES-TENDON; IN-VIVO; ULTRASOUND; ULTRASONOGRAPHY; MUSCLE; ALTA; US AB Obtaining accurate and readily repeatable measurements is a prerequisite for using measures of soft tissue structures both clinically and in the research setting. Few studies have evaluated the interrater reliability of ultrasound measurements of tendons. The objective of this study was to determine the accuracy and reliability of a new method of sonographic measurement of patellar tendon length using direct dissection as the gold standard. Four cadaveric knees were sonographically evaluated by two independent investigators. Two custom designed straps with nylon strapping and stainless steel wire were used to firmly mark position on the leg and create an acoustic shadow on the ultrasound image. Anatomic landmarks were the distal patellar pole and the bony ridge on the anterior proximal tibia. After sonographic evaluation, the knee was dissected to expose the patellar tendon, which was measured using digital calipers. Intraclass correlation coefficients (ICC) were used to determine reliability of measurements between observers, where ICC > 0.75 was considered good and >0.9 was considered excellent. Validity was measured using a Bland-Altman plot, which measures bias between measurement methods as well as variability of scatter. Three sonographic measurements were made by each investigator on each tendon. The length of each of the four tendons based on the mean values of sonographic measurements was 53.8 mm, 53.4 mm, 49.4 mm and 46.8 mm. The length based on visual inspection of the dissected tissue was 54.6 mm, 52.8 mm, 49.8 mm and 46.9 mm. The calculated ICC between raters was 0.96. On the Bland-Altman plot, the bias, or mean difference between sonographic and visual measures, was 0.17 mm, with a standard deviation of 0.71. The 95% limit of agreement was 21.55 to 1.22 mm. Measurement of patellar tendon length with ultrasound using adjustable surface markers and calipers is highly accurate and has good interrater reliability. (E-mail: gellhorn@uw.edu) (C) 2012 World Federation for Ultrasound in Medicine & Biology. C1 [Gellhorn, Alfred C.; Morgenroth, David C.; Goldstein, Barry] Univ Washington, Dept Rehabil Med, Seattle, WA 98105 USA. [Morgenroth, David C.] VA Puget Sound Hlth Care Syst, Rehabil Res & Dev Ctr, Seattle, WA USA. RP Gellhorn, AC (reprint author), Univ Washington, Dept Rehabil Med, 4245 Roosevelt Way,NE,Box 354740, Seattle, WA 98105 USA. EM gellhorn@uw.edu OI Morgenroth, David/0000-0002-0226-7775 FU Walter and Anita Stolov Fund FX This work was supported by a grant from the Walter and Anita Stolov Fund. NR 28 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-5629 J9 ULTRASOUND MED BIOL JI Ultrasound Med. Biol. PD MAY PY 2012 VL 38 IS 5 BP 719 EP 726 DI 10.1016/j.ultrasmedbio.2012.01.020 PG 8 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA 922VZ UT WOS:000302577900001 PM 22425379 ER PT J AU Brawner, BM Davis, ZM Fannin, EF Alexander, KA AF Brawner, Bridgette M. Davis, Zupenda M. Fannin, Ehriel F. Alexander, Kamila A. TI Clinical Depression and Condom Use Attitudes and Beliefs Among African American Adolescent Females SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE LA English DT Article DE adolescent females; African American; condom use; depression; HIV; sexual health ID SELF-EFFICACY; RISK BEHAVIOR; SEX PARTNERS; AT-RISK; COMMUNICATION; INTERVENTIONS; PREDICTORS; DISTRESS; VALIDITY; YOUTH AB Depression, HIV, and other sexually transmitted diseases (STDs) are growing concerns among African American adolescent females. Theoretical models contribute to identification of mediators of condom use; however, minimal research has addressed the explicit relationship between clinical depression and condom use in African American adolescent females. The authors report results from quantitative surveys with clinically depressed (n = 64) and nondepressed (n = 64) African American adolescent females in two large metropolitan cities in the eastern United States. Theoretical mediators of condom use in the study sample-attitudes, subjective norms, perceived behavioral control, and intentions-were investigated. Significant differences existed between the groups in condomuse frequency (U = 356.5, p = .037); however, there were no statistically significant differences in condom use attitudes and beliefs. Although clinically depressed and nondepressed African American adolescent females may hold similar attitudes and beliefs about condom use, differences in condom use frequency may be a psychopathologic occurrence. Copyright (C) 2012 Association of Nurses in AIDS Care C1 [Brawner, Bridgette M.; Fannin, Ehriel F.; Alexander, Kamila A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Davis, Zupenda M.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. FU Substance Abuse and Mental Health Services Administration at the American Nurses Association Minority Fellowship Program [5 SM058566-02]; Hampton-Penn Center for Health Disparities Research [NINR P20NR008361]; Fontaine Society Fellowship at the University of Pennsylvania FX This work was supported by funding to Dr. Brawner from the Substance Abuse and Mental Health Services Administration at the American Nurses Association Minority Fellowship Program [5 SM058566-02], the Hampton-Penn Center for Health Disparities Research [NINR P20NR008361], and the Distinguished Postdoctoral Fellowship and the Fontaine Society Fellowship at the University of Pennsylvania. We thank the study participants, their families, and our local community partners for their assistance with this study. NR 31 TC 4 Z9 4 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1055-3290 J9 J ASSOC NURSE AIDS C JI J. Assoc. Nurses Aids Care PD MAY-JUN PY 2012 VL 23 IS 3 BP 184 EP 194 DI 10.1016/j.jana.2011.03.005 PG 11 WC Nursing SC Nursing GA 183NJ UT WOS:000321822500002 PM 21737313 ER PT J AU Ahalt, C Walter, LC Yourman, L Eng, C Perez-Stable, EJ Smith, AK AF Ahalt, Cyrus Walter, Louise C. Yourman, Lindsey Eng, Catherine Perez-Stable, Eliseo J. Smith, Alexander K. TI "Knowing is Better": Preferences of Diverse Older Adults for Discussing Prognosis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE prognosis; elderly; disability; diverse; PACE ID CANCER-PATIENTS PREFERENCES; OF-LIFE CARE; INFORMATION NEEDS; TERMINAL ILLNESS; MORTALITY; ATTITUDES; COMMUNICATION; END; VALIDATION; DISCLOSURE AB Prognosis is critical in individualizing care for older adults with late life disability. Evidence suggests that preferences for prognostic information may be culturally determined. Yet little is known about the preferences of diverse elders for discussing prognosis. To determine the preferences for discussing prognosis of a diverse sample of older adults with late-life disability We interviewed 60 older adults with mean age 78 and mean 2.5 Activities of Daily Living dependencies. Participants were recruited from San Francisco's On Lok program, the first Program of All-inclusive Care for the Elderly (PACE). Participants were interviewed in English, Spanish, and Cantonese, and responded to scenarios in which their doctors estimated they had 5 years and 1 year left to live. Open-ended questions explored the reasons for their responses. Results were analyzed qualitatively using grounded theory. Sixty-five percent of participants wanted to discuss the prognosis if their doctor estimated they had < 5 years to live and 75% if the estimate was < 1 year. Three themes were prominent among patients who wanted to discuss prognosis: to prepare, to make the most of the life they had left, and to make medical or health-related decisions. Those who preferred not to discuss prognosis described emotional difficulty, the uncertainty of prognosis, or that it would not be useful. Nearly all participants said that doctors should not make assumptions based on race or ethnicity, though differences between ethnic groups emerged. Most patients in this diverse sample of disabled elders were interested in discussing prognosis, while a substantial minority was not. Among those participants who preferred to discuss prognosis, many said that prognostic information would be important as they made difficult medical and personal decisions in late-life. Clinicians should inquire about preferences for discussing prognosis before sharing prognostic estimates. C1 [Ahalt, Cyrus; Walter, Louise C.; Yourman, Lindsey; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Walter, Louise C.; Yourman, Lindsey; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Eng, Catherine] Lok Lifeways, San Francisco, CA USA. [Perez-Stable, Eliseo J.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. EM aksmith@ucsf.edu.ph FU Center for Aging in Diverse Communities of the Resource Centers for Minority Aging [P30-AG15272]; National Institute on Aging, National Institutes of Health; National Center for Research Resources UCSF-CTSI [UL1 RR024131]; Atlantic Philanthropies; Society of General Internal Medicine; John A. Hartford Foundation; Association of Specialty Professors FX Dr. Smith was supported by a pilot grant from the Center for Aging in Diverse Communities, grant no. P30-AG15272 of the Resource Centers for Minority Aging Research program funded by the National Institute on Aging, National Institutes of Health. Additional support was provided by the National Center for Research Resources UCSF-CTSI (UL1 RR024131), Atlantic Philanthropies, the Society of General Internal Medicine, the John A. Hartford Foundation, and the Association of Specialty Professors. NR 42 TC 23 Z9 23 U1 5 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2012 VL 27 IS 5 BP 568 EP 575 DI 10.1007/s11606-011-1933-0 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 926YM UT WOS:000302869300017 PM 22127798 ER PT J AU Hermes, EDA Wells, TS Smith, B Boyko, EJ Gackstetter, GG Miller, SC Smith, TC AF Hermes, Eric D. A. Wells, Timothy S. Smith, Besa Boyko, Edward J. Gackstetter, Gary G. Miller, Shannon C. Smith, Tyler C. CA Millennium Cohort Study Team TI Smokeless tobacco use related to military deployment, cigarettes and mental health symptoms in a large, prospective cohort study among US service members SO ADDICTION LA English DT Article DE Afghanistan; Iraq war; military personnel; post-traumatic stress disorder; risk factors; smokeless tobacco; tobacco use disorder; veterans; war ID READJUSTMENT RATING-SCALE; MILLENNIUM COHORT; UNITED-STATES; PRIMARY-CARE; FOLLOW-UP; PERSONNEL; SMOKING; PREVALENCE; VALIDATION; STRESS AB Aims To characterize smokeless tobacco initiation and persistence in relation to deployment, combat, occupation, smoking and mental health symptoms. Design Prospective cohort, utilizing self-reported survey data from the Millennium Cohort Study. Setting US military service members in all branches including active duty, reserve and National Guard. Participants Population-based sample of 45 272 participants completing both baseline (July 2001June 2003; n = 77 047) and follow-up (June 2004-January 2006; n = 55 021) questionnaires (follow-up response rate = 71.4%). Measurements Self-reported smokeless tobacco initiation and persistence. Findings Over the study period, 72.4% did not deploy, 13.7% deployed without combat exposures and 13.9% deployed with combat exposures, while 1.9% were smokeless tobacco initiators and 8.9% were persistent users. The odds of initiation were greater for deployers with combat exposure [odds ratio (OR), 1.76; 95% confidence interval (CI), 1.49-2.09], deployers without combat exposure (OR, 1.31; 95% CI, 1.07-1.60) and those who deployed multiple times (OR, 1.67; 95% CI, 1.31-2.14), as well as in smoking recidivists/ initiators (OR, 4.65; 95% CI, 3.82-5.66) and those reporting posttraumatic stress disorder symptoms (OR, 1.54; CI, 1.15-2.07). A similar pattern for higher odds of persistent use was observed for deployment and combat exposure, but not for smoking and mental health symptoms. Military occupation was not significantly associated with initiation or persistence. Conclusions Deployment and combat exposure in the US military are associated with increased risk of smokeless tobacco initiation and persistence while smoking and symptoms of post-traumatic stress disorder increase the odds for initiation. Research is needed on aspects of military service amenable to the reduction or prevention of tobacco consumption. C1 [Hermes, Eric D. A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. [Wells, Timothy S.; Smith, Besa; Smith, Tyler C.] USN, Dept Deployment Hlth Res, Hlth Res Ctr, San Diego, CA 92152 USA. [Boyko, Edward J.] ERIC, VA Puget Sound, Seattle, WA USA. [Gackstetter, Gary G.] Analyt Serv Inc, Arlington, VA USA. [Miller, Shannon C.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA. [Miller, Shannon C.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. [Miller, Shannon C.] Univ Cincinnati, Ctr Treatment Res & Educ Addict Disorders CeTREAD, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. RP Hermes, EDA (reprint author), Yale Univ, Sch Med, Dept Psychiat, Ste 901,300 George St, New Haven, CT 06511 USA. EM eric.hermes@yale.edu OI Boyko, Edward/0000-0002-3695-192X FU US Army Medical Research and Materiel Command, Fort Detrick, Maryland; Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland FX The authors state that they have no financial disclosures or other conflicts of interest in the design, analysis or preparation of this manuscript. The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command, Fort Detrick, Maryland. The funding organization had no role in the design and conduct of the study; collection, analysis or preparation of data,; or preparation, review or approval of the manuscript.; The Millennium Cohort Study Team includes Gregory C. Gray MD, MPH (College of Public Health and Health Professions, University of Florida, Gainesville, Florida), James R. Riddle DVM, MPH (Air Force Research Laboratory, Wright-Patterson Air Force Base, Dayton, Ohio), Paul J. Amoroso MD, MPH (Madigan Army Medical Center, Fort Lewis, Washington), Tomoko I. Hooper MD, MPH (Uniformed Services University on the Health Sciences, Bethesda, Maryland) and Margaret A. K. Ryan MD, MPH (US Naval Hospital Camp Pendleton, Camp Pendleton, California). We are indebted to the Millennium Cohort Study participants, without whom these analyses would not be possible. We thank Scott L. SeggermanBS, MS, from the Defense Manpower Data Center, Seaside, California. We also thank the professionals from the US Army Medical Research and Materiel Command, especially those from the Military Operational Medicine Research Program, Fort Detrick, Maryland. We thank Melissa Bagnell MPH; Gina Creaven, MBA; James Davies BS; Gia Gumbs, MPH; Nisara Granado MPH, PhD; Lesley Henry BA; Dennis Hernando BS; Jaime Horton BS; Isabel Jacobson MPH; Kelly Jones MPH; Lauren Kipp BA; Cynthia LeardMann MPH; Travis Leleu BS; Gordon Lynch; Jamie McGrew BS; Hope McMaster PhD; Stacie Nguyen BS; Amanda Pietrucha MPH; Teresa Powell MS; Kari Sausedo MA; Amber Seelig MPH; Beverly Sheppard BS; Katherine Snell BS; Steven Speigle; Marleen Welsh PhD; Martin White MPH; James Whitmer; and CharleneWongMPH; from the Department of Deployment Health Research and Michelle LeWark BA, from the Naval Health Research Center, San Diego, California. We appreciate the support of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland. These individuals provided assistance as part of their official duties as employees of the Department of Defense and none received additional financial compensation. The VA Puget Sound provided support for Dr Boyko's participation in this research. NR 49 TC 8 Z9 8 U1 2 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0965-2140 J9 ADDICTION JI Addiction PD MAY PY 2012 VL 107 IS 5 BP 983 EP 994 DI 10.1111/j.1360-0443.2011.03737.x PG 12 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 919QW UT WOS:000302344500029 PM 22126651 ER PT J AU Anderson, J Caplan, L Yazdany, J Robbins, ML Neogi, T Michaud, K Saag, KG O'Dell, JR Kazi, S AF Anderson, Jaclyn Caplan, Liron Yazdany, Jinoos Robbins, Mark L. Neogi, Tuhina Michaud, Kaleb Saag, Kenneth G. O'Dell, James R. Kazi, Salahuddin TI Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice SO ARTHRITIS CARE & RESEARCH LA English DT Article ID HEALTH-ASSESSMENT QUESTIONNAIRE; ACUTE-PHASE REACTANTS; LONG-TERM OUTCOMES; ACTIVITY INDEX; ACTIVITY SCORE; ROUTINE ASSESSMENT; 28-JOINT COUNTS; REMISSION; TRIALS; VALIDATION AB Objective Although the systematic measurement of disease activity facilitates clinical decision making in rheumatoid arthritis (RA), no recommendations currently exist on which measures should be applied in clinical practice in the US. The American College of Rheumatology (ACR) convened a Working Group (WG) to comprehensively evaluate the validity, feasibility, and acceptability of available RA disease activity measures and derive recommendations for their use in clinical practice. Methods. The Rheumatoid Arthritis Clinical Disease Activity Measures Working Group conducted a systematic review of the literature to identify RA disease activity measures. Using exclusion criteria, input from an Expert Advisory Panel (EAP), and psychometric analysis, a list of potential measures was created. A survey was administered to rheumatologists soliciting input. The WG used these survey results in conjunction with the psychometric analyses to derive final recommendations. Results. Systematic review of the literature resulted in identification of 63 RA disease activity measures. Application of exclusion criteria and ratings by the EAP narrowed the list to 14 measures for further evaluation. Practicing rheumatologists rated 9 of these 14 measures as most useful and feasible. From these 9 measures, the WG selected 6 with the best psychometric properties for inclusion in the final set of ACR-recommended RA disease activity measures. Conclusion. We recommend the Clinical Disease Activity Index, Disease Activity Score with 28-joint counts (erythrocyte sedimentation rate or C-reactive protein), Patient Activity Scale (PAS), PAS-II, Routine Assessment of Patient Index Data with 3 measures, and Simplified Disease Activity Index because they are accurate reflections of disease activity; are sensitive to change; discriminate well between low, moderate, and high disease activity states; have remission criteria; and are feasible to perform in clinical settings. C1 [Kazi, Salahuddin] Dallas VA Med Ctr, Dallas, TX 75216 USA. [Saag, Kenneth G.] Univ Alabama, Tuscaloosa, AL 35487 USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Michaud, Kaleb; O'Dell, James R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Neogi, Tuhina] Boston Univ, Sch Med, Boston, MA 02118 USA. [Neogi, Tuhina] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Robbins, Mark L.] Harvard Vanguard Med Associates, Boston, MA USA. [Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Caplan, Liron] Univ Colorado, Sch Med, Denver, CO USA. [Caplan, Liron] Denver VAMC, Denver, CO USA. RP Kazi, S (reprint author), Dallas VA Med Ctr, 4500 S Lancaster Rd 11, Dallas, TX 75216 USA. EM salahuddin.kazi@va.gov OI Anderson, Jaclyn/0000-0002-0893-3900; Neogi, Tuhina/0000-0002-9515-1711 FU Mayo Foundation; Amgen; AstraZeneca; Lilly; Genentech; Merck; Horizon; Sanofi-Aventis; Novartis; Pfizer; Centocor FX Dr. Anderson owns stock and/or stock options in Abbot Laboratories. Dr. Michaud has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from the Mayo Foundation. Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Amgen, AstraZeneca, Lilly, Genentech, Merck, Horizon, Sanofi-Aventis, Novartis, and Pfizer. Dr. Kazi has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Genentech and Centocor. NR 28 TC 136 Z9 141 U1 0 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2012 VL 64 IS 5 BP 640 EP 647 DI 10.1002/acr.21649 PG 8 WC Rheumatology SC Rheumatology GA 918EQ UT WOS:000302232500002 PM 22473918 ER PT J AU Daikh, DI St Clair, EW AF Daikh, David I. St Clair, E. William TI Updated Recommendations for the Treatment of Rheumatoid Arthritis: Another Step on a Long Road SO ARTHRITIS CARE & RESEARCH LA English DT Editorial Material ID T-CELL LYMPHOMA; DISEASE; RISK C1 [Daikh, David I.] Univ Calif San Francisco, Dept Rheumatol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA. RP Daikh, DI (reprint author), Univ Calif San Francisco, Dept Rheumatol, San Francisco VA Med Ctr, 4150 Clement St,111R, San Francisco, CA 94121 USA. EM david.daikh@ucsf.edu FU NIAID NIH HHS [U19 AI056363] NR 12 TC 5 Z9 5 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2012 VL 64 IS 5 BP 648 EP 651 DI 10.1002/acr.21659 PG 4 WC Rheumatology SC Rheumatology GA 918EQ UT WOS:000302232500003 PM 22473919 ER PT J AU Barrera, TL Zeno, D Bush, AL Barber, CR Stanley, MA AF Barrera, Terri L. Zeno, Darrell Bush, Amber L. Barber, Catherine R. Stanley, Melinda A. TI Integrating Religion and Spirituality Into Treatment for Late-Life Anxiety: Three Case Studies SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Article DE religion; spirituality; cognitive behavioral therapy; late-life anxiety; generalized anxiety disorder ID STATE WORRY QUESTIONNAIRE; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; OLDER-ADULTS; GERIATRIC ANXIETY; PSYCHOMETRIC PROPERTIES; AFRICAN-AMERICANS; ELDERLY-PATIENTS; PRIMARY-CARE; DISORDER AB Generalized anxiety disorder (GAD) is common in older adults and, although cognitive behavioral therapy (CBT) is an efficacious treatment for late-life GAD, effect sizes are only moderate and attrition rates are high. One way to increase treatment acceptability and enhance current cognitive behavioral treatments for GAD in older adults might be to incorporate religion/spirituality (R/S). The cases presented here illustrate the use of a 12-week modular CBT intervention for late-life anxiety, designed to allow incorporation of R/S elements in accordance with patient preferences. The three women treated using this protocol chose different levels and methods of R/S integration into therapy. All three women showed substantial improvement in worry symptoms, as well as a variety of secondary outcomes following treatment; these gains were maintained at 6-month follow-up. These preliminary results suggest that the incorporation of R/S into CBT might be beneficial for older adults with GAD. Strengths, limitations, and future directions are discussed. C1 [Barrera, Terri L.] Univ Houston, Anxiety Disorder Clin, VA HSR&D Houston Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77204 USA. [Barber, Catherine R.; Stanley, Melinda A.] Baylor Coll Med, Houston, TX 77030 USA. [Barber, Catherine R.] Univ St Thomas, St Paul, MN USA. RP Barrera, TL (reprint author), Univ Houston, Anxiety Disorder Clin, VA HSR&D Houston Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, 126 Heyne Bldg, Houston, TX 77204 USA. EM terri.barrera@gmail.com OI Barrera, Terri/0000-0003-0854-4216 NR 65 TC 6 Z9 7 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD MAY PY 2012 VL 19 IS 2 BP 346 EP 358 PG 13 WC Psychology, Clinical SC Psychology GA 918TV UT WOS:000302274900014 ER PT J AU Ghazi, ER Kling, MA Propert, K Okawa, J Werth, VP AF Ghazi, E. R. Kling, M. A. Propert, K. Okawa, J. Werth, V. P. TI Increased depression in cutaneous lupus erythematosus compared to the general population and dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 75th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2012 CL Raleigh, NC SP Soc Investigat Dermatol C1 [Ghazi, E. R.; Kling, M. A.; Okawa, J.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Propert, K.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ghazi, E. R.] UMDNJ RWJMS, Piscataway, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2012 VL 132 SU 1 MA 095 BP S16 EP S16 PG 1 WC Dermatology SC Dermatology GA 926XV UT WOS:000302866900094 ER PT J AU Jones, JT Sandsmark, EK Salazar, M Walkosz, BJ Dellavalle, RP AF Jones, J. T. Sandsmark, E. K. Salazar, M. Walkosz, B. J. Dellavalle, R. P. TI Internet survey of tattoo skin care SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 75th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2012 CL Raleigh, NC SP Soc Investigat Dermatol C1 [Jones, J. T.; Sandsmark, E. K.; Salazar, M.; Dellavalle, R. P.] Univ Colorado, Sch Med, Aurora, CO USA. [Jones, J. T.; Dellavalle, R. P.] Colorado Sch Publ Hlth, Aurora, CO USA. [Walkosz, B. J.] Klein Buendel Inc, Golden, CO USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Dermatol Serv, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2012 VL 132 SU 1 MA 281 BP S48 EP S48 PG 1 WC Dermatology SC Dermatology GA 926XV UT WOS:000302866900282 ER PT J AU Katiyar, SK Jones, V Nandakumar, V AF Katiyar, S. K. Jones, V. Nandakumar, V. TI Green tea catechins reactivate silenced tumor suppressor genes, p16INK4a and Cip1/p21, in UV-irradiated mouse skin and skin tumors by reducing DNA methylation and increasing histone acetylation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 75th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2012 CL Raleigh, NC SP Soc Investigat Dermatol C1 [Katiyar, S. K.; Jones, V.; Nandakumar, V.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2012 VL 132 SU 1 MA 677 BP S115 EP S115 PG 1 WC Dermatology SC Dermatology GA 926XV UT WOS:000302866900678 ER PT J AU Lee, KC Weinstock, MA AF Lee, K. C. Weinstock, M. A. TI Association of eyeglasses use with periocular keratinocyte carcinomas and actinic keratosis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 75th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2012 CL Raleigh, NC SP Soc Investigat Dermatol C1 [Lee, K. C.; Weinstock, M. A.] Brown Univ, Providence, RI 02912 USA. [Weinstock, M. A.] US Dept Vet Affairs, Cooperat Studies Program, Washington, DC USA. [Lee, K. C.; Weinstock, M. A.] VA Med Ctr, Providence, RI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2012 VL 132 SU 1 MA 256 BP S43 EP S43 PG 1 WC Dermatology SC Dermatology GA 926XV UT WOS:000302866900257 ER PT J AU Wieczorek, IT Propert, KJ Okawa, J Werth, VP AF Wieczorek, I. T. Propert, K. J. Okawa, J. Werth, V. P. TI Progression from cutaneous to systemic lupus erythematosus by ACR criteria usually occurs with mild disease and few systemic symptoms SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 75th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 09-12, 2012 CL Raleigh, NC SP Soc Investigat Dermatol C1 [Wieczorek, I. T.; Okawa, J.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Wieczorek, I. T.; Okawa, J.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Propert, K. J.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2012 VL 132 SU 1 MA 264 BP S45 EP S45 PG 1 WC Dermatology SC Dermatology GA 926XV UT WOS:000302866900267 ER PT J AU Kangovi, S Edwards, M Woloszynek, S Mitra, N Feldman, H Kaplan, BS Meyers, KE AF Kangovi, Shreya Edwards, Meredith Woloszynek, Stephen Mitra, Nandita Feldman, Harold Kaplan, Bernard S. Meyers, Kevin E. TI Renin-angiotensin-aldosterone system inhibitors in pediatric focal segmental glomerulosclerosis SO PEDIATRIC NEPHROLOGY LA English DT Article DE Focal segmental glomerulosclerosis; Renin-angiotensin-aldosterone system ID RESISTANT NEPHROTIC SYNDROME; CHILDREN; PROTEINURIA; CREATININE; ENALAPRIL; BLOCKADE; ADULTS AB Conventional immunosuppressive therapy for primary pediatric focal segmental glomerulosclerosis (FSGS) is potentially toxic and only moderate evidence supports its effectiveness. Renin-angiotensin-aldosterone (RAAS) inhibition monotherapy is anecdotally used in selected patients as an alternative to conventional therapy. We performed a retrospective cohort study of children with primary FSGS seen at a tertiary care academic hospital between 1986 and 2008. We classified patients into two groups based upon initial treatment: RAAS inhibition monotherapy (RIM) and conventional therapy (CT). The primary endpoint was progression to end-stage renal disease (ESRD). Secondary endpoints were remission of proteinuria, relapse, and death. The cohort consisted of 67 patients. Mean baseline urine protein/creatinine ratio (Up/c) was 8.0 (5.2, 10.7) mg/mg, and mean baseline estimated glomerular filtration rate (eGFR) was 115.0 (101.8, 128.1) mL/min/1.73 m(2). Patients in the RIM group were more likely to have lower eGFR (100.8 mL/min/1.73 m(2) vs 132.9 mL/min/1.73 m(2), p = 0.01) and less proteinuria (4.4 vs.14.4, p < 0.01). Renal failure occurred in 22.9% of the RIM group vs 40.6% in the CT group (log-rank p = 0.07). After adjustment for African-American race, time period of presentation, baseline age, eGFR, and Up/c, patients in the RIM group had a 0.11 hazard ratio of progressing to renal failure compared with patients in the CT group (p < 0.01). Children treated initially with RIM may have better outcomes than those treated with CT. C1 [Kangovi, Shreya] Philadelphia VA Med Ctr, Robert Wood Johnson VA Clin Scholars Program, Dept Vet Affairs, Philadelphia, PA 19104 USA. [Edwards, Meredith; Woloszynek, Stephen; Kaplan, Bernard S.; Meyers, Kevin E.] Childrens Hosp Philadelphia, Div Nephrol, Philadelphia, PA 19104 USA. [Mitra, Nandita; Feldman, Harold] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Kangovi, S (reprint author), Philadelphia VA Med Ctr, Robert Wood Johnson VA Clin Scholars Program, Dept Vet Affairs, 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu OI Clement, Meredith/0000-0002-0283-6368 NR 15 TC 3 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0931-041X J9 PEDIATR NEPHROL JI Pediatr. Nephrol. PD MAY PY 2012 VL 27 IS 5 BP 813 EP 819 DI 10.1007/s00467-011-2056-x PG 7 WC Pediatrics; Urology & Nephrology SC Pediatrics; Urology & Nephrology GA 918ZG UT WOS:000302289700017 PM 22116578 ER PT J AU Bakaeen, FG AF Bakaeen, Faisal G. TI Learning Goals: Expectations of Residents Versus Faculty SO JOURNAL OF SURGICAL RESEARCH LA English DT Editorial Material C1 [Bakaeen, Faisal G.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA. [Bakaeen, Faisal G.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA. RP Bakaeen, FG (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA. EM fbakaeen@bcm.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD MAY PY 2012 VL 174 IS 1 BP 88 EP 89 DI 10.1016/j.jss.2011.02.010 PG 2 WC Surgery SC Surgery GA 916SK UT WOS:000302123300021 PM 21470633 ER PT J AU Sher, L Stanley, BH Posner, K Arendt, M Grunebaum, MF Neria, Y Mann, JJ Oquendo, MA AF Sher, Leo Stanley, Barbara H. Posner, Kelly Arendt, Mikkel Grunebaum, Michael F. Neria, Yuval Mann, Joseph John Oquendo, Maria A. TI Decreased suicidal ideation in depressed patients with or without comorbid posttraumatic stress disorder treated with selective serotonin reuptake inhibitors: An open study SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic stress disorder; Major depressive disorder; Suicidal ideation; Selective serotonin reuptake inhibitors ID BORDERLINE PERSONALITY-DISORDER; MAJOR DEPRESSION; DOUBLE-BLIND; PSYCHIATRIC OUTPATIENTS; CLINICAL-FEATURES; ANXIETY DISORDERS; MOOD DISORDER; WAR VETERANS; PTSD; PLACEBO AB Comorbidity of posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) is associated with higher morbidity including suicidal ideation and behavior. Selective serotonin reuptake inhibitors (SSRIs) are a known treatment for PTSD, MOD and comorbid PTSD and MDD. Since the patients with comorbid MOD and PTSD (PTSD-MDD) are sicker, we hypothesize a poorer response to treatment compared to patients with MOD only. Ninety-six MDD patients were included in the study: 76 with MDD only and 20 with PTSD-MDD. Demographic and clinical parameters at baseline were assessed. We examined clinical parameters before and after 3 months of open SSRI treatment in subjects with PTSD-MDD and compared this group to individuals with MDD only. At baseline, PTSD-MDD patients had higher Hamilton Depression Rating Scale and Buss-Durkee Hostility Scale scores compared with MOD only subjects. There was a significant decrease in scores on the Hamilton Depression Rating Scale, Beck Depression Inventory, Beck Hopelessness Scale, and Beck Scale for Suicidal Ideation after 3 months of treatment with SSRIs in both groups. The magnitude of improvement in Beck Scale for Suicidal Ideation scores was greater in the PTSD-MDD group compared to the MDD only subjects. Symptoms of depression including suicidal ideation improved in MDD patients with or without comorbid PTSD after 3 months of treatment with SSRIs but improvement in suicidal ideation was greater in the PTSD-MDD group. Our finding has not supported the hypothesis that a response to treatment is poorer in the PTSD-MDD group which may indicate that sicker patients benefit more from the treatment. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, MHPCC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu RI Stanley, Barbara/J-8736-2013 FU Conte Center for the Neurobiology of Mental Disorders [5 P50 MH62185, MH48514, MH59710, AA15630]; Nina Rahn Fund FX This study was supported by the Conte Center for the Neurobiology of Mental Disorders (5 P50 MH62185), MH48514, MH59710, AA15630, and the Nina Rahn Fund. NR 63 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD APR 30 PY 2012 VL 196 IS 2-3 BP 261 EP 266 DI 10.1016/j.psychres.2011.11.010 PG 6 WC Psychiatry SC Psychiatry GA 962MG UT WOS:000305548600016 PM 22397913 ER PT J AU Gros, DF Price, M Magruder, KM Frueh, BC AF Gros, Daniel F. Price, Matthew Magruder, Kathryn M. Frueh, B. Christopher TI Symptom overlap in posttraumatic stress disorder and major depression SO PSYCHIATRY RESEARCH LA English DT Article DE Posttraumatic stress disorder; Major depressive disorder; Comorbidity; Transdiagnostic treatment; Hybrid models of psychopathology ID PRIMARY-CARE CLINICS; ADMINISTERED PTSD SCALE; DSM-IV ANXIETY; PSYCHOMETRIC PROPERTIES; MOOD DISORDERS; VETERANS; COMORBIDITY; PSYCHOPATHOLOGY; CLASSIFICATION; PREVALENCE AB Over the past decade there has been consistent criticism of the diagnostic criteria of posttraumatic stress disorder (PTSD) because of its high comorbidity with other mental disorders. Part of the problem surrounding PTSD may be related to the heterogeneity of its symptoms. In fact, recent research has identified a subset of PTSD symptoms, including symptoms of numbing and dysphoria, that may explain much of the overlap between PTSD and major depressive disorder (MDD). The present study sought to extend prior work by investigating the various subsets of PTSD symptoms in individuals from all four diagnostic combinations of PTSD and MDD (no MDD-PTSD, MDD-only, PTSD-only, and comorbid MDD-PTSD). Consenting participants completed diagnostic interviews and were categorized into the four groups. Based on responses to a self-report measure of PTSD symptoms, participants with no MDD-PTSD reported the least severe symptoms while the participants with comorbid MDD-PTSD reported the most severe symptoms. Interesting, participants in the MDD-only and PTSD-only groups consistently reported similar scores across all PTSD symptom scales. These findings further highlight the problematic diagnostic criteria and comorbidity in PTSD and emphasize the need to incorporate transdiagnostic treatment practices that focus on the overlapping symptoms, rather than specific diagnostic categories. Published by Elsevier Ltd. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.; Price, Matthew; Magruder, Kathryn M.] Med Univ S Carolina, Charleston, SC 29425 USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Veterans Affairs Health Services Research and Development (VA HSRD) [VCR-99-010-2]; [T32MH018869] FX This work was partially supported by grant VCR-99-010-2 from Veterans Affairs Health Services Research and Development (VA HSR&D) and several authors are members of the Ralph H. Johnson VAMC Research Enhancement Award Program (REA08-261; PI: Leonard Egede, M.D.). Dr. Price is supported by T32MH018869. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. There are no conflicts of interest to disclose. NR 36 TC 40 Z9 40 U1 3 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD APR 30 PY 2012 VL 196 IS 2-3 BP 267 EP 270 DI 10.1016/j.psychres.2011.10.022 PG 4 WC Psychiatry SC Psychiatry GA 962MG UT WOS:000305548600017 PM 22386220 ER PT J AU Hata, S Taniguchi, M Yi, PA Ikeuchi, T Fagan, AM Holtzman, DM Bateman, R Sohrabi, HR Martins, RN Gandy, S Urakami, K Suzuki, T AF Hata, Saori Taniguchi, Miyako Yi Piao Ikeuchi, Takeshi Fagan, Anne M. Holtzman, David M. Bateman, Randall Sohrabi, Hamid R. Martins, Ralph N. Gandy, Sam Urakami, Katsuya Suzuki, Toshiharu CA Japanese Alzheimers Dis TI Multiple gamma-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects SO MOLECULAR NEURODEGENERATION LA English DT Article DE Alzheimer's disease; Cerebrospinal fluid; gamma-secretase; Alcadein; beta-amyloid ID BETA-PROTEIN PRECURSOR; AMYLOID DEPOSITION; IN-VIVO; PHOSPHORYLATION; METABOLISM; A-BETA(42); MUTATIONS; BINDING; PLASMA AB Background: Alcadein(alpha) (Alc(alpha)) is a neuronal membrane protein that colocalizes with the Alzheimer's amyloid-beta precursor protein (APP). Successive cleavage of APP by beta- and gamma-secretases generates the aggregatable amyloid-beta peptide (A beta), while cleavage of APP or Alc(alpha) by alpha- and gamma-secretases generates non-aggregatable p3 or p3-Alc(alpha) peptides. A beta and p3-Alc(alpha) can be recovered from human cerebrospinal fluid (CSF). We have previously reported alternative processing of APP and Alc(alpha) in the CSF of some patients with sporadic mild cognitive impairment (MCI) and AD (SAD). Results: Using the sandwich enzyme-linked immunosorbent assay (ELISA) system that detects total p3-Alc(alpha), we determined levels of total p3-Alc(alpha) in CSF from subjects in one of four diagnostic categories (elderly controls, MCI, SAD, or other neurological disease) derived from three independent cohorts. Levels of A beta 40 correlated with levels of total p3-Alc(alpha) in all cohorts. Conclusions: We confirm that A beta 40 is the most abundant A beta species, and we propose a model in which CSF p3-Alc(alpha) can serve as a either (1) a nonaggregatable surrogate marker for gamma-secretase activity; (2) as a marker for clearance of transmembrane domain peptides derived from integral protein catabolism; or (3) both. We propose the specification of an MCI/SAD endophenotype characterized by co-elevation of levels of both CSF p3-Alc(alpha) and A beta 40, and we propose that subjects in this category might be especially responsive to therapeutics aimed at modulation of gamma-secretase function and/or transmembrane domain peptide clearance. These peptides may also be used to monitor the efficacy of therapeutics that target these steps in A beta metabolism. C1 [Hata, Saori; Yi Piao; Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido, Japan. [Taniguchi, Miyako; Urakami, Katsuya] Tottori Univ, Fac Med, Sch Hlth Sci, Dept Biol Regulat, Yonago, Tottori 683, Japan. [Ikeuchi, Takeshi] Niigata Univ, Brain Res Inst, Dept Mol Neurosci, Niigata, Japan. [Fagan, Anne M.; Holtzman, David M.; Bateman, Randall] Washington Univ, Sch Med, Dept Neurol, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA. [Sohrabi, Hamid R.; Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Ctr Excellence Alzheimers Dis Res & Care, Joondalup, WA, Australia. [Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA. [Gandy, Sam] James J Peters Vet Adm Med Ctr, Bronx, NY USA. RP Suzuki, T (reprint author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Sapporo, Hokkaido, Japan. EM tsuzuki@pharm.hokudai.ac.jp RI Hata, Saori /A-3829-2012; Suzuki, Toshiharu/B-5342-2013; Sohrabi, Hamid Reza/D-2744-2013; Sohrabi, Hamid R Sohrabi/L-2461-2016 OI Sohrabi, Hamid Reza/0000-0001-8017-8682; Sohrabi, Hamid R Sohrabi/0000-0001-8017-8682 FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) [20390018, 22890001]; Ministry of Health, Labor and Welfare (MHLW); New Energy and Industrial Technology Development Organization (NEDO) in Japan; Northern Advancement Center for Science & Technology (NOASTEC); Terumo Life Science Foundation; NIA Alzheimer's Disease Research Center [P50 005138]; National Center for Research Resources (NCRR) [UL1 RR024992]; Veterans Administration; [P50 AG05681]; [P01-AG03991]; [P01-AG26276] FX This work was supported in part by Grants-in-Aid for Scientific Research (20390018 to TS) and Grant-in-Aid for Research Activity Start-up (22890001 to SH) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), a grant from the Ministry of Health, Labor and Welfare (MHLW), and a grant from the New Energy and Industrial Technology Development Organization (NEDO) in Japan. S.H. was supported by Northern Advancement Center for Science & Technology (NOASTEC) and Terumo Life Science Foundation. S.G. was supported by the NIA Alzheimer's Disease Research Center grant P50 005138 to Mary Sano and by the Veterans Administration. The Washington University in St Louis Alzheimer's Disease Center Biomarker Core is supported by P50 AG05681 [J.C.M.], P01-AG03991 [J.C.M.], P01-AG26276 [J.C.M.]. This publication was made possible by Grant Number UL1 RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 31 TC 8 Z9 8 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD APR 25 PY 2012 VL 7 AR 16 DI 10.1186/1750-1326-7-16 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 993FH UT WOS:000307840900001 PM 22534039 ER PT J AU Scherzer, R Estrella, M Li, YM Choi, AI Deeks, SG Grunfeld, C Shlipak, MG AF Scherzer, Rebecca Estrella, Michelle Li, Yongmei Choi, Andy I. Deeks, Steven G. Grunfeld, Carl Shlipak, Michael G. TI Association of tenofovir exposure with kidney disease risk in HIV infection SO AIDS LA English DT Article DE antiretroviral therapy; HIV; kidney disease; tenofovir ID ANTIRETROVIRAL-NAIVE PATIENTS; MARGINAL STRUCTURAL MODELS; TUBULAR DYSFUNCTION; DISOPROXIL FUMARATE; FANCONI-SYNDROME; RENAL TOXICITY; DIABETES-INSIPIDUS; RANDOMIZED-TRIAL; THERAPY; ADHERENCE AB Objective: Despite widespread HAART use, HIV disease remains associated with increased risk of kidney disease. Whether tenofovir use is associated with higher risk of kidney disease is controversial. Design: We evaluated the association of cumulative and ever exposure to tenofovir on kidney outcomes in 10 841 HIV-infected patients from the Veterans Health Administration who initiated antiretroviral therapy from 1997 to 2007. Methods: Cox proportional hazards and marginal structural models evaluated associations between tenofovir and time to first occurrence of proteinuria (two consecutive urine dipstick measurements >= 30 mg/dl), rapid decline in kidney function (>= 3 ml/min per 1.73 m(2) annual decline), and chronic kidney disease (CKD; estimated glomerular filtration rate <60 ml/min per 1.73 m(2)). Results: Median follow-up ranged from 3.9 years (proteinuria) to 5.5 years (CKD), during which 3400 proteinuria, 3078 rapid decline, and 533 CKD events occurred. After multivariable adjustment, each year of exposure to tenofovir was associated with 34% increased risk of proteinuria [95% confidence interval (CI) 25-45, P < 0.0001], 11% increased risk of rapid decline (3-18, P = 0.0033), and 33% increased risk of CKD (18-51, P < 0.0001). Preexisting renal risk factors did not appear to worsen the effects of tenofovir. Other antiretroviral drugs showed weaker or inconsistent associations with kidney disease events. Among those who discontinued tenofovir use, risk of kidney disease events did not appear to decrease during follow-up. Conclusion: Tenofovir exposure was independently associated with increased risk for three types of kidney disease events, and did not appear to be reversible. Because subtle kidney function decline affects long-term morbidity and mortality, the balance between efficacy and probable adverse effects requires further study. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Scherzer, Rebecca; Li, Yongmei; Choi, Andy I.; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Scherzer, Rebecca; Li, Yongmei; Choi, Andy I.; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Estrella, Michelle] Johns Hopkins Sch Med, Baltimore, MD USA. [Deeks, Steven G.] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, Dept Med, Box 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU National Institutes of Health [K23DK080645-1A1, 1R03AG034871-01, K24AI069994, R01 DK066488-01, K23DK081317]; National Center for Research Resources [KL2 RR024130]; American Heart Association; Veterans Affairs Public Health Strategic Healthcare Group; Merck; Bristol-Myers Squibb; Gilead; Roche Molecular Sciences; Abbott; Gilead Sciences; EMD Serono; Theratechnologies FX This study was supported by the National Institutes of Health [K23DK080645-1A1 (A.I.C.), 1R03AG034871-01 (A.I.C./M.G.S.), K24AI069994, R01 DK066488-01 (M.G.S./A.I.C.), K23DK081317 (M.E.)], the National Center for Research Resources (KL2 RR024130), the American Heart Association Established Investigator Award (MGS), and the Veterans Affairs Public Health Strategic Healthcare Group, which were administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. These funding sources had no involvement in the design or execution of this study. S.G.D. receives research support from Merck, Bristol-Myers Squibb, Gilead, and Roche Molecular Sciences. C. G. has received prior research funding and/or honorarium from Merck, Bristol-Myers Squibb, Abbott, Gilead Sciences, EMD Serono and Theratechnologies. NR 38 TC 160 Z9 165 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD APR 24 PY 2012 VL 26 IS 7 BP 867 EP 875 DI 10.1097/QAD.0b013e328351f68f PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 926EB UT WOS:000302813000012 PM 22313955 ER PT J AU Wong, SPY Kreuter, W O'Hare, AM AF Wong, Susan P. Y. Kreuter, William O'Hare, Ann M. TI Treatment Intensity at the End of Life in Older Adults Receiving Long-term Dialysis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID STAGE RENAL-DISEASE; HEART-FAILURE; CARE C1 [Wong, Susan P. Y.; O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Kreuter, William] Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 Pacific St NE,POB 359945, Seattle, WA 98195 USA. EM spywong@uw.edu FU NIA NIH HHS [5K23AG028980] NR 9 TC 63 Z9 63 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD APR 23 PY 2012 VL 172 IS 8 BP 661 EP 663 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 930HQ UT WOS:000303128700015 PM 22529233 ER PT J AU Cowan, RE Fregly, BJ Boninger, ML Chan, L Rodgers, MM Reinkensmeyer, DJ AF Cowan, Rachel E. Fregly, Benjamin J. Boninger, Michael L. Chan, Leighton Rodgers, Mary M. Reinkensmeyer, David J. TI Recent trends in assistive technology for mobility SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Review DE Disability; Assistive technology; Robotics ID ANKLE-FOOT ORTHOSIS; SYSTEM; PROSTHETICS; WHEELCHAIR; VISION; DESIGN; INJURY; GAIT AB Loss of physical mobility makes maximal participation in desired activities more difficult and in the worst case fully prevents participation. This paper surveys recent work in assistive technology to improve mobility for persons with a disability, drawing on examples observed during a tour of academic and industrial research sites in Europe. The underlying theme of this recent work is a more seamless integration of the capabilities of the user and the assistive technology. This improved integration spans diverse technologies, including powered wheelchairs, prosthetic limbs, functional electrical stimulation, and wearable exoskeletons. Improved integration is being accomplished in three ways: 1) improving the assistive technology mechanics; 2) improving the user-technology physical interface; and 3) sharing of control between the user and the technology. We provide an overview of these improvements in user-technology integration and discuss whether such improvements have the potential to be transformative for people with mobility impairments. C1 [Cowan, Rachel E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA. [Fregly, Benjamin J.] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15260 USA. [Chan, Leighton] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA. [Rodgers, Mary M.] Univ Maryland, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA. [Rodgers, Mary M.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA. [Reinkensmeyer, David J.] Univ Calif Irvine, Dept Mech & Aerosp Engn, Dept Anat & Neurobiol, Dept Biomed Engn, Irvine, CA 92697 USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. RP Cowan, RE (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA. EM rcowan@med.miami.edu RI Fregly, Benjamin/O-6860-2016 OI Fregly, Benjamin/0000-0003-1166-4358; Boninger, Michael/0000-0001-6966-919X NR 31 TC 26 Z9 26 U1 4 U2 57 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD APR 20 PY 2012 VL 9 AR 20 DI 10.1186/1743-0003-9-20 PG 8 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA 981ZY UT WOS:000307012700001 PM 22520500 ER PT J AU Reinkensmeyer, DJ Bonato, P Boninger, ML Chan, L Cowan, RE Fregly, BJ Rodgers, MM AF Reinkensmeyer, David J. Bonato, Paolo Boninger, Michael L. Chan, Leighton Cowan, Rachel E. Fregly, Benjamin J. Rodgers, Mary M. TI Major trends in mobility technology research and development: Overview of the results of the NSF-WTEC European study SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Editorial Material AB Mobility technologies, including wheelchairs, prostheses, joint replacements, assistive devices, and therapeutic exercise equipment help millions of people participate in desired life activities. Yet, these technologies are not yet fully transformative because many desired activities cannot be pursued or are difficult to pursue for the millions of individuals with mobility related impairments. This WTEC study, initiated and funded by the National Science Foundation, was designed to gather information on European innovations and trends in technology that might lead to greater mobility for a wider range of people. What might these transformative technologies be and how might they arise? Based on visits to leading mobility technology research labs in western Europe, the WTEC panel identified eight major trends in mobility technology research. This commentary summarizes these trends, which are then described in detail in companion papers appearing in this special issue. C1 [Reinkensmeyer, David J.] Univ Calif Irvine, Dept Biomed Engn, Dept Anat & Neurobiol, Dept Mech & Aerosp Engn, Irvine, CA 92697 USA. [Bonato, Paolo] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept PM&R, Boston, MA 02114 USA. [Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Chan, Leighton] NIH, Dept Rehabil Med, Ctr Clin, Bethesda, MD 20892 USA. [Cowan, Rachel E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA. [Fregly, Benjamin J.] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA. [Rodgers, Mary M.] Univ Maryland, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA. [Rodgers, Mary M.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA. RP Reinkensmeyer, DJ (reprint author), Univ Calif Irvine, Dept Biomed Engn, Dept Anat & Neurobiol, Dept Mech & Aerosp Engn, 4200 Engn Gateway, Irvine, CA 92697 USA. EM dreinken@uci.edu RI Fregly, Benjamin/O-6860-2016 OI Fregly, Benjamin/0000-0003-1166-4358; Boninger, Michael/0000-0001-6966-919X NR 0 TC 10 Z9 10 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD APR 20 PY 2012 VL 9 AR 22 DI 10.1186/1743-0003-9-22 PG 4 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA 940AO UT WOS:000303862600001 PM 22520596 ER PT J AU Grover, FL AF Grover, Frederick L. TI Current Status of Off-Pump Coronary-Artery Bypass SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID RANDOMIZED-TRIAL; ON-PUMP; SURGERY C1 [Grover, Frederick L.] Univ Colorado, Sch Med, Dept Surg, Denver, CO 80202 USA. [Grover, Frederick L.] Denver Vet Affairs Med Ctr, Cardiothorac Surg Sect, Denver, CO USA. RP Grover, FL (reprint author), Univ Colorado, Sch Med, Dept Surg, Denver, CO 80202 USA. NR 6 TC 2 Z9 2 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 19 PY 2012 VL 366 IS 16 BP 1541 EP 1543 DI 10.1056/NEJMe1203194 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 927UE UT WOS:000302934800015 PM 22449294 ER PT J AU Hope, MD Dyverfeldt, P Acevedo-Bolton, G Wrenn, J Foster, E Tseng, E Saloner, D AF Hope, Michael D. Dyverfeldt, Petter Acevedo-Bolton, Gabriel Wrenn, Jarrett Foster, Elyse Tseng, Elaine Saloner, David TI Post-stenotic dilation: Evaluation of ascending aortic dilation with 4D flow MR imaging SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Letter DE Aneurysm; Valve-related aortic disease; Post-stenotic dilation; Bicuspid aortic valve; 4D flow; Shear stress C1 [Hope, Michael D.; Dyverfeldt, Petter; Acevedo-Bolton, Gabriel; Wrenn, Jarrett; Saloner, David] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Foster, Elyse] Univ Calif San Francisco, Dept Cardiol, San Francisco, CA 94143 USA. [Tseng, Elaine] San Francisco VA Med Ctr, Dept Cardiothorac Surg, San Francisco, CA USA. RP Hope, MD (reprint author), Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. EM michael.hope@ucsf.edu OI Dyverfeldt, Petter/0000-0002-3051-661X FU NINDS NIH HHS [K25 NS058573] NR 5 TC 10 Z9 10 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 J9 INT J CARDIOL JI Int. J. Cardiol. PD APR 19 PY 2012 VL 156 IS 2 BP E40 EP E42 DI 10.1016/j.ijcard.2011.08.018 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 909QX UT WOS:000301580400006 PM 21907425 ER PT J AU Basch, E Aronson, N Berg, A Flum, D Gabriel, S Goodman, SN Helfand, M Ioannidis, JPA Lauer, M Meltzer, D Mittman, B Newhouse, R Normand, SL Schneeweiss, S Slutsky, J Tinetti, M Yancy, C AF Basch, Ethan Aronson, Naomi Berg, Alfred Flum, David Gabriel, Sherine Goodman, Steven N. Helfand, Mark Ioannidis, John P. A. Lauer, Michael Meltzer, David Mittman, Brian Newhouse, Robin Normand, Sharon-Lise Schneeweiss, Sebastian Slutsky, Jean Tinetti, Mary Yancy, Clyde CA Methodology Comm Patient-Centered TI Methodological Standards and Patient-Centeredness in Comparative Effectiveness Research The PCORI Perspective SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID IMPLEMENTATION-RESEARCH; RANDOMIZED-TRIALS; PROPENSITY SCORE; CLINICAL-TRIALS; QUALITY IMPROVEMENT; PUBLICATION BIAS; MEDICATIONS; EXPERIENCE; BENEFITS; LESSONS AB Rigorous methodological standards help to ensure that medical research produces information that is valid and generalizable, and are essential in patient-centered outcomes research (PCOR). Patient-centeredness refers to the extent to which the preferences, decision-making needs, and characteristics of patients are addressed, and is the key characteristic differentiating PCOR from comparative effectiveness research. The Patient Protection and Affordable Care Act signed into law in 2010 created the Patient-Centered Outcomes Research Institute (PCORI), which includes an independent, federally appointed Methodology Committee. The Methodology Committee is charged to develop methodological standards for PCOR. The 4 general areas identified by the committee in which standards will be developed are (1) prioritizing research questions, (2) using appropriate study designs and analyses, (3) incorporating patient perspectives throughout the research continuum, and (4) fostering efficient dissemination and implementation of results. A Congressionally mandated PCORI methodology report (to be issued in its first iteration in May 2012) will begin to provide standards in each of these areas, and will inform future PCORI funding announcements and review criteria. The work of the Methodology Committee is intended to enable generation of information that is relevant and trustworthy for patients, and to enable decisions that improve patient-centered outcomes. JAMA. 2012;307(15):1636-1640 www.jama.com C1 [Basch, Ethan] Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, New York, NY 10463 USA. [Aronson, Naomi] Blue Cross Blue Shield Assoc, Chicago, IL USA. [Berg, Alfred; Flum, David] Univ Washington, Seattle, WA 98195 USA. [Gabriel, Sherine] Mayo Clin, Rochester, MN USA. [Goodman, Steven N.; Ioannidis, John P. A.] Stanford Univ, Stanford, CA 94305 USA. [Helfand, Mark] Portland VA Med Ctr, Portland, OR USA. [Lauer, Michael] NHLBI, Bethesda, MD 20892 USA. [Meltzer, David] Univ Chicago, Chicago, IL 60637 USA. [Mittman, Brian] Dept Vet Affairs, Sepulveda, CA USA. [Newhouse, Robin] Univ Maryland, Baltimore, MD 21201 USA. [Normand, Sharon-Lise; Schneeweiss, Sebastian] Harvard Univ, Sch Med, Boston, MA USA. [Normand, Sharon-Lise] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Slutsky, Jean] Agcy Healthcare Res & Qual, Rockville, MD USA. [Tinetti, Mary] Yale Univ, New Haven, CT USA. [Yancy, Clyde] Northwestern Univ, Chicago, IL 60611 USA. RP Basch, E (reprint author), Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, 307 63rd St, New York, NY 10463 USA. EM ebasch@mskcc.org RI Schneeweiss, Sebastian/C-2125-2013; Meltzer, David/C-2926-2009 OI Meltzer, David/0000-0003-2790-7393 FU PCORI of the Methodology Committee FX The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. All of the authors reported receiving funding from PCORI as members of the Methodology Committee, including compensation for travel and lodging for PCORI-related meetings as well as time spent providing service to the PCORI. NR 45 TC 97 Z9 97 U1 4 U2 27 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 18 PY 2012 VL 307 IS 15 BP 1636 EP 1640 DI 10.1001/jama.2012.466 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 927GU UT WOS:000302896100026 ER PT J AU Prochazka, AV Caverly, TJ AF Prochazka, Allan V. Caverly, Tanner J. TI Radical prostatectomy and watchful waiting for localized prostate cancer did not differ for quality of life SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Prochazka, Allan V.] Denver VAMC, Denver, CO USA. Univ Colorado, Denver Sch Med, Denver, CO 80202 USA. RP Prochazka, AV (reprint author), Denver VAMC, Denver, CO USA. NR 2 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 17 PY 2012 VL 156 IS 8 AR JC4-3 DI 10.7326/0003-4819-156-8-201204170-02003 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 930PO UT WOS:000303151800002 PM 22508743 ER PT J AU Tan, Y Li, XK Prabhu, SD Brittian, KR Chen, Q Yin, X McClain, CJ Zhou, ZX Cai, L AF Tan, Yi Li, Xiaokun Prabhu, Sumanth D. Brittian, Kenneth R. Chen, Qiang Yin, Xia McClain, Craig J. Zhou, Zhanxiang Cai, Lu TI Angiotensin II Plays a Critical Role in Alcohol-Induced Cardiac Nitrative Damage, Cell Death, Remodeling, and Cardiomyopathy in a Protein Kinase C/Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Dependent Manner SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE alcoholic cardiomyopathy; angiotensin II; cardiac cell death; losartan; oxidative and nitrative stress; protein kinase C ID CHRONIC ETHANOL INGESTION; OXIDATIVE STRESS; DIABETIC CARDIOMYOPATHY; PKC-EPSILON; HEART; APOPTOSIS; EXPRESSION; RENIN; PEROXYNITRITE; PREVENTION AB Objectives The purpose of this study was to examine the cellular and molecular mechanisms underlying alcoholic cardiomyopathy. Background The mechanism for alcoholic cardiomyopathy remains largely unknown. Methods The chronic cardiac effects of alcohol were examined in mice feeding with alcohol or isocaloric control diet for 2 months. Signaling pathways of alcohol-induced cardiac cell death were examined in H9c2 cells. Results Compared with controls, hearts from alcohol-fed mice exhibited increased apoptosis, along with significant nitrative damage, demonstrated by 3-nitrotyrosine abundance. Alcohol exposure to H9c2 cells induced apoptosis, accompanied by 3-nitrotyrosine accumulation and nicotinamide adenine dinucleotide phosphate oxidase (NOX) activation. Pre-incubation of H9c2 cells with urate (peroxynitrite scavenger), N-G-nitro-L-arginine methyl ester (a nitric oxide synthase inhibitor), manganese(III) tetrakis(1-methyl-4-pyridyl)porphyrin (a superoxide dismutase mimetic), and apocynin (NOX inhibitor) abrogated alcohol-induced apoptosis. Furthermore, alcohol exposure significantly increased the expression of angiotensin II and its type 1 receptor (AT1). A protein kinase C (PKC)-alpha/beta 1 inhibitor or PKC-beta 1 small interfering RNA and an AT1 blocker prevented alcohol-induced activation of NOX, and the AT1 blocker losartan significantly inhibited the expression of PKC-beta 1, indicating that alcohol-induced activation of NOX is mediated by PKC-beta 1 via AT1. To define the role of AT1-mediated PKC/NOX-derived superoxide generation in alcohol-induced cardiotoxicity, mice with knockout of the AT1 gene and wild-type mice were simultaneously treated with alcohol for 2 months. The knockout AT1 gene completely prevented cardiac nitrative damage, cell death, remodeling, and dysfunction. More importantly, pharmacological treatment of alcoholic mice with superoxide dismutase mimetic also significantly prevented cardiac nitrative damage, cell death, and remodeling. Conclusions Alcohol-induced nitrative stress and apoptosis, which are mediated by angiotensin II interaction with AT1 and subsequent activation of a PKC-beta 1-dependent NOX pathway, are a causal factor in the development of alcoholic cardiomyopathy. (J Am Coll Cardiol 2012;59:1477-86) (C) 2012 by the American College of Cardiology Foundation C1 [Tan, Yi; Li, Xiaokun; Cai, Lu] Wenzhou Med Coll, Chinese Amer Res Inst Diabet Complicat, Wenzhou, Peoples R China. [Tan, Yi; Chen, Qiang; Yin, Xia; Cai, Lu] Univ Louisville, Kosair Childrens Hosp Res Inst, Dept Pediat, Louisville, KY 40202 USA. [Prabhu, Sumanth D.] Univ Alabama, Dept Med Cardiovasc Dis, Birmingham, AL USA. [Prabhu, Sumanth D.] Birmingham VA Med Ctr, Birmingham, AL USA. [McClain, Craig J.; Cai, Lu] Univ Louisville, Dept Med, Robley Rex Vet Affairs Med Ctr, Louisville, KY 40202 USA. [McClain, Craig J.; Cai, Lu] Univ Louisville, Dept Pharmacol & Toxicol, Robley Rex Vet Affairs Med Ctr, Louisville, KY 40202 USA. [Zhou, Zhanxiang] Univ N Carolina, Dept Nutr, Greensboro, NC 27412 USA. RP Cai, L (reprint author), Univ Louisville, Dept Pediat, 570 S Preston St,Baxter 1,Suite 304F, Louisville, KY 40202 USA. EM 10cai001@louisville.edu FU American Diabetes Association [1-11-BS-17]; Zhejiang Province; Wenzhou Medical College; National Institutes of Health [R01AA014623, HL099014, HL078825, R37AA010762, P01AA017103]; Department of Veterans Affairs FX Supported, in part, by grants from the American Diabetes Association (1-11-BS-17 to Dr. Cai), Zhejiang Province (Extremely Key Subject Building Project "Pharmacology and Biochemical Pharmaceutics 2009") and Wenzhou Medical College (Starting-Up Fund for Chinese-American Research Institute for Diabetic Complications to Drs. Cai and Li), National Institutes of Health (R01AA014623 to Dr. Zhou, HL099014 and HL078825 to Dr. Prabhu, R37AA010762 and P01AA017103 to Dr. McClain), and the Department of Veterans Affairs (to Drs. Prabhu and McClain). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 25 TC 32 Z9 33 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 17 PY 2012 VL 59 IS 16 BP 1477 EP 1486 DI 10.1016/j.jacc.2011.12.034 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 925TW UT WOS:000302785500010 PM 22497828 ER PT J AU Ford, J Keedy, S Reilly, J Gershon, E Sweeney, JA AF Ford, Judith Keedy, Sarah Reilly, James Gershon, Elliott Sweeney, John A. TI Schizophrenia and Psychotic Bipolar Disease Patients Show Same Abnormalities of the Corollary Discharge Mechanism SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat C1 [Ford, Judith] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith] UCSF, San Francisco, CA USA. [Keedy, Sarah] Univ Illinois, Chicago, IL USA. [Reilly, James] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Gershon, Elliott] Univ Chicago, Sch Med, Chicago, IL 60637 USA. [Sweeney, John A.] Univ Texas SW Med Sch, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 56 BP 16S EP 16S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000051 ER PT J AU Jahshan, C Wynn, JK Mathis, KI Gibson, C Tripp, C Weiner, K Green, MF AF Jahshan, Carol Wynn, Jonathan K. Mathis, Kristopher I. Gibson, Crystal Tripp, Cory Weiner, Katie Green, Michael F. TI Cross-Diagnostic Comparison of Mismatch Negativity and P3a in Bipolar Disorder and Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE bipolar disorder; schizophrenia; mismatch negativity; P3a; auditory processing C1 W Los Angeles VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 261 BP 81S EP 81S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000256 ER PT J AU Hurford, IM March, ME Richard, J Gur, RE Gur, RC AF Hurford, Irene M. March, Mary E. Richard, Jan Gur, Raquel E. Gur, Ruben C. TI A Brief Cognitive Assessment Tool for Schizophrenia (B-CATS): Correlation of a 10-Minute Clinical Tool with a Computerized Neurocognitive Battery SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE Schizophrenia; Cognition; Assessment; Neuropsychology C1 [Hurford, Irene M.; March, Mary E.; Richard, Jan; Gur, Raquel E.; Gur, Ruben C.] Univ Penn, Philadelphia, PA 19104 USA. [Hurford, Irene M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 303 BP 94S EP 94S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000298 ER PT J AU Perez-Rodriguez, MM Roussos, P Bevilacqua, L Yuan, QP Zhou, ZF Hodgkinson, C Ripoll, L Goodman, M Koenigsberg, HW Goldman, D Siever, LJ New, AS AF Perez-Rodriguez, M. Mercedes Roussos, Panos Bevilacqua, Laura Yuan, Qiaoping Zhou, Zhifeng Hodgkinson, Colin Ripoll, Luis Goodman, Marianne Koenigsberg, Harold W. Goldman, David Siever, Larry J. New, Antonia S. TI Exploratory Association Study of 130 Candidate Genes in Patients with Borderline Personality Disorder and Healthy Controls SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE Borderline Personality Disorder; Genetics; Dopamine beta hydroxylase; Association study C1 [Perez-Rodriguez, M. Mercedes; Roussos, Panos; Ripoll, Luis; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.; New, Antonia S.] Mt Sinai Sch Med, New York, NY USA. [Perez-Rodriguez, M. Mercedes; Roussos, Panos; Ripoll, Luis; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.; New, Antonia S.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY USA. [Bevilacqua, Laura; Yuan, Qiaoping; Zhou, Zhifeng; Hodgkinson, Colin; Goldman, David] NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA. RI Perez Rodriguez, Maria/B-9410-2013; Roussos, Panos/J-7090-2013 OI Perez Rodriguez, Maria/0000-0001-5137-1993; Roussos, Panos/0000-0002-4640-6239 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 492 BP 155S EP 155S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000487 ER PT J AU Yao, JK Reddy, RD Doughedy, GG Magan, S Gurklis, J Sonel, A Sonel, E Kisslinger, BL Chengappa, RKN Keshavan, MS AF Yao, Jeffrey K. Reddy, Ravinder D. Doughedy, George G. Magan, Sharon Gurklis, John Sonel, Ali Sonel, Elif Kisslinger, Benjamin L. Chengappa, Roy K. N. Keshavan, Matcheri S. TI Association of hsCRP with High-Risk of Cardiovascular Disease in Patients with Early Course Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE high-sensitivity C-reactive protein; Early course schizophrenia; Cardiovascular disease; HDL cholesterol; Lipoprotein (a) C1 [Reddy, Ravinder D.; Chengappa, Roy K. N.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.; Doughedy, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Magan, Sharon; Gurklis, John; Kisslinger, Benjamin L.] VA Pittsburgh Healthcare Syst, Med Serv, Pittsburgh, PA USA. [Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Keshavan, Matcheri S.] Harvard Univ, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 534 BP 168S EP 169S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000529 ER PT J AU Vizueta, N Townsend, JD Torrisi, S Aquino, AR Fischer, J Bookheimer, SY Altshuler, LL AF Vizueta, Nathalie Townsend, Jennifer D. Torrisi, Salvatore Aquino, Ana R. Fischer, Jeffrey Bookheimer, Susan Y. Altshuler, Lori L. TI Elucidating State Versus Trait-Related Functional MRI Deficits in Bipolar II Disorder: A Longitudinal Investigation SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE Bipolar II Disorder; functional MRI; emotional faces; amygdala; treatment response C1 [Vizueta, Nathalie; Townsend, Jennifer D.; Torrisi, Salvatore; Aquino, Ana R.; Fischer, Jeffrey; Bookheimer, Susan Y.; Altshuler, Lori L.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Altshuler, Lori L.] W Los Angles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 646 BP 206S EP 206S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466000641 ER PT J AU Bellin, E Wong, E Simantov, J Bang, C Hazlett, E Elder, G Tang, CY Carpenter, D Mitsis, EM AF Bellin, Elisheva Wong, Edmund Simantov, Jessie Bang, Charlene Hazlett, Erin Elder, Gregory Tang, Cheuk Y. Carpenter, David Mitsis, Effie M. TI Resting State Functional Connectivity in Blast-Related Mild Traumatic Brain Injury in OIF/OEF Combat Veterans With and Without PTSD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE fMRI; Default Mode Network; blast related mild TBI; combat veterans C1 [Bellin, Elisheva; Simantov, Jessie; Bang, Charlene; Elder, Gregory; Mitsis, Effie M.] James J Peters VAMC, Bronx, NY USA. [Wong, Edmund; Hazlett, Erin; Elder, Gregory; Tang, Cheuk Y.; Carpenter, David; Mitsis, Effie M.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 786 BP 247S EP 248S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466001099 ER PT J AU Rosell, DR Mennes, M Chu, KW New, AS Siever, LJ Milham, MP Hazlett, EA AF Rosell, Daniel R. Mennes, Maarten Chu, King-Wai New, Antonia S. Siever, Larry J. Milham, Michael P. Hazlett, Erin A. TI Distinct Patterns of Altered Fronto-Parietal and Cingulo-Opercular Network Functional Connectivity in Borderline and Schizotypal Personality Disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE functional connectivity; borderline; schizotypal; task positive; default mode C1 [Rosell, Daniel R.; New, Antonia S.; Siever, Larry J.; Hazlett, Erin A.] Mt Sinai Sch Med, New York, NY USA. [Chu, King-Wai; New, Antonia S.; Siever, Larry J.; Hazlett, Erin A.] James J Peters VA Med Ctr, VISN3 MIRECC, Bronx, NY USA. [Mennes, Maarten] NYU Langone Sch Med, Phyllis Green & Randolph Cowen Inst Pediat Neuros, New York, NY USA. [Milham, Michael P.] Child Mind Inst, Ctr Developing Brain, New York, NY USA. RI Mennes, Maarten/C-9924-2011 OI Mennes, Maarten/0000-0002-7279-3439 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 792 BP 249S EP 249S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466001105 ER PT J AU Hazlett, EA Carpenter, D Goldstein, KE Haznedar, MM New, A Goodman, M Byne, W Siever, LJ Koenigsberg, HW Chu, KW AF Hazlett, Erin A. Carpenter, David Goldstein, Kim E. Haznedar, M. Mehmet New, Antonia Goodman, Marianne Byne, William Siever, Larry J. Koenigsberg, Harold W. Chu, King-Wai TI White Matter Integrity in Schizophrenia and Schizotypal Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE schizophrenia; schizotypal personality disorder; diffusion tensor imaging; white matter; cingulum C1 [Hazlett, Erin A.; Carpenter, David; Goldstein, Kim E.; Haznedar, M. Mehmet; New, Antonia; Goodman, Marianne; Byne, William; Siever, Larry J.; Koenigsberg, Harold W.] Mt Sinai Sch Med, New York, NY USA. [Hazlett, Erin A.; New, Antonia; Goodman, Marianne; Byne, William; Siever, Larry J.; Chu, King-Wai] James J Peters VAMC, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 824 BP 261S EP 261S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466001137 ER PT J AU Fryer, SL Woods, SW Shanbhag, H Kiehl, KA Calhoun, VD Pearlson, GD Roach, BJ Ford, JM McGlashan, TH Mathalon, DH AF Fryer, Susanna L. Woods, Scott W. Shanbhag, Harshad Kiehl, Kent A. Calhoun, Vince D. Pearlson, Godfrey D. Roach, Brain J. Ford, Judith M. McGlashan, Thomas H. Mathalon, Daniel H. TI Functional Connectivity Alterations During Auditory Target Detection in Youth at Clinical High-Risk for Psychosis SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE schizophrenia prodrome; psychosis risk; functional connectivity; auditory oddball; dorsolateral prefrontal cortex C1 [Fryer, Susanna L.; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fryer, Susanna L.; Shanbhag, Harshad; Roach, Brain J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Woods, Scott W.; Calhoun, Vince D.; Pearlson, Godfrey D.; McGlashan, Thomas H.; Mathalon, Daniel H.] Yale Univ, New Haven, CT USA. [Kiehl, Kent A.; Calhoun, Vince D.] Univ New Mexico, Albuquerque, NM 87131 USA. [Kiehl, Kent A.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA. [Pearlson, Godfrey D.] Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 837 BP 265S EP 265S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466001150 ER PT J AU Garrett, CT Alexander, PP Fisher, MA So, RP Powell, VBS Vinogradov, S AF Garrett, Coleman T. Alexander, Phillip P. Fisher, Melissa A. So, Rachel P. Powell, V. Brooke S. Vinogradov, Sophia TI Neuroplasticity-Based Cognitive Training Generalizes to Improved Semantic Clustering in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 67th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry CY MAY 03-05, 2012 CL Philadelphia, PA SP Soc Biol Psychiat DE Cognitive Training; Schizophrenia; Semantic Clustering C1 [Garrett, Coleman T.; Alexander, Phillip P.; So, Rachel P.; Powell, V. Brooke S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Fisher, Melissa A.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 SU S MA 1003 BP 316S EP 316S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GL UT WOS:000302466001314 ER PT J AU Malkoski, SP Haeger, SM Cleaver, TG Rodriguez, KJ Li, H Lu, SL Feser, WJ Baron, AE Merrick, D Lighthall, JG Ijichi, H Franklin, W Wang, XJ AF Malkoski, Stephen P. Haeger, Sarah M. Cleaver, Timothy G. Rodriguez, Karen J. Li, Howard Lu, Shi-Long Feser, William J. Baron, Anna E. Merrick, Daniel Lighthall, Jessyka G. Ijichi, Hideaki Franklin, Wilbur Wang, Xiao-Jing TI Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma SO CLINICAL CANCER RESEARCH LA English DT Article ID TGF-BETA; DEFECTIVE EXPRESSION; HISTOLOGICAL TYPES; MOUSE MODELS; BASAL-CELLS; STEM-CELLS; CANCER; METASTASIS; HEAD; MICE AB Purpose: Lung adenocarcinoma and lung squamous cell carcinoma (SCC) are the most common non-small cell lung cancer (NSCLC) subtypes. This study was designed to determine whether reduced expression of TGF beta type II receptor (TGF beta RII) promotes lung adenocarcinoma and SCC carcinogenesis. Experimental Design: We examined TGF beta RII expression at the protein and mRNA levels in human NSCLC samples and assessed the relationship between TGF beta RII expression and clinicopathologic parameters. To determine whether sporadic TGF beta RII deletion in airway epithelial cells induces NSCLC formation, we targeted TGF beta RII deletion alone and in combination with oncogenic Kras(G12D) to murine airways using a keratin 5 (K5) promoter and inducible Cre recombinase. Results: Reduced TGF beta RII expression in human NSCLC is associated with male gender, smoking, SCC histology, reduced differentiation, increased tumor stage, increased nodal metastasis, and reduced survival. Homozygous or heterozygous TGF beta RII deletion in mouse airway epithelia increases the size and number of Kras(G12D)-initiated adenocarcinoma and SCC. TGF beta RII deletion increases proliferation, local inflammation, and TGF beta ligand elaboration; TGF beta RII knockdown in airway epithelial cells increases migration and invasion. Conclusions: Reduced TGF beta RII expression in human NSCLC is associated with more aggressive tumor behavior and inflammation that is, at least partially, mediated by increased TGF beta 1 expression. TGF beta RII deletion in mouse airway epithelial cells promotes adenocarcinoma and SCC formation, indicating that TGF beta RII loss plays a causal role in lung carcinogenesis. That TGF beta RII shows haploid insufficiency suggests that a 50% TGF beta RII protein reduction would negatively impact lung cancer prognosis. Clin Cancer Res; 18(8); 2173-83. (C) 2012 AACR. C1 [Malkoski, Stephen P.; Haeger, Sarah M.; Cleaver, Timothy G.; Rodriguez, Karen J.; Li, Howard] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Malkoski, Stephen P.; Franklin, Wilbur; Wang, Xiao-Jing] Univ Colorado Denver, Dept Pathol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Lu, Shi-Long; Wang, Xiao-Jing] Univ Colorado Denver, Dept Otolaryngol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Feser, William J.; Baron, Anna E.] Univ Colorado Denver, Dept Biostat & Informat, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Merrick, Daniel] Denver VA Med Ctr, Dept Pathol, Denver, CO USA. [Ijichi, Hideaki] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan. [Lighthall, Jessyka G.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Malkoski, SP (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Colorado Sch Publ Hlth, 12700 E 19th Ave,RC2,Room 9112,Mail Stop C272, Aurora, CO 80045 USA. EM Stephen.Malkoski@ucdenver.edu; XJ.Wang@ucdenver.edu FU NIH/NCI [F32 CA119467, K08 CA131483]; NIH/NIDCR [R01 DE015953]; Oregon Medical Research Foundation; National Lung Cancer Partnership; [T32 CA106195]; [P30 CA 069533]; [P30 CA046934]; [P50 CA058187] FX This work was supported by the NIH/NCI (F32 CA119467 and K08 CA131483 to S. P. Malkoski) and NIH/NIDCR (R01 DE015953 to X.-J. Wang). S. P. Malkoski was also supported by T32 CA106195, the Oregon Medical Research Foundation, and the National Lung Cancer Partnership. The OHSU BioLibrary is supported by P30 CA 069533 and the Colorado Lung SPORE Tissue Bank is supported by P30 CA046934 and P50 CA058187. NR 41 TC 26 Z9 27 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 15 PY 2012 VL 18 IS 8 BP 2173 EP 2183 DI 10.1158/1078-0432.CCR-11-2557 PG 11 WC Oncology SC Oncology GA 927KW UT WOS:000302907300009 PM 22399565 ER PT J AU Dangi, A Sumpter, TL Kimura, S Stolz, DB Murase, N Raimondi, G Vodovotz, Y Huang, C Thomson, AW Gandhi, CR AF Dangi, Anil Sumpter, Tina L. Kimura, Shoko Stolz, Donna B. Murase, Noriko Raimondi, Giorgio Vodovotz, Yoram Huang, Chao Thomson, Angus W. Gandhi, Chandrashekhar R. TI Selective Expansion of Allogeneic Regulatory T Cells by Hepatic Stellate Cells: Role of Endotoxin and Implications for Allograft Tolerance SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SINUSOIDAL ENDOTHELIAL-CELLS; RAT-LIVER TRANSPLANTATION; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; ISCHEMIA/REPERFUSION INJURY; KUPFFER CELLS; IN-VIVO; RETINOIC ACID; DNA-SYNTHESIS; ACTIVATION AB Hepatic stellate cells (HSCs) may play an important role in hepatic immune regulation by producing numerous cytokines/chemokines and expressing Ag-presenting and T cell coregulatory molecules. Due to disruption of the endothelial barrier during cold-ischemic storage and reperfusion of liver grafts, HSCs can interact directly with cells of the immune system. Endotoxin (LPS), levels of which increase in liver diseases and transplantation, stimulates the synthesis of many mediators by HSCs. We hypothesized that LPS-stimulated HSCs might promote hepatic tolerogenicity by influencing naturally occurring immunosuppressive CD4(+) CD25(+)Foxp3(+) regulatory T cells (Tregs). Following their portal venous infusion, allogeneic CD4(+) T cells, including Tregs, were found closely associated with HSCs, and this association increased in LPS-treated livers. In vitro, both unstimulated and LPS-stimulated HSCs upregulated Fas (CD95) expression on conventional CD4(+) T cells and induced their apoptosis in a Fas/Fas ligand-dependent manner. By contrast, HSCs induced Treg proliferation, which required cell-cell contact and was MHC class II-dependent. This effect was augmented when HSCs were pretreated with LPS. LPS increased the expression of MHC class II, CD80, and CD86 and stimulated the production of IL-1 alpha, IL-1 beta, IL-6, IL-10 and TNF-alpha by HSCs. Interestingly, production of IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha was strongly inhibited, but that of IL-10 enhanced in LPS-pretreated HSC/Treg cocultures. Adoptively transferred allogeneic HSCs migrated to the secondary lymphoid tissues and induced Treg expansion in lymph nodes. These data implicate endotoxin-stimulated HSCs as important immune regulators in liver transplantation by inducing selective expansion of tolerance-promoting Tregs and reducing inflammation and alloimmunity. The Journal of Immunology, 2012, 188: 3667-3677. C1 [Dangi, Anil; Kimura, Shoko; Murase, Noriko; Raimondi, Giorgio; Huang, Chao; Thomson, Angus W.; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA 15213 USA. [Sumpter, Tina L.] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15213 USA. [Stolz, Donna B.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15213 USA. [Thomson, Angus W.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA. [Gandhi, Chandrashekhar R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. [Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Gandhi, CR (reprint author), Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Dept Surg, E-1540 BST,200 Lothrop St, Pittsburgh, PA 15213 USA. EM Gandhics@msx.upmc.edu FU National Institutes of Health [PO1A1081678, DK071753]; American Diabetes Association; Joseph A. Patrick Research Fellowship in Transplantation; Clinical and Translational Science Institute; National Center for Research Resources [UL1 RR024153]; American Society of Transplantation FX This work was supported by National Institutes of Health Grant PO1A1081678. G. R. is supported by a Junior Faculty Grant from the American Diabetes Association, a Joseph A. Patrick Research Fellowship in Transplantation, and a Clinical and Translational Science Institute Pilots to Expand Investigator Repertoire grant (funded through Grant UL1 RR024153 from the National Center for Research Resources). T. L. S. was the recipient of an American Society of Transplantation Basic Science Fellowship. S. K. is supported by National Institutes of Health Grant DK071753. NR 77 TC 31 Z9 33 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 15 PY 2012 VL 188 IS 8 BP 3667 EP 3677 DI 10.4049/jimmunol.1102460 PG 11 WC Immunology SC Immunology GA 923TD UT WOS:000302641400013 PM 22427640 ER PT J AU Li, DW Zhao, HY Kranzler, HR Oslin, D Anton, RF Farrer, LA Gelernter, J AF Li, Dawei Zhao, Hongyu Kranzler, Henry R. Oslin, David Anton, Raymond F. Farrer, Lindsay A. Gelernter, Joel TI Association of COL25A1 with Comorbid Antisocial Personality Disorder and Substance Dependence SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Addiction; amyloid plaque; antisocial personality disorder (ASPD); association; collagen XXV alpha 1 (COL25A1); substance dependence ID MULTILOCUS GENOTYPE DATA; ALZHEIMERS-DISEASE; DRUG-DEPENDENCE; CANDIDATE GENES; POPULATION; BEHAVIOR; STRATIFICATION; FREQUENCIES; ALCOHOLISM; INFERENCE AB Background: Antisocial personality disorder (ASPD) is a psychiatric disorder characterized by a long-term pattern of manipulating, exploiting, or violating the rights of others. Methods: Subjects ascertained for genetic studies of substance dependence (SD) and diagnosed with ASPD and comorbid SD were included in a two-stage genetic association study. In the discovery stage, 627 single nucleotide polymorphisms (SNPs) located in 179 candidate genes for addiction were analyzed in a case-control cohort and family-based cohort. The significant findings were replicated in an independent case-control cohort. Results: One SNP, rs13134663, in the collagen XXV alpha 1 gene (COL25A1) was significantly associated with ASPD in both African Americans and European Americans (smallest p values were .0002 and .0004, respectively). There was also evidence of association with the same SNP in independent samples of African American and European American cases and control subjects (p = .035 and .033, respectively). Analysis of the combined set of case-control subjects yielded an allelic p value of 9 x 10(-6) with odds ratio (95% confidence interval) of 1.3 (1.16, 1.47) (smallest p = 1 x 10(-7); Bonferroni threshold p = .00012). Conclusions: The COL25A1 gene, located at chromosome 4q25, encodes the collagen-like Alzheimer amyloid plaque component precursor, a type II transmembrane protein specifically expressed in neurons; it co-localizes with amyloid beta in senile plaques in Alzheimer disease brains. This SNP maps to the transcription factor binding site and is conserved in 17 vertebrates, including mice and rats. Our findings suggest that COL25A1 may be associated with ASPD, especially in the context of SD. C1 [Gelernter, Joel] Yale Univ, Dept Psychiat, Sch Med, Vet Affairs Connecticut Healthcare Ctr, West Haven, CT 06516 USA. [Zhao, Hongyu] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Med, West Haven, CT 06516 USA. [Zhao, Hongyu; Gelernter, Joel] Yale Univ, Dept Genet, Sch Med, West Haven, CT 06516 USA. [Kranzler, Henry R.; Oslin, David] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, Henry R.; Oslin, David] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 4, Philadelphia, PA USA. [Anton, Raymond F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Gelernter, J (reprint author), Yale Univ, Dept Psychiat, Sch Med, Vet Affairs Connecticut Healthcare Ctr, 950 Campbell Ave,116A2, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu RI Li, Dawei/A-3466-2011 OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health, United States [DA12849, DA12690, DA028909, AA017535, AA12870, AA11330]; National Institutes of Health [N01-HG-65403]; Alkermes; GlaxoSmithKline; Gilead; Lundbeck; Roche; Merck; Eli Lilly; Johnson Johnson; Hythiam Inc.; Alcohol Clinical Trials Initiative FX This work was supported by the research Grants DA12849, DA12690, DA028909, AA017535, AA12870, and AA11330 from the National Institutes of Health, United States. Genotyping services were provided by the Center for Inherited Disease Research. The Center for Inherited Disease Research is fully funded through a Federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403).; Dr. Kranzler has been a paid consultant for Alkermes, GlaxoSmithKline, Gilead, Lundbeck, and Roche. He has received research support from Merck. Dr. Anton has received honoraria or grant support from Eli Lilly, Johnson & Johnson, Alkermes, GlaxoSmithKline, Merck, and Hythiam Inc. Drs. Kranzler and Anton also report associations with Eli Lilly, Janssen, Schering Plough, Lundbeck, Alkermes, GlaxoSmithKline, Abbott, and Johnson & Johnson, as these companies provide support to the American College of Neuropsychopharmacology Alcohol Clinical Trials Initiative and both receive support from the Alcohol Clinical Trials Initiative. The other authors reported no biomedical financial interests or potential conflicts of interest. NR 38 TC 9 Z9 9 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2012 VL 71 IS 8 BP 733 EP 740 DI 10.1016/j.biopsych.2011.12.011 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 921GA UT WOS:000302464900015 PM 22297151 ER PT J AU Hsue, PY Scherzer, R Grunfeld, C Nordstrom, SM Schnell, A Kohl, LP Nitta, E Martin, JN Deeks, SG Weiss, EJ AF Hsue, Priscilla Y. Scherzer, Rebecca Grunfeld, Carl Nordstrom, Sarah M. Schnell, Amanda Kohl, Louis P. Nitta, Elaine Martin, Jeffrey N. Deeks, Steven G. Weiss, Ethan J. TI HIV Infection Is Associated With Decreased Thrombin Generation SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ANTIRETROVIRAL THERAPY; VENOUS THROMBOSIS; CELL-ACTIVATION; D-DIMER; INFLAMMATION; COAGULATION; BIOMARKERS; MARKERS; ADULTS; FRAM AB Background. Excess risk of cardiovascular disease occurs in effectively treated individuals with human immunodeficiency virus (HIV) infection. Although elevated plasma D-dimer levels are associated with increased morbidity and mortality, the impact of HIV infection on coagulation in vivo has not been well studied. Methods. We measured D-dimers, antithrombin, endogenous thrombin potential (ETP; a functional measure of thrombin generation in vitro), thrombin/antithrombin complexes (TAT; a measure of thrombin generation in vivo), tissue factor, prothrombin fragment 1 + 2 (F1+2), and normalized APC sensitivity ratio (nAPCsr) in 199 HIV-positive men who were receiving antiretroviral therapy and had an undetectable HIV RNA level, in 79 HIV-positive untreated men, and in 39 uninfected controls. Results. Median antithrombin levels were higher while the ETP was lower among HIV-infected adults (treated and untreated), compared with controls. There were few differences between coagulation markers in the 2 HIV groups. Compared with controls, the nAPCsr was lower in treated men and the TAT level was lower in untreated individuals. We observed little difference among measured levels of D-dimer, tissue factor, or F1+2 between HIV-infected individuals and controls. Antiretroviral therapy exposure was associated with a lower antithrombin level, a lower nAPCsr, and a lower ETP, while history of opportunistic infection was associated with a higher nAPCsr. Conclusions. HIV infection is associated with decreased thrombin generation, as measured by the ETP, and an increased antithrombin level. These data suggest that HIV infection may not be associated with increased propensity toward clotting, as has been suggested on the basis of isolated measures of D-dimer levels. C1 [Hsue, Priscilla Y.; Schnell, Amanda; Nitta, Elaine] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. [Martin, Jeffrey N.; Deeks, Steven G.] San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94110 USA. [Nordstrom, Sarah M.; Kohl, Louis P.; Weiss, Ethan J.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Scherzer, Rebecca; Grunfeld, Carl] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Hsue, PY (reprint author), San Francisco Gen Hosp, Div Cardiol, Room 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA. EM phsue@medsfgh.ucsf.edu FU NIH [R01 HL095310]; Centers for AIDS Research at UCSF [PO AI27763]; CFAR Network of Integrated Systems [R24 AI067039]; UCSF CTSI [UL1 RR024131]; NIAID [RO1 AI087145, K24AI069994, AI 76174] FX This work was supported by grants from the NIH (R01 HL095310). The SCOPE cohort was supported by the Centers for AIDS Research at UCSF (PO AI27763), CFAR Network of Integrated Systems (R24 AI067039), the UCSF CTSI (UL1 RR024131), and the NIAID (RO1 AI087145, K24AI069994, AI 76174). NR 25 TC 11 Z9 11 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2012 VL 54 IS 8 BP 1196 EP 1203 DI 10.1093/cid/cis014 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 915EW UT WOS:000302007900027 PM 22438347 ER PT J AU Basak, SK Rao, NP Oh, S Mysore, VS Srivatsan, ES Batra, RK AF Basak, Saroj Kumar Rao, Nagesh P. Oh, Scott Mysore, Veena S. Srivatsan, Eri S. Batra, Raj K. TI Tumor cell heterogeneity and chromosomal abnormality in malignant pleural effusion (MPE) samples of lung cancer SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Basak, Saroj Kumar; Rao, Nagesh P.; Oh, Scott; Mysore, Veena S.; Srivatsan, Eri S.; Batra, Raj K.] Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 5346 DI 10.1158/1538-7445.AM2012-5346 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701504122 ER PT J AU Chang, I Liu, J Majid, S Saini, S Zaman, MS Yamamura, S Shahryari, V Chiyomaru, T Deng, GR Dahiya, R Tanaka, Y AF Chang, Inik Liu, Jan Majid, Shahana Saini, Sharanjot Zaman, Mohd S. Yamamura, Soichiro Shahryari, Vary Chiyomaru, Takeshi Deng, Guoren Dahiya, Rajvir Tanaka, Yuichiro TI Protective effect of catechol-O-methyltransferase-mediated 4-hydroxyestradiol metabolism in human renal cell cancers SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Chang, Inik; Liu, Jan; Majid, Shahana; Saini, Sharanjot; Zaman, Mohd S.; Yamamura, Soichiro; Shahryari, Vary; Chiyomaru, Takeshi; Deng, Guoren; Dahiya, Rajvir; Tanaka, Yuichiro] San Francisco VA Med Ctr, San Francisco, CA USA. [Chang, Inik; Liu, Jan; Majid, Shahana; Saini, Sharanjot; Zaman, Mohd S.; Yamamura, Soichiro; Shahryari, Vary; Chiyomaru, Takeshi; Deng, Guoren; Dahiya, Rajvir; Tanaka, Yuichiro] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 1860 DI 10.1158/1538-7445.AM2012-1860 PG 1 WC Oncology SC Oncology GA V43SQ UT WOS:000209701500102 ER PT J AU Chiyomaru, T Zaman, MS Majid, S Deng, GR Yamamura, S Shahryari, V Saini, S Hirata, H Ueno, K Chang, I Tanaka, Y Enikida, H Nakagawa, M Dahiya, R AF Chiyomaru, Takeshi Zaman, Mohd Saif Majid, Shahana Deng, Guoren Yamamura, Soichiro Shahryari, Varahram Saini, Sharanjot Hirata, Hiroshi Ueno, Koji Chang, Inik Tanaka, Yuichiro Enikida, Hideki Nakagawa, Masayuki Dahiya, Rajvir TI Genistein suppresses prostate cancer growth through inhibition of oncogenic miR-151 SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Chiyomaru, Takeshi; Zaman, Mohd Saif; Majid, Shahana; Deng, Guoren; Yamamura, Soichiro; Shahryari, Varahram; Saini, Sharanjot; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Chiyomaru, Takeshi; Zaman, Mohd Saif; Majid, Shahana; Deng, Guoren; Yamamura, Soichiro; Shahryari, Varahram; Saini, Sharanjot; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Enikida, Hideki; Nakagawa, Masayuki] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Urol, Kagoshima 890, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 2299 DI 10.1158/1538-7445.AM2012-2299 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701502312 ER PT J AU Pham, H Chen, M Takahashi, H Reber, HA Hines, J Eibl, G AF Hung Pham Chen, Monica Takahashi, Hiroki Reber, Howard A. Hines, Joe Eibl, Guido TI Vitamin 03 induces 15-Hydroxyprostaglandin Dehydrogenase to suppress pancreatic cancer cell proliferation SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Hung Pham] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Chen, Monica; Takahashi, Hiroki; Reber, Howard A.; Hines, Joe; Eibl, Guido] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 62 DI 10.1158/1538-7445.AM2012-62 PG 2 WC Oncology SC Oncology GA V43SR UT WOS:000209701605243 ER PT J AU Li, GM Ghosh, R Rivas, P Reddick, RL Kumar, AP AF Li, Guiming Ghosh, Rita Rivas, Paul Reddick, Robert Lee Kumar, Addanki Pratap TI Resveratrol induces autophagy in prostate cancer cells and intervention suppresses the progression of PIN in animals SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Li, Guiming; Ghosh, Rita; Rivas, Paul; Kumar, Addanki Pratap] UT Hlth Sci Ctr, Dept Urol, San Antonio, TX USA. [Reddick, Robert Lee] UT Hlth Sci Ctr, Dept Pathol, San Antonio, TX USA. [Kumar, Addanki Pratap] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 2585 DI 10.1158/1538-7445.AM2012-2585 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701503400 ER PT J AU Mortazavi, F Rettig, M AF Mortazavi, Fariborz (Fred) Rettig, Matthew TI PAK1 kinase promotes cell motility through CRK serine phosphorylation in non-small cell lung cancer cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Mortazavi, Fariborz (Fred); Rettig, Matthew] Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 228 DI 10.1158/1538-7445.AM2012-228 PG 1 WC Oncology SC Oncology GA V43SQ UT WOS:000209701501386 ER PT J AU Park, C Lee, IS Nitsche, C Gerloff, A Go, VLW Grippo, PJ Pandol, SJ Gukovskaya, AS Edderkaoui, M AF Park, ChangHwan Lee, In Soek Nitsche, Claudia Gerloff, Andreas Go, Vay Liang W. Grippo, Paul J. Pandol, Stephen J. Gukovskaya, Anna S. Edderkaoui, Mouad TI Novel model of pancreatic cancer induced by smoking compound NNK SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Park, ChangHwan; Lee, In Soek; Nitsche, Claudia; Gerloff, Andreas; Go, Vay Liang W.; Pandol, Stephen J.; Gukovskaya, Anna S.; Edderkaoui, Mouad] Univ Calif Los Angeles, Los Angeles, CA USA. [Park, ChangHwan; Lee, In Soek; Nitsche, Claudia; Gerloff, Andreas; Go, Vay Liang W.; Pandol, Stephen J.; Gukovskaya, Anna S.; Edderkaoui, Mouad] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Grippo, Paul J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 1337 DI 10.1158/1538-7445.AM2012-1337 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701504383 ER PT J AU Tobi, M Yang, YX Kaplan, D Gupta, R Rambus, M Naumoff, J Leavell, B Patel, P Sochacki, P Hatfield, J Lawson, J AF Tobi, Martin Yang, Yu-Xiao Kaplan, David Gupta, Rasna Rambus, MaryAnn Naumoff, Joanne Leavell, Bonita Patel, Pragnesh Sochacki, Paula Hatfield, James Lawson, James TI A non-invasive test for right-sided colonic neoplasia in diabetics at increased risk, independent of drug therapy and demographics SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Tobi, Martin; Yang, Yu-Xiao; Kaplan, David; Lawson, James] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gupta, Rasna; Rambus, MaryAnn; Naumoff, Joanne; Leavell, Bonita; Patel, Pragnesh; Sochacki, Paula; Hatfield, James] Detroit VA Med Ctr, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 4519 DI 10.1158/1538-7445.AM2012-4519 PG 1 WC Oncology SC Oncology GA V43SR UT WOS:000209701601008 ER PT J AU Vaid, M Prasad, R Singh, T Sun, Q Katiyar, SK AF Vaid, Mudit Prasad, Ram Singh, Tripti Sun, Qian Katiyar, Santosh K. TI Grape seed proanthocyanidins inhibit UV-induced tolerogenic T-cell response through DNA repair-dependent functional activation of Langerhans cells SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Vaid, Mudit; Prasad, Ram; Singh, Tripti; Sun, Qian; Katiyar, Santosh K.] Univ Alabama Birmingham, Birmingham, AL USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 1599 DI 10.1158/1538-7445.AM2012-1599 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701503331 ER PT J AU Vira, D Basak, SK Lai, C Fishbein, MC Batra, RK Wang, MB Srivatsan, ES AF Vira, Darshni Basak, Saroj K. Lai, Chi Fishbein, Michael C. Batra, Raj K. Wang, Marilene B. Srivatsan, Eri S. TI Immunohistochemical variations in the expression of cancer stem cell and macrophage markers in primary and recurrent oral squamous cell carcinomas SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Vira, Darshni; Basak, Saroj K.; Lai, Chi; Fishbein, Michael C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Batra, Raj K.; Wang, Marilene B.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Healthcare Syst, Los Angeles, CA 90095 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 5355 DI 10.1158/1538-7445.AM2012-5355 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701504131 ER PT J AU Weinstein, D Rambus, M Levi, E Yuan, MJ Lawson, MJ Tobi, M AF Weinstein, Douglas Rambus, MaryAnn Levi, Edi Yuan, Mei J. Lawson, Michael J. Tobi, Martin TI Adnab-9: A prospective stool biomarker for pancreatic ductal adenocarcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Weinstein, Douglas; Tobi, Martin] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Rambus, MaryAnn; Levi, Edi] Detroit VA Med Ctr, Detroit, MI USA. [Yuan, Mei J.] People Liberat Army Hosp, Beijing, Peoples R China. [Lawson, Michael J.] Kaiser Permanente Med Grp, Sacramento, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 3699 DI 10.1158/1538-7445.AM2012-3699 PG 1 WC Oncology SC Oncology GA V43SR UT WOS:000209701601361 ER PT J AU Yamamura, S Sharanjot, S Shahana, M Hirata, H Ueno, K Chang, I Chiyomaru, T Tanaka, Y Dahiya, R AF Yamamura, Soichiro Sharanjot, Saini Shahana, Majid Hirata, Hiroshi Ueno, Koji Chang, Inik Chiyomaru, Takeshi Tanaka, Yuichiro Dahiya, Rajvir TI MicroRNA-141 inhibits proliferation and invasion by suppressing the Wnt signaling pathway in renal cell carcinoma SO CANCER RESEARCH LA English DT Meeting Abstract C1 [Yamamura, Soichiro; Sharanjot, Saini; Shahana, Majid; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Chiyomaru, Takeshi; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, San Francisco, CA USA. [Yamamura, Soichiro; Sharanjot, Saini; Shahana, Majid; Hirata, Hiroshi; Ueno, Koji; Chang, Inik; Chiyomaru, Takeshi; Tanaka, Yuichiro; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD APR 15 PY 2012 VL 72 SU 8 MA 3149 DI 10.1158/1538-7445.AM2012-3149 PG 2 WC Oncology SC Oncology GA V43SQ UT WOS:000209701503100 ER PT J AU Rayess, H Wang, MB Srivatsan, ES AF Rayess, Hani Wang, Marilene B. Srivatsan, Eri S. TI Cellular senescence and tumor suppressor gene p16 SO INTERNATIONAL JOURNAL OF CANCER LA English DT Review DE senescence; tumor suppressor gene p16 ID FACTOR-KAPPA-B; HISTONE METHYLTRANSFERASE ACTIVITY; POLYCOMB GROUP PROTEINS; P16(INK4A) EXPRESSION; SELF-RENEWAL; CYCLE ARREST; IN-VIVO; TRANSCRIPTIONAL REPRESSION; PREMATURE SENESCENCE; HETEROCHROMATIN FOCI AB Cellular senescence is an irreversible arrest of cell growth. Biochemical and morphological changes occur during cellular senescence, including the formation of a unique cellular morphology such as flattened cytoplasm. Function of mitochondria, endoplasmic reticulum and lysosomes are affected resulting in the inhibition of lysosomal and proteosomal pathways. Cellular senescence can be triggered by a number of factors including, aging, DNA damage, oncogene activation and oxidative stress. While the molecular mechanism of senescence involves p16 and p53 tumor suppressor genes and telomere shortening, this review is focused on the mechanism of p16 control. The p16-mediated senescence acts through the retinoblastoma (Rb) pathway inhibiting the action of the cyclin dependant kinases leading to G1 cell cycle arrest. Rb is maintained in a hypophosphorylated state resulting in the inhibition of transcription factor E2F1. Regulation of p16 expression is complex and involves epigenetic control and multiple transcription factors. PRC1 (Pombe repressor complex (1) and PRC2 (Pombe repressor complex (2) proteins and histone deacetylases play an important role in the promoter hypermethylation for suppressing p16 expression. While transcription factors YY1 and Id1 suppress p16 expression, transcription factors CTCF, Sp1 and Ets family members activate p16 transcription. Senescence occurs with the inactivation of suppressor elements leading to the enhanced expression of p16. C1 [Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, VAGLAHS, Dept Surg, Los Angeles, CA 90073 USA. [Rayess, Hani; Wang, Marilene B.; Srivatsan, Eri S.] VA Greater Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Rayess, Hani] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Dept Surg, Los Angeles, CA 90073 USA. RP Srivatsan, ES (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VAGLAHS, Dept Surg, 11301 Wilshire Blvd,Bldg 304, Los Angeles, CA 90073 USA. EM esrivats@ucla.edu FU NIH [R21 CA116826-01]; VAGLAHS; West Los Angeles Surgical Education Research Center; Veterans Administration, Washington, DC FX Grant sponsor: NIH; Grant number: R21 CA116826-01; Grant sponsors: VAGLAHS, West Los Angeles Surgical Education Research Center, Veterans Administration, Washington, DC NR 122 TC 128 Z9 144 U1 3 U2 55 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 15 PY 2012 VL 130 IS 8 BP 1715 EP 1725 DI 10.1002/ijc.27316 PG 11 WC Oncology SC Oncology GA 897WV UT WOS:000300692300001 PM 22025288 ER PT J AU Caesar, I Gandy, S AF Caesar, Ina Gandy, Sam TI Evidence that an APOE epsilon 4 'double whammy' increases risk for Alzheimer's disease SO BMC MEDICINE LA English DT Editorial Material DE Alzheimer's disease; epilepsy; apolipoprotein; cerebral amyloidosis ID TEMPORAL-LOBE EPILEPSY; IMPROVES COGNITIVE PERFORMANCE; APOLIPOPROTEIN-E; HIPPOCAMPAL SCLEROSIS; SENILE PLAQUES; PEPTIDE; COG1410; POLYMORPHISMS; CONFUSION; INJURY AB Temporal lobe epilepsy (TLE) is associated with some of the same neuropathological features as those reported for early stages of typical Alzheimer's disease (AD). The APOE epsilon 4 allele is associated with a gene-dose-dependent increase in AD risk and in the severity of amyloid-beta (A beta) pathology. In a study published in the current BMC Medicine, Sue Griffin and colleagues studied markers of brain resilience in the amputated temporal lobes of TLE patients. They discovered compelling evidence that the APOE epsilon 3 isoform in TLE patients is apparently more neuroprotective from A beta toxicity than is the APOE epsilon 4 isoform, as shown by the reduced levels of neuronal damage, glial activation, and expression of IL-1 alpha in the APOE epsilon 3/epsilon 3 brains. This result points to a new property of APOE isoforms: not only are APOE epsilon 4 alleles associated with increased brain amyloid plaque burden, but these alleles are also apparently inferior to APOE epsilon 3 alleles in conveying resistance to A beta neurotoxicity. This 'double whammy' result opens up a new direction for studies aimed at elucidating the relevant neurobiological activities of APOE isoforms in the pathogenesis of AD. Please see related article: http://www.biomedcentral.com/1741-7015/10/35 C1 [Caesar, Ina; Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Caesar, Ina; Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Caesar, Ina; Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Caesar, Ina; Gandy, Sam] James J Peters VA Med Ctr, New York, NY 10468 USA. RP Caesar, I (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM ina.caesar@mssm.edu NR 30 TC 5 Z9 5 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD APR 13 PY 2012 VL 10 AR 36 DI 10.1186/1741-7015-10-36 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 945TK UT WOS:000304298800002 PM 22502767 ER PT J AU Wang, J Ferruzzi, MG Ho, L Blount, J Janle, EM Gong, B Pan, Y Gowda, GAN Raftery, D Arrieta-Cruz, I Sharma, V Cooper, B Lobo, J Simon, JE Zhang, CF Cheng, A Qian, XJ Ono, K Teplow, DB Pavlides, C Dixon, RA Pasinetti, GM AF Wang, Jun Ferruzzi, Mario G. Ho, Lap Blount, Jack Janle, Elsa M. Gong, Bing Pan, Yong Gowda, G. A. Nagana Raftery, Daniel Arrieta-Cruz, Isabel Sharma, Vaishali Cooper, Bruce Lobo, Jessica Simon, James E. Zhang, Chungfen Cheng, Alice Qian, Xianjuan Ono, Kenjiro Teplow, David B. Pavlides, Constantine Dixon, Richard A. Pasinetti, Giulio M. TI Brain-Targeted Proanthocyanidin Metabolites for Alzheimer's Disease Treatment SO JOURNAL OF NEUROSCIENCE LA English DT Article ID MOUSE MODEL; SYNAPTIC PLASTICITY; TRANSGENIC MICE; INGESTION; BEHAVIOR; MEMORY AB While polyphenolic compounds have many health benefits, the potential development of polyphenols for the prevention/treatment of neurological disorders is largely hindered by their complexity as well as by limited knowledge regarding their bioavailability, metabolism, and bioactivity, especially in the brain. We recently demonstrated that dietary supplementation with a specific grape-derived polyphenolic preparation (GP) significantly improves cognitive function in a mouse model of Alzheimer's disease (AD). GP is comprised of the proanthocyanidin (PAC) catechin and epicatechin in monomeric (Mo), oligomeric, and polymeric forms. In this study, we report that following oral administration of the independent GP forms, only Mo is able to improve cognitive function and only Mo metabolites can selectively reach and accumulate in the brain at a concentration of similar to 400 nM. Most importantly, we report for the first time that a biosynthetic epicatechin metabolite, 3'-O-methyl-epicatechin-5-O-beta-glucuronide (3'-O-Me-EC-Gluc), one of the PAC metabolites identified in the brain following Mo treatment, promotes basal synaptic transmission and long-term potentiation at physiologically relevant concentrations in hippocampus slices through mechanisms associated with cAMP response element binding protein (CREB) signaling. Our studies suggest that select brain-targeted PAC metabolites benefit cognition by improving synaptic plasticity in the brain, and provide impetus to develop 3'-O-Me-EC-Gluc and other brain-targeted PAC metabolites to promote learning and memory in AD and other forms of dementia. C1 [Wang, Jun; Ho, Lap; Gong, Bing; Pan, Yong; Arrieta-Cruz, Isabel; Cheng, Alice; Qian, Xianjuan; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ferruzzi, Mario G.; Janle, Elsa M.; Cooper, Bruce; Lobo, Jessica] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Ferruzzi, Mario G.; Janle, Elsa M.; Cooper, Bruce; Lobo, Jessica] Purdue Univ, Dept Food & Nutr, W Lafayette, IN 47907 USA. [Gowda, G. A. Nagana; Raftery, Daniel] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. [Blount, Jack; Sharma, Vaishali; Zhang, Chungfen; Dixon, Richard A.] Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73401 USA. [Pavlides, Constantine] Rockefeller Univ, New York, NY 10021 USA. [Simon, James E.] Rutgers State Univ, Dept Plant Biol & Plant Pathol, New Brunswick, NJ 08901 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [Wang, Jun; Ho, Lap] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU NIH [PO1AT004511, AG027818]; Department of Veterans Affairs; Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at University of California Los Angeles; Samuel Roberts Noble Foundation FX This work was supported by grants from the NIH (PO1AT004511) and Department of Veterans Affairs to G.M.P., the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at University of California Los Angeles to D.B.T., NIH Grant AG027818 to D.B.T., and the Samuel Roberts Noble Foundation (R.A.D.). NR 20 TC 65 Z9 67 U1 3 U2 29 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR 11 PY 2012 VL 32 IS 15 BP 5144 EP 5150 DI 10.1523/JNEUROSCI.6437-11.2012 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 925WT UT WOS:000302793500013 PM 22496560 ER PT J AU Arjomandi, M Haight, T Sadeghi, N Redberg, R Gold, WM AF Arjomandi, Mehrdad Haight, Thaddeus Sadeghi, Nasrat Redberg, Rita Gold, Warren M. TI Reduced Exercise Tolerance and Pulmonary Capillary Recruitment with Remote Secondhand Smoke Exposure SO PLOS ONE LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; CABIN AIR-QUALITY; ACUTE CORONARY SYNDROMES; DIFFUSING-CAPACITY; FLIGHT ATTENDANTS; SINGLE EXHALATION; CARBON-MONOXIDE; POSITION PAPER; DISEASE; ASSOCIATION AB Rationale: Flight attendants who worked on commercial aircraft before the smoking ban in flights (pre-ban FAs) were exposed to high levels of secondhand smoke (SHS). We previously showed never-smoking pre-ban FAs to have reduced diffusing capacity (Dco) at rest. Methods: To determine whether pre-ban FAs increase their Dco and pulmonary blood flow ((Q) over dotc) during exercise, we administered a symptom-limited supine-posture progressively increasing cycle exercise test to determine the maximum work (watts) and oxygen uptake ((V) over doto(2)) achieved by FAs. After 30 min rest, we then measured Dco and (Q) over dotc at 20, 40, 60, and 80 percent of maximum observed work. Results: The FAs with abnormal resting Dco achieved a lower level of maximum predicted work and (V) over doto(2) compared to those with normal resting Dco (mean +/- SEM; 88.7 +/- 2.9 vs. 102.5 +/- 3.1% predicted (V) over doto(2); p = 0.001). Exercise limitation was associated with the FAs' FEV1 (r = 0.33; p = 0.003). The Dco increased less with exercise in those with abnormal resting Dco (mean +/- SEM: 1.36 +/- 0.16 vs. 1.90 +/- 0.16 ml/min/mmHg per 20% increase in predicted watts; p = 0.020), and amongst all FAs, the increase with exercise seemed to be incrementally lower in those with lower resting Dco. Exercise-induced increase in (Q) over dotc was not different in the two groups. However, the FAs with abnormal resting Dco had less augmentation of their Dco with increase in (Q) over dotc during exercise (mean +/- SEM: 0.93 +/- 0.06 vs. 1.47 +/- 0.09 ml/min/mmHg per L/min; p<0.0001). The Dco during exercise was inversely associated with years of exposure to SHS in those FAs with >= 10 years of pre-ban experience (r = -0.32; p = 0.032). Conclusions: This cohort of never-smoking FAs with SHS exposure showed exercise limitation based on their resting Dco. Those with lower resting Dco had reduced pulmonary capillary recruitment. Exposure to SHS in the aircraft cabin seemed to be a predictor for lower Dco during exercise. C1 [Arjomandi, Mehrdad; Redberg, Rita; Gold, Warren M.] Univ Calif San Francisco, Flight Attendants Med Res Inst, Ctr Excellence, San Francisco, CA 94143 USA. [Gold, Warren M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Arjomandi, Mehrdad; Gold, Warren M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Arjomandi, Mehrdad; Redberg, Rita] San Francisco VA Med Ctr, San Francisco, CA USA. [Haight, Thaddeus] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Sadeghi, Nasrat] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. RP Arjomandi, M (reprint author), Univ Calif San Francisco, Flight Attendants Med Res Inst, Ctr Excellence, San Francisco, CA 94143 USA. EM mehrdad.arjomandi@ucsf.edu FU The Flight Attendants Medical Research Institute; The National Institutes of Health [K23 HL083099]; Northern California Institute for Research and Education; University of California San Francisco Cardiovascular Research Institute FX Funding provided by The Flight Attendants Medical Research Institute, The National Institutes of Health (K23 HL083099), Northern California Institute for Research and Education and the University of California San Francisco Cardiovascular Research Institute Faculty Development Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 2 Z9 2 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 6 PY 2012 VL 7 IS 4 AR e34393 DI 10.1371/journal.pone.0034393 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 955JA UT WOS:000305012700031 PM 22493689 ER PT J AU Loewenstein, G Volpp, KG Asch, DA AF Loewenstein, George Volpp, Kevin G. Asch, David A. TI Incentives in Health Different Prescriptions for Physicians and Patients SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Loewenstein, George; Volpp, Kevin G.; Asch, David A.] Univ Penn, Penn CMU Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA 19104 USA. [Loewenstein, George; Volpp, Kevin G.; Asch, David A.] Univ Penn, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Univ Penn, Dept Med, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Univ Penn, Dept Hlth Care Management, Wharton Sch, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Asch, David A.] Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.; Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Loewenstein, G (reprint author), Carnegie Mellon Univ, 5000 Forbes Ave,BP 319D, Pittsburgh, PA 15213 USA. EM gl20@andrew.cmu.edu OI Asch, David/0000-0002-7970-286X FU NIA NIH HHS [P30 AG034546] NR 10 TC 10 Z9 10 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 4 PY 2012 VL 307 IS 13 BP 1375 EP 1376 DI 10.1001/jama.2012.387 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 919AY UT WOS:000302294200021 PM 22474198 ER PT J AU Werner, RM AF Werner, Rachel M. TI Will Using Medicare Data to Rate Doctors Benefit Patients? SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID PAY-FOR-PERFORMANCE; REPORT CARDS; QUALITY C1 [Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Werner, RM (reprint author), Univ Penn, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu NR 16 TC 4 Z9 4 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 3 PY 2012 VL 156 IS 7 BP 532 EP U1500 DI 10.7326/0003-4819-156-7-201204030-00396 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 921GP UT WOS:000302466400007 PM 22331620 ER PT J AU Xie, AL AF Xie, Ailiang TI Effect of sleep on breathing - Why recurrent apneas are only seen during sleep SO JOURNAL OF THORACIC DISEASE LA English DT Article ID RESPIRATORY MUSCLE; LUNG-VOLUME; REM-SLEEP; VENTILATION; WAKEFULNESS; THRESHOLD; MECHANICS; AROUSAL; PATTERN; ONSET C1 [Xie, Ailiang] Univ Wisconsin, Dept Med, Madison, WI USA. [Xie, Ailiang] William S Middleton Mem Vet Adm Med Ctr, Pulm Physiol Lab, Madison, WI 53705 USA. RP Xie, AL (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pulm Physiol Lab, 2500 Overlook Terrace, Madison, WI 53705 USA. EM axie@facstaff.wisc.edu NR 26 TC 0 Z9 0 U1 0 U2 0 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 J9 J THORAC DIS JI J. Thorac. Dis. PD APR PY 2012 VL 4 IS 2 BP 194 EP 197 DI 10.3978/j.issn.2072-1439.2011.04.04 PG 4 WC Respiratory System SC Respiratory System GA 087UR UT WOS:000314789900014 PM 22833825 ER PT J AU Davis, KC Schraufnagel, TJ Jacques-Tiura, AJ Norris, J George, WH Kiekel, PA AF Davis, Kelly Cue Schraufnagel, Trevor J. Jacques-Tiura, Angela J. Norris, Jeanette George, William H. Kiekel, Preston A. TI Childhood Sexual Abuse and Acute Alcohol Effects on Men's Sexual Aggression Intentions SO PSYCHOLOGY OF VIOLENCE LA English DT Article DE childhood sexual abuse; alcohol; sexual aggression; cognitive distortions; condom use resistance ID ASSAULT PERPETRATION; IMPLICIT THEORIES; COLLEGE-STUDENTS; RISK BEHAVIOR; VIOLENCE; IMPACT; SAMPLE; MALES; RAPE; EXPECTANCIES AB Although research has established childhood sexual abuse (CSA) as a risk factor for men's perpetration of sexual aggression, there has been little investigation of the factors undergirding this association. This study represents one of the first to use a laboratory-based sexual aggression analogue coupled with an alcohol administration protocol to investigate the pathways through which CSA and alcohol influence men's self-reported sexual aggression intentions. Method: After completing background questionnaires, male social drinkers (N = 220) were randomly assigned to a control, placebo, low alcohol dose or high alcohol dose condition. Following beverage consumption, participants read a sexual scenario in which the female partner refused to have unprotected sexual intercourse, after which they completed dependent measures. Results: Path analysis indicated that men with a CSA history and intoxicated men perceived the female character as more sexually aroused and reported stronger sexual entitlement cognitions, both of which were in turn associated with greater condom use resistance and higher sexual aggression intentions. Exploratory analyses revealed that intoxication moderated the effects of CSA history on sexual entitlement cognitions, such that sexual entitlement cognitions were highest for men who had a CSA history and consumed alcohol. Conclusions: Findings suggest that CSA history may facilitate sexual assault perpetration through its effects on in-the-moment cognitions and that these effects may be exacerbated by alcohol intoxication. C1 [Davis, Kelly Cue] Univ Washington, Sch Social Work, Seattle, WA 98105 USA. [Schraufnagel, Trevor J.] Univ Washington, Seattle, WA 98105 USA. [Schraufnagel, Trevor J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Jacques-Tiura, Angela J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. [Norris, Jeanette; Kiekel, Preston A.] Univ Washington, Alcohol & Drug Abuse Inst, Seattle, WA 98105 USA. [George, William H.] Univ Washington, Dept Psychol, Seattle, WA 98105 USA. RP Davis, KC (reprint author), Univ Washington, Sch Social Work, Box 354900, Seattle, WA 98105 USA. EM kcue@uw.edu FU NIAAA NIH HHS [R21 AA016283, R01 AA017608-01A2, R21 AA016283-01A1, R01 AA014512, R01 AA017608] NR 44 TC 15 Z9 15 U1 2 U2 20 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 2152-0828 J9 PSYCHOL VIOLENCE JI Psychol. Violence PD APR PY 2012 VL 2 IS 2 SI SI BP 179 EP 193 DI 10.1037/a0027185 PG 15 WC Psychology, Clinical; Criminology & Penology; Family Studies SC Psychology; Criminology & Penology; Family Studies GA 087EX UT WOS:000314745200007 PM 22754720 ER PT J AU Gandhi, CR Huang, C Stolz, DB AF Gandhi, Chandrashekhar R. Huang, Chao Stolz, Donna B. TI Endotoxin-stimulated hepatic stellate cells promote survival of hepatocytes in endotoxemia by inducing endoplasmic reticulum stress and autophagy SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gandhi, Chandrashekhar R.; Huang, Chao; Stolz, Donna B.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305297 ER PT J AU Gooch, JL Ecelbarger, C Reddy, RN Tsukerman, S Madsen, K AF Gooch, Jennifer L. Ecelbarger, Carolyn Reddy, Ramesh N. Tsukerman, Susanna Madsen, Kirsten TI Impaired kidney function and anatomy in dietarily-rescued calcineurin (alpha isoform) knockout mice SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Gooch, Jennifer L.; Reddy, Ramesh N.] Emory Univ, Atlanta, GA 30322 USA. [Gooch, Jennifer L.] US Dept Vet Affairs, Decatur, GA USA. [Madsen, Kirsten] Univ So Denmark, Dept Cardiovasc & Renal Res, Odense, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711306327 ER PT J AU Ho, L Bloom, PA Vega, JG Pasinetti, GM AF Ho, Lap Bloom, Patricia A. Vega, Joan Griffiths Pasinetti, Giulio Maria TI Exploring The Molecular Mechanisms Underlying The Efficacy of Mindfulness Based Stress Reduction In Alleviating Psychological Stress in Alzheimer's Disease Caregivers SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Ho, Lap; Bloom, Patricia A.; Vega, Joan Griffiths; Pasinetti, Giulio Maria] Mt Sinai Sch Med, New York, NY USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Ctr, Bronx, NY USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Educ Ctr, Bronx, NY USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 28 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711306109 ER PT J AU Knable, LA Wang, J Ferruzzi, MG Vempati, P Freire, D Gong, B Pasinetti, GM AF Knable, Lindsay Alexis Wang, Jun Ferruzzi, Mario G. Vempati, Prashant Freire, Daniele Gong, Bing Pasinetti, Giulio Maria TI Nasal Spray of Bioactive Polyphenol Metabolites as a Novel Therapy for Alzheimer's Disease and Other Forms of Dementia SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Knable, Lindsay Alexis; Wang, Jun; Vempati, Prashant; Freire, Daniele; Gong, Bing; Pasinetti, Giulio Maria] Mt Sinai Sch Med, New York, NY USA. [Wang, Jun; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ferruzzi, Mario G.] Purdue Univ, W Lafayette, IN 47907 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711306428 ER PT J AU Melton, DW Gelfond, J Chen, YX McManus, L Shireman, P AF Melton, David Wayne Gelfond, Jonathan Chen, Yongxin McManus, Linda Shireman, Paula TI Unique microRNA expression patterns associated with macrophage infiltration following skeletal muscle injury SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Melton, David Wayne; Gelfond, Jonathan; Chen, Yongxin; McManus, Linda; Shireman, Paula] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Melton, David Wayne; Chen, Yongxin; Shireman, Paula] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711304810 ER PT J AU Murray, DR Valente, AJ Siebenlist, U Chandrasekar, B AF Murray, David R. Valente, Anthony J. Siebenlist, Ulrich Chandrasekar, Bysani TI CIKS is critical mediator of isoproterenol/beta-AR induced cardiomyocyte hypertrophy in vitro and in vivo SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Murray, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Valente, Anthony J.] Univ Texas HSC, San Antonio, TX USA. [Siebenlist, Ulrich] NIAID, Lab Immunoregulat, NIH, Bethesda, MD 20892 USA. [Chandrasekar, Bysani] SLVHCS, New Orleans, LA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711304479 ER PT J AU Pasinetti, GM Gordon, W Dams-O'Connor, K Zhao, W Ho, L AF Pasinetti, Giulio Maria Gordon, Wayne Dams-O'Connor, Kristen Zhao, Wei Ho, Lap TI Traumatic Brain Injury (TBI) Induces Down-Regulation of Olfactory Receptors That Are Ectopically Expressed In The Brain: Implications In TBI-Mediated Tauopathy SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Pasinetti, Giulio Maria; Gordon, Wayne; Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA. [Pasinetti, Giulio Maria; Zhao, Wei; Ho, Lap] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711306514 ER PT J AU Roy, A Khadem, S Donnelly, BF Gong, F Pastor-Soler, NM Chang, YPC Subramanya, AR AF Roy, Ankita Khadem, Shaheen Donnelly, Bridget F. Gong, Fan Pastor-Soler, Nuria M. Chang, Y. P. Christy Subramanya, Arohan R. TI Alternatively spliced PY cassette exons in WNK1 enhance sensitivity to aldosterone via the E3 ubiquitin ligase Nedd4-2 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Roy, Ankita; Khadem, Shaheen; Donnelly, Bridget F.; Gong, Fan; Pastor-Soler, Nuria M.; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Chang, Y. P. Christy] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305462 ER PT J AU Schultz, K Boyd, J Byrd, JP McKenney, M Chawla, A Alloosh, M Teague, S Sacks, H Sturek, M AF Schultz, Kyle Boyd, Jack Byrd, James Patrick McKenney, Mikaela Chawla, Aarti Alloosh, Mouhamad Teague, Shawn Sacks, Harold Sturek, Michael TI Surgical excision of coronary epicardial adipose tissue provides evidence for its role in coronary artery disease SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Schultz, Kyle; Boyd, Jack; Byrd, James Patrick; McKenney, Mikaela; Chawla, Aarti; Alloosh, Mouhamad; Teague, Shawn; Sturek, Michael] Indiana Univ Sch Med, Indianapolis, IN USA. [Sacks, Harold] VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711302588 ER PT J AU Shalhoub, PJ Brancato, SJ Foecking, EM Fargo, KN AF Shalhoub, Philip J. Brancato, Sam J. Foecking, Eileen M. Fargo, Keith N. TI A bilateral pudendal nerve injury model in male rats SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Shalhoub, Philip J.; Brancato, Sam J.] Loyola Univ Chicago, Stritch Sch Med, Dept Urol, Maywood, IL USA. [Foecking, Eileen M.] Loyola Univ Chicago, Stritch Sch Med, Dept Otolaryngol, Maywood, IL USA. [Fargo, Keith N.] Loyola Univ Chicago, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL USA. [Foecking, Eileen M.; Fargo, Keith N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. RI Brancato, Sam/K-3266-2014 OI Brancato, Sam/0000-0002-3760-5818 NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305870 ER PT J AU Soto-Pina, AE Rani, S Franklin, C Hinojosa-Laborde, C Strong, R AF Soto-Pina, Alexandra Estela Rani, Sheela Franklin, Cynthia Hinojosa-Laborde, Carmen Strong, Randy TI Investigating the contribution of the adrenal medulla and sympathetic nerves in the regulation of dexamethasone-induced hypertension SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Soto-Pina, Alexandra Estela; Rani, Sheela; Franklin, Cynthia; Hinojosa-Laborde, Carmen; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Soto-Pina, Alexandra Estela; Rani, Sheela; Strong, Randy] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711301533 ER PT J AU Sutherland, KM Bentley, T LaFemina, M Ho, G Hirsch, J Frank, J AF Sutherland, Katherine Marie Bentley, Trevor LaFemina, Michael Ho, Gwen Hirsch, Jan Frank, James TI Claudin-4 interacts with the small GTPase Rap1 and accelerates epithelial repair SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Sutherland, Katherine Marie; LaFemina, Michael; Ho, Gwen; Hirsch, Jan; Frank, James] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sutherland, Katherine Marie; LaFemina, Michael; Hirsch, Jan; Frank, James] San Francisco VA Med Ctr, San Francisco, CA USA. [Bentley, Trevor] No Calif Inst Res & Educ, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711306237 ER PT J AU Vempati, P Gong, B Zhao, W Wang, J Devi, LA Pasinetti, GM AF Vempati, Prashant Gong, Bing Zhao, Wei Wang, Jun Devi, Lakshmi A. Pasinetti, Giulio M. TI Complement-derived anaphylatoxin, C5a-mediated signaling pathway is a novel pharmacological target for IVIG-regulated humoral immunotherapy in Alzheimer's Disease SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Vempati, Prashant; Gong, Bing; Zhao, Wei; Wang, Jun; Devi, Lakshmi A.; Pasinetti, Giulio M.] Mt Sinai Sch Med, New York, NY USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711306159 ER PT J AU Wang, HZ Porter, L Sarwar, Z McManus, LM Shireman, PK AF Wang, Hanzhou Porter, Laurel Sarwar, Zaheer McManus, Linda M. Shireman, Paula K. TI Proinflammatory macrophage ablation in CD11b-diphtheria toxin receptor (DTR) transgenic mice impairs skeletal muscle regeneration SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Wang, Hanzhou; Porter, Laurel; Sarwar, Zaheer; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 6 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711302344 ER PT J AU Wang, J Ferruzzi, M Janle, EM Tang, CY Gong, B Varghese, M Ho, L Pasinetti, GM AF Wang, Jun Ferruzzi, Mario Janle, Elsa M. Tang, Cheuk Ying Gong, Bing Varghese, Merina Ho, Lap Pasinetti, Giulio M. TI Systems Biology Evaluation of Combi-Phenol on Metabolic Syndrome-Induced Brain Dysfunction SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Wang, Jun; Tang, Cheuk Ying; Gong, Bing; Varghese, Merina; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, New York, NY USA. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ferruzzi, Mario; Janle, Elsa M.] Purdue Univ, W Lafayette, IN 47907 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711305741 ER PT J AU Wick, MJ Loomis, ZL Hersh, LB Dempsey, EC AF Wick, Marilee J. Loomis, Zoe L. Hersh, Louis B. Dempsey, Edward C. TI Mechanisms that decrease human Neprilysin gene expression in cigarette smoke-induced pulmonary vascular disease SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology Meeting CY APR 21-25, 2012 CL San Diego, CA C1 [Wick, Marilee J.; Loomis, Zoe L.; Dempsey, Edward C.] Univ Colorado, Cardiovasc Pulm Res Lab, Aurora, CO USA. [Wick, Marilee J.; Loomis, Zoe L.; Dempsey, Edward C.] Denver VAMC, Denver, CO USA. [Hersh, Louis B.] Univ Kentucky, Lexington, KY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2012 VL 26 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 032IZ UT WOS:000310711303596 ER PT J AU Jaber, N Dou, ZX Lin, RZ Zhang, JH Zong, WX AF Jaber, Nadia Dou, Zhixun Lin, Richard Z. Zhang, Jianhua Zong, Wei-Xing TI Mammalian PIK3C3/VPS34 The key to autophagic processing in liver and heart SO AUTOPHAGY LA English DT Editorial Material DE VPS34; PIK3C3; autophagy; endocytosis; PtdIns3K; PtdIns3P; liver; heart; cancer AB PIK3C3/Vps34 is the class III PtdIns3K that is evolutionarily conserved from yeast to mammals. Its central role in mammalian autophagy has been suggested through the use of pharmacological inhibitors and the study of its binding partners. However, the precise role of PIK3C3 in mammals is not clear. Using mouse strains that allow tissue-specific deletion of PIK3C3, we have described an essential role of PIK3C3 in regulating autophagy, and liver and heart function. C1 [Jaber, Nadia; Dou, Zhixun; Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA. [Lin, Richard Z.] SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA. [Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Lin, Richard Z.] Northport VA Med Ctr, Northport, NY USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Birmingham, AL USA. RP Zong, WX (reprint author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA. EM wzong@notes.cc.sunysb.edu RI Lin, Richard/J-1754-2014 OI Lin, Richard/0000-0002-3473-7276; Zhang, Jianhua/0000-0002-2128-9574 FU NCI NIH HHS [R01 CA129536, R01 CA136754]; NIDDK NIH HHS [R01 DK062722]; NIGMS NIH HHS [R01 GM097355] NR 0 TC 10 Z9 10 U1 0 U2 6 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD APR PY 2012 VL 8 IS 4 BP 707 EP 708 DI 10.4161/auto.19627 PG 2 WC Cell Biology SC Cell Biology GA 960QQ UT WOS:000305403400020 PM 22498475 ER PT J AU Saifu, HN Asch, SM Goetz, MB Smith, JP Graber, CJ Schaberg, D Sun, BC AF Saifu, Hemen N. Asch, Steven M. Goetz, Matthew Bidwell Smith, Jason P. Graber, Christopher J. Schaberg, Dennis Sun, Benjamin C. TI Evaluation of Human Immunodeficiency Virus and Hepatitis C Telemedicine Clinics SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED-TRIAL; CARE; VETERANS; POPULATION AB Background: Geographical barriers to subspecialty care may prevent optimal care of patients living in rural areas. We assess the impact of human immunodeficiency virus (HIV) and hepatitis C telemedicine consultation on patient-oriented outcomes in a rural Veterans Affairs population. Methods: This was a pre- and post-intervention study comparing telemedicine with in-person subspecialty clinic visits for HIV and hepatitis C. Eligible patients resided in 2 rural catchment areas. The primary binary outcome was clinic completion. We estimated a logistic regression model with patient-level fixed effects. This approach controls for the clustering of visits by patient, uses each patient's in-person clinic experience as an internal control group, and eliminates confounding by person-level factors. We also surveyed patients to assess satisfaction and patient-perceived reductions in health visit-related time. Results: There were 43 patients who accounted for 94 telemedicine visits and 128 in-person visits. Clinic completion rates were higher for telemedicine (76%) than for in-person visits (61%). In regression analyses, telemedicine was strongly predictive of clinic completion (OR 2.2; 95% confidence interval [CI]: 1.0-4.7). The adjusted effect of telemedicine on clinic completion rate was 13% (95% CI: 12-13). Of the 30 patients (70%) who completed the survey, more than 95% rated telemedicine at the highest level of satisfaction and preferred telemedicine to in-person clinic visits. Patients reported a significant reduction in health visit-related time (median 340 minutes, interquartile range 250-440), mostly due to decreased travel time. Conclusions: HIV and hepatitis C telemedicine clinics are associated with improved access, high patient satisfaction, and reduction in health visit-related time. (Am J Manag Care. 2012;18(4):207-212) C1 [Saifu, Hemen N.; Asch, Steven M.; Goetz, Matthew Bidwell; Smith, Jason P.; Graber, Christopher J.; Schaberg, Dennis; Sun, Benjamin C.] VA Greater Los Angeles Hlth Syst, Dept Med, Los Angeles, CA USA. [Asch, Steven M.; Goetz, Matthew Bidwell; Graber, Christopher J.; Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Sun, Benjamin C.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA. RP Saifu, HN (reprint author), Off 3246,Mail Stop 111G,Bldg 500,Wing 3E,11301 Wi, Los Angeles, CA 90073 USA. EM Hemen.Saifu@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU VA grant [RRP 09-127]; VA HIV/Hepatitis Quality Enhancement Research Initiative FX This study was supported by VA grant RRP 09-127 and the VA HIV/Hepatitis Quality Enhancement Research Initiative. NR 17 TC 10 Z9 10 U1 0 U2 4 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2012 VL 18 IS 4 BP 207 EP 212 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 001EK UT WOS:000308443000003 PM 22554009 ER PT J AU West, TW Hess, C Cree, BAC AF West, Timothy W. Hess, Christopher Cree, Bruce A. C. TI Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies SO SEMINARS IN NEUROLOGY LA English DT Article DE myelitis; myelopathy; demyelinating; inflammatory ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRIMARY SJOGRENS-SYNDROME; CENTRAL-NERVOUS-SYSTEM; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANGIOTENSIN-CONVERTING ENZYME; POLYMERASE-CHAIN-REACTION; VARICELLA-ZOSTER-VIRUS; NEUROMYELITIS-OPTICA; MULTIPLE-SCLEROSIS; CEREBROSPINAL-FLUID AB Acute transverse myelitis is a rare neurologic condition that has an estimated incidence of up to 3 per 100,000 patient years (0.003%). Although rare, acute transverse myelitis can have devastating neurologic effects with up to two-thirds of patients having a moderate to severe degree of residual disability. The term acute transverse myelitis was previously reserved for idiopathic cases, but currently is used to encompass the general clinical syndrome, whether or not the cause is known. Once adequate neuroimaging has ruled out a compressive etiology, and a lumbar puncture has demonstrated signs of inflammation within the cerebrospinal fluid, a workup of causes for an acute transverse myelitis must be undertaken. Determining the etiology of transverse myelitis can be challenging because there are autoimmune, inflammatory, and infectious diseases associated with acute transverse myelitis. The authors discuss an approach to acute transverse myelitis including clinical symptoms, neuroimaging, and biomarkers that may aid the clinician in diagnosis. C1 [West, Timothy W.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA. [Hess, Christopher] San Francisco VA Med Ctr, Div Neuroradiol, UCSF Dept Radiol & Biomed Imaging, San Francisco, CA USA. [Cree, Bruce A. C.] Univ Calif San Francisco, Dept Neurol, Div Clin Neurol, Multiple Sclerosis Ctr, San Francisco, CA USA. RP West, TW (reprint author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 W Bonneville Ave, Las Vegas, NV 89106 USA. EM westt3@ccf.org OI Hess, Christopher/0000-0002-5132-5302 NR 150 TC 13 Z9 15 U1 0 U2 16 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD APR PY 2012 VL 32 IS 2 BP 97 EP 113 DI 10.1055/s-0032-1322586 PG 17 WC Clinical Neurology SC Neurosciences & Neurology GA 987NC UT WOS:000307423200002 PM 22961185 ER PT J AU Ganguly, K Abrams, GM AF Ganguly, Karunesh Abrams, Gary M. TI Management of Chronic Myelopathy Symptoms and Activities of Daily Living SO SEMINARS IN NEUROLOGY LA English DT Article DE myelopathy; spinal cord injury; spasticity; pain ID SPINAL-CORD-INJURY; PLACEBO-CONTROLLED TRIAL; NEUROPATHIC PAIN; AUTONOMIC DYSREFLEXIA; HETEROTOPIC OSSIFICATION; INPATIENT REHABILITATION; MULTIPLE-SCLEROSIS; BOTULINUM TOXIN; SPASTICITY; EPIDEMIOLOGY AB Many disorders can injure the spinal cord resulting in long-term chronic myelopathy. Spinal cord dysfunction influences the homeostasis of multiple organ systems ranging from the heart or lung to the integument, thus presenting a wide variety of challenges for medical management. Although most of our knowledge about the consequences of myelopathies derives from the study of traumatic spinal cord injuries, similar complications occur in myelopathies of all etiologies. The authors survey some of the important clinical issues that the general neurologist needs to consider in caring for patients with chronic spinal cord disease. C1 [Ganguly, Karunesh; Abrams, Gary M.] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Abrams, Gary M.] Univ Calif San Francisco, Dept Rehabil Serv, San Francisco, CA 94121 USA. RP Abrams, GM (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Gary.Abrams@ucsf.edu NR 66 TC 0 Z9 0 U1 0 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 J9 SEMIN NEUROL JI Semin. Neurol. PD APR PY 2012 VL 32 IS 2 BP 161 EP 168 DI 10.1055/s-0032-1322582 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 987NC UT WOS:000307423200008 PM 22961191 ER PT J AU Reynolds, JA Sedarat, A Oliva, I Tatishchev, S Pisegna, JR Farrell, JJ AF Reynolds, Justin A. Sedarat, Alireza Oliva, Irma Tatishchev, Sergei Pisegna, Joseph R. Farrell, James J. TI Incremental Value of EUS-FNA Compared With CT/MRI in the Management of Pancreatic Neuroendocrine Tumors (pNETs): Defining the Pivotal Role of EUS-FNA SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) CY MAY 19-22, 2012 CL San Diego, CA C1 [Reynolds, Justin A.; Sedarat, Alireza; Farrell, James J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Oliva, Irma; Tatishchev, Sergei] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Pisegna, Joseph R.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2012 VL 75 IS 4 SU S BP 184 EP 184 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 946CU UT WOS:000304328001022 ER PT J AU Somsouk, M Ng, SW Kornfield, R McQuaid, KR Lampiris, H Inadomi, JM AF Somsouk, Ma Ng, Susie W. Kornfield, Rachel McQuaid, Kenneth R. Lampiris, Harry Inadomi, John M. TI Colorectal Neoplasia in HIV-Infected Individuals During Screening and Surveillance Colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) CY MAY 19-22, 2012 CL San Diego, CA C1 [Somsouk, Ma; Ng, Susie W.; Kornfield, Rachel; McQuaid, Kenneth R.; Lampiris, Harry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Somsouk, Ma] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [McQuaid, Kenneth R.; Lampiris, Harry] San Francisco VA Med Ctr, San Francisco, CA USA. [Inadomi, John M.] Univ Washington, Sch Med, Seattle, WA USA. RI Inadomi, John/A-6221-2014 OI Inadomi, John/0000-0001-6776-8661 NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2012 VL 75 IS 4 SU S BP 344 EP 344 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 946CU UT WOS:000304328001495 ER PT J AU Azoulay, L Gralnek, IM Provenzale, D Talley, J Griffin, JM AF Azoulay, Leor Gralnek, Ian M. Provenzale, Dawn Talley, Jennifer Griffin, Joan M. TI Evaluating the Impact of Health Literacy on Knowledge, Attitudes, and Beliefs Toward Colorectal Cancer (CRC) and CRC Screening in Veterans. The Value Study: Veterans as Leaders in Understanding and Education SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) CY MAY 19-22, 2012 CL San Diego, CA C1 [Azoulay, Leor] Technion Israel Inst Technol, Israel Sch Med TEAMS, Haifa, Israel. [Gralnek, Ian M.] Rambam Med Ctr, Haifa, Israel. [Provenzale, Dawn] Durham VA Med Ctr, Durham, NC USA. [Provenzale, Dawn] Duke Univ, Durham, NC USA. [Talley, Jennifer] W Los Angles VA Med Ctr, Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [Griffin, Joan M.] Minneappolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Griffin, Joan M.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2012 VL 75 IS 4 SU S BP 346 EP 346 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 946CU UT WOS:000304328001500 ER PT J AU Paucar, M Winnberg, E Walker, R Svenningsson, P AF Paucar, Martin Winnberg, Elisabeth Walker, Ruth Svenningsson, Per TI A case of Huntington disease like-1 with long disease duration SO PRION LA English DT Meeting Abstract C1 [Paucar, Martin] Karolinska Hosp Huddinge, Stockholm, Sweden. [Winnberg, Elisabeth] Ersta Nursing Sch, Inst Nursing Sci, Stockholm, Sweden. [Walker, Ruth] James Peters Vet Med Affair Ctr, Dept Neurol, Bronx, NY USA. [Svenningsson, Per] Ctr Mol Med, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 J9 PRION JI Prion PD APR-JUN PY 2012 VL 6 SU S BP 132 EP 133 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 944WK UT WOS:000304234300275 ER PT J AU Cabrera, J Norman, R AF Cabrera, Juan Norman, Rocio TI Post-Traumatic Attention Disorder in the chronic mild Traumatic Brain Injury Population: A Case Study using Direct Attention Training and methylphenidate SO BRAIN INJURY LA English DT Meeting Abstract C1 [Cabrera, Juan; Norman, Rocio] Dept Vet Affairs, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0525 BP 577 EP 578 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600480 ER PT J AU Brenner, L Homaifar, B Bahraini, N Lott, S Harwood, J Schneider, A Nagamoto, H AF Brenner, Lisa Homaifar, Beeta Bahraini, Nazanin Lott, Shea Harwood, Jeri Schneider, Alexandra Nagamoto, Herbert TI Executive Dysfunction and Suicide in United States Veterans SO BRAIN INJURY LA English DT Meeting Abstract C1 [Brenner, Lisa; Homaifar, Beeta; Bahraini, Nazanin; Lott, Shea; Schneider, Alexandra] Educ & Clin Ctr MIRECC, VISN Mental Illness Res 19, Denver, CO USA. [Harwood, Jeri] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Nagamoto, Herbert] Denver VA Med Ctr, Mental Hlth Serv, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0705 BP 675 EP 676 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600652 ER PT J AU Arciniegas, DB Frey, KL Wortzel, HS Wagner, PJ Newman, J Anderson, CA AF Arciniegas, David B. Frey, Kimberly L. Wortzel, Hal S. Wagner, Peter J. Newman, Jody Anderson, C. Alan TI Norm-Adjusted Mini-Mental State Examination and Frontal Assessment Battery Scores Predict Inpatient Rehabilitation Outcomes after Traumatic Brain Injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Arciniegas, David B.; Frey, Kimberly L.; Wagner, Peter J.; Newman, Jody; Anderson, C. Alan] Univ Colorado, Denver Sch Med, Neurobehav Disorders Program, Dept Psychiat, Aurora, CO USA. [Arciniegas, David B.; Frey, Kimberly L.; Wagner, Peter J.; Newman, Jody; Anderson, C. Alan] Univ Colorado, Denver Sch Med, Neurobehav Disorders Program, Dept Neurol, Aurora, CO USA. [Wortzel, Hal S.] Denver Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 19, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0768 BP 709 EP 710 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600712 ER PT J AU Wilkinson, CW Peskind, ER Colasurdo, EA Pagulayan, KF Shofer, JB AF Wilkinson, Charles W. Peskind, Elaine R. Colasurdo, Elizabeth A. Pagulayan, Kathleen F. Shofer, Jane B. TI Prevalence and Characteristics of Chronic Pituitary Dysfunction after Blast-related Mild Traumatic Brain Injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Wilkinson, Charles W.; Peskind, Elaine R.; Colasurdo, Elizabeth A.; Pagulayan, Kathleen F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Shofer, Jane B.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0804 BP 732 EP 732 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600748 ER PT J AU Arciniegas, DB Wortzel, HS Wagner, PJ Frey, KL Anderson, CA AF Arciniegas, David B. Wortzel, Hal S. Wagner, Peter J. Frey, Kimberly L. Anderson, C. Alan TI Clock Drawing Performance Predicts Inpatient Rehabilitation Outcomes after Traumatic Brain Injury SO BRAIN INJURY LA English DT Meeting Abstract C1 [Arciniegas, David B.; Wagner, Peter J.; Frey, Kimberly L.; Anderson, C. Alan] Univ Colorado, Denver Sch Med, Neurobehav Disorders Program, Dept Psychiat, Aurora, CO USA. [Arciniegas, David B.; Wagner, Peter J.; Frey, Kimberly L.; Anderson, C. Alan] Univ Colorado, Denver Sch Med, Dept Neurol, Aurora, CO USA. [Wortzel, Hal S.] Denver Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 19, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0832 BP 748 EP 749 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600774 ER PT J AU Pasinetti, G Gordon, W Ho, L Zhao, W AF Pasinetti, Giulio Gordon, Wayne Ho, Lap Zhao, Wei TI Role of Olfactory Receptor in Traumatic Brain Injury-Associated Tauopathy SO BRAIN INJURY LA English DT Meeting Abstract C1 [Gordon, Wayne; Ho, Lap; Zhao, Wei] Mt Sinai Sch Med, New York, NY USA. [Pasinetti, Giulio] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0835 BP 750 EP 750 PG 1 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600777 ER PT J AU Carlson, K O'Neil, ME Ensley, M Tun, SM Hutson, L Storzbach, D AF Carlson, Kathleen O'Neil, Maya Elin Ensley, Megan Tun, Saw-Myo Hutson, Lee Storzbach, Daniel TI Associations between Post-concussive Symptoms and Psychosocial Problems Endorsed by United States Veterans of the Iraq and Afghanistan Wars SO BRAIN INJURY LA English DT Meeting Abstract C1 [Carlson, Kathleen; O'Neil, Maya Elin; Ensley, Megan; Tun, Saw-Myo; Hutson, Lee; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR-MAY PY 2012 VL 26 IS 4-5 MA 0885 BP 779 EP 780 PG 2 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 943EZ UT WOS:000304104600826 ER PT J AU Bandyopadhyay, M Rohrer, B AF Bandyopadhyay, Mausumi Rohrer, Baerbel TI Matrix Metalloproteinase Activity Creates Pro-Angiogenic Environment in Primary Human Retinal Pigment Epithelial Cells Exposed to Complement SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID CHOROIDAL NEOVASCULAR MEMBRANES; ACTIVATED PROTEIN-KINASE; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; BRUCHS MEMBRANE; ALTERNATIVE PATHWAY; TARGETED INHIBITOR; DRUSEN FORMATION; ATTACK COMPLEX; MOUSE MODEL AB PURPOSE. Mechanistic studies have shown that inflammation, complement activation, extracellular matrix (ECM) turnover, growth factor imbalance, and oxidative stress are fundamental components of age-related macular degeneration (AMD). Matrix metalloproteinases (MMPs) mediate ECM turnover but also process various bioactive molecules. Here, we tested whether complement attack on RPE monolayers changes MMP secretion and activation, thereby altering the availability of growth factors in the extracellular space. METHODS. Human embryonic RPE monolayers with stable transepithelial resistance (TER) were established. Complement activation was induced with H2O2 and normal human serum. MMP-2/9, vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) protein, and mRNA levels were analyzed by Western blotting, ELISA, and real-time PCR; activity of MMP-2/9 by gelatin zymography. RESULTS. Complement activation resulted in a loss of TER, which required transient membrane attack complex formation, activation of the alternative pathway, and VEGF secretion and signaling. Despite the generation of reactive oxygen species, cellular integrity or intracellular adenosine triphosphate (ATP) levels were unaffected. However, expression of MMP-2/9 and their protease activity was elevated. Inhibition of MMP-2/9 activity increased PEDF and decreased VEGF levels in the apical and basal supernatants but had no effect on their expression levels. VEGF levels in the supernatant correlated with the level TER reduction. CONCLUSIONS. These studies suggest that complement activation, by altering the expression and activation of MMPs, has the ability to generate a proangiogenic environment by altering the balance between VEGF and PEDF. Our findings link reported results that have been associated with AMD pathogenesis; oxidative stress; complement activation; VEGF/PEDF ratio; and MMP activity. (Invest Ophthalmol Vis Sci. 2012;53:1953-1961) DOI:10.1167/iovs.11-8638 C1 [Bandyopadhyay, Mausumi; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Div Res, Dept Neurosci, Charleston, SC 29425 USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, 167 Ashley Ave,SEI 511, Charleston, SC 29425 USA. EM rohrer@musc.edu FU National Institutes of Health [R01EY019320, C06 RR015455]; Department of Veterans Affairs [I01 RX000444]; Foundation Fighting Blindness; Research to Prevent Blindness, New York, New York (RPB) FX Supported in part by the National Institutes of Health Grant R01EY019320; Department of Veterans Affairs Grant I01 RX000444; Foundation Fighting Blindness; and an unrestricted grant to MUSC from Research to Prevent Blindness, New York, New York (RPB). BR is a Research to Prevent Blindness Olga Keith Wiess Scholar. Animal studies were conducted in a facility constructed with support from the National Institutes of Health Grant C06 RR015455. NR 71 TC 25 Z9 25 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2012 VL 53 IS 4 BP 1953 EP 1961 DI 10.1167/iovs.11-8638 PG 9 WC Ophthalmology SC Ophthalmology GA 937PC UT WOS:000303669400032 PM 22408008 ER PT J AU Feil, DG Zhu, CW Sultzer, DL AF Feil, Denise G. Zhu, Carolyn W. Sultzer, David L. TI The relationship between cognitive impairment and diabetes self-management in a population-based community sample of older adults with Type 2 diabetes SO JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Diabetes mellitus; Cognitive impairment; Self-management; Comorbidity; Health behaviors ID MEDICATION ADHERENCE; GLYCEMIC CONTROL; PRACTICE GUIDELINES; ALZHEIMERS-DISEASE; HEMOGLOBIN A(1C); DEMENTIA; MELLITUS; HEALTH; PREVALENCE; DECLINE AB Although nearly one-third of older diabetics are cognitively impaired, their diabetes management remains poorly understood. To examine the relationship between cognitive impairment and diabetes self-management in a population-based community sample of older adults with Type 2 diabetes. Cross-sectional observational analysis. 1,398 persons with diabetes, aged 60 years or older, who responded to the 2003 Health and Retirement Study Diabetes Survey. We conducted logistic regressions on the effects of cognitive impairment on respondents' self-management ability after controlling for diabetes comorbidities, demographics, and clinical characteristics. Participants with greater cognitive impairment were less likely to adhere to exercise (Adjusted Odds ratio [AOR] = 0.725 and 0.712 for moderate and severe cognitive impairment, both P < 0.05), and to diet (AOR = 0.906 and 0.618 for moderate and severe cognitive impairment, both P < 0.01). Cognitive impairment is associated with worse self-care and may pose challenges to diabetic older persons, notably in diet and exercise. Cognitive screening may be indicated in this high risk group. C1 [Feil, Denise G.; Sultzer, David L.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Greater Los Angeles VA Healthcare Syst, W LA Vet Hlth Care Ctr, Los Angeles, CA 90073 USA. [Zhu, Carolyn W.] Mt Sinai Sch Med, JJP VA Med Ctr, New York, NY USA. RP Feil, DG (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Greater Los Angeles VA Healthcare Syst, W LA Vet Hlth Care Ctr, 11301 Wilshire Blvd,Bldg 401 116 AE, Los Angeles, CA 90073 USA. EM denise.feil@va.gov NR 60 TC 19 Z9 22 U1 5 U2 24 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0160-7715 J9 J BEHAV MED JI J. Behav. Med. PD APR PY 2012 VL 35 IS 2 BP 190 EP 199 DI 10.1007/s10865-011-9344-6 PG 10 WC Psychology, Clinical SC Psychology GA 940BP UT WOS:000303865300008 PM 21503710 ER PT J AU Pevnick, JM Claver, M Dobalian, A Asch, SM Stutman, HR Tomines, A Fu, P AF Pevnick, Joshua M. Claver, Maria Dobalian, Aram Asch, Steven M. Stutman, Harris R. Tomines, Alan Fu, Paul, Jr. TI Provider Stakeholders' Perceived Benefit from a Nascent Health Information Exchange: A Qualitative Analysis SO JOURNAL OF MEDICAL SYSTEMS LA English DT Article DE Medical informatics; Community networks; Health policy; Qualitative research; Organizational case studies; Community based participatory research ID SANTA-BARBARA; CARE; PRIVACY; SYSTEMS AB We sought to better understand the perceived costs and benefits of joining a nascent health information exchange (HIE) from the perspective of potential provider organization participants. We therefore conducted semi-structured interviews with organizational representatives. Interview transcriptions were thematically coded, and coded text was subsequently aggregated to summarize the breadth and depth of responses. Although no respondents expected HIE to result in net financial benefit to their organization, all respondents recognized some potential benefits, and some respondents expected HIE to result in overall organizational benefit. Disproportionate benefit was expected for the poorest, sickest patients. Many respondents had concerns about HIE increasing the risk of data security breaches, and these concerns were most pronounced at larger organizations. We found little evidence of organizational concern regarding loss of patients to other organizations or publication of unfavorable quality data. If HIE's greatest benefactors are indeed the poorest, sickest patients, our current health care financing environment will make it difficult to align HIE costs with benefits. To sustain HIE, state and federal governments may need to consider ongoing subsidies. Furthermore, these governments will need to ensure that policies regulating data exchange have sufficient nationwide coordination and liability limitations that the perceived organizational risks of joining HIEs do not outweigh perceived benefits. HIE founders can address organizational concerns by attempting to coordinate HIE policies with those of their largest founding organizations, particularly for data security policies. Early HIE development and promotional efforts should not only focus on potential benefits, but should also address organizational concerns. C1 [Pevnick, Joshua M.] Cedars Sinai Med Ctr, Dept Med, Div Gen Internal Med, Los Angeles, CA 90048 USA. [Claver, Maria] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Dobalian, Aram; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dobalian, Aram; Tomines, Alan; Fu, Paul, Jr.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Asch, Steven M.] RAND Hlth, Los Angeles, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Stutman, Harris R.] Mem Care Hlth Syst, Miller Childrens Hosp, Long Beach, CA USA. [Tomines, Alan; Fu, Paul, Jr.] Harbor UCLA Med Ctr, Div Gen & Emergency Pediat, Torrance, CA 90509 USA. [Tomines, Alan; Fu, Paul, Jr.] Los Angeles Biomed Res Inst, Torrance, CA USA. RP Pevnick, JM (reprint author), Cedars Sinai Med Ctr, Dept Med, Div Gen Internal Med, 8700 Beverly Blvd,Room B220, Los Angeles, CA 90048 USA. EM jpevnick@gmail.com FU Office of the National Coordinator for Health Information Technology; Department of Veterans Affairs FX This study was funded by the Office of the National Coordinator for Health Information Technology. This work was also supported by a health services research and development fellowship from the Department of Veterans Affairs (to JMP). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of their employers, including the Department of Veterans Affairs and the United States government. NR 14 TC 10 Z9 10 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0148-5598 J9 J MED SYST JI J. Med. Syst. PD APR PY 2012 VL 36 IS 2 BP 601 EP 613 DI 10.1007/s10916-010-9524-x PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 939PS UT WOS:000303825500026 PM 20703673 ER PT J AU Lorizio, W Wu, AHB Beattie, MS Rugo, H Tchu, S Kerlikowske, K Ziv, E AF Lorizio, Wendy Wu, Alan H. B. Beattie, Mary S. Rugo, Hope Tchu, Simone Kerlikowske, Karla Ziv, Elad TI Clinical and biomarker predictors of side effects from tamoxifen SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Tamoxifen; Side effects; Predictors; Biomarkers; Endoxifen; Breast cancer treatment ID QUALITY-OF-LIFE; SURGICAL ADJUVANT BREAST; MENOPAUSAL HOT FLASHES; CYP2D6 GENOTYPE; ESTROGEN-RECEPTOR; CANCER PREVENTION; JAPANESE-AMERICAN; RISK-FACTORS; WOMEN; SYMPTOMS AB Tamoxifen decreases breast cancer recurrence, mortality, and breast cancer risk in high-risk women. Despite these proven benefits, tamoxifen use is often limited due to side effects. We identified predictors of tamoxifen-induced side effects based on clinical variables and serum tamoxifen metabolite biomarkers in a cross-sectional study of patients taking tamoxifen. We enrolled 241 women and collected data on demographics, tamoxifen use and side effects, as well as potential clinical and serum predictors. We used logistic regression models and adjusted for age, body mass index, ethnicity, education, prior post-menopausal hormone therapy (HT), tamoxifen duration, and endoxifen levels to identify factors associated with side effects. Common tamoxifen attributed side effects were hot flashes (64%), vaginal dryness (35%), sleep problems (36%), weight gain (6%), and depression, irritability or mood swings (6%). In multi-variate models, tamoxifen duration, age, prior post-menopausal HT, and endoxifen levels all predicted side effects. Women who had been on tamoxifen for > 12 months were less likely to report side effects (OR 0.15, 95% CI 0.04-0.58) or severe side effects (OR 0.05, 95% CI 0.005-0.58) compared to women on tamoxifen for < 12 months. Compared to women younger than 50, women who were age 60-70 and older than 70 were less likely to report side effects (OR 0.22, 95% CI 0.03-1.35; OR 0.13, 95% CI 0.01-0.99; respectively). Women who previously took post-menopausal HT were more likely to report severe side effects. Women with higher endoxifen levels were more likely to report side effects (OR 1.67, 95% CI 1.01-2.77 per standard deviation increase in endoxifen). Clinicians should consider closely monitoring adherence in women taking tamoxifen, especially in younger women, and women who previously took HT. The association between endoxifen levels and side effects is consistent with the data that suggest that endoxifen is the most highly active metabolite of tamoxifen. C1 [Lorizio, Wendy; Ziv, Elad] UCSF Helen Diller Family Canc Res Bldg, San Francisco, CA 94158 USA. [Lorizio, Wendy; Beattie, Mary S.; Ziv, Elad] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Lorizio, Wendy] Univ Calif San Francisco, Dept Med, Div Clin Pharmacol & Expt Therapeut, San Francisco, CA USA. [Lorizio, Wendy; Beattie, Mary S.; Rugo, Hope; Ziv, Elad] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Wu, Alan H. B.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Wu, Alan H. B.; Tchu, Simone] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Beattie, Mary S.; Ziv, Elad] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Beattie, Mary S.; Ziv, Elad] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. [Beattie, Mary S.; Rugo, Hope] UCSF Med Ctr Mt Zion, San Francisco, CA 94143 USA. [Rugo, Hope] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA. [Tchu, Simone] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA. [Kerlikowske, Karla] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94121 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med & Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Lorizio, W (reprint author), UCSF Helen Diller Family Canc Res Bldg, 1450 3rd St,Room 289,Box 3116, San Francisco, CA 94158 USA. EM wlorizio@hotmail.com RI Ziv, Elad/L-5396-2014 FU National Institute of General Medical Sciences (NIGMS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [T32 GM007546]; University of California San Francisco; California Breast Cancer Research Program (CBCRP) [14OB-0166]; National Cancer Institute (NCI) [P50 CA58207]; Center for Translational and Policy Research in Personalized Medicine (TRANSPERS) National Institutes of Health/National Cancer Institute (NIH/NCI) [P01 CA130818-02A1] FX This work was supported by the National Institute of General Medical Sciences (NIGMS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Award T32 GM007546, University of California San Francisco, Clinical Pharmacology Fellowship Training Program (W. Lorizio); California Breast Cancer Research Program (CBCRP) Grant 14OB-0166 (E. Ziv); National Cancer Institute (NCI) Grant P50 CA58207 funded UCSF Breast SPORE; the Center for Translational and Policy Research in Personalized Medicine (TRANSPERS) National Institutes of Health/National Cancer Institute (NIH/NCI) Grant P01 CA130818-02A1 (M. S. Beattie), and materials and instrumentation for the AmpliChip CYP450 Test were donated by Roche Molecular Systems, Inc. We thank Viktoriya Krepkiy (Ziv Lab) for helping with participants and administrative support. NR 55 TC 31 Z9 31 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD APR PY 2012 VL 132 IS 3 SI SI BP 1107 EP 1118 DI 10.1007/s10549-011-1893-4 PG 12 WC Oncology SC Oncology GA 933RL UT WOS:000303379800033 PM 22207277 ER PT J AU Manichaikul, A Palmas, W Rodriguez, CJ Peralta, CA Divers, J Guo, XQ Chen, WM Wong, QN Williams, K Kerr, KF Taylor, KD Tsai, MY Goodarzi, MO Sale, MM Diez-Roux, AV Rich, SS Rotter, JI Mychaleckyj, JC AF Manichaikul, Ani Palmas, Walter Rodriguez, Carlos J. Peralta, Carmen A. Divers, Jasmin Guo, Xiuqing Chen, Wei-Min Wong, Quenna Williams, Kayleen Kerr, Kathleen F. Taylor, Kent D. Tsai, Michael Y. Goodarzi, Mark O. Sale, Michele M. Diez-Roux, Ana V. Rich, Stephen S. Rotter, Jerome I. Mychaleckyj, Josyf C. TI Population Structure of Hispanics in the United States: The Multi-Ethnic Study of Atherosclerosis SO PLOS GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; GENETIC-VARIATION; GENOTYPE DATA; PATTERNS; SCANS; RISK; LOCI; ACCULTURATION; INFERENCE; VARIANTS AB Using similar to 60,000 SNPs selected for minimal linkage disequilibrium, we perform population structure analysis of 1,374 unrelated Hispanic individuals from the Multi-Ethnic Study of Atherosclerosis (MESA), with self-identification corresponding to Central America (n=93), Cuba (n=50), the Dominican Republic (n=203), Mexico (n=708), Puerto Rico (n=192), and South America (n=111). By projection of principal components (PCs) of ancestry to samples from the HapMap phase III and the Human Genome Diversity Panel (HGDP), we show the first two PCs quantify the Caucasian, African, and Native American origins, while the third and fourth PCs bring out an axis that aligns with known South-to-North geographic location of HGDP Native American samples and further separates MESA Mexican versus Central/South American samples along the same axis. Using k-means clustering computed from the first four PCs, we define four subgroups of the MESA Hispanic cohort that show close agreement with self-identification, labeling the clusters as primarily Dominican/Cuban, Mexican, Central/South American, and Puerto Rican. To demonstrate our recommendations for genetic analysis in the MESA Hispanic cohort, we present pooled and stratified association analysis of triglycerides for selected SNPs in the LPL and TRIB1 gene regions, previously reported in GWAS of triglycerides in Caucasians but as yet unconfirmed in Hispanic populations. We report statistically significant evidence for genetic association in both genes, and we further demonstrate the importance of considering population substructure and genetic heterogeneity in genetic association studies performed in the United States Hispanic population. C1 [Manichaikul, Ani; Chen, Wei-Min; Sale, Michele M.; Rich, Stephen S.; Mychaleckyj, Josyf C.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA. [Manichaikul, Ani; Chen, Wei-Min] Univ Virginia, Dept Publ Hlth Sci, Div Biostat & Epidemiol, Charlottesville, VA USA. [Palmas, Walter] Columbia Univ, Dept Med, New York, NY USA. [Rodriguez, Carlos J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27103 USA. [Rodriguez, Carlos J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol, Winston Salem, NC USA. [Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Divers, Jasmin] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA. [Guo, Xiuqing; Taylor, Kent D.; Goodarzi, Mark O.; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. [Wong, Quenna; Williams, Kayleen; Kerr, Kathleen F.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA. [Tsai, Michael Y.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Sale, Michele M.] Univ Virginia, Dept Med, Charlottesville, VA USA. [Sale, Michele M.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA USA. [Diez-Roux, Ana V.] Univ Michigan, Dept Epidemiol, Ctr Social Epidemiol & Populat Hlth, Ann Arbor, MI 48109 USA. RP Manichaikul, A (reprint author), Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22903 USA. EM amanicha@virginia.edu RI Kerr, Kathleen/A-2893-2013 OI Manichaikul, Ani/0000-0002-5998-795X FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-95159, N01-HC-95169, RR-024156, N02-HL-6-4278]; United States Environmental Protection Agency (EPA); MESA Air investigators [RD83169701]; MESA investigators; [R01HL071051]; [R01HL071205]; [R01HL071250]; [R01HL071251]; [R01HL071252]; [R01HL071258]; [R01HL071259] FX MESA and the MESA SHARe project are conducted and supported by contracts N01-HC-95159 through N01-HC-95169 and RR-024156 from the National Heart, Lung, and Blood Institute (NHLBI). MESA Air is conducted and supported by the United States Environmental Protection Agency (EPA) in collaboration with MESA Air investigators, with support provided by grant RD83169701. Funding for MESA SHARe genotyping was provided by NHLBI Contract N02-HL-6-4278. MESA Family is conducted and supported in collaboration with MESA investigators; support is provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071252, R01HL071258, R01HL071259. The authors thank the participants of the MESA study, the Coordinating Center, MESA investigators, and study staff for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org. The NHLBI was involved in design and data collection of the MESA Study. The funders had no role in performing the analyses presented in this paper, nor in the decision to publish or in preparation of the manuscript. NR 35 TC 35 Z9 35 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD APR PY 2012 VL 8 IS 4 BP 285 EP 298 AR e1002640 DI 10.1371/journal.pgen.1002640 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA 934KA UT WOS:000303441800021 PM 22511882 ER PT J AU Boyce, RD Handler, SM Karp, JF Hanlon, JT AF Boyce, Richard D. Handler, Steven M. Karp, Jordan F. Hanlon, Joseph T. TI Age-Related Changes in Antidepressant Pharmacokinetics and Potential Drug-Drug Interactions: A Comparison of Evidence-Based Literature and Package Insert Information SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article DE aged; antidepressants; drug interactions; drug product package inserts; pharmacokinetics ID HEALTHY MALE-SUBJECTS; CIMETIDINE INTERACTION; CLINICAL PHARMACOKINETICS; ELDERLY PATIENTS; STEADY-STATE; NORTRIPTYLINE PHARMACOKINETICS; PSYCHOTROPIC MEDICATIONS; CYTOCHROME P4502D6; POOR METABOLIZERS; IMPAIRS CLEARANCE AB Background: Antidepressants are among the most commonly prescribed psychotropic agents for older patients. Little is known about the best source of pharmacotherapy information to consult about key factors necessary to safely prescribe these medications to older patients. Objective: The Objective of this study was to synthesize and contrast information in the package insert (PI) with information found in the scientific literature about age-related changes of antidepressants in systemic clearance and potential pharmacokinetic drug drug interactions (DDIs). Methods: A comprehensive search of two databases (MEDLINE and EMBASE from January 1, 1975 to September 30, 2011) with the use of a combination of search terms (antidepressants, pharmacokinetics, and drug interactions) was conducted to identify relevant English language articles. This information was independently reviewed by two researchers and synthesized into tables. These same two researchers examined the most up-to-date PIs for the 26 agents available at the time of the study to abstract quantitative information about age-related decline in systemic clearance and potential DDIs. The agreement between the two information sources was tested with K statistics. Results: The literature reported age-related clearance changes for 13 antidepressants, whereas the PIs only had evidence about 4 antidepressants (kappa < 0.4). Similarly, the literature identified 45 medications that could potentially interact with a specific antidepressant, whereas the PIs only provided evidence about 12 potential medication antidepressant DDIs (kappa < 0.4). Conclusion: The evidence-based literature compared with PIs is the most complete pharmacotherapy information source about both age-related clearance changes and pharmacokinetic DDIs with antidepressants. Future rigorously designed observational studies are needed to examine the combined risk of antidepressants with age-related decline in clearance and potential DDIs on important health outcomes such as falls and fractures in older patients. (Am J Geriatr Pharmacother. 2012;10:139-150) (C) 2012 Elsevier HS Journals, Inc. All rights reserved. C1 [Boyce, Richard D.; Handler, Steven M.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Boyce, Richard D.; Handler, Steven M.; Hanlon, Joseph T.] Univ Pittsburgh, Geriatr Pharmaceut Outcomes & Geroinformat Res &, Pittsburgh, PA 15213 USA. [Handler, Steven M.; Hanlon, Joseph T.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Handler, Steven M.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Handler, Steven M.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Karp, Jordan F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Karp, Jordan F.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Biomed Informat, 3471 5th Ave,Kaufman Bldg,Suite 500, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu OI Handler, Steven/0000-0002-3940-3224; Boyce, Richard/0000-0002-2993-2085 FU Agency for Healthcare Research and Quality [K12HS019461, R01HS018721, R01 HS017695]; National Institute on Aging [K07AG033174, P30AG024827, T32 AG021885, R01AG034056, R56AG0207017, AG033575]; National Institute of Nursing Research [R01 NR010135]; National Center for Research Resources [KL2 RR024154, 3 UL1 RR024153-04S4]; Department of Veterans Affairs Health Services Research [IIR-06-062] FX We thank Subashan Perera, PhD, for his help calculating the kappa statistics. Dr. Richard Boyce received support from the Agency for Healthcare Research and Quality (grant K12HS019461). Additional support for the co-authors was provided by the Agency for Healthcare Research and Quality (grants R01HS018721 and R01 HS017695), National Institute on Aging (grants K07AG033174, P30AG024827, T32 AG021885, R01AG034056, R56AG0207017, and AG033575), National Institute of Nursing Research (grant R01 NR010135), National Center for Research Resources (grants KL2 RR024154 and 3 UL1 RR024153-04S4), and Department of Veterans Affairs Health Services Research (grant IIR-06-062). The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality or any of the other funding sources. NR 109 TC 9 Z9 9 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD APR PY 2012 VL 10 IS 2 BP 139 EP 150 DI 10.1016/j.amjopharm.2012.01.001 PG 12 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 930MC UT WOS:000303142500007 PM 22285509 ER PT J AU Brown, JE Fominaya, C Christensen, KJ McConnell, SA Lamp, KC AF Brown, Jack E. Fominaya, Cory Christensen, Keith J. McConnell, Scott A. Lamp, Kenneth C. TI Daptomycin Experience in Critical Care Patients: Results from a Registry SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE bacteremia; daptomycin; Enterococcus faecium; intensive care; sepsis; Staphylococcus aureus ID SEVERE SEPSIS; VANCOMYCIN; OUTCOMES; THERAPY; NEPHROTOXICITY; INFECTIONS; PATHOGENS; SAFETY AB BACKGROUND: Vancomycin is often the drug of choice in critically ill patients with gram-positive infections, although circumstances often prevent its use. In these situations, clinicans are frequently left with limited data regarding alternative agents. OBJECTIVE: To describe patients with reported sepsis receiving daptomycin in a critical care unit. METHODS: This multicenter, noncomparative, noninterventional study identified patients in critical care units, using the Cubicin Outcomes Registry and Experience (CORE) 2005-2009 registry. A descriptive account of patient characteristics, infectious etiology, outcomes at the end of daptomycin therapy, and 30-day mortality is reported. Nonevaluable patients were excluded from the efficacy analysis but included in the safety analysis. RESULTS: We identified 128 patients, 98 (77%) of whom were evaluable for efficacy. Patient characteristics for the efficacy population were 55 (56%) males, 30 (31%) aged 66 years or older, 38 (39%) had creatinine clearance less than 30 mL/min, and 27 (28%) were on dialysis. Common underlying diseases included acute or chronic renal failure 44 (45%), hypertension 40 (41%), and diabetes 27 (28%). Seventy-two (73%) patients were bacteremic. The most common pathogens found were methicillin-resistant Staphylococcus aureus (32%), vancomycin-resistant Enterococcus faecium (21%), and coagulase-negative staphylococci (20%). Prior to daptomycin, antibiotics were used in 84 (86%) patients, most commonly vancomycin (65/84; 77%). The median (range) initial daptomycin dose was 6 mg/kg (3-10) and duration of 10 days (1-58). Overall success rate was 70% (31% cured; 39% improved). Twelve adverse events possibly related to daptomycin were reported in 9 of 128 (7%) patients in the safety population; 4 of these in 4 (3%) patients were serious. The mortality rate within 30 days of completing daptomycin was 42 of 128 (33%) patients. CONCLUSIONS: These data provide preliminary results on the use of daptomycin in critically ill patients with complicated conditions. Controlled studies are needed to best evaluate daptomycin use in these patients. C1 [Lamp, Kenneth C.] Cubist Pharmaceut Inc, Registry Res, Lexington, MA USA. [Brown, Jack E.] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14260 USA. [Brown, Jack E.] Univ Rochester, Sch Med, Buffalo, NY USA. [Fominaya, Cory] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Christensen, Keith J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA. [McConnell, Scott A.] Cubist Pharmaceut Inc, Sci Training & Operat, Omaha, NE USA. RP Lamp, KC (reprint author), Cubist Pharmaceut Inc, Registry Res, Lexington, MA USA. EM kenneth.lamp@cubist.com FU Cubist Pharmaceuticals FX This study was funded by Cubist Pharmaceuticals, of which Dr. Brown was an employee at the time of the study, Dr. Christensen has received honoraria for consultant work with Cubist Pharmaceuticals; and Drs. McConnell and Lamp are employees of and own stock in Cubist Pharmaceuticals. NR 16 TC 4 Z9 4 U1 0 U2 1 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD APR PY 2012 VL 46 IS 4 BP 495 EP 502 DI 10.1345/aph.1Q490 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 930XE UT WOS:000303177300004 PM 22454446 ER PT J AU Poon, H Chang, MH Fung, HB AF Poon, Henry Chang, Mei H. Fung, Horatio B. TI Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureus SO CLINICAL THERAPEUTICS LA English DT Review DE ceftaroline; cephalosporin; community-acquired pneumonia; methicillin-resistant Staphylococcus aureus; skin and skin structure infections ID IN-VITRO ACTIVITY; COMMUNITY-ACQUIRED PNEUMONIA; SKIN-STRUCTURE INFECTIONS; RABBIT ENDOCARDITIS MODEL; GRAM-NEGATIVE PATHOGENS; SOFT-TISSUE INFECTIONS; COMPLICATED SKIN; VANCOMYCIN-INTERMEDIATE; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL ACTIVITY AB Background: Ceftaroline is a cephalosporin with expanded gram-positive activity recently approved for clinical uses by the US Food and Drug Administration. Objective: This article provides an overview of the in vitro and in vivo activities, mechanism of action, pharmacologic and pharmacokinetic properties, clinical efficacy, and tolerability of ceftaroline. Methods: Relevant information was identified through a search of Pub Med (1990 April 2011), EM-BASE (1990 April 2011), International Pharmaceutical Abstracts (1970 April 2011), and Google Scholar using the key words ceftaroline, PPI-0903, PPI-0903M, T-91825, and TAK-599. A review of the reference lists of identified articles, a search of the US Food and Drug Administration Web site, and posters and abstracts from scientific meetings yielded additional publications. Results: In vitro, ceftaroline exhibits activity against most aerobic gram-positive isolates, common aerobic gram-negative respiratory pathogens, and some gram-positive anaerobes. The MIC range for most Staphylococcus aureus isolates, including vancomycin-resistant strains was between <= 0.008 and 4 mu g/mL. In Phase III studies (CANVAS 1 and CANVAS 2), ceftaroline was found to be noninferior to vancomycin + aztreonam for the treatment of complicated skin and skin-structure infections, with a clinical cure rate of 91.6% among clinically evaluable patients (ceftaroline versus vancomycin + aztreonam: difference, -1.1; 95% CI, -4.2 to 2.0; P = NS). Ceftaroline's efficacy has also been assessed for the treatment of community-acquired pneumonia in 2 Phase III studies (FOCUS 1 and FOCUS 2) and was equivalent to ceftriaxone, with cure rates of 84.3% and 77.7%, respectively, among clinically evaluable patients in the combined analysis (ceftaroline versus ceftriaxone: difference, 6.7; 95% CI, 1.6 to 11.8). The recommended dosage for patients 18 years and older is 600 mg IV every 12 hours. Dosage adjustment is necessary in patients with renal impairment (creatinine clearance <= 50 mL/min). The pharmacokinetic properties of ceftaroline in patients with hepatic impairments are currently unavailable. Ceftaroline appeared to be well tolerated generally. The most frequently (>3%) reported adverse events were nausea, headaches, diarrhea, pruritus, rash, and insomnia; all were usually mild to moderate, self-limiting, and of little clinical significance. Conclusions: Ceftaroline is a cephalosporin with broad gram-positive activity, including Methicillin-resistant S aureus and vancomycin-resistant S aureus. Its gram-negative activity includes common respiratory pathogens and members of the Enterobacteriaceae. Clinical trials have reported that ceftaroline was noninferior to ceftriaxone, and vancomycin + aztreonam for the treatment of community-acquired pneumonia and complicated skin and skin-structure infections, respectively. (Clin Ther. 2012;34:743-765) Published by Elsevier HS Journals, Inc. C1 [Poon, Henry; Chang, Mei H.; Fung, Horatio B.] James J Peters Vet Affairs Med Ctr, Serv Pharm, Bronx, NY 10468 USA. RP Poon, H (reprint author), James J Peters Vet Affairs Med Ctr, Serv Pharm, 130 W Kingsbridge Rd 119, Bronx, NY 10468 USA. EM Henry.Poon@VA.gov NR 89 TC 17 Z9 19 U1 0 U2 12 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD APR PY 2012 VL 34 IS 4 BP 743 EP 765 DI 10.1016/j.clinthera.2012.02.025 PG 23 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 931KZ UT WOS:000303220100002 PM 22444785 ER PT J AU Le, DE Bragadeesh, T Zhao, Y Wang, YG Zha, DG Kaul, S AF Le, D. Elizabeth Bragadeesh, Thanjavur Zhao, Yan Wang, Yue-Gang Zha, Daogang Kaul, Sanjiv TI Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A(2A) receptor agonist SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING LA English DT Article DE Regadenoson; Stress testing; Myocardial contrast echocardiography ID EMISSION COMPUTED-TOMOGRAPHY; PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY; ARTERY-DISEASE; DIPYRIDAMOLE-STRESS; CONSCIOUS DOGS; BLOOD-FLOW; ULTRASOUND CONTRAST; PROGNOSTIC VALUE; PERFUSION; SAFETY AB Aims Regadenoson is comparable to adenosine in pharmacologic radionuclide stress tests but has not been studied with stress myocardial contrast echocardiography. This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A(2A) receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography. Methods and results Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 mu g kg(-1), 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. Regadenoson decreased blood pressure but did not change heart rate. It increased coronary blood flow significantly (P < 0.05) for 30 min, which was attenuated in proportion to coronary stenosis severity. Whereas myocardial blood volume maximally increased by 0.5-0.75-fold in the control region, it did not change in the region supplied by the non-flow limiting stenosis. Perfusion defects were visually and quantitatively detectable for as long as 10 min after administration of regadenoson. No arrhythmias were noted with regadenoson either prior to or during myocardial contrast echocardiography. Conclusion Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. The optimum time for image acquisition was 3-10 min after drug administration. C1 [Le, D. Elizabeth] Portland VA Med Ctr, Portland, OR USA. [Le, D. Elizabeth; Bragadeesh, Thanjavur; Zhao, Yan; Kaul, Sanjiv] Oregon Hlth & Sci Univ, Div Cardiovasc Med, Portland, OR 97239 USA. [Wang, Yue-Gang; Zha, Daogang] So Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China. RP Le, DE (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,P3CAR, Portland, OR USA. EM lee@ohsu.edu FU Cardiovascular Therapeutics (Palo Alto, CA, USA); Bracco Research SA (Geneva, Switzerland); Philips Ultrasound (Andover, MA, USA); Portland Veterans Affairs Medical Center (Portland, OR, USA); Nanfang Hospital of Southern Medical University (GuangZhou, China); National Natural Science Foundation of China FX Supported in part by grants from Cardiovascular Therapeutics (Palo Alto, CA, USA), Bracco Research SA (Geneva, Switzerland), and Philips Ultrasound (Andover, MA, USA). D.E.L. also received support from the Portland Veterans Affairs Medical Center (Portland, OR, USA). Y.-G.W. and D.Z. were supported by Nanfang Hospital of Southern Medical University (GuangZhou, China) and the National Natural Science Foundation of China. NR 39 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2047-2404 J9 EUR HEART J-CARD IMG JI Eur. Heart J.-Cardiovasc. Imaging PD APR PY 2012 VL 13 IS 4 BP 298 EP 308 DI 10.1093/ejechocard/jer232 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 931NS UT WOS:000303227200005 PM 22067143 ER PT J AU Spain, RI George, RJS Salarian, A Mancini, M Wagner, JM Horak, FB Bourdette, D AF Spain, R. I. George, R. J. St. Salarian, A. Mancini, M. Wagner, J. M. Horak, F. B. Bourdette, D. TI Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed SO GAIT & POSTURE LA English DT Article DE Gait; Postural balance; Multiple sclerosis; Outcome measurement; Rehabilitation ID DISABILITY STATUS SCALE; TIMED 25-FOOT WALK; FUNCTIONAL COMPOSITE; CLINICAL DISABILITY; TRUNK ACCELEROMETRY; IMPAIRMENT; STABILIZATION; SYSTEM; IMPACT; MS AB While balance and gait limitations are hallmarks of multiple sclerosis (MS), standard stopwatch-timed measures practical for Use in the clinic are insensitive in minimally affected patients. This prevents early detection and intervention for mobility problems. The study sought to determine if body-worn sensors could detect differences in balance and gait between people with MS with normal walking speeds and healthy controls. Thirty-one MS and twenty-eight age- and sex-matched control subjects were tested using body-worn sensors both during quiet stance and gait (Timed Up and Go test, TUG). Results were compared to stopwatch-timed measures. Stopwatch durations of the TUG and Timed 25 Foot Walk tests were not significantly different between groups. However, during quiet stance with eyes closed, people with MS had significantly greater sway acceleration amplitude than controls (p = 0.02). During gait, people with MS had greater trunk angular range of motion in roll (medio-lateral flexion, p = 0.017) and yaw (axial rotation, p = 0.026) planes. Turning duration through 180 degrees was also longer in MS (p = 0.031). Thus, body-worn motion sensors detected mobility differences between MS and healthy controls when traditional timed tests could not. This portable technology provides objective and quantitative mobility data previously not obtainable in the clinic, and may prove a useful outcome measure for early mobility changes in MS. Published by Elsevier B.V. C1 [Spain, R. I.; Bourdette, D.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, MS Ctr ExcellenceWest, Portland, OR 97239 USA. [Spain, R. I.; Bourdette, D.] Oregon Hlth & Sci Univ, Neurol Serv, Portland, OR 97239 USA. [Spain, R. I.; George, R. J. St.; Mancini, M.; Horak, F. B.; Bourdette, D.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Salarian, A.] Oregon Hlth & Sci Univ, Balance Disorders Lab, Beaverton, OR USA. [Wagner, J. M.] St Louis Univ, Dept Phys Therapy & Athlet Training, St Louis, MO 63103 USA. RP Spain, RI (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, MS Ctr ExcellenceWest, Mail Code CR120 3181,SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM spainr@ohsu.edu RI Salarian, Arash/E-8311-2016 OI Salarian, Arash/0000-0001-7332-0062 FU National MS Society; Medical Research Foundation of Oregon; Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research; VA Rehabilitation Research & Development service FX Mr. Joshua Adams is acknowledged for his assistance with data collection. Dr. Spain received grant support for this project from the National MS Society Mentor Based Post-doctoral Fellowship in Rehabilitation, and the Medical Research Foundation of Oregon Early Clinical Investigator Award. This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Dr. Spain is a Career Development Award recipient from the VA Rehabilitation Research & Development service. NR 30 TC 66 Z9 66 U1 4 U2 22 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD APR PY 2012 VL 35 IS 4 BP 573 EP 578 DI 10.1016/j.gaitpost.2011.11.026 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 931ON UT WOS:000303229300009 PM 22277368 ER PT J AU Brooks, VL Cassaglia, PA Zhao, D Goldman, RK AF Brooks, Virginia L. Cassaglia, Priscila A. Zhao, Ding Goldman, Robert K. TI Baroreflex Function in Females: Changes With the Reproductive Cycle and Pregnancy SO GENDER MEDICINE LA English DT Review DE 3 alpha-OH-DHP; baroreflex sensitivity; sympathetic nerve activity; insulin; hemorrhage ID OBESE ZUCKER RATS; SYMPATHETIC-NERVE ACTIVITY; CONSCIOUS RABBITS; MENSTRUAL-CYCLE; BRAIN INSULIN; HEART-RATE; CHRONOTROPIC BAROREFLEXES; ESTROUS-CYCLE; SENSITIVITY; REFLEX AB This review briefly describes the changes in baroreflex function that occur during female reproductive life, specifically during the reproductive cycle and pregnancy. The sensitivity or gain of baroreflex control of heart rate and sympathetic activity fluctuates during the reproductive cycle, reaching a peak when gonadal hormone levels increase, during the follicular phase in women and proestrus in rats. The increase in baroreflex sensitivity (BRS) is likely mediated by estrogen because ovariectomy in rats eliminates the BRS increase, the cyclic profile of changes in BRS mirror the changes in estrogen, and estrogen acts in the brainstem to increase BRS. In contrast, pregnancy depresses both BRS and the maximal level of sympathetic activity and heart rate evoked by severe hypotension. The decrease in BRS may be mediated by a reduction in the actions of insulin in the arcuate nucleus to support the baroreflex. In addition, increased levels of the neurosteroid progesterone metabolite 3 alpha-OH-DHP act downstream in the rostral ventrolateral medulla to suppress maximal baroreflex increases in sympathetic activity. Consequently, these changes in baroreflex function impair blood pressure regulation in the presence of hypotensive challenges such as orthostasis and hemorrhage, a common event during delivery. As a result, peripartum hemorrhage is a major cause of human maternal death. (Gend Med. 2012;9:61-67) (C) 2012 Elsevier HS Journals, Inc. All rights reserved. C1 [Brooks, Virginia L.; Cassaglia, Priscila A.; Zhao, Ding] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Zhao, Ding] Hebei Med Univ, Sch Pharm, Shijiazhuang, Peoples R China. [Goldman, Robert K.] Portland VA Med Ctr, Dept Surg, Portland, OR USA. RP Brooks, VL (reprint author), Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, L-334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM brooksv@ohsu.edu FU National Institutes of Health [HL088552]; American Heart Association [09GRNT2060630] FX This work was supported in part by grant HL088552 from the National Institutes of Health and by Grant-in-Aid 09GRNT2060630 from the American Heart Association. All authors contributed to the writing of the manuscript and also contributed to the design, conduct, or analysis of aspects of the research from the authors' lab described in this review. NR 45 TC 11 Z9 12 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1550-8579 J9 GENDER MED JI Gend. Med. PD APR PY 2012 VL 9 IS 2 BP 61 EP 67 DI 10.1016/j.genm.2012.02.004 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 930WZ UT WOS:000303176700001 PM 22483197 ER PT J AU Bellande, B Winicur, Z Gallo, B Turner, M Saulino, M Heath, S Bennett, S Nelson, ME Reese, C Larson, A Dawidowicz, S Boche, J Cox, K AF Bellande, Bruce Winicur, Zev Gallo, Bruno Turner, Michael Saulino, Michael Heath, Susan Bennett, Susan Nelson, Mary Elizabeth Reese, Cynthia Larson, Andrea Dawidowicz, Suzanne Boche, Jamie Cox, Kathleen TI Competency-Based Curricula in DBS and ITB Therapies for Movement Disorders SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Bellande, Bruce] DWA Healthcare Commun Grp, Indianapolis, IN USA. [Cox, Kathleen] DWA Healthcare Commun Grp, Med Sci & Educ Div, Carmel, IN USA. [Gallo, Bruno] Univ Miami, Miami, FL USA. [Turner, Michael] Goodman Campbell Brain & Spine, Indianapolis, IN USA. [Saulino, Michael] MossRehab, Elkins Pk, PA USA. [Heath, Susan] San Francisco VA Med Ctr, San Francisco, CA USA. [Bennett, Susan] SUNY Buffalo, Buffalo, NY 14260 USA. [Nelson, Mary Elizabeth] PM&R Med Coll Wisconsin, Milwaukee, WI USA. [Reese, Cynthia; Larson, Andrea; Dawidowicz, Suzanne; Boche, Jamie] Medtronic, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P06022 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204803369 ER PT J AU Davis, M Smith, C Sheehy, C Batish, SD Swanson, P Bird, T AF Davis, Marie Smith, Corrine Sheehy, Connor Batish, Sat Dev Swanson, Phillip Bird, Thomas TI Novel Mutations in Ataxia Telangiectasia and AOA2 Associated with Prolonged Survival SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Davis, Marie; Smith, Corrine; Sheehy, Connor; Swanson, Phillip] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Batish, Sat Dev] Athena Diagnost Inc, Worcester, MA USA. [Bird, Thomas] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P05028 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204803004 ER PT J AU Erten-Lyons, D Woltjer, R Dodge, H Silbert, L Kramer, P Kaye, J AF Erten-Lyons, Deniz Woltjer, Randall Dodge, Hiroko Silbert, Lisa Kramer, Patricia Kaye, Jeffrey TI Neuropathological Basis of Age-Associated Brain Atrophy SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Erten-Lyons, Deniz] Portland VA Med Ctr, Portland, OR USA. [Woltjer, Randall; Silbert, Lisa; Kramer, Patricia; Kaye, Jeffrey] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dodge, Hiroko] Oregon Hlth & Sci Univ, Plymouth, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P05053 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204802412 ER PT J AU Harel, N Song, KH Tang, X Spungen, A Strittmatter, S AF Harel, Noam Song, Kang Ho Tang, Xin Spungen, Ann Strittmatter, Stephen TI A Hebbian Approach to Retraining Spared Circuits after Spinal Cord Injury SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Harel, Noam] Mt Sinai Sch Med, Bronx, NY USA. [Song, Kang Ho; Tang, Xin; Strittmatter, Stephen] Yale Univ, New Haven, CT USA. [Spungen, Ann] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY USA. RI Strittmatter, Stephen/F-5739-2011 OI Strittmatter, Stephen/0000-0001-8188-3092 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P02005 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204801123 ER PT J AU Overs, S Fitzpatrick, M Dryden, J Whitham, R Cameron, M AF Overs, Shannon Fitzpatrick, Mary Dryden, John Whitham, Ruth Cameron, Michelle TI The Effects of Dalfampridine on Walking Speed, Endurance, and Community Participation in a Veteran Population: A Retrospective Cohort Study SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Overs, Shannon] Neurol OHSU, Portland, OR USA. [Fitzpatrick, Mary; Whitham, Ruth; Cameron, Michelle] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P04123 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204802357 ER PT J AU Pugh, MJ Amuan, M AF Pugh, Mary Jo Amuan, Megan TI The Nexus of Traumatic Brain Injury and Epilepsy in Veterans from Afghanistan and Iraq SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Pugh, Mary Jo] Verdict S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Amuan, Megan] CHQOER Edith Nourse Rogers Mem VA Hosp, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA S06001 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204800409 ER PT J AU Pugh, MJ Amuan, M AF Pugh, Mary Jo Amuan, Megan TI The Nexus of Traumatic Brain Injury and Epilepsy in Veterans from Afghanistan and Iraq SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Pugh, Mary Jo] Verdict S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Amuan, Megan] CHQOER Edith Nourse Rogers Mem VA Hosp, Bedford, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA IN52002 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204800043 ER PT J AU Ross, W Duda, J Abbott, R Petrovitch, H Tanner, C Masaki, K Uyehara-Lock, J Launer, L White, L AF Ross, Web Duda, John Abbott, Robert Petrovitch, Helen Tanner, Caroline Masaki, Kamal Uyehara-Lock, Jane Launer, Lenore White, Lon TI Association of Coffee and Caffeine Consumption with Brain Lewy Pathology in the Honolulu-Asia Aging Study SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Ross, Web] VA Pacific Isl Hlth Care Syst, Honolulu, HI USA. [Duda, John] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Abbott, Robert] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Petrovitch, Helen] Pacific Hlth Res & Educ Inst, Kailua, HI USA. [Tanner, Caroline] Parkinsons Inst, Sunnyvale, CA USA. [Masaki, Kamal] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA. [Launer, Lenore] NIA, NIH, Washington, DC USA. [White, Lon] Kuakini Med Ctr, Honolulu, HI USA. [Uyehara-Lock, Jane] U Hawaii John A Burns Sch Med, Honolulu, HI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA S42005 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204803107 ER PT J AU Salinthone, S Bourdette, D Carr, D AF Salinthone, Sonemany Bourdette, Dennis Carr, Daniel TI The Natural Antioxidant alpha-Tocopherol (Vitamin E) Activates the cAMP Signaling Cascade and Alters Immune Cell Function: Implications for MS Therapy SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Salinthone, Sonemany; Carr, Daniel] Portland VA Med Ctr, Portland, OR USA. [Bourdette, Dennis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P05100 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204803082 ER PT J AU Teng, EM Tassniyom, K Lu, P AF Teng, Edmond Tassniyom, Kanida Lu, Po TI Reduced Quality of Life Ratings in Mild Cognitive Impairment: Analyses of Subject and Informant Responses SO NEUROLOGY LA English DT Meeting Abstract CT 64th Annual Meeting of the American-Academy-of-Neurology (AAN) CY APR 21-28, 2012 CL New Orleans, LA SP Amer Acad Neurol (AAN) C1 [Teng, Edmond] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Tassniyom, Kanida] Khon Kaen Univ, Khon Kaen, Thailand. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2012 VL 78 SU 1 MA P04208 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 931GQ UT WOS:000303204802117 ER PT J AU James, IB Wang, Z Hannon, MJ Kwoh, CK AF James, I. B. Wang, Z. Hannon, M. J. Kwoh, C. K. TI SPECIFIC KNEE PAIN PATTERNS ON THE KNEE PAIN MAP ARE ASSOCIATED WITH DIFFERENT LEVELS OF FUNCTIONAL PERFORMANCE - DATA FROM THE OAI SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress on Osteoarthritis CY APR 26-29, 2012 CL Barcelona, SPAIN C1 [James, I. B.; Wang, Z.; Hannon, M. J.; Kwoh, C. K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kwoh, C. K.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2012 VL 20 SU 1 BP S253 EP S254 PG 2 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 931MF UT WOS:000303223300527 ER PT J AU Ruhdorfer, AS Dannhauer, T Wirth, W Hudelmaier, M Sattler, M Kwoh, CK Guermazi, A Hunter, DJ Benichou, O Eckstein, F AF Ruhdorfer, A. S. Dannhauer, T. Wirth, W. Hudelmaier, M. Sattler, M. Kwoh, C. K. Guermazi, A. Hunter, D. J. Benichou, O. Eckstein, F. CA OAI Investigators TI THIGH MUSCLE CROSS-SECTIONAL AREAS AND STRENGTH ARE NOT REDUCED IN ADVANCED VERSUS EARLY PAINFUL KNEE OSTEOARTHRITIS - A BETWEEN-KNEE WITHIN-PERSON COMPARISON IN OAI PARTICIPANTS SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress on Osteoarthritis CY APR 26-29, 2012 CL Barcelona, SPAIN C1 [Ruhdorfer, A. S.; Dannhauer, T.; Wirth, W.; Hudelmaier, M.; Sattler, M.; Eckstein, F.] Paracelsus Med Univ, Salzburg, Austria. [Dannhauer, T.; Wirth, W.; Hudelmaier, M.; Eckstein, F.] Chondrometr GmbH, Ainring, Germany. [Kwoh, C. K.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA. [Kwoh, C. K.] VA Pittsburgh Hlthcare Syst, Pittsburgh, PA USA. [Guermazi, A.] Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA. [Guermazi, A.] BICL, Boston, MA USA. [Hunter, D. J.] Royal N Shore Hosp, Sydney, NSW, Australia. [Hunter, D. J.] Univ Sydney, No Clin Sch, Sydney, NSW 2006, Australia. [Benichou, O.] Eli Lilly & Co, Indianapolis, IN 46285 USA. RI Hunter, David/A-4622-2010 OI Hunter, David/0000-0003-3197-752X NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2012 VL 20 SU 1 BP S215 EP S215 PG 1 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 931MF UT WOS:000303223300454 ER PT J AU Singh, JA Kwoh, C Richardson, D Chen, W Ibrahim, S AF Singh, J. A. Kwoh, C. Richardson, D. Chen, W. Ibrahim, S. TI FEMALE GENDER IS PROTECTIVE FOR OUTCOMES AFTER PRIMARY TOTAL KNEE ARTHROPLASTY: A RISK-ADJUSTED ANALYSIS SO OSTEOARTHRITIS AND CARTILAGE LA English DT Meeting Abstract CT World Congress on Osteoarthritis CY APR 26-29, 2012 CL Barcelona, SPAIN C1 [Singh, J. A.] Univ Alabama, Birmingham, AL USA. [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kwoh, C.] Univ Pittsburgh, Pittsburgh, PA USA. [Kwoh, C.] Pittsburgh VA Med Ctr, Pittsburgh, PA USA. [Richardson, D.; Chen, W.; Ibrahim, S.] Univ Penn, Philadelphia, PA 19104 USA. [Richardson, D.; Chen, W.; Ibrahim, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD APR PY 2012 VL 20 SU 1 BP S294 EP S294 PG 1 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 931MF UT WOS:000303223300613 ER PT J AU Finley, EP Pugh, MJ Noel, PH Brown, PJ AF Finley, Erin P. Pugh, Mary Jo Noel, Polly H. Brown, Peter J. TI Validating a Measure of Self-Efficacy for Life Tasks in Male OEF/OIF Veterans SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE OEF/OIF veterans; developmental tasks; depression; anxiety; self-efficacy theory ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DIAGNOSES; AFGHANISTAN VETERANS; DEVELOPMENTAL TASKS; PERCEIVED CONTROL; IRAQ; ADULTHOOD; DEPRESSION; DEPLOYMENT; ASSOCIATION AB This paper describes the development and preliminary validation of a scale to assess perceived self-efficacy to complete culturally and age-appropriate life tasks (Self-Efficacy for Life Tasks, or SELT) among male veterans of Afghanistan (Operation Enduring Freedom; OEF) and Iraq (Operation Iraqi Freedom; OIF). The SELT scale was developed for this population in a multistage process that included: 1) semi-structured interviews inquiring about expectations of self among OEF/OIF veterans; 2) content analysis to inductively derive a list of priority life tasks; 3) item development; 4) field-testing; and 5) preliminary instrument validation. Forty-one veterans completed the final instrument along with measures of anxiety and depression symptoms, positive and negative social support, and postdeployment life stressors. We tested two scoring methods, one using a simple mean and one a weighted mean. Using either scoring method, SELT had statistically significant negative correlations with anxiety, depression, and being separated from partner, as well as strong positive correlations with postdeployment social support. These findings support the construct validity of the SELT scale in the population of male OEF/OIF veterans. Future research examining the relationship between SELT and long-term outcomes using longitudinal designs will be needed to assess predictive validity. C1 [Finley, Erin P.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Finley, Erin P.; Pugh, Mary Jo; Noel, Polly H.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Pugh, Mary Jo] S Texas Vet Hlth Care Syst, Dept Epidemiol & Biostat, San Antonio, TX USA. [Brown, Peter J.] Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA. RP Finley, EP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, 7703 Floyd Curl Dr,MSC 7879, San Antonio, TX 78229 USA. EM finleye@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Finley, Erin/0000-0003-4497-7721 NR 54 TC 1 Z9 1 U1 1 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD APR PY 2012 VL 13 IS 2 BP 143 EP 157 DI 10.1037/a0023607 PG 15 WC Psychology, Social SC Psychology GA 932CQ UT WOS:000303268400004 ER PT J AU Henao-Martinez, AF Fernandez, JF Adams, SG Restrepo, C AF Henao-Martinez, Andres F. Fernandez, Juan F. Adams, Sandra G. Restrepo, Carlos TI Lung Bullae With Air-Fluid Levels: What Is the Appropriate Therapeutic Approach? SO RESPIRATORY CARE LA English DT Article DE COPD; air-fluid levels; infection; therapy; inflammation; bullae ID BULLOUS EMPHYSEMA; PERCUTANEOUS DRAINAGE; FILLED BULLA; DISEASE AB Air-fluid levels within emphysematous lung bullae are a relatively uncommon occurrence in patients with preexisting bullous disease, and are not commonly reported. We report 2 cases of new onset air-fluid levels in patients with underlying bullous disease with substantially different clinical presentations but with clinical improvement after medical therapy only. C1 [Henao-Martinez, Andres F.] Univ Colorado, Sch Med, Div Infect Dis, Aurora, CO 80045 USA. [Fernandez, Juan F.; Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pulm & Crit Care, San Antonio, TX 78229 USA. [Restrepo, Carlos] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Adams, Sandra G.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Henao-Martinez, AF (reprint author), Univ Colorado, Sch Med, Div Infect Dis, 12700 E 19th Ave, Aurora, CO 80045 USA. EM andres.henaomartinez@ucdenver.edu OI Henao-Martinez, Andres/0000-0001-7363-8652 NR 25 TC 1 Z9 1 U1 0 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD APR PY 2012 VL 57 IS 4 BP 642 EP 645 DI 10.4187/respcare.01372 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 927RT UT WOS:000302928500018 PM 22005505 ER PT J AU Harris, BS Baicu, CF Haghshenas, N Kasiganesan, H Scholz, D Rackley, MS Miquerol, L Gros, D Mukherjee, R O'Brien, TX AF Harris, Brett S. Baicu, Catalin F. Haghshenas, Nicole Kasiganesan, Harinath Scholz, Dimitri Rackley, Mary S. Miquerol, Lucile Gros, Daniel Mukherjee, Rupak O'Brien, Terrence X. TI Remodeling of the peripheral cardiac conduction system in response to pressure overload SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE connexin40; connexin43; connexin45; hyperpolarization-activated cyclic nucleotide-gated channel 4; Purkinje fibers; cardiac hypertrophy; cardiac activation ID BRAIN NATRIURETIC PEPTIDE; FACTOR GENE-EXPRESSION; CURRENT I-F; HEART-FAILURE; COLOCALIZATION ANALYSIS; ATRIAL-FIBRILLATION; PURKINJE-FIBERS; CONNEXIN45; HYPERTROPHY; JUNCTION AB Harris BS, Baicu CF, Haghshenas N, Kasiganesan H, Scholz D, Rackley MS, Miquerol L, Gros D, Mukherjee R, O'Brien TX. Remodeling of the peripheral cardiac conduction system in response to pressure overload. Am J Physiol Heart Circ Physiol 302: H1712-H1725, 2012. First published February 3, 2012; doi: 10.1152/ajpheart.00621.2011.-How chronic pressure overload affects the Purkinje fibers of the ventricular peripheral conduction system (PCS) is not known. Here, we used a connexin (Cx)40 knockout/enhanced green fluorescent protein knockin transgenic mouse model to specifically label the PCS. We hypothesized that the subendocardially located PCS would remodel after chronic pressure overload and therefore analyzed cell size, markers of hypertrophy, and PCS-specific Cx and ion channel expression patterns. Left ventricular hypertrophy with preserved systolic function was induced by 30 days of surgical transaortic constriction. After transaortic constriction, we observed that PCS cardiomyocytes hypertrophied by 23% (P < 0.05) and that microdissected PCS tissue exhibited upregulated markers of hypertrophy. PCS cardiomyocytes showed a 98% increase in the number of Cx40-positive gap junction particles, with an associated twofold increase in gene expression (P < 0.05). We also identified a 50% reduction in Cx43 gap junction particles located at the interface between PCS cardiomyocytes and the working cardiomyocyte. In addition, we measured a fourfold increase of an ion channel, hyperpolarization-activated cyclic nucleotide-gated channel (HCN)4, throughout the PCS (P < 0.05). As a direct consequence of PCS remodeling, we found that pressure-overloaded hearts exhibited marked changes in ventricular activation patterns during normal sinus rhythm. These novel findings characterize PCS cardiomyocyte remodeling after chronic pressure overload. We identified significant hypertrophic growth accompanied by modified expression of Cx40, Cx43, and HCN4 within PCS cardiomyocytes. We found that a functional outcome of these changes is a failure of the PCS to activate the ventricular myocardium normally. Our findings provide a proof of concept that pressure overload induces specific cellular changes, not just within the working myocardium but also within the specialized PCS. C1 [Harris, Brett S.; Haghshenas, Nicole; O'Brien, Terrence X.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Baicu, Catalin F.; Kasiganesan, Harinath; Rackley, Mary S.; O'Brien, Terrence X.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Mukherjee, Rupak] Med Univ S Carolina, Dept Cardiothorac Surg, Charleston, SC 29425 USA. [Scholz, Dimitri] UCD Conway, Dublin, Ireland. [Miquerol, Lucile; Gros, Daniel] Univ Aix Marseille 2, Marseille, France. [O'Brien, Terrence X.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Harris, BS (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 173 Ashley Ave, Charleston, SC 29425 USA. EM harrisbs@musc.edu FU National Center for Research Resources [5-P20-RR-016434-010]; Research and Development Service of the Department of Veterans Affairs FX This work was supported by National Center for Research Resources Grant 5-P20-RR-016434-010 (to B. S. Harris) and a Merit Award from the Research and Development Service of the Department of Veterans Affairs (to T. X. O'Brien). NR 42 TC 5 Z9 6 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR PY 2012 VL 302 IS 8 BP H1712 EP H1725 DI 10.1152/ajpheart.00621.2011 PG 14 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 927MK UT WOS:000302911500016 PM 22307665 ER PT J AU Subramanian, A Liang, MK AF Subramanian, Anuradha Liang, Mike K. TI A 60-year literature review of stump appendicitis: the need for a critical view SO AMERICAN JOURNAL OF SURGERY LA English DT Review DE Stump appendicitis; Retained appendix; Appendicitis; Perforated appendicitis; Complicated appendicitis; Recurrent appendicitis ID LAPAROSCOPIC APPENDECTOMY; COMPLICATION; PATIENT AB BACKGROUND: Stump appendicitis is an underreported and poorly defined condition. It is the development of obstruction and inflammation of the residual appendix after appendectomy. This is a review of the basic clinical, pathological, and surgical significance of stump appendicitis, and the "critical view" required for prevention. DATA SOURCES: PubMed MEDLINE search was performed using terms "stump appendicitis" and "retained appendix" to obtain reported cases of stump appendicitis. Sixty-one cases were identified. Each case was charted based on 14 variables. Data were analyzed. CONCLUSIONS: Stump appendicitis warrants early detection. Patients can present with abdominal pain, nausea, and vomiting. A prior history of appendectomy can delay the diagnosis. A diagnosis can be made with an abdominal ultrasound or computed tomography scan. If treated early, laparoscopic or open completion appendectomy can be performed. If diagnosis is delayed and perforation is found, extensive resection is often required. A "critical view," as described in this article, is key for prevention. Published by Elsevier Inc. C1 [Subramanian, Anuradha; Liang, Mike K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Liang, MK (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM ml3@bcm.edu RI Liang, Mike/L-8493-2015 OI Liang, Mike/0000-0001-7063-7291 NR 19 TC 11 Z9 11 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD APR PY 2012 VL 203 IS 4 BP 503 EP 507 DI 10.1016/j.amjsurg.2011.04.009 PG 5 WC Surgery SC Surgery GA 927ND UT WOS:000302913700015 PM 22153086 ER PT J AU Hu, D Lau, OD Wang, L Wang, GY Schaue, D Zhu, L Huang, M Lin, Y Dennis, M Abemayor, E Elashoff, DA Dubinett, SM McBride, WH Sharma, S Wu, B St John, MA AF Hu, David Lau, Ontario D. Wang, Linda Wang, Guanyu Schaue, Dorthe Zhu, Li Huang, Min Lin, Yuan Dennis, Miranda Abemayor, Elliot Elashoff, David A. Dubinett, Steven M. McBride, William H. Sharma, Sherven Wu, Ben St John, Maie A. TI A Novel Modular Polymer Platform for the Treatment of Head and Neck Squamous Cell Carcinoma in an Animal Model SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID CANCER; RADIOTHERAPY; CISPLATIN; INHIBITION; DELIVERY AB Objective: To evaluate the therapeutic efficacy of a novel modular polymer platform in the treatment of head and neck squamous cell carcinoma (HNSCC). Design: In vivo study. Setting: Academic research laboratory. Subjects and Methods: C3H/HeJ mice and SCID/beige mice were randomized to receive implantation of no polymer, plain polymer, plain polymer with local cisplatin injection, or cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive 4 Gy of external beam radiation for 4 days or no radiation. Tumor size was measured until the mice were humanely killed. At necropsy, the tumors were excised and weighed. Results: There was a significant reduction in tumor growth using this novel polymer platform. The cisplatin-secreting polymer effectively reduced human head and neck tumor growth in SCID mice by 17-fold and SCC VII/SF tumors in C3H/HeJ mice by more than 16-fold compared with the control, plain polymer, and plain polymer + intratumoral cisplatin injection groups (P = .01 for both). We also observed a statistically significant lower tumor weight in mice treated with cisplatin polymer and concomitant radiation compared with the radiation alone and control groups. Conclusions: We demonstrate the efficacy of a novel polymer platform in delivering cisplatin to a partially resected SCC in a murine model. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan for validation in the context of a prospective trial in patients with unresectable advanced or recurrent HNSCC. C1 [Hu, David; Lau, Ontario D.; Dennis, Miranda; Abemayor, Elliot; St John, Maie A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Dept Surg, Los Angeles, CA 90095 USA. [Wang, Guanyu; Zhu, Li; Lin, Yuan; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Wang, Guanyu; Zhu, Li; Lin, Yuan; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA. [Huang, Min; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Elashoff, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. [Wu, Ben] Univ Calif Los Angeles, David Geffen Sch Med, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90095 USA. [Wu, Ben] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA. [Wang, Linda; Wu, Ben] Univ Calif Los Angeles, David Geffen Sch Med, Dept Bioengn, Los Angeles, CA 90095 USA. [Schaue, Dorthe; McBride, William H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA. [Zhu, Li] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA. [Huang, Min; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP St John, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Dept Surg, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. RI lin, yuan/E-6062-2011 FU NCATS NIH HHS [UL1 TR000124]; NIDCR NIH HHS [K23 DE021193]; PHS HHS [K23] NR 20 TC 5 Z9 5 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2012 VL 138 IS 4 BP 412 EP 417 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 926YU UT WOS:000302870800013 PM 22508626 ER PT J AU Saunders, JK Rosman, AS Neihaus, D Gouge, TH Melis, M AF Saunders, John K. Rosman, Alan S. Neihaus, Dena Gouge, Thomas H. Melis, Marcovalerio TI Safety of Hepatic Resections in Obese Veterans SO ARCHIVES OF SURGERY LA English DT Article ID BODY-MASS-INDEX; ARTERY-BYPASS-SURGERY; QUALITY IMPROVEMENT PROGRAM; INDEPENDENT RISK-FACTOR; HEPATOCELLULAR-CARCINOMA; DIABETES-MELLITUS; PERIOPERATIVE MORTALITY; COLORECTAL-CANCER; CARDIAC-SURGERY; GRAFT-SURGERY AB Objective: To determine the effects of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) on outcomes after liver resection performed at Veterans Affairs medical centers. Design, Setting, and Patients: We queried the Veterans Affairs Surgical Quality Improvement Program database for liver resections (2005-2008) and grouped the patients into 5 BMI categories: normal weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9), obese class 1 (BMI 30.0-34.9), obese class 2 (BMI 35.0-39.9), and obese class 3 (BMI >= 40.0). Differences in risk factors and perioperative complications across groups were analyzed in univariate and multivariate analyses. Results: Of 403 patients who underwent hepatectomy, 106 (26%) were normal weight, 161 (40%) were overweight, 94 (23%) were obese class 1, 31 (8%) were obese class 2, and 11 (3%) were obese class 3. Among these groups, higher BMI was associated with increased rates of hypertension (52%, 61%, 77%, 77%, and 73%, respectively; P=.002) and diabetes (18%, 27%, 36%, 39%, and 45%, respectively; P=.04) and lower incidence of smokers (53%, 35%, 30%, 16%, and 9%, respectively; P<.001). The BMI groups were similar in demographic characteristics and metrics correlating with preexisting liver disease. There were no differences across BMI groups in overall and specific morbidity or in length of stay. Compared with the other groups, obese class 3 patients received more blood transfusions (mean [SD], 4.3 [2.7] in obese class 3 patients vs 1.1 [0.2] in normal-weight patients; P=.02) and had a higher 30-day mortality (27% in obese class 3 patients vs 6% in normal-weight patients; P=.05). Multivariate analyses confirmed obese class 3 as an independent predictor of postoperative mortality. Conclusions: Obesity did not increase postoperative complications after liver resection in veterans. After adjusting for other clinical factors, extreme obesity (BMI >= 40.0) was an independent risk factor for increased mortality. C1 [Melis, Marcovalerio] NYU, Sch Med, Dept Surg, New York Harbor Healthcare Syst Vet Affairs Med C, New York, NY 10010 USA. [Rosman, Alan S.] James J Peters Vet Affairs Med Ctr, Div Gastroenterol, Bronx, NY USA. RP Melis, M (reprint author), NYU, Sch Med, Dept Surg, New York Harbor Healthcare Syst Vet Affairs Med C, 423 E 23rd St,Room 4153 N, New York, NY 10010 USA. EM marcovalerio.melis@nyumc.org OI Gouge, Thomas/0000-0001-8381-4146 NR 45 TC 17 Z9 18 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD APR PY 2012 VL 147 IS 4 BP 331 EP 337 DI 10.1001/archsurg.2011.1404 PG 7 WC Surgery SC Surgery GA 927JX UT WOS:000302904600008 PM 22184133 ER PT J AU Hahn, ME Wright, ES Segal, AD Orendurff, MS Ledoux, WR Sangeorzan, BJ AF Hahn, Michael E. Wright, Elise S. Segal, Ava D. Orendurff, Michael S. Ledoux, William R. Sangeorzan, Bruce J. TI Comparative Gait Analysis of Ankle Arthrodesis and Arthroplasty: Initial Findings of a Prospective Study SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Arthritis; Arthrodesis; Arthroplasty; Mobility; Gait Analysis ID TERM-FOLLOW-UP; KINEMATIC CHANGES; TOTAL REPLACEMENT; FUSION; PROSTHESIS; MOVEMENT AB Background: Little is known about functional outcomes of ankle arthroplasty compared with arthrodesis. This study compared pre-surgical and post-surgical gait measures in both patient groups. Methods: Eighteen patients with end-stage ankle arthritis participated in an ongoing longitudinal study (pre-surgery, 12 months post-surgery) involving gait analysis, assessment of pain and physical function. Outcome measures included temporal-distance, kinematic and kinetic data, the Short Form 36 (SF-36) body pain score, and average daily step count. A mixed effects linear model was used to detect effects of surgical group (arthrodesis and arthroplasty, n = 9 each) with walking speed as a covariate (alpha = 0.05). Results: Both groups were similar in demographics and anthropometrics. Followup time was the same for each group. There were no complications in either group. Pain decreased (p < 0.001) and gait function improved (gait velocity, p = 0.02; stride length, p = 0.035) in both groups. Neither group increased average daily step count. Joint range of motion (ROM) differences were observed between groups after surgery (increased hip ROM in arthrodesis, p = 0.001; increased ankle ROM in arthroplasty, p = 0.036). Peak plantar flexor moment increased in arthrodesis patients and decreased in arthroplasty patients (p = 0.042). Conclusion: Initial findings of this ongoing clinical study indicate pain reduction and improved gait function 12 months after surgery for both treatments. Arthroplasty appears to regain more natural ankle joint function, with increased ROM. Longterm follow up should may reveal more clinically meaningful differences. C1 [Hahn, Michael E.; Ledoux, William R.; Sangeorzan, Bruce J.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.; Sangeorzan, Bruce J.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Hahn, Michael E.; Wright, Elise S.; Segal, Ava D.; Orendurff, Michael S.; Ledoux, William R.; Sangeorzan, Bruce J.] Rehabil Res & Dev Ctr Excellence Limb Loss Preven, VA Puget Sound, Dept Vet Affairs VA, Seattle, WA USA. RP Hahn, ME (reprint author), Ctr Excellence Limb Loss Prevent & Prosthet Engn, VA Puget Sound, 1660 S Columbian Way,MS-151, Seattle, WA 98108 USA. EM mehahn@uw.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs [A4513R, A4883C A4843C] FX Funds were received in support of this article from the Department of Veterans Affairs, grants A4513R and A4883C A4843C. NR 28 TC 23 Z9 25 U1 0 U2 13 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD APR PY 2012 VL 33 IS 4 BP 282 EP 289 DI 10.3113/FAI.2012.0282 PG 8 WC Orthopedics SC Orthopedics GA 927DV UT WOS:000302888100006 PM 22735200 ER PT J AU Weber, JR Aubin, PM Ledoux, WR Sangeorzan, BJ AF Weber, Joel R. Aubin, Patrick M. Ledoux, William R. Sangeorzan, Bruce J. TI Second Metatarsal Length is Positively Correlated With Increased Pressure and Medial Deviation of the Second Toe in a Robotic Cadaveric Simulation of Gait SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Second Metatarsal; Plantar Pressure; Metatarsophalangeal Joint; Second Toe; Gait Simulation AB Background: The term 'crossover second toe' has been used to describe a deformity of the second metatarsophalangeal joint (MTPJ) that includes a progressive migration of the second toe in a dorsal and medial direction. The long onset and complex anatomy of the deformity has led to uncertainty about its etiology and treatment. The purpose of this study was to investigate the relationship between second metatarsal length and second MTPJ plantar pressure and joint angles during gait. We hypothesized that elongation of the second metatarsal would increase the plantar pressure underneath the second MTPJ and be associated with a deviation of the MTPJ angles in a dorsal and medial direction. Methods: Incremental surgical elongation of the second metatarsal was performed on six cadaveric feet. A robotic gait simulator (RGS) simulated physiologic tibial motion, tendon loading, and ground reaction forces (GRF) on the cadaveric feet. We determined the peak pressure and pressure-time integral under the second MTPJ during gait, as well as the transverse and sagittal MTPJ angles. Results: Second metatarsal peak pressure and pressure-time integral were positively correlated with an increase in second metatarsal length. First metatarsal peak pressure and pressure-time integral were significantly negatively associated with second metatarsal length. MTPJ transverse plane angle was positively associated with second metatarsal length but sagittal angle was not. Conclusion: Our results support the hypothesis that second metatarsal length is positively associated with medial deviation of the second toe and increased plantar pressure underneath the second MTPJ. Clinical Relevance: It is biomechanically plausible that this association could lead to the joint instability seen in crossover toe patients. C1 [Ledoux, William R.] RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, Seattle, WA 98108 USA. RP Ledoux, WR (reprint author), RR&D Ctr Excellence Limb Loss Prevent & Prosthet, VA Puget Sound, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs Rehabilitation Research and Development Service [A4843C]; University of Washington FX Funds were received in support of this article from the Department of Veterans Affairs Rehabilitation Research and Development Service grant A4843C and the University of Washington Medical Student Research Training Program. NR 18 TC 6 Z9 6 U1 2 U2 2 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD APR PY 2012 VL 33 IS 4 BP 312 EP 319 DI 10.3113/FAI.2012.0312 PG 8 WC Orthopedics SC Orthopedics GA 927DV UT WOS:000302888100009 PM 22735203 ER PT J AU Pereira, RI Snell-Bergeon, JK Erickson, C Schauer, IE Bergman, BC Rewers, M Maahs, DM AF Pereira, Rocio I. Snell-Bergeon, Janet K. Erickson, Christopher Schauer, Irene E. Bergman, Bryan C. Rewers, Marian Maahs, David M. TI Adiponectin Dysregulation and Insulin Resistance in Type 1 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CORONARY-ARTERY CALCIFICATION; ADIPOSE-SPECIFIC PROTEIN; SERUM ADIPONECTIN; SENSITIVITY; ASSOCIATION; OBESITY; CACTI AB Context: Type 1 diabetes (T1D) is associated with insulin resistance despite elevated levels of the insulin-sensitizing protein adiponectin. Whether the expected positive correlation between adiponectin and insulin sensitivity is preserved in a T1D population is unknown. Objective: We measured the correlation between total and high-molecular-weight (HMW) adiponectin and insulin sensitivity in T1D patients and nondiabetic controls and identified determinants of adiponectin levels in patients with T1D. Design and Participants: Fasting total and HMW adiponectin were measured in 86 subjects from the Coronary Artery Calcification in T1D (CACTI) cohort (39 T1D, 47 nondiabetic; age 45 +/- 8 yr; 55% female). The association of adiponectin levels with insulin sensitivity was analyzed. Setting: The study was conducted at an academic research institute. Methods: Fasting total and HMW adiponectin were measured by RIA and ELISA, respectively. Insulin sensitivity was measured by a hyperinsulinemic-euglycemic clamp. Multivariate linear regression was used to identify determinants of adiponectin levels. Results: Adiponectin levels positively correlated with insulin sensitivity in both subject groups (total adiponectin, r = 0.33 P < 0.05 for T1D, r = 0.29 P < 0.05 controls), but insulin sensitivity was lower in T1D subjects at any given level of total or HMW adiponectin. Adiponectin levels were independently associated with age, gender, and trunk fat, but these variables did not account for increased adiponectin in patients with T1D. Conclusion: Adiponectin levels are positively correlated with insulin sensitivity in T1D patients. However, T1D patients have decreased insulin sensitivity compared with controls at every level of adiponectin, suggesting an important adaptive change of adiponectin set point. (J Clin Endocrinol Metab 97: E642-E647, 2012) C1 [Pereira, Rocio I.] Denver Hlth & Hosp Author, Denver, CO 80204 USA. [Pereira, Rocio I.; Erickson, Christopher; Schauer, Irene E.; Bergman, Bryan C.] Univ Colorado, Div Endocrinol Metab & Diabet, Aurora, CO 80045 USA. [Snell-Bergeon, Janet K.; Rewers, Marian; Maahs, David M.] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80045 USA. [Schauer, Irene E.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Pereira, RI (reprint author), Univ Colorado, Div Endocrinol, Anschutz Med Campus,MS 8106, Aurora, CO 80045 USA. EM rocio.pereira@ucdenver.edu OI Bergman, Bryan/0000-0002-9561-1052 FU National Institutes of Health [M01 RR000051]; National Institutes of Health, National Heart, Lung, and Blood Institute [R01 HL61753, R01 HL079611]; Diabetes Endocrinology Research Center [P30 DK57516]; National Institutes of Health, National Center for Research Resources [K23 RR022238]; American Diabetes Association [1-10-JF-50, DK075360] FX This study was performed at the Clinical Translational Research Center at the University of Colorado Denver, supported by National Institutes of Health Grant M01 RR000051, and at the Barbara Davis Center for Childhood Diabetes (Aurora, CO). Author contributions included the following: R. I. P. researched data and wrote the manuscript. J.K.S.-B. researched data and contributed to discussion and edited the manuscript. C. E. researched data and reviewed the manuscript. I. S. and B. B. researched data and contributed to discussion and reviewed the manuscript. M. R. contributed to discussion and edited the manuscript. D. M. M. researched data and contributed to discussion and reviewed the manuscript. The contents of this manuscript are solely the responsibility of the authors and do not necessarily reflect the views of the National Institutes of Health or other funders.; This work was supported by the National Institutes of Health, National Heart, Lung, and Blood Institute Grants R01 HL61753 and R01 HL079611, and the Diabetes Endocrinology Research Center Clinical Investigation Core Grant P30 DK57516. Additional support was provided by the National Institutes of Health, National Center for Research Resources Grant K23 RR022238 (to R. I. P.), American Diabetes Association Junior Faculty Award 1-10-JF-50 (to J.K.S.-B.), and Grant DK075360 (to D.M.M.). NR 19 TC 32 Z9 32 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2012 VL 97 IS 4 BP E642 EP E647 DI 10.1210/jc.2011-2542 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 925US UT WOS:000302787800019 PM 22278421 ER PT J AU DuPriest, EA Kupfer, P Lin, B Sekiguchi, K Purnell, JQ Saunders, KE Chatkupt, TT Bagby, SP AF DuPriest, E. A. Kupfer, P. Lin, B. Sekiguchi, K. Purnell, J. Q. Saunders, K. E. Chatkupt, T. T. Bagby, S. P. TI Accelerated growth without prepubertal obesity in nutritionally programmed microswine offspring SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Article DE Appetite; catch-up growth; feed intake; linear growth; maternal protein restriction ID AMINO-ACID-CONCENTRATIONS; LOW-BIRTH-WEIGHT; LOW-PROTEIN DIET; ADULT HYPERTENSION; GESTATIONAL-AGE; FETAL; RESTRICTION; PIGS; RAT; LIFE AB Poor fetal growth and associated prepubertal growth acceleration are linked to increased risk of cardiometabolic dysfunction in later life, but whether obesity is integral to 'catch-up' growth and its ensuing risks are unknown. In microswine offspring exposed to perinatal maternal protein restriction (MPR), we measured body and organ sizes (during MPR); linear growth and weight gain (birth to 5 months of age); feed intake and utilization efficiency (5-14 weeks); and body composition at 6 and 11 weeks of age (by dual-energy X-ray absorptiometry, DEXA). During MPR, low protein offspring (LPO) showed asymmetric growth restriction with reduced body weight (Wt):length (Lth) at birth and elevated heart Wt: liver Wt ratio by 2 weeks of age. In LPO, after slow early postnatal growth (0-5 weeks), subsequent linear growth on ad libitum normal feed was absolutely accelerated (cm/week; P < 0.001) over 6-11 weeks but normal thereafter, whereas absolute weight gain (kg/week) was similar to controls but accelerated relative to lower LPO nadir weights. Concurrently, rates of fat and lean tissue accrual in LPO over 6-11 weeks were similar to normal protein offspring in absolute terms (g/5 weeks) but increased relative to lower mass at 6 weeks, yielding normal lean: Lth but reduced fat: Lth ratios at 11 weeks. LPO had higher relative feed intake (g/kg/meal) in both sexes and higher feed efficiency in females over 5-11 weeks of age. Findings suggest that postnatal linear growth acceleration preserved thinness in juvenile LPO. Given separately reported abnormalities of vascular (Bagby et al., 2011) and adipocyte function in juvenile LPO, (DuPriest et al., 2011) findings demonstrate that perinatal MPR programs catch-up growth and cardiovascular abnormalities independently of obesity. C1 [Bagby, S. P.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, Portland, OR 97201 USA. [DuPriest, E. A.; Bagby, S. P.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. [DuPriest, E. A.; Kupfer, P.; Lin, B.; Sekiguchi, K.; Bagby, S. P.] Portland VA Med Ctr, Res Serv, Portland, OR USA. [DuPriest, E. A.] Warner Pacific Coll, Dept Nat Sci & Hlth, Portland, OR USA. [Saunders, K. E.; Chatkupt, T. T.] Oregon Hlth & Sci Univ, Dept Comparat Med, Portland, OR 97201 USA. RP Bagby, SP (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, 3303 SW Bond Ave,CH12R, Portland, OR 97201 USA. EM bagbys@ohsu.edu RI Biguzzi, Felipe/E-4724-2015 FU NIH/NICHD [1P01 HD34430, R01 HD042570]; Medical Research Foundation of Oregon; Eagles Foundation of Spokane, WA, USA; American Heart Association [0415530Z]; Oregon Health & Science University FX Work was supported by NIH/NICHD 1P01 HD34430, R01 HD042570, Medical Research Foundation of Oregon and the Eagles Foundation of Spokane, WA, USA. E.A. DuPriest was supported by American Heart Association Pacific Mountain Affiliate Predoctoral Fellowship Award No. 0415530Z and by the Oregon Health & Science University Tartar Trust Fellowship. NR 39 TC 2 Z9 2 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD APR PY 2012 VL 3 IS 2 BP 92 EP 102 DI 10.1017/S2040174412000037 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 929KQ UT WOS:000303061700004 PM 25101919 ER PT J AU Harrington, AT Hsia, JC Mendez, E Clarridge, JE AF Harrington, Amanda T. Hsia, Jennifer C. Mendez, Eduardo Clarridge, Jill E., III TI A lingual abscess caused by Streptococcus intermedius SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID GLOSSAL ABSCESS; MILLERI GROUP; CONSTELLATUS; ANGINOSUS AB Lingual abscesses are rare. We describe a case in a healthy female with no recent history of trauma. The organism recovered by culture of drainage material collected prior to antibiotic treatment was Streptococcus intermedius, an organism recognized as flora of the oropharynx and associated with abscess formation. The isolate was resistant to clindamycin, which was the antibiotic therapy that the patient received. C1 [Harrington, Amanda T.; Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Dept Pathol & Lab Med, Seattle, WA 98108 USA. [Harrington, Amanda T.; Clarridge, Jill E., III] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Hsia, Jennifer C.; Mendez, Eduardo] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA 98108 USA. [Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. RP Clarridge, JE (reprint author), VA Puget Sound Hlth Care Syst, Dept Pathol & Lab Med, Seattle, WA 98108 USA. EM Jill.clarridge@va.gov FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 12 TC 0 Z9 0 U1 0 U2 0 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD APR PY 2012 VL 61 IS 4 BP 590 EP 592 DI 10.1099/jmm.0.036913-0 PG 3 WC Microbiology SC Microbiology GA 927CJ UT WOS:000302884300020 PM 22116986 ER PT J AU Grudzen, CR Hwang, U Cohen, JA Fischman, M Morrison, S AF Grudzen, Corita R. Hwang, Ula Cohen, Jason A. Fischman, Michael Morrison, Sean TI Characteristics of Emergency Department Patients Who Receive a Palliative Care Consultation SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL-TRIAL; LUNG-CANCER; OF-LIFE; INTERVENTION; MANAGEMENT; VALIDITY; PROJECT; SERVICE; IMPACT AB Background: A large gap exists between the practice of emergency medicine and palliative care. Although hospice and palliative medicine has recently been recognized as a subspecialty of emergency medicine, few palliative care teams routinely interact with emergency providers, and primary palliative care skills among emergency providers are lacking. Objective: To identify the proportion and characteristics of patients who receive a palliative care consultation and arrive via the emergency department (ED). Methods: A descriptive study of adult ED patients from an urban, academic tertiary care hospital who received a palliative care consultation in January 2005 or January 2009. Results: In January 2005, 100 of the 161 consults (62%) arrived via the ED versus 63 of 124 consults (51%) in January 2009 (p = 0.06). Mean days from admission to consultation in January 2005 were six days (standard deviation 11), versus nine days (SD 26) in January 2009 (p = 0.35). Three of the 100 consultations (3%) in January 2005 were initiated in the ED, versus 4 of the 64 (6%) in January 2009. Conclusions: At an urban academic medical center with a well-developed palliative care service, the majority of palliative care consultations were for patients who arrive via the ED. Despite this, only a small minority of consultations originated from emergency providers and consultation was on average initiated days into a patient's hospital stay. C1 [Grudzen, Corita R.; Hwang, Ula] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Grudzen, Corita R.; Hwang, Ula; Morrison, Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hwang, Ula; Morrison, Sean] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Fischman, Michael] St Georges Univ, St Georges, Grenada. RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA. EM corita.grudzen@mssm.edu OI Grudzen, Corita/0000-0003-3039-8497 FU American Cancer Society; National Institute on Aging [K23 AG031218, K24 AG022345]; Patricia Levinson Fund FX Dr. Grudzen was supported by a Mentored Research Scholar Grant from the American Cancer Society, Dr. Hwang by a Mentored Patient-Oriented Career Development Award from the National Institute on Aging (K23 AG031218), Dr. Cohen by a grant from the Patricia Levinson Fund, and Dr. Morrison by a Mid-Career Investigator Award in Patient Oriented Research (K24 AG022345) from the National Institute on Aging. NR 30 TC 17 Z9 17 U1 2 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2012 VL 15 IS 4 BP 396 EP 399 DI 10.1089/jpm.2011.0376 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 926TM UT WOS:000302854700006 PM 22468771 ER PT J AU Schenker, Y Smith, AK Arnold, RM Fernandez, A AF Schenker, Yael Smith, Alexander K. Arnold, Robert M. Fernandez, Alicia TI "Her Husband Doesn't Speak Much English": Conducting a Family Meeting with an Interpreter SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID CARE-UNIT PATIENTS; LANGUAGE BARRIERS; HEALTH-CARE; MEDICAL INTERPRETATION; RESIDENT PHYSICIANS; PALLIATIVE CARE; COMMUNICATION; SATISFACTION; SERVICES; SPANISH AB A growing percentage of critically ill patients and their families in the United States speak limited English. We present the case of a palliative care consult conducted across language barriers to frame a discussion about the use of interpreters for family meetings, including the evidence for using a professional interpreter, the burden experienced by interpreters involved in end-of-life discussions, potential challenges encountered when conducting a family meeting with an interpreter, and recommended best practices for interpreter use in these settings. C1 [Schenker, Yael; Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA 15213 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Fernandez, Alicia] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. RP Schenker, Y (reprint author), Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM schenkery@upmc.edu FU National Palliative Care Research Center; Arnold P. Gold Foundation FX Dr. Schenker was supported by a Junior Faculty Career Development Award from the National Palliative Care Research Center. Dr. Fernandez was supported by an Arnold P. Gold Foundation Professorship. NR 45 TC 2 Z9 2 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2012 VL 15 IS 4 BP 494 EP 498 DI 10.1089/jpm.2011.0169 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 926TM UT WOS:000302854700025 PM 22107068 ER PT J AU Gomes, MM Brawner, BM AF Gomes, Melissa M. Brawner, Bridgette M. TI The mistrust endures: Attitudes and beliefs about participation in biobehavioral research among urban adolescent females and their parents SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Gomes, Melissa M.] Virginia Commonwealth Univ, Richmond, VA USA. [Brawner, Bridgette M.] Univ Penn, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2012 VL 21 IS 4 MA P98 BP 38 EP 38 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 926UE UT WOS:000302856600099 ER PT J AU Liang, MK Subramanian, A Awad, SS AF Liang, Mike K. Subramanian, Anuradha Awad, Samir S. TI Laparoscopic Transcutaneous Closure of Central Defects in Laparoscopic Incisional Hernia Repair SO SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES LA English DT Article DE hernia; incisional hernia; laparoscopic; pseudorecurrence; eventration; diastasis; recurrence; seroma ID PREFASCIAL POLYPROPYLENE MESH; VENTRAL HERNIA; RECURRENCE AB Purpose: The aim of this technical report is to investigate the safety, efficacy, and outcome of transcutaneous closure of central defects (TCCD) for laparoscopic incisional hernia repair (LIHR). Methods: Twenty-two patients with incisional hernias underwent a LIHR-TCCD repair. After clearance of the abdominal wall from adhesions, laparoscopic central closures were performed trans-cutaneously with 0-polypropelene sutures placed every 1 cm of the defect starting at the cranial-most edge of the hernia and ending at the caudal-most edge of the hernia. A standard LIHR was performed with coated polyester mesh placed with at least 6 cm of overlap with mesh on all borders. Transfascial sutures with 0-polypropelene sutures were placed every 4 cm circumferentially, and titanium tacks were used to secure the mesh to the peritoneum every 1cm. Results: The mean age was 52 years and the mean body mass index was 35 kg/m(2). The mean hernia defect was 4.7cm x 7.2 cm with a mean area of 37 cm(2). There were no mortalities and no major peri-operative morbidities. Minor complications included 2 (9%) cases of pneumonia/pneumonitis. There were no clinically significant seromas, no radiographic or clinical eventrations, and no hernia recurrences with a mean follow-up of 21 months. Conclusions: LIHR-TCCD is safe and technically feasible in incisional hernias of width < 10 cm. By closing the central defect, seromas and eventrations can be reduced. C1 [Liang, Mike K.; Subramanian, Anuradha; Awad, Samir S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. RP Liang, MK (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM ml3@bcm.edu RI Liang, Mike/L-8493-2015 OI Liang, Mike/0000-0001-7063-7291 NR 20 TC 10 Z9 12 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1530-4515 J9 SURG LAPARO ENDO PER JI Surg. Laparosc. Endosc. Pct. Tech. PD APR PY 2012 VL 22 IS 2 BP E66 EP E70 DI 10.1097/SLE.0b013e3182471fd2 PG 5 WC Surgery SC Surgery GA 925OW UT WOS:000302771700005 PM 22487642 ER PT J AU Pham, H Robinson-Cohen, C Biggs, ML Ix, JH Mukamal, KJ Fried, LF Kestenbaum, B Siscovick, DS de Boer, IH AF Pham, Hien Robinson-Cohen, Cassianne Biggs, Mary L. Ix, Joachim H. Mukamal, Kenneth J. Fried, Linda F. Kestenbaum, Bryan Siscovick, David S. de Boer, Ian H. TI Chronic Kidney Disease, Insulin Resistance, and Incident Diabetes in Older Adults SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID HOMEOSTASIS MODEL ASSESSMENT; IMPAIRED GLUCOSE-TOLERANCE; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ASYMMETRIC DIMETHYLARGININE; CYSTATIN-C; VITAMIN-D; SECRETION; HEALTH AB Background and objectives Insulin resistance is a complication of advanced CKD. Insulin resistance is less well characterized in earlier stages of CKD. The response of the pancreatic beta cell, effects on glucose tolerance, and risk of diabetes are not clear. Design, setting, participants, & measurements The Cardiovascular Health Study included 4680 adults without baseline diabetes. The Chronic Kidney Disease Epidemiology Collaboration creatinine equation was used to obtain the estimated GFR (eGFR). Insulin resistance was evaluated as fasting insulin concentration. The insulin sensitivity index, beta cell function, and glucose tolerance were assessed by oral glucose tolerance testing. Incident diabetes was defined as fasting glucose >= 126 mg/dl, nonfasting glucose >= 200 mg/dl, or use of glucose-lowering medications. Results Mean age was 72.5 years (range, 65-98 years). Mean eGFR was 72.2 (SD 17.1) ml/min per 1.73 m(2). After adjustment, each 10 ml/min per 1.73 m(2) lower eGFR was associated with a 2.2% higher fasting insulin concentration (95% confidence interval [CI], 1.4%, 2.9%; P<0.001) and a 1.1% lower insulin sensitivity index (95% Cl, 0.03%, 2.2%; P=0.04). Surprisingly, eGFR was associated with an augmented beta cell function index (P<0.001), lower 2-hour glucose concentration (P=0.002), and decreased risk of glucose intolerance (P=0.006). Over a median 12 years' follow-up, 437 participants (9.3%) developed diabetes. eGFR was not associated with the risk of incident diabetes. Conclusions Among older adults, lower eGFR was associated with insulin resistance. However, with lower eGFR, beta cell function was appropriately augmented and risks of impaired glucose tolerance and incident diabetes were not increased. Clin J Am Soc Nephrol 7: 588-594, 2012. doi: 10.2215/CJN.11861111 C1 [Pham, Hien; Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Pham, Hien; Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Dept Med, Seattle, WA 98195 USA. [Robinson-Cohen, Cassianne; Kestenbaum, Bryan; Siscovick, David S.; de Boer, Ian H.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Biggs, Mary L.] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Mukamal, Kenneth J.] Harvard Univ, Sch Med, Boston, MA USA. [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Fried, Linda F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolytr Div, Pittsburgh, PA USA. [Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med & Epidemiol, Seattle, WA 98195 USA. RP Pham, H (reprint author), Univ Washington, Div Nephrol, 1959 NE Pacific St, Seattle, WA 98195 USA. EM hiena@uw.edu OI Robinson-Cohen, Cassianne/0000-0003-4783-7046 FU National Heart, Lung, and Blood Institute [HL080295, N01-HC-85239, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133]; National Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058]; National Institute of Diabetes and Digestive and Kidney Diseases [DK-087726] FX This research was supported by the National Heart, Lung, and Blood Institute (Grant HL080295 and Contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, and N01-HC-45133), with additional contributions from the National Institute of Neurological Disorders and Stroke. Additional support was provided by the National Institute on Aging (Grants AG-023629, AG-15928, AG-20098, and AG-027058) and the National Institute of Diabetes and Digestive and Kidney Diseases (Grant DK-087726). NR 44 TC 18 Z9 19 U1 1 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2012 VL 7 IS 4 BP 588 EP 594 DI 10.2215/CJN.11861111 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 918WK UT WOS:000302281900011 PM 22383749 ER PT J AU Carter, CE Gansevoort, RT Scheven, L Lambers Heerspink, HJ Shlipak, MG de Jong, PE Ix, JH AF Carter, Caitlin E. Gansevoort, Ronald T. Scheven, Lieneke Lambers Heerspink, Hiddo J. Shlipak, Michael G. de Jong, Paul E. Ix, Joachim H. TI Influence of Urine Creatinine on the Relationship between the Albumin-to-Creatinine Ratio and Cardiovascular Events SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; ABNORMAL DIURNAL RHYTHM; MUSCLE MASS; BLOOD-PRESSURE; ALBUMIN/CREATININE RATIO; NONDIABETIC INDIVIDUALS; EXCRETION; RISK; MICROALBUMINURIA; DISEASE AB Background and objectives In the albumin-to-creatinine ratio (spot-ACR), urine creatinine corrects for tonicity but also reflects muscle mass. Low muscle mass is associated with cardiovascular disease (CVD). We hypothesized that the spot-ACR would be higher in women, lower-weight persons, and older individuals, independent of timed urine albumin excretion (24hr-UAE), and accordingly, that spot-ACR would be more strongly associated with CVD events than 24hr-UAE in these subgroups. Design, setting, participants, & methods 2627 PREVEND (Prevention of Renal and Vascular End-stage Disease) participants with 24hr-UAE <30 mg/d were followed for CVD events for 11 years. Cox regression evaluated associations of spot-ACR and 24hr-UAE with CVD events by sex, weight, and age. Results Female sex (26%), lower weight (2% per 5 kg), and older age (4% per 5 years) were associated with higher spot-ACR independent of 24hr-UAE (P<0.001). Spot urine albumin concentration (hazard ratio [HR], 1.26 per In-SD higher) and 1/spot urine creatinine concentration (HR, 1.16 per In-SD higher) were associated with CVD events. Spot-ACR was more strongly associated with CVD events than either component of the ratio (HR, 1.41 per In-SD higher). Associations of spot-ACR >= 10 mg/g versus less (FIR, 2.33) and 24hr-UAE >= 10 mg/d versus less (HR, 2.09) with CVD events were similar, and there were no significant differences across subgroups (P for interactions >0.06). Conclusions In community-living individuals with 24hr-UAE <30 mg/d, spot-ACR is higher in women, older persons, and lower-weight persons, independent of 24hr-UAE. Low spot urine creatinine is associated with CVD risk, but high urine albumin is a stronger determinant of the association of spot-ACR with CVD than is low urine creatinine. Clin J Am Soc Nephrol 7: 595-603, 2012. doi: 10.2215/CJN.09300911 C1 [Carter, Caitlin E.; Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, San Diego, CA 92161 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Gansevoort, Ronald T.; Scheven, Lieneke; Lambers Heerspink, Hiddo J.; de Jong, Paul E.] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Ctr, San Diego, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, 3350 La Jolla Village Dr,Mail Code 111-H, San Diego, CA 92161 USA. EM joeix@ucsd.edu RI Lambers Heerspink, Hiddo/K-3358-2014 OI Lambers Heerspink, Hiddo/0000-0002-3126-3730 FU National Heart, Lung, and Blood Institute [T32 HL007261, R01HL096851]; Dutch Kidney Foundation; Veterans Affairs San Diego Healthcare System FX This study was supported by grants T32 HL007261 (C.E.C.) and R01HL096851 (J.H.I.) from the National Heart, Lung, and Blood Institute. The PREVEND Study was made possible by grants from the Dutch Kidney Foundation. Dade Behring (Marburg, Germany) generously supplied equipment (Behring Nephelometer II) and reagents for nephelometric measurement of urinary albumin concentration. This material is the result of work supported with resources of the Veterans Affairs San Diego Healthcare System. NR 36 TC 12 Z9 12 U1 1 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2012 VL 7 IS 4 BP 595 EP 603 DI 10.2215/CJN.09300911 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 918WK UT WOS:000302281900012 PM 22383750 ER PT J AU Kraut, JA Madias, NE AF Kraut, Jeffrey A. Madias, Nicolaos E. TI Differential Diagnosis of Nongap Metabolic Acidosis: Value of a Systematic Approach SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID RENAL TUBULAR-ACIDOSIS; URINE OSMOLAL GAP; SERUM ELECTROLYTE PATTERNS; ANION GAP; BASE DISTURBANCES; AMMONIUM-CHLORIDE; EXCRETION; FAILURE; DISEASE; PCO2 AB Nongap metabolic acidosis is a common form of both acute and chronic metabolic acidosis. Because derangements in renal acid-base regulation are a common cause of nongap metabolic acidosis, studies to evaluate renal acidification often serve as the mainstay of differential diagnosis. However, in many cases, information obtained from the history and physical examination, evaluation of the electrolyte pattern (to determine if a nongap acidosis alone or a combined nongap and high anion gap metabolic acidosis is present), and examination of the serum potassium concentration (to characterize the disorder as hyperkalemic or hypokalemic in nature) is sufficient to make a presumptive diagnosis without more sophisticated studies. If this information proves insufficient, indirect estimates or direct measurement of urinary NH4+ concentration, measurement of urine pH, and assessment of urinary HCO3- excretion can help in establishing the diagnosis. This review summarizes current information concerning the pathophysiology of this electrolyte pattern and the value and limitations of all of the diagnostic studies available. It also provides a systematic and cost-effective approach to the differential diagnosis of nongap metabolic acidosis. Clin J Am Soc Nephrol 7: 671-679, 2012. doi: 10.2215/CJN.09450911 C1 [Kraut, Jeffrey A.] Vet Adm Greater Angeles Healthcare Syst VHAGLA, Med Res Serv, Los Angeles, CA USA. [Madias, Nicolaos E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Madias, Nicolaos E.] St Elizabeths Med Ctr, Div Nephrol, Dept Med, Boston, MA USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA 90095 USA. [Kraut, Jeffrey A.] Vet Adm Greater Los Angeles Healthcare Syst VHAGL, Div Nephrol, Los Angeles, CA USA. RP Kraut, JA (reprint author), VHAGLA Healthcare Syst, Div Nephrol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkraut@ucla.edu FU Veterans Administration FX This work is supported in part by funds from the Veterans Administration. NR 54 TC 6 Z9 6 U1 2 U2 8 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2012 VL 7 IS 4 BP 671 EP 679 DI 10.2215/CJN.09450911 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 918WK UT WOS:000302281900022 PM 22403272 ER PT J AU Shurin, MR Naiditch, H Gutkin, DW Umansky, V Shurin, GV AF Shurin, M. R. Naiditch, H. Gutkin, D. W. Umansky, V. Shurin, G. V. TI ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents SO CURRENT MEDICINAL CHEMISTRY LA English DT Review DE Chemotherapy; chemomodulation; chemoimmunomodulation; immunostimulation; immunosuppression; paclitaxel ID SUPPRESSOR T-CELLS; LOW-DOSE CYCLOPHOSPHAMIDE; ANTIGEN-PROCESSING MACHINERY; ACUTE LYMPHOBLASTIC-LEUKEMIA; ADVANCED BREAST-CANCER; VIRUS-INDUCED LYMPHOMA; HUMAN DENDRITIC CELLS; ADOPTIVE IMMUNOTHERAPY; MEDIATED-IMMUNITY; ANTICANCER DRUGS AB Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain "immunogenic" forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain "danger" signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed. C1 [Shurin, M. R.; Naiditch, H.; Gutkin, D. W.; Shurin, G. V.] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA. [Shurin, M. R.] Univ Pittsburgh, Dept Immunol, Med Ctr, Pittsburgh, PA USA. [Gutkin, D. W.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Umansky, V.] German Canc Res Ctr, Skin Canc Unit, D-6900 Heidelberg, Germany. [Umansky, V.] Univ Hosp Mannheim, Heidelberg, Germany. RP Shurin, MR (reprint author), UPMC, Dept Pathol, 3550 Terrace St,Scaife Hall S735, Pittsburgh, PA 15261 USA. EM shurinmr@upmc.edu FU NIH NCI [RO1 CA154369]; Dr. Mildred Scheel Foundation [108992]; Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer FX This work was supported by the NIH NCI RO1 CA154369 grant (M. R. S.), Dr. Mildred Scheel Foundation for Cancer Research Grant 108992 (V. U.), and the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer (V. U.). NR 135 TC 15 Z9 15 U1 0 U2 9 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 0929-8673 J9 CURR MED CHEM JI Curr. Med. Chem. PD APR PY 2012 VL 19 IS 12 BP 1792 EP 1803 PG 12 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 925VD UT WOS:000302789000007 PM 22414087 ER PT J AU Wilson, LS Pregenzer, M Basu, R Bertenthal, D Torres, J Asgari, M Chren, MM AF Wilson, Leslie S. Pregenzer, Mark Basu, Rituparna Bertenthal, Daniel Torres, Jeanette Asgari, Maryam Chren, Mary-Margaret TI Fee Comparisons of Treatments for Nonmelanoma Skin Cancer in a Private Practice Academic Setting SO DERMATOLOGIC SURGERY LA English DT Article ID BASAL-CELL CARCINOMA; MOHS MICROGRAPHIC SURGERY; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; SURGICAL EXCISION; FOLLOW-UP; FACE; COST; MANAGEMENT; CARE AB OBJECTIVE To compare fees for biopsy, treatment procedure, repair, and 2-month follow-up for nonmelanoma skin cancer (NMSC) treatments: electrodesiccation and curettage (ED&C), excision, and Mohs micrographic surgery (MMS). METHODS A cost comparison of 936 primary NMSCs diagnosed in 1999/2000 at a University affiliated dermatology practice. Clinical data was from medical record review. 2007 Medicare Fee Schedule costs determined fees for surgical care. Pearson chi-square tests, t-tests and analysis of variance compared fee differences. Linear regression determined independent effects of tumor and treatment characteristics on fees. RESULTS Mean fees/lesion were $463 for ED&C, $1,222 for excision, and $2,085 for MMS (p < .001). For all treatments, primary procedure costs were highest (38%, 45%, and 41%). Total repair fees were higher with MMS ($735) vs excisions ($197). Fees were higher for head and neck tumors (p < .001), H-zone tumors (p < .001), and tumors smaller than 10 mm in diameter (p = .04). Regression models predicted that the treatment fees would be $2,109 for MMS and $1,252 for excision (p < .001). Tumor size greater than 10 mm in diameter (added $128), tumors on the head and neck (added $966), and MMS (added $857 vs excision) were independently related to higher fees (p < .001). CONCLUSION Even after adjusting for risk factors, MMS has higher fees than excision for primary NMSC. Repairs accounted for the majority of this difference. These fee comparisons provide a basis for comparative effectiveness studies of treatments for this common cancer. C1 [Wilson, Leslie S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wilson, Leslie S.] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA. [Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Pregenzer, Mark] Univ Calif Los Angeles, Dept Pharmaceut Serv, Ronald Reagan Med Ctr, Los Angeles, CA USA. [Basu, Rituparna] San Francisco VA Med Ctr, Dept Pharm, San Francisco, CA USA. [Basu, Rituparna] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. [Bertenthal, Daniel; Chren, Mary-Margaret] Vet Adm Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA. [Torres, Jeanette] San Francisco VA Med Ctr, No Calif Inst Res & Educ, Oakland, CA USA. [Asgari, Maryam] Kaiser Permanente No Calif, Dept Dermatol, Oakland, CA USA. RP Wilson, LS (reprint author), 3333 Calif St,Box 0613,Suite 420, San Francisco, CA 94013 USA. EM wilsonl@pharmacy.ucsf.edu RI Asgari, Maryam/O-4947-2016 FU NIAMS NIH HHS [R01 AR054983, K24 AR052667] NR 36 TC 12 Z9 12 U1 2 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1076-0512 J9 DERMATOL SURG JI Dermatol. Surg. PD APR PY 2012 VL 38 IS 4 BP 570 EP 584 DI 10.1111/j.1524-4725.2011.02231.x PG 15 WC Dermatology; Surgery SC Dermatology; Surgery GA 917DH UT WOS:000302152200005 PM 22145798 ER PT J AU Durazzo, TC Meyerhoff, DJ Nixon, SJ AF Durazzo, Timothy C. Meyerhoff, Dieter J. Nixon, Sara Jo TI A comprehensive assessment of neurocognition in middle-aged chronic cigarette smokers SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Cigarette smoking; Cognition; Neurocognition; Assessment; Middle-age ID ANTISOCIAL PERSONALITY-DISORDER; ALCOHOL-DEPENDENT INDIVIDUALS; COGNITIVE DECLINE; FEMALE ALCOHOLICS; SMOKING HISTORY; BRAIN; INTELLIGENCE; EFFICIENCY; NICOTINE; ADULTS AB Background: The majority of studies investigating the neurocognitive consequences of chronic smoking have been conducted with adults 60 years and older. Therefore, the scope of neurocognitive dysfunction associated with chronic cigarette smoking in middle age (i.e., 30-60 age range) has not been fully delineated. Methods: Twenty-seven (44 +/- 9 years of age; 4 females) non-smoking and 30 smoking (49 +/- 8 years of age; 4 females) participants completed a comprehensive neurocognitive battery and measures of fine motor dexterity and postural stability. All participants were free of biomedical or psychiatric conditions that may have influenced neurocognitive and motor function. Results: Smokers performed significantly worse than non-smokers on the following domains: auditory-verbal and visuospatial learning, visuospatial memory, cognitive efficiency, executive skills, general intelligence, processing speed, fine motor dexterity and postural stability. The differences between smokers and non-smokers evidenced moderate to strong effect sizes and were not mediated by age, education, vocational level, estimated verbal intelligence or alcohol consumption. In smokers, a greater number of lifetime years of smoking was related to poorer performance on measures of cognitive efficiency, processing speed and visuospatial skills. Conclusions: Results from this middle-aged cohort replicated previous research and provides novel findings indicating that chronic smoking was associated with inferior performance on measures of general intelligence, visuospatial learning and memory and fine motor dexterity. Research that relates measures of neurobiological function/integrity to neurocognition is needed to better understand the mechanisms contributing to the poorer performance across multiple domains demonstrated by smokers. Published by Elsevier Ireland Ltd. C1 [Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis CIND, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Nixon, Sara Jo] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Nixon, Sara Jo] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu RI Nixon, Sara/L-1369-2014 OI Nixon, Sara/0000-0003-1179-2851 FU National Institute on Drug Abuse [DA24136, DA13677]; National Institute on Alcohol Abuse and Alcoholism [AA10788] FX This material is the result of work supported by the National Institute on Drug Abuse DA24136 to TCD and DA13677 to SJN, the National Institute on Alcohol Abuse and Alcoholism AA10788 to DJM, with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco CA. The sponsors had no role in study design, data collection, analysis and interpretation, manuscript preparation and in the decision to submit the manuscript for publication. NR 63 TC 32 Z9 32 U1 1 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2012 VL 122 IS 1-2 BP 105 EP 111 DI 10.1016/j.drugalcdep.2011.09.019 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 925CW UT WOS:000302739300015 PM 21992872 ER PT J AU Roth, CL Elfers, CT Figlewicz, DP Melhorn, SJ Morton, GJ Hoofnagle, A Yeh, MM Nelson, JE Kowdley, KV AF Roth, Christian L. Elfers, Clinton T. Figlewicz, Dianne P. Melhorn, Susan J. Morton, Gregory J. Hoofnagle, Andrew Yeh, Matthew M. Nelson, James E. Kowdley, Kris V. TI Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation SO HEPATOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; 25-HYDROXYVITAMIN D-3; HYPOVITAMINOSIS-D; OXIDATIVE STRESS; HUMAN MONOCYTES; CHILDREN; ADOLESCENTS; EXPRESSION; MICE AB Childhood obesity is associated with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). Recent studies have found associations between vitamin D deficiency (VDD), insulin resistance (IR), and NAFLD among overweight children. To further explore mechanisms mediating these effects, we fed young (age 25 days) Sprague-Dawley rats with a low-fat diet (LFD) alone or with vitamin D depletion (LFD+VDD). A second group of rats was exposed to a Westernized diet (WD: high-fat/high-fructose corn syrup) that is more typically consumed by overweight children, and was either replete (WD) or deficient in vitamin D (WD+VDD). Liver histology was assessed using the nonalcoholic steatohepatitis (NASH) Clinical Research Network (CRN) scoring system and expression of genes involved in inflammatory pathways were measured in liver and visceral adipose tissue after 10 weeks. In VDD groups, 25-OH-vitamin D levels were reduced to 29% (95% confidence interval [CI]: 23%-36%) compared to controls. WD+VDD animals exhibited significantly greater hepatic steatosis compared to LFD groups. Lobular inflammation as well as NAFLD Activity Score (NAS) were higher in WD+VDD versus the WD group (NAS: WD+VDD 3.2 +/- 0.47 versus WD 1.50 +/- 0.48, P < 0.05). Hepatic messenger RNA (mRNA) levels of Toll-like receptors (TLR)2, TLR4, and TLR9, as well as resistin, interleukins (IL)-1 beta, IL-4, and IL-6 and oxidative stress marker heme oxygenase (HO)-1, were higher in WD+VDD versus WD animals (P < 0.05). Logistic regression analyses showed significant associations between NAS score and liver mRNA levels of TLRs 2, 4, and 9, endotoxin receptor CD14, as well as peroxisome proliferator activated receptor (PPAR)?, and HO-1. Conclusion: VDD exacerbates NAFLD through TLR-activation, possibly by way of endotoxin exposure in a WD rat model. In addition it causes IR, higher hepatic resistin gene expression, and up-regulation of hepatic inflammatory and oxidative stress genes. (HEPATOLOGY 2012) C1 [Roth, Christian L.] Seattle Childrens Hosp, Res Inst, Div Endocrinol, Seattle, WA 98101 USA. [Figlewicz, Dianne P.; Melhorn, Susan J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Morton, Gregory J.; Hoofnagle, Andrew; Yeh, Matthew M.; Kowdley, Kris V.] Univ Washington, Dept Med, Seattle, WA USA. [Nelson, James E.; Kowdley, Kris V.] Benaroya Res Inst, Seattle, WA USA. [Kowdley, Kris V.] Virginia Mason Med Ctr, Inst Digest Dis, Seattle, WA 98101 USA. RP Roth, CL (reprint author), Seattle Childrens Hosp, Res Inst, Div Endocrinol, 1900 9th Ave, Seattle, WA 98101 USA. EM christian.roth@seattlechildrens.org FU Center of Integrative Brain Research, Seattle Children's Research Institute FX Supported by pilot funding from the Center of Integrative Brain Research, Seattle Children's Research Institute, granted (to C.L.R.). NR 47 TC 85 Z9 91 U1 4 U2 31 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2012 VL 55 IS 4 BP 1103 EP 1111 DI 10.1002/hep.24737 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 916AW UT WOS:000302069900013 PM 21994008 ER PT J AU Lamunu, D Chapman, KN Nsubuga, P Muzanyi, G Mulumba, Y Mugerwa, MA Goldberg, S Bozeman, L Engle, M Saukkonen, J Mastranunzio, S Mayanja-Kizza, H Johnson, JL AF Lamunu, D. Chapman, K. N. Nsubuga, P. Muzanyi, G. Mulumba, Y. Mugerwa, M. A. Goldberg, S. Bozeman, L. Engle, M. Saukkonen, J. Mastranunzio, S. Mayanja-Kizza, H. Johnson, J. L. TI Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; non-participation; clinical trial; moxifloxacin; anti-tuberculosis agents ID RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; PARTICIPATION; RECRUITMENT; GUIDELINES; ATTITUDES; SELF AB SETTING: Clinical trials can provide a high standard of patient care and contribute to scientific knowledge; however, only a fraction of the patients screened participate and receive treatment as part of a trial. OBJECTIVE: To explore reasons why patients were not enrolled in an international tuberculosis (TB) treatment trial and to compare experiences among study sites. DESIGN: An analysis of reasons why patients were not enrolled was conducted among patients screened for a TB clinical trial at 26 sites in North and South America, Africa, and Europe. RESULTS: Staff at study sites screened 1119 potential candidates for the trial: 61% (n = 686) were not enrolled due to 1) failure to meet eligibility criteria (n = 405, 59%), 2) site's decision (n = 168, 24%), or 3) candidate's choice (n = 113, 16%). Study staff recorded a total of 144 reasons for why they believed patients chose not to participate, including concerns over research (28%), conflicts with work or school (21%), and lifestyle and family issues (20%). Socio-demographic and geographic factors also influenced participation. CONCLUSION: Increased evaluation of screening outcomes and of specific interventions, such as improved education and communication about trial procedures, may increase the efficiency of screening and enrollment in clinical trials. C1 [Lamunu, D.; Nsubuga, P.; Muzanyi, G.; Mulumba, Y.; Mugerwa, M. A.; Mastranunzio, S.; Mayanja-Kizza, H.; Johnson, J. L.] Uganda CWRU Res Collaborat, Kampala, Uganda. [Chapman, K. N.; Goldberg, S.; Bozeman, L.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Engle, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Engle, M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Saukkonen, J.] Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA. [Mayanja-Kizza, H.] Makerere Univ, Fac Med, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Johnson, J. L.] Case Western Reserve Univ, Sch Med, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA. [Johnson, J. L.] Univ Hosp Case Med Ctr, Cleveland, OH USA. RP Lamunu, D (reprint author), Uganda CWRU Res Collaborat, POB 663, Kampala, Uganda. EM DLamunu@mucwru.or.ug OI Mayanja-Kizza, Harriet/0000-0002-9297-6208 FU Tuberculosis Trials Consortium; United States Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Global Alliance for Tuberculosis Drug Development FX The authors thank the volunteers and site staff who participated in this study, P-J Feng and N Scott for their outstanding statistical and epidemiological support and assistance, W McKenzie for editorial review, and A Vernon for technical and editorial review. This study was supported by the Tuberculosis Trials Consortium and the United States Centers for Disease Control and Prevention.; Tuberculosis Clinical Trials Consortium Study 28 was supported by the Centers for Disease Control and Prevention and the Global Alliance for Tuberculosis Drug Development. MFX and MFX placebo tablets were donated by Bayer Pharmaceuticals. NR 17 TC 4 Z9 4 U1 1 U2 5 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD APR PY 2012 VL 16 IS 4 BP 480 EP 485 DI 10.5588/ijtld.11.0434 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 919OA UT WOS:000302336300011 PM 22640513 ER PT J AU Donde, A Wong, H Frelinger, J Power, K Balmes, JR Arjomandi, M AF Donde, Aneesh Wong, Hofer Frelinger, Jessica Power, Karron Balmes, John R. Arjomandi, Mehrdad TI Effects of Exercise on Systemic Inflammatory, Coagulatory, and Cardiac Autonomic Parameters in an Inhalational Exposure Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HEART-RATE-VARIABILITY; DIESEL-EXHAUST INHALATION; VASCULAR DYSFUNCTION; ULTRAFINE PARTICLES; PHYSICAL-EXERCISE; OZONE; YOUNG; MEN; FIBRINOLYSIS; VENTILATION AB Background: Intermittent moderate-intensity exercise is used in human inhalational exposure studies to increase the effective dose of air pollutants. Objective: To investigate the inflammatory, coagulatory, and autonomic effects of intermittent moderate-intensity exercise. Methods: We measured hemodynamic, electrocardiographic, inflammatory, and coagulatory parameters in peripheral blood of 25 healthy subjects across an exercise protocol that included running on a treadmill or pedaling a cycle ergometer for 30 minutes every hour over 4 hours in a climate-controlled chamber with a target ventilation of 20 L/min/m(2) body surface area. Results: Intermittent moderate-intensity exercise induced a systemic proinflammatory response characterized by increases in leukocyte counts, C-reactive protein, monocyte chemoattractant protein-I, and interleukin-6, but did not change coagulation tendency or heart rate variability. Conclusion: Interpretation of pollutant-induced inflammatory responses in inhalational exposure studies should account for signals and noises caused by exercise, especially when the effect size is small. C1 [Arjomandi, Mehrdad] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Donde, Aneesh; Wong, Hofer; Frelinger, Jessica; Power, Karron; Balmes, John R.; Arjomandi, Mehrdad] Univ Calif San Francisco, Human Exposure Lab, Div Occupat & Environm Med, San Francisco, CA 94121 USA. [Balmes, John R.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Frelinger, Jessica; Arjomandi, Mehrdad] Vet Affairs Med Ctr, Pulm Res Grp, San Francisco, CA 94121 USA. RP Arjomandi, M (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Vet Affairs Med Ctr, Dept Med, Bldg 203,Room 3A-128,Mailstop 111-D,4150 Clement, San Francisco, CA 94121 USA. EM mehrdad.arjomandi@ucsf.edu FU California Air Resources Board; NIH/NHLBI [K23 HL083099]; Northern California Institute for Research and Education; University of California San Francisco Cardiovascular Research Institute FX This study was funded by California Air Resources Board, NIH/NHLBI K23 HL083099, the Northern California Institute for Research and Education, and the University of California San Francisco Cardiovascular Research Institute Faculty Development Funds. NR 35 TC 5 Z9 5 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2012 VL 54 IS 4 BP 466 EP 470 DI 10.1097/JOM.0b013e318246f1d4 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 923AB UT WOS:000302589300013 PM 22418276 ER PT J AU Fick, DM Semla, TP AF Fick, Donna M. Semla, Todd P. TI 2012 American Geriatrics Society Beers Criteria: New Year, New Criteria, New Perspective SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material DE Beers list; Beers criteria; medications; older adults; drugs ID OLDER HOSPITALIZED-PATIENTS C1 [Fick, Donna M.] Penn State Univ, Sch Nursing, University Pk, PA 16802 USA. [Fick, Donna M.] Penn State Univ, Coll Med, Dept Psychiat, University Pk, PA 16802 USA. [Semla, Todd P.] US Dept Vet Affairs, Natl Pharm Benefits Management Serv, Hines, IL USA. RP Fick, DM (reprint author), Care of Campanellu CM, Amer Geriatr Soc, 40 Fulton St,18th Floor, New York, NY 10038 USA. FU NINR NIH HHS [R01 NR011042] NR 4 TC 36 Z9 36 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 IS 4 BP 614 EP 615 DI 10.1111/j.1532-5415.2012.03922.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 923MR UT WOS:000302623900003 PM 22376003 ER PT J AU Fick, D Semla, T Beizer, J Dombrowski, R Brandt, N DuBeau, CE Flanagan, N Hanlon, J Hollmann, P Linnebur, S Nau, D Rehm, B Sandhu, S Steinman, M AF Fick, Donna Semla, Todd Beizer, Judith Dombrowski, Robert Brandt, Nicole DuBeau, Catherine E. Flanagan, Nina Hanlon, Joseph Hollmann, Peter Linnebur, Sunny Nau, David Rehm, Bob Sandhu, Satinderpal Steinman, Michael CA Amer Geriatrics Soc 2012 Beers TI American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Beers list; medications; Beers Criteria; drugs; older adults ID ADVERSE DRUG-REACTIONS; EXPLICIT CRITERIA; CLINICAL-TRIALS; OUTPATIENTS; POPULATION; EVENTS; SCALE; AGE C1 [Amer Geriatrics Soc 2012 Beers] Amer Geriatr Soc, New York, NY USA. [Fick, Donna] Penn State Univ, Sch Nursing, University Pk, PA 16802 USA. [Fick, Donna] Penn State Univ, Coll Med, Dept Psychiat, University Pk, PA 16802 USA. [Semla, Todd] Natl Pharm Benefits Management Serv, US Dept Vet Affairs, Chicago, IL USA. [Semla, Todd] Northwestern Univ, Chicago, IL 60611 USA. [Beizer, Judith] St Johns Univ, New York, NY USA. [Brandt, Nicole] Univ Maryland, Baltimore, MD 21201 USA. [Dombrowski, Robert] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [DuBeau, Catherine E.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Flanagan, Nina] Binghamton Univ, Dunmore, PA USA. [Hanlon, Joseph] Univ Pittsburgh, Sch Med, Dept Med Geriatr Med, Pittsburgh, PA USA. [Hanlon, Joseph] Vet Adm Hlth Syst, Geriatr Educ & Res & Clin Ctr, Pittsburgh, PA USA. [Hollmann, Peter] Blue Cross Blue Shield Rhode Isl, Cranston, RI USA. [Linnebur, Sunny] Univ Colorado, Sch Pharm & Pharmaceut Sci, Aurora, CO USA. [Nau, David] Pharm Qual Alliance Inc, Baltimore, MD USA. [Rehm, Bob] Natl Comm Qual Assurance, Washington, DC USA. [Sandhu, Satinderpal] MetroHlth Med Ctr, Cleveland, OH USA. [Sandhu, Satinderpal] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Steinman, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. RP Fick, D (reprint author), Care of Campanelli CM, Amer Geriatr Soc, 40 Fulton St,18th Floor, New York, NY 10038 USA. FU John A. Hartford Foundation; Talyst; Econometrics; Health Resources and Services Administration; State of Maryland Office of Health Care Quality; National Institute of Health (NIH) for National Institute of Nursing Research [R01 NR011042, R01NR012242]; National Institute on Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [R01 HS017695, R01HS018721] FX Sue Radcliff, Independent Researcher, Denver, Colorado, provided research services. Susan E. Aiello, DVM, ELS, provided editorial services. Christine Campanelli and Elvy Ickowicz, MPH, provided additional research and administrative support. The development of this paper was supported in part by an unrestricted grant from the John A. Hartford Foundation.; Drs. Dombrowski, Flanagan, Hanlon, Hollmann, Rehm, Sandhu, and Steinman indicated no conflicts of interest. Dr. Beizer is an author and editor for LexiComp, Inc. She is on the Pharmacy and Therapeutics Committee for Part D at Medco Health Solutions. Dr. Brandt is on the Pharmacy and Therapeutics Committees at Omnicare and receives grants from Talyst (research grant), Econometrics (research grant), Health Resources and Services Administration (educational grant), and the State of Maryland Office of Health Care Quality (educational grant). Dr. Dubeau serves as a consultant for Pfizer, Inc. (urinary incontinence) and the New England Research Institute (nocturia). Dr. Fick is partially supported by the National Institute of Health (NIH) for National Institute of Nursing Research grants R01 NR011042 and R01NR012242. Dr. Hanlon is supported in part by National Institute on Aging grants and contracts (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056), a National Institute of Nursing Research grant (R01 NR010135), and Agency for Healthcare Research and Quality grants (R01 HS017695, R01HS018721). Dr. Linnebur receives an honorarium for serving as a member of the Pharmacy and Therapeutics NR 35 TC 443 Z9 473 U1 5 U2 47 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 IS 4 BP 616 EP 631 DI 10.1111/j.1532-5415.2012.03923.x PG 16 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 923MR UT WOS:000302623900004 ER PT J AU Thorpe, CT Thorpe, JM Kind, AJH Bartels, CM Everett, CM Smith, MA AF Thorpe, Carolyn T. Thorpe, Joshua M. Kind, Amy J. H. Bartels, Christie M. Everett, Christine M. Smith, Maureen A. TI Receipt of Monitoring of Diabetes Mellitus in Older Adults with Comorbid Dementia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE diabetes mellitus; dementia; guideline adherence; care quality; Medicare ID MEDICARE CLAIMS DATA; ALZHEIMERS-DISEASE; UNITED-STATES; CARE; RISK; VALIDATION; IMPACT; PREVALENCE; ACCURACY; INDEX AB OBJECTIVES: To examine the extent to which receipt of recommended monitoring of diabetes mellitus (DM) differed for participants with and without comorbid dementia, as well as the effect of other comorbidities on monitoring of DM in individuals with comorbid dementia. DESIGN: Retrospective cohort study. SETTING: Secondary analysis of 2005/2006 claims and enrollment data for a 5% national random sample of Medicare beneficiaries. PARTICIPANTS: Two hundred eighty-eight thousand eight hundred five Medicare fee-for-service beneficiaries with a diagnosis of DM before 2006, 44,717 (16%) of whom had evidence of comorbid dementia in claims. MEASUREMENTS: Established algorithms were used to determine whether patients received at least one glycosylated hemoglobin (HbA1c) test, one low-density lipoprotein cholesterol (LDL-C) test, and one annual eye examination in 2006 and to construct variables representing comorbidities common in DM, sociodemographic characteristics, and patterns of healthcare utilization. RESULTS: In unadjusted and fully adjusted models, the presence of dementia reduced the likelihood of receiving HbA1c tests, LDL-C tests, and eye examinations, with effects being smallest for HbA1c tests. The effects of other comorbidities on DM monitoring in participants with dementia varied according to the nature of the comorbidity and the specific test. CONCLUSION: Dementia reduces the likelihood that individuals with DM will receive recommended annual monitoring for DM. More research is needed to understand reasons for lower monitoring in this subgroup and how this affects functioning, adverse events, and quality of life. J Am Geriatr Soc 60:644-651, 2012. C1 [Thorpe, Carolyn T.; Thorpe, Joshua M.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15261 USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Kind, Amy J. H.] Univ Wisconsin, Div Geriatr, Sch Med & Publ Hlth, Madison, WI USA. [Bartels, Christie M.] Univ Wisconsin, Rheumatol Sect, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Everett, Christine M.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Everett, Christine M.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Kind, Amy J. H.] William S Middleton Hosp, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Thorpe, CT (reprint author), Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, 919 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA. EM ctthorpe@pitt.edu RI Thorpe, Joshua/C-1188-2013 FU Health Innovation Program; University of Wisconsin Institute for Clinical and Translational Research; National Center for Research Resources, National Institutes of Health [1UL1RR025011]; University of Wisconsin School of Medicine and Public Health FX Support was provided by the Health Innovation Program and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research, Grant 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health. Additional funding for this project was provided by the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program. NR 36 TC 14 Z9 14 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 IS 4 BP 644 EP 651 DI 10.1111/j.1532-5415.2012.03907.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 923MR UT WOS:000302623900007 PM 22428535 ER PT J AU Espinoza, SE Jung, I Hazuda, H AF Espinoza, Sara E. Jung, Inkyung Hazuda, Helen TI Frailty Transitions in the San Antonio Longitudinal Study of Aging SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE frailty; older adults; transitions ID OLDER MEXICAN-AMERICANS; CARDIOVASCULAR HEALTH; WOMENS HEALTH; ADULTS; EXERCISE; OBESITY; INFLAMMATION; MORTALITY; PEOPLE AB OBJECTIVES: To examine frailty transitions in Mexican American (MA) and European American (EA) older adults. DESIGN: Longitudinal, observational cohort study. SETTING: Socioeconomically diverse neighborhoods in San Antonio, Texas. PARTICIPANTS: Three hundred twelve MA and 285 EA community-dwelling older adults (>65) with frailty information at baseline (1992-1996) and transition information at follow-up (2000/01) in the San Antonio Longitudinal Study of Aging. MEASUREMENTS: Five frailty characteristics (weight loss, exhaustion, weakness, slowness, and low physical activity), frailty score (0-5), and overall frailty state (nonfrail = 0 characteristics, prefrail = 1 or 2, frail = >= 3) were assessed at baseline. Transitions (progressed, regressed, or no change) were assessed for frailty score and state. Odds ratios (ORs) of progression and regression in individual characteristics were estimated using generalized estimating equations adjusted for age, sex, ethnic group, socioeconomic status, comorbidity, diabetes, and follow-up interval. RESULTS: Diabetes mellitus with macrovascular complications (OR = 1.84, 95% confidence interval (CI) = 1.02-3.33), fewer years of education (OR = 0.96, 95% CI = 0.93-1.0) and follow-up interval (OR = 1.3, 95% CI = 1.17-1.46) were significant predictors of progression in any frailty characteristic. Mortality increased with greater frailty state, and prefrail individuals were more likely than frail individuals to regress. CONCLUSION: Diabetes mellitus with macrovascular complications and fewer years of education are important predictors of progression in any frailty characteristic. Because of greater risk of death than for the nonfrail state and greater likelihood of regression than for the frail state, the prefrail state may be an optimal target for intervention. J Am Geriatr Soc 60:652-660, 2012. C1 [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Hazuda, Helen] Univ Texas Hlth Sci Ctr San Antonio, Vet Res Disseminat & Implementat Ctr, S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Hazuda, Helen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Hazuda, Helen] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Jung, Inkyung] Yonsei Univ, Coll Med, Dept Biostat, Seoul, South Korea. RP Espinoza, SE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Med, 7703 Floyd Curl Dr,Mail Code 7875, San Antonio, TX 78229 USA. EM espinozas2@uthscsa.edu FU National Institute on Aging [R01-AG10444, R01-AG16518]; National Center for Research Resources (NCRR) [M01-RR01345]; Harold Amos Medical Faculty Development Program; Robert Wood Johnson Foundation; NCRR [KL2 RR025766] FX This research was supported by National Institute on Aging Grants R01-AG10444 and R01-AG16518 and National Center for Research Resources (NCRR) Grant M01-RR01345. This work was also supported by The Harold Amos Medical Faculty Development Program with the Robert Wood Johnson Foundation and Clinical Translational Science Award KL2 RR025766 from NCRR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCRR of the National Institutes of Health. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U. S. government. This material is the result of work supported with resources and the use of facilities at the Audie Murphy Veterans Affairs Medical Center, San Antonio, Texas. The authors gratefully acknowledge Adrienne Boulton for her assistance in writing the computer programs used to construct the criteria for classifying frailty in the SALSA study. NR 32 TC 36 Z9 37 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 IS 4 BP 652 EP 660 DI 10.1111/j.1532-5415.2011.03882.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 923MR UT WOS:000302623900008 PM 22316162 ER PT J AU Huh, JT Weaver, CM Martin, JL Caskey, NH O'Riley, A Kramer, BJ AF Huh, Joung T. Weaver, Christopher M. Martin, Jennifer L. Caskey, Nicholas H. O'Riley, Alisa Kramer, Betty Josea TI Effects of a Late-Life Suicide Risk-Assessment Training on Multidisciplinary Healthcare Providers SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE late-life suicide; suicide prevention training; multidisciplinary education ID COMPLETED SUICIDE; OLDER PATIENTS; AGE; IDEATION; ADULTS AB Older adults are among the highest at risk for completing suicide, and they are more likely to seek mental health services from providers outside of traditional mental health care, but providers across the spectrum of care have limited training in suicide risk assessment and management and particularly lack training in suicide prevention for older adults. An educational program was developed to increase awareness and improve suicide risk assessment and management training for a range of healthcare providers who may see older adults in their care settings. One hundred thirty-two participants from two Veterans Affairs Medical Centers participated in a 6.5-hour-long workshop in the assessment and management of suicide risk in older adults. Participants were asked to complete pre- and postworkshop case notes and report on subjective changes in knowledge, attitudes, and confidence in assessment and managing suicide risk in older adults. Participants included social workers, nurses, physicians, psychologists, and occupational therapists from a variety of care settings, including outpatient and inpatient medical, outpatient and inpatient mental health, specialty clinics, home, and community. After the workshop, participants demonstrated improvement in the overall quality of case notes (P = .001), greater ability to recognize important conceptual suicide risk categories (P = .003), and reported heightened awareness of the importance of late-life suicide. The results suggest that educational training may have beneficial effect on the ability of multidisciplinary care providers to identify and manage suicide risk in elderly adults. J Am Geriatr Soc 60:775-780, 2012. C1 [Huh, Joung T.] Palo Alto Univ, Geriatr Res Educ & Clin Ctr, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Weaver, Christopher M.] Palo Alto Univ, Dept Psychol, Palo Alto, CA 94304 USA. [Martin, Jennifer L.; Caskey, Nicholas H.; Kramer, Betty Josea] Vet Affairs Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Martin, Jennifer L.; Kramer, Betty Josea] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA 90095 USA. [Caskey, Nicholas H.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. [O'Riley, Alisa] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA. RP Huh, JT (reprint author), Palo Alto Univ, Geriatr Res Educ & Clin Ctr, Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave,182B, Palo Alto, CA 94304 USA. EM terri.huh@va.gov FU VA Palo Alto Health Care System; VA Greater Los Angeles Health Care System; National Institutes of Health, National Institute on Aging [K23 AG028452] FX This material is the result of work supported with resources and facilities at the VA Palo Alto Health Care System, the VA Greater Los Angeles Health Care System, and by National Institutes of Health, National Institute on Aging Grant K23 AG028452 (Martin). NR 16 TC 7 Z9 7 U1 0 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 IS 4 BP 775 EP 780 DI 10.1111/j.1532-5415.2011.03843.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 923MR UT WOS:000302623900025 PM 22288717 ER PT J AU De La Garza, BH Muir, ER Shih, YYI Duong, TQ AF De La Garza, Bryan H. Muir, Eric R. Shih, Yen-Yu I. Duong, Timothy Q. TI 3D magnetic resonance microscopy of the ex vivo retina SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE ultra high-resolution MRI; high field; MRI contrast agents; T1 and T2 contrast; manganese; MEMRI; photoreceptors ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW; FUNCTIONAL MRI; RAT RETINA; MOUSE; RESOLUTION; DEGENERATION; QUANTIFICATION; LAYERS; BRAIN AB 3D-MR microscopy at 11.7T and 20 x 20 x 57 mu m resolution was performed on formalin-fixed rat eyes with: (I) no contrast agent and (II) Gadodiamide (Omniscan (R)) added to the fixative. Group I data showed generally poor contrast among layers. Group II data showed markedly better lamina-specific contrast with the nerve fiber + ganglion cell layer and inner nuclear layer being hypointense, and the inner plexiform, outer plexiform, outer nuclear layer, and the segments being hyperintense. The signal-to-noise ratio in group II was higher than group I, consistent with Gadodiamide acting as a T1-contrast agent. All major retinal layers were assigned and their thicknesses quantified with corroboration by histology. MR microscopy allows nondestructive examination of valuable specimens and could have applications in disease and in vivo. Magn Reson Med, 2011. (C) 2011 Wiley Periodicals, Inc. C1 [De La Garza, Bryan H.; Muir, Eric R.; Shih, Yen-Yu I.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Div Res, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008; Muir, Eric/H-8830-2013 OI Shih, Yen-Yu Ian/0000-0001-6529-911X FU NIH/NEI [R01 EY014211, EY018855, R01EY09702]; Department of Veterans Affairs FX Grant sponsor: NIH/NEI; Grant numbers: R01 EY014211, EY018855, and R01EY09702; Grant sponsor: MERIT Award from the Department of Veterans Affairs. NR 24 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0740-3194 J9 MAGN RESON MED JI Magn. Reson. Med. PD APR PY 2012 VL 67 IS 4 BP 1154 EP 1158 DI 10.1002/mrm.23082 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 909AF UT WOS:000301533500031 PM 22009721 ER PT J AU Morley, JF Xie, SX Hurtig, HI Stern, MB Colcher, A Horn, S Dahodwala, N Duda, JE Weintraub, D Chen-Plotkin, AS Van Deerlin, V Falcone, D Siderowf, A AF Morley, James F. Xie, Sharon X. Hurtig, Howard I. Stern, Matthew B. Colcher, Amy Horn, Stacy Dahodwala, Nabila Duda, John E. Weintraub, Daniel Chen-Plotkin, Alice S. Van Deerlin, Vivianna Falcone, Dana Siderowf, Andrew TI Genetic influences on cognitive decline in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE genetics; Parkinson's disease; cognitive symptoms; apolipoprotein E; microtubule-associated protein tau ID DEMENTIA RATING-SCALE; APOLIPOPROTEIN-E; ALPHA-SYNUCLEIN; RISK; APOE; ALLELE; TAU; ONSET; SUSCEPTIBILITY; ASSOCIATION AB The role of genetic factors in cognitive decline associated with Parkinson's disease (PD) is unclear. We examined whether variations in apolipoprotein E (APOE), microtubule-associated protein tau (MAPT), or catechol-O-methytransferase (COMT) genotypes are associated with cognitive decline in PD. We performed a prospective cohort study of 212 patients with a clinical diagnosis of PD. The primary outcome was change in Mattis Dementia Rating Scale version 2 score. Linear mixed-effects models and survival analysis were used to test for associations between genotypes and change in cognitive function over time. The e4 allele of APOE was associated with more rapid decline (loss of 2.9; 95% confidence interval [CI]: 1.74.1) of more points per year; P < 0.001) in total score and an increased risk of a =10 point drop during the follow-up period (hazard ratio, 2.8; 95% CI: 1.45.4; P = 0.003). MAPT haplotype and COMT genotype were associated with measures of memory and attention, respectively, over the entire follow-up period, but not with the overall rate of cognitive decline. These results confirm and extend previously described genetic associations with cognitive decline in PD and imply that individual genes may exert effects on specific cognitive domains or at different disease stages. Carrying at least one APOE e4 allele is associated with more rapid cognitive decline in PD, supporting the idea of a component of shared etiology between PD dementia and Alzheimer's disease. Clinically, these results suggest that genotyping can provide information about the risk of future cognitive decline for PD patients. (C) 2012 Movement Disorder Society C1 [Morley, James F.; Hurtig, Howard I.; Stern, Matthew B.; Colcher, Amy; Horn, Stacy; Dahodwala, Nabila; Duda, John E.; Chen-Plotkin, Alice S.; Siderowf, Andrew] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. [Xie, Sharon X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19107 USA. [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19107 USA. [Van Deerlin, Vivianna; Falcone, Dana] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19107 USA. [Xie, Sharon X.; Hurtig, Howard I.; Stern, Matthew B.; Colcher, Amy; Horn, Stacy; Duda, John E.; Weintraub, Daniel; Chen-Plotkin, Alice S.; Van Deerlin, Vivianna; Falcone, Dana; Siderowf, Andrew] Univ Penn, Sch Med, Morris K Udall Ctr Excellence Parkinsons Dis Res, Philadelphia, PA 19107 USA. [Morley, James F.; Duda, John E.; Weintraub, Daniel] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. RP Siderowf, A (reprint author), Univ Penn, Sch Med, Dept Neurol, 330 S 9th St,2nd Floor, Philadelphia, PA 19107 USA. EM andrew.siderowf@uphs.upenn.edu FU Morris K. Udall Parkinson's Disease Research Center of Excellence; National Institute for Neurological Disorders and Stroke [NS-053488]; Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement [SAP4100027296] FX This work was supported by a Morris K. Udall Parkinson's Disease Research Center of Excellence grant from the National Institute for Neurological Disorders and Stroke (NS-053488) and by SAP4100027296, a health research grant awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77. NR 43 TC 42 Z9 43 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2012 VL 27 IS 4 BP 512 EP 518 DI 10.1002/mds.24946 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 921HP UT WOS:000302469000050 PM 22344634 ER PT J AU Walker, RH Schulz, VP Tikhonova, IR Mahajan, MC Mane, S Muniz, MA Gallagher, PG AF Walker, Ruth H. Schulz, Vincent P. Tikhonova, Irina R. Mahajan, Milind C. Mane, Shrikant Muniz, Maritza Arroyo Gallagher, Patrick G. TI Genetic diagnosis of neuroacanthocytosis disorders using exome sequencing SO MOVEMENT DISORDERS LA English DT Article DE exome sequencing; neuroacanthocytosis; chorea; chorea-acanthocytosis ID CHOREA-ACANTHOCYTOSIS; PERSONALIZED MEDICINE; MUTATION; DISCOVERY; FRAMEWORK; ALIGNMENT; ACCURATE; DISEASE; PATIENT; PROTEIN AB Neuroacanthocytoses are neurodegenerative disorders marked by phenotypic and genetic heterogeneity. There are several associated genetic loci, and many defects, including gene deletions and insertions, and missense, nonsense, and splicing mutations, have been found spread over hundreds of kilobases of genomic DNA. In some cases, specific diagnosis is unclear, particularly in the early stages of disease or when there is an atypical presentation. Determination of the precise genetic defect allows assignment of the diagnosis and permits carrier detection and genetic counseling. The objective of this report was to utilize exome sequencing for genetic diagnosis in the neuroacanthocytosis syndromes. Genomic DNA from 2 patients with clinical features of chorea-acanthocytosis was subjected to targeted exon capture. Captured DNA was subjected to ultrahigh throughput next-generation sequencing. Sequencing data were assembled, filtered against known human variant genetic databases, and results were analyzed. Both patients were compound heterozygotes for mutations in the VPS13A gene, the gene associated with chorea-acanthocytosis. Patient 1 had a 4-bp deletion that removes the 5' donor splice site of exon 58 and a nucleotide substitution that disrupts the 5' donor splice site of exon 70. Patient 2 had a dinucleotide deletion in exon 16 and a dinucleotide insertion in exon 33. No mutations were identified in the XK, PANK2, or JPH3 gene loci. Exome sequencing is a valuable diagnostic tool in the neuroacanthocytosis syndromes. These studies may provide a better understanding of the function of the associated proteins and provide insight into the pathogenesis of these disorders. (c) 2011 Movement Disorder Society C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Schulz, Vincent P.; Gallagher, Patrick G.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. [Tikhonova, Irina R.; Mahajan, Milind C.; Mane, Shrikant; Gallagher, Patrick G.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Tikhonova, Irina R.; Mahajan, Milind C.; Mane, Shrikant] Yale Univ, Yale Ctr Genome Anal, Orange, CT USA. [Muniz, Maritza Arroyo] Univ Puerto Rico, Dept Med, Neurol Sect, San Juan, PR 00936 USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, 130 W Kingsbridge Rd,127, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu OI Schulz, Vincent/0000-0001-6333-4284 NR 32 TC 10 Z9 10 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2012 VL 27 IS 4 BP 539 EP 543 DI 10.1002/mds.24020 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 921HP UT WOS:000302469000054 PM 22038564 ER PT J AU Jin, YM Ratnam, K Chuang, PY Fan, Y Zhong, YF Dai, Y Mazloom, AR Chen, EY D'Agati, V Xiong, HB Ross, MJ Chen, N Ma'ayan, A He, JC AF Jin, Yuanmeng Ratnam, Krishna Chuang, Peter Y. Fan, Ying Zhong, Yifei Dai, Yan Mazloom, Amin R. Chen, Edward Y. D'Agati, Vivette Xiong, Huabao Ross, Michael J. Chen, Nan Ma'ayan, Avi He, John Cijiang TI A systems approach identifies HIPK2 as a key regulator of kidney fibrosis SO NATURE MEDICINE LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; HIV-ASSOCIATED NEPHROPATHY; RENAL INTERSTITIAL FIBROSIS; DNA-DAMAGE RESPONSE; TGF-BETA; URETERAL OBSTRUCTION; N-ACETYLCYSTEINE; APOPTOSIS; MICE; TRANSCRIPTION AB Kidney fibrosis is a common process that leads to the progression of various types of kidney disease. We used an integrated computational and experimental systems biology approach to identify protein kinases that regulate gene expression changes in the kidneys of human immunodeficiency virus (HIV) transgenic mice (Tg26 mice), which have both tubulointerstitial fibrosis and glomerulosclerosis. We identified homeo-domain interacting protein kinase 2 (HIPK2) as a key regulator of kidney fibrosis. HIPK2 was upregulated in the kidneys of Tg26 mice and in those of patients with various kidney diseases. HIV infection increased the protein concentrations of HIPK2 by promoting oxidative stress, which inhibited the seven in absentia homolog 1 (SIAH1)-mediated proteasomal degradation of HIPK2. HIPK2 induced apoptosis and the expression of epithelial-to-mesenchymal transition markers in kidney epithelial cells by activating the p53, transforming growth factor beta (TGF-beta)-SMAD family member 3 (Smad3) and Wnt-Notch pathways. Knockout of HIPK2 improved renal function and attenuated proteinuria and kidney fibrosis in Tg26 mice, as well as in other murine models of kidney fibrosis. We therefore conclude that HIPK2 is a potential target for anti-fibrosis therapy. C1 [Jin, Yuanmeng; Ratnam, Krishna; Chuang, Peter Y.; Fan, Ying; Zhong, Yifei; Dai, Yan; Ross, Michael J.; He, John Cijiang] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA. [Jin, Yuanmeng; Chen, Nan] Jiao Tong Univ Sch Med, Ruijin Hosp, Dept Nephrol, Shanghai, Peoples R China. [Mazloom, Amin R.; Chen, Edward Y.; Ma'ayan, Avi; He, John Cijiang] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA. [Mazloom, Amin R.; Chen, Edward Y.; Ma'ayan, Avi] SBCNY, New York, NY USA. [D'Agati, Vivette] Columbia Univ, Dept Pathol, New York, NY USA. [Xiong, Huabao] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA. [He, John Cijiang] James J Peters Vet Adm Med Ctr, New York, NY USA. RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA. EM avi.maayan@mssm.edu; cijiang.he@mssm.edu FU US National Institutes of Health (NIH) [1R01DK078897]; Veterans Affairs Merit Award; NIH [1R01DK088541, P01-DK-56492, 1RC4DK090860, RC2OD006536, 5P50GM071558, 5K08DK082760]; Chinese 973 fund [2012CB517601] FX The authors acknowledge and thank G.L. Gusella (Mount Sinai School of Medicine, New York) for providing the lentiviral construct, E. Huang (University of California San Francisco) for providing the HIPK2 KO mice, P. Mundel (Massachusetts General Hospital, Boston) for synaptopodin antibody and conditionally immortalized murine podocyte cell line, L. Holzman (University of Pennsylvania, Philadelphia) for nephrin antibody and R.H. Goodman (Oregon Health and Science University, Portland) for WT-HIPK2 and KD-HIPK2 constructs. We also thank R. Iyengar and P. Klotman for critical suggestions on experimental design and for other valuable contributions. J.C.H. is supported by US National Institutes of Health (NIH) grant 1R01DK078897 and a Veterans Affairs Merit Award; J.C.H. and A.M. are supported by NIH 1R01DK088541, NIH P01-DK-56492 and NIH 1RC4DK090860; A.M. is supported by NIH RC2OD006536 and 5P50GM071558; P.Y.C. is supported by NIH 5K08DK082760. N.C. is supported by Chinese 973 fund 2012CB517601. NR 56 TC 52 Z9 53 U1 3 U2 24 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD APR PY 2012 VL 18 IS 4 BP 580 EP 588 DI 10.1038/nm.2685 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 923KI UT WOS:000302617800035 PM 22406746 ER PT J AU Cidav, Z Marcus, SC Mandell, DS AF Cidav, Zuleyha Marcus, Steven C. Mandell, David S. TI Implications of Childhood Autism for Parental Employment and Earnings SO PEDIATRICS LA English DT Article DE autism; developmental disabilities; family impact; economic burden ID HEALTH-CARE UTILIZATION; SPECTRUM DISORDERS; UNITED-STATES; CHILDREN; EXPENDITURES; FAMILIES; COSTS; DISABILITIES; MEDICAID AB OBJECTIVE: To examine changes in parental labor force participation, hours of work, and annual earnings associated with childhood autism spectrum disorders (ASD). METHODS: We used the 2002-2008 Medical Expenditure Panel Survey to examine parental labor market outcomes of children with ASD relative to children with another health limitation and children without health limitations. A logit model was used to estimate parental labor force participation. A tobit model was used to estimate parental hours of work and earnings. RESULTS: On average, mothers of children with ASD earn 35% ($7189) less than the mothers of children with another health limitation and 56% ($14 755) less than the mothers of children with no health limitation. They are 6% less likely to be employed and work 7 hours less per week, on average, than mothers of children with no health limitation. There were no statistically significant differences in fathers' labor market outcomes across 3 groups. On average, children with ASD are 9% less likely to have both parents working. Family earnings of children with ASD are 21% ($10 416) less than those of children with another health limitation and 28% ($17 763) less than those of children with no health limitation. Family weekly hours of work are an average of 5 hours less than those of children with no health limitation. CONCLUSIONS: Families of children with ASD face significant economic burden. Given the substantial health care expenses associated with ASD, the economic impact of having lower income in addition to these expenses is substantial. It is essential to design universal health care and workplace policies that recognize the full impact of autism. Pediatrics 2012;129:617-623 C1 [Cidav, Zuleyha] Univ Penn, Childrens Hosp Philadelphia, Ctr Autism Res, Ctr Mental Hlth Policy & Serv Res,Perelman Sch Me, Philadelphia, PA 19104 USA. [Cidav, Zuleyha; Mandell, David S.] Univ Penn, Perelman Sch Med, Ctr Mental Hlth Policy & Serv Res, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Cidav, Z (reprint author), Univ Penn, Childrens Hosp Philadelphia, Ctr Autism Res, Ctr Mental Hlth Policy & Serv Res,Perelman Sch Me, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM zcidav@upenn.edu RI Mandell, David/H-2730-2012 OI Mandell, David/0000-0001-8240-820X FU National Institute of Mental Health [R01 MH 077000] FX This study is funded by a grant from the National Institute of Mental Health (R01 MH 077000). NR 24 TC 50 Z9 51 U1 3 U2 21 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2012 VL 129 IS 4 BP 617 EP 623 DI 10.1542/peds.2011-2700 PG 7 WC Pediatrics SC Pediatrics GA 922IX UT WOS:000302541700038 PM 22430453 ER PT J AU Smith, DM Damschroder, LJ Kim, SYH Ubel, PA AF Smith, Dylan M. Damschroder, Laura J. Kim, Scott Y. H. Ubel, Peter A. TI What's It Worth? Public Willingness to Pay to Avoid Mental Illnesses Compared With General Medical Illnesses SO PSYCHIATRIC SERVICES LA English DT Article ID HEALTH-SERVICES; CARE; PREFERENCES; DEPRESSION; STIGMA; EXPENDITURE; RESOURCES; KNOWLEDGE; INTERNET; SCALE AB Objective: Allocation of resources for the treatment of mental illness is low relative to the burden imposed by these illnesses. The reason for this discrepancy has not been established. Few studies have directly and systematically compared public evaluations of the importance of treating mental illnesses and general medical illnesses. This study assessed public willingness to pay for treatments of mental health conditions and of general medical conditions to determine whether willingness to pay less for mental health treatments is due to the perception that mental health conditions are less burdensome. Methods: U.S. adults (N=710) in a nationally representative sample were provided with descriptions of two mental and three general medical illnesses. Respondents rated their willingness to pay to avoid each illness and then their perception of the burdensomeness of each illness. Results: Participants rated the two mental illnesses as relatively more burdensome than the general medical illnesses, but the amount they were willing to pay to avoid the mental illnesses was lower. Specifically, participants were willing to pay 40% less to avoid the mental illnesses compared with the general medical conditions, for a comparable benefit in terms of quality of life. Conclusions: Even though respondents recognized that severe mental illnesses can dramatically lower quality of life, they were less willing to pay to avoid such illnesses than they were to pay to cure less burdensome general medical illnesses. (Psychiatric Services 63:319-324, 2012; doi: 10.1176/appi.ps.201000036) C1 [Smith, Dylan M.] SUNY Stony Brook, Dept Prevent Med, Hlth Sci Ctr, Stony Brook, NY 11794 USA. [Damschroder, Laura J.] Hlth Serv Res & Dev Serv, US Dept Vet Affairs, Med Ctr, Ann Arbor, MI USA. [Kim, Scott Y. H.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Kim, Scott Y. H.] Univ Michigan, Sch Med, Ctr Bioeth & Social Sci Med, Ann Arbor, MI USA. [Ubel, Peter A.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA. [Ubel, Peter A.] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27706 USA. RP Smith, DM (reprint author), SUNY Stony Brook, Dept Prevent Med, Hlth Sci Ctr, Level 3 080, Stony Brook, NY 11794 USA. EM dylan.m.smith@stonybrook.edu OI Damschroder, Laura/0000-0002-3657-8459 FU National Institute of Child Health and Development [R01HD040789] FX This research was supported by grant R01HD040789 from the National Institute of Child Health and Development. The authors are grateful for the assistance of the team at Knowledge Networks, especially Mike Dennis, Ph.D., Bill McCready, Ph.D., Vicki Pineau, M.S., and Poom Nukulkij, M.A. NR 32 TC 6 Z9 6 U1 6 U2 40 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2012 VL 63 IS 4 BP 319 EP 324 DI 10.1176/appi.ps.201000036 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 925KN UT WOS:000302760200006 PM 22388473 ER PT J AU Duffy, SA Kilbourne, AM Austin, KL Dalack, GW Woltmann, EM Waxmonsky, J Noonan, D AF Duffy, Sonia A. Kilbourne, Amy M. Austin, Karen L. Dalack, Gregory W. Woltmann, Emily M. Waxmonsky, Jeanette Noonan, Devon TI Risk of Smoking and Receipt of Cessation Services Among Veterans With Mental Disorders SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; CIGARETTE-SMOKING; HEALTH-CARE; AFRICAN-AMERICANS; SCHIZOPHRENIA; PREVALENCE; MOTIVATION; SMOKERS; IMPACT AB Objective: The purpose of this study was to determine rates of smoking and receipt of provider recommendations to quit smoking among patients with mental disorders treated in U.S. Department of Veterans Affairs (VA) treatment settings. Methods: The authors conducted a secondary analysis of the yearly, cross-sectional 2007 Veterans Health Administration Outpatient Survey of Healthcare Experiences of Patients (N=224,193). Logistic regression was used to determine the independent association of mental health diagnosis and the dependent variables of smoking and receipt of provider recommendations to quit smoking. Results: Patients with mental disorders had greater odds of smoking, compared with those without mental disorders (p<.05). Those with various mental disorders reported similar rates of receiving services (more than 60% to 80% reported receiving selected services), compared with those without these disorders, except that those with schizophrenia had more than 30% lower odds of receiving advice to quit smoking from their physicians (p<.05). Moreover, those who had co-occurring posttraumatic stress disorder or substance use disorders had significantly greater odds of reporting that they received advice to quit, recommendations for medications, and physician discussions of quitting methods, compared with those without these disorders (p<.05). Older patients, male patients, members of ethnic minority groups, those who were unmarried, those who were disabled or unemployed, and those living in rural areas had lower odds of receiving selected services (p<.05). Conclusions: The majority of patients with mental disorders served by the VA reported receiving cessation services, yet their smoking rates remained high, and selected groups were at risk for receiving fewer cessation services, suggesting the continued need to disseminate cessation services. (Psychiatric Services 63:325-332, 2012; doi: 10.1176/appi.ps.201100097) C1 [Duffy, Sonia A.; Kilbourne, Amy M.; Austin, Karen L.; Woltmann, Emily M.] US Dept Vet Affairs, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Duffy, Sonia A.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Kilbourne, Amy M.; Dalack, Gregory W.; Noonan, Devon] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Waxmonsky, Jeanette] Univ Colorado, Depress Ctr, Sch Med, Aurora, CO USA. [Waxmonsky, Jeanette] Univ Colorado, Dept Psychiat, Sch Med, Aurora, CO USA. RP Duffy, SA (reprint author), US Dept Vet Affairs, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor Ctr Clin Management Res, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM bump@umich.edu RI Waxmonsky, Jeanette/L-4739-2013 FU U.S. Department of Veterans Affairs (VA); Health Services Research and Development Service [HR 07-115]; National Institute of Mental Health [MH 74509] FX This work was supported by the U.S. Department of Veterans Affairs (VA), Health Services Research and Development Service (HR 07-115) and grant MH 74509 from the National Institute of Mental Health. The authors thank the VA Office of Quality and Performance for providing access to the Survey of Healthcare Experiences of Patients (SHEP) data. The views expressed in this article are those of the authors and do not necessarily represent the views of the VA. NR 60 TC 18 Z9 18 U1 3 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2012 VL 63 IS 4 BP 325 EP 332 DI 10.1176/appi.ps.201100097 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 925KN UT WOS:000302760200007 PM 22337005 ER PT J AU Nath, SB Marcus, SC AF Nath, Sara Bressi Marcus, Steven C. TI Impact of Psychotic Disorders on Discharge Dispositions of Adults 65 or Older After a General Medical Inpatient Stay SO PSYCHIATRIC SERVICES LA English DT Article ID MENTAL-HEALTH-SERVICES; EXCESS MORTALITY; SCHIZOPHRENIA; ILLNESS; CARE; COMORBIDITY; ASSOCIATION; COSTS AB Objective: This study examined the extent to which a psychotic disorder, as well as demographic and clinical characteristics, predicted the discharge disposition of adults aged 65 or older after a hospital stay for a general medical illness. Methods: Data from a nationally representative sample of hospital discharges among persons 65 years of age or older (N=2,334,130) were drawn from the 2007 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project. A series of multivariate logistic regression models were constructed to examine the impact of psychotic disorders and demographic and clinical characteristics on four discharge dispositions-routine discharge, home care, nursing facility, or in-hospital mortality-among patients with or without a psychotic disorder. Results: Patients with a psychotic disorder (N=23,751) were significantly more likely than those without a psychotic disorder (N=2,310,379) to be discharged to home care (OR=1.60) or to a nursing facility (OR=4.49) or to die in the hospital (OR=1.95). Patients with a psychotic disorder were more likely than patients without a psychotic disorder to be discharged to a nursing facility if they were also male (OR=4.96), between 65 and 74 years old (OR=6.05), or admitted from another inpatient facility (OR=6.14) or if their illness was of mild or moderate severity (OR=4.87). Conclusions: The significantly increased likelihood for referral to skilled home care and nursing facilities after hospital discharge among psychotic patients highlights the need for viable and dynamic community-based care options for maintaining the health and well-being of older adults with a psychotic disorder after an acute care event. (Psychiatric Services 63: 333-337, 2012; doi: 10.1176/appi.ps.201100332) C1 [Nath, Sara Bressi] Bryn Mawr Coll, Grad Sch Social Work & Social Res, Bryn Mawr, PA 19010 USA. [Marcus, Steven C.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Nath, SB (reprint author), Bryn Mawr Coll, Grad Sch Social Work & Social Res, 300 Airdale Rd, Bryn Mawr, PA 19010 USA. EM snath@brynmawr.edu FU Ortho-McNeil Janssen FX Dr. Marcus has received grant support from Ortho-McNeil Janssen and has served as a consultant to AstraZeneca. Dr. Bressi Nath reports no competing interests. NR 26 TC 3 Z9 3 U1 3 U2 10 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2012 VL 63 IS 4 BP 333 EP 337 DI 10.1176/appi.ps.201100332 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 925KN UT WOS:000302760200008 PM 22337008 ER PT J AU Godleski, L Darkins, A Peters, J AF Godleski, Linda Darkins, Adam Peters, John TI Outcomes of 98,609 US Department of Veterans Affairs Patients Enrolled in Telemental Health Services, 2006-2010 SO PSYCHIATRIC SERVICES LA English DT Article ID TELEPSYCHIATRY; MANAGEMENT; IMPLEMENTATION; TELEHEALTH; TELEVISION AB Objective: The study assessed clinical outcomes of 98,609 mental health patients before and after enrollment in telemental health services of the U.S. Department of Veterans Affairs between 2006 and 2010. Methods: The study compared number of inpatient psychiatric admissions and days of psychiatric hospitalization among patients who participated in remote clinical videoconferencing during an average period of six months before and after their enrollment in the telemental health services. Results: Between. 2006 and 2010, psychiatric admissions of telemental health patients decreased by an average of 24.2% (annual range 16.3%-38.7%), and the patients' days of hospitalization decreased by an average of 26.6% (annual range 16.5%-43.5%). The number of admissions and the days of hospitalization decreased for both men and women and in 83.3% of the age groups. Conclusions: This four-year study, the first large-scale assessment of telemental health services, found that after initiation of such services, patients' hospitalization utilization decreased by an average of approximately 25%. (Psychiatric Services 63:383-385, 2012; doi: 10.1176/appi.ps.201100206) C1 [Godleski, Linda] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Godleski, Linda] US Dept Vet Affairs, Natl Telemental Hlth Ctr, West Haven, CT 06516 USA. [Darkins, Adam; Peters, John] US Dept Vet Affairs, Off Telehlth Serv, Washington, DC USA. RP Godleski, L (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. EM linda.godles-ki2@va.gov NR 15 TC 39 Z9 39 U1 1 U2 6 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2012 VL 63 IS 4 BP 383 EP 385 DI 10.1176/appi.ps.201100206 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 925KN UT WOS:000302760200017 PM 22476305 ER PT J AU Burgess, DJ Joseph, A van Ryn, M Carnes, M AF Burgess, Diana Jill Joseph, Anne van Ryn, Michelle Carnes, Molly TI Does Stereotype Threat Affect Women in Academic Medicine? SO ACADEMIC MEDICINE LA English DT Article ID TEST-PERFORMANCE; MATH PERFORMANCE; GENDER DISCRIMINATION; AFRICAN-AMERICANS; LEADERSHIP; IDENTITY; SEX; MEN; FACULTY; NEGOTIATIONS AB Multiple complex factors contribute to the slow pace of women's advancement into leadership positions in academic medicine. In this article, the authors propose that stereotype threat-under which individuals who are members of a group characterized by negative stereotypes in a particular domain perform below their actual abilities in that domain when group membership is emphasized-may play an important role in the underrepresentation of women in leadership positions in academic medicine. Research to objectively assess the impact of stereotype threat for women in academic medicine is feasible and necessary to confirm this hypothesis. Still, a number of conditions present in the academic medicine community today have been shown to trigger stereotype threat in other settings, and stereotype threat fits with existing research on gender in academic medicine. In the meantime, academic health centers should implement relatively simple measures supported by experimental evidence from other settings to reduce the risk of stereotype threat, including (1) introducing the concept of stereotype threat to the academic medicine community, (2) engaging all stakeholders, male and female, to promote identity safety by enacting and making faculty aware of policies to monitor potential instances of discrimination, and training faculty to provide performance feedback that is free of gender bias, (3) counteracting the effects of sex segregation at academic health centers by increasing exposure to successful female leaders, (4) reducing gender stereotype priming by avoiding stereotypically male criteria for promotion, grants, and awards, and (5) building leadership efficacy among female physicians and scientists. C1 [Burgess, Diana Jill] Univ Minnesota, Minneapolis VA Med Ctr, CCDOR, Dept Vet Affairs Med Ctr,Sch Med, Minneapolis, MN 55417 USA. [Burgess, Diana Jill] Univ Minnesota, Dept Med, Sch Med, Minneapolis, MN 55417 USA. [Joseph, Anne] Univ Minnesota, Appl Clin Res Program, Sch Med, Minneapolis, MN 55417 USA. [van Ryn, Michelle] Univ Minnesota, Dept Family Med & Community Hlth, Sch Med, Minneapolis, MN 55417 USA. [Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA. [Carnes, Molly] Meriter Hosp, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Sch Med & Publ Hth, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Coll Engn, Madison, WI USA. [Carnes, Molly] Univ Wisconsin, Women Sci & Engn Leadership Inst, Coll Engn, Madison, WI USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Women Vet Hlth Program, Madison, WI USA. RP Burgess, DJ (reprint author), Univ Minnesota, Minneapolis VA Med Ctr, CCDOR, Dept Vet Affairs Med Ctr,Sch Med, 1 Vet Dr,152-2E, Minneapolis, MN 55417 USA. EM Diana.Burgess@va.gov RI Burgess, Diana/A-1946-2016 FU National Institutes of Health [R01 GM088477, DP4 GM096822] FX Dr. Carnes is funded in part by grants from the National Institutes of Health (R01 GM088477 and DP4 GM096822). NR 66 TC 33 Z9 34 U1 1 U2 42 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD APR PY 2012 VL 87 IS 4 BP 506 EP 512 DI 10.1097/ACM.0b013e318248f718 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 917AB UT WOS:000302143200025 PM 22361794 ER PT J AU Majumder, S Caccamo, A Medina, DX Benavides, AD Javors, MA Kraig, E Strong, R Richardson, A Oddo, S AF Majumder, Smita Caccamo, Antonella Medina, David X. Benavides, Adriana D. Javors, Martin A. Kraig, Ellen Strong, Randy Richardson, Arlan Oddo, Salvatore TI Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 ss and enhancing NMDA signaling SO AGING CELL LA English DT Article DE learning and memory; mTOR; NMDA; aging; IL-1 ss; cytokines ID LONG-TERM-MEMORY; PROTEIN-SYNTHESIS; AMYLOID-BETA; SPAN; MTOR; TOR; PATHWAY; LTP; CONSOLIDATION; INTERLEUKIN-1 AB Understanding the factors that contribute to age-related cognitive decline is imperative, particularly as age is the major risk factor for several neurodegenerative disorders. Levels of several cytokines increase in the brain during aging, including IL-1 beta, whose levels positively correlate with cognitive deficits. Previous reports show that reducing the activity of the mammalian target of rapamycin (mTOR) extends lifespan in yeast, nematodes, Drosophila, and mice. It remains to be established, however, whether extending lifespan with rapamycin is accompanied by an improvement in cognitive function. In this study, we show that 18-month-old mice treated with rapamycin starting at 2 months of age perform significantly better on a task measuring spatial learning and memory compared to age-matched mice on the control diet. In contrast, rapamycin does not improve cognition when given to 15-month-old mice with pre-existing, age-dependent learning and memory deficits. We further show that the rapamycin-mediated improvement in learning and memory is associated with a decrease in IL-1 beta levels and an increase in NMDA signaling. This is the first evidence to show that a small molecule known to increase lifespan also ameliorates age-dependent learning and memory deficits. C1 [Majumder, Smita; Caccamo, Antonella; Medina, David X.; Oddo, Salvatore] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Majumder, Smita; Caccamo, Antonella; Medina, David X.; Strong, Randy; Richardson, Arlan; Oddo, Salvatore] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Benavides, Adriana D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Kraig, Ellen; Richardson, Arlan] S Texas Vet Hlth Care Syst, Dept Cellular & Struct Biol, San Antonio, TX USA. [Strong, Randy] S Texas Vet Hlth Care Syst, Dept Pharmacol, San Antonio, TX USA. [Javors, Martin A.] S Texas Vet Hlth Care Syst, Dept Psychiat, San Antonio, TX USA. [Strong, Randy; Richardson, Arlan] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Strong, Randy; Richardson, Arlan] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. RP Oddo, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM oddo@uthscsa.edu FU NIA [K99/R00AG29729-4, R01AG037637, RC2AG036613]; Glenn Foundation FX This work was supported by NIA grant awards: K99/R00AG29729-4 and R01AG037637 (Oddo, Principal Investigator); RC2AG036613 (Richardson, Principal Investigator, Strong and Oddo, Project Co-leaders), and by an award from the Glenn Foundation to S.O. NR 45 TC 74 Z9 79 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD APR PY 2012 VL 11 IS 2 BP 326 EP 335 DI 10.1111/j.1474-9726.2011.00791.x PG 10 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 908WF UT WOS:000301523000018 PM 22212527 ER PT J AU Vijayan, A Palevsky, PM AF Vijayan, Anitha Palevsky, Paul M. TI Dosing of Renal Replacement Therapy in Acute Kidney Injury SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Review DE Acute kidney injury; renal replacement therapy; hemodialysis; hemofiltration; hemodiafiltration; continuous renal replacement therapy ID CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; CONTINUOUS VENOVENOUS HEMOFILTRATION; ULTRAFILTRATION FLOW-RATES; TOTAL-BODY WATER; INTERMITTENT HEMODIALYSIS; SOLUTE CLEARANCES; RANDOMIZED-TRIAL; ACUTE DIALYSIS; UREA REMOVAL AB The impact of the intensity of renal replacement therapy on outcomes in patients with acute kidney injury has been studied intensively during the past decade. In this review, we consider the concept of dose of renal replacement therapy in acute kidney injury and summarize the recent clinical trials addressing this topic. Although several single-center trials suggest that more intensive therapy is associated with improved outcomes, 2 large multicenter randomized trials do not find a benefit with higher doses of therapy. Based on these studies, we provide recommendations for the delivered intensity of renal replacement therapy in acute kidney injury. Am J Kidney Dis. 59(4): 569-576. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Vijayan, Anitha] Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Rm 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 FU Cytopherx Inc; B. Braun; Spectral Diagnostics Inc. FX Financial Disclosure: Dr Vijayan is a consultant for Astute Medical and receives research support from Cytopherx Inc and B. Braun. Dr Palevsky is a consultant for Sanofi-Aventis and Cytopherx Inc and receives research support from Spectral Diagnostics Inc. NR 51 TC 12 Z9 12 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 BP 569 EP 576 DI 10.1053/j.ajkd.2011.11.035 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500328 PM 22244680 ER PT J AU Delos Santos, R Obhrai, J Norman, D Watnick, S AF Delos Santos, Rowena Obhrai, Jagdeep Norman, Douglas Watnick, Suzanne TI CARDIOVASCULAR RISK IN THE KIDNEY TRANSPLANT POPULATION SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Delos Santos, Rowena; Obhrai, Jagdeep; Norman, Douglas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Watnick, Suzanne] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 69 BP A32 EP A32 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500071 ER PT J AU Malhotra, R Hamadeh, Z Acharya, A Ansari, N AF Malhotra, Rakesh Hamadeh, Zaher Acharya, Anjali Ansari, Naheed TI OCCULT RENAL INVOLVEMENT IN POLYARTERITIS NODOSA: THE ROLE OF RENAL ANGIOGRAPHY SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Malhotra, Rakesh] Mt Sinai Sch Med, James J Peters VA Med Ctr, Bronx, NY USA. [Hamadeh, Zaher; Acharya, Anjali; Ansari, Naheed] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 157 BP A54 EP A54 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500159 ER PT J AU Yu, M Young, B Rodriguez, R Himmelfarb, J Kestenbaum, B AF Yu, Margaret Young, Bessie Rodriguez, Rudy Himmelfarb, Jonathan Kestenbaum, Bryan TI A RARE CASE OF CONCURRENT HEREDITARY HYPOPHOSPHATEMIA AND GLOMERULONEPHRITIS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 09-13, 2012 CL Washington, DC SP Natl Kidney Fdn C1 [Yu, Margaret; Young, Bessie; Rodriguez, Rudy; Himmelfarb, Jonathan; Kestenbaum, Bryan] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Kidney Res Inst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2012 VL 59 IS 4 MA 307 BP A91 EP A91 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 916QE UT WOS:000302117500309 ER PT J AU Kutner, NG Johansen, KL Zhang, R Huang, Y Amaral, S AF Kutner, N. G. Johansen, K. L. Zhang, R. Huang, Y. Amaral, S. TI Perspectives on the New Kidney Disease Education Benefit: Early Awareness, Race and Kidney Transplant Access in a USRDS Study SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Access to transplantation; African Americans; kidney transplantation; patient education; United States Renal Data System; waiting list ID STAGE RENAL-DISEASE; PATIENT EDUCATION; DIALYSIS; HEMODIALYSIS AB Education services for Stage-IV chronic kidney disease patients were added in 2010 as a Part B covered benefit under the Medicare Improvements for Patients and Providers Act. Desired outcomes include early pursuit of kidney transplantation by more patients and reduction of racial disparities in access to transplantation. During 20052007, a United States Renal Data System (USRDS) special study surveyed 1123 patients in a national cohort who had recently started dialysis, identified themselves as black or white, and were reported by their physician as potentially eligible transplant candidates. Patients were asked if kidney transplantation had been discussed with them before they initiated renal replacement therapy, and survey responses were linked with subsequent wait listing and transplant events in USRDS registry files. KaplanMeier analyses showed a significant association between early transplant awareness and subsequent wait listing. Adjusted Cox models showed a significant race/early transplant awareness interaction, however, with the impact of early awareness on wait listing much stronger for whites. Ongoing support and education about kidney transplantation for patients after dialysis start could help to build on early education and foster greater quality improvement in patient outcomes. C1 [Kutner, N. G.; Johansen, K. L.; Zhang, R.; Huang, Y.] Emory Univ, Rehabil Qual Life Special Studies Ctr, US Renal Data Syst, Atlanta, GA 30322 USA. [Johansen, K. L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94143 USA. [Johansen, K. L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Amaral, S.] Childrens Hosp Philadelphia, Div Nephrol, Philadelphia, PA 19104 USA. RP Kutner, NG (reprint author), Emory Univ, Rehabil Qual Life Special Studies Ctr, US Renal Data Syst, Atlanta, GA 30322 USA. EM nkutner@emory.edu FU National Institutes of Health [HHSN267200715004C, N01-DK-7-5004] FX This study was supported by National Institutes of Health contract HHSN267200715004C, ADB No. N01-DK-7-5004 (Dr. Kutner). The interpretation and reporting of the data presented here are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. We are grateful for patients' participation in the study and for contributions of the CDS Steering Committee: Glenn M. Chertow, George A. Kaysen, Kirsten L. Johansen and Jordi Goldstein, USRDS Nutrition Special Studies Center; Lawrence Hunsicker, USRDS Economics Special Studies Center; Donna Brogan and Nancy G. Kutner, USRDS Rehabilitation/Quality of Life Special Studies Center; Allan J. Collins, Shu-Cheng Chen and Sarah Pederson, USRDS Coordinating Center; Doug Marsh and Vickie Peters, ESRD Network Coordinating Center; Sondra Frenz, DataBanque Research Services; Lawrence Y. Agodoa and Paul W. Eggers, NIDDK; Pam Frederick and Condict Martak, CMS. NR 22 TC 12 Z9 12 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2012 VL 12 IS 4 BP 1017 EP 1023 DI 10.1111/j.1600-6143.2011.03898.x PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA 915WP UT WOS:000302058600028 PM 22226386 ER PT J AU Cuevas, A O'Brien, K Press, N Poat, J Saha, S AF Cuevas, Adolfo O'Brien, Kerth Press, Nancy Poat, Jennifer Saha, Somnath TI RACE CONCORDANT PATIENT-PROVIDER RELATIONSHIPS IN DIABETES AND HYPERTENSION CARE: VIEWS OF PATIENTS FROM THREE CULTURAL GROUPS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Cuevas, Adolfo; O'Brien, Kerth] Portland State Univ, Portland, OR 97207 USA. [Press, Nancy; Poat, Jennifer; Saha, Somnath] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. EM acuevas@pdx.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S230 EP S230 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400896 ER PT J AU Heckman, C Darlow, S Cohen-Filipic, J Kloss, J Munshi, T Manne, S AF Heckman, Carolyn Darlow, Susan Cohen-Filipic, Jessye Kloss, Jacqueline Munshi, Teja Manne, Sharon TI PSYCHIATRIC SYMPTOMS OF YOUNG ADULT FEMALE INDOOR TANNERS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Heckman, Carolyn; Darlow, Susan; Munshi, Teja] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Cohen-Filipic, Jessye] Portland VA Med Ctr, Portland, OR USA. [Kloss, Jacqueline] Drexel Univ, Philadelphia, PA 19104 USA. [Manne, Sharon] Canc Inst New Jersey, New Brunswick, NJ USA. EM carolyn.heckman@fccc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S160 EP S160 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400621 ER PT J AU Hoerster, KD Jakupcak, M AF Hoerster, Katherine D. Jakupcak, Matthew TI ASSOCIATION BETWEEN MENTAL HEALTH AND PHYSICAL ACTIVITY ENGAGEMENT AMONG IRAQ/AFGHANISTAN WAR VETERANS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hoerster, Katherine D.; Jakupcak, Matthew] VA Puget Sound Healthcare Syst, Seattle Div, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Hoerster, Katherine D.; Jakupcak, Matthew] Univ Washington, Seattle, WA 98195 USA. EM k_hoerster@hotmail.com NR 0 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S42 EP S42 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400160 ER PT J AU Lombardero, A Campbell, DG Harris, KJ Chaney, EF Lanto, AB Rubenstein, LV AF Lombardero, Anayansi Campbell, Duncan G. Harris, Kari J. Chaney, Edmund F. Lanto, Andrew B. Rubenstein, Lisa V. TI PREVALENCE AND CORRELATES OF SMOKING STATUS AMONG PATIENTS WITH DEPRESSION IN VA PRIMARY CARE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Harris, Kari J.] Univ Montana, Sch Publ Hlth Sci, Missoula, MT 59812 USA. [Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Chaney, Edmund F.] Vet Affairs Puget Sound, Hlth Serv Res & Dev, Seattle, WA USA. [Lanto, Andrew B.] Vet Affairs Greater Angeles, Hlth Serv Res & Dev, Los Angeles, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. EM anayansi.lombardero@umontana.ed NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S46 EP S46 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400179 ER PT J AU Lovejoy, TI Dobscha, SK Morasco, BJ AF Lovejoy, Travis I. Dobscha, Steven K. Morasco, Benjamin J. TI CHRONIC PAIN TREATMENT AND MEDICAL UTILIZATION AMONG PATIENTS WITH HEPATITIS C SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lovejoy, Travis I.; Dobscha, Steven K.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. EM travis.lovejoy@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S248 EP S248 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092401049 ER PT J AU Smitherman, AH Clements, KL Thorn, B Ward, LC Kilgo, GR AF Smitherman, Anna H. Clements, Kristi L. Thorn, Beverly Ward, L. Charles Kilgo, Gary R. TI VALIDATION OF A NEW THREE FACTOR MODEL OF CATASTROPHIZING IN A CLINICAL SAMPLE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Smitherman, Anna H.; Thorn, Beverly] Univ Alabama, Tuscaloosa, AL 35487 USA. [Clements, Kristi L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Ward, L. Charles] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. [Kilgo, Gary R.] Kilgo Headache Clin, Tuscaloosa, AL USA. EM ahsmitherman@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S38 EP S38 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400145 ER PT J AU Smitherman, AH Clements, KL Thorn, B Ward, LC AF Smitherman, Anna H. Clements, Kristi L. Thorn, Beverly Ward, L. Charles TI MEASURING CATASTROPHIZING: A NEW LOOK AT COMPONENTS OF THE CONSTRUCT SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Smitherman, Anna H.; Thorn, Beverly] Univ Alabama, Tuscaloosa, AL 35487 USA. [Clements, Kristi L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Ward, L. Charles] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. EM ahsmitherman@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2012 VL 43 SU 1 BP S38 EP S38 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 916HQ UT WOS:000302092400146 ER PT J AU Li, J Hsu, HC Yang, P Wu, Q Li, H Edgington, LE Bogyo, M Kimberly, RP Mountz, JD AF Li, Jun Hsu, Hui-Chen Yang, PingAr Wu, Qi Li, Hao Edgington, Laura E. Bogyo, Matthew Kimberly, Robert P. Mountz, John D. TI Treatment of Arthritis by Macrophage Depletion and Immunomodulation Testing an Apoptosis-Mediated Therapy in a Humanized Death Receptor Mouse Model SO ARTHRITIS AND RHEUMATISM LA English DT Article ID COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING FACTOR; RHEUMATOID-ARTHRITIS; SYNOVIAL FIBROBLASTS; INFLAMMATORY ARTHRITIS; MONOCLONAL-ANTIBODY; ANTI-DR5 ANTIBODY; NECROSIS-FACTOR; T-LYMPHOCYTES; C57BL/6 MICE AB Objective. To determine the therapeutic efficacy and immunomodulatory effect of an anti-human death receptor 5 (DR5) antibody, TRA-8, in eliminating macrophage subsets in a mouse model of type II collagen-induced arthritis (CIA). Methods. A human/mouse-chimeric DR5-transgenic mouse, under the regulation of a mouse 3-kb promoter and a loxP-flanked STOP cassette, was generated and crossed with an ubiquitous Cre (Ubc.Cre) mouse and a lysozyme M-Cre (LysM.Cre)-transgenic mouse to achieve inducible or macrophage-specific expression. Chicken type II collagen was used to induce CIA in mice, which were then treated with an anti-human DR5 antibody, TRA-8. Clinical scores, histopathologic severity, macrophage apoptosis and depletion, and T cell subset development were evaluated. Results. In human/mouse DR5-transgenic Ubc.Cre mice with CIA, transgenic DR5 was most highly expressed on CD11b+ macrophages, with lower expression on CD4+ T cells. In human/mouse DR5-transgenic LysM.Cre mice, transgenic DR5 was restrictively expressed on macrophages. Both in vivo near-infrared imaging of caspase activity and TUNEL staining demonstrated that TRA-8 rapidly induced apoptosis of macrophages in inflamed synovium. Depletion of pathogenic macrophages by TRA-8 led to significantly reduced clinical scores for arthritis; decreased macrophage infiltration, synovial hyperplasia, osteoclast formation, joint destruction, cathepsin activity, and inflammatory cytokine expression in joints; reduced numbers of Th17 cells; and an increased number of Treg cells in draining lymph nodes. Conclusion. The anti-human DR5 antibody TRA-8 was efficacious in reducing the severity of arthritis via targeted depletion of macrophages and immunomodulation. Our data provide preclinical evidence that TRA-8 is a potential novel biologic agent for rheumatoid arthritis therapy. C1 [Mountz, John D.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. [Edgington, Laura E.; Bogyo, Matthew] Stanford Univ, Stanford, CA 94305 USA. RP Mountz, JD (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Suite 307,Shel Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA. EM jdmountz@uab.edu RI Li, Hao/N-7406-2015 OI Li, Hao/0000-0002-2171-8826; Kimberly, Robert/0000-0002-5330-3086; Edgington-Mitchell, Laura/0000-0002-6810-6149 FU Lupus Research Institute; Daiichi Sankyo; Arthritis Foundation; American College of Rheumatology Research and Education Foundation; Alliance for Lupus Research; Department of Veterans Affairs [1I01BX000600-01]; NIH [R01-AI-083705-01A2, 1-R01-EB-005011-06, 1-AI-071110-01A1, ARRA-R01-AI-71110-02S1, P30-AR-048311, P30-AR-046031] FX Supported by grants from the Lupus Research Institute (to Dr. Hsu) and Daiichi Sankyo (to Dr. Mountz). Additional support was provided by the Arthritis Foundation (Postdoc Fellowship Award to Dr. J. Li), the American College of Rheumatology Research and Education Foundation (Within Our Reach grant), the Alliance for Lupus Research (Target Identification in Lupus grant), the Department of Veterans Affairs (Merit Review grant 1I01BX000600-01), and the NIH (grants R01-AI-083705-01A2 to Dr. Hsu, 1-R01-EB-005011-06 to Dr. Bogyo, 1-AI-071110-01A1 and ARRA-R01-AI-71110-02S1 to Dr. Mountz, P30-AR-048311 to the Rheumatic Diseases Core Centers including Analytical Genomics and Transgenics Core, Comprehensive Flow Cytometry Core, and Analytic Imaging and Immunoreagent Core, and P30-AR-046031 to the Center for Metabolic Bone Disease-Histomorphometry and Molecular Analysis Core). NR 48 TC 20 Z9 20 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD APR PY 2012 VL 64 IS 4 BP 1098 EP 1109 DI 10.1002/art.33423 PG 12 WC Rheumatology SC Rheumatology GA 921KC UT WOS:000302475500019 PM 22006294 ER PT J AU Ortiz-Lopez, C Lomonaco, R Orsak, B Finch, J Chang, Z Kochunov, VG Hardies, J Cusi, K AF Ortiz-Lopez, Carolina Lomonaco, Romina Orsak, Beverly Finch, Joan Chang, Zhi Kochunov, Valeria G. Hardies, Jean Cusi, Kenneth TI Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) SO DIABETES CARE LA English DT Article ID INSULIN-RESISTANCE; HEPATIC STEATOSIS; MELLITUS; STEATOHEPATITIS; SECRETION; OBESITY; GLUCOSE; LIPOTOXICITY; PATHOGENESIS; POPULATION AB OBJECTIVE-Prediabetes and type 2 diabetes mellitus (T2DM) are believed to be common and associated with a worse metabolic profile in patients with nonalcoholic fatty liver disease (NAFLD). However, no previous study has systematically screened this population. RESEARCH DESIGN AND METHODS-We studied the prevalence and the metabolic impact of prediabetes and T2DM in 118 patients with NAFLD. The control group comprised 20 subjects without NAFLD matched for age, sex, and adiposity. We measured 1) plasma glucose, insulin, and free fatty acid (FFA) concentration during an oral glucose tolerance test; 2) liver fat by magnetic resonance spectroscopy (MRS); 3) liver and muscle insulin sensitivity (euglycemic insulin clamp with 3-[H-3]glucose); and 4) indexes of insulin resistance (IR) at the level of the liver (HIRi=endogenous glucose production X fasting plasma insulin [FPI]) and adipose tissue (Adipo-IRi=fasting FFA X FPI). RESULTS-Prediabetes and T2DM was present in 85% versus 30% in controls (P < 0.0001), all unaware of having abnormal glucose metabolism. NAFLD patients were IR at the level of the adipose tissue, liver, and muscle (all P < 0.01-0.001). Muscle and liver insulin sensitivity were impaired in patients with NAFLD to a similar degree, whether they had prediabetes or T2DM. Only adipose tissue IR worsened in T2DM and correlated with the severity of muscle (r = 0.34; P < 0.001) and hepatic (r = 0.57; P < 0.0001) IR and steatosis by MRS (r = 0.35; P < 0.0001). CONCLUSIONS-Patients with NAFLD may benefit from early screening for T2DM, because the prevalence of abnormal glucose metabolism is much higher than previously appreciated. Regardless of glucose tolerance status, severe IR is common. In patients with T2DM, adipose tissue IR appears to play a major role in the severity of NAFLD. C1 [Ortiz-Lopez, Carolina; Orsak, Beverly; Chang, Zhi; Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA. [Lomonaco, Romina; Cusi, Kenneth] Univ Florida, Div Endocrinol Diabet & Metab, Gainesville, FL USA. [Finch, Joan; Cusi, Kenneth] Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA. [Kochunov, Valeria G.; Hardies, Jean] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Cusi, Kenneth] Malcolm Randall Vet Adm Med Ctr, Gainesville, FL USA. RP Cusi, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA. EM cusi@uthscsa.edu FU Burroughs Wellcome Fund; American Diabetes Association [1-08-CR-08]; Veterans Affairs Medical Research Fund; National Center for Research Resources [UL 1RR025767] FX This work was supported by the Burroughs Wellcome Fund (K.C.), by the American Diabetes Association (1-08-CR-08; K.C.), by the Veterans Affairs Medical Research Fund, and by Award Number UL 1RR025767 from the National Center for Research Resources. NR 38 TC 67 Z9 72 U1 0 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2012 VL 35 IS 4 BP 873 EP 878 DI 10.2337/dc11-1849 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 914OB UT WOS:000301959600037 PM 22374640 ER PT J AU Lee, CC Bloem, CJ Kasa-Vubu, JZ Liang, LJ AF Lee, C. C. Bloem, C. J. Kasa-Vubu, J. Z. Liang, L. -J. TI Effect of oral phytoestrogen on androgenicity and insulin sensitivity in postmenopausal women SO DIABETES OBESITY & METABOLISM LA English DT Article DE androgenicity insulin sensitivity; phytoestrogen; postmenopausal women; transdermal oestrogen ID RED-CLOVER; ESTROGEN; SOY; ISOFLAVONES; METABOLISM; BINDING; HUMANS; LIPIDS AB Aim: The aim of this study was to determine and compare the effect of treatment with transdermal oestrogen and phytoestrogen on insulin sensitivity and sex hormone-binding globulin (SHBG) levels in healthy postmenopausal women. Methods: Forty-three healthy postmenopausal women aged 68 +/- 7 (mean +/- SD) years who were not receiving hormonal replacement therapy completed a 3 month randomized drug therapy study. The participants were randomized to one of four groups: 0.05 mg or 0.1 mg transdermal oestrogen/ day, or 40 or 80 mg oral phytoestrogen (Promensil)/day insulin sensitivity was indirectly measured using the quantitative insulin sensitivity check index (QUICKI). SHBG, total testosterone, oestradiol, and fasting glucose and insulin levels for calculation of insulin sensitivity were obtained at baseline and at monthly intervals during the 3 months of therapy. Results: In healthy nondiabetic postmenopausal women, the rate of change in QUICKI was significantly different between the red clover based phytoestrogen and transdermal oestrogen groups, so that after three months of therapy, QUICKI with red clover based phytoestrogen therapy was lower than that in the transdermal oestrogen group, p = 0.01. Red clover based phytoestrogen therapy was not associated with any changes in SHBG levels whereas transdermal estrogen therapy significantly increased SHBG levels, p = 0.05. Conclusions: In contrast to transdermal oestrogen therapy, oral phytoestrogen therapy does not decrease androgenicity and is associated with a decrease in insulin sensitivity. These effects are similar to those of raloxifene and consistent with phytoestrogen's selective oestrogen receptor modulator properties. C1 [Lee, C. C.] Ctr Geriatr Res Educ & Clin, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Lee, C. C.; Liang, L. -J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Bloem, C. J.] Univ Michigan, Dept Cardiac Surg, Ann Arbor, MI 48109 USA. [Kasa-Vubu, J. Z.] Univ Michigan Hlth Syst, Dept Pediat, Div Pediat Endocrinol, Ann Arbor, MI USA. RP Lee, CC (reprint author), Ctr Geriatr Res Educ & Clin, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,GRECC 11-G, Los Angeles, CA 90073 USA. EM cathy.c.lee@ucla.edu FU NCRR NIH HHS [RR-00042]; NIA NIH HHS [AG 08808]; NIDDK NIH HHS [P60DK2572] NR 15 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8902 EI 1463-1326 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD APR PY 2012 VL 14 IS 4 BP 315 EP 319 DI 10.1111/j.1463-1326.2011.01532.x PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 903LD UT WOS:000301117100004 PM 22077482 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Focus and relevance in the management of GI bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol Hepatol, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol Hepatol, Portland, OR 97201 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2012 VL 75 IS 4 BP 861 EP 863 DI 10.1016/j.gie.2011.12.006 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 917NZ UT WOS:000302186100023 PM 22325810 ER PT J AU Jiang, B Larson, JC Drapala, PW Perez-Luna, VH Kang-Mieler, JJ Brey, EM AF Jiang, Bin Larson, Jeffery C. Drapala, Pawel W. Perez-Luna, Victor H. Kang-Mieler, Jennifer J. Brey, Eric M. TI Investigation of lysine acrylate containing poly(N-isopropylacrylamide) hydrogels as wound dressings in normal and infected wounds SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS LA English DT Article DE poly(N-isopropylacrylamide); wound dressings; antimicrobial agents; hydrogels; wound infection ID POLYHEXAMETHYLENE BIGUANIDE; CELL-ADHESION; DETACHMENT; ATTACHMENT; DELIVERY; CHITOSAN; COLLAGEN AB The design of materials for cutaneous wound dressings has advanced from passive wound covers to bioactive materials that promote skin regeneration and prevent infection. Crosslinked poly(N-isopropylacrylamide) (PNIPAAm)-based hydrogels have been investigated for a number of biomedical applications. While these materials can be used for drug delivery, limited cell interactions restrict their biological activity. In this article, acryoyl-lysine (A-Lys) was incorporated into poly(ethylene glycol) crosslinked PNIPAAm to enhance biological activity. A-Lys could be incorporated into the hydrogels to improve cellular interaction in vitro, while maintaining swelling properties and thermoresponsive behavior. Polyhexamethylene biguanide, an antimicrobial agent, could be encapsulated and released from the hydrogels and resulted in decreased bacteria counts within 2 hours. Two in vivo animal wound models were used to evaluate the hydrogel wound dressing. First, application of the hydrogels to a rodent cutaneous wound healing model resulted in significant increase in healing rate when compared with controls. Moreover, the hydrogels were also able to decrease bacteria levels in an infected wound model. These results suggest that PNIPAAm hydrogels containing A-Lys are promising wound dressings due to their ability to promote healing and deliver active antimicrobial drugs to inhibit infection. (c) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2012. C1 [Jiang, Bin; Larson, Jeffery C.; Kang-Mieler, Jennifer J.; Brey, Eric M.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Jiang, Bin; Larson, Jeffery C.; Brey, Eric M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Drapala, Pawel W.; Perez-Luna, Victor H.] IIT, Dept Chem & Biol Engn, Chicago, IL 60616 USA. RP Brey, EM (reprint author), IIT, Dept Biomed Engn, Chicago, IL 60616 USA. EM brey@iit.edu OI Jiang, Bin/0000-0003-2390-4312 FU CIS Pharma FX Contract grant sponsors: CIS Pharma NR 24 TC 9 Z9 9 U1 2 U2 33 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1552-4973 J9 J BIOMED MATER RES B JI J. Biomed. Mater. Res. Part B PD APR PY 2012 VL 100B IS 3 BP 668 EP 676 DI 10.1002/jbm.b.31991 PG 9 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 901RE UT WOS:000300983700009 PM 22121043 ER PT J AU Basile, JN Bloch, MJ AF Basile, Jan N. Bloch, Michael J. TI NHANES Data Highlight the Clinical Characteristics of Those With Poorly Controlled Hypertension SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article C1 [Bloch, Michael J.] Univ Nevada, Sch Med, SC & MedSchool Associates N, Reno, NV 89557 USA. [Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Bloch, MJ (reprint author), Univ Nevada, Sch Med, MedSch Associates N, 1500 E 2nd St,Suite 302, Reno, NV 89557 USA. EM mbloch@aol.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD APR PY 2012 VL 14 IS 4 BP 267 EP 268 DI 10.1111/j.1751-7176.2012.00596.x PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 916BV UT WOS:000302072500013 PM 22458751 ER PT J AU Anstead, GM Sutton, DA Graybill, JR AF Anstead, Gregory M. Sutton, Deanna A. Graybill, John R. TI Adiaspiromycosis Causing Respiratory Failure and a Review of Human Infections Due to Emmonsia and Chrysosporium spp. SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PULMONARY ADIASPIROMYCOSIS; DIMORPHIC FUNGUS; CRESCENS; PATIENT; DISEASE; PATHOGEN; ZONATUM; REGION; AGENTS; LUNG AB We report a case of a 27-year-old male who presented with respiratory distress that required mechanical ventilation. Transbronchial biopsy revealed adiaspores of the fungus Emmonsia crescens within granulomata, a condition known as adiaspiromycosis. The patient received amphotericin products and corticosteroids, followed by itraconazole, and made a full recovery. Emmonsia crescens is a saprobe with a wide distribution that is primarily a rodent pathogen. The clinical characteristics of the 20 cases of human pulmonary adiaspiromycosis reported since the last comprehensive case review in 1993 are described here, as well as other infections recently reported for the genus Emmonsia. Pulmonary adiaspiromycosis has been reported primarily in persons without underlying host factors and has a mild to severe course. It remains uncertain if the optimal management of severe pulmonary adiaspiromycosis is supportive or if should consist of antifungal treatment, corticosteroids, or a combination of the latter two. The classification of fungi currently in the genus Emmonsia has undergone considerable revision since their original description, including being grouped with the genus Chrysosporium at one time. Molecular genetics has clearly differentiated the genus Emmonsia from the Chrysosporium species. Nevertheless, there has been a persistent confusion in the literature regarding the clinical presentation of infection with fungi of these two genera; to clarify this matter, the reported cases of invasive Chrysosporium infections were reviewed. Invasive Chrysosporium infections typically occur in impaired hosts and can have a fatal course. Based on limited in vitro susceptibility data for Chrysosporium zonatum, amphotericin B is the most active drug, itraconazole susceptibility is strain-dependent, and fluconazole and 5-fluorocytosine are not active. C1 [Anstead, Gregory M.; Graybill, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Sutton, Deanna A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, Fungus Testing Lab, San Antonio, TX 78229 USA. [Anstead, Gregory M.] S Texas Vet Healthcare Syst, Div Infect Dis, Dept Med, San Antonio, TX USA. RP Anstead, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. EM anstead@uthscsa.edu NR 73 TC 26 Z9 29 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2012 VL 50 IS 4 BP 1346 EP 1354 DI 10.1128/JCM.0226-11 PG 9 WC Microbiology SC Microbiology GA 917CC UT WOS:000302148700034 PM 22259200 ER PT J AU Simpson, TL Moore, SA Luterek, J Varra, AA Hyerle, L Bush, K Mariano, MJ Liu, CF Kivlahan, DR AF Simpson, Tracy L. Moore, Sally A. Luterek, Jane Varra, Alethea A. Hyerle, Lynne Bush, Kristen Mariano, Mary Jean Liu, Chaun-Fen Kivlahan, Daniel R. TI Psychiatric Correlates of Medical Care Costs Among Veterans Receiving Mental Health Care SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE mental health and violence; violence exposure; war ID POSTTRAUMATIC-STRESS-DISORDER; EXTREME STRESS; STRUCTURED INTERVIEW; PHYSICAL HEALTH; TRAUMA EXPOSURE; COMPLEX PTSD; WOMEN; SYMPTOMS; SOMATIZATION; ASSOCIATION AB Research on increased medical care costs associated with posttraumatic sequelae has focused on posttraumatic stress disorder (PTSD). However, the provisional diagnosis of Disorders of Extreme Stress Not Otherwise Specified (DESNOS) encompasses broader trauma-related difficulties and may be uniquely related to medical costs. We investigated whether DESNOS severity was associated with greater nonmental health medical care costs in veterans receiving mental health care. Participants were 106 men and 105 women receiving VA outpatient mental health treatment. A standardized interview assessed DESNOS severity. The dependent variables consisted of primary and specialty medical treatment costs. Sequential zero-inflated negative binomial regression was used to evaluate the variance in medical costs accounted for by DESNOS severity, controlling for PTSD severity and established predisposing, enabling, and need-based health care factors. Contrary to our hypothesis, in fully adjusted models, DESNOS severity independently added a significant amount of variance to lower specialty medical care costs, whereas PTSD did not consistently account for significant variance in medical care costs. Greater DESNOS severity appears to be associated with lower specialty medical care costs but not primary care costs. These findings may indicate that patients with DESNOS symptoms are at risk for being underreferred for specialty care. C1 [Simpson, Tracy L.; Bush, Kristen] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA 98108 USA. [Simpson, Tracy L.; Moore, Sally A.; Luterek, Jane; Varra, Alethea A.; Mariano, Mary Jean; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Liu, Chaun-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Luterek, Jane] VA Puget Sound Hlth Care Syst, Seattle Div, Womens Trauma & Recovery Ctr, Seattle, WA 98108 USA. [Varra, Alethea A.] VA Puget Sound Hlth Care Syst, PTSD Inpatient Program, Seattle, WA 98108 USA. [Liu, Chaun-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Div, Seattle, WA 98108 USA. RP Simpson, TL (reprint author), VA Puget Sound Hlth Care Syst, CESATE, 1660 S Columbian Way,116-WTRC, Seattle, WA 98108 USA. EM Tracy.Simpson@va.gov NR 38 TC 0 Z9 0 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD APR PY 2012 VL 27 IS 6 BP 1005 EP 1022 DI 10.1177/0886260511424496 PG 18 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA 917NY UT WOS:000302186000002 PM 22203617 ER PT J AU So, K Koralek, AC Ganguly, K Gastpar, MC Carmena, JM AF So, Kelvin Koralek, Aaron C. Ganguly, Karunesh Gastpar, Michael C. Carmena, Jose M. TI Assessing functional connectivity of neural ensembles using directed information SO JOURNAL OF NEURAL ENGINEERING LA English DT Article ID GRANGER CAUSALITY; NETWORKS AB Neurons in the brain form highly complex networks through synaptic connections. Traditionally, functional connectivity between neurons has been explored using methods such as correlations, which do not contain any notion of directionality. Recently, an information-theoretic approach based on directed information theory has been proposed as a way to infer the direction of influence. However, it is still unclear whether this new approach provides any additional insight beyond conventional correlation analyses. In this paper, we present a modified procedure for estimating directed information and provide a comparison of results obtained using correlation analyses on both simulated and experimental data. Using physiologically realistic simulations, we demonstrate that directed information can outperform correlation in determining connections between neural spike trains while also providing directionality of the relationship, which cannot be assessed using correlation. Secondly, applying our method to rodent and primate data sets, we demonstrate that directed information can accurately estimate the conduction delay in connections between different brain structures. Moreover, directed information reveals connectivity structures that are not captured by correlations. Hence, directed information provides accurate and novel insights into the functional connectivity of neural ensembles that are applicable to data from neurophysiological studies in awake behaving animals. C1 [So, Kelvin; Ganguly, Karunesh; Gastpar, Michael C.; Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA. [Koralek, Aaron C.; Ganguly, Karunesh; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, San Francisco, CA USA. [Gastpar, Michael C.] Ecole Polytech Fed EPFL, Sch Comp & Commun Sci, Lausanne, Switzerland. [Carmena, Jose M.] Univ Calif Berkeley, UCB UCSF Joint Grad Grp Bioengn, Berkeley, CA 94720 USA. [Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA. RP So, K (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu OI Koralek, Aaron/0000-0001-5205-0171 FU National Science Foundation CDI; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development; American Heart Association/American Stroke Association FX The research reported here was supported by the National Science Foundation CDI Type-I grant to MCG and JMC, and the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development, and the American Heart Association/American Stroke Association to KG. NR 28 TC 13 Z9 13 U1 0 U2 6 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 J9 J NEURAL ENG JI J. Neural Eng. PD APR PY 2012 VL 9 IS 2 AR 026004 DI 10.1088/1741-2560/9/2/026004 PG 13 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA 917AK UT WOS:000302144100004 PM 22328616 ER PT J AU Canolty, RT Cadieu, CF Koepsell, K Ganguly, K Knight, RT Carmena, JM AF Canolty, Ryan T. Cadieu, Charles F. Koepsell, Kilian Ganguly, Karunesh Knight, Robert T. Carmena, Jose M. TI Detecting event-related changes of multivariate phase coupling in dynamic brain networks SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE neuronal oscillations; phase-locking value; functional networks; multivariate analysis ID COHERENCE; MECHANISM AB Canolty RT, Cadieu CF, Koepsell K, Ganguly K, Knight RT, Carmena JM. Detecting event-related changes of multivariate phase coupling in dynamic brain networks. J Neurophysiol 107: 2020-2031, 2012. First published January 12, 2011; doi: 10.1152/jn. 00610.2011.Oscillatory phase coupling within large-scale brain networks is a topic of increasing interest within systems, cognitive, and theoretical neuroscience. Evidence shows that brain rhythms play a role in controlling neuronal excitability and response modulation (Haider B, McCormick D. Neuron 62: 171-189, 2009) and regulate the efficacy of communication between cortical regions (Fries P. Trends Cogn Sci 9: 474-480, 2005) and distinct spatiotemporal scales (Canolty RT, Knight RT. Trends Cogn Sci 14: 506-515, 2010). In this view, anatomically connected brain areas form the scaffolding upon which neuronal oscillations rapidly create and dissolve transient functional networks (Lakatos P, Karmos G, Mehta A, Ulbert I, Schroeder C. Science 320: 110-113, 2008). Importantly, testing these hypotheses requires methods designed to accurately reflect dynamic changes in multivariate phase coupling within brain networks. Unfortunately, phase coupling between neurophysiological signals is commonly investigated using suboptimal techniques. Here we describe how a recently developed probabilistic model, phase coupling estimation (PCE; Cadieu C, Koepsell K Neural Comput 44: 3107-3126, 2010), can be used to investigate changes in multivariate phase coupling, and we detail the advantages of this model over the commonly employed phase-locking value (PLV; Lachaux JP, Rodriguez E, Martinerie J, Varela F. Human Brain Map 8: 194-208, 1999). We show that the N-dimensional PCE is a natural generalization of the inherently bivariate PLV. Using simulations, we show that PCE accurately captures both direct and indirect (network mediated) coupling between network elements in situations where PLV produces erroneous results. We present empirical results on recordings from humans and nonhuman primates and show that the PCEestimated coupling values are different from those using the bivariate PLV. Critically on these empirical recordings, PCE output tends to be sparser than the PLVs, indicating fewer significant interactions and perhaps a more parsimonious description of the data. Finally, the physical interpretation of PCE parameters is straightforward: the PCE parameters correspond to interaction terms in a network of coupled oscillators. Forward modeling of a network of coupled oscillators with parameters estimated by PCE generates synthetic data with statistical characteristics identical to empirical signals. Given these advantages over the PLV, PCE is a useful tool for investigating multivariate phase coupling in distributed brain networks. C1 [Canolty, Ryan T.; Ganguly, Karunesh; Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA. [Canolty, Ryan T.; Cadieu, Charles F.; Koepsell, Kilian; Ganguly, Karunesh; Knight, Robert T.; Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Cadieu, Charles F.; Koepsell, Kilian] Univ Calif Berkeley, Redwood Ctr Theoret Neurosci, Berkeley, CA 94720 USA. [Ganguly, Karunesh] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Ganguly, Karunesh; Knight, Robert T.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Knight, Robert T.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA. RP Carmena, JM (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, 754 Sutardja Dai Hall,MC 1764, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu FU DARPA [N66001-10-C-2008]; National Science Foundation [CBET-0954243, IIS-0917342]; National Institute of Neurological Disorders and Stroke [NIH-R01-NS21135] FX This work was supported by DARPA Contract N66001-10-C-2008 (to J. M. Carmena), National Science Foundation Grant CBET-0954243 (to J. M. Carmena), National Science Foundation Grant IIS-0917342 (to C. F. Cadieu and K. Koepsell), and National Institute of Neurological Disorders and Stroke Grant NIH-R01-NS21135 (to R. T. Knight). NR 25 TC 13 Z9 13 U1 0 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD APR PY 2012 VL 107 IS 7 BP 2020 EP 2031 DI 10.1152/jn.00610.2011 PG 12 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 922GG UT WOS:000302534600022 PM 22236706 ER PT J AU Blomberg, BA Gharavi, MH Saboury, B Werner, TJ Torigian, D Cheng, G Lim, E Akers, SR Alavi, A AF Blomberg, B. A. Gharavi, M. H. Saboury, B. Werner, T. J. Torigian, D. Cheng, G. Lim, E. Akers, S. R. Alavi, A. TI Effect of aging and smoking on FDG-uptake in atherosclerotic plaques assessed by multiple-time-point PET/CT imaging SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT 3rd Symposium on Multimodality Cardiovascular Molecular Imaging CY APR 19-21, 2012 CL Natl Inst Hlth (NIH), Bethesda, MD HO Natl Inst Hlth (NIH) C1 [Blomberg, B. A.; Gharavi, M. H.; Saboury, B.; Werner, T. J.; Torigian, D.; Alavi, A.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Cheng, G.; Lim, E.; Akers, S. R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD APR PY 2012 VL 53 IS 4 MA 3 BP 665 EP 665 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 920BV UT WOS:000302377300057 ER PT J AU Saboury, B Blomberg, BA Gharavi, MH Werner, TJ Lim, E Torigian, D Cheng, G Akers, SR Alavi, A AF Saboury, B. Blomberg, B. A. Gharavi, M. H. Werner, T. J. Lim, E. Torigian, D. Cheng, G. Akers, S. R. Alavi, A. TI Optimized visual assessment of atherosclerotic plaque burden by delayed-time-point FDG-PET/CT imaging: a new observation SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT 3rd Symposium on Multimodality Cardiovascular Molecular Imaging CY APR 19-21, 2012 CL Natl Inst Hlth (NIH), Bethesda, MD HO Natl Inst Hlth (NIH) C1 [Saboury, B.; Blomberg, B. A.; Gharavi, M. H.; Werner, T. J.; Torigian, D.; Alavi, A.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Lim, E.; Cheng, G.; Akers, S. R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD APR PY 2012 VL 53 IS 4 MA 19 BP 670 EP 670 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 920BV UT WOS:000302377300073 ER PT J AU Brown, CJ Foley, KT Lowman, JD Allman, RM Roth, DL AF Brown, C. J. Foley, K. T. Lowman, J. D. Allman, R. M. Roth, D. L. TI Impact of a Hospital Mobility Program on Function after Discharge SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Brown, C. J.; Allman, R. M.] Birmingham VAMC, Birmingham, AL USA. [Foley, K. T.; Lowman, J. D.] UAB, Sch Hlth Profess, Birmingham, AL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S5 EP S5 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800014 ER PT J AU Brown, RT Kiely, DK Bharel, M Patel, M Ard, KL Blazey-Martin, D Mitchell, SL AF Brown, R. T. Kiely, D. K. Bharel, M. Patel, M. Ard, K. L. Blazey-Martin, D. Mitchell, S. L. TI Use of Health Services in Older Homeless Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Brown, R. T.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Brown, R. T.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kiely, D. K.; Mitchell, S. L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Bharel, M.] Boston Healthcare Homeless Program, Boston, MA USA. [Patel, M.] St Elizabeths Med Ctr, Dept Med, Boston, MA USA. [Ard, K. L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Blazey-Martin, D.] Tufts Med Ctr, Dept Med, Boston, MA USA. [Mitchell, S. L.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S49 EP S49 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800141 ER PT J AU Brown, RT Kiely, DK Bharel, M Mitchell, SL AF Brown, R. T. Kiely, D. K. Bharel, M. Mitchell, S. L. TI Factors Associated with Geriatric Syndromes in Older Homeless Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Brown, R. T.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Brown, R. T.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kiely, D. K.; Mitchell, S. L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Bharel, M.] Boston Healthcare Homeless Program, Boston, MA USA. [Mitchell, S. L.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S47 EP S47 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800135 ER PT J AU Edes, T Levy, C Goedken, D Kinosian, B AF Edes, T. Levy, C. Goedken, D. Kinosian, B. TI Where Heroes Meet Angels: the Medical Foster Home. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Kinosian, B.] Univ PA, Philadelphia, PA USA. [Kinosian, B.] Philadelphia VAMC, CHERP, Philadelphia, PA USA. [Edes, T.; Goedken, D.] US Dept Vet Affairs, Washington, DC USA. [Levy, C.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S112 EP S113 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800326 ER PT J AU Espinoza, S Hazuda, H AF Espinoza, S. Hazuda, H. TI Lower Extremity Function Mediates the Association between Diabetes and Frailty. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Espinoza, S.; Hazuda, H.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Espinoza, S.; Hazuda, H.] UT Hlth Sci Ctr, Div Clin Epidemiol, San Antonio, TX USA. [Espinoza, S.; Hazuda, H.] UT Hlth Sci Ctr, Div Geriatr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S219 EP S219 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800637 ER PT J AU Espinoza, S Darvin, K Halade, D Breeding, L Richardson, A AF Espinoza, S. Darvin, K. Halade, D. Breeding, L. Richardson, A. TI Protein Biomarkers for Frailty. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Espinoza, S.; Darvin, K.; Halade, D.; Breeding, L.; Richardson, A.] UT Hlth Sci Ctr, Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Espinoza, S.; Richardson, A.] S Texas Vet Healthcare Syst, GRECC, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S218 EP S219 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800636 ER PT J AU Fung, CH Martin, J Jouldjian, S Josephson, K Alessi, C AF Fung, C. H. Martin, J. Jouldjian, S. Josephson, K. Alessi, C. TI Difficulty with Use of Positive Airway Pressure Equipment among Older Adults with Sleep Apnea. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Fung, C. H.; Martin, J.; Jouldjian, S.; Josephson, K.; Alessi, C.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. [Fung, C. H.; Martin, J.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S127 EP S127 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800369 ER PT J AU Garcia, CH Espinoza, S Hazuda, H AF Garcia, C. H. Espinoza, S. Hazuda, H. TI Strong Association Between Low Health Literacy and Poor Health Status among Hispanic Elderly Patients. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Garcia, C. H.; Espinoza, S.; Hazuda, H.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Espinoza, S.; Hazuda, H.] S Texas Vet Healthcare Syst, Med, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S164 EP S164 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800477 ER PT J AU Goodson, W Bloch, A Santos-Modesitt, W Yaffe, K King, AC Barnes, DE AF Goodson, W. Bloch, A. Santos-Modesitt, W. Yaffe, K. King, A. C. Barnes, D. E. TI The Effects of Aerobic Exercise and Stretching on Self-Reported Sleep Quality in Community Dwelling Older Adults with Cognitive Complaints: A Randomized, Controlled Trial. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Goodson, W.; Santos-Modesitt, W.; Yaffe, K.; Barnes, D. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Goodson, W.; Santos-Modesitt, W.; Yaffe, K.; Barnes, D. E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bloch, A.] Alliant Univ, San Francisco, CA USA. [King, A. C.] Stanford Univ, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S67 EP S67 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800194 ER PT J AU Hanson, AJ Bayer-Carter, JL Green, PS Montine, TJ Baker, LD Watson, GS Bonner, LM Callaghan, M Leverenz, JB Walter, BK Tsai, EC Wilkinson, CW Zhang, J Craft, S AF Hanson, A. J. Bayer-Carter, J. L. Green, P. S. Montine, T. J. Baker, L. D. Watson, G. S. Bonner, L. M. Callaghan, M. Leverenz, J. B. Walter, B. K. Tsai, E. C. Wilkinson, C. W. Zhang, J. Craft, S. TI Lipid-depleted apolipoproteins and amyloid peptides are influenced by APOE genotype and cognitive diagnosis SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Hanson, A. J.; Bayer-Carter, J. L.; Green, P. S.; Montine, T. J.; Baker, L. D.; Watson, G. S.; Leverenz, J. B.; Tsai, E. C.; Wilkinson, C. W.; Zhang, J.; Craft, S.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Hanson, A. J.; Bayer-Carter, J. L.; Green, P. S.; Montine, T. J.; Baker, L. D.; Watson, G. S.; Bonner, L. M.; Callaghan, M.; Leverenz, J. B.; Walter, B. K.; Tsai, E. C.; Wilkinson, C. W.; Craft, S.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S7 EP S7 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800019 ER PT J AU Howe, JL Griffith, JL AF Howe, J. L. Griffith, J. L. TI A Training Model to Strengthen Team-based Primary Care for Older Rural Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Howe, J. L.; Griffith, J. L.] Mt Sinai Sch Med, New York, NY USA. [Howe, J. L.; Griffith, J. L.] James J Peter VAMC, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S205 EP S206 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800598 ER PT J AU Huang, DL Chan, KC Young, BA AF Huang, D. L. Chan, K. C. Young, B. A. TI Poor Oral Health and Quality of Life in US Older Adults with Diabetes. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Huang, D. L.; Young, B. A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Huang, D. L.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Young, B. A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S185 EP S185 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800538 ER PT J AU Huang, DL Rosenberg, DE Petz, SD Belza, B AF Huang, D. L. Rosenberg, D. E. Petz, S. D. Belza, B. TI Food Access in Aging Adults with Impaired Mobility. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Huang, D. L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Huang, D. L.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Rosenberg, D. E.] Grp Hlth Res Inst, Seattle, WA USA. [Petz, S. D.; Belza, B.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Belza, B.] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S169 EP S169 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800491 ER PT J AU Hughes, M Wey, M Bai, X Martinez, A Fernandez, E Strong, R AF Hughes, M. Wey, M. Bai, X. Martinez, A. Fernandez, E. Strong, R. TI Effect of rapamycin in a mouse model of synucleinopathy. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Hughes, M.] UTHSCSA, Sch Med, San Antonio, TX USA. [Wey, M.; Bai, X.; Martinez, A.; Fernandez, E.; Strong, R.] Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Fernandez, E.; Strong, R.] S Texas Vet Hlth Care Network, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S115 EP S115 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800334 ER PT J AU Hung, WW Dunn, CM Moodhe, NE Gottesman, EM Morano, B Boockvar, KS AF Hung, W. W. Dunn, C. M. Moodhe, N. E. Gottesman, E. M. Morano, B. Boockvar, K. S. TI Improving quality of care for older veterans through a RHIO-enhanced Care Transitions Intervention (CTI). SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Hung, W. W.; Dunn, C. M.; Moodhe, N. E.; Gottesman, E. M.; Morano, B.; Boockvar, K. S.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. [Hung, W. W.; Morano, B.; Boockvar, K. S.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S59 EP S59 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800171 ER PT J AU Jawad, M Villarreal, D Sanchez-Reilly, S Ross, J Lee, S Restrepo, M Tidwell, J AF Jawad, M. Villarreal, D. Sanchez-Reilly, S. Ross, J. Lee, S. Restrepo, M. Tidwell, J. TI Geriatric Palliative Care and Medical Intensive Care teams Collaborating to increase Geriatric Palliative Care Services for Older Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Jawad, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Villarreal, D.; Sanchez-Reilly, S.; Ross, J.; Lee, S.; Restrepo, M.; Tidwell, J.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S231 EP S231 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800673 ER PT J AU Kinosian, B Edes, T Hossain, M AF Kinosian, B. Edes, T. Hossain, M. TI Veterans Using Primary Care Housecalls Outside the VA: Still Better than Expected SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Kinosian, B.] Philadelphia VAMC, CHERP, Philadelphia, PA USA. [Kinosian, B.] Univ PA, Philadelphia, PA USA. [Edes, T.; Hossain, M.] Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S4 EP S4 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800011 ER PT J AU Mather, M Patel, T Espinoza, S AF Mather, M. Patel, T. Espinoza, S. TI Improving Transitions to Home in Older Veterans after Hospitalization. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Mather, M.; Patel, T.; Espinoza, S.] S Texas Vet Healthcare Syst, GRECC, San Antonio, TX USA. [Mather, M.; Patel, T.; Espinoza, S.] UT Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S57 EP S57 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800164 ER PT J AU Park, M Martin, J Fung, C Jouldjian, S Josephson, K Alessi, C AF Park, M. Martin, J. Fung, C. Jouldjian, S. Josephson, K. Alessi, C. TI Sedative-hypnotic Use Among Older Veterans With Insomnia And Unrecognized Sleep Apnea. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Park, M.] Western Univ Hlth Sci, Pomona, CA USA. [Martin, J.; Fung, C.; Jouldjian, S.; Josephson, K.; Alessi, C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA. [Martin, J.; Alessi, C.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S103 EP S104 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800300 ER PT J AU Ramaswamy, R Williams, A Kelley, AS Clark, EM AF Ramaswamy, R. Williams, A. Kelley, A. S. Clark, E. M. TI Fulfilling an ACGME Competency: Impact of a Novel Communication Skills Curriculum. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Ramaswamy, R.; Williams, A.; Kelley, A. S.; Clark, E. M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Ramaswamy, R.; Williams, A.; Clark, E. M.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S40 EP S40 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800115 ER PT J AU Reuben, DB Ganz, DA Roth, C McCreath, H Ramirez, K Wenger, NS AF Reuben, D. B. Ganz, D. A. Roth, C. McCreath, H. Ramirez, K. Wenger, N. S. TI Team Care to Manage Chronic Illnesses in Older Persons. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 03-05, 2012 CL Seattle, WA SP Amer Geriatr Soc C1 [Reuben, D. B.; Ganz, D. A.; McCreath, H.; Ramirez, K.; Wenger, N. S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Roth, C.] RAND Corp, Santa Monica, CA USA. [Ganz, D. A.] Greater Los Angeles VAMC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2012 VL 60 SU 4 SI SI BP S109 EP S109 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921FZ UT WOS:000302464800317 ER PT J AU Lopes-Virella, MF Carter, RE Baker, NL Lachin, J Virella, G AF Lopes-Virella, Maria F. Carter, Rickey E. Baker, Nathaniel L. Lachin, John Virella, Gabriel CA DCCT EDIC Res Grp TI High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE albuminuria; diabetic nephropathy; immune complexes; modified lipoproteins ID LOW-DENSITY-LIPOPROTEIN; GLYCATION END-PRODUCTS; EURODIAB PROSPECTIVE COMPLICATIONS; RENAL-DISEASE; RISK-FACTORS; FOLLOW-UP; NEPHROPATHY; PROGRESSION; MELLITUS; PATHOGENESIS AB Background. Modified low-density lipoprotein (LDL) immune complexes (IC) have proinflammatory properties and play a role in albuminuria development. Methods. We measured oxidized LDL (oxLDL) and advanced glycation end-product (AGE)-LDL in IC isolated from sera of Type 1 diabetic subjects followed for 14-20 years and studied their association with abnormal albuminuria. Patients with albumin excretion rates (AER) < 40 mg/24 h at baseline and follow-up (n = 302) were deemed resistant to developing abnormal albuminuria. Patients with AER < 40 mg/24 h at baseline whose AER levels progressed to > 40 mg/24 h were considered prone to abnormal albuminuria (n = 185), those who progress to AER > 299 mg/24 h were considered as having macroalbuminuria (n = 57). The odds of developing abnormal albuminuria were estimated by logistic regression based on natural log-transformed levels of oxLDL and AGE-LDL in IC and stratified by baseline AER decile. Results. OxLDL and AGE-LDL were significantly higher in IC isolated from patients progressing to abnormal albuminuria. In unadjusted conditional logistic analysis, an increase of 1 SD in oxLDL and AGE-LDL levels in IC significantly increased the odds ratio (OR) for development of macroalbuminuria, respectively, by a factor of 2.5 and 1.8 (P < 0.001, P = 0.008). The increased odds of developing macroalbuminuria remained significant when adjusted for treatment group, diabetes duration, retinopathy, baseline hemoglobin A1c and LDL (OR = 2.5 and 1.8, respectively, P < 0.01). Conclusion. Higher levels of oxLDL and AGE-LDL in circulating IC were associated with increased odds to develop abnormal albuminuria. C1 [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Med Univ S Carolina, Lab Serv, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Carter, Rickey E.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN USA. [Baker, Nathaniel L.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Lachin, John] George Washington Univ, Ctr Biostat, Washington, DC USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM virellam@musc.edu OI Lachin, John/0000-0001-9838-2841 FU National Institutes of Health/NHLBI [PO1 HL 55782]; NIH/NIDDK [R01 DK081352]; Juvenile Diabetes Foundation [2006-49]; Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center; Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the NIH; National Center for Research Resources through the GCRC; Genentech Inc; NIDDK FX This work was supported by a Program Project funded by the National Institutes of Health/NHLBI (PO1 HL 55782), by an RO1 Grant funded by NIH/NIDDK (R01 DK081352) and by a Juvenile Diabetes Foundation Grant (2006-49). The work was also supported by the Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government.; The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology and Metabolic Diseases (NIDDK) of the NIH. Additional support was provided by the National Center for Research Resources through the GCRC program and by Genentech Inc through a Cooperative Research and Development Agreement with the NIDDK. NR 46 TC 11 Z9 11 U1 0 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD APR PY 2012 VL 27 IS 4 BP 1416 EP 1423 DI 10.1093/ndt/gfr454 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 919GM UT WOS:000302310700023 PM 21856760 ER PT J AU Noel, PH Wang, CP Bollinger, MJ Pugh, MJ Copeland, LA Tsevat, J Nelson, KM Dundon, MM Hazuda, HP AF Noel, Polly H. Wang, Chen-Pin Bollinger, Mary J. Pugh, Mary J. Copeland, Laurel A. Tsevat, Joel Nelson, Karin M. Dundon, Margaret M. Hazuda, Helen P. TI Intensity and Duration of Obesity-Related Counseling: Association With 5-Year BMI Trends Among Obese Primary Care Patients SO OBESITY LA English DT Article ID BODY-MASS INDEX; HEALTH-SERVICES RESEARCH; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; LONGITUDINAL DATA; RANDOMIZED-TRIAL; NATIONAL TRENDS; POPULATION; MANAGEMENT; ADULTS AB We examined 5-year trends in BMI among obese primary care patients to determine whether obesity-related education such as nutrition counseling or a weight management program was associated with declines in BMI. Veterans with BMI = 30 kg/m(2) and = 1 primary care visits in fiscal year 2002 were identified from the Veterans Health Administration's (VHA) national databases. Outpatient visits from fiscal year 2002-2006 for nutrition counseling, exercise, or weight management were grouped into five categories varying in intensity and duration: (i) intenseand- sustained, (ii) intense-only, (iii) irregular, (iv) limited, and (v) no counseling. Generalized estimating equation assessed associations between obesity-related counseling and BMI trend (annual rate of BMI change fiscal year 2002-2006) among cohort members with complete race/ethnic data (N = 179,881). Multinomial logistic regression compared intensity and duration of counseling among patients whose net BMI increased or decreased by = 10% vs. remained stable. Compared with patients receiving " intense-and-sustained" counseling, the BMI trend of those receiving " intense-only" or " irregular" counseling was not significantly different, but patients receiving " no counseling" or " limited counseling" had significantly higher rates of decreasing BMI (-0.12 and -0.08 BMI per year; P < 0.01, respectively). This was especially true for veterans in their 50-60s, compared with the oldest veterans who were most likely to lose weight. In contrast, younger veterans (18-35 years) were least likely to lose weight; their BMI tended to increase regardless of counseling intensity and duration. Enhanced efforts are needed to detect and combat increasing weight trajectories among veterans who are already obese, especially among those aged 18-35 who are at greatest risk. C1 [Noel, Polly H.; Wang, Chen-Pin; Bollinger, Mary J.; Pugh, Mary J.; Copeland, Laurel A.; Hazuda, Helen P.] VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Noel, Polly H.; Wang, Chen-Pin; Pugh, Mary J.; Copeland, Laurel A.; Hazuda, Helen P.] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Tsevat, Joel] Cincinnati VAMC, Cincinnati, OH USA. [Tsevat, Joel] Univ Cincinnati, Cincinnati, OH USA. [Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. [Dundon, Margaret M.] VA Western New York Healthcare Syst, Batavia, NY USA. RP Noel, PH (reprint author), VERDICT S Texas Vet Hlth Care Syst, San Antonio, TX USA. EM noelp@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 05-121] FX The research reported here was supported by the Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service (project no. IIR 05-121). The authors thank Leila C. Kahwati, MD, MPH, Deputy Chief Consultant for Preventive Medicine, Office of Patient Care Services, Veterans Health Administration, for her review and suggestions. All of the authors except Dr Wang are employees of the Department of Veterans Affairs. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 48 TC 6 Z9 6 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD APR PY 2012 VL 20 IS 4 BP 773 EP 782 DI 10.1038/oby.2011.335 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 917AC UT WOS:000302143300010 PM 22134198 ER PT J AU King, JT Gordon, AJ Perkal, MF Crystal, S Rosenthal, RA Rodriguez-Barradas, MC Butt, AA Gibert, CL Rimland, D Simberkoff, MS Justice, AC AF King, Joseph T., Jr. Gordon, Adam J. Perkal, Melissa F. Crystal, Stephen Rosenthal, Ronnie A. Rodriguez-Barradas, Maria C. Butt, Adeel A. Gibert, Cynthia L. Rimland, David Simberkoff, Michael S. Justice, Amy C. TI Disparities in Rates of Spine Surgery for Degenerative Spine Disease Between HIV-Infected and Uninfected Veterans SO SPINE LA English DT Article DE disparities; HIV/AIDS; outcomes; spine; surgery ID HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL-PRACTICE GUIDELINE; AMERICAN PAIN SOCIETY; OF-THE-LITERATURE; LOW-BACK-PAIN; DISC DEGENERATION; MULTIPLE IMPUTATION; LUMBAR SPINE; LUNG-CANCER; ANTIRETROVIRAL THERAPY AB Study Design. Retrospective analysis of nationwide Veterans Health Administration clinical and administrative data. Objective. Examine the association between HIV infection and the rate of spine surgery for degenerative spine disease. Summary of Background Data. Combination antiretroviral therapy has prolonged survival in HIV-infected patients, increasing the prevalence of chronic conditions such as degenerative spine disease that may require spine surgery. Methods. We studied all HIV-infected patients under care in the Veterans Health Administration from 1996 to 2008 (n = 40,038) and uninfected comparator patients (n = 79,039) matched on age, sex, race, year, and geographic region. The primary outcome was spine surgery for degenerative spine disease, defined by International Classification of Diseases, Ninth Revision procedure and diagnosis codes. We used a multivariate Poisson regression to model spine surgery rates by HIV infection status, adjusting for factors that might affect suitability for surgery (demographics, year, comorbidities, body mass index, combination antiretroviral therapy, and laboratory values). Results. Two hundred twenty-eight HIV-infected and 784 uninfected patients underwent spine surgery for degenerative spine disease during 700,731 patient-years of follow-up (1.44 surgeries per 1000 patient-years). The most common procedures were spinal decompression (50%) and decompression and fusion (33%); the most common surgical sites were the lumbosacral (50%) and cervical (40%) spine. Adjusted rates of surgery were lower for HIV-infected patients (0.86 per 1000 patient-years of follow-up) than for uninfected patients (1.41 per 1000 patient-years; incidence rate ratio 0.61, 95% confidence interval: 0.51-0.74, P < 0.001). Among HIV-infected patients, there was a trend toward lower rates of spine surgery in patients with detectable viral load levels (incidence rate ratio 0.76, 95% confidence interval: 0.55-1.05, P = 0.099). Conclusion. In the Veterans Health Administration, HIV-infected patients experience significantly reduced rates of surgery for degenerative spine disease. Possible explanations include disease prevalence, emphasis on treatment of nonspine HIV-related symptoms, surgical referral patterns, impact of HIV on surgery risk-benefit ratio, patient preferences, and surgeon bias. C1 [King, Joseph T., Jr.] VA Connecticut Healthcare Syst, Neurosurg Sect, Dept Surg, West Haven, CT USA. [King, Joseph T., Jr.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA. [Gordon, Adam J.; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA. [Gordon, Adam J.; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gordon, Adam J.; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Perkal, Melissa F.; Rosenthal, Ronnie A.] VA Connecticut Healthcare Syst, Dept Surg, West Haven, CT USA. [Perkal, Melissa F.; Rosenthal, Ronnie A.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Crystal, Stephen] Rutgers State Univ, Ctr Pharmacotherapy Chron Dis Management & Outcom, New Brunswick, NJ 08903 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Dept Med, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Gibert, Cynthia L.] VA Med Ctr, Dept Med, Div Infect Dis, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Rimland, David] Atlanta VA Med Ctr, Dept Med, Infect Dis Sect, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Simberkoff, Michael S.] VA New York Harbor Healthcare Syst, Dept Med, Infect Dis Sect, New York, NY USA. [Simberkoff, Michael S.] NYU, Sch Med, New York, NY USA. [Justice, Amy C.] VA Connecticut Healthcare Syst, Dept Med, Gen Internal Med Sect, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA. RP King, JT (reprint author), VA Connecticut Healthcare Syst 112, Neurosurg Sect, 950 Campbell Ave, West Haven, CT 06516 USA. EM Joseph.KingJr@va.gov FU National Institutes of Health NIAAA [U10-AA13566]; National Institutes of Health NIA [R01-AG029154]; National Institutes of Health NHLBI [R01-HL095136, R01-HL090342, RCI-HL100347]; National Institutes of Health NIAID [U01-A1069918]; National Institutes of Health NIMH [P30-MH062294]; Veterans Health Administration Office of Research and Development [VA REA 08-266]; Office of Academic Affiliations FX National Institutes of Health: NIAAA (U10-AA13566), NIA (R01-AG029154), NHLBI (R01-HL095136; R01-HL090342; RCI-HL100347), NIAID (U01-A1069918), NIMH (P30-MH062294), and the Veterans Health Administration Office of Research and Development (VA REA 08-266) and Office of Academic Affiliations (Medical Informatics Fellowship) funds were received to support this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript. NR 86 TC 2 Z9 2 U1 8 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD APR 1 PY 2012 VL 37 IS 7 BP 612 EP 622 DI 10.1097/BRS.0b013e318228f32d PG 11 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 918QV UT WOS:000302266400019 PM 21697770 ER PT J AU Hartwell, KJ Back, SE McRae-Clark, AL Shaftman, SR Brady, KT AF Hartwell, Karen J. Back, Sudie E. McRae-Clark, Aimee L. Shaftman, Stephanie R. Brady, Kathleen T. TI Motives for using: A comparison of prescription opioid, marijuana and cocaine dependent individuals SO ADDICTIVE BEHAVIORS LA English DT Article DE Opiates; Marijuana; Cocaine; Motives; IDTS ID ECOLOGICAL MOMENTARY ASSESSMENT; ALCOHOL-USE; COPING SKILLS; MOTIVATION; SITUATIONS; REASONS; USERS; DRUG; MEN AB Identification of the motives for drug use is critical to the development of effective interventions. Furthermore, consideration of the differences in motives for drug use across substance dependent populations may assist in tailoring interventions. To date, few studies have systematically compared motives for substance use across drug classes. The current study examined motives for drug use between non-treatment seeking individuals with current prescription opioid, marijuana, or cocaine dependence. Participants (N=227) completed the Inventory of Drug-Taking Situations (IDTS; Annis, Turner & Sklar,1997), which contains eight subscales assessing motives for drug use. The findings revealed that prescription opioid dependent individuals scored significantly higher than all other groups on the Physical Discomfort, Testing Personal Control and Conflict with Others subscales. Both the prescription opioid and cocaine dependent groups scored significantly higher than the marijuana group on the Urges or a Temptation to Use subscale. In contrast, marijuana dependent individuals scored highest on the Pleasant Emotions and Pleasant Times with Others subscales. The marked differences revealed in motives for drug use could be used in the development and implementation of specific treatment interventions for prescription opioid, marijuana and cocaine dependent individuals. Published by Elsevier Ltd. C1 [Hartwell, Karen J.] Med Univ S Carolina, Clin Neurosci Div, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hartwell, Karen J.; Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA. [Shaftman, Stephanie R.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP Hartwell, KJ (reprint author), Med Univ S Carolina, Clin Neurosci Div, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM hartwelk@musc.edu RI McRae-Clark, Aimee/I-3341-2013 OI McRae-Clark, Aimee/0000-0002-9774-318X FU NIH [K23 DA021228, R21 DA22424, P50 DA0165511] FX This work was supported in part by NIH grants K23 DA021228 (SEB), R21 DA22424 (ALM) and P50 DA0165511 (KTB). NR 34 TC 9 Z9 9 U1 3 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD APR PY 2012 VL 37 IS 4 BP 373 EP 378 DI 10.1016/j.addbeh.2011.11.014 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 911BD UT WOS:000301691400003 PM 22284583 ER PT J AU Broyles, LM Rosenberger, E Hanusa, BH Kraemer, KL Gordon, AJ AF Broyles, Lauren M. Rosenberger, Emily Hanusa, Barbara H. Kraemer, Kevin L. Gordon, Adam J. TI Hospitalized Patients' Acceptability of Nurse-Delivered Screening, Brief Intervention, and Referral to Treatment SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Patient Acceptance of Health Care; Alcohol Consumption; Inpatients; Nursing; Counseling ID BRIEF ALCOHOL INTERVENTION; PRIMARY HEALTH-CARE; DISORDERS IDENTIFICATION TEST; VETERANS-AFFAIRS; AUDIT-C; PHYSICIANS; ATTITUDES; ADVICE; IMPLEMENTATION; PARTICIPATE AB Background: Inpatient healthcare providers in the United States may soon be required to offer alcohol screening, brief intervention, and referral to treatment (SBIRT) for hospital accreditation, but little is known about inpatient acceptability for SBIRT, particularly when performed by nonphysician providers such as nurses. The purpose of this study was to assess patient acceptability for and comfort with nurse-delivered SBIRT care among hospitalized patients and to identify factors associated with SBIRT acceptability. Methods: We conducted a cross-sectional survey of 370 hospitalized medical-surgical patients at a large university-affiliated medical center, which is part of the U.S. Department of Veterans Affairs. Results: Patient acceptability for 8 of 10 individual nurse-delivered SBIRT tasks was >84%. Patients were more accepting of SBIRT tasks if they felt able to determine their alcohol risk, able to reduce alcohol-related health risks, and expressed some degree of concern about their own use of alcohol. Approximately 20% of patients reported some degree of personal discomfort with alcohol-related discussions. Patients who were less comfortable with these discussions had lower perceived ability to reduce alcohol-related health risk, were >60 years old, had a positive AUDIT-C screening, and were of nonblack race. Conclusions: Among hospitalized patients, patient acceptability for nurse-delivered SBIRT is high, and alcohol-related risk perceptions appear to be important factors associated with acceptability for SBIRT tasks. Providers can proceed with greater confidence in SBIRT-related discussions with most hospitalized patients but may need particular sensitivity and skill addressing alcohol with patient subgroups such as older patients and those with positive alcohol screenings. C1 [Broyles, Lauren M.; Hanusa, Barbara H.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.; Hanusa, Barbara H.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr VISN4, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Gordon, Adam J.] Univ Pittsburgh, Ctr Res Healthcare, Pittsburgh, PA USA. [Rosenberger, Emily] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM Lauren.Broyles@va.gov FU American Nurses Foundation (ANF); Health Services Research & Development service of the U.S. Department of Veterans Affairs [CDA10-014] FX The authors thank the staff nurses, nursing leadership, and Veteran participants for their support and participation in the study. In addition, the authors thank John D. Harding, Jr., BA, and Caroline DeMeis, MPH, for their patient recruitment efforts. Funding for this study was provided by a 2009 American Nurses Foundation (ANF) grant; LMB is the 2009 Council for the Advancement of Nursing Science/ANF Scholar. LMB is currently supported by a Career Development Award (CDA) from the Health Services Research & Development service of the U.S. Department of Veterans Affairs. The material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Pittsburgh, PA. LMB is currently supported by a Career Development Award (CDA10-014) from the Health Services Research & Development service of the U.S. Department of Veterans Affairs. NR 34 TC 15 Z9 15 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD APR PY 2012 VL 36 IS 4 BP 725 EP 731 DI 10.1111/j.1530-0277.2011.01651.x PG 7 WC Substance Abuse SC Substance Abuse GA 916AN UT WOS:000302068900021 PM 22250713 ER PT J AU van Ryn, J Baruch, L Clemens, A AF van Ryn, Joanne Baruch, Lawrence Clemens, Andreas TI Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Coagulation assays; Dabigatran; Dabigatran etexilate; Direct thrombin inhibitor AB BACKGROUND: Point-of-care devices for measurement of the international normalized ratio (INR) are commonly used to monitor therapy and maintain therapeutic levels of anticoagulation in patients treated with vitamin K antagonists. Dabigatran, a new oral, reversible direct thrombin inhibitor approved for stroke prevention in patients with atrial fibrillation does not require routine coagulation monitoring. However, case reports have identified falsely elevated point-of-care INR levels in patients treated with dabigatran using one of these devices (Hemochron). This in vitro study was designed to verify this issue. METHODS: We compared INR levels in whole blood and plasma using a Hemochron Jr. Signature + point-of-care device (International Technidyne Corporation, Edison, NJ) with routine laboratory monitoring, using blood from healthy volunteers that was spiked with increasing concentrations of dabigatran. RESULTS: Prothrombin time and INR levels were increased about 2- to 4-fold with the point-of-care device compared with laboratory measures across the plasma dabigatran concentration range 50-1400 ng/mL. At plasma concentrations of dabigatran likely to be observed in patients, at a dose of 150 mg twice daily (60-275 ng/mL), whole blood point-of-care INR values increased from 1.7 to 4.0, versus 1.1 to 1.5 measured with the laboratory coagulometer. Similar differences in prothrombin time were observed in plasma samples. CONCLUSIONS: INR levels in patients taking dabigatran are substantially higher using a Hemochron Jr. point-of-care device compared with laboratory values. We discourage the use of these devices specifically, as well as the use of the INR in general, for measuring the anticoagulant effect of dabigatran. (C) 2012 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2012) 125, 417-420 C1 [van Ryn, Joanne] Boehringer Ingelheim Pharma GmbH & Co KG, Dept CardioMetabol Dis Res, D-88397 Biberach, Germany. [Baruch, Lawrence] James J Peters VA Med Ctr, Program Med, Bronx, NY USA. [Clemens, Andreas] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Dev & Med Affairs, Ingelheim, Germany. RP van Ryn, J (reprint author), Boehringer Ingelheim Pharma GmbH & Co KG, Dept CardioMetabol Dis Res, Birkendorfer Str 65, D-88397 Biberach, Germany. EM joanne.vanryn@boehringer-ingelheim.com FU Boehringer Ingelheim FX Boehringer Ingelheim. NR 6 TC 46 Z9 47 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD APR PY 2012 VL 125 IS 4 BP 417 EP 420 DI 10.1016/j.amjmed.2011.10.017 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 916RH UT WOS:000302120400028 PM 22306274 ER PT J AU Zile, MR Baicu, CF Stroud, RE Laer, AV Arroyo, J Mukherjee, R Jones, JA Spinale, FG AF Zile, Michael R. Baicu, Catalin F. Stroud, Robert E. An Van Laer Arroyo, Jazmine Mukherjee, Rupak Jones, Jeffrey A. Spinale, Francis G. TI Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE hypertrophy; proteases; left ventricular ID CARDIAC-RESTRICTED OVEREXPRESSION; PRESERVED EJECTION FRACTION; FIBRILLAR COLLAGEN CONTENT; DIASTOLIC FUNCTION ROLE; MATRIX-METALLOPROTEINASE; MYOCARDIAL-INFARCTION; HEART-FAILURE; CYCLIC STRAIN; GROWTH-FACTOR; CANCER-CELLS AB Zile MR, Baicu CF, Stroud RE, Van Laer A, Arroyo J, Mukherjee R, Jones JA, Spinale FG. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol 302: H1429-H1437, 2012. First published January 27, 2012; doi: 10.1152/ajpheart.00580.2011.-Increased myocardial extracellular matrix collagen represents an important structural milestone during the development of left ventricular (LV) pressure overload (PO); however, the proteolytic pathways that contribute to this process are not fully understood. This study tested the hypothesis that membrane type 1-matrix metalloproteinase (MT1-MMP) is directly induced at the transcriptional level in vivo during PO and is related to changes in LV collagen content. PO was induced in vivo by transverse aortic constriction in transgenic mice containing the full length human MT1-MMP promoter region ligated to luciferase (MT1-MMP Prom mice). MT1-MMP promoter activation (luciferase expression), expression, and activity; collagen volume fraction (CVF); and left atrial dimension were measured at 1 (n = 8), 2 (n = 12), and 4 (n = 17) wk following PO. Non-PO mice (n = 10) served as controls. Luciferase expression increased by fivefold at 1 wk, fell at 2 wk, and increased again by ninefold at 4 wk of PO (P < 0.05). MT1-MMP expression and activity increased at 1 wk, fell at 2 wk, and increased again at 4 wk after PO. CVF increased at 1 wk, remained unchanged at 2 wk, and increased by threefold at 4 wk of PO (P < 0.05). There was a strong positive correlation between CVF and MT1-MMP activity (r = 0.80, P < 0.05). Left atrial dimension remained unchanged at 1 and 2 wk but increased by 25% at 4 wk of PO. When a mechanical load was applied in vitro to LV papillary muscles isolated from MT1-MMP Prom mice, increased load caused MT1-MMP promoter activation to increase by twofold and MT1-MMP expression to increase by fivefold (P < 0.05). These findings challenge the canonical belief that PO suppresses overall matrix proteolytic activity, but rather supports the concept that certain proteases, such as MT1-MMP, play a pivotal role in PO-induced matrix remodeling and fibrosis. C1 [Zile, Michael R.; Baicu, Catalin F.; An Van Laer] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Stroud, Robert E.; Arroyo, Jazmine; Mukherjee, Rupak; Jones, Jeffrey A.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Spinale, Francis G.] Univ S Carolina, Sch Med, Columbia, SC USA. [Spinale, Francis G.] Wm Jennings Bryan Dorn Dept Vet Affairs Med Ctr, Columbia, SC USA. RP Zile, MR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Ashley River Towers,25 Courtenay Dr,Rm 7067, Charleston, SC 29425 USA. EM zilem@musc.edu FU National Heart, Lung, and Blood Institute [HL-057952, HL-059165, HL-095608]; Research Service of the Department of Veterans Affairs FX This work is supported by National Heart, Lung, and Blood Institute Grants HL-057952, HL-059165, and HL-095608 (to F. G. Spinale) and the Research Service of the Department of Veterans Affairs (to M. R. Zile and F. G. Spinale). NR 43 TC 27 Z9 27 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR PY 2012 VL 302 IS 7 BP H1429 EP H1437 DI 10.1152/ajpheart.00580.2011 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 919PR UT WOS:000302341000008 PM 22287584 ER PT J AU Funk, JA Schnellmann, RG AF Funk, Jason A. Schnellmann, Rick G. TI Persistent disruption of mitochondrial homeostasis after acute kidney injury SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE mitochondria; ischemia; rhabdomyolysis; proximal tubules ID ACUTE-RENAL-FAILURE; ISCHEMIA/REPERFUSION INJURY; PROXIMAL TUBULE; OXIDANT INJURY; CELL-DEATH; BIOGENESIS; RAT; DYSFUNCTION; FISSION; PATHOPHYSIOLOGY AB Funk JA, Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury. Am J Physiol Renal Physiol 302: F853-F864, 2012. First published December 7, 2011; doi:10.1152/ajprenal.00035.2011.-While mitochondrial dysfunction is a pathological process that occurs after acute kidney injury (AKI), the state of mitochondrial homeostasis during the injury and recovery phases of AKI remains unclear. We examined markers of mitochondrial homeostasis in two nonlethal rodent AKI models. Myoglobinuric AKI was induced by glycerol injection into rats, and mice were subjected to ischemic AKI. Animals in both models had elevated serum creatinine, indicative of renal dysfunction, 24 h after injury which partially recovered over 144 h postinjury. Markers of proximal tubule function/injury, including neutrophil gelatinase-associated lipocalin and urine glucose, did not recover during this same period. The persistent pathological state was confirmed by sustained caspase 3 cleavage and evidence of tubule dilation and brush-border damage. Respiratory proteins NDUFB8, ATP synthase beta, cytochrome c oxidase subunit I (COX I), and COX IV were decreased in both injury models and did not recover by 144 h. Immunohistochemical analysis confirmed that COX IV protein was progressively lost in proximal tubules of the kidney cortex after ischemia-reperfusion (I/R). Expression of mitochondrial fission protein Drp1 was elevated after injury in both models, whereas the fusion protein Mfn2 was elevated after glycerol injury but decreased after I/R AKI. LC3-I/II expression revealed that autophagy increased in both injury models at the later time points. Markers of mitochondrial biogenesis, such as PGC-1 alpha and PRC, were elevated in both models. These findings reveal that there is persistent disruption of mitochondrial homeostasis and sustained tubular damage after AKI, even in the presence of mitochondrial recovery signals and improved glomerular filtration. C1 [Funk, Jason A.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institutes of Health (NIH) [GM 084147, C06 RR-015455]; NIH/National Institute of Environmental Health Sciences [T32ES012878-05]; NIH/National Heart, Lung, and Blood Institute [T32HL007260-34]; Biomedical Laboratory of the Department of Veterans Affairs; South Carolina Clinical and Translational Research (SCTR) Institute; Medical University of South Carolina CTSA, NIH/NCRR [UL1RR029882] FX This study was supported by National Institutes of Health (NIH) Grant GM 084147, the NIH/National Institute of Environmental Health Sciences Training Program in Environmental Stress Signaling T32ES012878-05 and NIH/National Heart, Lung, and Blood Institute Training to Improve Cardiovascular Therapies T32HL007260-34, and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. Animal facilities were funded by NIH Grant C06 RR-015455. This publication was supported, in part, by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina CTSA, NIH/NCRR Grant UL1RR029882. NR 44 TC 52 Z9 55 U1 2 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2012 VL 302 IS 7 BP F853 EP F864 DI 10.1152/ajprenal.00035.2011 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 919PC UT WOS:000302339500007 PM 22160772 ER PT J AU Saigusa, T Reichert, R Guare, J Siroky, BJ Gooz, M Steele, S Fenton, RA Bell, PD Kolb, RJ AF Saigusa, Takamitsu Reichert, Ryan Guare, Jennifer Siroky, Brian J. Gooz, Monika Steele, Stacy Fenton, Robert A. Bell, P. Darwin Kolb, Robert J. TI Collecting duct cells that lack normal cilia have mislocalized vasopressin-2 receptors SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE aquaporin 2; epithelial Na channel; hypertension; polycystic kidney disease ID POLYCYSTIC KIDNEY-DISEASE; EPITHELIAL NA+ CHANNEL; INTRAFLAGELLAR TRANSPORT; SUBCELLULAR-DISTRIBUTION; WATER REABSORPTION; V2 RECEPTOR; PROTEIN; EXPRESSION; GROWTH; GENE AB Saigusa T, Reichert R, Guare J, Siroky BJ, Gooz M, Steele S, Fenton RA, Bell PD, Kolb RJ. Collecting duct cells that lack normal cilia have mislocalized vasopressin-2 receptors. Am J Physiol Renal Physiol 302: F801-F808, 2012. First published December 28, 2011; doi:10.1152/ajprenal.00253.2011.-Polycystic kidney disease (PKD) is a ciliopathy characterized by renal cysts and hypertension. These changes are presumably due to altered fluid and electrolyte transport in the collecting duct (CD). This is the site where vasopressin (AVP) stimulates vasopressin-2 receptor (V2R)-mediated aquaporin-2 (AQP2) insertion into the apical membrane. Since cysts frequently occur in the CD, we studied V2R and AQP2 trafficking and function in CD cell lines with stunted and normal cilia [cilia (-), cilia (+)] derived from the orpk mouse (hypomorph of the Tg737/Ift88 gene). Interestingly, only cilia (-) cells grown on culture dishes formed domes after apical AVP treatment. This observation led to our hypothesis that V2R mislocalizes to the apical membrane in the absence of a full-length cilium. Immunofluorescence indicated that AQP2 localizes to cilia and in a subapical compartment in cilia (+) cells, but AQP2 levels were elevated in both apical and basolateral membranes in cilia (-) cells after apical AVP treatment. Western blot analysis revealed V2R and glycosylated AQP2 in biotinylated apical membranes of cilia (-) but not in cilia (+) cells. In addition, apical V2R was functional upon apical desmopressin (DDAVP) treatment by demonstrating increased cAMP, water transport, and benzamil-sensitive equivalent short-circuit current (I-sc) in cilia (-) cells but not in cilia (+) cells. Moreover, pretreatment with a PKA inhibitor abolished DDAVP stimulation of I-sc in cilia (-) cells. Thus we propose that structural or functional loss of cilia leads to abnormal trafficking of AQP2/V2R leading to enhanced salt and water absorption. Whether such apical localization contributes to enhanced fluid retention and hypertension in PKD remains to be determined. C1 [Saigusa, Takamitsu; Reichert, Ryan; Guare, Jennifer; Gooz, Monika; Steele, Stacy; Bell, P. Darwin] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Kolb, Robert J.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Bell, P. Darwin] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Siroky, Brian J.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA. [Fenton, Robert A.] Aarhus Univ, Dept Biomed, Aarhus, Denmark. RP Bell, PD (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 173 Ashley Ave,CRI 211, Charleston, SC 29425 USA. EM bellpd@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [T32 DK007752, K01 DK075652, P30 DK074038, R01 DK32032]; Veterans Affairs Merit Grant; Dialysis Clinics, Inc. FX This research was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants T32 DK007752, K01 DK075652, P30 DK074038, and R01 DK32032, a Veterans Affairs Merit Grant, and Dialysis Clinics, Inc. NR 37 TC 16 Z9 16 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2012 VL 302 IS 7 BP F801 EP F808 DI 10.1152/ajprenal.00253.2011 PG 8 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 919PC UT WOS:000302339500002 PM 22205228 ER PT J AU Roane, BM Dolan, DC Bramoweth, AD Rosenthal, L Taylor, DJ AF Roane, Brandy M. Dolan, Diana C. Bramoweth, Adam D. Rosenthal, Leon Taylor, Daniel J. TI Altering Unhelpful Beliefs About Sleep with Behavioral and Cognitive Therapies SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE Insomnia; DBAS; Unhelpful beliefs; Cognitive therapy; Behavior therapy; CBTi ID CLINICAL CASE SERIES; DYSFUNCTIONAL BELIEFS; INSOMNIA; METAANALYSIS; PHARMACOTHERAPY; ATTITUDES; CRITERIA; UPDATE; TRIAL AB Multi-component treatment of insomnia is widely practiced; although, the additive benefit of a cognitive therapy component to specifically target unhelpful beliefs about sleep has not been conclusively determined. A chart review study at a sleep medicine clinic of 45 insomnia patients evaluated scores on the Dysfunctional Beliefs and Attitudes Scale (DBAS-16) before, during, and after cognitive behavioral therapy for insomnia (CBTi). Treatment followed standard practice, which consisted of behavioral therapy approaches during the first half of treatment and cognitive therapy during the latter portion. DBAS-16 scores improved significantly after behavioral treatment, t(44) = 6.02, P < .001, d = .9, and improved significantly again after the cognitive component of treatment, t(19) = 7.11, P < .001, d = 1.59. A comparison of the change scores, however, demonstrated no significant difference in the effects of behavioral and cognitive therapies, t(19) = 5.1, P < .562, d = .17, which suggests that cognitive therapy did not produce a greater change compared to behavioral components. Analysis of the DBAS-16 individual items suggests that the two treatment components-behavioral and cognitive therapies-may affect unhelpful beliefs about sleep differently. These findings support the need for future research to explore the effectiveness of selecting insomnia treatment components based on individual presentation. C1 [Taylor, Daniel J.] Univ N Texas, Dept Psychol, Denton, TX 76203 USA. [Rosenthal, Leon] Sleep Med Associates Texas PA, Dallas, TX USA. [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dolan, Diana C.] Wilford Hall USAF Med Ctr, Lackland AFB, TX USA. [Roane, Brandy M.] Brown Univ, Sleep Sci Res Lab, Providence, RI 02912 USA. [Roane, Brandy M.] Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA. RP Taylor, DJ (reprint author), Univ N Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. EM Daniel.Taylor@unt.edu OI Bramoweth, Adam/0000-0002-3535-0292 NR 17 TC 2 Z9 2 U1 1 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD APR PY 2012 VL 36 IS 2 SI SI BP 129 EP 133 DI 10.1007/s10608-011-9417-4 PG 5 WC Psychology, Clinical SC Psychology GA 919GR UT WOS:000302311400003 ER PT J AU Haynes, PL Ancoli-Israel, S Walter, CM McQuaid, JR AF Haynes, Patricia L. Ancoli-Israel, Sonia Walter, Christina M. McQuaid, John R. TI Preliminary Evidence for a Relationship Between Sleep Disturbance and Global Attributional Style in Depression SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE Sleep; Depression; Learned helplessness; Actigraphy ID COGNITIVE-BEHAVIORAL THERAPY; MAJOR DEPRESSION; HOPELESSNESS DEPRESSION; PSYCHIATRIC-DISORDERS; LEARNED HELPLESSNESS; WRIST ACTIVITY; INSOMNIA; SYMPTOMS; LIFE; QUESTIONNAIRE AB We hypothesized that a negative, stable, and global attributional style would mediate the relationship between sleep continuity and depression. Twenty-three currently depressed and 31 never-depressed participants completed the Attributional Styles Questionnaire and wore an actigraph during the course of 1 week. Linear and logistic regression techniques were used to calculate path coefficients to test the mediating relationship. Results indicated that a global attributional style mediated the relationship between poor sleep continuity (frequency of awakenings), delayed morning waketime, increased total time spent in bed, and depression. Reverse mediation analyses indicated that these relationships may be bidirectional. No effects were found for stable or internal attributions. These results suggest that global attributions may, in part, mediate the relationship between sleep disturbances and depression. They also provide data consistent with the hypothesis that disrupted sleep is associated with learned helplessness. Prospective studies are necessary to test the directionality of these relationships. C1 [Haynes, Patricia L.] Univ Arizona, Dept Psychiat, So Arizona VA Hlth Care Syst, Tucson, AZ 85724 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, San Diego, CA 92103 USA. [Walter, Christina M.] Arizona State Univ, So Arizona VA Hlth Care Syst, Univ Arizona, Tempe, AZ 85287 USA. [McQuaid, John R.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Haynes, PL (reprint author), Univ Arizona, Dept Psychiat, So Arizona VA Hlth Care Syst, 1501 N Campbell Ave,POB 245002, Tucson, AZ 85724 USA. EM thaynes@email.arizona.edu NR 46 TC 2 Z9 2 U1 5 U2 14 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD APR PY 2012 VL 36 IS 2 SI SI BP 140 EP 148 DI 10.1007/s10608-011-9416-5 PG 9 WC Psychology, Clinical SC Psychology GA 919GR UT WOS:000302311400005 ER PT J AU Sosa, MAG De Gasperi, R Elder, GA AF Sosa, Miguel A. Gama De Gasperi, Rita Elder, Gregory A. TI Modeling human neurodegenerative diseases in transgenic systems SO HUMAN GENETICS LA English DT Review ID ZINC-FINGER NUCLEASES; SITE-SPECIFIC RECOMBINATION; AMYLOID PRECURSOR PROTEIN; AMYOTROPHIC-LATERAL-SCLEROSIS; CAENORHABDITIS-ELEGANS MODEL; HUMAN ALPHA-SYNUCLEIN; EMBRYONIC STEM-CELLS; FRONTOTEMPORAL LOBAR DEGENERATION; INTRACYTOPLASMIC SPERM INJECTION; ASTROCYTE-SPECIFIC EXPRESSION AB Transgenic systems are widely used to study the cellular and molecular basis of human neurodegenerative diseases. A wide variety of model organisms have been utilized, including bacteria (Escherichia coli), plants (Arabidopsis thaliana), nematodes (Caenorhabditis elegans), arthropods (Drosophila melanogaster), fish (zebrafish, Danio rerio), rodents (mouse, Mus musculus and rat, Rattus norvegicus) as well as non-human primates (rhesus monkey, Macaca mulatta). These transgenic systems have enormous value for understanding the pathophysiological basis of these disorders and have, in some cases, been instrumental in the development of therapeutic approaches to treat these conditions. In this review, we discuss the most commonly used model organisms and the methodologies available for the preparation of transgenic organisms. Moreover, we provide selected examples of the use of these technologies for the preparation of transgenic animal models of neurodegenerative diseases, including Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and Parkinson's disease (PD) and discuss the application of these technologies to AD as an example of how transgenic modeling has affected the study of human neurodegenerative diseases. C1 [Sosa, Miguel A. Gama; De Gasperi, Rita] Vet Affairs Med Ctr, James J Peters Dept, Res & Dev Serv, Bronx, NY 10468 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Elder, Gregory A.] NYU, Dept Psychiat, Mt Sinai Sch Med, New York, NY 10016 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Elder, Gregory A.] NYU, Mt Sinai Sch Med, Friedman Brain Inst, New York, NY USA. [Elder, Gregory A.] Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.] NYU, Dept Neurol, Mt Sinai Sch Med, New York, NY 10016 USA. RP Sosa, MAG (reprint author), Vet Affairs Med Ctr, James J Peters Dept, Res & Dev Serv, 3F-20,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM miguel.gama-sosa@mssm.edu FU Alzheimer's Association [IIRG-07-57318]; Department of Veterans Affairs [1 I01 BX000342-01]; National Institute on Aging [P50 AG005138] FX Supported by the Alzheimer's Association (IIRG-07-57318), Department of Veterans Affairs (1 I01 BX000342-01) and the National Institute on Aging (P50 AG005138). NR 328 TC 48 Z9 49 U1 6 U2 65 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 EI 1432-1203 J9 HUM GENET JI Hum. Genet. PD APR PY 2012 VL 131 IS 4 BP 535 EP 563 DI 10.1007/s00439-011-1119-1 PG 29 WC Genetics & Heredity SC Genetics & Heredity GA 911NX UT WOS:000301725900002 ER PT J AU Gros, DF Simms, LJ Antony, MM McCabe, RE AF Gros, Daniel F. Simms, Leonard J. Antony, Martin M. McCabe, Randi E. TI Development and Psychometric Evaluation of the Multidimensional Assessment of Social Anxiety (MASA) SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE social anxiety; social phobia; hybrid model; Multidimensional Assessment of Social Anxiety; MASA ID DIMENSIONAL CLASSIFICATION-SYSTEM; DSM-IV ANXIETY; SPECIAL SECTION; PARADIGM SHIFT; MOOD DISORDERS; FIT INDEXES; PHOBIA; PSYCHOPATHOLOGY; INVENTORY; SCALE AB Objective: Hybrid models of psychopathology propose to combine the current categorical diagnostic system with shared symptom dimensions common across various disorders. Recently, the first empirically derived hybrid model of social anxiety was developed, including both a specific factor for the diagnostic category of social anxiety and 5 nonspecific factors for related symptoms. The present investigation developed a self-report measure-the Multidimensional Assessment of Social Anxiety (MASA)-based on this model to further the research on hybrid models. Method: This investigation included three studies across large undergraduate (N = 411; 52.3% male; mean [M] age = 19.6) and clinical (N = 684; 61.4% female; M age = 35.8) samples, involving the administration of the MASA item pool and existing measures of related constructs. Results: Through a series of psychometric evaluations, the initial 466-item pool was reduced to a final 38-item measure that represented 6 distinct scales with adequate model fit, internal consistency, test-retest reliability, and convergent and discriminant validity. Conclusions: Together, these studies likely will lead to additional research and advances in the development of the hybrid models of the mood and anxiety disorders through the dissemination and administration of the MASA. (C) 2012 Wiley Periodicals, Inc. J. Clin. Psychol. 68: 432-447, 2012. C1 [Gros, Daniel F.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Simms, Leonard J.] SUNY Buffalo, Buffalo, NY 14260 USA. [Antony, Martin M.] Ryerson Univ, Toronto, ON, Canada. [McCabe, Randi E.] McMaster Univ, Anxiety Treatment & Res Ctr, Hamilton, ON L8S 4L8, Canada. RP Gros, DF (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu RI Antony, Martin/K-1991-2012 OI Antony, Martin/0000-0002-3508-377X NR 41 TC 13 Z9 13 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD APR PY 2012 VL 68 IS 4 BP 432 EP 447 DI 10.1002/jclp.21838 PG 16 WC Psychology, Clinical SC Psychology GA 916CD UT WOS:000302073400007 PM 24469929 ER PT J AU Estrada, CA Dolansky, MA Singh, MK Oliver, BJ Callaway-Lane, C Splaine, M Gilman, S Patrician, PA AF Estrada, Carlos A. Dolansky, Mary A. Singh, Mamta K. Oliver, Brant J. Callaway-Lane, Carol Splaine, Mark Gilman, Stuart Patrician, Patricia A. TI Mastering improvement science skills in the new era of quality and safety: the Veterans Affairs National Quality Scholars Program SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE LA English DT Article DE clinical competence; curriculum; fellowships and scholarships; health personnel; education; interprofessional relations; program development; program evaluation; quality improvement; quality of health care; United States Department of Veterans Affairs ID IMPROVING PATIENT SAFETY; INTERNAL-MEDICINE; CONTROLLED-TRIAL; EDUCATION; HEALTH; CARE; COLLABORATION; TEAMWORK; PERFORMANCE; EXPERIENCE AB Rationale, aims and objectives Healthcare professionals need a new skill set to ensure the success of quality improvement in healthcare. The Department of Veterans Affairs (VA) initiated the VA National Quality Scholars fellowship in 1998; its mission is to improve the quality of care, ensure safety, accelerate healthcare re-design, and advance the improvement science by educating the next generation of leaders in quality and safety. We describe the critical need for leadership in quality and safety and interprofessional education, illustrate the curriculum, provide lessons learned by fellows, summarize key lessons learned from the implementation of an interprofessional education approach, and present most recent accomplishments. Methods Narrative review. Results As of 2011, 106 program alumni are embedded in the health care delivery system across the United States. Since 2009, when nurse fellows joined the program, of the first nine graduating interdisciplinary fellows, the tailored curriculum has resulted in five advanced academic degrees, 42 projects, 29 teaching activities, 44 presentations, 36 publications, six grants funded or submitted, and two awards. Conclusions The VA National Quality Scholars program continues to nurture and develop leaders for the new millennium focusing on interprofessional education. The nations' health care systems need strong interdisciplinary leaders in advanced quality improvement science who are dedicated to improving the overall quality of health and health care. C1 [Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL 35294 USA. [Singh, Mamta K.] Case Western Reserve Univ, Louis Stokes Cleveland VA Med Ctr, Patient Based Programs, Cleveland, OH 44106 USA. [Dolansky, Mary A.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Singh, Mamta K.] Case Western Reserve Univ, Ctr Excellence Primary Care Educ, Cleveland, OH 44106 USA. [Oliver, Brant J.] White River Junct Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, White River Jct, VT USA. [Oliver, Brant J.] Dartmouth Med Sch, Colby Sawyer Coll, Hanover, NH USA. [Callaway-Lane, Carol] Vanderbilt Univ, Sch Nursing, Vet Affairs Natl Qual Scholars Jr Fac, Nashville, TN 37240 USA. [Callaway-Lane, Carol] VA Tennessee Valley Healthcare Syst, Nashville, TN USA. [Splaine, Mark] Dartmouth Med Sch, Ctr Leadership & Improvement, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Gilman, Stuart] VA Off Acad Affiliat, Washington, DC USA. [Patrician, Patricia A.] Univ Alabama Birmingham, Vet Affairs Natl Qual Scholars Program, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Patrician, Patricia A.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Program, FOT 732,510 20th St S, Birmingham, AL 35294 USA. EM carlos.estrada@va.gov FU Veterans Affairs Office of Academic Affiliations, Washington, DC; QSEN initiative; Robert Wood Johnson Foundation FX The VAQS Program is supported by the Veterans Affairs Office of Academic Affiliations, Washington, DC.; Support for the Senior Nursing Fellows is currently provided by the QSEN initiative funded by the Robert Wood Johnson Foundation. NR 45 TC 4 Z9 4 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1356-1294 J9 J EVAL CLIN PRACT JI J. Eval. Clin. Pract. PD APR PY 2012 VL 18 IS 2 BP 508 EP 514 DI 10.1111/j.1365-2753.2011.01816.x PG 7 WC Health Care Sciences & Services; Medical Informatics; Medicine, General & Internal SC Health Care Sciences & Services; Medical Informatics; General & Internal Medicine GA 902QQ UT WOS:000301053800041 PM 22304698 ER PT J AU Ahluwalia, SC Levin, JR Lorenz, KA Gordon, HS AF Ahluwalia, Sangeeta C. Levin, Jennifer R. Lorenz, Karl A. Gordon, Howard S. TI Missed Opportunities for Advance Care Planning Communication During Outpatient Clinic Visits SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE qualitative research; advance care planning; heart failure; physician-patient communication ID OF-LIFE CARE; DOCTOR-PATIENT COMMUNICATION; CHRONIC HEART-FAILURE; PALLIATIVE CARE; LUNG-CANCER; CONTROLLED-TRIAL; ILL PATIENTS; BAD-NEWS; END; SKILLS AB Early provider-patient communication about future care is critical for patients with heart failure (HF); however, advance care planning (ACP) discussions are often avoided or occur too late to usefully inform care over the course of the disease. To identify opportunities for physicians to engage in ACP discussions and to characterize physicians' responses to these opportunities. Qualitative study of audio-recorded outpatient clinic visits. Fifty-two patients a parts per thousand yenaEuro parts per thousand 65 years recently hospitalized for HF with one or more post-discharge follow-up outpatient visits, and their physicians (n = 44), at two Veterans Affairs Medical Centers. Using content analysis methods, we analyzed and coded transcripts of outpatient follow-up visits for 1) patient statements pertaining to their future health or their future physical, psychosocial and spiritual/existential care needs, and 2) subsequent physician responses to patient statements, using an iterative consensus-based coding process. In 13 of 71 consultations, patients expressed concerns, questions, and thoughts regarding their future care that gave providers opportunities to engage in an ACP discussion. The majority of these opportunities (84%) were missed by physicians. Instead, physicians responded by terminating the conversation, hedging their responses, denying the patient's expressed emotion, or inadequately acknowledging the sentiment underlying the patient's statement. Physicians often missed the opportunity to engage in ACP despite openers patients provided that could have prompted such discussions. Communication training efforts should focus on helping physicians identify patient openers and providing a toolbox to encourage appropriate physician responses; in order to successfully leverage opportunities to engage in ACP discussions. C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA. [Levin, Jennifer R.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gordon, Howard S.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA. [Gordon, Howard S.] VA Ctr Management Complex Chron Care, Chicago, IL USA. [Gordon, Howard S.] Univ Illinois, Coll Med, Dept Med, Gen Internal Med Sect, Chicago, IL USA. [Gordon, Howard S.] Univ Illinois, Coll Med, Dept Med, Sect Hlth Promot Res, Chicago, IL USA. RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, 11301 Wilshire Blvd,111-G, Los Angeles, CA 90064 USA. EM sangeeta.ahluwalia@va.gov RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 FU United States Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service [ECV-02-254]; Office of Academic Affiliations' VA at the VA Greater Los Angeles HSR&D Center of Excellence FX This work was supported in part by #ECV-02-254 (PI: Gordon) from the United States Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service. The views expressed in the article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Ahluwalia is supported by an Office of Academic Affiliations' VA Associated health Postdoctoral Fellowship Program at the VA Greater Los Angeles HSR&D Center of Excellence. NR 58 TC 12 Z9 12 U1 1 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2012 VL 27 IS 4 BP 445 EP 451 DI 10.1007/s11606-011-1917-0 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 912YM UT WOS:000301837900014 PM 22038469 ER PT J AU Baxi, SM Kohlwes, J AF Baxi, Sanjiv M. Kohlwes, Jeff TI ST-Segment Elevation and Minimally Reactive Pupils SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE neurology; cardiovascular; emergency medicine C1 [Baxi, Sanjiv M.; Kohlwes, Jeff] Univ Calif San Francisco, Dept Internal Med, San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. RP Baxi, SM (reprint author), Univ Calif San Francisco, Dept Internal Med, San Francisco Vet Adm Med Ctr, VAMC 11,4150 Clement St, San Francisco, CA 94121 USA. EM sanjiv.baxi@ucsf.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2012 VL 27 IS 4 BP 478 EP 479 DI 10.1007/s11606-011-1847-x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 912YM UT WOS:000301837900019 PM 21935754 ER PT J AU Sanders, JL Fitzpatrick, AL Boudreau, RM Arnold, AM Aviv, A Kimura, M Fried, LF Harris, TB Newman, AB AF Sanders, Jason L. Fitzpatrick, Annette L. Boudreau, Robert M. Arnold, Alice M. Aviv, Abraham Kimura, Masayuki Fried, Linda F. Harris, Tamara B. Newman, Anne B. TI Leukocyte Telomere Length Is Associated With Noninvasively Measured Age-Related Disease: The Cardiovascular Health Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Leukocyte telomere length; Disease burden; Noninvasive measurements; Aging ID CAROTID ATHEROSCLEROSIS; OXIDATIVE STRESS; RISK-FACTORS; MORTALITY; ADULTS; DEMENTIA; DYNAMICS; PERFORMANCE; SENESCENCE; DEPRESSION AB Background. Most studies of leukocyte telomere length (LTL) focus on diagnosed disease in one system. A more encompassing depiction of health is disease burden, defined here as the sum of noninvasively measured markers of structure or function in different organ systems. We determined if (a) shorter LTL is associated with greater age-related disease burden and (b) shorter LTL is less strongly associated with disease in individual systems or diagnosed chronic conditions (cardiovascular disease, stroke, pulmonary disease, diabetes, kidney disease, arthritis, or depression). Methods. LTL was measured by Southern blots of terminal restriction fragment length. Age-related disease was measured noninvasively and included carotid intima-media thickness, lung vital capacity, white matter grade, cystatin-C, and fasting glucose; each graded 0 (best tertile), 1 (middle tertile), or 2 (worst tertile) and summed (0 to 10) to estimate disease burden. Of 419 participants randomly selected for LTL measurement, 236 had disease burden assessed (mean [SD] age 74.2 [4.9] years, 42.4% male, 86.8% white, and 13.2% black). Results. Mean (SD) LTL was 6,312 (615) bp, and disease score was 4.7 (2.1) points. An SD higher disease score (beta[SE] = -132 [47] bp, p < .01), age (beta[SE] = -107 [46], p = .02) or carotid thickness (beta[SE] = -95 [40] bp, p = .02) was associated with shorter LTL, but diagnosed conditions or number of conditions were not associated with LTL. Disease score attenuated the effect of age on LTL by 35%. Conclusion. LTL was associated with a characterization of age-related disease burden across multiple physiologic systems, which was comparable to, but independent of, its association with age. C1 [Sanders, Jason L.; Boudreau, Robert M.; Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Sanders, Jason L.] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA 15213 USA. [Fitzpatrick, Annette L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Arnold, Alice M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Aviv, Abraham; Kimura, Masayuki] Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Human Dev & Aging, Newark, NJ 07103 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA. RP Sanders, JL (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Bellefield Profess Bldg,4th Floor,130 N Bellefiel, Pittsburgh, PA 15213 USA. EM sanders.jason@medstudent.pitt.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Boudreau, Robert/0000-0003-0162-5187 FU Royalty Research Fund; University of Washington; Healthcare Foundation of New Jersey; National Institute on Aging [R01-AG-023629, 5-P30-AG-024827, AG-021593, AG-020132]; National Heart, Lung, and Blood Institute [R01-HL-80698-01, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-45133, N01-HC-75150, N01-HC-55222, U01 HL080295]; National Institute of Neurological Disorders and Stroke FX This research was supported by the Royalty Research Fund, the University of Washington, the Healthcare Foundation of New Jersey, the National Institute on Aging (grants R01-AG-023629 and 5-P30-AG-024827), and the National Heart, Lung, and Blood Institute (R01-HL-80698-01). The CHS is supported by the National Heart, Lung, and Blood Institute (contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-45133, N01-HC-75150, N01-HC-55222, and U01 HL080295), the National Institute on Aging (grants AG-021593 and AG-020132), and the National Institute of Neurological Disorders and Stroke. A full list of participating Cardiovascular Health Study investigators and institutions can be found at the study's website (http://www.chs-nhlbi.org). Role of sponsor(s): The investigators retained full independence in the conduct of this research. NR 45 TC 31 Z9 33 U1 4 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2012 VL 67 IS 4 BP 409 EP 416 DI 10.1093/gerona/glr173 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 914TE UT WOS:000301974500011 PM 21934123 ER PT J AU Swanson, RA AF Swanson, Raymond A. TI One cell's poison is another cell's cure SO NATURE NEUROSCIENCE LA English DT Editorial Material ID CEREBRAL-ISCHEMIA; BCL-X; APOPTOSIS; MECHANISMS; DYNAMICS; BRAIN; DEATH AB A drug that promotes cell death in cancer cells prevents cell death in post-ischemic neurons. These contrasting effects stem from the distinct actions of the anti-apoptotic protein Bcl-x(L) and its cleavage product, Delta N-Bcl-x(L). C1 [Swanson, Raymond A.] Univ Calif San Francisco, Neurol & Rehabil Serv, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Swanson, RA (reprint author), Univ Calif San Francisco, Neurol & Rehabil Serv, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. EM raymond.swanson@ucsf.edu OI Swanson, Raymond/0000-0002-3664-5359 FU NINDS NIH HHS [R01 NS041421] NR 15 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD APR PY 2012 VL 15 IS 4 BP 505 EP 506 PG 2 WC Neurosciences SC Neurosciences & Neurology GA 916PA UT WOS:000302114500005 PM 22449958 ER PT J AU Yenari, MA Han, HS AF Yenari, Midori A. Han, Hyung Soo TI Neuroprotective mechanisms of hypothermia in brain ischaemia SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID FOCAL CEREBRAL-ISCHEMIA; FACTOR-KAPPA-B; ASPHYXIAL CARDIAC-ARREST; TO-MODERATE HYPOTHERMIA; SIGNAL-REGULATED KINASE; WHOLE-BODY HYPOTHERMIA; NECROSIS-FACTOR-ALPHA; RNA-BINDING PROTEIN; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA AB Cooling can reduce primary injury and prevent secondary injury to the brain after insults in certain clinical settings and in animal models of brain insult. The mechanisms that underlie the protective effects of cooling - also known as therapeutic hypothermia are slowly beginning to be understood. Hypothermia influences multiple aspects of brain physiology in the acute, subacute and chronic stages of ischaemia. It affects pathways leading to excitotoxicity, apoptosis, inflammation and free radical production, as well as blood flow, metabolism and blood-brain barrier integrity. Hypothermia may also influence neurogenesis, gliogenesis and angiogenesis after injury. It is likely that no single factor can explain the neuroprotection provided by hypothermia, but understanding its myriad effects may shed light on important neuroprotective mechanisms. C1 [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Han, Hyung Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, Taegu 700422, South Korea. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM Yenari@alum.mit.edu FU US National Institutes of Health [NS40516]; Veteran's Merit Award; Ministry of Health & Welfare, Republic of Korea [A100870]; Industrial Strategic technology development program [10035197]; Ministry of Knowledge Economy (MKE) Korea FX This work was supported by grants from the US National Institutes of Health (NS40516 to M.Y.), the Veteran's Merit Award (M.Y.), the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100870 to H.S.H.) and the Industrial Strategic technology development program (10035197 to H.S.H.), which is funded by the Ministry of Knowledge Economy (MKE), Korea. Grants to M.Y. were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. NR 126 TC 149 Z9 164 U1 2 U2 32 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-003X J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD APR PY 2012 VL 13 IS 4 BP 267 EP 278 DI 10.1038/nrn3174 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 914IH UT WOS:000301942500010 PM 22353781 ER PT J AU Porcel, JM Leung, CC Restrepo, MI Lee, P AF Porcel, Jose M. Leung, Chi Chiu Restrepo, Marcos I. Lee, Pyng TI Year in review 2011: Respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging SO RESPIROLOGY LA English DT Review DE endobronchial ultrasonography; pleural effusion; pneumonia; positron emission tomography; tuberculosis ID COMMUNITY-ACQUIRED PNEUMONIA; TRANSBRONCHIAL NEEDLE ASPIRATION; BRONCHOALVEOLAR LAVAGE FLUID; GAMMA RELEASE ASSAYS; INTERFERON-GAMMA; MYCOBACTERIUM-TUBERCULOSIS; ACTIVE TUBERCULOSIS; PARAPNEUMONIC EFFUSION; RESISTANT TUBERCULOSIS; PULMONARY SARCOIDOSIS C1 [Porcel, Jose M.] Arnau de Vilanova Univ Hosp, Dept Internal Med, Biomed Res Insitute Lleida, Pleural Dis Unit, Lleida 25198, Spain. [Leung, Chi Chiu] Tuberculosis & Chest Serv, Dept Hlth, Hong Kong, Hong Kong, Peoples R China. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, Audie L Murphy VA Hosp, VERDICT,S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Lee, Pyng] Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore. RP Porcel, JM (reprint author), Arnau de Vilanova Univ Hosp, Dept Internal Med, Biomed Res Insitute Lleida, Pleural Dis Unit, Avda Alcalde Rovira Roure 80, Lleida 25198, Spain. EM jporcelp@yahoo.es RI Restrepo, Marcos/H-4442-2014 FU Instituto de Salud Carlos III [FIS 09/00199]; NIH/NHLBI [K23HL096054] FX J.M.P. has received a research grant from the Instituto de Salud Carlos III (FIS 09/00199). M.I.R.'s time is partially covered by the NIH/NHLBI Grant K23HL096054. NR 82 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1323-7799 J9 RESPIROLOGY JI Respirology PD APR PY 2012 VL 17 IS 3 BP 573 EP 582 DI 10.1111/j.1440-1843.2012.02128.x PG 10 WC Respiratory System SC Respiratory System GA 915DO UT WOS:000302004300025 PM 22248294 ER PT J AU Slatore, CG Goy, ER O'Hearn, DJ Boudreau, EA O'Malley, JP Peters, D Ganzini, L AF Slatore, Christopher G. Goy, Elizabeth R. O'Hearn, Daniell J. Boudreau, Eilis A. O'Malley, Jean P. Peters, Dawn Ganzini, Linda TI Sleep Quality and Its Association With Delirium Among Veterans Enrolled in Hospice SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Sleep quality; delirium; hospice; Veterans ID ADVANCED CANCER-PATIENTS; OF-LIFE; WAKE DISTURBANCES; OLDER PERSONS; CAREGIVERS; DISTRESS; PEOPLE; END; DEPRESSION; MELATONIN AB Objectives: The objectives of this study were to describe sleep quality and evaluate the association of sleep quality with delirium onset among patients enrolled in hospice. Design: The study utilized secondary data from a prospective, observational, longitudinal study. Setting: Veterans enrolled in hospice were recruited from the Portland Veterans Affairs Medical Center, Portland, Oregon. Participants: The cohort consisted of 105 patients, of whom 73% had at least one sleep measurement. Measurements: Sleep quality was measured with the Pittsburgh Sleep Quality Index. Delirium was measured with the Confusion Assessment Method. Other important variables were recorded from the medical record and/or longitudinal interviews with patients and their caregivers. Cox regression was used to estimate hazard ratios (HRs) to measure the association between sleep quality and delirium onset. Results: Of the patients who could be assessed, 44% had poor average sleep quality and 58% reported at least one episode of poor sleep. Overall, sleep quality did not appear to worsen as patients neared death although an increasing number of patients were unable to report on sleep quality. Poor sleep quality was associated with an increased risk of developing delirium, with an HR of 2.37 (95% CI: 1.50-3.74), for every one point worsening in the sleep quality score on a 4-point scale. Conclusions: Poor sleep quality was common among Veteran patients enrolled in hospice. These findings may help guide decision making between clinicians, patients, and families regarding the likely impact of sleep disturbance and may help identify patients at higher risk of developing delirium. (Am J Geriatr Psychiatry 2012; 20:317-326) C1 [Slatore, Christopher G.; Goy, Elizabeth R.; Ganzini, Linda] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR USA. [Slatore, Christopher G.; O'Hearn, Daniell J.; Boudreau, Eilis A.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.; O'Hearn, Daniell J.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Boudreau, Eilis A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Slatore, CG (reprint author), 3710SW,US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Slatore, Christopher/0000-0003-0958-8122 FU Department of Veterans Affairs; VA HSRD; Portland VA Medical Center; Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources (NCRR) [UL1 RR024140 01] FX The study was funded by a Merit Review Award from the Clinical Sciences Research and Development Program, Department of Veterans Affairs (Dr. Ganzini). Drs. Slatore and Goy are recipients of VA HSRD Career Development Awards. Drs. Slatore, Goy, O'Hearn, Boudreau, and Ganzini are supported by resources from the Portland VA Medical Center. Dr. Dawn Peters and Jean O'Malley are supported by resources from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 01 from the National Center for Research Resources (NCRR). The Department of Veterans Affairs did not have a role in the conduct of the study, in the collection, management, analysis, or interpretation of data, or in the preparation of the manuscript. NR 36 TC 7 Z9 7 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD APR PY 2012 VL 20 IS 4 BP 317 EP 326 DI 10.1097/JGP.0b013e3182487680 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 912SA UT WOS:000301818800006 PM 22367162 ER PT J AU Devanand, DP Mintzer, J Schultz, S Sultzer, D de la Pena, D Gupta, S Colon, S Schimming, C Pelton, GH Andrews, H Levin, B AF Devanand, D. P. Mintzer, Jacob Schultz, Susan Sultzer, David de la Pena, Danilo Gupta, Sanjay Colon, Sylvia Schimming, Corbett Pelton, Gregory H. Andrews, Howard Levin, Bruce TI The Antipsychotic Discontinuation in Alzheimer Disease Trial: Clinical Rationale and Study Design SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Agitation; Alzheimer disease; antipsychotic; discontinuation trial; psychosis; risperidone ID PLACEBO-CONTROLLED TRIALS; NURSING-HOME RESIDENTS; DOUBLE-BLIND; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; NEUROPSYCHIATRIC INVENTORY; BEHAVIORAL DISTURBANCES; TARDIVE-DYSKINESIA; LEWY BODIES; DEMENTIA AB Objectives: Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients with psychosis or agitation receive open treatment with risperidone for 16 weeks. Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks. Methods: Several design features provide unique strengths to this trial: identification of target symptoms and systematic open Antipsychotic treatment with only responders randomized in the discontinuation trial, use of a single antipsychotic medication, two clinically relevant time-points for discontinuation to evaluate the impact of duration of treatment on relapse, exclusion of patients at increased risk of stroke, assessment of several affected symptom domains, and state-of-the-art approaches to assess relapse and handle dropout. Conclusions: This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment. Given the warnings about antipsychotic use in patients with dementia, studies of this type are essential to determine the optimal duration of treatment that confers the greatest benefit to risk ratio and to improve evidence-based treatment strategies. (Am J Geriatr Psychiatry 2012; 20:362-373) C1 [Devanand, D. P.; Pelton, Gregory H.] Columbia Univ, Coll Phys & Surg, New York State Psychiat Inst, Div Geriatr Psychiat, New York, NY USA. [Devanand, D. P.; Pelton, Gregory H.; Andrews, Howard] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY USA. [Devanand, D. P.; Pelton, Gregory H.; Andrews, Howard] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA. [Devanand, D. P.; Pelton, Gregory H.; Andrews, Howard] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. [Levin, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Mintzer, Jacob] Med Univ S Carolina, Dept Neurosci, Div Translat Res, Charleston, SC 29425 USA. [Mintzer, Jacob] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Schultz, Susan] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA. [Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Sultzer, David] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [de la Pena, Danilo] Res Ctr Clin Studies Inc, Norwalk, CT USA. [Gupta, Sanjay] Global Res & Consulting, Buffalo, NY USA. [Colon, Sylvia] VA Med Ctr, Dept Psychiat, Tuscaloosa, AL USA. [Schimming, Corbett] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Devanand, DP (reprint author), 1051 Riverside Dr,Unit 126, New York, NY 10032 USA. EM dpd3@columbia.edu FU NIH [R01 AG021488, R01 AG17761]; Department of Veterans Affairs; National Institutes of Health; Novartis; Eli Lilly; Elan; Esai; Danone; Genentech; Janssen; Avid; Pfizer; Baxter; Wyeth; Alzheimer Disease Cooperative Study; Forest Research Institute; Takeda Pharmaceuticals; GSK; Roche; Lundbeck; Toyoma Pharmaceuticals; Bristol Myers Squibb; Astra Zeneca; Myriad; Ono Pharmaceuticals; Memory Pharmaceuticals; Takeda; Forest FX This study was supported by NIH grants R01 AG021488, R01 AG17761 and the Department of Veterans Affairs. Risperidone tablets (0.25, 0.5, 1, or 2 mg) and matching placebo were donated by Janssen Pharmaceutical, which had no other role in this study.; Dr. Devanand has received grants from the National Institutes of Health, research support from Novartis and Eli Lilly, and has served as a consultant to GSK, Bristol Myers Squibb, and Sanofi-Aventis. Dr. Mintzer has received research support from Elan, Esai, Danone, Genentech, Janssen, Avid, Pfizer, Baxter, Wyeth, and Eli Lilly, has served as a consultant to Antigenics, and is majority owner of Bio Pharma Connex, a company whose mission is to bring biotechnology to Latin America. Dr. Schultz has received research support from Baxter Healthcare in cooperation with the Alzheimer Disease Cooperative Study. Dr. Sultzer has received research support from the National Institutes of Health, Eli Lilly, and Forest Research Institute, and has served as a consultant to Eli Lilly. Dr. de la Pena has received research support from Takeda Pharmaceuticals, GSK, Eli Lilly, Elan, Janssen, Wyeth, Roche, Lundbeck, Toyoma Pharmaceuticals, Pfizer, and Bristol Myers Squibb. Dr. Gupta has received research support from Eli Lilly, Pfizer, Astra Zeneca, GSK, Myriad, Ono Pharmaceuticals, Memory Pharmaceuticals, Takeda, and has served as a consultant to Eli Lilly, and has been on the Speaker's Bureau for Eli Lilly, Pfizer, Astra Zeneca, Merck, Forest, Novartis, and GSK. Dr. Pelton has received research support from GSK, Novartis, and Forest and has served as a consultant to Bristol Myers Squibb and Pfizer. NR 44 TC 7 Z9 7 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD APR PY 2012 VL 20 IS 4 BP 362 EP 373 DI 10.1097/JGP.0b013e3182110563 PG 12 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 912SA UT WOS:000301818800011 PM 21407047 ER PT J AU Benmansour, S Weaver, RS Barton, AK Adeniji, OS Frazer, A AF Benmansour, Saloua Weaver, Rami S. Barton, Amanda K. Adeniji, Opeyemi S. Frazer, Alan TI Comparison of the Effects of Estradiol and Progesterone on Serotonergic Function SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Chronoamperometry; estradiol; FST; progesterone; serotonin transporter; SSRI ID ESTROGEN-RECEPTOR-BETA; PROTEIN-COUPLED RECEPTOR; FORCED-SWIMMING TEST; CENTRAL-NERVOUS-SYSTEM; RAT HIPPOCAMPAL-FORMATION; GROWTH-FACTOR RECEPTOR; ANXIETY-LIKE BEHAVIOR; BREAST-CANCER; REPLACEMENT THERAPY; DORSAL HIPPOCAMPUS AB Background: Ovarian hormones may contribute to the vulnerability to depression, as well as to the response to antidepressants (ADs). Previously, we reported that acute systemic treatment with estradiol or progesterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to inhibit serotonin transporter function in ovariectomized rats. In this study, behavioral consequences, as well as receptor mechanisms underlying these hormonal effects, were investigated. Methods: Using the forced swimming test, the acute effect of estradiol and/or progesterone on fluvoxamine's AD-like effects was investigated. Using in vivo chronoamperometry, the effect of local application of estradiol or progesterone into the hippocampus of ovariectomized rats on serotonin (5-HT) clearance, as well as on the ability of fluvoxamine to slow 5-HT clearance, were investigated. Results: The decreased immobility and increased swimming caused by fluvoxamine in the forced swimming test was blocked in rats treated with estradiol and/or progesterone. Local application of estradiol, but not progesterone, slowed 5-HT clearance and both hormones blocked the ability of fluvoxamine to slow 5-HT clearance. Use of hormone receptor agonists and antagonists, revealed that the effects of estradiol are mediated by activation of membrane, as well as nuclear estrogen receptors (ER). The AD-like effect of estradiol involved ER beta and G-protein coupled receptor 30, whereas its blockade of fluvoxamine's effects was ER alpha-mediated. The effects of progesterone occurred solely by activation of intracellular progesterone receptors. Conclusions: Targeting of ER beta or G-protein coupled receptor 30 might reveal a strategy to permit beneficial effects of estrogen without its deleterious effect on selective serotonin reuptake inhibitor efficacy. C1 [Benmansour, Saloua; Weaver, Rami S.; Barton, Amanda K.; Adeniji, Opeyemi S.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Benmansour, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,MC 7764, San Antonio, TX 78229 USA. EM benmansour@uthscsa.edu FU National Alliance for Research on Schizophrenia and Depression; Department of Veterans Affairs; National Institute of Mental Health [MH090386]; Forest Research Institute; Eli Lilly and Company; Wyeth Pharmaceuticals; H. Lundbeck A/S FX This research was supported by funds from the National Alliance for Research on Schizophrenia and Depression to SB, the Department of Veterans Affairs, and the National Institute of Mental Health (MH090386) to AF.; Dr. Benmansour, Ms. Weaver, Ms. Barton, and Mr. Adeniji have no biomedical financial interests or potential conflicts of interest. Dr. Frazer has been on advisory boards for Cyberonics, Inc.; H. Lundbeck A/S; and Takeda Pharmaceuticals America, Inc., and he has consulted and/or received research support for preclinical studies from Forest Research Institute, Eli Lilly and Company, Wyeth Pharmaceuticals, and H. Lundbeck A/S. NR 81 TC 20 Z9 21 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2012 VL 71 IS 7 BP 633 EP 641 DI 10.1016/j.biopsych.2011.11.023 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 910RV UT WOS:000301659900012 PM 22225849 ER PT J AU Sandholm, J Kauppila, JH Pressey, C Tuomela, J Jukkola-Vuorinen, A Vaarala, M Johnson, MR Harris, KW Selander, KS AF Sandholm, Jouko Kauppila, Joonas H. Pressey, Christine Tuomela, Johanna Jukkola-Vuorinen, Arja Vaarala, Markku Johnson, Martin R. Harris, Kevin W. Selander, Katri S. TI Estrogen receptor-alpha and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Toll-like receptor 9; Invasion; Estradiol; Testosterone ID NF-KAPPA-B; SUBCELLULAR-LOCALIZATION; HELICOBACTER-PYLORI; MEDIATOR PRODUCTION; ANDROGEN RECEPTOR; CELLULAR INVASION; EPITHELIAL-CELLS; IN-VIVO; TLR9; TOLL-LIKE-RECEPTOR-9 AB Toll-like receptor 9 (TLR9) is a cellular DNA-receptor, which is widely expressed in cancer. Synthetic TLR9-ligands induce cancer cell invasion in vitro, but the role of TLR9 in cancer pathophysiology remains unclear. Increased TLR9 expression has been, however, detected in estrogen receptor negative (ER-) breast cancers. In this study, we investigated the effects of ER alpha expression and sex steroid hormones on TLR9 expression in human ER+ (MCF-7, T47-D) and ER- (MDA-MB-231) breast cancer cell lines in vitro. We also studied TLR9 mRNA expression in archival breast cancer specimens (n = 12) with qRT-PCR, using primer sets that detect only the TLR9A isoform or the isoforms A and B (TLR9A/B). The TLR9 mRNA expression was detected in 10/12 specimens with both primer sets, and in 1/12 with only the TLR9A or the TLR9A/B primer sets. The basal TLR9 mRNA expression levels were significantly lower in the ER+ cell lines as compared with the ER- MDA-MB-231 cells. The transfection of ER alpha cDNA into MDA-MB-231 cells also resulted in down-regulation of TLR9 expression. While sex steroids had no effect on TLR9 expression in MCF-7 cells, testosterone (10(-8) M) induced TLR9 expression in MDA-MB-231 and T47-D cells. Although bicalutamide blocked this testosterone effect in MDA-MB-231 cells, in T47-D cells bicalutamide increased TLR9 expression and only partially blocked the testosterone effects. Estradiol (10(-8) M) induced TLR9 expression in T47-D cells. The invasive effects of synthetic TLR9-ligands were augmented by testosterone in vitro. This effect was lost in TLR9 siRNA MDA-MB-231 cells and also decreased by over-expression of ER alpha, which also inhibited NF-kappa B activation by TLR9-ligands. In conclusion, expression of TLR9 isoforms A and B can be detected in clinical breast cancer specimens. The ER alpha and sex steroid hormones regulate TLR9 expression and invasive effects in the breast cancer cells. Also, the commonly used hormonal cancer therapy bicalutamide affects TLR9 expression. C1 [Selander, Katri S.] Univ Alabama, Div Hematol Oncol, Dept Med, Birmingham, AL 35294 USA. [Kauppila, Joonas H.] Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland. [Kauppila, Joonas H.; Vaarala, Markku] Oulu Univ Hosp, Dept Surg, Oulu, Finland. [Jukkola-Vuorinen, Arja] Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland. [Kauppila, Joonas H.; Vaarala, Markku] Oulu Univ Hosp, Dept Pathol, Oulu, Finland. [Johnson, Martin R.] Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Selander, KS (reprint author), Univ Alabama, Div Hematol Oncol, Dept Med, SHEL 14,1825 Univ Blvd, Birmingham, AL 35294 USA. EM Katri.Selander@ccc.uab.edu RI perumal, murugiah/D-1565-2012; Kauppila, Joonas/P-1363-2015; Vaarala, Markku/B-4116-2013 OI Kauppila, Joonas/0000-0001-6740-3726; Vaarala, Markku/0000-0003-4735-815X FU Northern Finnish Duodecim Foundation; Finnish Cultural Foundation; Cancer Foundation of Northern Ostrobotnia; Oulu University Scholarship Foundation; Elsa U. Pardee Foundation FX This study was financially supported by grants from the Northern Finnish Duodecim Foundation (A. J.-V.), Finnish Cultural Foundation, Lapland Funds (A. J.-V. and K. S. S.), Cancer Foundation of Northern Ostrobotnia, Oulu University Scholarship Foundation (J. H. K.), and Elsa U. Pardee Foundation (K. S. S.). NR 34 TC 14 Z9 16 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD APR PY 2012 VL 132 IS 2 BP 411 EP 419 DI 10.1007/s10549-011-1590-3 PG 9 WC Oncology SC Oncology GA 909ER UT WOS:000301545900005 PM 21607583 ER PT J AU Penrod, JD Pronovost, PJ Livote, EE Puntillo, KA Walker, AS Wallenstein, S Mercado, AF Swoboda, SM Ilaoa, D Thompson, DA Nelson, JE AF Penrod, Joan D. Pronovost, Peter J. Livote, Elayne E. Puntillo, Kathleen A. Walker, Amy S. Wallenstein, Sylvan Mercado, Alice F. Swoboda, Sandra M. Ilaoa, Debra Thompson, David A. Nelson, Judith E. TI Meeting standards of high-quality intensive care unit palliative care: Clinical performance and predictors SO CRITICAL CARE MEDICINE LA English DT Article DE critical care; intensive care units; palliative care; quality improvement; quality indicators, health care ID OF-LIFE CARE; FAMILY-MEMBERS; ADVANCE DIRECTIVES; DECISION-MAKING; ICU; COMMUNICATION; INDICATORS; STATEMENT; SYMPTOMS; MEDICINE AB Objectives: High-quality care for intensive care unit patients and families includes palliative care. To promote performance improvement, the Agency for Healthcare Research and Quality's National Quality Measures Clearinghouse identified nine evidence-based processes of intensive care unit palliative care (Care and Communication Bundle) that are measured through review of medical record documentation. We conducted this study to examine how frequently the Care and Communication Bundle processes were performed in diverse intensive care units and to understand patient factors that are associated with such performance. Design: Prospective, multisite, observational study of performance of key intensive care unit palliative care processes. Settings: A surgical intensive care unit and a medical intensive care unit in two different large academic health centers and a medical-surgical intensive care unit in a medium-sized community hospital. Patients: Consecutive adult patients with length of intensive care unit stay >= 5 days. Interventions: None. Measurements and Main Results: Between November 2007 and December 2009, we measured performance by specified day after intensive care unit admission on nine care process measures: identify medical decision-maker, advance directive and resuscitation preference, distribute family information leaflet, assess and manage pain, offer social work and spiritual support, and conduct interdisciplinary family meeting. Muttivariable regression analysis was used to determine predictors of performance of five care processes. We enrolled 518 (94.9%) patients and 336 (83.6%) family members. Performances on pain assessment and management measures were high. In contrast, interdisciplinary family meetings were documented for <20% of patients by intensive care unit day 5. Performance on other measures ranged from 8% to 43%, with substantial variation across and within sites. Chronic comorbidity burden and site were the most consistent predictors of care process performance. Conclusions: Across three intensive care units in this study, performance of key palliative care processes (other than pain assessment and management) was inconsistent and infrequent. Available resources and strategies should be utilized for performance improvement in this area of high importance to patients, families, and providers. (Crit Care Med 2012; 40:1105-1112) C1 [Walker, Amy S.; Mercado, Alice F.; Nelson, Judith E.] Mt Sinai Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY USA. [Penrod, Joan D.; Livote, Elayne E.] James J Peters VA Med Ctr, Ctr Res Hlth Care Syst & Sites Care, Bronx, NY USA. [Penrod, Joan D.] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Pronovost, Peter J.] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Qual & Safety Res Grp, Baltimore, MD USA. Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Sch Nursing, Baltimore, MD 21218 USA. [Swoboda, Sandra M.; Thompson, David A.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. [Puntillo, Kathleen A.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Wallenstein, Sylvan] Mt Sinai Sch Med, Dept Community Med, New York, NY USA. [Ilaoa, Debra] Norman Reg Hlth Syst, Norman, OK USA. RP Nelson, JE (reprint author), Mt Sinai Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY USA. EM judith.nelson@mssm.edu FU National Institute on Aging [R21 AG029955, AG024476, AG034234]; Department of Veterans Affairs, Health Services Research and Development Service [REA-08-260]; Providence Health and Science Center FX Supported, in part, by R21 AG029955 from the National Institute on Aging. During the period of this work, Dr. Nelson was supported by a K02 Independent Scientist Research Career Development Award AG024476, followed by a K07 Academic Career Leadership Award, AG034234, both from the National Institute on Aging. Additional support was provided by the Department of Veterans Affairs, Health Services Research and Development Service (grant REA-08-260). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.; Dr. Nelson consulted for the Voluntary Hospital Association, Inc. and Veterans Integrated Service Network 3 of the Department of Veterans Affairs. Dr. Puntillo consulted for Veterans Integrated Service Network 3 of the Department of Veterans Affairs and received honoraria/speaking fees from Providence Health and Science Center. The remaining authors have not disclosed any potential conflicts of interest NR 31 TC 22 Z9 22 U1 3 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD APR PY 2012 VL 40 IS 4 BP 1105 EP 1112 DI 10.1097/CCM.0b013e3182374a50 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 912QC UT WOS:000301813700008 PM 22202706 ER PT J AU Thakkar, K Alsarraj, A Fong, E Holub, JL Gilger, MA El Serag, HB AF Thakkar, Kalpesh Alsarraj, Abeer Fong, Emily Holub, Jennifer L. Gilger, Mark A. El Serag, Hashem B. TI Prevalence of Colorectal Polyps in Pediatric Colonoscopy SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Colonic polyps; Hematochezia; Colonoscopy ID JUVENILE POLYPS; HYPERPLASTIC POLYPS; COLONIC POLYPS; RISK-FACTORS; LARGE-BOWEL; FOLLOW-UP; CHILDREN; CANCER; EXPERIENCE; MANAGEMENT AB The available data regarding the prevalence, types, and clinical determinants of colonic polyps in children is limited. We aimed to estimate the prevalence of colorectal polyps in a large cohort of children. We conducted a cross-sectional study to determine the presence, number, and location of colorectal polyps reported in all children (0-20 years) who underwent colonoscopy at 14 pediatric facilities between January 2000 and December 2007 recorded in Pediatric Endoscopy Database System Clinical Outcomes Research Initiative (PEDS-CORI). We compared procedures with and without polyps with respect to procedure indication, age, sex, and race. We also reviewed a sample of histopathologic reports from one participating center. We analyzed 13,115 colonoscopy procedures performed in 11,637 patients. Colorectal polyps were reported in 810 procedures (6.1%; 95% CI: 5.7-6.5%) performed in 705 patients, and in 12% of patients with lower GI bleeding. Children with colorectal polyps were significantly younger (8.9 years vs. 11.9 years; p < 0.0001), male (58.3% vs. 49.0%; p < 0.001), non-white race (27.5% vs. 21.9%; p < 0.001), and had lower GI bleeding (54.4% vs. 26.6%; p < 0.001) as compared to children without polyps. In a sample of 122 patients with polyps from a single center, the histological types were solitary juvenile in 91 (70.5%), multiple juvenile in 20 (15.5%), adenoma in 14 (10.9%) and hyperplastic polyps in four patients (3.1%). Colorectal polyps are detected in 6.1% overall and in 12.0% among those with lower gastrointestinal bleeding during pediatric colonoscopy. Approximately 26% are multiple juvenile or adenoma. C1 [Thakkar, Kalpesh; Gilger, Mark A.] Texas Childrens Hosp, Sect Pediat Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA. [Alsarraj, Abeer; El Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Alsarraj, Abeer; El Serag, Hashem B.] Baylor Coll Med, Gastroenterol Sect, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. [Alsarraj, Abeer; El Serag, Hashem B.] Baylor Coll Med, Sect Hlth Serv Res, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. [Fong, Emily] Baylor Univ, Waco, TX 76798 USA. [Holub, Jennifer L.] Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland, OR 97201 USA. RP Thakkar, K (reprint author), Texas Childrens Hosp, Sect Pediat Gastroenterol Hepatol & Nutr, 6621 Fannin St,CCC 1010, Houston, TX 77030 USA. EM kthakkar@bcm.tmc.edu FU NIDDK [U01DK57132]; AstraZeneca; Novartis; Bard International; Pentax USA; ProVation; Endosoft; GIVEN Imaging; Ethicon FX The study was supported with funding from NIDDK U01DK57132. In addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. The commercial entities had no involvement in this research. NR 28 TC 10 Z9 13 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2012 VL 57 IS 4 BP 1050 EP 1055 DI 10.1007/s10620-011-1972-8 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 912XV UT WOS:000301835600033 PM 22147243 ER PT J AU Standiford, HC Chan, S Tripoli, M Weekes, E Forrest, GN AF Standiford, Harold C. Chan, Shannon Tripoli, Megan Weekes, Elizabeth Forrest, Graeme N. TI Antimicrobial Stewardship at a Large Tertiary Care Academic Medical Center: Cost Analysis Before, During, and After a 7-Year Program SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INFECTIOUS-DISEASES SOCIETY; AMERICA; IMPACT AB BACKGROUND. An antimicrobial stewardship program was fully implemented at the University of Maryland Medical Center in July 2001 (beginning of fiscal year [FY] 2002). Essential to the program was an antimicrobial monitoring team (AMT) consisting of an infectious diseases-trained clinical pharmacist and a part-time infectious diseases physician that provided real-time monitoring of antimicrobial orders and active intervention and education when necessary. The program continued for 7 years and was terminated in order to use the resources to increase infectious diseases consults throughout the medical center as an alternative mode of stewardship. DESIGN. A descriptive cost analysis before, during, and after the program. PATIENTS/SETTING. A large tertiary care teaching medical center. METHODS. Monitoring the utilization (dispensing) costs of the antimicrobial agents quarterly for each FY. RESULTS. The utilization costs decreased from $44,181 per 1,000 patient-days at baseline prior to the full implementation of the program (FY 2001) to $23,933 (a 45.8% decrease) by the end of the program (FY 2008). There was a reduction of approximately $3 million within the first 3 years, much of which was the result of a decrease in the use of antifungal agents in the cancer center. After the program was discontinued at the end of FY 2008, antimicrobial costs increased from $23,933 to $31,653 per 1,000 patient-days, a 32.3% increase within 2 years that is equivalent to a $ 2 million increase for the medical center, mostly in the antibacterial category. CONCLUSIONS. The antimicrobial stewardship program, using an antimicrobial monitoring team, was extremely cost effective over this 7-year period. Infect Control Hosp Epidemiol 2012; 33(4): 338-345 C1 [Standiford, Harold C.; Tripoli, Megan] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Standiford, Harold C.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Chan, Shannon] Alfred I DuPont Hosp Children, Dept Pediat, Wilmington, DE USA. [Weekes, Elizabeth] Denver Hlth, Dept Pharm, Denver, CO USA. [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR USA. RP Standiford, HC (reprint author), Univ Maryland, Med Ctr, 110 S Paca St,6th Floor, Baltimore, MD 21201 USA. EM hstandiford@umm.edu NR 10 TC 58 Z9 60 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2012 VL 33 IS 4 SI SI BP 338 EP 345 DI 10.1086/664909 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 911KW UT WOS:000301716700005 PM 22418628 ER PT J AU Jones, M Huttner, B Madaras-Kelly, K Nechodom, K Nielson, C Goetz, MB Neuhauser, MM Samore, MH Rubin, MA AF Jones, Makoto Huttner, Benedikt Madaras-Kelly, Karl Nechodom, Kevin Nielson, Christopher Goetz, Matthew Bidwell Neuhauser, Melinda M. Samore, Matthew H. Rubin, Michael A. TI Parenteral to Oral Conversion of Fluoroquinolones: Low-Hanging Fruit for Antimicrobial Stewardship Programs? SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; CRITICALLY-ILL PATIENTS; HOSPITALIZED-PATIENTS; INTRAABDOMINAL INFECTIONS; EARLY SWITCH; CIPROFLOXACIN; ANTIBIOTICS; THERAPY; INTERVENTION; TUBE AB OBJECTIVE. To estimate avoidable intravenous (IV) fluoroquinolone use in Veterans Affairs (VA) hospitals. DESIGN. A retrospective analysis of bar code medication administration (BCMA) data. SETTING. Acute care wards of 128 VA hospitals throughout the United States. METHODS. Data were analyzed for all medications administered on acute care wards between January 1, 2006, and December 31, 2010. Patient-days receiving therapy were expressed as fluoroquinolone-days (FD) and divided into intravenous (IV; all doses administered intravenously) and oral (PO; at least one dose administered per os) FD. We assumed IV fluoroquinolone use to be potentially avoidable on a given IV FD when there was at least 1 other medication administered via the enteral route. RESULTS. Over the entire study period, 884,740 IV and 830,572 PO FD were administered. Overall, avoidable IV fluoroquinolone use accounted for 46.8% of all FD and 90.9% of IV FD. Excluding the first 2 days of all IV fluoroquinolone courses and limiting the analysis to the non-ICU setting yielded more conservative estimates of avoidable IV use: 20.9% of all FD and 45.9% of IV FD. Avoidable IV use was more common for levofloxacin and more frequent in the ICU setting. There was a moderate correlation between avoidable IV FD and total systemic antibiotic use (r=0.32). CONCLUSIONS. Unnecessary IV fluoroquinolone use seems to be common in the VA system, but important variations exist between facilities. Antibiotic stewardship programs could focus on this patient safety issue as a "low-hanging fruit" to increase awareness of appropriate antibiotic use. Infect Control Hosp Epidemiol 2012; 33(4): 362-367 C1 [Jones, Makoto; Huttner, Benedikt; Nechodom, Kevin; Samore, Matthew H.; Rubin, Michael A.] Univ Utah, IDEAS Ctr, VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA. [Jones, Makoto; Huttner, Benedikt; Nechodom, Kevin; Samore, Matthew H.; Rubin, Michael A.] Univ Utah, Div Epidemiol, Salt Lake City, UT 84148 USA. [Madaras-Kelly, Karl] Idaho State Univ, Boise VA Med Ctr, Idaho Falls, ID USA. [Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Idaho Falls, ID USA. [Nielson, Christopher] VA Sierra Nevada Hlth Care Syst, Reno, NV USA. [Nielson, Christopher] Univ Nevada, Sch Med, Reno, NV 89557 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Neuhauser, Melinda M.] VA Pharm Benefits Management Serv, Hines, IL USA. RP Jones, M (reprint author), Univ Utah, IDEAS Ctr, VA Salt Lake City Hlth Care Syst, 500 Foothill Dr, Salt Lake City, UT 84148 USA. EM makoto.jones@va.gov RI Huttner, Benedikt/M-5616-2014 OI Huttner, Benedikt/0000-0002-1749-9464; Goetz, Matthew/0000-0003-4542-992X FU career development award [CDA 10-030-02]; Geneva University Hospitals FX Financial support. M.J. was supported by a career development award (CDA 10-030-02) and B. H. was supported by a fellowship grant from Geneva University Hospitals. NR 28 TC 14 Z9 15 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2012 VL 33 IS 4 SI SI BP 362 EP 367 DI 10.1086/664767 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 911KW UT WOS:000301716700008 PM 22418631 ER PT J AU DeBoyes, T Sherrod, Q El-Masry, M Williams, EA Chiu, MW AF DeBoyes, Telia Sherrod, Quyn El-Masry, Monica Williams, Eric A. Chiu, Melvin W. TI Circumscribed palmar hypokeratosis SO INTERNATIONAL JOURNAL OF DERMATOLOGY LA English DT Letter ID PLANTAR HYPOKERATOSIS; MALFORMATION C1 [DeBoyes, Telia] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Ctr Hlth Sci 52 121, Los Angeles, CA 90095 USA. [El-Masry, Monica] Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. [Williams, Eric A.] Kaiser Permanente Med Ctr, Dept Dermatol, Santa Rosa, CA USA. [Chiu, Melvin W.] W Los Angeles Vet Affairs Med Ctr, Dermatol Serv, Los Angeles, CA USA. RP DeBoyes, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Ctr Hlth Sci 52 121, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mchiu@mednet.ucla.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0011-9059 J9 INT J DERMATOL JI Int. J. Dermatol. PD APR PY 2012 VL 51 IS 4 BP 486 EP 488 DI 10.1111/j.1365-4632.2010.04547.x PG 3 WC Dermatology SC Dermatology GA 912GZ UT WOS:000301785100025 PM 21671909 ER PT J AU Kirkpatrick, WR Najvar, LK Vallor, AC Wiederhold, NP Bocanegra, R Pfeiffer, J Perkins, K Kugler, AR Sweeney, TD Patterson, TF AF Kirkpatrick, William R. Najvar, Laura K. Vallor, Ana C. Wiederhold, Nathan P. Bocanegra, Rosie Pfeiffer, Juergen Perkins, Kimberly Kugler, Alan R. Sweeney, Theresa D. Patterson, Thomas F. TI Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE ABIP; animal model; Aspergillus; prophylaxis ID GALACTOMANNAN ENZYME-IMMUNOASSAY; CELL TRANSPLANT RECIPIENTS; ANTIFUNGAL PROPHYLAXIS; FUNGAL-INFECTIONS; QUANTITATIVE PCR; FUMIGATUS BURDEN; MOLD INFECTIONS; LIPID COMPLEX; MURINE MODEL; DEOXYCHOLATE AB Amphotericin B inhalation powder (ABIP) is a novel dry-powder amphotericin B formulation that is directly delivered to the lung, resulting in elevated lung tissue drug concentrations of this polyene. We evaluated the prophylactic efficacy of single dose administration of ABIP in a guinea pig model of invasive pulmonary aspergillosis. Guinea pigs were immunosuppressed with cyclophosphamide and cortisone acetate and challenged with Aspergillus fumigatus conidia in an aerosol chamber. Guinea pigs received prophylaxis with a single inhaled dose of ABIP at 0.05, 0.5, 4 or 10 mg/kg administered 24 h prior to infection. Treatment with oral voriconazole at doses of 5 or 10 mg/kg twice daily beginning 24 h post-challenge served as the positive control. Improvements in survival were observed with ABIP prophylaxis. A single inhaled dose of 4 mg/kg ABIP and treatment with 5 mg/kg voriconazole both improved median and percentage survival compared with untreated controls. In addition, pulmonary fungal burden, as assessed by cfu, quantitative PCR and galactomannan, was also reduced in a dose-dependent fashion with ABIP prophylaxis as well as with both doses of voriconazole treatment. Single-dose prophylaxis with inhaled ABIP as prophylaxis demonstrated a significant survival advantage and reductions in pulmonary fungal burden in this model of invasive pulmonary aspergillosis. Optimization of the dose and dosing frequency of ABIP dose may help to further enhance the anti-Aspergillus activity of this novel amphotericin B formulation. C1 [Kirkpatrick, William R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Kirkpatrick, William R.; Najvar, Laura K.; Bocanegra, Rosie; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Vallor, Ana C.] Univ Incarnate Word, San Antonio, TX USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Pfeiffer, Juergen; Perkins, Kimberly; Kugler, Alan R.; Sweeney, Theresa D.] Nektar Therapeut, San Francisco, CA USA. [Kugler, Alan R.] Coastal Pharma Grp, Montara, CA USA. RP Kirkpatrick, WR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kirkpatrick@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU Nektar Therapeutics, San Francisco, CA, USA; Pfizer; Schering-Plough; Merck; Basilea; Astellas FX This work was supported by a grant from Nektar Therapeutics, San Francisco, CA, USA.; N. P. W. has received research support from Pfizer, Schering-Plough, Merck, Basilea and Astellas, and has served as a consultant for Merck and Viamet. T. F. P. has received research support from Basilea, Astellas, Merck, Pfizer and Schering-Plough, and has served as a consultant for Basilea, Astellas, Merck, Pfizer, Toyama and Viamet. J. P., K. P., A. R. K. and T. D. S. were employees of Nektar Therapeutics and held stock in the company at the time of these studies. All the remaining authors report no conflicts of interest. NR 36 TC 8 Z9 8 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2012 VL 67 IS 4 BP 970 EP 976 DI 10.1093/jac/dkr567 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 910YQ UT WOS:000301684900026 PM 22240402 ER PT J AU Terpstra, JL Chavez, LJ Ayala, GX AF Terpstra, Jennifer L. Chavez, Laura J. Ayala, Guadalupe X. TI An Intervention to Increase Caregiver Support for Asthma Management in Middle School-Aged Youth SO JOURNAL OF ASTHMA LA English DT Article DE adolescents; asthma control; caregiver; quality of life; self-efficacy; self-management ID QUALITY-OF-LIFE; PEDIATRIC ASTHMA; CHILDHOOD ASTHMA; SELF-EFFICACY; CHILDREN; PARENTS; IMPACT; ADOLESCENTS; STUDENTS; BARRIERS AB Objective. Asthma control requires adherence to a treatment regimen. Caregiver involvement is a key determinant of adolescent asthma control, but the involvement must recognize the youth's developmental stage and need for autonomy. This article describes the evaluation of a pilot asthma management intervention for middle school-aged youth and their adult network members, including caregivers, based on caregiver findings. Methods. Following approval from San Diego State University's Institutional Review Board and school district authorization, two middle schools were randomized into one of two conditions: 6-weekly group-based skills training for the adolescents followed by 6-weekly targeted newsletters for caregivers and others (Group 1) versus group-based skills training for adolescents only (Group 2). Outcome evaluation examined pre-post changes by study condition. Results. Caregivers in both groups reported improvements in quality of life (QOL) and access to asthma care resources among their adolescents. Caregiver self-efficacy increased significantly among Group 1 versus Group 2 caregivers, while Group 2 caregivers (those who did not receive newsletters) reported that their adolescents had more responsibility for their asthma care compared with Group 2 caregivers. Conclusions. The adolescent-only intervention resulted in improvements in caregivers' QOL and parenting behaviors that promoted the adolescent's access to asthma resources. When caregivers were directed with intervention materials, their self-efficacy increased. Those who did not receive materials reported that their adolescents had more responsibility for their asthma care. The latter finding may reflect an unintended consequence of an adolescent-only intervention as it may communicate to caregivers to assume less responsibility for their child's asthma care. C1 [Ayala, Guadalupe X.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92123 USA. [Ayala, Guadalupe X.] San Diego State Univ, Inst Behav & Community Hlth, San Diego, CA 92123 USA. [Chavez, Laura J.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Chavez, Laura J.] Vet Affairs Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. [Terpstra, Jennifer L.] Ctr Excellence Intervent & Prevent Sci, Carlton, Vic, Australia. RP Ayala, GX (reprint author), San Diego State Univ, Grad Sch Publ Hlth, 9245 Sky Pk Court,Suite 220, San Diego, CA 92123 USA. EM ayala@mail.sdsu.edu FU American Lung Association [CG-939-N] FX In this study, the third author was funded by the American Lung Association through grant no. CG-939-N. NR 33 TC 5 Z9 6 U1 0 U2 3 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD APR PY 2012 VL 49 IS 3 BP 267 EP 274 DI 10.3109/02770903.2012.656866 PG 8 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 909AP UT WOS:000301534600008 PM 22316141 ER PT J AU Meyer, DJ Messer, J Singh, T Thomas, PJ Woyczynski, WA Kaye, J Lerner, AJ AF Meyer, David J. Messer, Jason Singh, Tanya Thomas, Peter J. Woyczynski, Wojbor A. Kaye, Jeffrey Lerner, Alan J. TI Random local temporal structure of category fluency responses SO JOURNAL OF COMPUTATIONAL NEUROSCIENCE LA English DT Article DE Category Fluency Test; Semantic memory; Cognitive impairment; Alzheimer's disease; Statistical temporal structure; Weibull distribution; Inter response times ID VERBAL FLUENCY; MEMORY RETRIEVAL; WEIBULL DISTRIBUTION; RECOGNITION MEMORY; ALZHEIMERS-DISEASE; FREE-RECALL; DIFFUSION; MODELS; TIME; DYNAMICS AB The Category Fluency Test (CFT) provides a sensitive measurement of cognitive capabilities in humans related to retrieval from semantic memory. In particular, it is widely used to assess progress of cognitive impairment in patients with dementia. Previous research shows that, in the first approximation, the intensity of tested individuals' responses within a standard 60-s test period decays exponentially with time, with faster decay rates for more cognitively impaired patients. Such decay rate can then be viewed as a global (macro) diagnostic parameter of each test. In the present paper we focus on the statistical properties of the properly de-trended time intervals between consecutive responses (inter-call times) in the Category Fluency Test. In a sense, those properties reflect the local (micro) structure of the response generation process. We find that a good approximation for the distribution of the de-trended inter-call times is provided by the Weibull Distribution, a probability distribution that appears naturally in this context as a distribution of a minimum of independent random quantities and is the standard tool in industrial reliability theory. This insight leads us to a new interpretation of the concept of "navigating a semantic space" via patient responses. C1 [Woyczynski, Wojbor A.] Case Western Reserve Univ, Dept Stat, Cleveland, OH 44106 USA. [Woyczynski, Wojbor A.] Case Western Reserve Univ, Ctr Stochast & Chaot Proc Sci & Technol, Cleveland, OH 44106 USA. [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Kaye, Jeffrey] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA. [Kaye, Jeffrey] Portland VA Med Ctr, Portland, OR 97239 USA. [Lerner, Alan J.] Case Western Reserve Univ, Case Med Ctr, Dept Neurol, Cleveland, OH 44106 USA. [Thomas, Peter J.] Oberlin Coll, Dept Neurosci, Oberlin, OH 44074 USA. [Thomas, Peter J.] Case Western Reserve Univ, Dept Math, Cleveland, OH 44106 USA. [Thomas, Peter J.] Case Western Reserve Univ, Dept Biol, Cleveland, OH 44106 USA. [Thomas, Peter J.] Case Western Reserve Univ, Dept Cognit Sci, Cleveland, OH 44106 USA. RP Woyczynski, WA (reprint author), Case Western Reserve Univ, Dept Stat, 11900 Euclid Ave, Cleveland, OH 44106 USA. EM waw@case.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU U.S. National Science Foundation [DUE-0634612]; National Science Foundation [DMS-0720142]; Oberlin College Libraries; National Institute on Aging [P30AG024978, P30AG08017, R01AG024059] FX This research has been supported by the U.S. National Science Foundation Grant "Interdisciplinary Training for Undergraduates in Biological and Mathematical Sciences" (DUE-0634612) administered by PJT; the first three authors were undergraduate students in biology and mathematics at Case while this work has been done. PJT was supported by the National Science Foundation's program in Mathematical Biology (DMS-0720142), and acknowledges research support from the Oberlin College Libraries. JK was supported by grants from the National Institute on Aging (P30AG024978, P30AG08017 and R01AG024059). NR 45 TC 4 Z9 4 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5313 J9 J COMPUT NEUROSCI JI J. Comput. Neurosci. PD APR PY 2012 VL 32 IS 2 BP 213 EP 231 DI 10.1007/s10827-011-0349-5 PG 19 WC Mathematical & Computational Biology; Neurosciences SC Mathematical & Computational Biology; Neurosciences & Neurology GA 912YH UT WOS:000301837200002 PM 21739237 ER PT J AU Goreshi, R Okawa, J Rose, M Feng, R Lee, LA Hansens, CB Bangert, CA Connolly, MK Davis, MD Callen, JP Fett, NM Fakharzadeh, SS Clarke, JT Werth, VP AF Goreshi, Renato Okawa, Joyce Rose, Matt Feng, Rui Lee, Lela A. Hansens, Christopher B. Bangert, Carolyn A. Connolly, M. Kari Davis, Mark D. Callen, Jeff P. Fett, Nicole M. Fakharzadeh, Steven S. Clarke, Jennie T. Werth, Victoria P. TI Evaluation of Reliability, Validity, and Responsiveness of the CDASI and the CAT-BM SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID CUTANEOUS ASSESSMENT-TOOL; JUVENILE DERMATOMYOSITIS; DISEASE; POLYMYOSITIS; VALIDATION; AGREEMENT; INDEX AB To properly evaluate therapies for cutaneous dermatomyositis (DM), it is essential to administer an outcome instrument that is reliable, valid, and responsive to clinical change, particularly when measuring disease activity. The purpose of this study was to compare two skin severity DM outcome measures, the Cutaneous Disease and Activity Severity Index (CDASI) and the Cutaneous Assessment Tool Binary Method (CAT-BM), with the Physician Global Assessment (PGA) as the "gold standard". Ten dermatologists evaluated 14 patients with DM using the CDASI, CAT-BM, and PGA scales. Inter- and intra-rater reliability, validity, responsiveness, and completion time were compared for each outcome instrument. Responsiveness was assessed from a different study population, where one physician evaluated 35 patients with 110 visits. The CDASI was found to have a higher inter- and intra-rater reliability. Regarding construct validity, both the CDASI and the CAT-BM were significant predictors of the PGA scales. The CDASI had the best responsiveness among the three outcome instruments examined. The CDASI had a statistically longer completion time than the CAT-BM by about 1.5 minutes. The small patient population may limit the external validity of the findings observed. The CDASI is a better clinical tool to assess skin severity in DM. C1 [Werth, Victoria P.] Univ Penn, Sch Med, Perelman Ctr Adv Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Goreshi, Renato; Okawa, Joyce; Rose, Matt; Fett, Nicole M.; Fakharzadeh, Steven S.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Feng, Rui] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lee, Lela A.] Univ Colorado, Denver, CO 80202 USA. [Hansens, Christopher B.] Univ Utah, Salt Lake City, UT USA. [Bangert, Carolyn A.] Univ Texas Houston, Houston, TX USA. [Connolly, M. Kari] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Davis, Mark D.] Mayo Clin, Rochester, MN USA. [Callen, Jeff P.] Univ Louisville, Louisville, KY 40292 USA. [Clarke, Jennie T.] Penn State Hershey, Hershey, PA USA. RP Werth, VP (reprint author), Univ Penn, Sch Med, Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Celgene Corporation; Department of Veterans Affairs Veterans Health Administration; Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health (NIH) [K24-AR 02207] FX This material is based on work supported by Celgene Corporation, the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by the National Institutes of Health (NIH K24-AR 02207) (VPW). NR 24 TC 11 Z9 12 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2012 VL 132 IS 4 BP 1117 EP 1124 DI 10.1038/jid.2011.440 PG 8 WC Dermatology SC Dermatology GA 910XZ UT WOS:000301683200010 PM 22217740 ER PT J AU Celli, A Mackenzie, DS Zhai, YJ Tu, CL Bikle, DD Holleran, WM Uchida, Y Mauro, TM AF Celli, Anna Mackenzie, Donald S. Zhai, Yongjiao Tu, Chia-Ling Bikle, Daniel D. Holleran, Walter M. Uchida, Yoshikazu Mauro, Theodora M. TI SERCA2-Controlled Ca2+-Dependent Keratinocyte Adhesion and Differentiation Is Mediated via the Sphingolipid Pathway: A Therapeutic Target for Darier's Disease SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID HAILEY-HAILEY-DISEASE; E-CADHERIN; RETICULUM CA2+; MOBILIZATION; CA2+-ATPASE; ACTIVATION; COMPONENTS; MUTATIONS; CATENIN; ATP2A2 AB Darier's disease (DD), caused by mutations in the endoplasmic reticulum (ER) Ca2+ ATPase ATP2A2 (SERCA2b), is a skin disease that exhibits impaired epidermal cell-to-cell adhesion and altered differentiation. Although previous studies have shown that keratinocyte Ca2+ sequestration and fluxes are controlled by sphingolipid signaling, the role of this signaling pathway in DD previously has not been investigated. We show here that sphingosine levels increase and sphingosine kinase (SPHK1) expression decreases after inactivating SERCA2b with the specific SERCA2 inhibitors thapsigargin (TG) or small interfering RNA to SERCA2b. Conversely, inhibiting sphingosine lyase rescues the defects in keratinocyte differentiation, E-cadherin localization, desmoplakin (DP) translocation, and ER Ca2+ sequestration seen in TG-treated keratinocytes. Here, we report early evidence that the keratinocyte sphingolipid and Ca2+ signaling pathways intersect in ATP2A2-controlled ER Ca2+ sequestration, E-cadherin and DP localization, and Ca2+-controlled differentiation, and thus may be important mediators in DD. C1 [Celli, Anna; Mackenzie, Donald S.; Zhai, Yongjiao; Mauro, Theodora M.] San Francisco Vet Adm Med Ctr, Dept Dermatol, San Francisco, CA USA. [Celli, Anna; Mackenzie, Donald S.; Zhai, Yongjiao; Holleran, Walter M.; Uchida, Yoshikazu; Mauro, Theodora M.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Tu, Chia-Ling; Bikle, Daniel D.] San Francisco Vet Adm Med Ctr, Endocrine Unit, San Francisco, CA USA. RP Celli, A (reprint author), Dept Vet Affairs Med Ctr, Dermatol Res Unit, 4150 Clement St,Box 190, San Francisco, CA 94121 USA. EM celli.anna@gmail.com FU National Institutes of Health [AR051930]; San Francisco Veterans Administration Medical Service FX This work was supported by National Institutes of Health grants AR051930 and the San Francisco Veterans Administration Medical Service. NR 36 TC 13 Z9 13 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2012 VL 132 IS 4 BP 1188 EP 1195 DI 10.1038/jid.2011.447 PG 8 WC Dermatology SC Dermatology GA 910XZ UT WOS:000301683200018 PM 22277942 ER PT J AU Butler, NJ Suhler, EB Rosenbaum, JT AF Butler, Nicholas J. Suhler, Eric B. Rosenbaum, James T. TI Interferon alpha 2b in the Treatment of Uveitic Cystoid Macular Edema SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE interferon alpha 2b; uveitis; cystoid; macular; edema ID ANTIINTERFERON ANTIBODIES; HEPATITIS-C; ALPHA; RETINOPATHY; PANUVEITIS; POSTERIOR AB Purpose: To determine the efficacy of interferon alpha 2b in the treatment of refractory, uveitic cystoid macular edema (CME). Methods: Retrospective chart review of 4 patients attending the uveitis clinic at the Casey Eye Institute, Oregon Health & Science University. Results: All 4 patients had uveitis and refractory CME, resistant to a variety of immunosuppressants. All patients, except one with severe scleral thinning, had tried and failed therapy with locally injected corticosteroids. Treatment with systemic interferon alpha 2b produced dramatic improvement in CME (central macular thickness: 563 to 267 mu m, p = .002) and visual acuity (logMAR: +0.81 to +0.45, p = .0004) in all 4 cases. All patients have been able to reduce the interferon dosage, but none has discontinued it completely. All patients had some mild adverse response that did not necessitate stopping therapy. Conclusions: Interferon alpha 2b is an effective option to treat refractory CME secondary to uveitis. C1 [Suhler, Eric B.; Rosenbaum, James T.] OHSU Casey Eye Inst, Portland, OR 97201 USA. [Butler, Nicholas J.] Wilmer Eye Inst, Baltimore, MD 21287 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. RP Rosenbaum, JT (reprint author), OHSU Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97201 USA. EM rosenbaj@ohsu.edu FU Research to Prevent Blindness; Stan and Madelle Rosenfeld Family Trust; William and Mary Bauman Foundation; William C. Kuzell Foundation FX We are grateful for support from Research to Prevent Blindness, the Stan and Madelle Rosenfeld Family Trust, the William and Mary Bauman Foundation, and the William C. Kuzell Foundation. NR 21 TC 6 Z9 7 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD APR PY 2012 VL 20 IS 2 BP 86 EP 90 DI 10.3109/09273948.2011.645989 PG 5 WC Ophthalmology SC Ophthalmology GA 908FL UT WOS:000301476200004 PM 22409560 ER PT J AU Charkoudian, LD Ying, GS Pujari, SS Gangaputra, S Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Suhler, EB Kempen, JH AF Charkoudian, Leon D. Ying, Gui-shuang Pujari, Siddharth S. Gangaputra, Sapna Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Kempen, John H. TI High-dose Intravenous Corticosteroids for Ocular Inflammatory Diseases SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE corticosteroids; inflammation; intravenous; noninfectious; uveitis ID PULSE METHYLPREDNISOLONE THERAPY; UVEITIS; GLUCOCORTICOIDS; MECHANISMS; DISORDERS; DRUGS AB Purpose: To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases. Methods: Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment. Results: Within <= 1 month of starting treatment, 57% of eyes achieved complete control of inflammation (95% confidence interval (CI): 33-83%), improving to 82% when near-complete control was included (95% CI: 61-96%). Most eyes (85%; 95% CI: 70-95%) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded. Conclusions: Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent. C1 [Kempen, John H.] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA. [Charkoudian, Leon D.; Ying, Gui-shuang; Kempen, John H.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Charkoudian, Leon D.] Emory Univ, Atlanta, GA 30322 USA. [Ying, Gui-shuang; Kempen, John H.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Pujari, Siddharth S.; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Pujari, Siddharth S.] LIONS NAB Eye Hosp, Miraj, Maharastra, India. [Gangaputra, Sapna; Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA. [Gangaputra, Sapna] Univ Wisconsin, Sch Med, Fundus Photograph Reading Ctr, Madison, WI USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Levy-Clarke, Grace A.] St Lukes Cataract & Laser Inst, Tarpon Springs, FL USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu FU National Eye Institute (Bethesda, MD) [EY014943]; Research to Prevent Blindness (New York, NY); Paul and Evanina Mackall Foundation (New York, NY); Research to Prevent Blindness; National Eye Institute; Unites States Veterans' Administration FX This study was supported primarily by the National Eye Institute (Bethesda, MD) Grant EY014943 (Dr. Kempen). Additional support was provided by Research to Prevent Blindness (New York, NY) and the Paul and Evanina Mackall Foundation (New York, NY). Dr. Kempen is a Research to Prevent Blindness James S. Adams Special Scholar Award recipient. Dr. Jabs and Dr. Rosenbaum were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the conduct of the study. Dr. Thorne is a Research to Prevent Blindness Harrington Special Scholar Award recipient. Dr. Levy-Clarke was previously supported by and Dr. Nussenblatt continues to be supported by intramural funds of the National Eye Institute. Dr. Suhler also received support from the Unites States Veterans' Administration. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; nor in the preparation, review, and approval of this paper. NR 25 TC 7 Z9 7 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD APR PY 2012 VL 20 IS 2 BP 91 EP 99 DI 10.3109/09273948.2011.646382 PG 9 WC Ophthalmology SC Ophthalmology GA 908FL UT WOS:000301476200005 PM 22409561 ER PT J AU Ishii, S Cauley, JA Greendale, GA Danielson, ME Nili, NS Karlamangla, A AF Ishii, S. Cauley, J. A. Greendale, G. A. Danielson, M. E. Nili, N. Safaei Karlamangla, A. TI Ethnic differences in composite indices of femoral neck strength SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bone size; Composite strength indices; Ethnic difference; Femoral neck strength; Hip geometry; Nativity ID BONE-MINERAL DENSITY; HIP FRACTURE RISK; NON-SPINE FRACTURES; OSTEOPOROTIC FRACTURES; PROXIMAL FEMUR; POSTMENOPAUSAL WOMEN; ELDERLY-WOMEN; WHITE WOMEN; PREDICTION; JAPANESE AB Bone mineral density does not explain race/ethnicity differences in hip fracture risk. In this study, we demonstrated that race/ethnicity differences in composite hip strength indices were consistent with documented race/ethnicity differences in hip fracture risk, suggesting that unlike bone density, the composite indices may represent ethnicity-independent measures of bone strength. African-American and Asian women have lower risks of hip fracture than Caucasian women, but such racial/ethnic variation in hip fracture risk cannot be explained by bone mineral density (BMD). The composite indices of femoral neck strength integrate femoral neck and body size with BMD and predict hip fracture risk in Caucasian women. We hypothesize that unlike race/ethnic differences in BMD, race/ethnic differences in the composite strength indices would be consistent with race/ethnic differences in hip fracture risk. We studied a community-based sample of Caucasian (n = 968), African-American (n = 512), Chinese (n = 221), and Japanese (n = 239) women, premenopausal or in early perimenopause, from the Study of Women's Health Across the Nation. Unadjusted indices were similar in Caucasian and African-American women but higher in Asian women. After adjusting for age, body mass index, and menopause status, all three minority groups had higher composite strength indices than Caucasian women. Foreign-born Japanese women had higher unadjusted and adjusted composite strength indices than US-born Japanese women, but such differences by nativity were not observed in Chinese women. We concluded that composite strength indices have the potential to explain racial/ethnic differences in hip fracture risk, suggesting that composite strength indices may represent ethnicity-independent measures of bone strength. This contention needs to be verified by further research on the fracture predictive ability of composite strength indices in multi-ethnic longitudinal cohorts. C1 [Ishii, S.] VA Greater Los Angeles Healthcare Syst, GRECC, Los Angeles, CA 90073 USA. [Greendale, G. A.; Nili, N. Safaei; Karlamangla, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Cauley, J. A.; Danielson, M. E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. RP Ishii, S (reprint author), VA Greater Los Angeles Healthcare Syst, GRECC, 11301 Wilshire Blvd,Bldg 220,Room 302, Los Angeles, CA 90073 USA. EM sishii@ucla.edu OI Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health (NIH), DHHS, through National Institute on Aging (NIA); National Institute of Nursing Research (NINR); NIH Office of Research on Women's Health (ORWH) [NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center; VA Advanced Geriatrics Fellowship; NIA [AG026463, AG028748] FX The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), and the NIH Office of Research on Women's Health (ORWH) (grants NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495). Dr. Ishii was supported by VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center; and VA Advanced Geriatrics Fellowship. The Hip Strength Through the Menopausal Transition has grant support from the NIA (AG026463). The SWAN Hip Strength Sub-Study has grant support from the NIA (AG028748). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, NINR, ORWH, VA or the NIH. We thank the study staff at each of the following sites and all the women who participated in SWAN: Clinical centers: University of Michigan, Ann Arbor-MaryFran Sowers, PI; Massachusetts General Hospital, Boston, MA-Joel Finkelstein, PI 1999-present; Robert Neer, PI 1994-1999; Rush University, Rush University Medical Center, Chicago, IL-Howard Kravitz, PI 2009-present; Lynda Powell, PI 1994-2009; University of California, Davis/Kaiser-Ellen Gold, PI; University of California, Los Angeles-Gail Greendale, PI; Albert Einstein College of Medicine, Bronx, NY-Rachel Wildman, PI 2010; Nanette Santoro, PI 2004-2010; University of Medicine and Dentistry-New Jersey Medical School, Newark-Gerson Weiss, PI 1994-2004; and the University of Pittsburgh, Pittsburgh, PA-Karen Matthews, PI. NIH program office: National Institute on Aging, Bethesda, MD-Sherry Sherman 1994-present, Marcia Ory 19942001; National Institute of Nursing Research, Bethesda, MD-Program Officers. Central laboratory: University of Michigan, Ann ArborDaniel McConnell (Central Ligand Assay Satellite Services). Coordinating center: University of Pittsburgh, Pittsburgh, PA-Kim SuttonTyrrell, PI 2001-present; New England Research Institutes, Watertown, MA-Sonja McKinlay, PI 1995-2001. Steering committee: Susan Johnson, Current Chair; Chris Gallagher, Former Chair. NR 49 TC 22 Z9 22 U1 0 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD APR PY 2012 VL 23 IS 4 BP 1381 EP 1390 DI 10.1007/s00198-011-1723-x PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 912IM UT WOS:000301790500020 PM 21927926 ER PT J AU Schmader, KE Levin, MJ Gnann, JW McNeil, SA Vesikari, T Betts, RF Keay, S Stek, JE Bundick, ND Su, SC Zhao, YL Li, XM Chan, ISF Annunziato, PW Parrino, J AF Schmader, Kenneth E. Levin, Myron J. Gnann, John W., Jr. McNeil, Shelly A. Vesikari, Timo Betts, Robert F. Keay, Susan Stek, Jon E. Bundick, Nickoya D. Su, Shu-Chih Zhao, Yanli Li, Xiaoming Chan, Ivan S. F. Annunziato, Paula W. Parrino, Janie TI Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID QUALITY-OF-LIFE; VARICELLA-ZOSTER; POSTHERPETIC NEURALGIA; IMMUNE-RESPONSES; OLDER-ADULTS; FUNCTIONAL STATUS; VIRUS; IMMUNOGENICITY; ZOSTAVAX; IMPACT AB Background. Herpes zoster (HZ) adversely affects individuals aged 50-59, but vaccine efficacy has not been assessed in this population. This study was designed to determine the efficacy, safety, and tolerability of zoster vaccine for preventing HZ in persons aged 50-59 years. Methods. This was a randomized, double-blind, placebo-controlled study of 22 439 subjects aged 50-59 years conducted in North America and Europe. Subjects were given 1 dose of licensed zoster vaccine (ZV) (Zostavax; Merck) and followed for occurrence of HZ for >= 1 year (mean, 1.3 years) postvaccination until accrual of >= 96 confirmed HZ cases (as determined by testing lesions swabs for varicella zoster virus DNA by polymerase chain reaction). Subjects were followed for all adverse events (AEs) from day 1 to day 42 postvaccination and for serious AEs (SAEs) through day 182 postvaccination. Results. The ZV reduced the incidence of HZ (30 cases in vaccine group, 1.99/1000 person-years vs 99 cases in placebo group, 6.57/1000 person-years). Vaccine efficacy for preventing HZ was 69.8% (95% confidence interval, 54.1-80.6). AEs were reported by 72.8% of subjects in the ZV group and 41.5% in the placebo group, with the difference primarily due to higher rates of injection-site AEs and headache. The proportion of subjects reporting SAEs occurring within 42 days postvaccination (ZV, 0.6%; placebo, 0.5%) and 182 days postvaccination (ZV, 2.1%; placebo, 1.9%) was similar between groups. Conclusions. In subjects aged 50-59 years, the ZV significantly reduced the incidence of HZ and was well tolerated. Clinical Trials Registration. NCT00534248. C1 [Schmader, Kenneth E.] Duke Univ, Durham, NC 27706 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC USA. [Levin, Myron J.] Univ Colorado, Sch Med, Aurora, CO USA. [Gnann, John W., Jr.] Univ Alabama Birmingham, Birmingham, AL USA. [Gnann, John W., Jr.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [McNeil, Shelly A.] Dalhousie Univ, Halifax, NS, Canada. [Vesikari, Timo] Univ Tampere, FIN-33101 Tampere, Finland. [Betts, Robert F.] Univ Rochester, New York, NY USA. [Keay, Susan] Vet Affairs Maryland Hlth Care Syst, Baltimore, MD USA. [Stek, Jon E.; Bundick, Nickoya D.; Su, Shu-Chih; Zhao, Yanli; Li, Xiaoming; Chan, Ivan S. F.; Annunziato, Paula W.; Parrino, Janie] Merck Sharp, Whitehouse Stn, NJ USA. [Stek, Jon E.; Bundick, Nickoya D.; Su, Shu-Chih; Zhao, Yanli; Li, Xiaoming; Chan, Ivan S. F.; Annunziato, Paula W.; Parrino, Janie] Dohme Corp, Whitehouse Stn, NJ USA. RP Parrino, J (reprint author), Merck Sharp, POB 1000,UG3CD 28, N Wales, PA 19454 USA. EM janie_parrino@merck.com FU Merck; Sharp; Dohme Corp; Baltimore Research and Education Foundation FX This work was supported by Merck, Sharp, and Dohme Corp (sponsor). In conjunction with the external investigators, this study was designed, executed, and analyzed by the sponsor. Although the sponsor formally reviewed a penultimate draft, the opinions expressed are those of the authors and may not necessarily reflect those of the sponsor. All co-authors approved the final version of the manuscript.; R. F. B, J. W. G, S. A. M, T. V, and K. E. Ss received grant payment from Merck, Sharp, & Dohme Corp for this study. J. E. S, N. D. B, S. C. S, Y. Z, X. L, I. S. F. C, P. W. A, and J. P. are Merck, Sharp, and Dohme Corp employees and hold stock and/or stock options in the company. M. J. L. is a consultant for Merck and shares intellectual property rights on Zostavax. S. K. has received grant funds administered by the Baltimore Research and Education Foundation for this study. NR 29 TC 126 Z9 134 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 IS 7 BP 922 EP 928 DI 10.1093/cid/cir970 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TB UT WOS:000301296200012 PM 22291101 ER PT J AU Justice, AC Freiberg, MS Tracy, R Kuller, L Tate, JP Goetz, MB Fiellin, DA Vanasse, GJ Butt, AA Rodriguez-Barradas, MC Gibert, C Oursler, KA Deeks, SG Bryant, K AF Justice, Amy C. Freiberg, Matthew S. Tracy, Russ Kuller, Lew Tate, Janet P. Goetz, Matthew Bidwell Fiellin, David A. Vanasse, Gary J. Butt, Adeel A. Rodriguez-Barradas, Maria C. Gibert, Cynthia Oursler, Kris Ann Deeks, Steven G. Bryant, Kendall CA VACS Project Team TI Does an Index Composed of Clinical Data Reflect Effects of Inflammation, Coagulation, and Monocyte Activation on Mortality Among Those Aging With HIV? SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ANTIRETROVIRAL THERAPY; COLLABORATIVE ANALYSIS; INFECTION; COHORT; FIBROSIS; COINFECTION; POPULATION; CLEARANCE; ANEMIA; MARKER AB Background. When added to age, CD4 count and human immunodeficiency virus type 1 (HIV-1) RNA alone (Restricted Index), hemoglobin, FIB-4 Index, hepatitis C virus (HCV), and estimated glomerular filtration rate improve prediction of mortality. Weighted and combined, these 7 routine clinical variables constitute the Veterans Aging Cohort Study (VACS) Index. Because nonroutine biomarkers of inflammation (interleukin 6 [IL-6]), coagulation (D-dimer), and monocyte activation (sCD14) also predict mortality, we test the association of these indices and biomarkers with each other and with mortality. Methods. Samples from 1302 HIV-infected veterans on antiretroviral therapy were analyzed. Indices were calculated closest to date of collection. We calculated Spearman correlations stratified by HIV-1 RNA and HCV status and measured association with mortality using C statistics and net reclassification improvement (NRI). Results. Of 1302 subjects, 915 had HIV-1 RNA < 500 copies/mL and 154 died. The VACS Index was more correlated with IL-6, D-dimer, and sCD14 than the Restricted Index (P < .001). It was also more predictive of mortality (C statistic, 0.76; 95% confidence interval [CI],.72-.80) than any biomarker (C statistic, 0.66-0.70) or the Restricted Index (C statistic, 0.71; 95% CI,.67-.75). Compared to the Restricted Index alone, NRI resulted from incremental addition of VACS Index components (10%), D-dimer (7%), and sCD14 (4%), but not from IL-6 (0%). Conclusions. Among HIV-infected individuals, independent of CD4, HIV-1 RNA, and age, hemoglobin and markers of liver and renal injury are associated with inflammation. Addition of D-dimer and sCD14, but not IL-6, improves the predictive accuracy of the VACS Index for mortality. C1 [Justice, Amy C.; Tate, Janet P.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Fiellin, David A.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Justice, Amy C.; Tate, Janet P.] Yale Univ, Gen Internal Med Sect, New Haven, CT USA. [Freiberg, Matthew S.; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Freiberg, Matthew S.; Kuller, Lew] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. [Tracy, Russ] Univ Vermont, Coll Med, Burlington, VT 05405 USA. [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Vanasse, Gary J.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. [Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA. [Oursler, Kris Ann] Baltimore Vet Affairs Hlth Care Syst, Baltimore, MD USA. [Oursler, Kris Ann] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bryant, Kendall] NIAAA, Bethesda, MD USA. RP Justice, AC (reprint author), VA CT Healthcare Syst 11ACSLG, Bldg 35A,Rm 2-212,950 Campbell Ave, West Haven, CT 06516 USA. EM amy.justice2@va.gov OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X FU National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism [U10-AA13566]; National Heart, Lung, and Blood Institute [R01-HL095136, R01-HL090342, RCI-HL100347]; National Institute on Aging [R01-AG029154, K23 AG024896]; Training Program in Environmental Epidemiology [T32 ES07069] FX This work was supported by the National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism (U10-AA13566), National Heart, Lung, and Blood Institute (R01-HL095136; R01-HL090342; RCI-HL100347), and National Institute on Aging (R01-AG029154; K23 AG024896). J. P. T. was supported by the Training Program in Environmental Epidemiology (T32 ES07069). NR 34 TC 98 Z9 98 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2012 VL 54 IS 7 BP 984 EP 994 DI 10.1093/cid/cir989 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 905TB UT WOS:000301296200023 PM 22337823 ER PT J AU Korrapati, MC Shaner, BE Schnellmann, RG AF Korrapati, Midhun C. Shaner, Brooke E. Schnellmann, Rick G. TI Recovery from Glycerol-Induced Acute Kidney Injury Is Accelerated by Suramin SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID ACUTE-RENAL-FAILURE; GELATINASE-ASSOCIATED LIPOCALIN; NF-KAPPA-B; HEME OXYGENASE-1; GENE-EXPRESSION; CELL-DEATH; RHABDOMYOLYSIS; ADHESION; MICE; MOLECULE-1 AB Acute kidney injury (AKI) is a common and potentially life-threatening complication after ischemia/reperfusion and exposure to nephrotoxic agents. In this study, we examined the efficacy and mechanism(s) of suramin in promoting recovery from glycerol-induced AKI, a model of rhabdomyolysis-induced AKI. After intramuscular glycerol injection (10 ml of 50% glycerol per kilogram) into male Sprague-Dawley rats, serum creatinine maximally increased at 24 to 72 h and then decreased at 120 h. Creatinine clearance (CrCl) decreased 75% at 24 to 72 h and increased at 120 h. Suramin (1 mg/kg i.v.) administered 24 h after glycerol accelerated recovery of renal function as demonstrated by increased CrCl, decreased renal kidney injury molecule-1, and improved histopathology 72 h after glycerol injection. Suramin treatment decreased interleukin-1 beta (IL-1 beta) mRNA, transforming growth factor-beta(1) (TGF-beta(1)), phospho-p65 of nuclear factor-kappa B (NF-kappa B), and cleaved caspase-3 at 48 h compared with glycerol alone. Suramin treatment also decreased glycerol-induced activation of intracellular adhesion molecule-1 (ICAM-1) and leukocyte infiltration at 72 h. Urinary/renal neutrophil gelatinase-associated lipocalin 2 (NGAL) levels, hemeoxygenase-1 expression, and renal cell proliferation were increased by suramin compared with glycerol alone at 72 h. Mechanistically, suramin decreases early glycerol-induced pro-inflammatory (IL-1 beta and NF-kappa B) and growth inhibitory (TGF-beta(1)) mediators, resulting in the prevention of late downstream inflammatory effects (ICAM-1 and leukocyte infiltration) and increasing compensatory nephrogenic repair. These results support the hypothesis that delayed administration of suramin is effective in abrogating apoptosis, attenuating inflammation, and enhancing nephrogenic repair after glycerol-induced AKI. C1 [Korrapati, Midhun C.; Shaner, Brooke E.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institutes of Health National Institute of General Medical Sciences [GM084147]; Biomedical Laboratory Research and Development of Department of Veterans Affairs; National Institutes of Health National Center for Research Resources [C06-RR015455]; South Carolina Clinical & Translational Research Institute; Medical University of South Carolina, National Institutes of Health National Center for Research Resources [UL1-RR029882] FX This study was supported by National Institutes of Health National Institute of General Medical Sciences [Grant GM084147]; and the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. Animal facilities were funded by National Institutes of Health National Center for Research Resources [Grant C06-RR015455]. This publication (or project) was also supported by the South Carolina Clinical & Translational Research Institute, with an academic home at the Medical University of South Carolina, National Institutes of Health National Center for Research Resources [Grant UL1-RR029882]. NR 57 TC 21 Z9 24 U1 3 U2 7 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD APR PY 2012 VL 341 IS 1 BP 126 EP 136 DI 10.1124/jpet.111.190249 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 908YX UT WOS:000301530100013 PM 22228809 ER PT J AU Braunstein, I Goodman, NG Rosenbach, M Okawa, J Shah, A Krathen, M Kovarik, CL Prak, EL Werth, VP AF Braunstein, Inbal Goodman, Noah G. Rosenbach, Misha Okawa, Joyce Shah, Asha Krathen, Michael Kovarik, Carrie L. Prak, Eline Luning Werth, Victoria P. TI Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE cutaneous lupus erythematosus; lenalidomide; lupus erythematosus; subacute cutaneous; lupus erythematosus; discoid; lupus erythematosus; tumid ID AICARDI-GOUTIERES-SYNDROME; SKIN-LESIONS; T-CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; DISEASE-ACTIVITY; DENDRITIC CELLS; SEVERITY INDEX; EXPRESSION; LYMPHOCYTES; RECRUITMENT AB Background: Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE). Objectives: We evaluate the use of lenalidomide in CLE and describe the skin and circulating leukocyte profile of treatment-refractory patients before and after treatment. Methods: Five subjects were treated with lenalidomide in an unblinded open-label study. Immunohistochemistry of skin was performed for T-cell markers, glycosaminoglycans, and CXCL10, an interferon-inducible chemokine, before and after treatment. Immunophenotyping and measurement of interferon-inducible genes from peripheral blood mononuclear cells was also performed before and after treatment. Results: Four subjects demonstrated clinical improvement of their skin, however one of these responders subsequently developed symptoms of systemic lupus erythematosus. Small changes in rare circulating leukocyte subsets, plasmacytoid dendritic cells, and regulatory T cells were observed with treatment and may correlate with clinical response. Treatment was associated with increased circulating HLA-DR expression and decreased markers of interferon-mediated pathways, regardless of clinical response. Limitations: Our results are limited by small sample size and the measurement of rare populations of circulating cell subsets. Conclusions: Lenalidomide may have usefulness as therapy for severe, treatment-refractory CLE. However, our preliminary data suggest that lenalidomide may activate T cells and trigger systemic disease in some patients with CLE. We also saw a different histologic and circulating leukocyte phenotype in the nonresponding subject. Further characterization of the skin and circulating leukocyte profile of treatment-refractory patients will improve our understanding of CLE. (J Am Acad Dermatol 2012;66:571-82.) C1 [Braunstein, Inbal; Rosenbach, Misha; Okawa, Joyce; Shah, Asha; Krathen, Michael; Kovarik, Carrie L.; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Goodman, Noah G.; Prak, Eline Luning] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Braunstein, Inbal; Okawa, Joyce; Shah, Asha; Krathen, Michael; Kovarik, Carrie L.; Werth, Victoria P.] Univ Penn, Dermatol Sect, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Alliance for Lupus Research; Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health [K24-AR 02207] FX Supported in part by the Alliance for Lupus Research, a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by the National Institutes of Health (K24-AR 02207) to Dr Werth. Celgene Corporation provided the drug free of charge. NR 38 TC 18 Z9 19 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 2012 VL 66 IS 4 BP 571 EP 582 DI 10.1016/j.jaad.2011.01.015 PG 12 WC Dermatology SC Dermatology GA 907UP UT WOS:000301444600011 PM 21821308 ER PT J AU Kozora, E Filley, CM Zhang, L Brown, MS Miller, DE Arciniegas, DB Pelzman, JL West, SG AF Kozora, E. Filley, C. M. Zhang, L. Brown, M. S. Miller, D. E. Arciniegas, D. B. Pelzman, J. L. West, S. G. TI Immune function and brain abnormalities in patients with systemic lupus erythematosus without overt neuropsychiatric manifestations SO LUPUS LA English DT Article DE autoantibodies; cognition; cytokines; lupus; neuroimaging ID CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; RHEUMATOID-ARTHRITIS; NEUROMETABOLIC ABNORMALITIES; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; ELEVATED LEVELS; INTERLEUKIN-6; CYTOKINES; INVOLVEMENT AB Objective: This study examined the relationship between immune, cognitive and neuroimaging assessments in subjects with systemic lupus erythematosus (SLE) without histories of overt neuropsychiatric (NP) disorders. Methods: In total, 84 subjects with nonNPSLE and 37 healthy controls completed neuropsychological testing from the American College of Rheumatology SLE battery. Serum autoantibody and cytokine measures, volumetric magnetic resonance imaging, and magnetic resonance spectroscopy data were collected on a subset of subjects. Results: NonNPSLE subjects had lower scores on measures of visual/complex attention, visuomotor speed and verbal memory compared with controls. No clinically significant differences between nonNPSLE patients and controls were found on serum measures of lupus anticoagulant, anticardiolipin antibodies, beta 2-glycoproteins, or pro-inflammatory cytokines (interleukin (IL)-1, IL-6, interferon alpha (IFN-alpha), and interferon gamma (IFN-gamma)). Higher scores on a global cognitive impairment index and a memory impairment index were correlated with lower IFN-alpha. Few associations between immune functions and neuroimaging parameters were found. Conclusions: Results indicated that nonNPSLE patients demonstrated cognitive impairment but not immune differences compared with controls. In these subjects, who were relatively young and with mild disease, no relationship between cognitive dysfunction, immune parameters, or previously documented neuroimaging abnormalities were noted. Immune measures acquired from cerebrospinal fluid instead of serum may yield stronger associations. Lupus (2012) 21, 402-411. C1 [Kozora, E.; Zhang, L.; Pelzman, J. L.] Natl Jewish Hlth, Denver, CO 80206 USA. [Filley, C. M.; Arciniegas, D. B.] Univ Colorado, Dept Neurol, Denver Sch Med, Denver, CO 80202 USA. [Kozora, E.; Filley, C. M.; Arciniegas, D. B.] Univ Colorado, Dept Psychiat, Denver Sch Med, Denver, CO 80202 USA. [Brown, M. S.; Miller, D. E.] Univ Colorado, Dept Radiol, Denver Sch Med, Denver, CO 80202 USA. [West, S. G.] Univ Colorado, Dept Rheumatol, Denver Sch Med, Denver, CO 80202 USA. [Filley, C. M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kozora, E (reprint author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA. EM kozorae@njhealth.org FU National Institute of Musculoskeletal and Skin Diseases [RO1 AR049152-02] FX This work was supported by the National Institute of Musculoskeletal and Skin Diseases (Grant RO1 AR049152-02). NR 60 TC 17 Z9 19 U1 3 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PD APR PY 2012 VL 21 IS 4 BP 402 EP 411 DI 10.1177/0961203311429116 PG 10 WC Rheumatology SC Rheumatology GA 909RZ UT WOS:000301583400006 PM 22170761 ER PT J AU Baker, LD Asthana, S Cholerton, BA Wilkinson, CW Plymate, SR Green, PS Merriam, GR Fishel, MA Watson, GS Cherrier, MM Kletke, ML Mehta, PD Craft, S AF Baker, Laura D. Asthana, Sanjay Cholerton, Brenna A. Wilkinson, Charles W. Plymate, Stephen R. Green, Pattie S. Merriam, George R. Fishel, Mark A. Watson, G. Stennis Cherrier, Monique M. Kletke, Monica L. Mehta, Pankaj D. Craft, Suzanne TI Cognitive response to estradiol in postmenopausal women is modified by high cortisol SO NEUROBIOLOGY OF AGING LA English DT Article DE Estrogen; Stress; Hypothalamic-pituitary-adrenal (HPA); Cognition; Executive function; Memory; A beta; Amyloid; IGF; Postmenopausal ID GROWTH-FACTOR-I; ESTROGEN REPLACEMENT THERAPY; MEDIAL PREFRONTAL CORTEX; CORTICOTROPIN-RELEASING-FACTOR; ACUTE PSYCHOSOCIAL STRESS; PITUITARY-ADRENAL AXIS; AMYLOID-BETA; WORKING-MEMORY; ALZHEIMERS-DISEASE; IMPROVES COGNITION AB Estradiol has potent favorable effects on brain function and behavior in animals while in human trials, the results are inconsistent. A number of potential mediating variables influencing response to estradiol have been proposed to account for this variability, 1 of which includes stress. We conducted a placebo-controlled study to examine joint and independent effects of estradiol and elevated levels of the stress hormone cortisol on cognition and biomarkers of aging and neurodegenerative disease. Thirty-nine healthy postmenopausal women (56-84 years) received 0.10 mg/dL of transdermal 17 beta-estradiol (E2) or placebo for 8 weeks. During the last 4 days of the trial, subjects also received 90 mg/day (30 mg 3 beta/day) of oral hydrocortisone (CORT) to induce stress-level elevations in cortisol, or a matched placebo. The 4 groups thus included placebo (placebo patch/placebo pill), CORT-alone (placebo patch/hydrocortisone), E2-alone (estradiol patch/placebo pill), and E2+CORT (estradiol patch/hydrocortisone). Eight weeks of E2 increased plasma estradiol by 167%, and 4 days of CORT increased plasma cortisol by 119%. Overall, E2 had favorable effects on verbal memory (p = 0.03), working memory (p = 0.02), and selective attention (p = 0.04), and the magnitude of these effects was attenuated for E2+CORT. E2-alone and E2+CORT had opposing effects on plasma levels of the amyloid-beta (A beta) biomarker (A beta 40/42 ratio, p < 0.05), with the more favorable response observed for E2-alone. CORT-induced increases in insulin-like growth factor-1 were blunted by E2 coadministration. Our findings indicate that cognitive and physiological responses to estradiol are adversely affected by elevated stress hormone levels of cortisol in healthy postmenopausal women. (C) 2012 Elsevier Inc. All rights reserved. C1 [Baker, Laura D.] VAPSHCS, GRECC S 182, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Baker, Laura D.; Cholerton, Brenna A.; Wilkinson, Charles W.; Watson, G. Stennis; Cherrier, Monique M.; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Plymate, Stephen R.; Green, Pattie S.; Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Green, Pattie S.; Merriam, George R.; Kletke, Monica L.] VAPSHCS, Res & Dev, Seattle, WA 98108 USA. [Fishel, Mark A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Mehta, Pankaj D.] New York State Inst Basic Res Dev Disabil, Dept Immunol, New York, NY USA. RP Baker, LD (reprint author), VAPSHCS, GRECC S 182, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Ldbaker@uw.edu FU Office of Research and Development Medical Research Service; Geriatric Research, Education and Clinical Center of the Veterans Affairs Puget Sound Health Care System; National Alliance for Research on Schizophrenia and Depression (NARSAD) FX This work was supported by the Office of Research and Development Medical Research Service, the Geriatric Research, Education and Clinical Center of the Veterans Affairs Puget Sound Health Care System, and the National Alliance for Research on Schizophrenia and Depression (NARSAD). Berlex Laboratories provided the transdermal estradiol patches and matching placebo. We are grateful to the members of our laboratory who contributed many hours to this project including Karen Enstrom, R.N., Karen Hyde, R.N., Darla Chapman, R.N., Donna Davis, R.N., Jaime Tidwell, Dana Belongia, Tracia Clark, Amy Morgan, Michelle Keeling, and Margaret Pagoria. We also thank Elizabeth Colasurdo and Kathy Haugk for their assistance with the assays. NR 111 TC 3 Z9 3 U1 5 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2012 VL 33 IS 4 AR 829.e9 DI 10.1016/j.neurobiolaging.2011.07.002 PG 12 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 908RC UT WOS:000301506800032 PM 21855173 ER PT J AU Shi, M Furay, AR Sossi, V Aasly, JO Armaly, J Wang, Y Wszolek, ZK Uitti, RJ Hasegawa, K Yokoyama, T Zabetian, CP Leverenz, JB Stoessl, AJ Zhang, J AF Shi, Min Furay, Amy R. Sossi, Vesna Aasly, Jan O. Armaly, Jeff Wang, Yu Wszolek, Zbigniew K. Uitti, Ryan J. Hasegawa, Kazuko Yokoyama, Teruo Zabetian, Cyrus P. Leverenz, James B. Stoessl, A. Jon Zhang, Jing TI DJ-1 and alpha SYN in LRRK2 CSF do not correlate with striatal dopaminergic function SO NEUROBIOLOGY OF AGING LA English DT Article DE Parkinson's disease; LRRK2; Gene mutation; Biomarker; DJ-1; alpha-synuclein ID PARKINSONS-DISEASE AB Previous studies demonstrated decreased levels of DJ-1 and alpha-synuclein (alpha SYN) in human cerebrospinal fluid (CSF) in patients with Parkinson's disease (PD), but neither marker correlated with PD severity, raising the possibility that they may be excellent progression markers during early or preclinical phases of PD. Individuals carrying the leucine-rich repeat kinase 2 (LRRK2) gene mutation are at increased risk for PD, and the phenotype of LRRK2 patients is almost identical to sporadic PD. To determine whether dopaminergic dysfunction in the basal ganglia, as determined by positron emission tomography (PET) scans, correlates with CSF levels of DJ-1 and alpha SYN during preclinical stages, Luminex assays were used to analyze CSF samples from asymptomatic LRRK2 mutation carriers, along with carriers who presented with a clinical diagnosis of PD. The data revealed no statistically significant relationship between PET scan evidence of loss of striatal dopaminergic function and the CSF biomarkers DJ-1 and alpha SYN, except for a weak correlation between DJ-1 and methylphenidate binding, suggesting that the use of these potential biomarkers on their own to screen LRRK2 gene mutation carriers for PD is not appropriate. (C) 2012 Elsevier Inc. All rights reserved. C1 [Shi, Min; Furay, Amy R.; Armaly, Jeff; Wang, Yu; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Sossi, Vesna] Univ British Columbia, Dept Phys & Astron, Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada. [Aasly, Jan O.] St Olavs Hosp, Dept Neurol, Trondheim, Norway. [Wang, Yu] Huazhong Univ Sci & Technol, Dept Neurosurg, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China. [Wszolek, Zbigniew K.; Uitti, Ryan J.] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA. [Hasegawa, Kazuko; Yokoyama, Teruo] Sagamihara Natl Hosp, Dept Neurol, Natl Hosp Org, Sagamihara, Kanagawa, Japan. [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Stoessl, A. Jon] Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada. [Stoessl, A. Jon] Vancouver Coastal Hlth, Vancouver, BC, Canada. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU BLRD VA [I01 BX000531]; NIA NIH HHS [R01 AG025327, R01 AG033398, R01 AG033398-05]; NIEHS NIH HHS [R01 ES019277, R01 ES016873, R01 ES016873-03, R01 ES019277-01A1, R01 ES019277-02]; NINDS NIH HHS [P50 NS062684, P50 NS072187, R01 NS057567, R01 NS057567-05, R01 NS065070, R21 NS060252] NR 3 TC 4 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2012 VL 33 IS 4 AR 836.e5 DI 10.1016/j.neurobiolaging.2011.09.015 PG 3 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 908RC UT WOS:000301506800049 PM 22019052 ER PT J AU Zhang, XY Zhou, DF Shen, YC Zhang, PY Zhang, WF Liang, J Chen, DC Xiu, MH Kosten, TA Kosten, TR AF Zhang, Xiang Yang Zhou, Dong Feng Shen, Yu Cun Zhang, Pei Yan Zhang, Wu Fang Liang, Jun Chen, Da Chun Xiu, Mei Hong Kosten, Therese A. Kosten, Thomas R. TI Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia SO NEUROPHARMACOLOGY LA English DT Article DE Schizophrenia; Free radical; Oxidative stress; Antipsychotic treatment ID ANTIOXIDANT DEFENSE SYSTEM; ACID-REACTIVE SUBSTANCES; POLYUNSATURATED FATTY-ACIDS; FREE-RADICAL PATHOLOGY; LIPID-PEROXIDATION; OXIDATIVE STRESS; RAT-BRAIN; ANTIPSYCHOTIC-DRUGS; THERAPEUTIC IMPLICATIONS; ATYPICAL ANTIPSYCHOTICS AB Oxidative stress may be involved in the pathophysiology of schizophrenia. No double-blind study has compared the effects of typical and atypical antipsychotics on both antioxidant enzyme activity and nitric oxide (NO) levels in schizophrenic patients. Seventy-eight inpatients with chronic schizophrenia were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol using a double-blind design. Clinical efficacy was determined using the Positive and Negative Syndrome Scale. Blood superoxide dismutase (SOD) and plasma NO levels were measured in patients and 30 normal controls. Our results showed that following a 2-week washout period, levels of SOD and NO were significantly increased in patients with schizophrenia compared to normal controls. Both risperidone and haloperidol equivalently reduced the elevated blood SOD levels in schizophrenia, but neither medication reduced the elevated plasma NO levels in schizophrenia. Low blood SOD levels at baseline predicted greater symptom improvement during treatment, and greater change in SOD was correlated with greater symptom improvement. These results suggest that both typical and atypical antipsychotic drugs may at least partially normalize abnormal free radical metabolism in schizophrenia, and some free radical parameters at baseline may predict antipsychotic responses of schizophrenic patients. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Zhang, Xiang Yang; Zhou, Dong Feng; Shen, Yu Cun; Zhang, Wu Fang; Liang, Jun] Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China. [Zhang, Xiang Yang; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China. [Zhang, Xiang Yang; Zhang, Pei Yan; Chen, Da Chun; Xiu, Mei Hong] Beijing HuiLongGuan Hosp, Beijing, Peoples R China. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; zhoudf@bjmu.edu.cn; kosten@bcm.edu FU Stanley Medical Research Institute [03T-459, 05T-726]; Beijing Municipal Natural Science Foundation [7072035]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC),United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This study was partially funded by the Stanley Medical Research Institute (03T-459 and 05T-726), the Beijing Municipal Natural Science Foundation (ID: 7072035), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 58 TC 24 Z9 25 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD APR PY 2012 VL 62 IS 5-6 BP 1928 EP 1934 DI 10.1016/j.neuropharm.2011.12.014 PG 7 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 908EX UT WOS:000301474300003 PM 22227558 ER PT J AU Sonpavde, G Sternberg, CN AF Sonpavde, Guru Sternberg, Cora N. TI Neoadjuvant Chemotherapy for Invasive Bladder Cancer SO CURRENT UROLOGY REPORTS LA English DT Article DE Bladder cancer; Neoadjuvant therapy; Surgery AB Neoadjuvant cisplatin- based combination chemotherapy is an established standard for resectable muscle-invasive bladder cancer, a disease with a pattern of predominantly distant and early recurrences. Pathologic complete remission appears to be an intermediate surrogate for survival when employing combination chemotherapy. Moreover, baseline host and tumor tissue studies may enable the discovery of biomarkers predictive of activity. The neoadjuvant setting also provides a window of opportunity to evaluate novel biologic agents or rational combinations of biologic agents to obtain a signal of biologic activity. The residual tumor after neoadjuvant therapy may be exploited to study the mechanism of action and resistance. Cisplatin-ineligible patients warrant the evaluation of tolerable neoadjuvant regimens. Given that bladder cancer is characterized by initial localized presentation in the vast majority of cases, the paradigm of neoadjuvant therapy may expedite the development of novel systemic agents. C1 [Sonpavde, Guru] Baylor Coll Med, Sect Med Oncol, Dept Med, Texas Oncol,Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Sternberg, Cora N.] San Camillo Hosp, I-00152 Rome, Italy. [Sternberg, Cora N.] Forlanini Hosp, I-00152 Rome, Italy. RP Sternberg, CN (reprint author), San Camillo Hosp, Padigl Flajani 1,Circonvallaz Gianicolense 87, I-00152 Rome, Italy. EM cstern@mclink.it RI Mendez, Pedro /J-8955-2016 OI Mendez, Pedro /0000-0001-6713-7907 FU Cephalon; Celgene; Bristol-Myers Squibb; Pfizer; Bellicum Pharmaceuticals; Ascenta Therapeutics; Novartis; Cytogen; AstraZeneca; Imclone-Eli Lilly; Sanofi-Aventis; Cougar Biotech; Astellas FX Dr. Guru Sonpavde has served as board member for Novartis, Bristol-Myers Squibb, Pfizer, Dendreon, and Janssen; has received grants or research support or has grants pending from Cephalon, Celgene, Bristol-Myers Squibb, Pfizer, Bellicum Pharmaceuticals, Ascenta Therapeutics, Novartis, Cytogen, AstraZeneca, and Imclone-Eli Lilly; and has received honoraria from Wyeth/Pfizer, Novartis, Sanofi-Aventis, GlaxoSmithKline, Janssen Biotech, Dendreon, and Amgen. Dr. Cora Sternberg has received honoraria from Novartis, Pfizer, and GlaxoSmithKline; has received research support from Sanofi-Aventis, Cougar Biotech, and Astellas; and served on the advisory board or as a consultant for Bayer, Novartis, GlaxoSmithKline and Pfizer. NR 90 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1527-2737 J9 CURR UROL REP JI Curr. Urol. Rep. PD APR PY 2012 VL 13 IS 2 BP 136 EP 146 DI 10.1007/s11934-012-0236-2 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA V32HX UT WOS:000208943400004 PM 22314880 ER PT J AU Stengel, A Tache, Y AF Stengel, Andreas Tache, Yvette TI Yin and Yang - the Gastric X/A-like Cell as Possible Dual Regulator of Food Intake SO JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Review DE Desacyl ghrelin; Eating; Ghrelin; Nucleobindin; Obesity; Obestatin; Stomach ID DES-ACYL GHRELIN; HORMONE SECRETAGOGUE RECEPTOR; PROTEIN-COUPLED-RECEPTOR; AGOUTI-RELATED PROTEIN; HYPOTHALAMIC ARCUATE NUCLEUS; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA LEVELS; NEUROPEPTIDE-Y; BODY-WEIGHT; RAT STOMACH AB Ingestion of food affects secretion of hormones from enteroendocrine cells located in the gastrointestinal mucosa. These hormones are involved in the regulation of various gastrointestinal functions including the control of food intake. One cell in the stomach, the X/A-like has received much attention over the past years due to the production of ghrelin. Until now, ghrelin is the only known orexigenic hormone that is peripherally produced and centrally acting to stimulate food intake. Subsequently, additional peptide products of this cell have been described including desacyl ghrelin, obestatin and nesfatin-1. Desacyl ghrelin seems to be involved in the regulation of food intake as well and could play a counter-balancing role of ghrelin's orexigenic effect. In contrast, the initially proposed anorexigenic action of obestatin did not hold true and therefore the involvement of this peptide in the regulation of feeding is questionable. Lastly, the identification of nesfatin-1 in the same cell in different vesicles than ghrelin extended the function of this cell type to the inhibition of feeding. Therefore, this X/A-like cell could play a unique role by encompassing yin and yang properties to mediate not only hunger but also satiety. C1 [Stengel, Andreas] Univ Med Berlin, Charite, Dept Med, Div Psychosomat Med & Psychotherapy, Berlin, Germany. [Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, Ctr Neurobiol Stress,CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Stengel, A (reprint author), Obes Ctr Berlin, Div Psychosomat Med, Charitepl 1, D-10117 Berlin, Germany. EM andreas.stengel@charite.de FU Charite University; NIH [R01 DK-33061]; NIH Center Grant [DK-41301]; VA Research Career Scientist FX This work was supported by Charite University funding (A. S.) and NIH R01 DK-33061, NIH Center Grant DK-41301 (Animal Core) and VA Research Career Scientist (Y.T.). NR 165 TC 16 Z9 17 U1 0 U2 3 PU KOREAN SOC NEUROGASTERONTEROL & MOTILITY PI GANGNAM-GU PA RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU, SEOUL 135-839, SOUTH KOREA SN 2093-0879 EI 2093-0887 J9 J NEUROGASTROENTEROL JI J. Neurogastroenterol. Motil. PD APR PY 2012 VL 18 IS 2 BP 138 EP 149 DI 10.5056/jnm.2012.18.2.138 PG 12 WC Gastroenterology & Hepatology; Clinical Neurology SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 225XR UT WOS:000324999000005 PM 22523723 ER PT J AU Hsue, PY Scherzer, R Hunt, PW Schnell, A Bolger, AF Kalapus, SC Maka, K Martin, JN Ganz, P Deeks, SG AF Hsue, Priscilla Y. Scherzer, Rebecca Hunt, Peter W. Schnell, Amanda Bolger, Ann F. Kalapus, S. C. Maka, Kristinalisa Martin, Jeffrey N. Ganz, Peter Deeks, Steven G. TI Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE AIDS; carotid arteries; inflammation; atherosclerosis ID CARDIOVASCULAR RISK-FACTORS; ENDOTHELIAL SHEAR-STRESS; CORONARY-HEART-DISEASE; ANTIRETROVIRAL THERAPY; ATHEROSCLEROTIC LESIONS; MYOCARDIAL-INFARCTION; FLOW PATTERNS; IMMUNODEFICIENCY; ACTIVATION; PLAQUE AB Background-Shear stress gradients and inflammation have been causally associated with atherosclerosis development in carotid bifurcation regions. The mechanism underlying higher levels of carotid intima-media thickness observed among HIV-infected individuals remains unknown. Methods and Results-We measured carotid intima-media thickness progression and development of plaque in the common carotid, bifurcation region, and internal carotid artery in 300 HIV-infected persons and 47 controls. The median duration of follow-up was 2.4 years. When all segments were included, the rate of intima-media thickness progression was greater in HIV-infected subjects compared with controls after adjustment for traditional risk factors (0.055 vs. 0.024 mm/year, P=0.016). Rate of progression was also greater in the bifurcation region (0.067 vs. 0.025 mm/year, P=0.042) whereas differences were smaller in the common and internal regions. HIV-infected individuals had a greater incidence of plaque compared with controls in the internal (23% vs. 6.4%, P=0.0037) and bifurcation regions (34% vs. 17%, P=0.014). Among HIV-infected individuals, the rate of progression in the bifurcation region was more rapid compared with the common carotid, internal, or mean intima-media thickness; in contrast, progression rates among controls were similar at all sites. Baseline hsCRP was elevated in HIV-infected persons and was a predictor of progression in the bifurcation region. Conclusions-Atherosclerosis progresses preferentially in the carotid bifurcation region in HIV-infected individuals. hsCRP, a marker of inflammation, is elevated in HIV and is associated with progression in the bifurcation region. These data are consistent with a model in which the interplay between hemodynamic shear stresses and HIV-associated inflammation contribute to accelerated atherosclerosis. (J Am Heart Assoc. 2012; 1: jah3-e000422 doi: 10.1161/JAHA.111.000422.) C1 [Hsue, Priscilla Y.; Schnell, Amanda; Bolger, Ann F.; Maka, Kristinalisa; Ganz, Peter; Deeks, Steven G.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. [Hunt, Peter W.; Martin, Jeffrey N.; Deeks, Steven G.] San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94110 USA. [Scherzer, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Scherzer, Rebecca] Dept Med UCSF, San Francisco, CA USA. [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Hsue, PY (reprint author), San Francisco Gen Hosp, Div Cardiol, Room 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA. EM phsue@medsfgh.ucsf.edu FU Doris Duke Charitable Foundation; National Institutes of Health [K23 AI066885, K24AI069994, R01 HL095130, R01 AI052745, R01 CA119903, P30 AI27763, RO1 AI087145, MO1 RR000083]; UCSF CFAR [PO AI27763]; UCSF CTSI [UL1 RR024131]; amfAR [106710-40-RGRL]; Ragon Institute FX The work was supported by grants from the Doris Duke Charitable Foundation (Clinical Scientist Development Award to PYH), the National Institutes of Health (K23 AI066885, K24AI069994, R01 HL095130, R01 AI052745, R01 CA119903, P30 AI27763, RO1 AI087145, and MO1 RR000083), the UCSF CFAR (PO AI27763), the UCSF CTSI (UL1 RR024131), amfAR (106710-40-RGRL), and the Ragon Institute. NR 45 TC 32 Z9 32 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD APR PY 2012 VL 1 IS 2 AR UNSP jah3-e000422 DI 10.1161/JAHA.111.000422 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 243QY UT WOS:000326333200003 ER PT J AU Fisher, M Garrett, C Alexander, P Subramaniam, K Vinogradov, S AF Fisher, Melissa Garrett, Coleman Alexander, Phillip Subramaniam, Karuna Vinogradov, Sophia TI NEUROPLASTICITY-BASED COGNITIVE TRAINING IN SCHIZOPHRENIA: A FINAL REPORT ON THE EFFECTS 6-12 MONTHS LATER SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 [Fisher, Melissa; Garrett, Coleman; Alexander, Phillip; Subramaniam, Karuna; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fisher, Melissa; Garrett, Coleman; Alexander, Phillip; Subramaniam, Karuna; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2012 VL 136 SU 1 MA 163 BP S339 EP S339 PG 1 WC Psychiatry SC Psychiatry GA V45US UT WOS:000209842102025 ER PT J AU Rassovsky, Y Lee, J Nori, P Wu, AD Iacoboni, M Green, MF AF Rassovsky, Yuri Lee, Junghee Nori, Poorang Wu, Allan D. Iacoboni, Marco Green, Michael F. TI SPATIAL AND TEMPORAL PROPERTIES OF AFFECT PERCEPTION DEFICITS IN SCHIZOPHRENIA: A TMS STUDY SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 [Rassovsky, Yuri; Lee, Junghee; Nori, Poorang; Wu, Allan D.; Iacoboni, Marco; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA. [Rassovsky, Yuri] Bar Ilan Univ, Ramat Gan, Israel. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2012 VL 136 SU 1 MA 73 BP S306 EP S307 PG 2 WC Psychiatry SC Psychiatry GA V45US UT WOS:000209842101616 ER PT J AU Smith, MJ Horan, WP Karpouzian, T Abram, S Cobia, D Csernansky, JG AF Smith, Matthew J. Horan, William P. Karpouzian, Tatiana Abram, Samantha Cobia, Derin Csernansky, John G. TI EMPATHY DEFICITS ARE UNIQUELY ASSOCIATED WITH POOR FUNCTIONING IN SCHIZOPHRENIA SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 [Smith, Matthew J.; Karpouzian, Tatiana; Abram, Samantha; Cobia, Derin; Csernansky, John G.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Horan, William P.] Univ Calif Los Angeles, Los Angeles, CA USA. [Horan, William P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2012 VL 136 SU 1 MA 233 BP S365 EP S365 PG 1 WC Psychiatry SC Psychiatry GA V45US UT WOS:000209842102095 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Complications following gastrointestinal bleeding and their impact on outcome and death SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE complication of endoscopic procedure; esophago-gastro-duodenoscopy; gastrointestinal bleeding; gastrointestinal endoscopy; Markov chain modeling; outcome research; threshold analysis ID HEMORRHAGE; EPIDEMIOLOGY AB Background Bleeding from the upper gastrointestinal tract is one of the most common life-threatening morbidities encountered by gastroenterologists. A mathematical model has been developed to gain insights into how, after an initial event of upper gastrointestinal bleeding, complications can accumulate in individual patients and expose them to an increased risk of death. Methods The occurrence of complications and possible death after gastrointestinal bleeding are simulated using a Markov chain model. Results The accumulation of complications in an individual patient is influenced by the length of time a patient remains vulnerable to the probability of developing new complications. The model illustrates how the initial bleeding episode sets the stage for the occurrence of subsequent complications and how each subsequent complication increases in an exponential manner the risk for additional complications. Because of such a pattern, complications tend to cluster in a group of patients who run into an ever-increasing risk of multiple complications. Although the majority of patients go through their initial bleeding episode without ever experiencing any secondary complication, in a subset of patients the initial complication sets in motion a vicious cycle with frequently more than one consecutive complication after the initial gastrointestinal bleed. Conclusion The key to the successful management of a patient with gastrointestinal bleeding is to stop such a vicious cycle as early as possible, as each progression within the cycle renders the probability of additional complications more likely and its reversal more difficult. Eur J Gastroenterol Hepatol 24: 388-392 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 9 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD APR PY 2012 VL 24 IS 4 BP 388 EP 392 DI 10.1097/MEG.0b013e328350589e PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 905QY UT WOS:000301288700006 PM 22233622 ER PT J AU Leoutsakos, JMS Muthen, BO Breitner, JC Lyketsos, CG AF Leoutsakos, Jeannie-Marie S. Muthen, Bengt O. Breitner, John C. S. Lyketsos, Constantine G. CA ADAPT Res Team TI Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE NSAIDs; Alzheimer; prevention; dementia; growth mixture models ID AMYLOID-BETA-PROTEIN; MIXTURE MODELING ANALYSIS; MICROGLIAL CELLS; DOUBLE-BLIND; NSAID USE; IMPAIRMENT; DEMENTIA; AD; TRAJECTORIES; PROGRESSION AB Objective: We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease. Methods: Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease. We fit growth mixture models of Modified Mini-Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial and included class-specific effects of naproxen and celecoxib. Results: We identified three classes: "no decline", "slow decline", and "fast decline", and examined the effects of celecoxib and naproxen on linear slope and rate of change by class. Inclusion of quadratic terms improved fit of the model (-2 log likelihood difference: 369.23; p < 0.001) but resulted in reversal of effects over time. Over 4 years, participants in the slow-decline class on placebo typically lost 6.6 3MS points, whereas those on naproxen lost 3.1 points (p-value for difference: 0.19). Participants in the fast-decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p-value for difference from placebo: 0.04), whereas those on naproxen showed a typical decline of 24.9 points (p-value for difference from placebo: <0.0001). Conclusions: Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times. Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Leoutsakos, Jeannie-Marie S.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Leoutsakos, Jeannie-Marie S.; Lyketsos, Constantine G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Muthen, Bengt O.] Univ Calif Los Angeles, Los Angeles Grad Sch Educ & Informat Studies, Social Res Methodol Div, Los Angeles, CA USA. [Breitner, John C. S.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Breitner, John C. S.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. RP Leoutsakos, JMS (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. EM jeannie-marie@jhu.edu FU AstraZeneca; Eisai; Forest Laboratories; Janssen; Lilly; Novartis; Pfizer; NIH [T32AG026778, U01-AG15477, P50-AG005146] FX Dr Lyketsos is a consultant to GlaxoSmithKline and receives lecture honoraria and support for continuing medical education activities from AstraZeneca, Eisai, Forest Laboratories, Janssen, Lilly, Novartis, and Pfizer.; This study was supported by NIH grants T32AG026778, U01-AG15477, and P50-AG005146. NR 61 TC 35 Z9 36 U1 2 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD APR PY 2012 VL 27 IS 4 BP 364 EP 374 DI 10.1002/gps.2723 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 904WC UT WOS:000301228600004 PM 21560159 ER PT J AU Kaz, AM Luo, YX Dzieciatkowski, S Chak, A Willis, JE Upton, MP Leidner, RS Grady, WM AF Kaz, Andrew M. Luo, Yanxin Dzieciatkowski, Slavomir Chak, Amitabh Willis, Joseph E. Upton, Melissa P. Leidner, Rom S. Grady, William M. TI Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma SO GENES CHROMOSOMES & CANCER LA English DT Article ID SQUAMOUS-CELL CARCINOMAS; DNA METHYLATION; CANCER; PLAKOPHILIN-1; EXPRESSION; ADHESION; CADHERIN; DYSPLASIA; DESMOSOME; PROTEINS AB The aberrant DNA methylation of tumor suppressor genes occurs frequently in Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) and likely affects the initiation and progression of BE to EAC. In the present study, we discovered PKP1 as a novel methylated gene in EAC and then investigated the role of loss of PKP1, a constituent of the desmosome complex found in stratified epithelial layers, on the behavior of Barrett's esophagus and esophageal adenocarcinoma cells. By using primary esophageal tissue samples we determined that PKP1 was rarely methylated in normal squamous esophagus (5/55; 9.1%) and BE (5/39; 12.8%) and more frequently methylated in Barrett's esophagus with high-grade dysplasia (HGD) or EAC (20/60; 33.3%; P < 0.05). Furthermore, PKP1 levels were decreased in BE and HGD/EAC cases compared to normal squamous esophagus cases. Knockdown of PKP1 in the BE cell lines CP-A and CP-D (both normally express PKP1) resulted in increased cell motility. Thus, PKP1 loss secondary to promoter methylation, as well as other mechanisms, may promote the progression of BE to EAC in a subset of patients via decreased desmosome assembly and increased cell motility. (c) 2011 Wiley Periodicals, Inc. C1 [Kaz, Andrew M.; Luo, Yanxin; Dzieciatkowski, Slavomir; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. [Luo, Yanxin] Sixth Affiliated Hosp, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China. [Luo, Yanxin] Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou 510275, Guangdong, Peoples R China. [Chak, Amitabh; Leidner, Rom S.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA. [Willis, Joseph E.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA. [Upton, Melissa P.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA. EM akaz@fhcrc.org; wgrady@fhcrc.org FU NIH/NIDDK [5K08DK080630]; Takeda Pharmaceuticals North America; NIH [R21 5R21CA135692]; K24 Midcareer Award in Patient Oriented Research [DK002800]; Burroughs Wellcome Fund; NIH/NCI [U54CA143682, U01CA152756, U54CA163060] FX The authors thank Dr. James Wahl at the University of Nebraska Medical center for his generous gift of PKP1 antibody. This work was supported by NIH/NIDDK grant 5K08DK080630 (A. K.), an Investigator Initiated Research Award (Takeda Pharmaceuticals North America; W. M. G.), NIH R21 5R21CA135692 (A. C.), and a K24 Midcareer Award in Patient Oriented Research DK002800 (A. C.). Additional support was provided by Burroughs Wellcome Fund (W. M. G.), by NIH/NCI grant U54CA143682 (W. M. G.), U01CA152756 (W. M. G.), and U54CA163060 (W. M. G. and A.K.). NR 40 TC 9 Z9 9 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1045-2257 J9 GENE CHROMOSOME CANC JI Gene Chromosomes Cancer PD APR PY 2012 VL 51 IS 4 BP 384 EP 393 DI 10.1002/gcc.21923 PG 10 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA 889CL UT WOS:000300051000007 PM 22170739 ER PT J AU Turner, JA Chen, HJ Mathalon, DH Allen, EA Mayer, AR Abbott, CC Calhoun, VD Bustillo, J AF Turner, Jessica A. Chen, Hongji Mathalon, Daniel H. Allen, Elena A. Mayer, Andrew R. Abbott, Christopher C. Calhoun, Vince D. Bustillo, Juan TI Reliability of the amplitude of low-frequency fluctuations in resting state fMRI in chronic schizophrenia SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE ALFF; Schizophrenia; Stability ID NAIVE 1ST-EPISODE SCHIZOPHRENIA; FUNCTIONAL CONNECTIVITY; DEFICITS; MRI AB The resting state amplitude of low frequency fluctuations (ALFF) in functional magnetic resonance imaging has been shown to be reliable in healthy subjects, and to correlate with antipsychotic treatment response in antipsychotic-naive schizophrenia patients. We found moderate to high test-retest stability of ALFF in chronically treated schizophrenia patients assessed twice over a median interval of 2.5 months. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Turner, Jessica A.; Allen, Elena A.; Mayer, Andrew R.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM 87106 USA. [Turner, Jessica A.; Chen, Hongji; Abbott, Christopher C.; Calhoun, Vince D.; Bustillo, Juan] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA. RP Turner, JA (reprint author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA. EM jturner@mrn.org RI bustillo, juan/J-7067-2013; Turner, Jessica/H-7282-2015 OI Turner, Jessica/0000-0003-0076-8434; Mathalon, Daniel/0000-0001-6090-4974 FU NCATS NIH HHS [KL2 TR000089, UL1 TR000041]; NCRR NIH HHS [KL2 RR31976-1, 5P20RR021938, KL2 RR031976, KL2 RR031976-01, P20 RR021938, P20 RR021938-01A2, P20 RR021938-02, P20 RR021938-03, P20 RR021938-04, P20 RR021938-05]; NIMH NIH HHS [L30 MH092098-01, R01 MH076989, R01 MH076989-01A1, R01 MH076989-02, R01 MH076989-03, R01 MH076989-04, R01 MH076989-05, R01 MH084898, R01 MH084898-01A1, R01 MH084898-02, R01 MH084898-03, R01 MH084898-04, R01MH084898-01A1] NR 17 TC 29 Z9 32 U1 2 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD MAR 31 PY 2012 VL 201 IS 3 BP 253 EP 255 DI 10.1016/j.pscychresns.2011.09.012 PG 3 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 964RG UT WOS:000305713800013 PM 22541511 ER PT J AU Boninger, ML Cowan, RE AF Boninger, Michael L. Cowan, Rachel E. TI Why do we need improved mobility technology? SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Editorial Material C1 [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Cowan, Rachel E.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA. [Cowan, Rachel E.] Lois Pope Life Ctr, Miami, FL 33136 USA. RP Boninger, ML (reprint author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. EM boninger@upmc.edu OI Boninger, Michael/0000-0001-6966-919X FU NIA NIH HHS [P30 AG024827] NR 0 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD MAR 30 PY 2012 VL 9 AR 16 DI 10.1186/1743-0003-9-16 PG 2 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA 940AM UT WOS:000303862400001 PM 22463101 ER PT J AU Boninger, ML Cowan, RE Fregly, BJ AF Boninger, Michael L. Cowan, Rachel E. Fregly, Benjamin J. TI Structures promoting research, training, and technology transfer in mobility: lessons learned from a visit to European centers SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Article AB The purpose of this paper is to describe the education, research, technology transfer, and cooperative models that appear to have the greatest likelihood of successfully tackling the issue of technology to improve mobility. Ideally better models in each of these areas will lead to an increased number of researchers who are more productive. There will be increased international collaboration that will allow for better research with small and/or disadvantaged populations, and the research completed will lead to changes in clinical care that positively impact individuals with impair mobility. C1 [Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Cowan, Rachel E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA. [Fregly, Benjamin J.] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA. RP Boninger, ML (reprint author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3741 5th Ave,Suite 201, Pittsburgh, PA 15260 USA. EM boninger@upmc.edu RI Fregly, Benjamin/O-6860-2016 OI Fregly, Benjamin/0000-0003-1166-4358; Boninger, Michael/0000-0001-6966-919X FU NIA NIH HHS [P30 AG024827] NR 3 TC 0 Z9 0 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD MAR 30 PY 2012 VL 9 AR 19 DI 10.1186/1743-0003-9-19 PG 5 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA 940AM UT WOS:000303862400004 PM 22463495 ER PT J AU Reinkensmeyer, DJ Boninger, ML AF Reinkensmeyer, David J. Boninger, Michael L. TI Technologies and combination therapies for enhancing movement training for people with a disability SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Editorial Material ID SPINAL-CORD-INJURY; ROBOTIC-ASSISTED REHABILITATION; ANKLE-FOOT ORTHOSIS; UPPER-LIMB; VIRTUAL-REALITY; MOTOR RECOVERY; CHRONIC STROKE; GAIT; RATS; WALKING AB There has been a dramatic increase over the last decade in research on technologies for enhancing movement training and exercise for people with a disability. This paper reviews some of the recent developments in this area, using examples from a National Science Foundation initiated study of mobility research projects in Europe to illustrate important themes and key directions for future research. This paper also reviews several recent studies aimed at combining movement training with plasticity or regeneration therapies, again drawing in part from European research examples. Such combination therapies will likely involve complex interactions with motor training that must be understood in order to achieve the goal of eliminating severe motor impairment. C1 [Reinkensmeyer, David J.] Univ Calif Irvine, Dept Mech & Aerosp Engn, Irvine, CA 92697 USA. [Reinkensmeyer, David J.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA. [Reinkensmeyer, David J.] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA. [Boninger, Michael L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. RP Reinkensmeyer, DJ (reprint author), Univ Calif Irvine, Dept Mech & Aerosp Engn, 4200 Engn Gateway, Irvine, CA 92697 USA. EM dreinken@uci.edu OI Boninger, Michael/0000-0001-6966-919X NR 68 TC 17 Z9 18 U1 1 U2 16 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD MAR 30 PY 2012 VL 9 AR 17 DI 10.1186/1743-0003-9-17 PG 10 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA 940AM UT WOS:000303862400002 PM 22463132 ER PT J AU Zhou, XH Johnson, LL AF Zhou, Xiao-Hua Johnson, Laura Lee TI Preface SO STATISTICS IN MEDICINE LA English DT Article C1 [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, VA Puget Sound Hlth Care Syst, HSB, Seattle, WA 98195 USA. [Johnson, Laura Lee] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, VA Puget Sound Hlth Care Syst, HSB, 1705 Pacific St NE,F600, Seattle, WA 98195 USA. EM azhou@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0277-6715 J9 STAT MED JI Stat. Med. PD MAR 30 PY 2012 VL 31 IS 7 SI SI BP 601 EP 601 DI 10.1002/sim.4442 PG 1 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 903MY UT WOS:000301121900001 PM 22392624 ER PT J AU Zhou, XH Li, SL Tian, F Cai, BJ Xie, YM Pei, Y Kang, S Fan, M Li, JP AF Zhou, X. H. Li, S. L. Tian, F. Cai, B. J. Xie, Y. M. Pei, Y. Kang, S. Fan, M. Li, J. P. TI Building a disease risk model of osteoporosis based on traditional Chinese medicine symptoms and western medicine risk factors SO STATISTICS IN MEDICINE LA English DT Article DE GPLM; SVM-RFE; random forest; association rule learning; TCM symptoms ID PARTIAL LINEAR-MODELS; FRACTURE; WOMEN AB In the Traditional Chinese Medicine (TCM) cross-sectional survey conducted by our team, we were interested in determining the risk factors of osteoporosis. To analyze this TCM study, we had to deal with three statistical problems: (1) a very large number of potential risk factors, (2) interactions among potential risk factors, and (3) nonlinear effects of some continuous-scale risk factors. To address these analytic issues, we used two data mining methods, support vector machine recursive feature elimination and random forest; to deal with the curse of high-dimensional risk factors, we applied another data mining technique of association rule learning to discover the potential associations among risk factors. Finally, we employed the generalized partial linear model (GPLM) to determine nonlinear effects of an important continuous-scale risk factor. The final GPLM model shows that TCM symptoms play an important role in assessing the risk of osteoporosis. The GPLM also reveals a nonlinear effect of the important risk factor, menopause years, which might be missed by the generalized linear model. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Tian, F.; Xie, Y. M.; Li, J. P.] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China. [Zhou, X. H.; Li, S. L.; Cai, B. J.; Pei, Y.; Fan, M.] Renmin Univ China, Sch Stat, Beijing 100872, Peoples R China. [Zhou, X. H.] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zhou, X. H.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Kang, S.] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China. RP Xie, YM (reprint author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China. EM zhinanb2010@yahoo.com.cn FU National Science Foundation of China (NSFC) [30728019, 30873339] FX Dr. Xiao-Hua Zhou, PhD, is presently a Core Investigator and Biostatistics Unit Director at the Northwest HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Seattle, WA. Part of this work was supported by the two National Science Foundation of China grants (NSFC No. 30728019 to Dr. Zhou and NSFC No. 30873339 to Dr. Xie). This paper presents the findings and conclusions of the authors. It does not necessarily represent those of VA HSR&D Service. NR 23 TC 6 Z9 7 U1 3 U2 26 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0277-6715 J9 STAT MED JI Stat. Med. PD MAR 30 PY 2012 VL 31 IS 7 SI SI BP 643 EP 652 DI 10.1002/sim.4382 PG 10 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 903MY UT WOS:000301121900007 PM 22354891 ER PT J AU Zhou, XH Chen, B Xie, YM Tian, F Liu, H Liang, X AF Zhou, X. H. Chen, B. Xie, Y. M. Tian, F. Liu, H. Liang, X. TI Variable selection using the optimal ROC curve: An application to a traditional Chinese medicine study on osteoporosis disease SO STATISTICS IN MEDICINE LA English DT Article DE AUC; classification; ROC; variable selection ID ORACLE PROPERTIES; REGRESSION; CLASSIFICATION; MANAGEMENT; LASSO AB In biomedical studies, there are multiple sources of information available of which only a small number of them are associated with the diseases. It is of importance to select and combine these factors that are associated with the disease in order to predict the disease status of a new subject. The receiving operating characteristic (ROC) technique has been widely used in disease classification, and the classification accuracy can be measured with area under the ROC curve (AUC). In this article, we combine recent variable selection methods with AUC methods to optimize diagnostic accuracy of multiple risk factors. We first describe one new and some recent AUC-based methods for effectively combining multiple risk factors for disease classification. We then apply them to analyze the data from a new clinical study, investigating whether a combination of traditional Chinese medicine symptoms and standard Western medicine risk factors can increase discriminative accuracy in diagnosing osteoporosis (OP). Based on the results, we conclude that we can make a better diagnosis of primary OP by combining traditional Chinese medicine symptoms with Western medicine risk factors. Copyright (c) 2011 John Wiley & Sons, Ltd. C1 [Xie, Y. M.; Tian, F.; Liu, H.] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China. [Zhou, X. H.; Liang, X.] Renmin Univ, Sch Stat, Beijing 100872, Peoples R China. [Zhou, X. H.] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98101 USA. [Zhou, X. H.; Chen, B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Xie, YM (reprint author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China. EM zhinanb2005@yahoo.com.cn; tianfengzzz@126.com FU National Science Foundation of China (NSFC) [30728019, 30873339] FX Dr Xiao-Hua Zhou, PhD, is presently a Core Investigator and Biostatistics Unit Director at the Northwest HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Seattle, WA. Part of this work was supported by the two National Science Foundation of China grants (NSFC No. 30728019 and NSFC No. 30873339). This paper presents the findings and conclusions of the authors. It does not necessarily represent those of VA HSR&D Service. NR 30 TC 5 Z9 5 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD MAR 30 PY 2012 VL 31 IS 7 SI SI BP 628 EP 635 DI 10.1002/sim.3980 PG 8 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 903MY UT WOS:000301121900005 PM 21290404 ER PT J AU Chen, BB Glasser, JR Coon, TA Zou, CB Miller, HL Fenton, M McDyer, JF Boyiadzis, M Mallampalli, RK AF Chen, Bill B. Glasser, Jennifer R. Coon, Tiffany A. Zou, Chunbin Miller, Hannah L. Fenton, Moon McDyer, John F. Boyiadzis, Michael Mallampalli, Rama K. TI F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation SO BLOOD LA English DT Article ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; DEPENDENT KINASE 4; D1 DEGRADATION; HEMATOPOIETIC-CELLS; BCR-ABL; EXPRESSION; GENE; CALMODULIN; CANCER; IDENTIFICATION AB Hematologic maligancies exhibit a growth advantage by up-regulation of components within the molecular apparatus involved in cell-cycle progression. The SCF (Skip-Cullin1-F-box protein) E3 ligase family provides homeostatic feedback control of cell division by mediating ubiquitination and degradation of cell-cycle proteins. By screening several previously undescribed E3 ligase components, we describe the behavior of a relatively new SCF subunit, termed FBXL2, that ubiquitinates and destabilizes cyclin D2 protein leading to G(0) phase arrest and apoptosis in leukemic and B-lymphoblastoid cell lines. FBXL2 expression was strongly suppressed, and yet cyclin D2 protein levels were robustly expressed in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patient samples. Depletion of endogenous FBXL2 stabilized cyclin D2 levels, whereas ectopically expressed FBXL2 decreased cyclin D2 lifespan. FBXL2 did not bind a phosphodegron within its substrate, which is typical of other F-box proteins, but uniquely targeted a calmodulin-binding signature within cyclin D2 to facilitate its polyubiquitination. Calmodulin competes with the F-box protein for access to this motif where it bound and protected cyclin D2 from FBXL2. Calmodulin reversed FBXL2-induced G(0) phase arrest and attenuated FBXL2-induced apoptosis of lymphoblastoid cells. These results suggest an antiproliferative effect of SCFFBXL2 in lymphoproliferative malignancies. (Blood. 2012;119(13):3132-3141) C1 [Chen, Bill B.; Glasser, Jennifer R.; Coon, Tiffany A.; Zou, Chunbin; Miller, Hannah L.; Fenton, Moon; McDyer, John F.; Boyiadzis, Michael; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Chen, Bill B.; Glasser, Jennifer R.; Coon, Tiffany A.; Zou, Chunbin; Miller, Hannah L.; Fenton, Moon; McDyer, John F.; Boyiadzis, Michael; Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Glasser, Jennifer R.; Coon, Tiffany A.; Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, NW Dept Med 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174] FX This material is based on work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376, and HL098174 (to R.K.M.). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. NR 54 TC 35 Z9 38 U1 0 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD MAR 29 PY 2012 VL 119 IS 13 BP 3132 EP 3141 DI 10.1182/blood-2011-06-358911 PG 10 WC Hematology SC Hematology GA 916ZH UT WOS:000302141200029 PM 22323446 ER PT J AU Boekholdt, SM Arsenault, BJ Mora, S Pedersen, TR LaRosa, JC Nestel, PJ Simes, RJ Durrington, P Hitman, GA Welch, KMA DeMicco, DA Zwinderman, AH Clearfield, MB Downs, JR Tonkin, AM Colhoun, HM Gotto, AM Ridker, PM Kastelein, JJP AF Boekholdt, S. Matthijs Arsenault, Benoit J. Mora, Samia Pedersen, Terje R. LaRosa, John C. Nestel, Paul J. Simes, R. John Durrington, Paul Hitman, Graham A. Welch, K. M. A. DeMicco, David A. Zwinderman, Aeilko H. Clearfield, Michael B. Downs, John R. Tonkin, Andrew M. Colhoun, Helen M. Gotto, Antonio M., Jr. Ridker, Paul M. Kastelein, John J. P. TI Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; HIGH-DOSE ATORVASTATIN; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; LIPID PARAMETERS; CONTROLLED-TRIAL; A-I; WOMEN; MEN AB Context The associations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not been reliably documented. Objective To evaluate the relative strength of the associations of LDL-C, non-HDL-C, and apoB with cardiovascular risk among patients treated with statin therapy. Design Meta-analysis of individual patient data from randomized controlled statin trials in which conventional lipids and apolipoproteins were determined in all study participants at baseline and at 1-year follow-up. Data Sources Relevant trials were identified by a literature search updated through December 31, 2011. Investigators were contacted and individual patient data were requested and obtained for 62154 patients enrolled in 8 trials published between 1994 and 2008. Data Extraction Hazard ratios (HRs) and corresponding 95% CIs for risk of major cardiovascular events adjusted for established risk factors by 1-SD increase in LDL-C, non-HDL-C, and apoB. Results Among 38 153 patients allocated to statin therapy, 158 fatal myocardial infarctions, 1678 nonfatal myocardial infarctions, 615 fatal events from other coronary artery disease, 2806 hospitalizations for unstable angina, and 1029 fatal or nonfatal strokes occurred during follow-up. The adjusted HRs for major cardiovascular events per 1-SD increase were 1.13 (95% CI, 1.10-1.17) for LDL-C, 1.16 (95% CI, 1.12-1.19) for non-HDL-C, and 1.14 (95% CI, 1.11-1.18) for apoB. These HRs were significantly higher for non-HDL-C than LDL-C (P=.002) and apoB (P=.02). There was no significant difference between apoB and LDL-C (P=.21). Conclusion Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C, and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non-HDL-C than for LDL-C and apoB. JAMA. 2012;307(12):1302-1309 www.jama.com C1 [Arsenault, Benoit J.; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands. [Boekholdt, S. Matthijs] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands. [Zwinderman, Aeilko H.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands. [Mora, Samia; Ridker, Paul M.] Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA. [Pedersen, Terje R.] Oslo Univ Hosp, Ctr Prevent Med, Ulleval, Norway. [Pedersen, Terje R.] Univ Oslo, N-0316 Oslo, Norway. [LaRosa, John C.] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA. [Nestel, Paul J.] Baker Heart & Diabet Res Inst, Melbourne, Vic, Australia. [Simes, R. John] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. [Durrington, Paul] Univ Manchester, Sch Biomed, Manchester, Lancs, England. [Hitman, Graham A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Diabet & Metab Med, London, England. [Welch, K. M. A.] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA. [DeMicco, David A.] Global Pharmaceut Pfizer, New York, NY USA. [Clearfield, Michael B.] Touro Univ, Mare Isl, CA USA. [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Downs, John R.] S Texas Vet Hlth Care Syst, VERDICT, San Antonio, TX USA. [Colhoun, Helen M.] Univ Dundee, Med Res Inst, Dundee, Scotland. [Tonkin, Andrew M.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Gotto, Antonio M., Jr.] Weill Cornell Med Coll, New York, NY USA. RP Kastelein, JJP (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM j.j.kastelein@amc.uva.nl RI Boekholdt, Matthijs/G-7562-2014; Simes, Robert/P-1497-2014 OI Colhoun, Helen/0000-0002-8345-3288 FU Merck Sharpe Dohme; AstraZeneca; Pfizer; Quest Diagnostics; Amgen; CSL; Boehringer-Ingelheim; EU Innovative Medicines Initiative from Roche; EU Innovative Medicines Initiative from Pfizer; EU Innovative Medicines Initiative from Eli Lilly; EU Innovative Medicines Initiative from Boehringer-Ingelheim; EU Innovative Medicines Initiative from sanofi-aventis; EU Innovative Medicines Initiative from AstraZeneca; Novartis; Eli Lilly; Kowa FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest Drs Boekholdt and Arsenault report receipt of consultancy fees from Pfizer. Dr Mora reports receipt of research grant support through her institution from Merck Sharpe & Dohme and AstraZeneca; consultancy fees from Pfizer and Quest Diagnostics; and lecture honoraria from AstraZeneca and Abbott. Dr LaRosa reports receipt of consultancy fees from Pfizer and Amgen, and travel expenses from Pfizer. Dr Pedersen reports receipt of research grant support and lecture fees from Pfizer. Dr Nestel reports serving as a board member for AstraZeneca and Merck Sharpe & Dohme; receipt of consultancy fees from AstraZeneca; lecture honoraria from Merck Sharpe & Dohme; and travel expenses from AstraZeneca and Merck Sharpe & Dohme. Dr DeMicco reports being a full-time employee of Pfizer. Dr Tonkin reports receipt of consultancy fees from Amgen, AstraZeneca, CSL, and Boehringer-Ingelheim; and lecture honoraria from AstraZeneca, CSL, Merck Sharpe & Dohme, and Boehringer-Ingelheim. Dr Colhoun reports receipt of research grant support through the EU Innovative Medicines Initiative from Roche, Pfizer, Eli Lilly, Boehringer-Ingelheim, sanofi-aventis, and AstraZeneca; consultancy fees from Pfizer, sanofi-aventis, Novartis, and Eli Lilly; stocks from Roche; and lecture honoraria and travel expenses from Pfizer. Dr Gotto reports serving on the board of directors for Aegerion Pharmaceuticals and Arisaph Pharmaceuticals; being a member of advisory boards for DuPont and Vatera Capital; and receiving consultancy fees from AstraZeneca, Kowa, and Merck Sharpe & Dohme. Dr Ridker reports receipt of research grant funding from Novartis and AstraZeneca; serving as a consultant to ISIS, Vascular Biogenics, Merck Sharpe & Dohme, Abbott, and Boerringer-Ingelheim; and being listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. Dr Kastelein reports receipt of lecture honoraria from Merck Sharpe & Dohme, Roche, Novartis, ISIS, Genzyme, Pfizer, Kowa, and AstraZeneca. Drs Downs, Hitman, Durrington, Simes, Welch, Clearfield, and Zwinderman reported no conflicts of interest. NR 31 TC 261 Z9 271 U1 1 U2 26 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 28 PY 2012 VL 307 IS 12 BP 1302 EP 1309 DI 10.1001/jama.2012.366 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 914UP UT WOS:000301978400026 PM 22453571 ER PT J AU Hage, FG Lusa, L Dondi, M Giubbini, R Iskandrian, AE AF Hage, Fadi G. Lusa, Lara Dondi, Maurizio Giubbini, Raffaele Iskandrian, Ami E. TI COMPARISON OF EXERCISE MYOCARDIAL PERFUSION IMAGING AND EXERCISE ELECTROCARDIOGRAM IN DETECTING ISCHEMIA IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES MELLITUS: RESULT OF A PROSPECTIVE MULTICENTER STUDY IN DEVELOPING NATIONS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E1163 EP E1163 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326701274 ER PT J AU Hage, FG Wackers, FJT Bansal, S Chyun, DA Young, LH Inzucchi, S Iskandrian, AE AF Hage, Fadi G. Wackers, Frans J. Th Bansal, Shanti Chyun, Deborah A. Young, Lawrence H. Inzucchi, Silvio Iskandrian, Ami E. TI THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 Univ Alabama, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E1162 EP E1162 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326701273 ER PT J AU Le, DTE Nugent, M Zhao, Y Bragadeesh, T Alkayed, N Kaul, S AF Le, Dai-Trang Elizabeth Nugent, Matthew Zhao, Yan Bragadeesh, Thanjavur Alkayed, Nabil Kaul, Sanjiv TI MECHANISM OF MYOGENIC RESPONSE IN CORONARY AUTOREGULATION SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E426 EP E426 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326700427 ER PT J AU Lloyd, SG Liu, J AF Lloyd, Steven G. Liu, Jian TI HIGH-FAT, LOW-CARBOHYDRATE DIET RESULTS IN INCREASED MYOCARDIAL OXIDATIVE STRESS AND IMPAIRED MITOCHONDRIAL FUNCTION IN OBESE RATS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E446 EP E446 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326700447 ER PT J AU Lloyd, SG Wang, PP Tate, JM Douglas, SL AF Lloyd, Steven G. Wang, Peipei Tate, Joshua M. Douglas, Samuel L. TI IMPACT OF HIGH-FAT, LOW-CARBOHYDRATE DIET ON INSULIN SENSITIVITY AND TCA CYCLE SUBSTRATE ENTRY DURING ISCHEMIA-REPERFUSION SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E438 EP E438 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326700439 ER PT J AU Mukete, BN Sidhu, G Rosendorff, C AF Mukete, Bertrand N. Sidhu, Gurpreet Rosendorff, Clive TI EFFECTS OF LOW-DOSE THIAZIDE DIURETICS ON GLUCOSE TOLERANCE AND SERUM POTASSIUM A META-ANALYSIS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 Mt Sinai Sch Med, New York, NY USA. James J Peters VAMC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E1720 EP E1720 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326701831 ER PT J AU Schopfer, DW Regan, M Whooley, M AF Schopfer, David W. Regan, Mathilda Whooley, Mary TI GROWTH-DIFFERENTIATION FACTOR-15 PREDICTS CARDIOVASCULAR OUTCOMES IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE (THE HEART AND SOUL STUDY) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E1475 EP E1475 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326701586 ER PT J AU Tsai, T Patel, U Chang, TI Kennedy, KF Masoudi, F Matheny, M Kosiborod, M Messenger, J Rumsfeld, J Spertus, J AF Tsai, Thomas Patel, Uptal Chang, Tara I. Kennedy, Kevin F. Masoudi, Frederick Matheny, Michael Kosiborod, Mikhail Messenger, John Rumsfeld, John Spertus, John TI CONTEMPORARY INCIDENCE AND PREDICTORS OF ACUTE KIDNEY INJURY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS: INSIGHTS FROM THE NCDR CATH-PCI REGISTRY SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 61st Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 24-27, 2012 CL Chicago, IL SP Amer Coll Cardiol (ACC) C1 U Colorado Denver, Denver VA Med Ctr, Denver, CO USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 27 PY 2012 VL 59 IS 13 SU S BP E337 EP E337 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919LB UT WOS:000302326700338 ER PT J AU Xing, DQ Li, P Gong, KZ Yang, ZQ Yu, H Hage, FG Oparil, S Chen, YF AF Xing, Dongqi Li, Peng Gong, Kaizheng Yang, Zhengqin Yu, Hao Hage, Fadi G. Oparil, Suzanne Chen, Yiu-Fai TI Endothelial Cells Overexpressing Interleukin-8 Receptors Reduce Inflammatory and Neointimal Responses to Arterial Injury SO CIRCULATION LA English DT Article DE restenosis; endothelial cells; inflammation; receptors; interleukin-8; tissue therapy ID RAT CAROTID-ARTERY; PROGENITOR CELLS; BALLOON INJURY; ESTROGEN; REENDOTHELIALIZATION; DYSFUNCTION; MICE; INFILTRATION; NEUTROPHILS; DISEASE AB Background-Interleukin-8 (IL8) receptors IL8RA and IL8RB on neutrophil membranes bind to IL8 and direct neutrophil recruitment to sites of inflammation, including acutely injured arteries. This study tested whether administration of IL8RA- and/or IL8RB-transduced rat aortic endothelial cells (ECs) accelerates adhesion of ECs to the injured surface, thus suppressing inflammation and neointima formation in balloon-injured rat carotid arteries. We tested the hypothesis that targeted delivery of ECs by overexpressing IL8RA and IL8RB receptors prevents inflammatory responses and promotes structural recovery of arteries after endoluminal injury. Methods and Results-Young adult male rats received balloon injury of the right carotid artery and were transfused intravenously with ECs (total, 1.5 x 10(6) cells at 1, 3, and 5 hours after injury) transduced with adenoviral vectors carrying IL8RA, IL8RB, and IL8RA/RB (dual transduction) genes, AdNull (empty vector), or vehicle (no EC transfusion). ECs overexpressing IL8Rs inhibited proinflammatory mediators expression significantly (by 60% to 85%) and reduced infiltration of neutrophils and monocytes/macrophages into injured arteries at 1 day after injury, as well as stimulating a 2-fold increase in reendothelialization at 14 days after injury. IL8RA-EC, IL8RB-EC, and IL8RA/RB-EC treatment reduced neointima formation dramatically (by 80%, 74%, and 95%) at 28 days after injury. Conclusions-ECs with overexpression of IL8RA and/or IL8RB mimic the behavior of neutrophils that target and adhere to injured tissues, preventing inflammation and neointima formation. Targeted delivery of ECs to arteries with endoluminal injury provides a novel strategy for the prevention and treatment of cardiovascular disease. (Circulation. 2012;125:1533-1541.) C1 [Xing, Dongqi; Li, Peng; Yang, Zhengqin; Yu, Hao; Hage, Fadi G.; Oparil, Suzanne; Chen, Yiu-Fai] Univ Alabama, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA. [Gong, Kaizheng] Yangzhou Univ, Sch Clin Med 2, Dept Cardiol, Yangzhou, Peoples R China. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Chen, YF (reprint author), Univ Alabama, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, 1008 Zeigler Res Bldg,703 19th St S, Birmingham, AL 35294 USA. EM yfchen@uab.edu OI Hage, Fadi/0000-0002-1397-4942; Li, Peng/0000-0002-9026-9999 FU National Heart, Lung, and Blood Institute [HL080017, HL044195, HL07457]; American Heart Association [10POST3180007, 09BGIA2250367] FX This work was supported in part by National Heart, Lung, and Blood Institute grants HL080017 (to Dr Chen), HL044195 (to Dr Chen), and HL07457 (to Dr Oparil) and by American Heart Association grants 10POST3180007 (to Dr Gong) and 09BGIA2250367 (to Dr Xing). NR 33 TC 13 Z9 15 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 27 PY 2012 VL 125 IS 12 BP 1533 EP U232 DI 10.1161/CIRCULATIONAHA.111.078436 PG 15 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 916TA UT WOS:000302124900020 PM 22361324 ER PT J AU Berkowitz, SA Johansen, KL AF Berkowitz, Seth A. Johansen, Kirsten L. TI Does Motivational Interviewing Improve Outcomes? SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; MANAGEMENT; ADHERENCE; SUPPORT C1 [Berkowitz, Seth A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Berkowitz, SA (reprint author), Univ Calif San Francisco, Dept Med, 1545 Divisidero St,Box 0320, San Francisco, CA 94143 USA. EM Seth.Berkowitz@ucsf.edu OI Berkowitz, Seth/0000-0003-1030-4297 NR 10 TC 4 Z9 4 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 26 PY 2012 VL 172 IS 6 BP 463 EP 464 DI 10.1001/archinternmed.2012.155 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 914MI UT WOS:000301953800001 PM 22371877 ER PT J AU Steinman, MA Landefeld, CS Baron, RB AF Steinman, Michael A. Landefeld, C. Seth Baron, Robert B. TI Industry Support of CME - Are We at the Tipping Point? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Steinman, Michael A.; Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Steinman, Michael A.; Landefeld, C. Seth; Baron, Robert B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Steinman, Michael A.; Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. [Baron, Robert B.] Univ Calif San Francisco, Off Associate Dean Grad & Continuing Med Educ, San Francisco, CA 94143 USA. RP Steinman, MA (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. NR 5 TC 14 Z9 16 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 22 PY 2012 VL 366 IS 12 BP 1069 EP 1071 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 912BO UT WOS:000301769700003 PM 22435367 ER PT J AU Hall, DE Prochazka, AV Fink, AS AF Hall, Daniel E. Prochazka, Allan V. Fink, Aaron S. TI Informed consent for clinical treatment SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Review ID MEDICAL-ETHICS CURRICULUM; DECISION-MAKING; SURGICAL RESIDENTS; BREAST-CANCER; ELECTROCONVULSIVE-THERAPY; PATIENTS PERCEPTIONS; QUALITATIVE-ANALYSIS; PILOT PROJECT; PATIENTS WANT; SURGERY C1 [Fink, Aaron S.] Vet Affairs Med Ctr Atlanta, Surg Serv, Decatur, GA USA. [Fink, Aaron S.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. [Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Prochazka, Allan V.] Denver Vet Affairs Med Ctr, Ambulatory Care, Denver, CO USA. [Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Hall, Daniel E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Fink, AS (reprint author), Vet Affairs Med Ctr Atlanta, Surg Serv, Decatur, GA USA. EM afink01@comcast.net RI Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 FU HSRD VA [CDA 08-281] NR 77 TC 29 Z9 31 U1 5 U2 15 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0820-3946 EI 1488-2329 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD MAR 20 PY 2012 VL 184 IS 5 BP 533 EP 540 DI 10.1503/cmaj.112120 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 930OT UT WOS:000303149700030 PM 22392947 ER PT J AU Qaseem, A Chou, R Humphrey, LL Shekelle, P AF Qaseem, Amir Chou, Roger Humphrey, Linda L. Shekelle, Paul TI Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID PUBLICATION BIAS; FUNNEL PLOT C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. [Chou, Roger; Humphrey, Linda L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Shekelle, Paul] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA. NR 4 TC 1 Z9 1 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 20 PY 2012 VL 156 IS 6 BP 474 EP 475 DI 10.7326/0003-4819-156-6-201203200-00020 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 930PF UT WOS:000303150900025 ER PT J AU Win, AK Young, JP Lindor, NM Tucker, KM Ahnen, DJ Young, GP Buchanan, DD Clendenning, M Giles, GG Winship, I Macrae, FA Goldblatt, J Southey, MC Arnold, J Thibodeau, SN Gunawardena, SR Bapat, B Baron, JA Casey, G Gallinger, S Le Marchand, L Newcomb, PA Haile, RW Hopper, JL Jenkins, MA AF Win, Aung Ko Young, Joanne P. Lindor, Noralane M. Tucker, Katherine M. Ahnen, Dennis J. Young, Graeme P. Buchanan, Daniel D. Clendenning, Mark Giles, Graham G. Winship, Ingrid Macrae, Finlay A. Goldblatt, Jack Southey, Melissa C. Arnold, Julie Thibodeau, Stephen N. Gunawardena, Shanaka R. Bapat, Bharati Baron, John A. Casey, Graham Gallinger, Steven Le Marchand, Loic Newcomb, Polly A. Haile, Robert W. Hopper, John L. Jenkins, Mark A. TI Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID LYNCH-SYNDROME; BREAST-CANCER; COLON-CANCER; POLYMORPHISMS; INDIVIDUALS; ONSET; HNPCC; HMLH1; DIAGNOSIS; VARIANTS AB Purpose To determine whether cancer risks for carriers and noncarriers from families with a mismatch repair (MMR) gene mutation are increased above the risks of the general population. Patients and Methods We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1, n = 161; MSH2, n = 222; MSH6, n = 47; and PMS2, n = 16) and 1,029 their unaffected relatives who did not carry a mutation every 5 years at recruitment centers of the Colon Cancer Family Registry. For comparison of cancer risk with the general population, we estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers. Results Over a median follow-up of 5 years, mutation carriers had an increased risk of colorectal cancer (CRC; SIR, 20.48; 95% CI, 11.71 to 33.27; P < .001), endometrial cancer (SIR, 30.62; 95% CI, 11.24 to 66.64; P = .001), ovarian cancer (SIR, 18.81; 95% CI, 3.88 to 54.95; P < .001), renal cancer (SIR, 11.22; 95% CI, 2.31 to 32.79; P < .001), pancreatic cancer (SIR, 10.68; 95% CI, 2.68 to 47.70; P = .001), gastric cancer (SIR, 9.78; 95% CI, 1.18 to 35.30; P = .009), urinary bladder cancer (SIR, 9.51; 95% CI, 1.15 to 34.37; P = .009), and female breast cancer (SIR, 3.95; 95% CI, 1.59 to 8.13; P = .001). We found no evidence of their noncarrier relatives having an increased risk of any cancer, including CRC (SIR, 1.02; 95% CI, 0.33 to 2.39; P = .97). Conclusion We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of cancers, including some cancers not previously recognized as being a result of MMR mutations, and found no evidence of an increased risk of cancer for their noncarrier relatives. J Clin Oncol 30: 958-964. (C) 2012 by American Society of Clinical Oncology C1 [Jenkins, Mark A.] Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia. [Winship, Ingrid; Macrae, Finlay A.] Royal Melbourne Hosp, Parkville, Vic 3050, Australia. [Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia. [Young, Joanne P.; Buchanan, Daniel D.; Clendenning, Mark] Queensland Inst Med Res, Herston, Qld 4006, Australia. [Young, Joanne P.] Univ Queensland, Sch Med, Herston, Qld, Australia. [Tucker, Katherine M.] Prince Wales Hosp, Hereditary Canc Clin, Randwick, NSW 2031, Australia. [Young, Graeme P.] Flinders Univ S Australia, Flinders Ctr Canc Prevent & Control, Adelaide, SA, Australia. [Goldblatt, Jack] Univ Western Australia, Genet Serv Western Australia, Perth, WA 6009, Australia. [Goldblatt, Jack] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia. [Arnold, Julie] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Regist, Auckland, New Zealand. [Bapat, Bharati; Gallinger, Steven] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Bapat, Bharati] Univ Toronto, Toronto, ON, Canada. [Gallinger, Steven] Canc Care Ontario, Toronto, ON, Canada. [Lindor, Noralane M.; Thibodeau, Stephen N.; Gunawardena, Shanaka R.] Mayo Clin, Rochester, MN USA. [Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver Vet Affairs Med Ctr, Denver, CO USA. [Baron, John A.] Univ N Carolina, Chapel Hill, NC USA. [Casey, Graham; Haile, Robert W.] Univ So Calif, Los Angeles, CA USA. [Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Jenkins, MA (reprint author), Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, 207 Bouverie St,Level 3, Melbourne, Vic 3010, Australia. EM m.jenkins@unimelb.edu.au RI Gallinger, Steven/E-4575-2013; Bapat, Bharati/B-5839-2014; Jenkins, Mark/P-7803-2015 OI Jenkins, Mark/0000-0002-8964-6160; Giles, Graham/0000-0003-4946-9099; Win, Aung Ko/0000-0002-2794-5261; Buchanan, Daniel/0000-0003-2225-6675; Winship, Ingrid/0000-0001-8535-6003 FU NCI NIH HHS [U01 CA074783, P30 CA015704, U01 CA074794, U01 CA074799, U01 CA074800, U01 CA074806, U01 CA097735] NR 44 TC 123 Z9 128 U1 0 U2 17 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 20 PY 2012 VL 30 IS 9 BP 958 EP 964 DI 10.1200/JCO.2011.39.5590 PG 7 WC Oncology SC Oncology GA 923OK UT WOS:000302628400015 PM 22331944 ER PT J AU Patel, UD Garg, AX Krumholz, HM Shlipak, MG Coca, SG Sint, K Thiessen-Philbrook, H Koyner, JL Swaminathan, M Passik, CS Parikh, CR AF Patel, Uptal D. Garg, Amit X. Krumholz, Harlan M. Shlipak, Michael G. Coca, Steven G. Sint, Kyaw Thiessen-Philbrook, Heather Koyner, Jay L. Swaminathan, Madhav Passik, Cary S. Parikh, Chirag R. CA Translational Res Investigating TI Preoperative Serum Brain Natriuretic Peptide and Risk of Acute Kidney Injury After Cardiac Surgery SO CIRCULATION LA English DT Article DE acute kidney injury; cardiac surgical procedures; creatinine; natriuretic peptide, brain ID DECOMPENSATED HEART-FAILURE; GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION; SURGICAL-PROCEDURES; NONCARDIAC SURGERY; PROSPECTIVE COHORT; VENOUS CONGESTION; DYSFUNCTION; OUTCOMES; METAANALYSIS AB Background-Acute kidney injury (AKI) after cardiac surgery is associated with poor outcomes and is difficult to predict. We conducted a prospective study to evaluate whether preoperative brain natriuretic peptide (BNP) levels predict postoperative AKI among patients undergoing cardiac surgery. Methods and Results-The Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) study enrolled 1139 adults undergoing cardiac surgery at 6 hospitals from 2007 to 2009 who were selected for high AKI risk. Preoperative BNP was categorized into quintiles. AKI was common with the use of Acute Kidney Injury Network definitions; at least mild AKI was a >= 0.3-mg/dL or 50% rise in creatinine (n=407, 36%), and severe AKI was either a doubling of creatinine or the requirement of acute renal replacement therapy (n=58, 5.1%). In analyses adjusted for preoperative characteristics, preoperative BNP was a strong and independent predictor of mild and severe AKI. Compared with the lowest BNP quintile, the highest quintile had significantly higher risk of at least mild AKI (risk ratio, 1.87; 95% confidence interval, 1.40-2.49) and severe AKI (risk ratio, 3.17; 95% confidence interval, 1.06-9.48). After adjustment for clinical predictors, the addition of BNP improved the area under the curve to predict at least mild AKI (0.67-0.69; P=0.02) and severe AKI (0.73-0.75; P=0.11). Compared with clinical parameters alone, BNP modestly improved risk prediction of AKI cases into lower and higher risk (continuous net reclassification index; at least mild AKI: risk ratio, 0.183; 95% confidence interval, 0.061-0.314; severe AKI: risk ratio, 0.231; 95% confidence interval, 0.067-0.506). Conclusions-Preoperative BNP level is associated with postoperative AKI in high-risk patients undergoing cardiac surgery. If confirmed in other types of patients and surgeries, preoperative BNP may be a valuable component of future efforts to improve preoperative risk stratification and discrimination among surgical candidates. C1 [Patel, Uptal D.] Duke Univ, Sch Med, Durham VA Med Ctr, Durham, NC USA. [Patel, Uptal D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Garg, Amit X.; Thiessen-Philbrook, Heather] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. [Krumholz, Harlan M.; Coca, Steven G.; Sint, Kyaw; Parikh, Chirag R.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Coca, Steven G.; Parikh, Chirag R.] Vet Affairs Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Koyner, Jay L.] Univ Chicago, Dept Med, Nephrol Sect, Pritzker Sch Med, Chicago, IL 60637 USA. [Swaminathan, Madhav] Duke Univ, Sch Med, Dept Anesthesia, Durham, NC USA. [Passik, Cary S.] Danbury Hosp, Dept Surg, Danbury, CT USA. RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Room 21, West Haven, CT 06516 USA. EM chirag.parikh@yale.edu FU American Heart Association; National Heart, Lung, and Blood Institute [R01HL-085757]; National Institutes of Health from the National Center for Research Resources [UL1 RR024139] FX The research reported in this article was supported by the American Heart Association Clinical Development award and grant R01HL-085757 (to Dr Parikh) from the National Heart, Lung, and Blood Institute. The study was also supported by National Institutes of Health Clinical and Translational Science Award grant UL1 RR024139 (to Yale University) from the National Center for Research Resources. The plasma BNP assay was donated by Biosite. The granting agencies and Biosite, Inc did not participate in the protocol development, analysis, and interpretation of the results. NR 44 TC 31 Z9 38 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 20 PY 2012 VL 125 IS 11 BP 1347 EP U94 DI 10.1161/CIRCULATIONAHA.111.029686 PG 13 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 916PN UT WOS:000302115800012 PM 22322531 ER PT J AU Neely, BA Soper, JL Greig, DJ Carlin, KP Favre, EG Gulland, FMD Almeida, JS Janech, MG AF Neely, Benjamin A. Soper, Jennifer L. Greig, Denise J. Carlin, Kevin P. Favre, Elizabeth G. Gulland, Frances M. D. Almeida, Jonas S. Janech, Michael G. TI Serum profiling by MALDI-TOF mass spectrometry as a diagnostic tool for domoic acid toxicosis in California sea lions SO PROTEOME SCIENCE LA English DT Article DE Serum peptides; Neural network; Zalophus californianus; Neurotoxin ID MAGNETIC BEAD SEPARATION; ZALOPHUS-CALIFORNIANUS; CEREBROSPINAL-FLUID; CLINICAL SIGNS; BIOMARKERS; PEPTIDOME; MORTALITY; SCLEROSIS; TOXICITY; PROTEOME AB Background: There are currently no reliable markers of acute domoic acid toxicosis (DAT) for California sea lions. We investigated whether patterns of serum peptides could diagnose acute DAT. Serum peptides were analyzed by MALDI-TOF mass spectrometry from 107 sea lions (acute DAT n = 34; non-DAT n = 73). Artificial neural networks (ANN) were trained using MALDI-TOF data. Individual peaks and neural networks were qualified using an independent test set (n = 20). Results: No single peak was a good classifier of acute DAT, and ANN models were the best predictors of acute DAT. Performance measures for a single median ANN were: sensitivity, 100%; specificity, 60%; positive predictive value, 71%; negative predictive value, 100%. When 101 ANNs were combined and allowed to vote for the outcome, the performance measures were: sensitivity, 30%; specificity, 100%; positive predictive value, 100%; negative predictive value, 59%. Conclusions: These results suggest that MALDI-TOF peptide profiling and neural networks can perform either as a highly sensitive (100% negative predictive value) or a highly specific (100% positive predictive value) diagnostic tool for acute DAT. This also suggests that machine learning directed by populations of predictive models offer the ability to modulate the predictive effort into a specific type of error. C1 [Neely, Benjamin A.; Janech, Michael G.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Soper, Jennifer L.; Greig, Denise J.; Gulland, Frances M. D.] Marine Mammal Ctr, Sausalito, CA USA. [Carlin, Kevin P.] Natl Marine Mammal Fdn, San Diego, CA USA. [Almeida, Jonas S.] Univ Alabama Birmingham, Dept Pathol, Div Informat, Birmingham, AL 35294 USA. [Janech, Michael G.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Favre, Elizabeth G.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29425 USA. RP Janech, MG (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. EM janechmg@musc.edu OI Neely, Benjamin/0000-0001-6120-7695; Janech, Michael/0000-0002-3202-4811 FU Office of Naval Research [N00014-08-1-0341] FX The authors would like to thank all of the staff and volunteers at the Marine Mammal Center, and especially Bill Van Bonn, for their expertise and assistance. We also thank the members of the US Navy Marine Mammal Program and National Marine Mammal Foundation, especially Cynthia Smith, for their help in acquiring samples. We wish to thank John Arthur for his critical comments and advice. We would also acknowledge the members of the Nephrology Proteomics Laboratory for their technical support, as well as Jennifer Bethard at the MUSC Mass Spectrometry Facility for her expertise. We also thank Guiseppe Cardillo for providing assistance in ROC curve calculations, and Paul Nietert for statistical consultation provided through the Clinical Translational Science Award program at MUSC. Funding for this work was provided by the Office of Naval Research (N00014-08-1-0341). NR 36 TC 7 Z9 7 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1477-5956 J9 PROTEOME SCI JI Proteome Sci. PD MAR 19 PY 2012 VL 10 AR 18 DI 10.1186/1477-5956-10-18 PG 12 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 933QH UT WOS:000303376600001 PM 22429742 ER PT J AU Musset, B Clark, RA DeCoursey, TE Petheo, GL Geiszt, M Chen, YM Cornell, JE Eddy, CA Brzyski, RG El Jamali, A AF Musset, Boris Clark, Robert A. DeCoursey, Thomas E. Petheo, Gabor L. Geiszt, Miklos Chen, Yumin Cornell, John E. Eddy, Carlton A. Brzyski, Robert G. El Jamali, Amina TI NOX5 in Human Spermatozoa EXPRESSION, FUNCTION, AND REGULATION SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NADPH OXIDASE NOX5-S; ESOPHAGEAL ADENOCARCINOMA CELLS; OXYGEN SPECIES PRODUCTION; HUMAN SPERM SUSPENSIONS; GATED PROTON CHANNEL; HUMAN EOSINOPHILS; SUPEROXIDE-PRODUCTION; RESPIRATORY BURST; ELECTRON CURRENTS; HUMAN NEUTROPHILS AB Physiological and pathological processes in spermatozoa involve the production of reactive oxygen species (ROS), but the identity of the ROS-producing enzyme system(s) remains a matter of speculation. We provide the first evidence that NOX5 NADPH oxidase is expressed and functions in human spermatozoa. Immunofluorescence microscopy detected NOX5 protein in both the flagella/neck region and the acrosome. Functionally, spermatozoa exposed to calcium ionophore, phorbol ester, or H2O2 exhibited superoxide anion production, which was blocked by addition of superoxide dismutase, a Ca2+ chelator, or inhibitors of either flavoprotein oxidases (diphenylene iododonium) or NOX enzymes (GKT136901). Consistent with our previous overexpression studies, we found that H2O2-induced superoxide production by primary sperm cells was mediated by the non-receptor tyrosine kinase c-Abl. Moreover, the H(V)1 proton channel, which was recently implicated in spermatozoa motility, was required for optimal superoxide production by spermatozoa. Immunoprecipitation experiments suggested an interaction among NOX5, c-Abl, and H(V)1. H2O2 treatment increased the proportion of motile sperm in a NOX5-dependent manner. Statistical analyses showed a pH-dependent correlation between superoxide production and enhanced sperm motility. Collectively, our findings show that NOX5 is a major source of ROS in human spermatozoa and indicate a role for NOX5-dependent ROS generation in human spermatozoa motility. C1 [Clark, Robert A.; El Jamali, Amina] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Chen, Yumin; Cornell, John E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Eddy, Carlton A.; Brzyski, Robert G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Musset, Boris; DeCoursey, Thomas E.] Rush Univ, Med Ctr, Dept Physiol & Mol Biophys, Chicago, IL 60612 USA. [Petheo, Gabor L.; Geiszt, Miklos] Semmelweis Univ, Fac Med, Dept Physiol, H-1085 Budapest, Hungary. RP El Jamali, A (reprint author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM AkoulouzeBik@uthscsa.edu RI Musset, Boris/J-2520-2013 OI Musset, Boris/0000-0001-8242-8817; DeCoursey, Thomas/0000-0002-4263-180X FU National Institutes of Health [T32 HL04776, UL1 RR025767, KL2 RR025766, K01 DK084297, R01-GM087507, P30 CA054174, P30 AG013319, P01 AG019316]; Iacocca Family Foundation FX This work was supported, in whole or in part, by National Institutes of Health Grants T32 HL04776 (to A. E. J.), UL1 RR025767 (to A. E. J.), Clinical and Translational Science Awards pilot funding (to A. E. J.), KL2 RR025766 (to A. E. J.), K01 DK084297 (to A. E. J.), and Career Development Award R01-GM087507 (to T. E. D.) and an award from the Iacocca Family Foundation (to B. M.). Robert Clark is a scientific co-founder, member of the Scientific Advisory Board, and equity holder in GenKyoTex SA, a Swiss biotechnology start-up company with a primary goal of developing clinically useful inhibitors of the NOX family of NADPH oxidases.; Optical Imaging Facility of the University of Texas Health Science Center at San Antonio, which is supported by National Institutes of Health Grants P30 CA054174 (Cancer Therapy and Research Center), P30 AG013319 (Nathan Shock Center), and P01 AG019316 (Aging, Oxidative Stress and Cell Death). We thank Dr. Craig Witz for arranging initial access to human sperm samples from the University of Texas Medicine Fertility Center, Drs. Victoria Frohlich and Shivani Maffi for expert guidance on confocal microscopy image acquisition and analysis, Maria Gamez and Mario de la Pena for expert technical assistance, and Drs. Susan Smith, Yves Gorin, and Denis Feliers for helpful discussions. NR 72 TC 44 Z9 46 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 16 PY 2012 VL 287 IS 12 BP 9376 EP 9388 DI 10.1074/jbc.M111.314955 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 912KV UT WOS:000301797800068 PM 22291013 ER PT J AU Thomas, T Karr, S Kelley, KW McBane, S AF Thomas, Tyan Karr, Samantha Kelley, Kristi W. McBane, Sarah TI Overcoming barriers to scholarly activity in a clinical practice setting SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Editorial Material ID PHARMACY PRACTICE FACULTY C1 [Thomas, Tyan] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA 19104 USA. [Thomas, Tyan] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Karr, Samantha] Glendale Midwestern Univ, Coll Pharm, Glendale, AZ USA. [Kelley, Kristi W.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA. [Kelley, Kristi W.] Baptist Hlth Syst Inc, Trinity Med Ctr, Continu Clin, Birmingham, AL USA. [McBane, Sarah] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. RP Thomas, T (reprint author), Univ Sci Philadelphia, Philadelphia Coll Pharm, 600 S 43rd St, Philadelphia, PA 19104 USA. EM t.thomas@usp.edu NR 7 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD MAR 15 PY 2012 VL 69 IS 6 BP 465 EP 467 DI 10.2146/ajhp110290 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 943LO UT WOS:000304123700005 PM 22382476 ER PT J AU Poon, LH Lee, AJ Chiao, TB Kang, GA Heath, S Glass, GA AF Poon, Linda H. Lee, Audrey J. Chiao, Teresa B. Kang, Gail A. Heath, Susan Glass, Graham A. TI Pharmacist's role in a Parkinson's disease and movement disorders clinic SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE Ambulatory care; Clinical pharmacists; Clinical pharmacy; Department of Veterans Affairs; Movement disorders; Parkinson disease; Patient information; Pharmaceutical services; Team ID MANAGEMENT AB Purpose. The expanding role of a clinical pharmacist at a Veterans Affairs (VA) outpatient clinic for patients with Parkinson's disease (PD) and movement disorders is described. Summary. San Francisco VA Medical Center added a clinical pharmacist to the multidisciplinary team serving patients at an outpatient clinic operated by its Parkinson's Disease Research, Education and Clinical Center (PADRECC). During the first six months after joining the clinic team, the pharmacist met with 131 patients and made a total of 69 drug therapy recommendations that were implemented by neurologists, clinical nurse specialists, and other PADRECC providers. The results of a retrospective chart review suggested that in about 21% of the cases evaluated, the pharmacist's recommendations contributed to an improved medical outcome or the resolution of a medical problem. Anonymous surveys indicated that clinic providers (n = 33) and patients (n = 20) were satisfied with the pharmacist's services. Using a five-point Likert scale (scores ranged from 1 for "strongly disagree" to 5 for "strongly agree") that they had more time to devote to other clinic responsibilities with the pharmacist present in the clinic (mean score, 4.79); patients indicated that they had an improved understanding of their medications after speaking with the pharmacist (mean score, 4.88). Conclusion. A clinical pharmacist's regular involvement in an outpatient PD and movement disorders clinic has been well received by patients and clinic providers. The study results suggest that the pharmacist has made important contributions in areas such as therapeutic problem solving and medication education while freeing up providers for other responsibilities. C1 [Poon, Linda H.] San Francisco Vet Affairs Med Ctr VAMC, San Francisco, CA USA. [Poon, Linda H.; Chiao, Teresa B.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. [Poon, Linda H.; Lee, Audrey J.] Univ Pacific, Thomas J Long Sch Pharm & Hlth Sci, Stockton, CA 95211 USA. [Kang, Gail A.] Univ Calif San Francisco, Neurol Memory & Aging Ctr, San Francisco, CA 94143 USA. [Kang, Gail A.] San Francisco VA Med Ctr, Educ & Clin Ctr PADRECC, San Francisco, CA USA. [Heath, Susan; Glass, Graham A.] San Francisco VA Med Ctr, PADRECC, San Francisco, CA USA. [Glass, Graham A.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. RP Poon, LH (reprint author), San Francisco Vet Affairs Med Ctr 119, 4150 Clement St, San Francisco, CA 94121 USA. EM linda.poon@va.gov NR 10 TC 3 Z9 4 U1 1 U2 3 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD MAR 15 PY 2012 VL 69 IS 6 BP 518 EP 520 DI 10.2146/ajhp110127 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 943LO UT WOS:000304123700013 PM 22382484 ER PT J AU Tokhtaeva, E Sachs, G Sun, HY Dada, LA Sznajder, JI Vagin, O AF Tokhtaeva, Elmira Sachs, George Sun, Haiying Dada, Laura A. Sznajder, Jacob I. Vagin, Olga TI Identification of the amino acid region involved in the intercellular interaction between the beta(1) subunits of Na+/K+-ATPase SO JOURNAL OF CELL SCIENCE LA English DT Article DE Na+/K+-ATPase beta(1) subunit; Epithelial junction; Trans-dimerization ID NECTIN-LIKE MOLECULES; CELL-CELL-ADHESION; EPITHELIAL-CELLS; E-CADHERIN; NA,K-ATPASE; JUNCTIONS; ANKYRIN; ROLES; GLYCOSYLATION; MIGRATION AB Epithelial junctions depend on intercellular interactions between beta(1) subunits of the Na+/K+-ATPase molecules of neighboring cells. The interaction between dog and rat subunits is less effective than the interaction between two dog b1 subunits, indicating the importance of species-specific regions for beta(1)-beta(1) binding. To identify these regions, the species-specific amino acid residues were mapped on a high-resolution structure of the Na+/K+-ATPase beta(1) subunit to select those exposed towards the beta(1) subunit of the neighboring cell. These exposed residues were mutated in both dog and rat YFP-linked beta(1) subunits (YFP-beta(1)) and also in the secreted extracellular domain of the dog beta(1) subunit. Five rat-like mutations in the amino acid region spanning residues 198-207 of the dog YFP-beta(1) expressed in Madin Darby canine kidney (MDCK) cells decreased co-precipitation of the endogenous dog beta(1) subunit with YFP-beta(1) to the level observed between dog beta(1) and rat YFP-beta(1). In parallel, these mutations impaired the recognition of YFP-beta(1) by the dog-specific antibody that inhibits cell adhesion between MDCK cells. Accordingly, dog-like mutations in rat YFP-beta(1) increased both the (YFP-beta(1))-beta(1) interaction in MDCK cells and recognition by the antibody. Conversely, rat-like mutations in the secreted extracellular domain of the dog beta(1) subunit increased its interaction with rat YFP-beta(1) in vitro. In addition, these mutations resulted in a reduction of intercellular adhesion between rat lung epithelial cells following addition of the secreted extracellular domain of the dog beta(1) subunit to a cell suspension. Therefore, the amino acid region 198-207 is crucial for both trans-dimerization of the Na+/K+-ATPase beta(1) subunits and cell-cell adhesion. C1 [Tokhtaeva, Elmira; Sachs, George; Vagin, Olga] Univ Calif Los Angeles, Dept Physiol, Sch Med, Los Angeles, CA 90073 USA. [Tokhtaeva, Elmira; Sachs, George; Vagin, Olga] Vet Adm Greater Los Angeles Hlth Care Syst, VAGLAHS W LA, Los Angeles, CA 90073 USA. [Sun, Haiying; Dada, Laura A.; Sznajder, Jacob I.] Northwestern Univ, Div Pulm & Crit Care Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Vagin, O (reprint author), Univ Calif Los Angeles, Dept Physiol, Sch Med, Bldg 113,Room 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU National Institutes of Health [DK077149, DK058333, R37-HL48129] FX The work was supported by the National Institutes of Health [grant numbers DK077149 to O.V., DK058333 to G.S. and R37-HL48129 to J.I.S.]. Deposited in PMC for release after 12 months. NR 29 TC 9 Z9 11 U1 0 U2 1 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 J9 J CELL SCI JI J. Cell Sci. PD MAR 15 PY 2012 VL 125 IS 6 BP 1605 EP 1616 DI 10.1242/jcs.100149 PG 12 WC Cell Biology SC Cell Biology GA 930QY UT WOS:000303155400023 PM 22328500 ER PT J AU Ponce, NA Tsui, J Knight, SJ Afable-Munsuz, A Ladabaum, U Hiatt, RA Haas, JS AF Ponce, Ninez A. Tsui, Jennifer Knight, Sara J. Afable-Munsuz, Aimee Ladabaum, Uri Hiatt, Robert A. Haas, Jennifer S. TI Disparities in cancer screening in individuals with a family history of breast or colorectal cancer SO CANCER LA English DT Article DE family history; cancer screening; cancer disparities; breast cancer; colorectal cancer ID AFRICAN-AMERICAN WOMEN; SERVICES TASK-FORCE; RISK-ASSESSMENT; RECOMMENDATION STATEMENT; ETHNIC-DIFFERENCES; OVARIAN-CANCER; MAMMOGRAPHY; BARRIERS; AVERAGE; VALIDATION AB BACKGROUND: Understanding racial/ethnic disparities in cancer screening by family history risk could identify critical opportunities for patient and provider interventions tailored to specific racial/ethnic groups. The authors evaluated whether breast cancer (BC) and colorectal cancer (CRC) disparities varied by family history risk using a large, multiethnic population-based survey. METHODS: By using the 2005 California Health Interview Survey, BC and CRC screening were evaluated separately with weighted multivariate regression analyses, and stratified by family history risk. Screening was defined for BC as mammogram within the past 2 years for women aged 40 to 64 years; for CRC, screening was defined as annual fecal occult blood test, sigmoidoscopy within the past 5 years, or colonoscopy within the past 10 years for adults aged 50 to 64 years. RESULTS: The authors found no significant BC screening disparities by race/ ethnicity or income in the family history risk groups. Racial/ ethnic disparities were more evident in CRC screening, and the Latino-white gap widened among individuals with family history risk. Among adults with a family history for CRC, the magnitude of the Latino-white difference in CRC screening ( odds ratio [OR], 0.28; 95% confidence interval [CI], 0.11-0.60) was more substantial than that for individuals with no family history ( OR, 0.74; 95% CI, 0.59-0.92). CONCLUSIONS: Knowledge of their family history widened the Latino-white gap in CRC screening among adults. More aggressive interventions that enhance the communication between Latinos and their physicians about family history and cancer risk could reduce the substantial Latino-white screening disparity in Latinos most susceptible to CRC. Cancer 2012; 118: 1656-63. (C) 2011 American Cancer Society. C1 [Ponce, Ninez A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA. [Ponce, Ninez A.; Tsui, Jennifer] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. [Knight, Sara J.; Afable-Munsuz, Aimee; Hiatt, Robert A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Afable-Munsuz, Aimee] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, San Francisco, CA 94143 USA. [Ladabaum, Uri] Stanford Univ, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA. [Hiatt, Robert A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Haas, Jennifer S.] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. RP Ponce, NA (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, 650 Charles Young Dr S, Los Angeles, CA 90095 USA. EM nponce@ucla.edu OI Ponce, Ninez/0000-0001-5151-6718 FU University of California at San Francisco Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)-National Cancer Institute (NCI) [P01 CA 130818, NCI K07 CA100097]; Network for Multicultural Research on Health and Healthcare; Department of Family Medicine; David Geffen School of Medicine; University of California at Los Angeles (UCLA); Robert Wood Johnson Foundation; Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH) [UL1 RR 025758]; Harvard University FX This study was supported by the University of California at San Francisco Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)-National Cancer Institute (NCI) P01 CA 130818 (principal investigator [PI], K. Phillips), NCI K07 CA100097 (PI, N.A.P.), Network for Multicultural Research on Health and Healthcare, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles (UCLA), funded by the Robert Wood Johnson Foundation, and UCLA Summer Graduate Research Mentorship Program. This research was also conducted with support from the Health Disparities Research Program of Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH award #UL1 RR 025758 to J.S.H. and financial contributions from Harvard University and its affiliated academic health care centers). NR 52 TC 16 Z9 16 U1 3 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD MAR 15 PY 2012 VL 118 IS 6 BP 1656 EP 1663 DI 10.1002/cncr.26480 PG 8 WC Oncology SC Oncology GA 901NE UT WOS:000300973000022 PM 22009719 ER PT J AU Cavus, I Reinhart, RMG Roach, BJ Gueorguieva, R Teyler, TJ Clapp, WC Ford, JM Krystal, JH Mathalon, DH AF Cavus, Idil Reinhart, Robert M. G. Roach, Brian J. Gueorguieva, Ralitza Teyler, Timothy J. Clapp, Wesley C. Ford, Judith M. Krystal, John H. Mathalon, Daniel H. TI Impaired Visual Cortical Plasticity in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Evoked potential; long-term potentiation; plasticity; schizophrenia; visual cortex ID LONG-TERM POTENTIATION; PRINCIPAL-COMPONENTS-ANALYSIS; EVOKED POTENTIALS; SYNAPTIC PLASTICITY; CORTEX; IDENTIFICATION; INDUCTION; DEFICITS; CONVERGENCE; STIMULATION AB Background: Impaired cortical plasticity may be part of the core pathophysiology of schizophrenia (SZ). Long-term potentiation is a form of neuroplasticity that has been recently demonstrated in humans by showing that repetitive visual stimulation produces lasting enhancement of visual evoked potentials (VEP). Using this paradigm, we examined whether visual cortical plasticity is impaired in SZ. Methods: Electroencephalographic data were recorded from 19 SZ and 22 healthy control (HC) subjects during a visual long-term potentiation paradigm. Visual evoked potentials were elicited by standard visual stimuli (similar to.83 Hz, 2-minute blocks) at baseline and at 2, 4, and 20 minutes following exposure to visual high-frequency stimulation (HFS) (similar to 8.8 Hz, 2 minutes) designed to induce VEP potentiation. To ensure attentiveness during VEP assessments, subjects responded with a button press to infrequent (10%) target stimuli. Visual evoked potentials were subjected to principal components analysis. Two negative-voltage components prominent over occipital-parietal electrode sites were evident at 92 msec (C1) and at 146 msec (N1b). Changes in C1 and N1b component scores from baseline to the post-HFS assessments were compared between groups. Results: High-frequency stimulation produced sustained potentiation of visual C1 and N1b in HCs but not in SZs. The HCs and SZs had comparable HFS-driven electroencephalographic visual steady state responses. However, greater visual steady state responses to the HFS predicted greater N1b potentiation in HCs but not in SZs. Schizophrenia patients with greater N1b potentiation decreased their reaction times to target stimuli. Conclusions: Visual cortical plasticity is impaired in schizophrenia, consistent with hypothesized deficits in N-methyl-D-aspartate receptor function. C1 [Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv 116D, San Francisco, CA 94121 USA. [Cavus, Idil; Reinhart, Robert M. G.; Gueorguieva, Ralitza; Ford, Judith M.; Krystal, John H.; Mathalon, Daniel H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Gueorguieva, Ralitza] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Gueorguieva, Ralitza] Yale Univ, Sch Med, New Haven, CT USA. [Teyler, Timothy J.] Univ Idaho, Washington Wyoming Alaska Montana Idaho Reg Med E, Moscow, ID 83843 USA. [Clapp, Wesley C.] NeuroScouting LLC, Cambridge, MA USA. [Krystal, John H.] Vet Affairs Connecticut Healthcare Syst, Schizophrenia Biol Res Ctr, New Haven, CT USA. [Krystal, John H.] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974; Gueorguieva, Ralitza/0000-0003-0944-5973 FU National Institutes of Health-National Institute of Mental Health [1RO1MH06508-01A2]; VA Schizophrenia Biological Research Center; Janssen Research Foundation; AstraZeneca, Inc; Pfizer, Inc. FX This study was funded by National Institutes of Health-National Institute of Mental Health Grant# 1RO1MH06508-01A2 (TT, IC), and by the VA Schizophrenia Biological Research Center (JMF).; Dr. Cavus, is currently employed by Bristol-Myers Squibb, Inc, receives Bristol-Myers Squibb stock options, and reports that her name is included under a provisional patent titled "A noninvasive biomarker of human cortical plasticity and cognition," United States Patent and Trademark Office (USPTO) serial number 61/140,833. Previously she was employed by Pfizer Inc. This work was done during Dr. Cavus' employment at Yale University. Dr. Teyler reportsaconsulting appointment with Pfizer Laboratories and that his name is included under a provisional patent titled " A noninvasive biomarker of human cortical plasticity and cognition," USPTO serial number 61/140,833. Dr. Clapp reports that his name is included under a provisional patent titled " A noninvasive biomarker of human cortical plasticity and cognition," USPTO serial number 61/140,833. Dr. Clapp is currently employed full-time as a co-founder and chief scientist at NeuroScouting LLC. This work was done prior to the founding of NeuroScouting, while at Auckland University and University of California San Francisco. Dr. Krystal reports individual consultant agreements (each less than $10,000 per year) from Aisling Capital, LLC, AstraZeneca Pharmaceuticals, Biocortech, Brintnall & Nicolini, Inc., Easton Associates, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Lundbeck Research USA, Medivation, Inc., Merz Pharmaceuticals, MK Medical Communications, F. Hoffmann-La Roche Ltd, SK Holdings Co., Ltd, Sunovion Pharmaceuticals, Inc., Takeda Industries, and Teva Pharmaceutical Industries, Ltd. Dr. Krystal also reports serving on the Scientific Advisory Boards for Abbott Laboratories, Bristol-Myers Squibb, Eisai, Inc., Eli Lilly and Co., Forest Laboratories, Inc., Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., Pfizer Pharmaceuticals and Shire Pharmaceuticals. Dr. Krystal also reports Exercisable Warrant Options from Tetragenex Pharmaceuticals (value less than $ 150). Dr. Krystal also reports serving on the Board of Directors of the Coalition for Translational Research in Alcohol and Substance Use Disorders. Dr. Krystal also reports receiving research support from Janssen Research Foundation (provided drug and some study support to the Department of Veterans Affairs). Dr. Krystal also reports serving as Editor of Biological Psychiatry, which is associated with income greater than $ 10,000 per year. Dr. Krystal also reports being President for the American College of Neuropsychopharmacology. Dr. Krystal also reports that his name is included on a patent titled "Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia" (Patent #: 5,447,948, September 5, 1995), and on provisional patents titled "Targeting the glutamatergic system for the treatment of neuropsychiatric disorders" (PCTWO06108055A1) and "Intranasal administration of ketamine to treat depression" (pending). Dr. Mathalon reports research funding from AstraZeneca, Inc, consulting fees from Pfizer, Inc. and that his name is included under a provisional patent titled "A noninvasive biomarker of human cortical plasticity and cognition," USPTO serial number 61/140,833. All other authors report no biomedical financial interests or potential conflicts of interest. NR 68 TC 25 Z9 25 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 2012 VL 71 IS 6 BP 512 EP 520 DI 10.1016/j.biopsych.2012.01.013 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 899BX UT WOS:000300789100011 PM 22364738 ER PT J AU Moussaieff, A Yu, J Zhu, H Gattoni-Celli, S Shohami, E Kindy, MS AF Moussaieff, Arieh Yu, Jin Zhu, Hong Gattoni-Celli, Sebastiano Shohami, Esther Kindy, Mark S. TI Protective effects of incensole acetate on cerebral ischemic injury SO BRAIN RESEARCH LA English DT Article DE Cerebral ischemia; Inflammation; NF-kappa B; Neuroprotection; Incensole acetate; Boswellia ID KAPPA-B ACTIVATION; BRAIN-INJURY; IN-VIVO; BEHAVIORAL DEFICITS; DRUG DEVELOPMENT; BOSWELLIC ACIDS; NEUROPROTECTION; STROKE; RECEPTOR; CHANNELS AB The resin of Boswellia species is a major anti-inflammatory agent that has been used for centuries to treat various conditions including injuries and inflammatory conditions. Incensole acetate (IA), a major constituent of this resin, has been shown to inhibit NF-kappa B activation and concomitant inflammation, as well as the neurological deficit following head trauma. Here, we show that IA protects against ischemic neuronal damage and reper-fusion injury in mice, attenuating the inflammatory nature of ischemic damage. IA given post-ischemia, reduced infarct volumes and improved neurological activities in the mouse model of ischemic injury in a dose dependent fashion. The protection from damage was accompanied by inhibition of TNF-alpha, IL-1 beta and TGF-beta expression, as well as NF-kappa B activation following injury. In addition, IA is shown to have a therapeutic window of treatment up to 6 h after ischemic injury. Finally, the protective effects of IA were partially mediated by TRPV3 channels as determined by the TRPV3 deficient mice and channel blocker studies. This study suggests that the anti-inflammatory and neuroprotective activities of IA may serve as a novel therapeutic treatment for ischemic and reperfusion injury, and as a tool in the ongoing research of mechanisms for neurological damage. Published by Elsevier B.V. C1 [Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29403 USA. [Moussaieff, Arieh] Ariel Univ, Ctr Samaria, Ariel, Israel. [Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29403 USA. [Gattoni-Celli, Sebastiano; Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel. [Kindy, Mark S.] Clemson Univ, Dept Bioengn, Clemson, SC USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, Strom Thurmond Biomed Res Bldg,Room 503,114 Dough, Charleston, SC 29403 USA. EM kindyms@musc.edu FU National Institutes of Health [ES 016774]; Veterans Administration; National Science Foundation EPSCoR [EPS-0132573, EPS-0447660] FX We thank Aruna Bhat for her technical support and Eileen McFadden for secretarial support. Supported by grants from the National Institutes of Health (ES 016774, MSK), and the Veterans Administration (MSK, SGC) and the National Science Foundation EPSCoR grants (MSK, EPS-0132573 and EPS-0447660). NR 42 TC 11 Z9 12 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAR 14 PY 2012 VL 1443 BP 89 EP 97 DI 10.1016/j.brainres.2012.01.001 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 920RU UT WOS:000302425800008 PM 22284622 ER PT J AU Haines, M Brown, B Craig, J D'Este, C Elliott, E Klineberg, E McInnes, E Middleton, S Paul, C Redman, S Yano, EM AF Haines, Mary Brown, Bernadette Craig, Jonathan D'Este, Catherine Elliott, Elizabeth Klineberg, Emily McInnes, Elizabeth Middleton, Sandy Paul, Christine Redman, Sally Yano, Elizabeth M. CA Clin Networks Res Grp TI Determinants of successful clinical networks: the conceptual framework and study protocol SO IMPLEMENTATION SCIENCE LA English DT Article ID HEALTH-CARE; QUALITY; CANCER; IMPLEMENTATION; IMPROVEMENT; GUIDELINES; PROGRAM; IMPACT; MODEL AB Background: Clinical networks are increasingly being viewed as an important strategy for increasing evidence-based practice and improving models of care, but success is variable and characteristics of networks with high impact are uncertain. This study takes advantage of the variability in the functioning and outcomes of networks supported by the Australian New South Wales (NSW) Agency for Clinical Innovation's non-mandatory model of clinical networks to investigate the factors that contribute to the success of clinical networks. Methods/Design: The objective of this retrospective study is to examine the association between external support, organisational and program factors, and indicators of success among 19 clinical networks over a three-year period (2006-2008). The outcomes (health impact, system impact, programs implemented, engagement, user perception, and financial leverage) and explanatory factors will be collected using a web-based survey, interviews, and record review. An independent expert panel will provide judgements about the impact or extent of each network's initiatives on health and system impacts. The ratings of the expert panel will be the outcome used in multivariable analyses. Following the rating of network success, a qualitative study will be conducted to provide a more in-depth examination of the most successful networks. Discussion: This is the first study to combine quantitative and qualitative methods to examine the factors that contribute to the success of clinical networks and, more generally, is the largest study of clinical networks undertaken. The adaptation of expert panel methods to rate the impacts of networks is the methodological innovation of this study. The proposed project will identify the conditions that should be established or encouraged by agencies developing clinical networks and will be of immediate use in forming strategies and programs to maximise the effectiveness of such networks. C1 [Haines, Mary; Brown, Bernadette; Redman, Sally] Sax Inst, Haymarket, Australia. [Haines, Mary; Craig, Jonathan] Univ Sydney, Sch Publ Hlth, Camperdown, NSW, Australia. [D'Este, Catherine] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia. [Elliott, Elizabeth; Klineberg, Emily] Univ Sydney, Sch Clin, Childrens Hosp Westmead, Westmead, NSW 2145, Australia. [McInnes, Elizabeth; Middleton, Sandy] Australian Catholic Univ, Natl Ctr Clin Outcomes Res NaCCOR, Darlinghurst, NSW, Australia. [McInnes, Elizabeth; Middleton, Sandy] Nursing Res Inst St Vincents & Mater Hlth Sydney, Darlinghurst, NSW, Australia. [Paul, Christine] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Yano, Elizabeth M.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. RP Haines, M (reprint author), Sax Inst, Haymarket, Australia. EM mary.haines@saxinstitute.org.au RI D'ESTE, CATHERINE/G-7392-2013; Craig, Jonathan/E-2813-2013; Scott, Anthony/E-6636-2010 OI Craig, Jonathan/0000-0002-2548-4035; McInnes, Liz/0000-0002-0567-9679; Scott, Anthony/0000-0002-2851-5378; Middleton, Sandy/0000-0002-7201-4394 FU National Health and Medical Research Council of Australia [571447]; NSW Agency for Clinical Innovation as part of the National Health and Medical Research Council of Australia's (NHMRC) FX This research is supported by the National Health and Medical Research Council of Australia through their partnership project grant scheme (ID: 571447). This protocol has been approved by the University of Sydney, Human Research Ethics Committee in August 2011 (ID: 13988).; Hunter Watt and Kate Needham, who are part of the 'Clinical Networks Research Group', are employed by the NSW Agency for Clinical Innovation. This Agency has provided funds to support this research as part of the National Health and Medical Research Council of Australia's (NHMRC) partnership project grant scheme. These funds have been awarded on the basis of a NHMRC deed of agreement governing the governance and conduct of research in Australia. The other authors declare that they have no competing interests. NR 42 TC 10 Z9 10 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 13 PY 2012 VL 7 AR 16 DI 10.1186/1748-5908-7-16 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 930PK UT WOS:000303151400001 PM 22414246 ER PT J AU Temiyasathit, S Tang, WJ Leucht, P Anderson, CT Monica, SD Castillo, AB Helms, JA Stearns, T Jacobs, CR AF Temiyasathit, Sara Tang, W. Joyce Leucht, Philipp Anderson, Charles T. Monica, Stefanie D. Castillo, Alesha B. Helms, Jill A. Stearns, Tim Jacobs, Christopher R. TI Mechanosensing by the Primary Cilium: Deletion of Kif3A Reduces Bone Formation Due to Loading SO PLOS ONE LA English DT Article ID POLYCYSTIC KIDNEY-DISEASE; INTRAFLAGELLAR TRANSPORT PROTEINS; FLUID-FLOW; KINESIN-II; MOUSE; CELLS; OSTEOCYTES; EXPRESSION; MICE; SKELETOGENESIS AB Primary cilia, solitary microtubule-based structures that grow from the centriole and extend into the extracellular space, have increasingly been implicated as sensors of a variety of biochemical and biophysical signals. Mutations in primary cilium-related genes have been linked to a number of rare developmental disorders as well as dysregulation of cell proliferation. We propose that primary cilia are also important in mechanically regulated bone formation in adults and that their malfunction could play a role in complex multi-factorial bone diseases, such as osteoporosis. In this study, we generated mice with an osteoblast-and osteocyte-specific knockout of Kif3a, a subunit of the kinesin II intraflagellar transport (IFT) protein; IFT is required for primary cilia formation, maintenance, and function. These Col alpha 1(I) 2.3-Cre;Kif3a(fl/fl) mice exhibited no obvious morphological skeletal abnormalities. Skeletally mature Col alpha 1(I) 2.3-Cre;Kif3a(fl/fl) and control mice were exposed to 3 consecutive days of cyclic axial ulna loading, which resulted in a significant increase in bone formation in both the conditional knockouts and controls. However, Col alpha 1(I) 2.3-Cre;Kif3a(fl/fl) mice did exhibit decreased formation of new bone in response to mechanical ulnar loading compared to control mice. These results suggest that primary cilia act as cellular mechanosensors in bone and that their function may be critical for the regulation of bone physiology due to mechanical loading in adults. C1 [Temiyasathit, Sara; Tang, W. Joyce; Castillo, Alesha B.; Jacobs, Christopher R.] US Dept Vet Affairs, Bone & Joint Rehabil R&D Ctr, Palo Alto, CA USA. [Temiyasathit, Sara; Jacobs, Christopher R.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA. [Stearns, Tim] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA. [Jacobs, Christopher R.] Columbia Univ, Dept Biomed Engn, New York, NY USA. [Stearns, Tim] Stanford Univ, Dept Genet, Stanford, CA 94305 USA. [Castillo, Alesha B.; Jacobs, Christopher R.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA. [Leucht, Philipp] Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA. [Monica, Stefanie D.; Helms, Jill A.] Stanford Univ, Dept Surg Plast & Reconstruct Surg, Stanford, CA 94305 USA. [Anderson, Charles T.] Univ Calif Berkeley, Energy Biosci Inst, Berkeley, CA 94720 USA. RP Temiyasathit, S (reprint author), US Dept Vet Affairs, Bone & Joint Rehabil R&D Ctr, Palo Alto, CA USA. EM crj2111@columbia.edu RI Castillo, Alesha/A-8728-2014 OI Castillo, Alesha/0000-0002-1371-7567; Leucht, Philipp/0000-0002-8409-8513; Anderson, Charles/0000-0001-7481-3571 FU National Institutes of Health [R21AR054156]; Department of Veterans Affairs FX This work was supported by a National Institutes of Health grant R21AR054156 (CRJ), and ST was granted a fellowship by the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 23 Z9 23 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 12 PY 2012 VL 7 IS 3 AR e33368 DI 10.1371/journal.pone.0033368 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 920DF UT WOS:000302381500135 PM 22428034 ER PT J AU Walker, RH Moore, C Davies, G Dirling, LB Koch, RJ Meshul, CK AF Walker, Ruth H. Moore, Cindy Davies, Georgia Dirling, Lisa B. Koch, Rick J. Meshul, Charles K. TI Effects of Subthalamic Nucleus Lesions and Stimulation upon Corticostriatal Afferents in the 6-Hydroxydopamine- Lesioned Rat SO PLOS ONE LA English DT Article ID HIGH-FREQUENCY STIMULATION; DEEP-BRAIN-STIMULATION; MEDIUM SPINY NEURONS; INDUCED CONTRALATERAL ROTATIONS; EXTRACELLULAR GLUTAMATE LEVELS; TIME-DEPENDENT CHANGES; NIGRA PARS RETICULATA; HEMI-PARKINSON RATS; L-DOPA TREATMENT; STRIATAL GLUTAMATE AB Abnormalities of striatal glutamate neurotransmission may play a role in the pathophysiology of Parkinson's disease and may respond to neurosurgical interventions, specifically stimulation or lesioning of the subthalamic nucleus (STN). The major glutamatergic afferent pathways to the striatum are from the cortex and thalamus, and are thus likely to be sources of striatal neuronally-released glutamate. Corticostriatal terminals can be distinguished within the striatum at the electron microscopic level as their synaptic vesicles contain the vesicular glutamate transporter, VGLUT1. The majority of terminals which are immunolabeled for glutamate but are not VGLUT1 positive are likely to be thalamostriatal afferents. We compared the effects of short term, high frequency, STN stimulation and lesioning in 6-hydroxydopamine (6OHDA)-lesioned rats upon striatal terminals immunolabeled for both presynaptic glutamate and VGLUT1. 6OHDA lesions resulted in a small but significant increase in the proportions of VGLUT1-labeled terminals making synapses on dendritic shafts rather than spines. STN stimulation for one hour, but not STN lesions, increased the proportion of synapses upon spines. The density of presynaptic glutamate immuno-gold labeling was unchanged in both VGLUT1-labeled and -unlabeled terminals in 6OHDA-lesioned rats compared to controls. Rats with 6OHDA lesions+STN stimulation showed a decrease in nerve terminal glutamate immuno-gold labeling in both VGLUT1-labeled and -unlabeled terminals. STN lesions resulted in a significant decrease in the density of presynaptic immuno-gold-labeled glutamate only in VGLUT1-labeled terminals. STN interventions may achieve at least part of their therapeutic effect in PD by normalizing the location of corticostriatal glutamatergic terminals and by altering striatal glutamatergic neurotransmission. C1 [Walker, Ruth H.; Davies, Georgia; Koch, Rick J.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Moore, Cindy; Dirling, Lisa B.; Meshul, Charles K.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Neurocytol Lab, Res Serv, Portland, OR 97201 USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. EM ruth.walker@mssm.edu FU Department of Veterans Affairs FX This work was funded by Department of Veterans Affairs Merit awards to RHW and CKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 78 TC 7 Z9 7 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 12 PY 2012 VL 7 IS 3 AR e32919 DI 10.1371/journal.pone.0032919 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 920DF UT WOS:000302381500062 PM 22427909 ER PT J AU Luo, JH Rossouw, J Tong, E Giovino, GA Lee, C Chen, C Ockene, JK Qi, LH Margolis, KL AF Luo, Juhua Rossouw, Jacques Tong, Elisa Giovino, Gary A. Lee, Cathy Chen, Chu Ockene, Judith K. Qi, Lihong Margolis, Karen L. TI Smoking Cessation, Weight Gain, and Risk of Type 2 Diabetes Mellitus Among Postmenopausal Women SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID METAANALYSIS; COHORT C1 [Luo, Juhua] W Virginia Univ, Dept Community Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA. [Rossouw, Jacques] NHLBI, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Tong, Elisa] Univ Calif, Davis Med Ctr, Div Gen Internal Med, Sacramento, CA USA. [Giovino, Gary A.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Community Hlth & Hlth Behav, Buffalo, NY 14260 USA. [Lee, Cathy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Div Geriatr, Los Angeles, CA 90095 USA. [Lee, Cathy] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. [Chen, Chu] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Ockene, Judith K.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Qi, Lihong] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA. RP Luo, JH (reprint author), W Virginia Univ, Dept Community Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA. EM Jiluo@hsc.wvu.edu NR 9 TC 10 Z9 10 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 12 PY 2012 VL 172 IS 5 BP 438 EP 440 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 906XB UT WOS:000301381300017 PM 22412112 ER PT J AU Hershman, DL Wilde, ET Wright, JD Buono, DL Kalinsky, K Malin, JL Neugut, AI AF Hershman, Dawn L. Wilde, Elizabeth T. Wright, Jason D. Buono, Donna L. Kalinsky, Kevin Malin, Jennifer L. Neugut, Alfred I. TI Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID SINGLE-ADMINISTRATION PEGFILGRASTIM; ACUTE MYELOID-LEUKEMIA; DAILY FILGRASTIM; DOSE-DENSE; MYELODYSPLASTIC SYNDROME; SURGEON CHARACTERISTICS; CONSERVATION SURGERY; RANDOMIZED-TRIAL; PHASE-III; CHEMOTHERAPY AB Purpose In 2002, pegfilgrastim was approved by the US Food and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR)-negative tumors, were reported. We examined first-cycle colony-stimulating factor use (FC-CSF) before and after 2002 and estimated US expenditures for dose-dense chemotherapy. Methods We identified patients in Surveillance, Epidemiology, and End Results-Medicare greater than 65 years old with stages I to III breast cancer who had greater than one chemotherapy claim within 6 months of diagnosis(1998 to 2005) and classified patients with an average cycle length less than 21 days as having received dose-dense chemotherapy. The associations of patient, tumor, and physician-related factors with the receipt of any colony-stimulating factor (CSF) and FC-CSF use were analyzed by using generalized estimating equations. CSF costs were estimated for patients who were undergoing dose-dense chemotherapy. Results Among the 10,773 patients identified, 5,266 patients (48.9%) had a CSF claim. CSF use was stable between 1998 and 2002 and increased from 36.8% to 73.7% between 2002 and 2005, FC-CSF use increased from 13.2% to 67.9%, and pegfilgrastim use increased from 4.1% to 83.6%. In a multivariable analysis, CSF use was associated with age and chemotherapy type and negatively associated with black/Hispanic race, rural residence, and shorter chemotherapy duration. FC-CSF use was associated with high socioeconomic status but not with age or race/ethnicity. The US annual CSF expenditure for women with HR-positive tumors treated with dose-dense chemotherapy is estimated to be $38.8 million. Conclusion A rapid increase in FC-CSF use occurred over a short period of time, which was likely a result of the reported benefits of dose-dense chemotherapy and the ease of pegfilgrastim administration. Because of the increasing evidence that elderly HR-positive patients do not benefit from dose-dense chemotherapy, limiting pegfilgrastim use would combat the increasing costs of cancer care. J Clin Oncol 30: 806-812. (C) 2012 by American Society of Clinical Oncology C1 [Hershman, Dawn L.] Columbia Univ, Med Ctr, New York, NY 10032 USA. [Hershman, Dawn L.; Wilde, Elizabeth T.; Wright, Jason D.; Buono, Donna L.; Kalinsky, Kevin; Neugut, Alfred I.] New York Presbyterian Hosp, New York, NY USA. [Malin, Jennifer L.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Hershman, DL (reprint author), Columbia Univ, Med Ctr, 161 Ft Washington Ave,10-1068, New York, NY 10032 USA. EM dlh23@columbia.edu FU National Cancer Institute [NCI R01CA134964] FX Supported by Grant No. NCI R01CA134964 from the National Cancer Institute (D.L.H.). NR 30 TC 18 Z9 20 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 10 PY 2012 VL 30 IS 8 BP 806 EP 812 DI 10.1200/JCO.2011.37.7499 PG 7 WC Oncology SC Oncology GA 923NS UT WOS:000302626600015 PM 22312106 ER PT J AU Kriesel, JD Hobbs, MR Jones, BB Milash, B Nagra, RM Fischer, KF AF Kriesel, John D. Hobbs, Maurine R. Jones, Brandt B. Milash, Brett Nagra, Rashed M. Fischer, Kael F. TI Deep Sequencing for the Detection of Virus-Like Sequences in the Brains of Patients with Multiple Sclerosis: Detection of GBV-C in Human Brain SO PLOS ONE LA English DT Article ID HEPATITIS-G-VIRUS; C/HEPATITIS-G VIRUS; A-E HEPATITIS; MOLECULAR-CLONING; BLOOD-DONORS; INFECTION; PREVALENCE; DISEASE; GENOME; TRANSMISSION AB Multiple sclerosis (MS) is a demyelinating disease of unknown origin that affects the central nervous system of an estimated 400,000 Americans. GBV-C or hepatitis G is a flavivirus that is found in the serum of 1-2% of blood donors. It was originally associated with hepatitis, but is now believed to be a relatively non-pathogenic lymphotropic virus. Fifty frozen specimens from the brains of deceased persons affected by MS were obtained along with 15 normal control brain specimens. RNA was extracted and ribosomal RNAs were depleted before sequencing on the Illumina GAII. These 36 bp reads were compared with a non-redundant database derived from the 600,000+ viral sequences in GenBank organized into 4080 taxa. An individual read successfully aligned to the viral database was considered to be a "hit''. Normalized MS specimen hit rates for each viral taxon were compared to the distribution of hits in the normal controls. Seventeen MS and 11 control brain extracts were sequenced, yielding 4-10 million sequences ("reads'') each. Over-representation of sequence from at least one of 12 viral taxa was observed in 7 of the 17 MS samples. Sequences resembling other viruses previously implicated in the pathogenesis of MS were not significantly enriched in any of the diseased brain specimens. Sequences from GB virus C (GBV-C), a flavivirus not previously isolated from brain, were enriched in one of the MS samples. GBV-C in this brain specimen was confirmed by specific amplification in this single MS brain specimen, but not in the 30 other MS brain samples available. The entire 9.4 kb sequence of this GBV-C isolate is reported here. This study shows the feasibility of deep sequencing for the detection of occult viral infections in the brains of deceased persons with MS. The first isolation of GBV-C from human brain is reported here. C1 [Kriesel, John D.; Hobbs, Maurine R.; Jones, Brandt B.] Univ Utah, Dept Internal Med, Div Infect Dis, Salt Lake City, UT 84112 USA. [Milash, Brett] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Nagra, Rashed M.] W Los Angeles VA Med Ctr, Human Brain & Spinal Fluid Resource Ctr, Los Angeles, CA USA. [Fischer, Kael F.] ARUP Labs, Salt Lake City, UT USA. [Fischer, Kael F.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA. RP Kriesel, JD (reprint author), Univ Utah, Dept Internal Med, Div Infect Dis, Salt Lake City, UT 84112 USA. EM John.Kriesel@hsc.utah.edu RI Fischer, Kael/F-7756-2015 OI Fischer, Kael/0000-0002-7547-330X FU National Multiple Sclerosis Society FX This investigation was supported by grants from the National Multiple Sclerosis Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 10 Z9 11 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 8 PY 2012 VL 7 IS 3 AR e31886 DI 10.1371/journal.pone.0031886 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 929KT UT WOS:000303062000003 PM 22412845 ER PT J AU Seal, KH Shi, Y Cohen, G Cohen, BE Maguen, S Krebs, EE Neylan, TC AF Seal, Karen H. Shi, Ying Cohen, Gregory Cohen, Beth E. Maguen, Shira Krebs, Erin E. Neylan, Thomas C. TI Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and Afghanistan SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; OPERATIONS ENDURING FREEDOM; VIETNAM COMBAT VETERANS; CHRONIC NONCANCER PAIN; COMORBID CHRONIC PAIN; PRIMARY-CARE PATIENTS; MEDICATION USE; WAR; PTSD; PREVALENCE AB Context Record numbers of Iraq and Afghanistan veterans survive their war injuries and yet continue to experience pain and mental health problems, particularly post-traumatic stress disorder (PTSD). Little is known about the association of mental health disorders and prescription opioid use. Objective To investigate the effect of mental health disorders, particularly PTSD, on risks and adverse clinical outcomes associated with prescription opioid use. Design Retrospective cohort study involving 141 029 Iraq and Afghanistan veterans who received at least 1 non-cancer-related pain diagnosis within 1 year of entering the Department of Veterans Affairs (VA) health care system from October 1, 2005, through December 31, 2010. Main Outcome Measures Independent association of mental health disorders and the prescription of opioids, higher risk opioid use, and adverse clinical outcomes (eg, accidents and overdose) within 1 year of receiving a pain-related diagnosis. Results A total of 15 676 veterans were prescribed opioids within 1 year of their initial pain diagnosis. Compared with 6.5% of veterans without mental health disorders, 17.8% (adjusted relative risk [RR], 2.58; 95% CI, 2.49-2.67) of veterans with PTSD and 11.7% (adjusted RR, 1.74; 95% CI, 1.67-1.82) with other mental health diagnoses but without PTSD were significantly more likely to receive opioids for pain diagnoses. Of those who were prescribed pain medication, veterans with PTSD were more likely than those without mental health disorders to receive higher-dose opioids (22.7% vs 15.9%, adjusted RR, 1.42; 95% CI, 1.31-1.54), receive 2 or more opioids concurrently (19.8% vs 10.7%, adjusted RR, 1.87; 95% CI, 1.70-2.06), receive sedative hypnotics concurrently (40.7% vs 7.6%, adjusted RR, 5.46; 95% CI, 4.91-6.07), or obtain early opioid refills (33.8% vs 20.4%; adjusted RR, 1.64; 95% CI, 1.531.75). Receiving prescription opioids (vs not) was associated with an increased risk of adverse clinical outcomes for all veterans (9.5% vs 4.1%; RR, 2.33; 95% CI, 2.20-2.46), which was most pronounced in veterans with PTSD. Conclusion Among US veterans of Iraq and Afghanistan, mental health diagnoses, especially PTSD, were associated with an increased risk of receiving opioids for pain, high-risk opioid use, and adverse clinical outcomes. JAMA. 2012;307(9):940-947 www.jama.com C1 [Seal, Karen H.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Krebs, Erin E.] Indiana Univ Sch Med, Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA. [Krebs, Erin E.] Regenstrief Inst Inc, Indianapolis, IN USA. RP Seal, KH (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Med, 4150 Clement St,POB 111A-1, San Francisco, CA 94121 USA. EM karen.seal@ucsf.edu FU Department of Veterans Affairs (VA), Health Services Research and Development (HSRD) at the San Francisco VA Medical Center; VA HSRD [RCD 06-042, CD2 07-215]; National Institutes of Health, National Heart, Lung, and Blood Institute [K23 HL 094765-01] FX This work was financially supported by the Department of Veterans Affairs (VA), Health Services Research and Development (HSRD) Research Enhancement Award Program at the San Francisco VA Medical Center (Dr Seal), by VA HSRD Career Development Awards RCD 06-042 (Dr Maguen), and CD2 07-215 (Dr Krebs), and grant K23 HL 094765-01 from the National Institutes of Health, National Heart, Lung, and Blood Institute (Dr Cohen). NR 52 TC 135 Z9 135 U1 1 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 7 PY 2012 VL 307 IS 9 BP 940 EP 947 DI 10.1001/jama.2012.234 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 904CU UT WOS:000301172100022 PM 22396516 ER PT J AU Zhang, HM Dang, H Kamat, A Yeh, CK Zhang, BX AF Zhang, Hong-Mei Dang, Howard Kamat, Amrita Yeh, Chih-Ko Zhang, Bin-Xian TI Geldanamycin Derivative Ameliorates High Fat Diet-Induced Renal Failure in Diabetes SO PLOS ONE LA English DT Article ID INDUCED INSULIN-RESISTANCE; MITOCHONDRIAL CA2+ EFFLUX; PROXIMAL TUBULAR CELLS; BLOOD-GLUCOSE CONTROL; OXIDATIVE STRESS; MESANGIAL CELLS; MOLECULAR-MECHANISMS; BARDOXOLONE METHYL; SKELETAL-MUSCLE; KIDNEY-FUNCTION AB Diabetic nephropathy is a serious complication of longstanding diabetes and its pathogenesis remains unclear. Oxidative stress may play a critical role in the pathogenesis and progression of diabetic nephropathy. Our previous studies have demonstrated that polyunsaturated fatty acids (PUFA) induce peroxynitrite generation in primary human kidney mesangial cells and heat shock protein 90 beta 1 (hsp90 beta 1) is indispensable for the PUFA action. Here we investigated the effects of high fat diet (HFD) on kidney function and structure of db/db mice, a widely used rodent model of type 2 diabetes. Our results indicated that HFD dramatically increased the 24 h-urine output and worsened albuminuria in db/db mice. Discontinuation of HFD reversed the exacerbated albuminuria but not the increased urine output. Prolonged HFD feeding resulted in early death of db/db mice, which was associated with oliguria and anuria. Treatment with the geldanamycin derivative, 17-(dimethylaminoehtylamino)-17-demethoxygeldanamycin (17-DMAG), an hsp90 inhibitor, preserved kidney function, and ameliorated glomerular and tubular damage by HFD. 17-DMAG also significantly extended survival of the animals and protected them from the high mortality associated with renal failure. The benefit effect of 17-DMAG on renal function and structure was associated with a decreased level of kidney nitrotyrosine and a diminished kidney mitochondrial Ca2+ efflux in HFD-fed db/db mice. These results suggest that hsp90 beta 1 is a potential target for the treatment of nephropathy and renal failure in diabetes. C1 [Zhang, Hong-Mei] Fourth Mil Med Univ, Dept Clin Oncol, Xijing Hosp, Xian 710032, Peoples R China. [Zhang, Hong-Mei; Kamat, Amrita; Zhang, Bin-Xian] Univ Texas San Antonio, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. [Dang, Howard; Yeh, Chih-Ko; Zhang, Bin-Xian] Univ Texas San Antonio, Hlth Sci Ctr, Dept Comprehens Dent, San Antonio, TX USA. [Kamat, Amrita; Yeh, Chih-Ko; Zhang, Bin-Xian] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Zhang, HM (reprint author), Fourth Mil Med Univ, Dept Clin Oncol, Xijing Hosp, Xian 710032, Peoples R China. EM zhangb2@uthscsa.edu FU Mike Hogg Fund; National Institutes of Health (NIH); Department of Veterans Health Care; National Natural Science Foundation of China [30900673]; Natural Science Foundation of Shaanxi Province [SJ08-ZT10] FX This work was supported by the Mike Hogg Fund, National Institutes of Health (NIH), The Department of Veterans Health Care, the National Natural Science Foundation of China (No. 30900673), and Natural Science Foundation of Shaanxi Province(SJ08-ZT10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 11 Z9 12 U1 1 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 6 PY 2012 VL 7 IS 3 AR e32746 DI 10.1371/journal.pone.0032746 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 928XD UT WOS:000303021100027 PM 22412919 ER PT J AU Thombs, BD Coyne, JC Cuijpers, P de Jonge, P Gilbody, S Ioannidis, JPA Johnson, BT Patten, SB Turner, EH Ziegelstein, RC AF Thombs, Brett D. Coyne, James C. Cuijpers, Pim de Jonge, Peter Gilbody, Simon Ioannidis, John P. A. Johnson, Blair T. Patten, Scott B. Turner, Erick H. Ziegelstein, Roy C. TI Rethinking recommendations for screening for depression in primary care SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Article ID CASE-FINDING INSTRUMENTS; ANTIDEPRESSANT TRIALS; NATIONAL PATTERNS; RANDOMIZED-TRIAL; METAANALYSIS; EFFICACY; SEVERITY; OUTCOMES; PUBLICATION; DIAGNOSIS C1 [Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Biostat, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Sch Nursing, Montreal, PQ, Canada. McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada. [Coyne, James C.] Univ Penn, Sch Med, Behav Oncol Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Coyne, James C.] Univ Groningen, Hlth Psychol Sect, Dept Hlth Sci, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. [Cuijpers, Pim] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands. [Cuijpers, Pim] Vrije Univ Amsterdam, EMGO Inst, Amsterdam, Netherlands. [de Jonge, Peter] Univ Groningen, Interdisciplinary Ctr Psychiat Epidemiol, Univ Med Ctr, Groningen, Netherlands. [Gilbody, Simon] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England. Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Clin & Mol Epidemiol Unit, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Tufts Med Ctr, Boston, MA 02111 USA. Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Stanford, CA 94305 USA. [Johnson, Blair T.] Univ Connecticut, Dept Psychol, Storrs, CT USA. [Johnson, Blair T.] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA. [Patten, Scott B.] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [Patten, Scott B.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. [Ziegelstein, Roy C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. RP Thombs, BD (reprint author), McGill Univ, Dept Psychiat, Montreal, PQ, Canada. EM brett.thombs@mcgill.ca RI Turner, Erick/A-4848-2008; de Jonge, peter/L-6395-2013; Cuijpers, Pim/G-1703-2013; Patten, Scott/B-4434-2011 OI Turner, Erick/0000-0002-3522-3357; de Jonge, peter/0000-0002-0866-6929; Patten, Scott/0000-0001-9871-4041; Cuijpers, Pim/0000-0001-5497-2743; Thombs, Brett/0000-0002-5644-8432 FU Canadian Institutes of Health Research [MIN 92725]; NCCIH NIH HHS [R24 AT004641, R24AT004641] NR 47 TC 63 Z9 63 U1 1 U2 16 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD MAR 6 PY 2012 VL 184 IS 4 BP 413 EP 418 DI 10.1503/cmaj.111035 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 908BM UT WOS:000301465400009 PM 21930744 ER PT J AU Mueller, R Dawson, ES Meiler, J Rodriguez, AL Chauder, BA Bates, BS Felts, AS Lamb, JP Menon, UN Jadhav, SB Kane, AS Jones, CK Gregory, KJ Niswender, CM Conn, PJ Olsen, CM Winder, DG Emmitte, KA Lindsley, CW AF Mueller, Ralf Dawson, Eric S. Meiler, Jens Rodriguez, Alice L. Chauder, Brian A. Bates, Brittney S. Felts, Andrew S. Lamb, Jeffrey P. Menon, Usha N. Jadhav, Sataywan B. Kane, Alexander S. Jones, Carrie K. Gregory, Karen J. Niswender, Colleen M. Conn, P. Jeffrey Olsen, Christopher M. Winder, Danny G. Emmitte, Kyle A. Lindsley, Craig W. TI Discovery of 2-(2-Benzoxazoyl amino)-4-Aryl-5-Cyanopyrimidine as Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptor 5 (mGlu5): From an Artificial Neural Network Virtual Screen to an In Vivo Tool Compound SO CHEMMEDCHEM LA English DT Article DE addiction; allosteric modulators; artificial neural networks; metabotropic glutamate receptors; structure-activity relationships ID LOCOMOTOR-ACTIVITY; MICE; IDENTIFICATION; ANTAGONISTS; SUBTYPE-5; LEAD; 2-METHYL-6-(PHENYLETHYNYL)PYRIDINE; POTENTIATORS; PHARMACOLOGY; DISORDERS C1 [Mueller, Ralf; Meiler, Jens; Emmitte, Kyle A.; Lindsley, Craig W.] Vanderbilt Univ, Dept Chem, Stevenson Ctr 7330, Nashville, TN 37232 USA. [Dawson, Eric S.; Rodriguez, Alice L.; Chauder, Brian A.; Bates, Brittney S.; Felts, Andrew S.; Lamb, Jeffrey P.; Menon, Usha N.; Jadhav, Sataywan B.; Kane, Alexander S.; Jones, Carrie K.; Gregory, Karen J.; Niswender, Colleen M.; Conn, P. Jeffrey; Emmitte, Kyle A.; Lindsley, Craig W.] Vanderbilt Univ, Med Ctr MRBIV 12475, Dept Pharmacol, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst TVHS, Nashville, TN 37212 USA. [Gregory, Karen J.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia. [Olsen, Christopher M.; Winder, Danny G.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Med Ctr, Nashville, TN 37232 USA. RP Mueller, R (reprint author), Vanderbilt Univ, Dept Chem, Stevenson Ctr 7330, Stn B 351822, Nashville, TN 37232 USA. EM jens.meiler@vanderbilt.edu; craig.lindsley@vanderbilt.edu RI Conn, Peter/D-7848-2012; Olsen, Christopher/C-3542-2008; Winder, Danny/H-4857-2013 OI Olsen, Christopher/0000-0003-2700-0310; Gregory, Karen/0000-0002-3833-2137 FU US National Institutes of Health (NIH); US National Institute on Drug Abuse (NIDA) [R01DA023947-01]; US National Institute of Mental Health (NIMH) [R01090192-01] FX The authors warmly thank the US National Institutes of Health (NIH), and in particular the US National Institute on Drug Abuse (NIDA; R01DA023947-01) and the US National Institute of Mental Health (NIMH; R01090192-01), for support of our programs in drug discovery. The authors also thank Daryl F. Venable (Vanderbilt University, Nashville, USA) for technical assistance with the calcium flux and radioligand binding assays. NR 51 TC 15 Z9 15 U1 2 U2 7 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 1860-7179 J9 CHEMMEDCHEM JI ChemMedChem PD MAR 5 PY 2012 VL 7 IS 3 SI SI BP 406 EP 414 DI 10.1002/cmdc.201100510 PG 9 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 901DQ UT WOS:000300942300009 PM 22267125 ER PT J AU Cavasin, MA Demos-Davies, K Horn, TR Walker, LA Lemon, DD Birdsey, N Weiser-Evans, MCM Harral, J Irwin, DC Anwar, A Yeager, ME Li, M Watson, PA Nemenoff, RA Buttrick, PM Stenmark, KR McKinsey, TA AF Cavasin, Maria A. Demos-Davies, Kim Horn, Todd R. Walker, Lori A. Lemon, Douglas D. Birdsey, Nicholas Weiser-Evans, Mary C. M. Harral, Julie Irwin, David C. Anwar, Adil Yeager, Michael E. Li, Min Watson, Peter A. Nemenoff, Raphael A. Buttrick, Peter M. Stenmark, Kurt R. McKinsey, Timothy A. TI Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism SO CIRCULATION RESEARCH LA English DT Article DE histone deacetylase; pulmonary hypertension; proliferation; gene expression; signaling pathways ID PULMONARY ARTERIAL-HYPERTENSION; FORKHEAD TRANSCRIPTION FACTOR; CARDIAC-HYPERTROPHY; SURVIVAL; PROLIFERATION; INFLAMMATION; ACTIVATION; EMERGENCE; GROWTH; CELLS AB Rationale: Histone deacetylase (HDAC) inhibitors are efficacious in models of hypertension-induced left ventricular heart failure. The consequences of HDAC inhibition in the context of pulmonary hypertension with associated right ventricular cardiac remodeling are poorly understood. Objective: This study was performed to assess the utility of selective small-molecule inhibitors of class I HDACs in a preclinical model of pulmonary hypertension. Methods and Results: Rats were exposed to hypobaric hypoxia for 3 weeks in the absence or presence of a benzamide HDAC inhibitor, MGCD0103, which selectively inhibits class I HDACs 1, 2, and 3. The compound reduced pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. MGCD0103 improved pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. Similar results were obtained with an independent class I HDAC-selective inhibitor, MS-275. Reduced pulmonary arterial pressure in MGCD0103-treated animals was associated with blunted pulmonary arterial wall thickening because of suppression of smooth muscle cell proliferation. Right ventricular function was maintained in MGCD0103-treated animals. Although the class I HDAC inhibitor only modestly reduced right ventricular hypertrophy, it had multiple beneficial effects on the right ventricle, which included suppression of pathological gene expression, inhibition of proapoptotic caspase activity, and repression of proinflammatory protein expression. Conclusions: By targeting distinct pathogenic mechanisms, isoform-selective HDAC inhibitors have potential as novel therapeutics for pulmonary hypertension that will complement vasodilator standards of care. (Circ Res. 2012;110:739-748.) C1 [Cavasin, Maria A.; Demos-Davies, Kim; Horn, Todd R.; Walker, Lori A.; Lemon, Douglas D.; Irwin, David C.; Buttrick, Peter M.; McKinsey, Timothy A.] Univ Colorado Denver, Dept Med, Div Cardiol, Aurora, CO 80045 USA. [Birdsey, Nicholas; Watson, Peter A.] Univ Colorado Denver, Div Endocrinol Metab & Diabet, Aurora, CO 80045 USA. [Weiser-Evans, Mary C. M.; Nemenoff, Raphael A.] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO 80045 USA. [Harral, Julie; Anwar, Adil; Yeager, Michael E.; Li, Min; Stenmark, Kurt R.] Univ Colorado Denver, Dept Pediat, Div Pulm & Crit Care Med, Aurora, CO 80045 USA. [Watson, Peter A.] Denver VA Med Ctr, Denver, CO USA. RP McKinsey, TA (reprint author), Univ Colorado Denver, Dept Med, Div Cardiol, 12700 E 19th Ave, Aurora, CO 80045 USA. EM timothy.mckinsey@ucdenver.edu RI Walker, Lori/J-7098-2013 OI Walker, Lori/0000-0003-2556-8076 FU Department of Veterans Affairs FX P.A.W. was supported by a Department of Veterans Affairs Merit Award. NR 33 TC 72 Z9 73 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7330 J9 CIRC RES JI Circ.Res. PD MAR 2 PY 2012 VL 110 IS 5 BP 739 EP U250 DI 10.1161/CIRCRESAHA.111.258426 PG 22 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA 902NP UT WOS:000301045500014 PM 22282194 ER PT J AU Chipuk, JE McStay, GP Bharti, A Kuwana, T Clarke, CJ Siskind, LJ Obeid, LM Green, DR AF Chipuk, Jerry E. McStay, Gavin P. Bharti, Archana Kuwana, Tomomi Clarke, Christopher J. Siskind, Leah J. Obeid, Lina M. Green, Douglas R. TI Sphingolipid Metabolism Cooperates with BAK and BAX to Promote the Mitochondrial Pathway of Apoptosis SO CELL LA English DT Article ID RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; NEUTRAL SPHINGOMYELINASE; OUTER-MEMBRANE; BCL-2 FAMILY; CYTOCHROME-C; BH3 DOMAINS; HELA-CELLS; CERAMIDE AB Mitochondria are functionally and physically associated with heterotypic membranes, yet little is known about how these interactions impact mitochondrial outer-membrane permeabilization (MOMP) and apoptosis. We observed that dissociation of heterotypic membranes from mitochondria inhibited BAK/BAX-dependent cytochrome c (cyto c) release. Biochemical purification of neutral sphingomyelinases that correlated with MOMP sensitization suggested that sphingolipid metabolism coordinates BAK/BAX activation. Using purified lipids and enzymes, sensitivity to MOMP was achieved by in vitro reconstitution of the sphingolipid metabolic pathway. Sphingolipid metabolism inhibitors blocked MOMP from heavy membrane preparations but failed to influence MOMP in the presence of sphingolipid-reconstituted, purified mitochondria. Furthermore, the sphingolipid products, sphingosine-1-PO4 and hexadecenal, cooperated specifically with BAK and BAX, respectively. Sphingolipid metabolism was also required for cellular responses to apoptosis. Our studies suggest that BAK/BAX activation and apoptosis are coordinated through BH3-only proteins and a specific lipid milieu that is maintained by heterotypic membrane-mitochondrial interactions. C1 [Chipuk, Jerry E.; Bharti, Archana] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA. [McStay, Gavin P.; Green, Douglas R.] St Jude Childrens Hosp, Dept Immunol, Memphis, TN 38105 USA. [Kuwana, Tomomi] Univ Iowa, Carver Coll Med, Dept Pathol, Iowa City, IA 52252 USA. [Clarke, Christopher J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Siskind, Leah J.; Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Siskind, Leah J.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Div Gen Med & Geriatr, Charleston, SC 29425 USA. RP Chipuk, JE (reprint author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM jerry.chipuk@mssm.edu; douglas.green@stjude.org OI obeid, lina/0000-0002-0734-0847; Chipuk, Jerry Edward/0000-0002-1337-842X FU NIH [CA157740, P20AA017067, AI52735, CA69381, AG024478]; NCI Cancer Center Core [P30CA21765]; VA Merit; VA [CDA-2]; VA REAP; ACS [IRG-97-219-11]; Cancer Center [P30 CA138313]; COBRE in Lipidomics and Pathobiology [NIH/NCRRP20 RR17677]; American Lebanese Syrian Associated Charities; March of Dimes Foundation [5-FY11-74] FX We would like to thank Dr. Ronald Gordon (MSSM) for TEM analysis; Dr. Richard Kolesnick (Memorial Sloan-Kettering) for the asm-/- liver; Dr. Joseph Opferman (SJCRH) for the MxCre bak-/- bax-/f animals; all members of the Obeid and Hannun laboratories (MUSC) for excellent discussion and training in sphingolipid biology, especially Drs. K. Alexa Orr Gandy, Stefka Spassieva, and Xingjun Wu; The Hartwell Center for Bioinformatics and Biotechnology; and members of the Kuwana Laboratory for technical assistance. This work was supported by: NIH CA157740 (to J.E.C.), pilot project from NIH P20AA017067 (to J.E.C.), NIH AI52735 (to D. R. G.), CA69381 (to D. R. G.), NIH AG024478 (to T. K.), an NCI Cancer Center Core Grant P30CA21765 (SJCRH), VA Merit (to L.M.O.), VA CDA-2 Award (to L.J.S), pilot project from the VA REAP (to L.J.S., and L.M.O.), the ACS IRG # IRG-97-219-11 (subaward to L.J.S.), Lipidomics Shared Resource of the Hollings Cancer Center supported by a Cancer Center Support Grant (P30 CA138313), pilot project (to L.J.S) from the NIH/NCRRP20 RR17677 COBRE in Lipidomics and Pathobiology, and the American Lebanese Syrian Associated Charities. This work was also supported in part by a Research Grant 5-FY11-74 from the March of Dimes Foundation (to J.E.C.). NR 62 TC 142 Z9 148 U1 0 U2 40 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD MAR 2 PY 2012 VL 148 IS 5 BP 988 EP 1000 DI 10.1016/j.cell.2012.01.038 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 901RR UT WOS:000300985000018 PM 22385963 ER PT J AU Broyles, LM Tate, JA Happ, MB AF Broyles, Lauren M. Tate, Judith A. Happ, Mary Beth TI USE OF AUGMENTATIVE AND ALTERNATIVE COMMUNICATION STRATEGIES BY FAMILY MEMBERS IN THE INTENSIVE CARE UNIT SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article ID POSTTRAUMATIC-STRESS; VENTILATED PATIENTS; CRITICAL ILLNESS; DECISION-MAKING; HIGH-RISK; PATIENT; SYMPTOMS; LIFE; ICU; EXPERIENCES AB Background Little is known about communication between patients and their family members during critical illness and mechanical ventilation in the intensive care unit, including use of augmentative and alternative communication tools and strategies. Objectives To identify (1) which augmentative and alternative communication tools families use with nonspeaking intensive care patients and how they are used, and (2) what families and nurses say about communication of family members with nonspeaking intensive care patients. Methods A qualitative secondary analysis was conducted of existing data from a clinical trial testing interventions to improve communication between nurses and intensive care patients. Narrative study data (field notes, intervention logs, nurses' interviews) from 127 critically ill adults were reviewed for evidence of family involvement with augmentative and alternative communication tools. Qualitative content analysis was applied for thematic description of family members' and nurses' accounts of patient-family communication. Results Family involvement with augmentative and alternative communication tools was evident in 44% of the 93 patients who completed the parent study protocol. Spouses or significant others communicated with patients most often. Main themes describing patient-family communication included (1) families being unprepared and unaware, (2) families' perceptions of communication effectiveness, (3) nurses deferring to or guiding patient-family communication, (4) patients' communication characteristics, and (5) families' experience with and interest in augmentative and alternative communication tools. Conclusions Assessment by skilled bedside clinicians can reveal patients' communication potential and facilitate useful augmentative and alternative communication tools and strategies for patients and their families. (American Journal of Critical Care. 2012; 21(2): e21-e32) C1 [Broyles, Lauren M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Tate, Judith A.] Univ Pittsburgh, Dept Psychiat, NIMH, Pittsburgh, PA 15260 USA. [Happ, Mary Beth] Univ Pittsburgh, Dept Acute & Tertiary Care, UPMC Hlth Syst, Sch Nursing,Chair Nursing Sci, Pittsburgh, PA 15260 USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM Lauren.Broyles@va.gov RI Tate, Judith/C-7447-2015 FU National Institute for Nursing Research [5K24- NR010244]; National Institute for Child Health and Human Development [5R01 HD043988]; US Department of Veterans Affairs [CDA 10-014] FX This study was supported by grants (M. Happ, principal investigator) from the National Institute for Nursing Research (5K24- NR010244) and the National Institute for Child Health and Human Development (5R01 HD043988). Dr Broyles is currently supported by a Career Development Award (CDA 10-014) from the US Department of Veterans Affairs. This material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. Dr Tate is a National Institute of Mental Health postdoctoral research fellow in the clinical research training program in geriatric psychiatry at the University of Pittsburgh Department of Psychiatry (T32 MH19986, principal investigator, Reynolds). NR 61 TC 3 Z9 3 U1 3 U2 32 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 J9 AM J CRIT CARE JI Am. J. Crit. Care PD MAR 1 PY 2012 VL 21 IS 2 BP E21 EP E32 DI 10.4037/ajcc2012752 PG 12 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 031LC UT WOS:000310640300001 PM 22381993 ER PT J AU Al Gadban, MM German, J Truman, JP Soodavar, F Riemer, EC Twal, WO Smith, KJ Heller, D Hofbauer, AF Oates, JC Hammad, SM AF Al Gadban, Mohammed M. German, Jashalynn Truman, Jean-Philip Soodavar, Farzan Riemer, Ellen C. Twal, Waleed O. Smith, Kent J. Heller, Demarcus Hofbauer, Ann F. Oates, Jim C. Hammad, Samar M. TI Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus SO CELLULAR IMMUNOLOGY LA English DT Article DE Lupus; Nitric oxide synthase; Sphingosine 1-phosphate; Sphingosine kinase; Ceramide; Oxidized LDL ID TUMOR-NECROSIS-FACTOR; HIGH-DENSITY-LIPOPROTEIN; GIANT-CELL VASCULITIS; U937 MONOCYTIC CELLS; HUMAN T-CELLS; ENDOTHELIAL DYSFUNCTION; RHEUMATOID-ARTHRITIS; ACCELERATED ATHEROSCLEROSIS; MOLECULAR-MECHANISMS; SIGNAL-TRANSDUCTION AB Systemic lupus erythematosus (SLE) patients display impaired endothelial nitric oxide synthase (eNOS) function required for normal vasodilatation. SLE patients express increased compensatory activity of inducible nitric oxide synthase (iNOS) generating excess nitric oxide that may result in inflammation. We examined the effects of genetic deletion of NOS2 and NOS3, encoding iNOS and eNOS respectively, on accelerated vascular disease in MRL/lpr lupus mouse model. NOS2 and NOS3 knockout (KO) MRL/lpr mice had higher plasma levels of triglycerides (23% and 35%, respectively), ceramide (45% and 21%, respectively), and sphingosine 1-phosphate (S1P) (21%) compared to counterpart MRL/lpr controls. Plasma levels of the anti-inflammatory cytokine interleukin 10 (IL-10) in NOS2 and NOS3 KO MRL/lpr mice were lower (53% and 80%, respectively) than counterpart controls. Nodule-like lesions in the adventitia were detected in aortas from both NOS2 and NOS3 KO MRL/lpr mice. Immunohistochemical evaluation of the lesions revealed activated endothelial cells and lipid-laden macrophages (foam cells), elevated sphingosine kinase 1 expression, and oxidized low-density lipoprotein immune complexes (oxLDL-IC). The findings suggest that advanced vascular disease in NOS2 and NOS3 KO MRL/lpr mice maybe mediated by increased plasma triglycerides, ceramide and S1P; decreased plasma IL-10; and accumulation of oxLDL-IC in the vessel wall. The results expose possible new targets to mitigate lupus-associated complications. (C) 2012 Elsevier Inc. All rights reserved. C1 [Al Gadban, Mohammed M.; Truman, Jean-Philip; Soodavar, Farzan; Twal, Waleed O.; Smith, Kent J.; Hammad, Samar M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [German, Jashalynn; Heller, Demarcus] Med Univ S Carolina, Coll Grad Studies, Summer Undergrad Res Program, Charleston, SC 29425 USA. [Riemer, Ellen C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Hofbauer, Ann F.; Oates, Jim C.] Med Univ S Carolina, Dept Rheumatol & Immunol, Charleston, SC 29425 USA. [Hofbauer, Ann F.; Oates, Jim C.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hammad, SM (reprint author), Med Univ S Carolina, Dept Regenerat Med & Cell Biol, 114 Doughty St 629A,MSC 815, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU NIH [HL079274, K08AR002193, AR045476]; NIH (ARRA) [R01 HL079274-04S1]; South Carolina COBRE in Lipidomics and Pathobiology (from NCRR) [P20 RR17677]; Medical Research Service [NIH/NHLBI R25 HL092611]; Cancer Center Support Grant [P30 CA138313] FX This study was funded by NIH HL079274, NIH (ARRA) R01 HL079274-04S1, and the South Carolina COBRE in Lipidomics and Pathobiology (P20 RR17677 from NCRR) to SMH; NIH K08AR002193, NIH AR045476, and funding from Medical Research Service, Ralph H. Johnson VAMC, Charleston, to JCO; NIH/NHLBI R25 HL092611 for the MUSC College of Graduate Studies (J.G. and D.H.). We thank the MUSC Lipidomics Core Facility for sphingolipid analysis, the Histology Laboratory, Department of Pathology & Laboratory Medicine for tissue processing, and the MUSC Proteogenomics Facility for the use of the Bioplex system for cytokine determination. Imaging facilities were supported, in part, by Cancer Center Support Grant P30 CA138313 to the Hollings Cancer Center, MUSC. We thank Dr. Toshi Kawamori and Dr. Gabe Virella (MUSC) for providing antibodies. NR 80 TC 6 Z9 6 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0008-8749 J9 CELL IMMUNOL JI Cell. Immunol. PD MAR-APR PY 2012 VL 276 IS 1-2 BP 42 EP 51 DI 10.1016/j.cellimm.2012.03.007 PG 10 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 985JQ UT WOS:000307260800007 PM 22560558 ER PT J AU Bromley, E Adams, GF Brekke, JS AF Bromley, Elizabeth Adams, Gail Fox Brekke, John S. TI A Video Ethnography Approach for Linking Naturalistic Behaviors to Research Constructs of Neurocognition in Schizophrenia SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID ECOLOGICAL MOMENTARY ASSESSMENT; COMPLEX FIGURE TEST; QUALITY-OF-LIFE; COGNITIVE DEFICITS; SOCIAL COGNITION; CODING SYSTEM; TIME USE; NEUROPSYCHOLOGICAL ASSESSMENT; SELF-DETERMINATION; BIPOLAR DISORDER AB Few methods are available to explore the impact of neurocognition in schizophrenia on behaviors performed in usual contexts. The authors developed a video ethnography approach to examine the relationship between naturalistic behaviors and research constructs of neurocognition. Video ethnographers accompanied subjects through usual routines gathering continuous video data. Researchers developed codes to measure four behavioral domains observed on video. This paper describes the psychometric characteristics to be considered in the development of observational approaches. It also highlights differences between behaviors performed in usual environments and neuropsychological constructs. The authors demonstrate that everyday behaviors that have been shown to correspond to neurocognitive skills in a pilot feasibility study can be identified and rated. They further suggest that observational methods could provide novel strategies for linking research findings and clinical concerns. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:125-140) C1 [Bromley, Elizabeth; Adams, Gail Fox; Brekke, John S.] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Semel Inst,Dept Psychiat & Biobehav Sci, W Los Angeles VA Healthcare Ctr,Desert Pacific Mi, Los Angeles, CA 90024 USA. RP Bromley, E (reprint author), 10920 Wilshire Blvd,Suite 300, Los Angeles, CA USA. EM ebromley@ucla.edu FU VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); University of California, Los Angeles Faculty Senate Council on Research; Foundation for Psychocultural Research-UCLA Center for Culture, Brain and Development; University of Southern California Clinical and Translational Science Institute (CTSI) FX This work was supported by the VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC; Bromley, PI); the University of California, Los Angeles Faculty Senate Council on Research (Bromley, PI); the Foundation for Psychocultural Research-UCLA Center for Culture, Brain and Development (Adams), and the University of Southern California Clinical and Translational Science Institute (CTSI; Brekke, PI). NR 144 TC 0 Z9 0 U1 5 U2 9 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2012 VL 24 IS 2 BP 125 EP 140 PG 16 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 972MN UT WOS:000306281300101 PM 22772661 ER PT J AU Meyer, HB Katsman, A Sones, AC Auerbach, DE Ames, D Rubin, RT AF Meyer, Hilary B. Katsman, Alina Sones, Alexander C. Auerbach, Daniel E. Ames, Donna Rubin, Robert T. TI Yoga as an Ancillary Treatment for Neurological and Psychiatric Disorders: A Review SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; MULTIPLE-SCLEROSIS; REFRACTORY EPILEPSY; BIPOLAR DISORDER; DEPRESSION SCALE; MENTAL-HEALTH; HATHA-YOGA; THERAPY; SCHIZOPHRENIA; MEDITATION AB Yoga is gaining acceptance as an ancillary medical treatment, but there have been few studies evaluating its therapeutic benefits in neurological and major psychiatric conditions. The authors reviewed the literature in English on the efficacy of yoga for these disorders. Only randomized, controlled trials were included, with the exception of the only study of yoga for bipolar disorder, which was observational. Trials were excluded if yoga was not the central component of the intervention. Of seven randomized, controlled trials of yoga in patients with neurological disorders, six found significant, positive effects. Of 13 randomized, controlled trials of yoga in patients with psychiatric disorders, 10 found significant, positive effects. These results, although encouraging, indicate that additional randomized, controlled studies are needed to critically define the benefits of yoga for both neurological and psychiatric disorders. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:152-164) C1 [Ames, Donna; Rubin, Robert T.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Meyer, Hilary B.] W Los Angeles VA Med Ctr, Dept Psychiat, Los Angeles, CA USA. [Sones, Alexander C.] Washington Univ, St Louis, MO 63130 USA. [Auerbach, Daniel E.] Univ Calif Berkeley, Berkeley, CA 94720 USA. RP Ames, D (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. EM donna.ames@va.gov NR 93 TC 12 Z9 12 U1 1 U2 26 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2012 VL 24 IS 2 BP 152 EP 164 PG 13 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 972MN UT WOS:000306281300103 PM 22772663 ER PT J AU Braunstein, I Werth, VP AF Braunstein, Inbal Werth, Victoria P. TI Update on management of connective tissue panniculitides SO DERMATOLOGIC THERAPY LA English DT Article DE dermatomyositis; lupus erythematosus panniculitis; lupus profundus; morphea; morphea profunda ID LUPUS-ERYTHEMATOSUS PANNICULITIS; OF-THE-LITERATURE; T-CELL LYMPHOMA; LOCALIZED SCLERODERMA; SYSTEMIC-SCLEROSIS; JUVENILE DERMATOMYOSITIS; CUTANEOUS MANIFESTATION; LINEAR SCLERODERMA; MORPHEA PROFUNDA; DEEP MORPHEA AB In connective tissue diseases, panniculitis can be the sole manifestation or can occur along with the underlying disease process. The best described forms of connective tissue panniculitis are lupus erythematosus panniculitis and lupus profundus, panniculitis associated with dermatomyositis, and morphea- and scleroderma-associated panniculitis. These processes cause significant morbidity, such as deep atrophic scars, cosmetic disfigurement, and psychiatric sequelae. Because the inflammation is located in the subcutaneous adipose layer, topical therapies may not penetrate enough to be effective, and systemic agents are required. Despite the large number of reported cases and therapies, recommendations for treatment are based largely on case series and expert opinion due to a lack of controlled therapeutic trials. All treatments are off-label in the United States. The lack of validated clinical outcome measures makes systematic and controlled studies difficult. Nonetheless, further investigation into the most effective therapies for these conditions is needed. C1 [Braunstein, Inbal; Werth, Victoria P.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Div Dermatol, Philadelphia, PA USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development); National Institutes of Health (NIH) [K24-AR 02207] FX This material is based upon work supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and by the National Institutes of Health (NIH K24-AR 02207) to VPW. No conflict of interest to report. NR 83 TC 4 Z9 7 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1396-0296 EI 1529-8019 J9 DERMATOL THER JI Dermatol. Ther. PD MAR-APR PY 2012 VL 25 IS 2 SI SI BP 173 EP 182 DI 10.1111/j.1529-8019.2012.01489.x PG 10 WC Dermatology SC Dermatology GA 959AK UT WOS:000305281900006 PM 22741936 ER PT J AU Schnall, E Kalkstein, S Fitchett, G Salmoirago-Blotcher, E Ockene, J Tindle, HA Thomas, A Hunt, JR Wassertheil-Smoller, S AF Schnall, Eliezer Kalkstein, Solomon Fitchett, George Salmoirago-Blotcher, Elena Ockene, Judith Tindle, Hilary Aurora Thomas, Asha Hunt, Julie R. Wassertheil-Smoller, Sylvia TI Psychological and Social Characteristics Associated with Religiosity in Women's Health Initiative Participants SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Religion and health; Religion and psychology; Religious behavior and health; Religious attendance and health; Religious behavior and social support; Religious behavior and social strain; Religious behavior and psychological characteristics ID PHYSICAL HEALTH; SUPPORT; MORTALITY; ATTENDANCE; DETERMINANT; INTEGRATION; HOSTILITY; OPTIMISM; ANXIETY; HISTORY AB Measures of religiosity are linked to health outcomes, possibly indicating mediating effects of associated psychological and social factors. We examined cross-sectional data from 92,539 postmenopausal participants of the Women's Health Initiative Observational Study who responded to questions on religious service attendance, psychological characteristics, and social support domains. We present odds ratios from multiple logistic regressions controlling for covariates. Women attending services weekly during the past month, compared with those not attending at all in the past month, were less likely to be depressed [OR = 0.78; CI = 0.74-0.83] or characterized by cynical hostility [OR = 0.94; CI = 0.90-0.98], and more likely to be optimistic [OR = 1.22; CI = 1.17-1.26]. They were also more likely to report overall positive social support [OR = 1.28; CI = 1.24-1.33], as well as social support of four subtypes (emotional/informational support, affection support, tangible support, and positive social interaction), and were less likely to report social strain [OR = 0.91; CI = 0.88-0.94]. However, those attending more or less than weekly were not less likely to be characterized by cynical hostility, nor were they less likely to report social strain, compared to those not attending during the past month. C1 [Schnall, Eliezer] Yeshiva Univ, Yeshiva Coll, New York, NY 10033 USA. [Kalkstein, Solomon] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Fitchett, George] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Salmoirago-Blotcher, Elena; Ockene, Judith] Univ Massachusetts, Sch Med, Worcester, MA USA. [Tindle, Hilary Aurora] Univ Pittsburgh, Pittsburgh, PA USA. [Thomas, Asha] Sinai Hosp, Baltimore, MD 21215 USA. [Hunt, Julie R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, New York, NY USA. RP Schnall, E (reprint author), Yeshiva Univ, Yeshiva Coll, 500 W 185th St, New York, NY 10033 USA. EM schnall@yu.edu OI Salmoirago-Blotcher, Elena/0000-0003-4636-8698 FU NCI NIH HHS [R01 CA141596]; WHI NIH HHS [N01WH32102, N01WH22110, N01WH24152, N01WH32100, N01WH32101, N01WH32105, N01WH32106, N01WH32108, N01WH32109, N01WH32111, N01WH32112, N01WH32113, N01WH32115, N01WH32118, N01WH32119, N01WH32122, N01WH42107, N01WH42108, N01WH42109, N01WH42110, N01WH42111, N01WH42112, N01WH42113, N01WH42114, N01WH42115, N01WH42116, N01WH42117, N01WH42118, N01WH42119, N01WH42120, N01WH42121, N01WH42122, N01WH42123, N01WH42124, N01WH42125, N01WH42126, N01WH42129, N01WH42130, N01WH42131, N01WH42132, N01WH44221] NR 37 TC 7 Z9 7 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 EI 1573-6571 J9 J RELIG HEALTH JI J. Relig. Health PD MAR PY 2012 VL 51 IS 1 BP 20 EP 31 DI 10.1007/s10943-011-9549-6 PG 12 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA 958GS UT WOS:000305225100003 PM 22069057 ER PT J AU Tang, CY Eaves, E Dams-O'Connor, K Ho, L Leung, E Wong, E Carpenter, D Ng, J Gordon, W Pasinetti, G AF Tang, Cheuk Ying Eaves, Emily Dams-O'Connor, Kristen Ho, Lap Leung, Eric Wong, Edmund Carpenter, David Ng, Johnny Gordon, Wayne Pasinetti, Giulio TI DIFFUSE DISCONNECTIVITY IN TBI: A RESTING STATE FMRI AND DTI STUDY SO TRANSLATIONAL NEUROSCIENCE LA English DT Article DE Traumatic Brain Injury (TBI); Functional magnetic resonance imaging (fMRI); DTI; Cognitive Function ID TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; LATE-LIFE DEPRESSION; AXONAL INJURY; WORKING-MEMORY; FUNCTIONAL CONNECTIVITY; ALZHEIMERS-DISEASE; MRI; TASK; ABNORMALITIES AB Diffuse axonal injury is a common pathological consequence of Traumatic Brain Injury (TBI). Diffusion Tensor Imaging is an ideal technique to study white matter integrity using the Fractional Anisotropy (FA) index which is a measure of axonal integrity and coherence. There have been several reports showing reduced FA in individuals with TBI, which suggest demyelination or reduced fiber density in white matter tracts secondary to injury. Individuals with TBI are usually diagnosed with cognitive deficits such as reduced attention span, memory and executive function. In this study we sought to investigate correlations between brain functional networks, white matter integrity, and TBI severity in individuals with TBI ranging from mild to severe. A resting state functional magnetic resonance imaging protocol was used to study the default mode network in subjects at rest. FA values were decreased throughout all white matter tracts in the mild to severe TBI subjects. FA values were also negatively correlated with TBI injury severity ratings. The default mode network showed several brain regions in which connectivity measures were higher among individuals with TBI relative to control subjects. These findings suggest that, subsequent to TBI, the brain may undergo adaptation responses at the cellular level to compensate for functional impairment due to axonal injury. C1 [Tang, Cheuk Ying; Eaves, Emily; Leung, Eric; Wong, Edmund; Carpenter, David; Ng, Johnny] Mt Sinai Sch Med, Dept Radiol, New York, NY 10029 USA. [Tang, Cheuk Ying; Pasinetti, Giulio] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [Pasinetti, Giulio] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Tang, CY (reprint author), Mt Sinai Sch Med, Dept Radiol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1RR029887] FX The study was supported by discretionary funding to GMP and Grant Number #UL1RR029887, National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The authors would also like to thank the Image Analysis Core of the Mount Sinai Translational and Molecular Imaging Institute. NR 38 TC 18 Z9 20 U1 1 U2 11 PU VERSITA PI WARSAW PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND SN 2081-3856 J9 TRANSL NEUROSCI JI Transl. Neurosci. PD MAR PY 2012 VL 3 IS 1 BP 9 EP 14 DI 10.2478/s13380-012-0003-3 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 951CN UT WOS:000304698400002 PM 23459252 ER PT J AU Duong, TQ AF Duong, Timothy Q. TI Multimodal MRI of Experimental Stroke SO TRANSLATIONAL STROKE RESEARCH LA English DT Review DE MRI; Perfusion-diffusion mismatch; ADC; CBF; DWI; PWI; Experimental stroke model; Rodents; Oxygen challenge; Predictive mode; Magnetic resonance imaging; Rats; Hyperperfusion; fMRI ID CEREBRAL-BLOOD-FLOW; ISCHEMIC TISSUE-FATE; APPARENT DIFFUSION-COEFFICIENT; QUANTITATIVE PERFUSION; POSTISCHEMIC HYPERPERFUSION; PLASMINOGEN ACTIVATOR; ARTERY OCCLUSION; FOCAL ISCHEMIA; BRAIN-INJURY; RAT-BRAIN AB Stroke is the fourth leading cause of death and the leading cause of long-term disability in USA. Brain imaging data from experimental stroke models and stroke patients have shown that there is often a gradual progression of potentially reversible ischemic injury toward infarction. Reestablishing tissue perfusion and/or treating with neuroprotective drugs in a timely fashion are expected to salvage some ischemic tissues. Diffusion-weighted imaging based on magnetic resonance imaging (MRI) in which contrast is based on water motion can detect ischemic injury within minutes after onsets, whereas computed tomography and other imaging modalities fail to detect stroke injury for at least a few hours. Along with quantitative perfusion imaging, the perfusion-diffusion mismatch which approximates the ischemic penumbra could be imaged noninvasively. This review describes recent progresses in the development and application of multimodal MRI and image analysis techniques to study ischemic tissue at risk in experimental stroke in rats. C1 [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Physiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] Dept Vet Affairs, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Duong, Timothy Q.] SW Fdn Biomed Res, SW Natl Primate Res Ctr, San Antonio, TX 78284 USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, Dept Ophthalmol, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Duong, Timothy/B-8525-2008 FU NINDS NIH HHS [R01 NS045879] NR 67 TC 5 Z9 5 U1 1 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 J9 TRANSL STROKE RES JI Transl. Stroke Res. PD MAR PY 2012 VL 3 IS 1 SI SI BP 8 EP 15 DI 10.1007/s12975-011-0140-y PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 943YP UT WOS:000304164300003 PM 24323751 ER PT J AU Wang, TY Mancuso, JJ Sapozhnikova, V Dwelle, J Ma, LL Willsey, B Kazmi, SMS Qiu, JZ Li, XK Asmis, R Johnston, KP Feldman, MD Milner, TE AF Wang, Tianyi Mancuso, J. Jacob Sapozhnikova, Veronika Dwelle, Jordan Ma, Li L. Willsey, Brian Kazmi, S. M. Shams Qiu, Jinze Li, Xiankai Asmis, Reto Johnston, Keith P. Feldman, Marc D. Milner, Thomas E. TI Dual-wavelength multifrequency photothermal wave imaging combined with optical coherence tomography for macrophage and lipid detection in atherosclerotic plaques using gold nanoparticles SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE atherosclerosis; macrophage; lipid; nanorose; photothermal wave imaging; optical coherence tomography; two-photon luminescence microscopy ID CENTRAL-NERVOUS-SYSTEM; IRON-OXIDE; MAGNETIC-RESONANCE; CORONARY PLAQUE; IN-VITRO; CELLS; EXPRESSION; INFLAMMATION; MICROSCOPY; RUPTURE AB The objective of this study was to assess the ability of combined photothermal wave (PTW) imaging and optical coherence tomography (OCT) to detect, and further characterize the distribution of macrophages (having taken up plasmonic gold nanorose as a contrast agent) and lipid deposits in atherosclerotic plaques. Aortas with atherosclerotic plaques were harvested from nine male New Zealand white rabbits divided into nanorose- and saline-injected groups and were imaged by dual-wavelength (800 and 1210 nm) multifrequency (0.1, 1 and 4 Hz) PTW imaging in combination with OCT. Amplitude PTW images suggest that lateral and depth distribution of nanorose-loaded macrophages (confirmed by two-photon luminescence microscopy and RAM-11 macrophage stain) and lipid deposits can be identified at selected modulation frequencies. Radiometric temperature increase and modulation amplitude of superficial nanoroses in response to 4 Hz laser irradiation (800 nm) were significantly higher than native plaque (P < 0.001). Amplitude PTW images (4 Hz) were merged into a coregistered OCT image, suggesting that superficial nanorose-loaded macrophages are distributed at shoulders on the upstream side of atherosclerotic plaques (P < 0.001) at edges of lipid deposits. Results suggest that combined PTW-OCT imaging can simultaneously reveal plaque structure and composition, permitting characterization of nanorose-loaded macrophages and lipid deposits in atherosclerotic plaques. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.3.036009] C1 [Wang, Tianyi; Dwelle, Jordan; Kazmi, S. M. Shams; Qiu, Jinze; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Ma, Li L.; Willsey, Brian; Johnston, Keith P.] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA. [Mancuso, J. Jacob; Sapozhnikova, Veronika; Li, Xiankai; Asmis, Reto; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Milner, TE (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn,C0800, Austin, TX 78712 USA. EM terra.laser@gmail.com RI Qiu, Jinze /I-2272-2013 OI Qiu, Jinze /0000-0001-8466-1460 FU Veterans Administration; Welch Foundation [F-1319]; NSF [CBET-0968038]; Department of Energy Center for Frontiers of Subsurface Energy Security FX The authors would like to acknowledge the technical support from the University of Texas Health Science Center at San Antonio. This work was supported by a Veterans Administration merit grant to Feldman, a Welch Foundation grant F-1319 and NSF grant CBET-0968038 to Johnston, and the Department of Energy Center for Frontiers of Subsurface Energy Security. NR 59 TC 6 Z9 6 U1 1 U2 12 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD MAR PY 2012 VL 17 IS 3 AR 036009 DI 10.1117/1.JBO.17.3.036009 PG 10 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 937XJ UT WOS:000303697000016 PM 22502567 ER PT J AU Ren, XF Akiyoshi, K Grafe, MR Vandenbark, AA Hurn, PD Herson, PS Offner, H AF Ren, Xuefang Akiyoshi, Kozaburo Grafe, Marjorie R. Vandenbark, Arthur A. Hurn, Patricia D. Herson, Paco S. Offner, Halina TI Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity SO METABOLIC BRAIN DISEASE LA English DT Article DE Experimental stroke; Myelin reactive splenocytes; Inflammatory responses; Neurologic deficit ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MURINE EXPERIMENTAL STROKE; FOCAL CEREBRAL-ISCHEMIA; GROWTH-FACTOR-BETA; BASIC-PROTEIN; T-CELLS; MULTIPLE-SCLEROSIS; IMMUNE PRIVILEGE; IMMUNOLOGICAL-TOLERANCE AB Although inflammatory responses increase stroke severity, the role of immune cells specific for central nervous system (CNS) antigens remains controversial. Disruption of the blood-brain barrier (BBB) during stroke allows CNS antigens to leak into the peripheral circulation and enhances access of circulating leukocytes to the brain, including those specific for CNS antigens such as myelin oligodendrocyte glycoprotein (MOG) that can induce experimental autoimmune encephalomyelitis (EAE). We here demonstrate for the first time that myelin reactive splenocytes specific for MOG transferred into severe combined immunodeficient (SCID) mice can migrate into the infarct hemisphere of recipients subjected to 60 min middle cerebral artery occlusion (MCAO) and 96 h reperfusion; moreover these cells exacerbate infarct volume and worsen neurological deficits compared to animals transferred with naive splenocytes. These findings indicate that autoimmunity in the CNS can exert detrimental injury on brain cells and worsen the damage from ischemic stroke. C1 [Ren, Xuefang; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR 97239 USA. [Grafe, Marjorie R.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Dept Vet Affairs Med Ctr, Res Serv, Portland, OR USA. [Ren, Xuefang; Akiyoshi, Kozaburo; Grafe, Marjorie R.; Herson, Paco S.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Hurn, Patricia D.] Univ Texas Syst, Off Hlth Affairs, Austin, TX USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NR03521, NS49210]; Collins Medical Trust; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX We thank Dr. Heng Hu, Dr. Sushmita Sinha, Dr. Sheetal Bodhankar, Dr. Suzan Dziennis, Dr. Takeru Shimizu and Ms. Sandhya Subramanian for helpful discussions; Ms. Xiao Jing Nie for performing histological staining and Ms. Lisa Miller for help with experiments; and Ms. Eva Niehaus for assistance in preparing the manuscript. This work was supported by NIH Grants NR03521 (PDH), NS49210 (PDH) and the Collins Medical Trust (XR). This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 44 TC 16 Z9 16 U1 0 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD MAR PY 2012 VL 27 IS 1 BP 7 EP 15 DI 10.1007/s11011-011-9267-5 PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 940BM UT WOS:000303865000002 PM 21989743 ER PT J AU Xin, JP Fargo, KN Tanzer, L Sanders, VM Jones, KJ AF Xin, Junping Fargo, Keith N. Tanzer, Lisa Sanders, Virginia M. Jones, Kathryn J. TI Immune cell-mediated neuroprotection is independent of estrogen action through estrogen receptor-alpha SO METABOLIC BRAIN DISEASE LA English DT Article DE Estrogen; CD4(+) T cell; Facial motoneuron; Axotomy; Neuroprotection ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REGULATORY T-CELLS; FACIAL MOTONEURON SURVIVAL; NERVE TRANSECTION; EXPRESSION; TESTOSTERONE; AXOTOMY; MICE; LYMPHOCYTES; CNS AB It has been well documented that both estrogen and immune cells (CD4(+) T cells) mediate neuroprotection in the mouse facial nerve axotomy model. Estrogen has been shown to play an important role in regulating the immune response. However, it is unclear whether immune cell-mediated neuroprotection is dependent on estrogen signaling. In this study, using FACS staining, we confirmed that the majority of CD4(+) T cells express high levels of estrogen receptor-alpha (ER alpha), suggesting that CD4(+) T cell-mediated neuroprotection may be modulated by estrogen signaling. We previously found that immunodeficient Rag-2KO mice showed a significant increase in axotomy-induced facial motoneuron death compared to immunocompetent wild-type mice. Therefore, we investigated axotomy-induced facial motoneuron loss in immunodeficient Rag-2KO mice that received 17 beta-estradiol treatment or adoptive transfer of immune cells from mice lacking functional ER alpha. Our results indicate that while estradiol treatment failed to rescue facial motoneurons from axotomy-induced cell death in Rag-2KO mice, immune cells lacking ERa successfully restored facial motoneuron survival in Rag-2 KO mice to a wild-type level. Collectively, we concluded that CD4(+) T cell-mediated neuroprotection is independent of estrogen action through ERa. C1 [Xin, Junping; Fargo, Keith N.; Tanzer, Lisa] Loyola Univ, Med Ctr, Inst Neurosci, Maywood, IL 60153 USA. [Xin, Junping; Fargo, Keith N.; Tanzer, Lisa] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. [Sanders, Virginia M.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Jones, Kathryn J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. RP Xin, JP (reprint author), Loyola Univ, Med Ctr, Inst Neurosci, 2160 S 1st Ave, Maywood, IL 60153 USA. EM neuroimmune@gmail.com FU National Institutes of Health [NS40433]; VA [RRD CDA-2 B6598-W]; Muscular Dystrophy Association [MDA202906] FX K.J.J. and V.M.S. were supported by National Institutes of Health grant NS40433, and K.N.F. was supported by VA grant RR&D CDA-2 B6598-W. J.X. was supported by Muscular Dystrophy Association grant (MDA202906). We thank Tom Alexander for technical support, as well as Linda Poggensee and Dr. Nichole Mesnard for their editorial assistance. NR 40 TC 1 Z9 2 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD MAR PY 2012 VL 27 IS 1 BP 23 EP 28 DI 10.1007/s11011-011-9265-7 PG 6 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 940BM UT WOS:000303865000004 PM 21975535 ER PT J AU Subramanian, S Miller, LM Grafe, MR Vandenbark, AA Offner, H AF Subramanian, Sandhya Miller, Lisa M. Grafe, Marjorie R. Vandenbark, Arthur A. Offner, Halina TI Contribution of GPR30 for 1,25 dihydroxyvitamin D-3 protection in EAE SO METABOLIC BRAIN DISEASE LA English DT Article DE GPR30; EAE; 1,25 dihydroxyvitamin D-3; Estrogen ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; RECEPTOR; ACTIVATION; MICE AB Previous studies have demonstrated that vitamin D3-mediated protection in EAE occurs only in females and is dependent on the presence of diestrus levels of 17 beta-estradiol (E2). To evaluate the role of estrogen receptors in vitamin D3 treatment of EAE, we compared disease severity, CNS histopathology and immunological responses in vehicle and calcitrol (1,25 dihydroxyvitamin D-3) treated WT C57BL/6 mice vs. GPR30 membrane estrogen receptor (MER) knockout mice with MOG-35-55 peptide-induced EAE. Our results demonstrated that vitamin D-3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Regulatory effects of vitamin D-3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D-3-mediated protection in EAE. C1 [Subramanian, Sandhya; Miller, Lisa M.; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Portland, OR 97239 USA. [Miller, Lisa M.; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Grafe, Marjorie R.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Dept Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU National Multiple Sclerosis Society [RG3107-D-6]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Ms. Eva Niehaus for assistance in preparing the manuscript. This work was supported by National Multiple Sclerosis Society grant RG3107-D-6. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 22 TC 8 Z9 9 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD MAR PY 2012 VL 27 IS 1 BP 29 EP 35 DI 10.1007/s11011-011-9266-6 PG 7 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 940BM UT WOS:000303865000005 PM 21994003 ER PT J AU Taneja, R Bhargava, P Cuevas, C Dighe, MK AF Taneja, Ranu Bhargava, Puneet Cuevas, Carlos Dighe, Manjiri K. TI Common and Less-Common Renal Masses and Masslike Conditions SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Renal mass; Incidental renal mass; Genitourinary imaging; Kidney disease; Renal disease ID SOLITARY FIBROUS TUMOR; LYMPHOPLASMACYTIC SCLEROSING PANCREATITIS; UPPER URINARY-TRACT; IMAGING FINDINGS; CELL CARCINOMA; AUTOIMMUNE PANCREATITIS; PATHOLOGICAL CORRELATION; LYMPHOBLASTIC-LEUKEMIA; ACUTE PYELONEPHRITIS; MEDULLARY CARCINOMA AB As an increasing number of imaging examinations are performed, a greater number of incidental renal lesions are detected. Apart from the usual cysts and solid renal cell carcinomas, a variety of unusual benign and malignant renal lesions exist. Imaging is invaluable in characterizing these lesions and is confirmatory in some benign lesions. Renal cell carcinoma remains the diagnosis of exclusion; however, assessment of the imaging pattern in the appropriate clinical context can improve diagnostic accuracy. The objective of this article is to familiarize the radiologist with the imaging appearance of unusual non-neoplastic and neoplastic lesions and correlate with histopathologic studies when available. C1 [Bhargava, Puneet] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Taneja, Ranu] Changi Gen Hosp, Dept Radiol, Singapore 529889, Singapore. [Cuevas, Carlos; Dighe, Manjiri K.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Radiol, Mail Box 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 57 TC 1 Z9 1 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAR PY 2012 VL 50 IS 2 BP 245 EP + DI 10.1016/j.rcl.2012.02.006 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 941HW UT WOS:000303955300005 PM 22498441 ER PT J AU Bhargava, P Dighe, MK Lee, JH Wang, C AF Bhargava, Puneet Dighe, Manjiri K. Lee, Jean Hwa Wang, Carolyn TI Multimodality Imaging of Ureteric Disease SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Ureter; Imaging; Transitional cell carcinoma; Calculi; Urography ID TRANSITIONAL-CELL CARCINOMA; UNENHANCED HELICAL CT; UPPER URINARY-TRACT; URETEROPELVIC JUNCTION OBSTRUCTION; MAGNETIC-RESONANCE UROGRAPHY; SHOT INTRAVENOUS PYELOGRAM; UNSTABLE TRAUMA PATIENTS; RETROPERITONEAL FIBROSIS; VOIDING CYSTOURETHROGRAPHY; COMPUTED-TOMOGRAPHY AB The proximal ureter (upper) extends from the ureteropelvic junction to where the ureter crosses the sacroiliac joint, the middle ureter courses over the bony pelvis and iliac vessels, and the distal or pelvic (lower) ureter extends from the iliac vessels to the bladder. Benign and malignant lesions can affect the ureter and these may be caused by contiguous involvement from the kidney or bladder. The ureter can be imaged by computed tomography; magnetic resonance imaging; direct pyelography, both antegrade and retrograde; nuclear medicine diuretic scan; and voiding cystourethrography. This article discusses benign, malignant, neoplastic, nonneoplastic processes involving the ureter. C1 [Dighe, Manjiri K.; Lee, Jean Hwa; Wang, Carolyn] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. RP Dighe, MK (reprint author), Univ Washington, Med Ctr, Dept Radiol, Box 357115,1959 NE Pacific St, Seattle, WA 98195 USA. EM dighe@u.washington.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 117 TC 1 Z9 1 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAR PY 2012 VL 50 IS 2 BP 271 EP + DI 10.1016/j.rcl.2012.02.008 PG 30 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 941HW UT WOS:000303955300007 PM 22498443 ER PT J AU Mirochnik, B Bhargava, P Dighe, MK Kanth, N AF Mirochnik, Brandon Bhargava, Puneet Dighe, Manjiri K. Kanth, Nalini TI Ultrasound Evaluation of Scrotal Pathology SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Ultrasound; Testis; Scrotum imaging; Scrotal imaging; Torsion; Orchitis ID COLOR DOPPLER SONOGRAPHY; TESTICULAR EPIDERMOID CYSTS; RETE TESTIS; TUNICA ALBUGINEA; TUBULAR ECTASIA; GRAY-SCALE; DIAGNOSIS; TRAUMA; LYMPHOMA; APPEARANCE AB Palpable scrotal mass, acute scrotal pain, and enlarged scrotum are common scenarios in clinical practice. The imaging modality of choice to evaluate scrotal pathology is ultrasound (US). US is key in determining if a palpable abnormality is extratesticular or intratesticular and cystic or solid. US findings help narrow the differential to benign or malignant causes. Extratesticular lesions are more common and usually benign. Rarely, extratesticular solid lesions are malignant but US features are nonspecific. Accurately diagnosing rare benign intratesticular lesions is vital to avoid unnecessary orchiectomy. This article reviews extratesticular and intratesticular lesions presenting as a palpable mass and other conditions commonly seen. C1 [Bhargava, Puneet] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Mirochnik, Brandon; Kanth, Nalini] Nassau Univ, Med Ctr, Dept Radiol, E Meadow, NY 11554 USA. [Dighe, Manjiri K.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. RP Bhargava, P (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Radiol, Mail Box 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 49 TC 15 Z9 16 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAR PY 2012 VL 50 IS 2 BP 317 EP + DI 10.1016/j.rcl.2012.02.005 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 941HW UT WOS:000303955300009 PM 22498445 ER PT J AU Ruggiero, KJ Gros, K McCauley, JL Resnick, HS Morgan, M Kilpatrick, DG Muzzy, W Acierno, R AF Ruggiero, Kenneth J. Gros, Kirstin McCauley, Jenna L. Resnick, Heidi S. Morgan, Mark Kilpatrick, Dean G. Muzzy, Wendy Acierno, Ron TI Mental Health Outcomes Among Adults in Galveston and Chambers Counties After Hurricane Ike SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE disaster mental health; Hurricane Ike; resilience; recovery ID POSTTRAUMATIC-STRESS-DISORDER; PREVALENCE; DISASTER; COMORBIDITY; ILLNESS; KATRINA; TEXAS; PTSD AB Objective: To examine the mental health effects of Hurricane Ike, the third costliest hurricane in US history, which devastated the upper Texas coast in September 2008. Method: Structured telephone interviews assessing immediate effects of Hurricane Ike (damage, loss, displacement) and mental health diagnoses were administered via random digit-dial methods to a household probability sample of 255 Hurricane Ike-affected adults in Galveston and Chambers counties. Results: Three-fourths of respondents evacuated the area because of Hurricane Ike and nearly 40% were displaced for at least one week. Postdisaster mental health prevalence estimates were 5.9% for posttraumatic stress disorder, 4.5% for major depressive episode, and 9.3% for generalized anxiety disorder. Bivariate analyses suggested that peritraumatic indicators of hurricane exposure severity-such as lack of adequate clean clothing, electricity, food, money, transportation, or water for at least one week-were most consistently associated with mental health problems. Conclusions: The significant contribution of factors such as loss of housing, financial means, clothing, food, and water to the development and/or maintenance of negative mental health consequences highlights the importance of systemic postdisaster intervention resources targeted to meet basic needs in the postdisaster period. (Disaster Med Public Health Preparedness. 2012;6:26-32) C1 [Ruggiero, Kenneth J.; Gros, Kirstin; McCauley, Jenna L.; Resnick, Heidi S.; Kilpatrick, Dean G.; Muzzy, Wendy; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Morgan, Mark] Abt SRBI, New York, NY USA. RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. EM ruggierk@musc.edu FU National Institute of Mental Health (NIMH) [R34 MH77149] FX This study was supported by National Institute of Mental Health (NIMH) grant R34 MH77149 (Dr Ruggiero). NR 29 TC 11 Z9 11 U1 7 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD MAR PY 2012 VL 6 IS 1 BP 26 EP 32 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 925SO UT WOS:000302781800006 PM 22490934 ER PT J AU Wray, LO Szymanski, BR Kearney, LK McCarthy, JF AF Wray, Laura O. Szymanski, Benjamin R. Kearney, Lisa K. McCarthy, John F. TI Implementation of Primary Care-Mental Health Integration Services in the Veterans Health Administration: Program Activity and Associations with Engagement in Specialty Mental Health Services SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS LA English DT Article DE Primary care; Mental health; Engagement; Veterans ID RISK ALCOHOL-USE; COLLABORATIVE CARE; RANDOMIZED-TRIAL; TERM OUTCOMES; REFERRAL CARE; OLDER-ADULTS; PRISM-E; DEPRESSION; MANAGEMENT; SYSTEM AB This paper describes the status of the Veterans Health Administration (VHA) Primary Care-Mental Health Integration (PC-MHI) services implementation and presents an assessment of associations between receipt of PC-MHI services and likelihood of receiving a second specialty mental health (SMH) appointment following an initial SMH encounter. The total PC-MHI service recipients and encounters/month rose substantially between October 2007 and April 2011. Adjusting for important covariates, the likelihood of receiving a second SMH encounter within 3 months of an index SMH appointment was 1.37 times greater among individuals who had received a PC-MHI encounter within 3 months of the initial SMH appointment. Implementation of VHA PC-MHI services has substantially increased VHA capacity to deliver mental health services in primary care and findings indicate that PC-MHI services are associated with greater engagement in SMH treatment. Implementation of VHA PC-MHI services is progressing with new technical assistance strategies being deployed. C1 [Wray, Laura O.] US Dept Vet Affairs, Ctr Integrated Healthcare, Buffalo, NY 14215 USA. [Wray, Laura O.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY 14260 USA. [Szymanski, Benjamin R.; McCarthy, John F.] US Dept Vet Affairs, Off Mental Hlth Operat, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor, MI USA. [Kearney, Lisa K.] US Dept Vet Affairs, Off Mental Hlth Operat, Washington, DC USA. [Kearney, Lisa K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [McCarthy, John F.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. RP Wray, LO (reprint author), US Dept Vet Affairs, Ctr Integrated Healthcare, VAWNYHS 116 N,3495 Bailey Ave, Buffalo, NY 14215 USA. EM Laura.wray@va.gov NR 41 TC 36 Z9 36 U1 2 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9583 J9 J CLIN PSYCHOL MED S JI J. Clin. Psychol. Med. Settings PD MAR PY 2012 VL 19 IS 1 BP 105 EP 116 DI 10.1007/s10880-011-9285-9 PG 12 WC Psychology, Clinical SC Psychology GA 925PC UT WOS:000302772300012 PM 22383016 ER PT J AU Gruenewald, DA AF Gruenewald, David A. TI Can Health Care Rationing Ever Be Rational? SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article ID DECISION-MAKING; MEDICAL-CARE; END; AGE; INFORMATION; CANCER; PHYSICIANS; REFORM; OLDER AB Americans' appetite for life-prolonging therapies has led to unsustainable growth in health care costs. It is tempting to target older people for health care rationing based on their disproportionate use of health care resources and lifespan already lived, but aged-based rationing is unacceptable to many. Systems reforms can improve the efficiency of health care and may lessen pressure to ration services, but difficult choices still must be made to limit expensive, marginally beneficial interventions. In the absence of agreement on principles to govern health care resource allocation, a fair, open priority-setting process should be created to allow for reasonable disagreement on principles while being seen as legitimate by all stakeholders. At the patient-care level, careful discussions about the benefits and burdens of medical intervention and support for slow medicine a gentle, family-centered care approach for frail elders can do much to avoid harming these patients with aggressive yet unwanted medical care while reducing wasteful spending. C1 [Gruenewald, David A.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Gruenewald, David A.] VA Puget Sound Hlth Care Syst, Palliat Care & Hosp Serv, Seattle, WA USA. RP Gruenewald, DA (reprint author), Univ Washington, Sch Med, Seattle, WA 98195 USA. RI Embrett, Mark/H-4466-2014 OI Embrett, Mark/0000-0002-3969-0219 NR 42 TC 8 Z9 8 U1 0 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1073-1105 J9 J LAW MED ETHICS JI J. Law Med. Ethics PD SPR PY 2012 VL 40 IS 1 BP 17 EP 25 DI 10.1111/j.1748-720X.2012.00641.x PG 9 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA 915ZB UT WOS:000302065100003 PM 22458458 ER PT J AU Chambliss, WG Carroll, WA Kennedy, D Levine, D Mone, MA Ried, LD Shepherd, M Yelvigi, M AF Chambliss, Walter G. Carroll, Wesley A. Kennedy, Daniel Levine, Donald Mone, Michael A. Ried, L. Douglas Shepherd, Marv Yelvigi, Mukund TI Role of the pharmacist in preventing distribution of counterfeit medications SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Editorial Material DE Counterfeiting (drug); drug products; technology; pedigree AB Objective: To provide an overview of the counterfeit medication problem and recommendations of a joint American Pharmacists Association (APhA) Academy of Pharmaceutical Research and Science and APhA Academy of Pharmacy Practice and Management taskforce. Date sources: SciFinder and PubMed were searched from 1980 to March 2011 using the following keywords: counterfeit drug product, counterfeit medications, drug product authentication, drug product verification, and track-and-trace. Publications, presentations, and websites of organizations that research the counterfeit medication problem in the United States and other countries were reviewed. A representative from the security division of a pharmaceutical manufacturer and a representative from a supplier of anticounterfeiting technologies gave presentations to the taskforce. Summary: The taskforce recommends that pharmacists (1) purchase medications from known, reliable sources; (2) warn patients of the dangers of purchasing medications over the Internet; (3) confirm with distributors that products were purchased from manufacturers or other reliable sources; (4) monitor counterfeit product alerts; (5) examine products for suspicious appearance; (6) work with the pharmaceutical industry, distributors, and the Food and Drug Administration (FDA) to close gaps in the supply chain, especially for drugs in short supply; (7) use scanning technology in the pharmacy as part of a prescription verification process; (8) educate themselves, coworkers, and patients about the risks of counterfeit medications; and (9) report suspicious medications to FDA, the distributor, and the manufacturer. Conclusion: The consequence of a patient receiving a counterfeit medication in the United States could be catastrophic, and pharmacists must play an active role in preventing such an event from occurring. C1 [Chambliss, Walter G.] Univ Mississippi, Sch Pharm, Pharmaceut Sci Res Inst, University, MS 38677 USA. [Carroll, Wesley A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kennedy, Daniel] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levine, Donald] Merck Consumer Care, World Wide Clin Supply, Memphis, TN USA. [Mone, Michael A.] Cardinal Hlth, Supply Chain Integr & Senior Regulatory Counsel, Qual & Regulatory Affairs, Dublin, OH USA. [Ried, L. Douglas] Univ S Florida, Coll Pharm, Tampa, FL USA. [Shepherd, Marv] Univ Texas Austin, Coll Pharm, Ctr Pharmacoecon Studies, Austin, TX 78712 USA. [Yelvigi, Mukund] Pfizer Inc, Clin Supply Chain Management, New York, NY USA. RP Chambliss, WG (reprint author), Univ Mississippi, Sch Pharm, Pharmaceut Sci Res Inst, 100 Barr Hall, University, MS 38677 USA. EM wchambli@olemiss.edu NR 24 TC 3 Z9 3 U1 1 U2 15 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD MAR-APR PY 2012 VL 52 IS 2 BP 195 EP 199 DI 10.1331/JAPhA.2012.11085 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 927AS UT WOS:000302877900011 PM 22370383 ER PT J AU Eshghi, A Pinne, M Haake, DA Zuerner, RL Frank, A Cameron, CE AF Eshghi, Azad Pinne, Marija Haake, David A. Zuerner, Richard L. Frank, Ami Cameron, Caroline E. TI Methylation and in vivo expression of the surface-exposed Leptospira interrogans outer-membrane protein OmpL32 SO MICROBIOLOGY-SGM LA English DT Article ID SECONDARY STRUCTURE PREDICTION; HEPARIN-BINDING HEMAGGLUTININ; ESCHERICHIA-COLI; PATHOGENIC LEPTOSPIRA; RICKETTSIA-PROWAZEKII; BACTERIAL CHEMOTAXIS; PROTEOMIC ANALYSIS; RELEASE FACTORS; VIRULENCE; IDENTIFICATION AB Recent studies have revealed that bacterial protein methylation is a widespread post-translational modification that is required for virulence in selected pathogenic bacteria. In particular, altered methylation of outer-membrane proteins has been shown to modulate the effectiveness of the host immune response. In this study, 2D gel electrophoresis combined with MALDI-TOF MS identified a Leptospira interrogans serovar Copenhageni strain Fiocruz L1-130 protein, corresponding to ORF LIC11848, which undergoes extensive and differential methylation of glutamic acid residues. Immunofluorescence microscopy implicated LIC11848 as a surface-exposed outer-membrane protein, prompting the designation OmpL32. Indirect immunofluorescence microscopy of golden Syrian hamster liver and kidney sections revealed expression of OmpL32 during colonization of these organs. Identification of methylated surface-exposed outer-membrane proteins, such as OmpL32, provides a foundation for delineating the role of this post-translational modification in leptospiral virulence. C1 [Eshghi, Azad; Cameron, Caroline E.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. [Pinne, Marija] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Pinne, Marija; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Zuerner, Richard L.; Frank, Ami] ARS, Infect Bacterial Dis Res Unit, NADC, USDA, Ames, IA USA. RP Cameron, CE (reprint author), Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. EM caroc@uvic.ca FU University of Victoria; Pacific Century Graduate Scholarship; Natural Sciences and Engineering Research Council of Canada [327186]; British Columbia Proteomics Network; Canada Foundation for Innovation; British Columbia Knowledge Development Fund; VA; Public Health Service from the National Institute of Allergy and Infectious Diseases [AI-034431] FX The authors would like to thank Dr Martin Boulanger, University of Victoria, Victoria, BC, Canada, for his gift of the pET28a vector and assistance with construct design, Anna von Rossum and Marcus Barron for assistance with recombinant protein production, and Dr Christoph Borchers, Derek Smith, Jen Proc, Leanne Ohlund, Darryl Hardie and the members of the University of Victoria-Genome BC Proteomics Centre for their support and guidance with the proteomic analyses. This work was supported by a University of Victoria Fellowship, Graduate Scholarship and the Pacific Century Graduate Scholarship (A. E.), a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (327186; C. E. C.), the British Columbia Proteomics Network (C. E. C.), the Canada Foundation for Innovation (C. E. C.), the British Columbia Knowledge Development Fund (C. E. C.), VA Medical Research Funds (D. A. H.), and Public Health Service grant AI-034431 (D. A. H.) from the National Institute of Allergy and Infectious Diseases. C. E. C. is a Canada Research Chair in Molecular Pathogenesis and a Michael Smith Foundation for Health Research Scholar. NR 71 TC 11 Z9 11 U1 3 U2 18 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1350-0872 J9 MICROBIOL-SGM JI Microbiology-(UK) PD MAR PY 2012 VL 158 BP 622 EP 635 DI 10.1099/mic.0.054767-0 PN 3 PG 14 WC Microbiology SC Microbiology GA 926II UT WOS:000302824100004 PM 22174381 ER PT J AU Bishehsari, F Sharma, A Stello, K Toth, C O'Connell, MR Evans, AC LaRusch, J Muddana, V Papachristou, GI Whitcomb, DC AF Bishehsari, Faraz Sharma, Arun Stello, Kimberly Toth, Chad O'Connell, Michael Richard Evans, Anna C. LaRusch, Jessica Muddana, Venkata Papachristou, Georgios I. Whitcomb, David C. TI TNF-alpha gene (TNFA) variants increase risk for multi-organ dysfunction syndrome (MODS) in acute pancreatitis SO PANCREATOLOGY LA English DT Article DE Ystemic inflammatory response syndrome (SIRS); Genetic epidemiology; Shock; Modeling; Pancreas ID TUMOR-NECROSIS-FACTOR; INFLAMMATORY RESPONSE SYNDROME; CYTOKINE CASCADE PROGRESSION; SMALL-MOLECULE INHIBITION; PROMOTER POLYMORPHISM; 5'-FLANKING REGION; CYSTIC-FIBROSIS; UNITED-STATES; SEVERITY; ASSOCIATION AB Background/Objectives: Acute pancreatitis (AP) is a complex inflammatory syndrome with unpredictable progression to systemic inflammation and multi-organ dysfunction syndrome (MODS). Tumor necrosis factor alpha (TNF-alpha) is a cytokine that may link inflammation to the systemic inflammatory response syndrome (SIRS), which usually precedes MODS. Small genetic cohort studies of the TNFA promoter in AP produced ambiguous results. We performed a comprehensive evaluation of TNFA promoter variants to assess both susceptibility to AP and risk of progression to MODS. Methods: We prospectively ascertained 401 controls and 211 patients with AP that were assessed for persistent SIRS (>48 h) and MODS. MODS was defined as failure of >= 2 organ systems (cardiovascular, pulmonary, and/or renal) persisting more than 48 h. Subjects were genotyped by DNA sequencing and analyzed for SNPs at -1031 C/T (rs1799964), -863 A/C (rs1800630), -857 C/T (rs1799724), -308 A/C (rs1800629), and -238 A/C (r5361525). Results: Twenty-three of 211 AP patients (11%) developed MODS. TNFA promoter variants were not associated with susceptibility to AP. but progression to MODS was associated with the minor allele at -1031C (56.5% vs. 32.4% P = 0.022, OR: 2.7: 95%CI: 1.12-6.51) and -863A (43.5% vs. 21.8% P = 0.022, OR: 2.76: 95%CI: 1.12-6.74). Conclusion: TNFA promoter variants do not alter susceptibility to AP, but rather the TNF-alpha expression-enhancing -1031C and -863A alleles significantly increased the risk of AP progression to MODS. These data, within the context of previous studies, clarify the risk of specific genetic variants in TNFA and therefore the role of TNF-alpha in the overall AP syndrome. Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. C1 [Bishehsari, Faraz; Stello, Kimberly; Toth, Chad; O'Connell, Michael Richard; LaRusch, Jessica; Muddana, Venkata; Papachristou, Georgios I.; Whitcomb, David C.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. [Whitcomb, David C.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15213 USA. [Whitcomb, David C.] Univ Pittsburgh, Dept Physiol, Pittsburgh, PA 15213 USA. [Bishehsari, Faraz; Stello, Kimberly; Toth, Chad; O'Connell, Michael Richard; LaRusch, Jessica; Muddana, Venkata; Papachristou, Georgios I.; Whitcomb, David C.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA. [Sharma, Arun; Evans, Anna C.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Papachristou, Georgios I.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. RP Whitcomb, DC (reprint author), UPMC Gastroenterol Hepatol & Nutr Adm, Room 401-4,3708 5th Ave, Pittsburgh, PA 15213 USA. EM whitcomb@pitt.edu FU Medical Student Research Training (MSRT [T32DK063922]; [R01 DK061451] FX The authors gratefully acknowledge the critical review of M Michael Barmada PhD and the editorial assistance of Michelle Kienholz. Arun Sharma was supported by Medical Student Research Training (MSRT) supplement to T32DK063922 (DCW). Jessica LaRusch PhD was supported by T32DK063922 (DCW). Genotyping was supported by R01 DK061451 (DCW). This project used the University of Pittsburgh Genomics and Proteomics Core Laboratory (UL1 RR024153) and the UPCI Clinical Genomics Immunoproteomics and Sequencing Facility (NIH P30CA047904). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH. NR 41 TC 12 Z9 15 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PD MAR-APR PY 2012 VL 12 IS 2 BP 113 EP 118 DI 10.1016/j.pan.2012.02.014 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 929NY UT WOS:000303073800006 PM 22487520 ER PT J AU Morabia, A Zhang, FF Kappil, MA Flory, J Mirer, FE Santella, RM Wolff, M Markowitz, SB AF Morabia, Alfredo Zhang, Fang Fang Kappil, Maya A. Flory, Janine Mirer, Frank E. Santella, Regina M. Wolff, Mary Markowitz, Steven B. TI Biologic and epigenetic impact of commuting to work by car or using public transportation: A case-control study SO PREVENTIVE MEDICINE LA English DT Article DE Transportation; Physical activity; Inflammation; Epigenetic ID C-REACTIVE PROTEIN; PARTICULATE AIR-POLLUTION; GENOMIC DNA METHYLATION; CANCER-FREE POPULATION; PHYSICAL-ACTIVITY; INFLAMMATORY MARKERS; ELDERLY SUBJECTS; BLOOD MARKERS; TRANSIT; OBESITY AB Background and aims. Commuting by public transportation (PT) entails more physical activity and energy expenditure than by cars, but its biologic consequences are unknown. Methods. In 2009-2010, we randomly sampled New York adults, usually commuting either by car (n =79) or PT (n = 101). Measures comprised diet and physical activity questionnaires, weight and height, white blood cell (WBC) count, C reactive protein, (CRP) gene-specific methylation (IL-6), and global genomic DNA methylation (LINE-1 methylation). Results. Compared to the 101 PT commuters, the 79 car drivers were about 9 years older, 2 kg/m(2) heavier, more often non-Hispanic whites, and ate more fruits and more meats. The 2005 guidelines for physical activity were met by more car drivers than PT users (78.5% vs. 65.0%). There were no differences in median levels of CRP (car vs. PT: 0.6 vs. 0.5 mg/dl), mean levels of WBC (car vs. PT: 6.7 vs. 6.5 cells/mm(3)), LINE-1 methylation (car vs. PT: 78.0% vs. 78.3%), and promoter methylation of IL-6 (car vs. PT: 56.1% vs. 58.0%). Conclusions. PT users were younger and lighter than car drivers, but their commute mode did not translate into a lower inflammatory response or a higher DNA methylation, maybe because, overall, car drivers were more physically active. (C) 2012 Elsevier Inc. All rights reserved. C1 [Morabia, Alfredo; Markowitz, Steven B.] CUNY, Queens Coll, Ctr Biol Nat Syst, Flushing, NY 11367 USA. [Morabia, Alfredo; Kappil, Maya A.; Santella, Regina M.] Columbia Univ, New York, NY USA. [Zhang, Fang Fang] Tufts Univ, Boston, MA 02111 USA. [Flory, Janine] James J Peters VA Med Ctr, Bronx, NY USA. [Mirer, Frank E.] CUNY, Hunter Coll, Flushing, NY 11367 USA. [Flory, Janine; Wolff, Mary] Mt Sinai Sch Med, New York, NY USA. RP Morabia, A (reprint author), CUNY, Queens Coll, Ctr Biol Nat Syst, 65-30 Kissena Blvd, Flushing, NY 11367 USA. EM alfredo.morabia@qc.cuny.edu OI , Maya/0000-0003-2913-2392 FU CUNY; NIEHS Center at Columbia University [1606]; University of North Texas Health Science Center School of Public Health FX This COMIR (Commuting Mode and Inflammatory Response) project received financial support from the CUNY Collaborative Incentive Research Grant (CIRG) program, round 16, number 1606, from the NIEHS Center ES009089 at Columbia University, and from the University of North Texas Health Science Center School of Public Health Seed Program. Results have been presented orally at the Meeting of the International Society for Environmental Epidemiology (ISEE, Barcelona, September 14, 2011). The authors thank Tashia Amstislavski and Steves Vanderpool for their help in the recruitment and data collection. NR 36 TC 7 Z9 7 U1 3 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR-APR PY 2012 VL 54 IS 3-4 BP 229 EP 233 DI 10.1016/j.ypmed.2012.01.019 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 923BL UT WOS:000302593000009 PM 22313796 ER PT J AU Nath, SB Wong, YLI Marcus, SC Solomon, P AF Nath, Sara Bressi Wong, Yin-Ling Irene Marcus, Steven C. Solomon, Phyllis TI Predictors of Health Services Utilization among Persons with Psychiatric Disabilities Engaged in Supported Independent Housing SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE health services utilization; psychiatric rehabilitation; case management; supported housing ID SERIOUS MENTAL-ILLNESS; MEDICAL-CARE; DISORDERS; SCHIZOPHRENIA; PEOPLE; ACCESS AB Objective: Persons with psychiatric disabilities are at greater risk for medical comorbidity, and prior research suggests these persons may underutilize health services. In response, this study examined the impact of engagement in psychiatric rehabilitation services, including case management, on utilization of general health services among persons with psychiatric disabilities engaged in supported housing, while controlling for demographic and clinical characteristics. Methods: Poisson regression analyses were used to examine the impact of socio-demographic, clinical, and service characteristics on reported utilization of general health services in the past year. Results: Findings indicated supported housing residents receiving case management coupled with weekly contact with residential support services visited a general health practitioner more frequently than those with less support services. Conclusions and Implications: Study results suggest psychiatric rehabilitation services provided to persons in the context of safe and affordable housing may represent an important mechanism for enabling persons with psychiatric disorders to access needed medical care. C1 [Wong, Yin-Ling Irene; Marcus, Steven C.; Solomon, Phyllis] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Nath, SB (reprint author), Bryn Mawr Coll, Grad Sch Social Work & Social Res, 300 Airdale Rd, Bryn Mawr, PA 19010 USA. EM snath@brynmawr.edu FU NIMH NIH HHS [5-F31-MH67349] NR 46 TC 1 Z9 1 U1 5 U2 8 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD SPR PY 2012 VL 35 IS 4 BP 315 EP 323 DI 10.2975/35.4.2012.315.323 PG 9 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA 928GN UT WOS:000302971300005 PM 22491371 ER PT J AU Gildengers, A Tatsuoka, C Bialko, C Cassidy, KA Al Jurdi, RK Gyulai, L Mulsant, BH Young, RC Sajatovic, M AF Gildengers, Ariel Tatsuoka, Curtis Bialko, Christopher Cassidy, Kristin A. Al Jurdi, Rayan K. Gyulai, Laszlo Mulsant, Benoit H. Young, Robert C. Sajatovic, Martha TI Correlates of Treatment Response in Depressed Older Adults With Bipolar Disorder SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE bipolar disorder; elderly; geriatric; lamotrigine; mood stabilizer; anticonvulsant; depression ID WEEKLY SYMPTOMATIC STATUS; RATING-SCALE; II DISORDER; ANTIDEPRESSANT-TREATMENT; SUICIDAL-BEHAVIOR; NATURAL-HISTORY; TRIAL; LIFE; PREVENTION; PLASTICITY AB Aims: To identify baseline clinical factors associated with acute treatment response in depressed older adults with bipolar disorder (BD) receiving lamotrigine. Methods: Secondary analysis of a multisite, 12-week, open-label, uncontrolled study of add-on lamotrigine in 57 adults 60 years and older with BD I or II depression. Measures included the Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS). Cardiometabolic risk was measured with total serum cholesterol and the Cumulative Illness Rating Scale-Geriatric (CIRS-G) item # 13 (endocrine/metabolic burden). Neurocognitive (executive) function was evaluated using the Trail Making Test. Results: Greater reduction in MADRS from baseline was associated with higher baseline cardiometabolic burden at 6 and 9 weeks and lower YMRS scores at 9 weeks. At 12 weeks, improvement in the MADRS from baseline was no longer significantly related to baseline cardiometabolic burden or YMRS scores. A longitudinal mixed model of MADRS scores corroborated these findings with a significant finding of time-by-baseline cholesterol level interaction. In a subset of participants, better baseline executive function was related to greater improvement in the MADRS at 9 weeks but not at 6 or 12 weeks. Among all participants, higher baseline YMRS scores were related to greater likelihood of dropout. Conclusions: Lamotrigine appears to work best in depressed elderly patients with BD who have high cardiometabolic risk and low level of mania. Agents like lamotrigine that act primarily on neuroprogressive pathways involving oxidative stress, neurotrophins, and inflammation may be particularly effective in individuals with BD who have significant cardiometabolic burden because of their effects on shared vulnerability factors in BD and medical illness. C1 [Gildengers, Ariel] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Tatsuoka, Curtis] Case Western Reserve Univ, Sch Med, Dept Neurol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Bialko, Christopher; Cassidy, Kristin A.; Sajatovic, Martha] Case Western Reserve Univ, Sch Med, Dept Psychiat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Al Jurdi, Rayan K.] Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. [Gyulai, Laszlo] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA. [Gyulai, Laszlo] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Mulsant, Benoit H.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Young, Robert C.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. RP Gildengers, A (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM gildengersag@upmc.edu RI Sajatovic, Martha/I-8001-2014 OI Young, Robert/0000-0002-6380-6314 FU GlaxoSmithKline, Research Triangle Park, North Carolina, USA; Case Western Reserve University [UL1RR024989]; GlaxoSmithKline; Canadian Institutes of Health Research; NIH; Bristol-Myers Squibb; Wyeth; AstraZeneca; Janssen; Pfizer; Merck; Ortho-McNeil Janssen FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by an investigator-initiated research grant from GlaxoSmithKline, Research Triangle Park, North Carolina, USA, and grant UL1RR024989 from Case Western Reserve University Clinical and Translational Science Awards (CTSA). The CTSA is a component of the National Institute of Health (NIH) and NIH Roadmap for Medical Research. The contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the NIH. Ariel Gildengers, Rayan K. Al-Jurdi, Laszlo Gyulai, and Robert C. Young received funding for research from GlaxoSmithKline to conduct this investigator-initiated study. Benoit H. Mulsant has received funding for research from GlaxoSmithKline, the Canadian Institutes of Health Research, NIH, Bristol-Myers Squibb, and Wyeth. Robert C. Young has received funding for research from NIH, GlaxoSmithKline, AstraZeneca, and Janssen. Martha Sajatovic received research grants from AstraZeneca, Pfizer, Merck, and Ortho-McNeil Janssen; is a consultant for Cognition Group and United BioSource Corporation (Bracket); and receives royalties from Springer Press, Johns Hopkins University Press, and Oxford Press. All other authors have no conflicts to report. NR 42 TC 3 Z9 3 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD MAR PY 2012 VL 25 IS 1 SI SI BP 37 EP 42 DI 10.1177/0891988712436685 PG 6 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 923NM UT WOS:000302626000007 PM 22467845 ER PT J AU Price, EL Bereknyei, S Kuby, A Levinson, W Braddock, CH AF Price, Erika Leemann Bereknyei, Sylvia Kuby, Alma Levinson, Wendy Braddock, Clarence Henry, III TI New elements for informed decision making: A qualitative study of older adults' views SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Informed decision making; Shared decision making; New elements for informed decision making; Qualitative analysis; Focus groups; Older adults ID HEALTH-CARE; PATIENTS PREFERENCES; PATIENT INVOLVEMENT; CLINICAL DECISIONS; MEDICAL ENCOUNTER; PARTICIPATION; PHYSICIANS; TIME; COMMUNICATION; PERCEPTIONS AB Objective: To explore older adults' views of existing informed decision making (IDM) elements and investigate the need for additional elements. Methods: We recruited persons 65 and older to participate in six focus groups. Participants completed questionnaires about IDM preferences, and discussed videotapes of idealized patient-physician interactions in light of seven IDM elements: (1) discussion of the patient's role in decision making; (2) discussion of the clinical issue; (3) discussion of alternatives; (4) discussion of benefits/risks; (5) discussion of uncertainties; (6) assessment of patient understanding; and (7) exploration of patient preference. We used a modified grounded theory approach to assess agreement with existing IDM elements and identify new elements. Results: In questionnaires, 97-100% of 59 participants rated each IDM element as "somewhat" or "very" important. Qualitative analysis supported existing elements and suggested two more: opportunity for input from trusted others, and discussion of decisions' impacts on patients' daily lives. Elements overlapped with global communication themes. Conclusion: Focus groups affirmed existing IDM elements and suggested two more with particular relevance for older patients. Practice implications: Incorporation of additional IDM elements into clinical practice can enhance informed participation of older adults in decision making. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Price, Erika Leemann] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Price, Erika Leemann] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bereknyei, Sylvia; Braddock, Clarence Henry, III] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Kuby, Alma] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA. [Levinson, Wendy] Univ Toronto, Dept Med, Toronto, ON, Canada. RP Price, EL (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box VAMC-111, San Francisco, CA 94121 USA. EM erika.price@ucsf.edu OI Bereknyei Merrell, Sylvia /0000-0002-5525-0379 FU National Institute on Aging, National Institutes of Health [R01 AG18781-02] FX This study was supported by grant no. R01 AG18781-02 from the National Institute on Aging, National Institutes of Health. We would like to thank the National Opinion Research Center and focus group participants for their contributions. NR 37 TC 18 Z9 18 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD MAR PY 2012 VL 86 IS 3 BP 335 EP 341 DI 10.1016/j.pec.2011.06.006 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 924EA UT WOS:000302672700010 PM 21757315 ER PT J AU Berry, K Ioannou, GN AF Berry, K. Ioannou, G. N. TI Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation? SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Child's A Cirrhosis; hepatocellular carcinoma; liver transplantation; posttransplantation survival; survival benefit ID PERCUTANEOUS RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED-TRIAL; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; SURGICAL RESECTION; ETHANOL INJECTION; SURVIVAL BENEFIT; TRANSARTERIAL CHEMOEMBOLIZATION; CONVENIENT APPROXIMATION; MULTIVARIATE-ANALYSIS; PROGNOSTIC-FACTORS AB We aimed to estimate the survival benefit derived from transplantation in patients with stage II hepatocellular carcinoma (HCC) and Child's A cirrhosis, defined as the mean lifetime with transplantation minus the mean lifetime with treatments other than transplantation. We calculated the posttransplantation survival of all adult, first-time, deceased-donor, liver transplant recipients in the United States since the introduction of the Model for End-Stage Liver Disease based priority system in February 2002 (n = 36 791). We estimated the posttreatment survival of patients with Child's A cirrhosis and stage II HCC treated by radiofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgical resection by conducting a systematic review of the medical literature. In patients with Child's A cirrhosis and stage II HCC, the estimated median survival benefit of liver transplantation compared to RFA +/- TACE was 1.5 months at 3 years (range -3.5 to 5.6) and 5.7 months at 5 years (range 0.711.4), whereas compared to surgical resection it was 0.7 months at 3 years (range -2.9 to 3) and 2.8 months at 5 years (range -4.4 to 5.7). Liver transplantation in patients with stage II HCC and Child's A cirrhosis results in a very low survival benefit and may not constitute optimal use of scarce liver donor organs. C1 [Ioannou, G. N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA USA. [Berry, K.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Ioannou, G. N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA USA. EM georgei@medicine.washington.edu FU Health Resources and Services Administration [231-00-0115]; Office of Research and Development, Veterans Affairs FX This research was based on data derived from the United Network for Organ Sharing (UNOS) on January 21, 2011. This work was supported in part by Health Resources and Services Administration contract 231-00-0115. G.N.I. was supported by Research Enhancement Award Program, Office of Research and Development, Veterans Affairs. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services. NR 48 TC 31 Z9 31 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2012 VL 12 IS 3 BP 706 EP 717 DI 10.1111/j.1600-6143.2011.03853.x PG 12 WC Surgery; Transplantation SC Surgery; Transplantation GA 899QZ UT WOS:000300832500027 PM 22123435 ER PT J AU Mountz, JD Li, J Hsu, HC AF Mountz, John D. Li, Jun Hsu, Hui-Chen TI Systemic autoimmunity caused by fas deficiency in macrophages: A new perspective on the first identified autoimmunity gene SO ARTHRITIS AND RHEUMATISM LA English DT Editorial Material ID CELL-DEATH; MICE; LIGAND; ACTIVATION; APOPTOSIS; DISEASE; ANTIGEN; DEGRADATION; PREVENTION; ABLATION C1 [Mountz, John D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Mountz, John D.; Hsu, Hui-Chen] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, 701 S 19th St,Room 473 LHRB, Birmingham, AL 35294 USA. EM jdmountz@uab.edu FU NIAID NIH HHS [R01-AI-083705-01A2, R01-AI-71110-02S1, 1-AI-071110-01A1] NR 18 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAR PY 2012 VL 64 IS 3 BP 609 EP 612 DI 10.1002/art.34321 PG 4 WC Rheumatology SC Rheumatology GA 899SH UT WOS:000300835900003 PM 22139895 ER PT J AU Kezic, JM Davey, MP Glant, TT Rosenbaum, JT Rosenzweig, HL AF Kezic, Jelena M. Davey, Michael P. Glant, Tibor T. Rosenbaum, James T. Rosenzweig, Holly L. TI Interferon-gamma regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis SO ARTHRITIS AND RHEUMATISM LA English DT Article ID PROTEOGLYCAN-INDUCED ARTHRITIS; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; ENDOTOXIN-INDUCED UVEITIS; ACUTE ANTERIOR UVEITIS; ANKYLOSING-SPONDYLITIS; T-CELLS; INTRAVITAL MICROSCOPY; GENETIC-CONTROL; SYNOVIAL-FLUID; BALB/C MICE AB Objective The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory diseases that frequently result in uveitis. Despite the common co-occurrence of uveitis with arthritis, there has been no explanation for the susceptibility of the eye to inflammation. Using an innovative intravital videomicroscopic approach, we discovered the coexistence of uveitis with axial and peripheral joint inflammation in mice immunized with cartilage proteoglycan (PG). The aim of this study was to elucidate the characteristics of uveitis and test the impact of interferon-? (IFN?) deficiency on the eye versus the joint and spine. Methods. Female T cell receptor (TCR)-transgenic mice or IFN gamma -knockout mice crossed to TCR-transgenic mice were immunized with PG. Uveitis was assessed by intravital videomicroscopy and histology. The clinical and histopathologic severity of arthritis and spondylitis were evaluated. The bone remodeling process within the spine was assessed by whole-body near-infrared imaging. Immunoblotting and immunofluorescence staining were used to examine the expression of PG and ADAMTS-5 and to examine the cellular composition of eyes with uveitis. Results. PG neoepitopes along with the aggrecanase ADAMTS-5 were present in the eye, as they were the joint. Anterior uveitis developed in response to PG immunization. The cellular infiltrate consisted mainly of neutrophils and eosinophils. Unexpectedly, IFN gamma deficiency markedly exacerbated uveitis while ameliorating joint and spine disease, indicating divergent mechanisms that drive diseases in the eye versus the joints and spine. Conclusion. This study provides the first detailed description of a murine disease model in which uveitis coincides with arthritis and spondylitis. Our observations provide a great opportunity for understanding the pathogenesis of a relatively common but poorly understood disease. C1 [Kezic, Jelena M.; Davey, Michael P.; Rosenbaum, James T.; Rosenzweig, Holly L.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Davey, Michael P.; Rosenzweig, Holly L.] Portland VA Med Ctr, Portland, OR 97239 USA. [Glant, Tibor T.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. RP Rosenzweig, HL (reprint author), Oregon Hlth & Sci Univ, Mail Stop L 467 AD,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM rosenzwh@ohsu.edu FU NIH (National Eye Institute) [EY-021733, EY-019020, EY-019604]; William and Mary Bauman Foundation; Stan and Madelle Rosenfeld Family Trust; William C. Kuzell Foundation; American College of Rheumatology Research and Education Foundation; Research to Prevent Blindness Foundation; Novartis; Amgen FX Supported by the NIH (National Eye Institute grants EY-021733, EY-019020, and EY-019604), the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and the William C. Kuzell Foundation. Dr. Rosenzweig's work was also supported by the American College of Rheumatology Research and Education Foundation and the Research to Prevent Blindness Foundation.; Dr. Rosenbaum has received consulting fees, speaking fees, and/or honoraria from Novartis and Amgen (less than $10,000 each). NR 44 TC 7 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAR PY 2012 VL 64 IS 3 BP 762 EP 771 DI 10.1002/art.33404 PG 10 WC Rheumatology SC Rheumatology GA 899SH UT WOS:000300835900020 PM 21987263 ER PT J AU Schumacher, HR Sundy, JS Terkeltaub, R Knapp, HR Mellis, SJ Stahl, N Yancopoulos, GD Soo, Y King-Davis, S Weinstein, SP Radin, AR AF Schumacher, H. Ralph, Jr. Sundy, John S. Terkeltaub, Robert Knapp, Howard R. Mellis, Scott J. Stahl, Neil Yancopoulos, George D. Soo, Yuhwen King-Davis, Shirletta Weinstein, Steven P. Radin, Allen R. CA 0619 Study Grp TI Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial SO ARTHRITIS AND RHEUMATISM LA English DT Article ID ALLOPURINOL; ARTHRITIS; MANAGEMENT; CARE; INHIBITION; CRYSTALS; ANAKINRA; RISK AB Objective To evaluate the interleukin-1 inhibitor rilonacept (Interleukin-1 Trap) for prevention of gout flares occurring in the first few months following initiation of urate-lowering therapy. Methods. In this double-blind study, adult patients with hyperuricemia and gout were randomized to receive rilonacept administered subcutaneously once per week (loading dose 320 mg followed by 160 mg weekly) or placebo, and started on allopurinol (300 mg/day, titrated to serum urate <6 mg/dl). At study visits, physical and laboratory assessments were performed and information on any adverse events was ascertained. Results. Baseline characteristics were similar between the rilonacept and placebo groups (n = 41 and n = 42, respectively). The mean number of gout flares per patient through week 12 (primary efficacy end point) was markedly lower in the rilonacept group than in the placebo group (0.15 [6 flares] versus 0.79 [33 flares]; P = 0.0011). Fewer flares were observed with rilonacept as early as 4 weeks after initiation of treatment (P = 0.007). The proportion of patients experiencing a flare during the 12 weeks was lower in the rilonacept group than in the placebo group (14.6% versus 45.2%; P = 0.0037). No rebound in the flare rate was observed for 6 weeks after discontinuation of rilonacept or placebo at week 16. Adverse events were similar between groups, and no deaths or serious infectious adverse events were reported; the most common adverse events were infections (14.6% and 26.2% of rilonacept- and placebo-treated patients, respectively) and musculoskeletal disorders (14.6% and 21.4%, respectively). A higher percentage of rilonacept-treated patients (98%) compared with placebo-treated patients (79%) completed the primary 12-week evaluation period (P = 0.015). Conclusion. The current findings indicate that rilonacept significantly reduces the frequency of gout flares during the initial period of treatment with urate-lowering therapy, with a favorable safety profile. C1 [Schumacher, H. Ralph, Jr.] Univ Penn, VA Med Ctr, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph, Jr.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Sundy, John S.] Duke Univ, Med Ctr, Durham, NC USA. [Terkeltaub, Robert] Univ Calif San Diego, San Diego, CA 92103 USA. [Terkeltaub, Robert] San Diego VA Med Ctr, San Diego, CA USA. [Knapp, Howard R.] Montana State Univ, Billings, MT USA. [Mellis, Scott J.; Stahl, Neil; Yancopoulos, George D.; Soo, Yuhwen; King-Davis, Shirletta; Weinstein, Steven P.; Radin, Allen R.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA. RP Schumacher, HR (reprint author), Univ Penn, VA Med Ctr, 151K,Univ & Woodland Avenues, Philadelphia, PA 19104 USA. EM schumacr@mail.med.upenn.edu FU Regeneron Pharmaceuticals, Inc.; Regeneron; Takeda; Savient; Ardea; Pfizer; Xoma; Novartis; Regeneron through Duke University; URL Pharma FX Supported by Regeneron Pharmaceuticals, Inc.; Dr. Schumacher has received consulting fees, speaking fees, and/or honoraria from Regeneron, Takeda, Savient, Ardea, Pfizer, Xoma, and Novartis (less than $10,000 each). Dr. Sundy has received consulting fees from Regeneron and Novartis (less than $10,000 each) and receives sponsored research grants from Regeneron through Duke University. Dr. Terkeltaub has received consulting fees, speaking fees, and/or honoraria from Regeneron, Novartis, and URL Pharma (less than $10,000 each) and has served as a paid consultant to the investment analysts Guidepoint Global and the Coleman Group. Drs. Mellis, Stahl, Yancopoulos, Soo, Weinstein, and Radin and Ms King-Davis own stock in Regeneron. Dr. Mellis holds a patent, licensed to Regeneron, for the use of interleukin-1 antagonists to treat gout. NR 26 TC 44 Z9 46 U1 5 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD MAR PY 2012 VL 64 IS 3 BP 876 EP 884 DI 10.1002/art.33412 PG 9 WC Rheumatology SC Rheumatology GA 899SH UT WOS:000300835900032 PM 22223180 ER PT J AU Gee, AO Baker, BM Silverstein, AM Montero, G Esterhai, JL Mauck, RL AF Gee, Albert O. Baker, Brendon M. Silverstein, Amy M. Montero, Giana Esterhai, John L. Mauck, Robert L. TI Fabrication and evaluation of biomimetic-synthetic nanofibrous composites for soft tissue regeneration SO CELL AND TISSUE RESEARCH LA English DT Article DE Tissue engineering; Mechanical properties; Nanofiber; Scaffolds; Electrospinning; Mesenchymal stem cells ID HUMAN ARTICULAR-CARTILAGE; CROSS-LINKING AGENT; ENGINEERING SCAFFOLDS; IN-VITRO; EXTRACELLULAR-MATRIX; CELLULAR INFILTRATION; ELECTROSPUN SCAFFOLDS; GELATIN MICROSPHERES; COLLAGEN NANOFIBERS; BIOLOGICAL TISSUE AB Electrospun scaffolds hold promise for the regeneration of dense connective tissues, given their nanoscale topographies, provision of directional cues for infiltrating cells and versatile composition. Synthetic slow-degrading scaffolds provide long-term mechanical support and nanoscale instructional cues; however, these scaffolds suffer from a poor infiltration rate. Alternatively, nanofibrous constructs formed from natural biomimetic materials (such as collagen) rapidly infiltrate but provide little mechanical support. To take advantage of the positive features of these constructs, we have developed a composite scaffold consisting in both a biomimetic fiber fraction (i.e., Type I collagen nanofibers) together with a traditional synthetic (i.e., poly-[epsilon-caprolactone], PCL) fiber fraction. We hypothesize that inclusion of biomimetic elements will improve initial cell adhesion and eventual scaffold infiltration, whereas the synthetic elements will provide controlled and long-term mechanical support. We have developed a method of forming and crosslinking collagen nanofibers by using the natural crosslinking agent genipin (GP). Further, we have formed composites from collagen and PCL and evaluated the long-term performance of these scaffolds when seeded with mesenchymal stem cells. Our results demonstrate that GP crosslinking is cytocompatible and generates stable nanofibrous type I collagen constructs. Composites with varying fractions of the biomimetic and synthetic fiber families are formed and retain their collagen fiber fractions during in vitro culture. However, at the maximum collagen fiber fractions (20%), cell ingress is limited compared with pure PCL scaffolds. These results provide a new foundation for the development and optimization of biomimetic/synthetic nanofibrous composites for in vivo tissue engineering. C1 [Gee, Albert O.; Baker, Brendon M.; Silverstein, Amy M.; Montero, Giana; Esterhai, John L.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Baker, Brendon M.; Silverstein, Amy M.; Montero, Giana; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Esterhai, John L.; Mauck, Robert L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, 424G Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu FU National Institutes of Health [R01 AR056624]; Department of Veterans' Affairs [I01 RX000174]; Penn Center for Musculoskeletal Disorders [P30 AR050950]; Penn Department of Orthopaedic Surgery; National Science Foundation FX This work was supported by the National Institutes of Health (R01 AR056624, RLM), The Department of Veterans' Affairs (I01 RX000174, JLE) and the Penn Center for Musculoskeletal Disorders (P30 AR050950, RLM). Additional support was provided by the Penn Department of Orthopaedic Surgery (AOG) and a graduate fellowship from the National Science Foundation (BMB). NR 67 TC 11 Z9 11 U1 3 U2 45 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0302-766X J9 CELL TISSUE RES JI Cell Tissue Res. PD MAR PY 2012 VL 347 IS 3 BP 803 EP 813 DI 10.1007/s00441-011-1308-1 PG 11 WC Cell Biology SC Cell Biology GA 916YG UT WOS:000302138500027 PM 22287042 ER PT J AU Rector, TS Carson, PE Anand, IS McMurray, JJ Zile, MR McKelvie, RS Komajda, M Kuskowski, M Massie, BM AF Rector, Thomas S. Carson, Peter E. Anand, Inder S. McMurray, John J. Zile, Michael R. McKelvie, Robert S. Komajda, Michel Kuskowski, Michael Massie, Barry M. CA I-PRESERVE Trial Investigators TI Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial SO CIRCULATION-HEART FAILURE LA English DT Article DE diastolic heart failure; ARBs; quality of life ID QUALITY-OF-LIFE; CLINICAL CHARACTERISTICS; RANDOMIZED-TRIAL; DOUBLE-BLIND; DYSFUNCTION; PLACEBO; RELIABILITY; PREVALENCE; VALIDITY AB Background-The Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used in a large, multinational, randomized, placebo-controlled trial to measure adverse effects of heart failure with preserved ejection fraction (HF-PEF) on patients' lives and the effects of irbesartan. Methods and Results-Patients with symptomatic HF-PEF were randomly assigned to irbesartan (up to 300 mg daily) or placebo. The MLHFQ was administered at baseline (n=3605), month 6 (n=3137), month 14 (n=2904), and the end of study (median, 56 months, n=2205). Baseline MLHFQ scores of 43 +/- 21 indicated that HF-PEF had a substantial adverse effects. Estimated retest reliability was 0.80. Baseline MLHFQ scores were associated with other measures of the severity of heart failure including symptoms, signs of congestion, cardiac structure, and time to hospitalizations or deaths attributed to heart failure. Slight improvement in shortness of breath or fatigue was associated with significant improvement in MLHFQ scores (-5.9 and -5.0, P<0.0001). Compared with placebo, further improvement in MLHFQ scores was not observed with irbesartan after 6 months (mean adjusted difference, 0.4; 95% confidence interval, -0.8 to 1.7), 14 months (0.5; 95% confidence interval, -0.9 to 1.8), or the end of study (2.0; 95% confidence interval, -4.1 to 0.01). Conclusions-The MLHFQ scores are a reliable, valid, and sensitive measure of the adverse impact of HF-PEF on patients' lives. Irbesartan did not substantially improve MLHFQ scores during a long period of follow-up. C1 [Rector, Thomas S.; Anand, Inder S.] Univ Minnesota, Dept Vet Affairs Hlth Care Syst, Minneapolis, MN USA. [Rector, Thomas S.; Anand, Inder S.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Carson, Peter E.] Dept Vet Affairs Hlth Care Syst, Washington, DC USA. [Carson, Peter E.] Georgetown Univ Hosp, Washington, DC 20007 USA. [McMurray, John J.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow G12 8QQ, Lanark, Scotland. [Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [McKelvie, Robert S.] Populat Hlth Res Inst, Hamilton, ON, Canada. [McKelvie, Robert S.] McMaster Univ, Hamilton, ON, Canada. [Kuskowski, Michael] Hop La Pitie Salpetriere, Dept Cardiol, Paris, France. [Komajda, Michel] Univ Paris 06, Paris, France. [Komajda, Michel] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.] San Francisco Dept Vet Affairs Hlth Care Syst, San Francisco, CA USA. RP Rector, TS (reprint author), Minneapolis VA Hlth Care Syst, 1 Vet Dr, Minneapolis, MN 55417 USA. EM thomas.rector@va.gov FU Bristol-Myers Squibb; Sanofi-Aventis; Veterans Health Administration [HFP-98-001]; Servier FX The I-PRESERVE Trial was funded by Bristol-Myers Squibb and Sanofi-Aventis. Dr Rector was supported by the Veterans Health Administration [Health Services Research and Development grant HFP-98-001. All expressed views and conclusions are the authors' and do not necessarily represent the Veterans Health Administration.; Drs Anand, Carson, and Zile received consulting fees from Bristol-Myers Squibb and/or Sanofi-Aventis. Dr McMurray received support from Bristol-Myers Squibb (to Glasgow University) for his work on this trial. Dr Komajda received consulting fees from Bristol-Myers Squibb and Servier and lecture fees from Sanofi-Aventis. Dr McKelvie received consulting fees and lecture fees from Bristol-Myers Squibb and Sanofi-Aventis. Dr Massie received grant support and consulting fees from Bristol-Myers Squibb and Sanofi-Aventis. Drs Rector and Kuskowski have no industry relationships to disclose. Dr Rector receives royalty payments from the University of Minnesota for licensed use of the Minnesota Living with Heart Failure Questionnaire. NR 24 TC 17 Z9 18 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAR PY 2012 VL 5 IS 2 BP 217 EP 225 DI 10.1161/CIRCHEARTFAILURE.111.964221 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 916RL UT WOS:000302120800022 PM 22267751 ER PT J AU Doi, H Iyer, TK Carpenter, E Li, H Chang, KM Vonderheide, RH Kaplan, DE AF Doi, Hiroyoshi Iyer, Tara K. Carpenter, Erica Li, Hong Chang, Kyong-Mi Vonderheide, Robert H. Kaplan, David E. TI Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population SO HEPATOLOGY LA English DT Article ID SOLUBLE CD14; VIRUS-INFECTION; MICROBIAL TRANSLOCATION; LIVER-TRANSPLANTATION; IMMUNE ACTIVATION; LYMPHOCYTES; EXPRESSION; SERUM; INDIVIDUALS; COMPARTMENT AB Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Both advanced solid tumors and HCV have previously been associated with memory B-cell dysfunction. In this study, we sought to dissect the effect of viral infection, cirrhosis, and liver cancer on memory B-cell frequency and function in the spectrum of HCV disease. Peripheral blood from healthy donors, HCV-infected patients with F1-F2 liver fibrosis, HCV-infected patients with cirrhosis, patients with HCV-related HCC, and non-HCV-infected cirrhotics were assessed for B-cell phenotype by flow cytometry. Isolated B cells were stimulated with anticluster of differentiation (CD)40 antibodies and Toll-like receptor (TLR)9 agonist for assessment of costimulation marker expression, cytokine production, immunoglobulin (Ig) production, and CD4+ T-cell allostimulatory capacity. CD27+ memory B cells and, more specifically, CD27+IgM+ B cells were markedly less frequent in cirrhotic patients independent of HCV infection. Circulating B cells in cirrhotics were hyporesponsive to CD40/TLR9 activation, as characterized by CD70 up-regulation, tumor necrosis factor beta secretion, IgG production, and T-cell allostimulation. Last, blockade of TLR4 and TLR9 signaling abrogated the activation of healthy donor B cells by cirrhotic plasma, suggesting a role for bacterial translocation in driving B-cell changes in cirrhosis. Conclusion: Profound abnormalities in B-cell phenotype and function occur in cirrhosis independent of HCV infection. These B-cell defects may explain, in part, the vaccine hyporesponsiveness and susceptibility to bacterial infection in this population. (HEPATOLOGY 2012) C1 [Chang, Kyong-Mi; Kaplan, David E.] Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA. [Doi, Hiroyoshi; Iyer, Tara K.; Li, Hong; Chang, Kyong-Mi; Kaplan, David E.] Univ Penn, Div Gastroenterol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Carpenter, Erica; Vonderheide, Robert H.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA. [Vonderheide, Robert H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Vonderheide, Robert H.] Univ Penn, Div Hematol Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Med & Res Serv, Res Bldg 21,A402A,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM dakaplan@mail.med.upenn.edu OI Kaplan, David E./0000-0002-3839-336X FU NCI NIH HHS [R21 CA149908, R21 CA149908-01, T32 CA009140]; NIAAA NIH HHS [AA12849, R01 AA012849, R01 AA012849-05]; NIAID NIH HHS [R01 AI047519, AI47519, R01 AI047519-12]; NIDDK NIH HHS [L30 DK069063, L30 DK069063-01, P30 DK050306, P30 DK050306-15, P30-DK050306] NR 45 TC 21 Z9 22 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD MAR PY 2012 VL 55 IS 3 BP 709 EP 719 DI 10.1002/hep.24689 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 897YS UT WOS:000300699900008 PM 21932384 ER PT J AU Schwartz, AV Johnson, KC Kahn, SE Shepherd, JA Nevitt, MC Peters, AL Walkup, MP Hodges, A Williams, CC Bray, GA AF Schwartz, Ann V. Johnson, Karen C. Kahn, Steven E. Shepherd, John A. Nevitt, Michael C. Peters, Anne L. Walkup, Michael P. Hodges, Amelia Williams, Carrie C. Bray, George A. CA Look AHEAD Res Grp TI Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE BONE MINERAL DENSITY; WEIGHT LOSS; TYPE 2 DIABETES; OBESITY; GLYCEMIC CONTROL; PHYSICAL FITNESS ID OVERWEIGHT POSTMENOPAUSAL WOMEN; LIFE-STYLE INTERVENTION; X-RAY ABSORPTIOMETRY; FRACTURE RISK; CARDIOVASCULAR-DISEASE; HIP FRACTURE; OLDER WOMEN; BODY-WEIGHT; MASS; ADULTS AB Intentional weight loss is an important component of treatment for overweight patients with type 2 diabetes, but the effects on bone density are not known. We used data from the Look AHEAD trial to determine the impact of an intensive lifestyle weight loss intervention (ILI) compared with diabetes support and education (DSE) on changes in bone mineral density (BMD) over 12 months. Overweight and obese adults with type 2 diabetes were randomly assigned to ILI or DSE. In a substudy of BMD conducted at 5 of 16 clinical centers, hip, spine, and whole body dual X-ray absorptiometry scans were obtained at baseline and 1-year later on 642 of 739 ILI and 632 of 740 DSE participants. At baseline, mean age was 58.4 years, and average body mass index was 35.2?kg/m2. Total hip BMD T-score was <-2.5 in 1% and <-1.0 in 8%. At 1 year, weight loss was greater in ILI than DSE (-8.6% versus -0.7%), and glycemic control and fitness were also improved. Bone loss over 1 year was greater in ILI at the total hip (-1.4% versus -0.4%; p?= 30) and received primary care in one of six selected VHA regions were included. Outcomes were receipt of obesity care and weight loss during FY 2002 FY 2006. Covariates included baseline mental illness (major depression, posttraumatic stress disorder, and substance use disorders; ICD-9-CM codes 290-311); psychotropic medications associated with weight gain; comorbidity; and demographic characteristics. Results: Most patients were male (95%), non-Hispanic white (80%), older than 50 (mean +/- SD=61 +/- 12) with comorbid hypertension (65%) and dyslipidemia (50%). One-fifth (20%) had mental illness, primarily depression (8%) or posttraumatic stress disorder (6%). Ten percent of the sample lost weight, and 7% gained >= 10% from baseline weight). Although one-third (34%) received obesity care during the study period, receipt of this care was more common among patients with psychiatric diagnoses (46% versus 31%). In multivariable analysis, psychiatric patients prescribed obesogenic psychotropic medications were more likely than other patients to receive obesity care (interaction effect). Conclusions: VITA efforts to help obese patients manage their weight appeared more common for patients prescribed obesogenic psychotropic medication, especially those with psychiatric diagnoses. The results of this study represent an unusual example in which psychiatric patients were relatively more likely to receive care addressing cardiometabolic risk factors. (Psychiatric Services 63:230-236, 2012; doi: 10.1176/appi.ps.201100221) C1 [Copeland, Laurel Anne] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX 76502 USA. [Hicks, Paul B.] Cent Texas Vet Hlth Care Syst, Dept Med, Temple, TX 76502 USA. [Copeland, Laurel Anne] Scott & White Healthcare, Temple, TX USA. [Pugh, Mary Jo; Noel, Polly Hitchcock] S Texas Vet Hlth Care Syst, VERDICT Res, San Antonio, TX USA. [Pugh, Mary Jo] UT Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX USA. [Noel, Polly Hitchcock] UT Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX USA. RP Copeland, LA (reprint author), Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM laurelacopeland@gmail.com OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209 FU U.S. Department of Veterans Affairs (VA), Health Services Research and Development Services [IIR-05-121]; Central Texas Veterans Health Care System; Scott and White Healthcare (Temple, Texas); VERDICT Research at South Texas Veterans Health Care System; University of Texas Health Science Center San Antonio FX This work was supported by the U.S. Department of Veterans Affairs (VA), Health Services Research and Development Services IIR-05-121, with additional support from Central Texas Veterans Health Care System, Scott and White Healthcare (Temple, Texas), VERDICT Research at the South Texas Veterans Health Care System, and the University of Texas Health Science Center San Antonio. The views expressed in this article are those of the authors and do not necessarily represent the views of the VA. NR 31 TC 6 Z9 6 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2012 VL 63 IS 3 BP 230 EP 236 DI 10.1176/appi.ps.201100221 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 917NV UT WOS:000302185600007 PM 22307880 ER PT J AU Yang, S Mulvey, EP Loughran, TA Hanusa, BH AF Yang, Suzanne Mulvey, Edward P. Loughran, Thomas A. Hanusa, Barbara H. TI Psychiatric Symptoms and Alcohol Use in Community Violence by Persons With a Psychotic Disorder or Depression SO PSYCHIATRIC SERVICES LA English DT Article ID NATIONAL EPIDEMIOLOGIC SURVEY; RATING-SCALE; SUBSTANCE-ABUSE; MENTAL-DISORDER; RISK-ASSESSMENT; BEHAVIOR; SCHIZOPHRENIA; OTHERS; METAANALYSIS; MEDICATION AB Objective: Prior studies have shown a significant but modest association between mental disorders and violence and an increased risk in the presence of co-occurring substance use disorders. Categorical diagnoses, however, have limited utility when assessing dynamic risk state over time. This study used data from the MacArthur Violence Risk Assessment Study to examine the relationship of symptom levels and alcohol use to violence in repeated observations within two diagnostic groups. Methods: Participants with a primary categorical diagnosis of depression (N=386) or a psychotic disorder (N=201) were identified. Subscale scores for affective or positive symptoms from the Brief Psychiatric Rating Scale and self-reported alcohol consumption were tested in panel logistic models over five ten-week intervals for their concurrent and lagged relationship to violence. An interaction term between each type of symptom and alcohol use was also tested. Results: In models including the amount of alcohol consumed and symptom levels, a high level of affective symptoms was associated with violence during the next follow-up period only for participants with depression. There was a significant interaction between alcohol use and affective symptoms for participants with depression. Conclusions: The relationship of symptoms and alcohol use to community violence should be considered in the context of the individual's primary diagnosis. Further characterization of interactions between symptoms and substance use in relation to violent behavior may allow for more effective assessment of risk state and interventions for violence prevention. (Psychiatric Services 63:262-269, 2012; doi: 10.1176/appi.ps.201100354) C1 [Yang, Suzanne] VA Pittsburgh Healthcare Syst, Vet Integrated Serv Network VISN Mental Illness R, Pittsburgh, PA 15206 USA. [Yang, Suzanne] Univ Pittsburgh, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Yang, Suzanne] Univ Pittsburgh, Law & Psychiat Program, Pittsburgh, PA 15260 USA. [Mulvey, Edward P.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Loughran, Thomas A.] Univ Maryland, Dept Criminol, College Pk, MD 20742 USA. [Hanusa, Barbara H.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Hanusa, Barbara H.] VA Pittsburgh Healthcare Syst, VISN MIRECC 4, Pittsburgh, PA 15206 USA. RP Yang, S (reprint author), VA Pittsburgh Healthcare Syst, Vet Integrated Serv Network VISN Mental Illness R, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM yangs@upmc.edu FU National Institute of Mental Health [T32 MH16804]; U.S. Department of Veterans Affairs (VA), Office of Academic Affiliations FX During the preparation of the manuscript, Dr. Yang was supported by grant T32 MH16804 from the National Institute of Mental Health and by the U.S. Department of Veterans Affairs (VA), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment. Contents do not represent the views of the VA or the U.S. government. Dr. Yang thanks Kevin Kim, Ph.D., Candice Odgers, Ph.D., and Ada Youk, Ph.D., for valuable advice during data analysis and Bruno Falissard, M.D., Ph.D., for insightful comments on the manuscript. NR 40 TC 3 Z9 3 U1 2 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2012 VL 63 IS 3 BP 262 EP 269 DI 10.1176/appi.ps.201100354 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 917NV UT WOS:000302185600012 PM 22388531 ER PT J AU Renaud, B Brun-Buisson, C Santin, A Coma, E Noyez, C Fine, MJ Yealy, DM Labarere, J AF Renaud, Bertrand Brun-Buisson, Christian Santin, Aline Coma, Eva Noyez, Cecile Fine, Michael J. Yealy, Donald M. Labarere, Jose TI Outcomes of Early, Late, and No Admission to the Intensive Care Unit for Patients Hospitalized with Community-acquired Pneumonia SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID INFECTIOUS-DISEASES-SOCIETY; PREDICTION RULE; EMERGENCY-DEPARTMENT; CONTROLLED-TRIAL; SEVERITY-INDEX; RISK-FACTORS; VALIDATION; GUIDELINES; MORTALITY; CRITERIA AB Objectives: The objective was to compare outcomes associated with early, late, and no admission to the intensive care unit (ICU) for patients hospitalized with community-acquired pneumonia (CAP). Methods: This was a post hoc analysis of the original data from the Emergency Department Community-Acquired Pneumonia (EDCAP) and Pneumocom-1 prospective multicenter cohort studies of adult patients hospitalized with CAP. Propensity scoreadjusted analysis was used to compare 28-day mortality and hospital length of stay (LOS) for 199, 144, and 2,215 patients with early (i.e., ICU admission on the day of emergency department [ED] presentation), late, and no ICU admission. Results: Unadjusted 28-day mortality rates were 13.1, 19.4, and 5.7% for early, late, and no ICU admissions, respectively (p < 0.001). After adjusting for quintile of propensity score, the odds of 28-day mortality were higher for late ICU admissions relative to early ICU admissions (odds ratio [OR] = 2.63; 95% confidence interval [CI] = 1.42 to 4.90), and no ICU admissions (OR = 3.40; 95% CI = 2.11 to 5.48), but did not differ between early and no ICU admissions (OR = 1.29; 95% CI = 0.79 to 2.09). The median hospital LOS was 10 days for early (interquartile range [IQR] = 7 to 18), 15 days for late (IQR 9 to 23), and 6 days (IQR 4 to 9) for no ICU admissions (p < 0.001). Conclusions: This study suggests that late but not early admission to the ICU is associated with higher 28-day mortality for patients hospitalized with CAP. Patients admitted to the ICU have longer hospital LOS in comparison to those managed on the wards, particularly if they are admitted late to the ICU. ACADEMIC EMERGENCY MEDICINE 2012; 19:## (C) 2012 by the Society for Academic Emergency Medicine C1 [Renaud, Bertrand; Santin, Aline] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Urgence, Creteil, France. [Renaud, Bertrand; Brun-Buisson, Christian; Santin, Aline] Univ Paris 12, Fac Med, Creteil, France. [Coma, Eva] Hosp Duran & Reynals, Inst Catala Oncol, Serv Atencio Continuada USAC, Barcelona 08907, Spain. [Noyez, Cecile] Ctr Hosp Montauban, Emergency Dept, Montauban, France. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA. [Labarere, Jose] CHU Grenoble, Qual Care Unit, F-38043 Grenoble, France. [Labarere, Jose] Univ Grenoble 1, TIMC UMR CNRS 5525, Grenoble, France. RP Renaud, B (reprint author), Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Urgence, Creteil, France. EM bertrand.renaud@hmn.aphp.fr RI Labarere, Jose/N-1688-2014 OI Labarere, Jose/0000-0001-7621-6586 FU Direction de la Recherche Clinique d'Ile de France [AOM 89-145]; Departement de la Formation Continue des Medecins de l'Assistance Publique des Hopitaux de Paris (AP-HP); l'ARMUR (Association de Recherche en Medecine d'Urgence, Henri Mondor, Creteil) France; AQUARE (Association pour la QUAlite, la Recherche et l'Enseignement a l'Hopital Saint-Joseph (Paris)); GlaxoSmithKline France; Direction de la Recherche Clinique du Centre Hospitalier Universitaire de Grenoble FX This study was funded by the Direction de la Recherche Clinique d'Ile de France as part of the Programme Hospitalier de Recherche Clinique (Grant No. AOM 89-145). B. Renaud was supported by the Departement de la Formation Continue des Medecins de l'Assistance Publique des Hopitaux de Paris (AP-HP), by l'ARMUR (Association de Recherche en Medecine d'Urgence, Henri Mondor, Creteil) France; by AQUARE (Association pour la QUAlite, la Recherche et l'Enseignement a l'Hopital Saint-Joseph (Paris)); and by GlaxoSmithKline France. J. Labarere was supported by the Direction de la Recherche Clinique du Centre Hospitalier Universitaire de Grenoble. NR 36 TC 7 Z9 8 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAR PY 2012 VL 19 IS 3 BP 294 EP 303 DI 10.1111/j.1553-2712.2012.01301.x PG 10 WC Emergency Medicine SC Emergency Medicine GA 912EE UT WOS:000301776700007 PM 22435862 ER PT J AU Ikonomovic, MD Abrahamson, EE Price, JC Hamilton, RL Mathis, CA Paljug, WR Debnath, ML Cohen, AD Mizukami, K DeKosky, ST Lopez, OL Klunk, WE AF Ikonomovic, Milos D. Abrahamson, Eric E. Price, Julie C. Hamilton, Ronald L. Mathis, Chester A. Paljug, William R. Debnath, Manik L. Cohen, Anne D. Mizukami, Katsuyoshi DeKosky, Steven T. Lopez, Oscar L. Klunk, William E. TI Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study SO ACTA NEUROPATHOLOGICA LA English DT Article DE Alzheimer's disease; Brain amyloidosis; Pittsburgh Compound B; Plaques; Imaging ID PITTSBURGH COMPOUND-B; POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; SENILE PLAQUES; NEUROPATHOLOGIC ASSESSMENT; NEUROFIBRILLARY TANGLES; REGIONAL-DISTRIBUTION; BETA PROTEIN; PET; BRAIN AB Amyloid-beta (A beta) deposits are detectable in the brain in vivo using positron emission tomography (PET) and [C-11]-labeled Pittsburgh Compound B ([C-11]PiB); however, the sensitivity of this technique is not well understood. In this study, we examined A beta pathology in an individual who had clinical diagnoses of probable dementia with Lewy bodies and possible Alzheimer's disease (AD) but with no detectable [C-11]PiB PET retention ([C-11]PiB(-)) when imaged 17 months prior to death. Brain samples were processed in parallel with region-matched samples from an individual with a clinical diagnosis of probable AD and a positive [C-11]PiB PET scan ([C-11]PiB(+)) when imaged 10 months prior to death. In the [C-11]PiB(-) case, A beta plaques were sparse, occupying less than 2% cortical area, and were weakly labeled with 6-CN-PiB, a highly fluorescent derivative of PiB. In contrast, A beta plaques occupied up to 12% cortical area in the [C-11]PiB(+) case, and were intensely labeled with 6-CN-PIB. The [C-11]PiB(-) case had low levels of [H-3]PiB binding (<100 pmol/g) and A beta 1-42 (<500 pmol/g) concentration except in the frontal cortex where A beta 1-42 values (788 pmol/g) approached cortical values in the [C-11]PiB(+) case (800-1,700 pmol/g). In several cortical regions of the [C-11]PiB(-) case, A beta 1-40 levels were within the range of cortical A beta 1-40 values in the [C-11]PiB(+) case. Antemortem [C-11]PiB DVR values correlated well with region-matched postmortem measures of A beta 1-42 and A beta 1-40 in the [C-11]PiB(+), and with A beta 1-42 only in the [C-11]PiB(-) case. The low ratios of [H-3]PiB binding levels to Ab concentrations and 6-CN-PiB to Ab plaque loads in the [C-11]PiB(-) case indicate that Ab pathology in the brain may be associated with low or undetectable levels of [C-11]PiB retention. Studies in greater numbers of [C-11]PiB PET autopsy cases are needed to define the Ab concentration and [H-3]PiB binding levels required to produce a positive [C-11]PiB PET signal. C1 [Ikonomovic, Milos D.; Abrahamson, Eric E.; Paljug, William R.; Lopez, Oscar L.; Klunk, William E.] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.; Debnath, Manik L.; Cohen, Anne D.; Klunk, William E.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Price, Julie C.; Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Sch Med, Pittsburgh, PA 15213 USA. [Hamilton, Ronald L.] Univ Pittsburgh, Dept Neuropathol, Sch Med, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Mizukami, Katsuyoshi] Univ Tsukuba, Inst Clin Med, Dept Psychiat, Tsukuba, Ibaraki 305, Japan. [DeKosky, Steven T.] Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA. [DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. RP Ikonomovic, MD (reprint author), Univ Pittsburgh, Dept Neurol, Sch Med, 200 Lothrop St,BST S521, Pittsburgh, PA 15213 USA. EM ikonomovicmd@upmc.edu OI Klunk, William/0000-0001-5512-0251 FU National Institutes of Health [AG025204, AG025516, AG005133, AG014449, AG033042]; GE Healthcare; Phillip V. and Anna S. Brown Foundation; Snee-Reinhardt Charitable Foundation FX We gratefully acknowledge the technical expertise of Suganya Srinivasan, Lan Shao, Hui Wang, and Jonette Werley. We thank the staff at the University of Pittsburgh Alzheimer's Disease Research Center and PET facility for their efforts in conducting and analyzing these studies. We are indebted to our subjects and their families for the selfless contributions that made this work possible. This work was supported by the National Institutes of Health grants AG025204, AG025516, AG005133, AG014449, and AG033042, GE Healthcare, The Phillip V. and Anna S. Brown Foundation, and the Snee-Reinhardt Charitable Foundation. NR 52 TC 42 Z9 42 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD MAR PY 2012 VL 123 IS 3 BP 433 EP 447 DI 10.1007/s00401-012-0943-2 PG 15 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 913EJ UT WOS:000301856300009 PM 22271153 ER PT J AU Drye, LT Ismail, Z Porsteinsson, AP Rosenberg, PB Weintraub, D Marano, C Pelton, G Frangakis, C Rabins, PV Munro, CA Meinert, CL Devanand, DP Yesavage, J Mintzer, JE Schneider, LS Pollock, BG Lyketsos, CG AF Drye, Lea T. Ismail, Zahinoor Porsteinsson, Anton P. Rosenberg, Paul B. Weintraub, Daniel Marano, Christopher Pelton, Gregory Frangakis, Constantine Rabins, Peter V. Munro, Cynthia A. Meinert, Curtis L. Devanand, D. P. Yesavage, Jerome Mintzer, Jacobo E. Schneider, Lon S. Pollock, Bruce G. Lyketsos, Constantine G. CA CitAD Res Grp TI Citalopram for agitation in Alzheimer's disease: Design and methods SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer dementia; Citalopram; Agitation; Randomized trial ID PLACEBO-CONTROLLED TRIAL; NEUROPSYCHIATRIC-SYMPTOMS; ELDERLY-PATIENTS; NURSING-HOME; DOUBLE-BLIND; BEHAVIORAL DISTURBANCES; SEROTONIN TRANSPORTER; DEMENTED PATIENTS; DEPRESSION; ASSOCIATION AB Background: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms. Methods: CitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured. Conclusion: The authors believe the design elements in CitAD are important features to he included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD. (C) 2012 The Alzheimer's Association. All rights reserved. C1 [Drye, Lea T.; Frangakis, Constantine; Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Drye, Lea T.; Frangakis, Constantine; Meinert, Curtis L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA. [Ismail, Zahinoor; Pollock, Bruce G.] Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Rosenberg, Paul B.; Marano, Christopher; Rabins, Peter V.; Munro, Cynthia A.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Rosenberg, Paul B.; Marano, Christopher; Rabins, Peter V.; Munro, Cynthia A.; Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD USA. [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Pelton, Gregory; Devanand, D. P.] Columbia Univ, Div Geriatr Psychiat, New York State Psychiat Inst, New York, NY USA. [Pelton, Gregory; Devanand, D. P.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Yesavage, Jerome] Stanford Univ, Sch Med,Dept Vet Affairs, Med Res Serv Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA 94304 USA. [Yesavage, Jerome] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90033 USA. RP Drye, LT (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. EM ldrye@jhsph.edu OI Drye, Lea/0000-0002-2964-1878 FU National Institute on Aging; National Institute of Mental Health [R01AG031348] FX Grant funding: National Institute on Aging and National Institute of Mental Health, R01AG031348. NR 59 TC 21 Z9 21 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAR PY 2012 VL 8 IS 2 BP 121 EP 130 DI 10.1016/j.jalz.2011.01.007 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 914ZE UT WOS:000301991600005 PM 22301195 ER PT J AU Bennett, KO Billings, CJ Molis, MR Leek, MR AF Bennett, Keri O'Connell Billings, Curtis J. Molis, Michelle R. Leek, Marjorie R. TI Neural Encoding and Perception of Speech Signals in Informational Masking SO EAR AND HEARING LA English DT Article ID EVENT-RELATED POTENTIALS; SOUNDS VERTICAL-BAR; PASS NOISE MASKING; BROAD-BAND NOISE; NORMAL-HEARING; RECOGNITION; FREQUENCY; LISTENERS; WAVE; N1 AB Objective: To investigate the contributions of energetic and informational masking to neural encoding and perception in noise, using oddball discrimination and sentence recognition tasks. Design: P3 auditory evoked potential, behavioral discrimination, and sentence recognition data were recorded in response to speech and tonal signals presented to nine normal-hearing adults. Stimuli were presented at a signal to noise ratio of -3 dB in four background conditions: quiet, continuous noise, intermittent noise, and four-talker babble. Results: Responses to tonal signals were not significantly different for the three maskers. However, responses to speech signals in the four-talker babble resulted in longer P3 latencies, smaller P3 amplitudes, poorer discrimination accuracy, and longer reaction times than in any of the other conditions. Results also demonstrate significant correlations between physiological and behavioral data. As latency of the P3 increased, reaction times also increased and sentence recognition scores decreased. Conclusion: The data confirm a differential effect of masker type on the P3 and behavioral responses and present evidence of interference by an informational masker to speech understanding at the level of the cortex. Results also validate the use of the P3 as a useful measure to demonstrate physiological correlates of informational masking. C1 [Bennett, Keri O'Connell; Billings, Curtis J.; Molis, Michelle R.; Leek, Marjorie R.] Portland VA Med Ctr, NCRAR, Portland, OR 97239 USA. [Bennett, Keri O'Connell; Billings, Curtis J.; Molis, Michelle R.; Leek, Marjorie R.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Bennett, KO (reprint author), Portland VA Med Ctr, NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM keri.oconnell2@va.gov FU National Institute on Deafness and Other Communication Disorders [R01 DC 00626]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [C6116W, C6971M] FX This research was supported by a grant R01 DC 00626 from the National Institute on Deafness and Other Communication Disorders. Support was also provided by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [Career Development grants C6116W (to M.R.M.) and C6971M (to C.J.B.), and Senior Research Career Scientist award (to M.R.L.)]. The work was supported with resources and the use of facilities at the Portland VA Medical Center. NR 28 TC 12 Z9 12 U1 0 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD MAR-APR PY 2012 VL 33 IS 2 BP 243 EP 250 DI 10.1097/AUD.0b013e31823173fd PG 8 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 899YM UT WOS:000300852600009 PM 22367094 ER PT J AU Connolly, KR Thase, ME AF Connolly, Kevin Ryan Thase, Michael E. TI Emerging drugs for major depressive disorder SO EXPERT OPINION ON EMERGING DRUGS LA English DT Review DE bipolar disorder; major depressive disorder; medication; treatment ID SEROTONIN REUPTAKE INHIBITORS; PLACEBO-CONTROLLED-TRIAL; TREATMENT-RESISTANT DEPRESSION; RANDOMIZED CONTROLLED-TRIALS; EXTENDED-RELEASE QUETIAPINE; GLUTAMATE-RECEPTOR AGONISTS; BDNF MESSENGER-RNA; DOUBLE-BLIND; OLANZAPINE/FLUOXETINE COMBINATION; ADJUNCTIVE THERAPY AB Introduction: Major depressive disorder (MDD) remains a major public health concern, and one that continues to suffer an incompletely-met need for effective and acceptable treatments. The development of antidepressants, to date, has focused primarily on increasing monoamine neurotransmission with increasing efficacy while minimizing adverse effects. Medications currently recommended as 'first-line' are far more tolerable than the older medications they replaced, but as many as 70% of patients continue to suffer significant depressive symptoms after treatment with one of these agents, and as many as 50% will discontinue a trial due to issues with acceptability. This review will summarize antidepressants that have recently entered the market as well as those still in development to help characterize the current state of antidepressant development. Areas covered: Currently available first-line antidepressants are reviewed with respect to efficacy and tolerability, and their weaknesses are discussed as targets for future development. The background, clinical trial data and potential significance of the three most recently introduced antidepressants (trazodone-ER, desvenlafaxine and vilazodone) and the most recently approved augmentation agents (aripiprazole and quetiapine) are discussed. Following a review of the current market, all medications currently in Phase II or later clinical trials are listed and discussed, based on a thorough review of the US National Institutes of Health clinicaltrials.gov index for trials using medications to treat MDD and a search of the Informa Pharmaprojects database for medications currently being developed for a depression indication. Compounds thus identified were then used as search terms in a PubMed search of each medication. Based on pharmacologic properties, medications in development were grouped into those acting on: i) monoamine neurotransmission; ii) cholinergic neurotransmission; iii) glutamatergic neurotransmission; iv) opioid receptors; v) sigma receptors; vi) neurokinin receptors; vii) corticotrophin-releasing factor receptors and viii) other mechanisms. In the discussion of each, a brief review of the pharmacology and physiology of the related system is provided. Potential issues for the future of antidepressant development and an expert opinion are discussed. Expert opinion: The past decade has not yielded a large number of new antidepressants and, with the possible exception of agomelatine, none of the newer medications that have been introduced have decisively addressed the several unmet needs in this area of therapeutics. Among the various novel strategies that are being evaluated, results of several small studies of ketamine suggest that drugs that modulate glutamatergic neurotransmission may hold the greatest promise for exerting rapid and large antidepressant effects in patients who have not responded to SSRIs or SNRIs. C1 [Connolly, Kevin Ryan; Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Connolly, Kevin Ryan] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Connolly, KR (reprint author), Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM kevin.connolly2@va.gov FU Agency for Healthcare Research and Quality; Eli Lilly Co.; Forest Pharmaceuticals; GlaxoSmithKline; NIMH; Otsuka Pharmaceuticals; Pfizer Pharmaceuticals; Roche, Inc. FX KR Connolly states no conflict of interest and has received no payment in preparation of this manuscript. ME Thase has earned income as a consultant to Aldolor, Alkermes, AstraZeneca, Bristol-Myers Squibb, Dey Pharmaceuticals, Eli Lilly & Co., Forest Laboratories, Gerson Lehman Group, GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Inc., Merck (Organon; Schering-Plough), Neuronetics, Inc., Novartis, Otsuka, Ortho-McNeil (Johnson & Johnson), PamLab, Pfizer (Wyeth), PharmaNeuroboost, Rexahn, Roche, Inc., Shire US, Inc., Supernus, Takeda and Transcept. He has also received grants from the Agency for Healthcare Research and Quality, Eli Lilly & Co., Forest Pharmaceuticals, GlaxoSmithKline, NIMH, Otsuka Pharmaceuticals, Pfizer Pharmaceuticals and Roche, Inc. NR 107 TC 35 Z9 36 U1 6 U2 38 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1472-8214 EI 1744-7623 J9 EXPERT OPIN EMERG DR JI Expert Opin Emerg. Drugs PD MAR PY 2012 VL 17 IS 1 BP 105 EP 126 DI 10.1517/14728214.2012.660146 PG 22 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 915LA UT WOS:000302025800010 PM 22339643 ER PT J AU Gukovsky, I Pandol, SJ Mareninova, OA Shalbueva, N Jia, WZ Gukovskaya, AS AF Gukovsky, Ilya Pandol, Stephen J. Mareninova, Olga A. Shalbueva, Natalia Jia, Wenzhuo Gukovskaya, Anna S. TI Impaired autophagy and organellar dysfunction in pancreatitis SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE cathepsin; lysosome-associated membrane protein; lysosome; pancreatic mitochondria; permeability transition pore ID KEY PATHOLOGICAL RESPONSES; KAPPA-B ACTIVATION; CELL-DEATH; ACINAR-CELLS; PERMEABILITY TRANSITION; TRYPSINOGEN ACTIVATION; MITOCHONDRIA; PATHOGENESIS; MECHANISMS; PATHWAYS AB Recent findings from our group, obtained on experimental in vivo and ex vivo models of pancreatitis, reveal that this disease causes a profound dysfunction of key cellular organelles, lysosomes and mitochondria. We found that autophagy, the main cellular degradative, lysosome-driven process, is activated but also impaired in acute pancreatitis because of its' inefficient progression/resolution (flux) resulting from defective function of lysosomes. One mechanism underlying the lysosomal dysfunction in pancreatitis is abnormal processing (maturation) and activation of cathepsins, major lysosomal hydrolases; another is a decrease in pancreatic levels of key lysosomal membrane proteins LAMP-1 and LAMP-2. Our data indicate that lysosomal dysfunction plays an important initiating role in pancreatitis pathobiology. The impaired autophagy mediates vacuole accumulation in acinar cells; furthermore, the abnormal maturation and activation of cathepsins leads to increase in intra-acinar trypsin, the hallmark of pancreatitis; and LAMP-2 deficiency causes inflammation and acinar cell necrosis. Thus, the autophagic and lysosomal dysfunctions mediate key pathologic responses of pancreatitis. On the other hand, we showed that pancreatitis causes acinar cell mitochondria depolarization, mediated by the permeability transition pore (PTP). Genetic (via deletion of cyclophilin D) inactivation of PTP prevents mitochondrial depolarization and greatly ameliorates the pathologic responses of pancreatitis. Further, our data suggest that mitochondrial damage, by stimulating autophagy, increases the demand for efficient lysosomal degradation and therefore aggravates the pathologic consequences of lysosomal dysfunction. Thus, the combined autophagic, lysosomal and mitochondrial dysfunctions are key to the pathogenesis of pancreatitis. C1 [Gukovsky, Ilya; Pandol, Stephen J.; Mareninova, Olga A.; Shalbueva, Natalia; Gukovskaya, Anna S.] VA Greater Los Angeles Healthcare Syst, So Calif Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA USA. [Gukovsky, Ilya; Pandol, Stephen J.; Mareninova, Olga A.; Shalbueva, Natalia; Gukovskaya, Anna S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Jia, Wenzhuo] Beijing Hosp, Beijing, Peoples R China. [Gukovsky, Ilya; Pandol, Stephen J.; Mareninova, Olga A.; Shalbueva, Natalia; Gukovskaya, Anna S.] VA Greater Los Angeles Healthcare Syst, So Calif Res Ctr Cirrhosis, Los Angeles, CA USA. RP Gukovskaya, AS (reprint author), UCLA VA Greater Los Angeles, W Los Angeles VA Healthcare Ctr, Pancreat Res Grp, 11308 Wilshire Blvd,Blg 258,Rm 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU NCI NIH HHS [P01 CA163200]; NIAAA NIH HHS [P50 AA011999-09, AA19730, P50 AA011999, P50AA11999, R01 AA019730, R01 AA019730-01A1]; NIDDK NIH HHS [DK59936, R01 DK059936, R01 DK059936-09] NR 51 TC 41 Z9 44 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD MAR PY 2012 VL 27 SU 2 SI SI BP 27 EP 32 DI 10.1111/j.1440-1746.2011.07004.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 889AX UT WOS:000300047000007 PM 22320913 ER PT J AU Yano, EM Chaney, EF Campbell, DG Klap, R Simon, BF Bonner, LM Lanto, AB Rubenstein, LV AF Yano, Elizabeth M. Chaney, Edmund F. Campbell, Duncan G. Klap, Ruth Simon, Barbara F. Bonner, Laura M. Lanto, Andrew B. Rubenstein, Lisa V. TI Yield of Practice-Based Depression Screening In VA Primary Care Settings SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE depression; screening; primary care; health care delivery; veterans ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-COMORBIDITY-SURVEY; IDENTIFICATION TEST AUDIT; ALCOHOL-USE DISORDERS; MENTAL-HEALTH; MAJOR DEPRESSION; COLLABORATIVE MANAGEMENT; MEDICAL OUTPATIENTS; SUICIDAL IDEATION; UNITED-STATES AB BACKGROUND: Many patients who should be treated for depression are missed without effective routine screening in primary care (PC) settings. Yearly depression screening by PC staff is mandated in the VA, yet little is known about the expected yield from such screening when administered on a practice-wide basis. OBJECTIVE: We characterized the yield of practice-based screening in diverse PC settings, as well as the care needs of those assessed as having depression. DESIGN: Baseline enrollees in a group randomized trial of implementation of collaborative care for depression. PARTICIPANTS: Randomly sampled patients with a scheduled PC appointment in ten VA primary care clinics spanning five states. MEASUREMENTS: PHQ-2 screening followed by the full PHQ-9 for screen positives, with standardized sociodemographic and health status questions. RESULTS: Practice-based screening of 10,929 patients yielded 20.1% positive screens, 60% of whom were assessed as having probable major depression based on the PHQ-9 (11.8% of all screens) (n=1,313). In total, 761 patients with probable major depression completed the baseline assessment. Comorbid mental illnesses (e. g., anxiety, PTSD) were highly prevalent. Medical comorbidities were substantial, including chronic lung disease, pneumonia, diabetes, heart attack, heart failure, cancer and stroke. Nearly one-third of the depressed PC patients reported recent suicidal ideation (based on the PHQ-9). Sexual dysfunction was also common (73.3%), being both longstanding (95.1% with onset >6 months) and frequently undiscussed and untreated (46.7% discussed with any health care provider in past 6 months). CONCLUSIONS: Practice-wide survey-based depression screening yielded more than twice the positive-screen rate demonstrated through chart-based VA performance measures. The substantial level of comorbid physical and mental illness among PC patients precludes solo management by either PC or mental health (MH) specialists. PC practice-and provider-level guideline adherence is problematic without systems-level solutions supporting adequate MH assessment, PC treatment and, when needed, appropriate MH referral. C1 [Yano, Elizabeth M.; Klap, Ruth; Simon, Barbara F.; Lanto, Andrew B.; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Ctr Excellence Study Healt, Sepulveda, CA USA. [Yano, Elizabeth M.; Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Sci, Los Angeles, CA 90024 USA. [Chaney, Edmund F.; Bonner, Laura M.] VA Puget Sound Healthcare Syst, NW Ctr Outcomes Res, VA HSR&D Ctr Excellence, Seattle, WA USA. [Chaney, Edmund F.; Bonner, Laura M.] Univ Washington, Seattle, WA 98195 USA. [Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, Dept Med, Sepulveda, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Rubenstein, Lisa V.] RAND Hlth, Santa Monica, CA USA. RP Yano, EM (reprint author), VA Greater Los Angeles HSRD Ctr Excellence, 16111 Plummer St,Mailcode 152, Sepulveda, CA 91343 USA. EM elizabeth.yano@va.gov FU Department of Veterans Affairs (VA) Health Services Research and Development (HSRD) Service; Quality Enhancement Research Initiative (QUERI) [MHI 99-375, MNT 01-027]; VA HSRD [05-195]; VA Office of Academic Affiliations (OAA) at the Northwest Center for Outcomes Research FX This project was funded by the Department of Veterans Affairs (VA) Health Services Research and Development (HSR&D) Service and the Quality Enhancement Research Initiative (QUERI) (Project #MHI 99-375 and MNT 01-027). The manuscript reflects baseline data from a group randomized trial (Trial Registration No. NCT00105820). Dr. Yano is funded under a VA HSR&D Research Career Scientist award (Project #05-195). Dr. Campbell was funded by a VA Office of Academic Affiliations (OAA) Associated Health Postdoctoral Fellowship Program at the Northwest Center for Outcomes Research at the time the study was conducted; he is now Assistant Professor at the University of Montana. NR 65 TC 16 Z9 16 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2012 VL 27 IS 3 BP 331 EP 338 DI 10.1007/s11606-011-1904-5 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 912YP UT WOS:000301838500015 PM 21975821 ER PT J AU Bowden, MG Behrman, AL Woodbury, M Gregory, CM Velozo, CA Kautz, SA AF Bowden, Mark G. Behrman, Andrea L. Woodbury, Michelle Gregory, Chris M. Velozo, Craig A. Kautz, Steven A. TI Advancing Measurement of Locomotor Rehabilitation Outcomes to Optimize Interventions and Differentiate Between Recovery Versus Compensation SO JOURNAL OF NEUROLOGIC PHYSICAL THERAPY LA English DT Article DE measurement; rehabilitation; walking ID SPINAL-CORD-INJURY; RANDOMIZED CONTROLLED-TRIAL; CHRONIC STROKE SURVIVORS; GROUND REACTION FORCES; STEP ACTIVITY MONITOR; BODY-WEIGHT SUPPORT; AMBULATORY ACTIVITY; HEMIPARETIC WALKING; CLINICAL-TRIAL; MOTOR CONTROL AB Progress in locomotor rehabilitation has created an increasing need to understand the factors that contribute to motor behavior, to determine whether these factors are modifiable, and if so, to determine how best to modify them in a way that promotes improved function. Currently available clinical measures do not have the capacity to distinguish between neuromotor recovery and compensation for impaired underlying body structure/functions. This Special Interest article examines the state of outcomes measurement in physical therapy in regard to locomotor rehabilitation, and suggests approaches that may improve assessment of recovery and clinical decision-making capabilities. We examine historical approaches to measurement of locomotor rehabilitation outcomes, including rating scales, timed movement tasks, and laboratory-based outcome measures, and we discuss the emerging use of portable technology to assess walking in a free-living environment. The ability to accurately measure outcomes of rehabilitation, both in and away from the clinical/laboratory setting, allows assessment of skill acquisition, retention, and long-term carryover in a variety of environments. Accurate measurement allows behavioral changes to be observed, and assessments to be made, regarding an individual's ability to adapt during interventions and to incorporate new skills into real-world behaviors. The result of such an approach to assessment may be that interventions truly translate from clinical/laboratory to real-world environments. Future locomotor measurement tools must be based on a theoretical framework that can guide their use to accurately quantify treatment effects and provide a basis upon which to develop and refine therapeutic interventions. C1 [Bowden, Mark G.; Woodbury, Michelle; Gregory, Chris M.; Kautz, Steven A.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bowden, Mark G.; Woodbury, Michelle; Gregory, Chris M.; Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC USA. [Behrman, Andrea L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA. [Velozo, Craig A.] Univ Florida, Dept Occupat Therapy, NF SG Vet Hlth Syst, Gainesville, FL USA. RP Bowden, MG (reprint author), 77 President St,MSC 700, Charleston, SC 29425 USA. EM bowdenm@musc.edu OI Kautz, Steven/0000-0003-3151-8235 FU VA Career Development Award (Phase I) [B7177]; National Institutes of Health National Center for Medical and Rehabilitation Research (NICHD) [KI2 HD055929]; National Institute for Neurological Disorders Stroke; VA Merit Review [B3983-R]; VA Center of Excellence [F2182C] FX Funding : VA Career Development Award (Phase I): B7177; KI2 HD055929 National Institutes of Health National Center for Medical and Rehabilitation Research (NICHD) and National Institute for Neurological Disorders & Stroke; VA Merit Review grant B3983-R; and VA Center of Excellence grant #F2182C (Brain Rehabilitation Research Center). NR 59 TC 12 Z9 12 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1557-0576 J9 J NEUROL PHYS THER JI J. Neurol. Phys. Ther. PD MAR PY 2012 VL 36 IS 1 BP 38 EP 44 DI 10.1097/NPT.0b013e3182472cf6 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 915CS UT WOS:000302001500007 PM 22333921 ER PT J AU Litvan, I Goldman, JG Troster, AI Schmand, BA Weintraub, D Petersen, RC Mollenhauer, B Adler, CH Marder, K Williams-Gray, CH Aarsland, D Kulisevsky, J Rodriguez-Oroz, MC Burn, DJ Barker, RA Emre, M AF Litvan, Irene Goldman, Jennifer G. Troester, Alexander I. Schmand, Ben A. Weintraub, Daniel Petersen, Ronald C. Mollenhauer, Brit Adler, Charles H. Marder, Karen Williams-Gray, Caroline H. Aarsland, Dag Kulisevsky, Jaime Rodriguez-Oroz, Maria C. Burn, David J. Barker, Roger A. Emre, Murat TI Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; cognition; mild cognitive impairment; diagnostic criteria; dementia ID SLEEP BEHAVIOR DISORDER; DEMENTIA RATING-SCALE; CSF AMYLOID-BETA; NEUROPSYCHOLOGICAL CHARACTERISTICS; DECLINE; COHORT; MOCA; MULTICENTER; BIOMARKERS; CAMPAIGN AB Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD. The proposed diagnostic criteria are based on a literature review and expert consensus. This article provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The criteria will require validation, and possibly refinement, as additional research improves our understanding of the epidemiology, presentation, neurobiology, assessment, and long-term course of this clinical syndrome. These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage. (c) 2012 Movement Disorder Society C1 [Litvan, Irene] Univ Louisville, Dept Neurol, Div Movement Disorders, Louisville, KY 40292 USA. [Litvan, Irene] Frazier Rehab Neurosci Inst, Movement Disorders Program, Louisville, KY USA. [Goldman, Jennifer G.] Rush Univ, Med Ctr, Sect Parkinson Dis & Movement Disorders, Dept Neurol Sci, Chicago, IL 60612 USA. [Troester, Alexander I.] Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA. [Schmand, Ben A.] Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands. [Schmand, Ben A.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands. [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Petersen, Ronald C.] Mayo Clin, Mayo Alzheimers Dis Res Ctr, Rochester, MN USA. [Mollenhauer, Brit] Univ Gottingen, Gottingen, Germany. [Mollenhauer, Brit] Paracelsus Elena Klin, Kassel, Germany. [Adler, Charles H.] Mayo Clin, Dept Neurol, Parkinsons Dis & Movement Disorders Ctr, Scottsdale, AZ USA. [Marder, Karen] Columbia Univ, Dept Neurol, New York Presbyterian Hosp, Taub Inst Alzheimers Dis & Aging Brain,Med Ctr, New York, NY USA. [Williams-Gray, Caroline H.; Barker, Roger A.] Univ Cambridge, Dept Clin Neurosci, Cambridge Ctr Brain Repair, Cambridge, England. [Aarsland, Dag] Karolinska Inst, Stockholm, Sweden. [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway. [Aarsland, Dag] Univ Oslo, Akershus Univ Hosp, Oslo, Norway. [Kulisevsky, Jaime] Univ Autonoma Barcelona, St Pau Hosp, Dept Neurol, Movement Disorders Unit, E-08193 Barcelona, Spain. [Kulisevsky, Jaime] Univ Autonoma Barcelona, Inst Biomed Res IIB St Pau, E-08193 Barcelona, Spain. [Kulisevsky, Jaime; Rodriguez-Oroz, Maria C.] Ctr Invest Biomed Red Enfermedad Neurodegenerat, Barcelona, Spain. [Rodriguez-Oroz, Maria C.] Hosp Donostia, Dept Neurol, Donostia San Sebastian, Spain. [Rodriguez-Oroz, Maria C.] BioDonostia Res Inst, Neurosci Unit, San Sebatian, Spain. [Rodriguez-Oroz, Maria C.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain. [Burn, David J.] Newcastle Univ, Inst Hlth & Aging, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Emre, Murat] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Behav Neurol & Movement Disorders Unit, Istanbul, Turkey. RP Litvan, I (reprint author), Univ Calif San Diego, Movement Disorder Program, Dept Neurosci, 8950 Villa La Jolla Dr,Suite C112, La Jolla, CA 92037 USA. EM ilitvan@ucsd.edu OI Aarsland, Dag/0000-0001-6314-216X; Litvan, Irene/0000-0002-3485-3445 FU Medtronic; GlaxoSmithKline; National Parkinson Foundation; National Institutes of Health [P50 AG016574, U01 AG006786, NS36630, RR024156]; Parkinson's UK; European Union; Child Health and Development Institute; Michael J. Fox Foundation for Parkinson's Research; Teva Lundbeck; Springer FX A.I. T. has held consultancies with Medtronic, St. Jude Medical, and Boston Scientific, has served on the advisory board of St. Jude Medical, has received honoraria from Medtronic and the Parkinson's Disease Foundation, and has been awarded grants from Medtronic, GlaxoSmithKline, and the National Parkinson Foundation; D. W. has served on the advisory board of Teva Pharmaceuticals and has received honoraria from The Michael J. Fox Foundation for Parkinson's Research; R. P. has held consultancies with GE Healthcare and Elan Pharmaceuticals, has served on the advisory boards of Pfizer and Janssen Alzheimer Immunotherapy, has been awarded grants from the National Institutes of Health (P50 AG016574 and U01 AG006786), and has received royalties from Oxford University Press; C. H. A. has held consultancies with Merck Serono and Teva Pharmaceuticals; K. M. has been awarded grants from the National Institutes of Health (NS36630 and RR024156); D. B. has received honoraria from Merck Serono and The Michael J. Fox Foundation for Parkinson's Research and has received royalties from Henry Stewart Talks; R. B. has held consultancies with Oxford Biomedica, has served on the advisory board of Teva Lundbeck, has received honoraria from GlaxoSmithKline, has been awarded grants from Parkinson's UK, the European Union FP7 program, the Child Health and Development Institute, and The Michael J. Fox Foundation for Parkinson's Research, has been employed by the University of Cambridge, has received royalties from Wiley and Cambridge University Press, and has received monetary compensation from Springer for editorial work for the Journal of Neurology; and M. E. has held a consultancy with Merck Serono, has served on the advisory board of Merck Serono, has received honoraria from Merck Serono, and has received a clinical study grant from Teva Lundbeck. Full financial disclosures and author roles may be found in the online version of this article. NR 61 TC 425 Z9 439 U1 16 U2 87 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAR PY 2012 VL 27 IS 3 BP 349 EP 356 DI 10.1002/mds.24893 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 906IS UT WOS:000301339300006 PM 22275317 ER PT J AU Karp, JF Rollman, BL Reynolds, CF Morse, JQ Lotrich, F Mazumdar, S Morone, N Weiner, DK AF Karp, Jordan F. Rollman, Bruce L. Reynolds, Charles F., III Morse, Jennifer Q. Lotrich, Frank Mazumdar, Sati Morone, Natalia Weiner, Debra K. TI Addressing Both Depression and Pain in Late Life: The Methodology of the ADAPT Study SO PAIN MEDICINE LA English DT Article DE Clinical Trial; Geriatrics; Depression; Back Pain; Survival Analysis ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; PROBLEM-SOLVING THERAPY; PRIMARY-CARE PATIENTS; OLDER-ADULTS; MAJOR DEPRESSION; COLLABORATIVE CARE; CLINICAL-TRIALS; EXECUTIVE DYSFUNCTION; SUPPORTIVE THERAPY AB Objective. To describe the methodology of the first NIH-funded clinical trial for seniors with comorbid depression and chronic low back pain. Methods. Randomized controlled effectiveness trial using stepped care methodology. Participants are >= 60 years old. Phase 1 (6 weeks) is open treatment with venlafaxine xr 150 mg/day and supportive management (SM). Response is 2 weeks of PHQ-9 <= 5 and at least 30% improvement in the average numeric rating scale for pain. Nonresponders progress to phase 2 (14 weeks) in which they are randomized to high-dose venlafaxine xr (up to 300 mg/day) with problem solving therapy for depression and pain (PST-DP) or high-dose venlafaxine xr and continued SM. Primary outcomes are the univariate pain and depression response and both observed and self-reported disability. Survival analytic techniques will be used, and the clinical effect size will be estimated with the number needed to treat. We hypothesize that self-efficacy for pain management will mediate response for subjects randomized to venlafaxine xr and PST-DP. Results. Not applicable. Conclusions. The results of this trial will inform the care of these complex patients and further understanding of comorbid pain and depression in late life. C1 [Karp, Jordan F.; Rollman, Bruce L.; Reynolds, Charles F., III; Morse, Jennifer Q.; Lotrich, Frank; Mazumdar, Sati; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15260 USA. [Rollman, Bruce L.; Morone, Natalia; Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Mazumdar, Sati] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Karp, JF (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM karpjf@upmc.edu FU National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [AG033575, KL2 RR024154]; NIH Roadmap for Medical Research FX Supported by grant AG033575 (Karp) and by grant KL2 RR024154 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The content is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. Medications were provided by Pfizer for this investigator initiated trial. NR 97 TC 6 Z9 6 U1 5 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD MAR PY 2012 VL 13 IS 3 BP 405 EP 418 DI 10.1111/j.1526-4637.2011.01322.x PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 909NV UT WOS:000301572300010 PM 22313547 ER PT J AU Turner, EH Knoepflmacher, D Shapley, L AF Turner, Erick H. Knoepflmacher, Daniel Shapley, Lee TI Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database SO PLOS MEDICINE LA English DT Article ID PLACEBO-CONTROLLED TRIAL; EXTENDED-RELEASE TABLETS; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; CLINICAL-TRIALS; ACUTE EXACERBATION; REPORTING BIAS; 2ND-GENERATION ANTIPSYCHOTICS; OLANZAPINE TRIAL; SCHIZOPHRENIA AB Background: Publication bias compromises the validity of evidence-based medicine, yet a growing body of research shows that this problem is widespread. Efficacy data from drug regulatory agencies, e. g., the US Food and Drug Administration (FDA), can serve as a benchmark or control against which data in journal articles can be checked. Thus one may determine whether publication bias is present and quantify the extent to which it inflates apparent drug efficacy. Methods and Findings: FDA Drug Approval Packages for eight second-generation antipsychotics-aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injection (risperidone LAI), and ziprasidone-were used to identify a cohort of 24 FDA-registered premarketing trials. The results of these trials according to the FDA were compared with the results conveyed in corresponding journal articles. The relationship between study outcome and publication status was examined, and effect sizes derived from the two data sources were compared. Among the 24 FDA-registered trials, four (17%) were unpublished. Of these, three failed to show that the study drug had a statistical advantage over placebo, and one showed the study drug was statistically inferior to the active comparator. Among the 20 published trials, the five that were not positive, according to the FDA, showed some evidence of outcome reporting bias. However, the association between trial outcome and publication status did not reach statistical significance. Further, the apparent increase in the effect size point estimate due to publication bias was modest (8%) and not statistically significant. On the other hand, the effect size for unpublished trials (0.23, 95% confidence interval 0.07 to 0.39) was less than half that for the published trials (0.47, 95% confidence interval 0.40 to 0.54), a difference that was significant. Conclusions: The magnitude of publication bias found for antipsychotics was less than that found previously for antidepressants, possibly because antipsychotics demonstrate superiority to placebo more consistently. Without increased access to regulatory agency data, publication bias will continue to blur distinctions between effective and ineffective drugs. C1 [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Pharmacol, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA. [Turner, Erick H.] Portland VA Med Ctr, Behav Hlth & Neurosci Div, Portland, OR USA. [Knoepflmacher, Daniel; Shapley, Lee] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. RP Turner, EH (reprint author), Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. EM turnere@ohsu.edu FU Stanley Medical Research Institute [08D-1892]; Portland VA Research Foundation FX Grant support: Stanley Medical Research Institute, grant number 08D-1892 (http://www.stanleyresearch.org/dnn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Comments on methods: Stefan Leucht. Statistical input: David B. Wilson and Alex J. Sutton. Assistance with procurement of FDA and journal data: Julie Anderson. Administration of received grant funds: Portland VA Research Foundation. NR 67 TC 40 Z9 43 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD MAR PY 2012 VL 9 IS 3 AR e1001189 DI 10.1371/journal.pmed.1001189 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA 916VY UT WOS:000302132500009 PM 22448149 ER PT J AU Kelley, SD de Andrade, ARV Bickman, L Robin, AV AF Kelley, Susan Douglas de Andrade, Ana Regina Vides Bickman, Leonard Robin, Ashley V. TI The Session Report Form (SRF): Are Clinicians Addressing Concerns Reported by Youth and Caregivers? SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Youth; Caregiver; Clinician; Session Report Form; Treatment as usual; Describing practice; Respondent differences ID INFORMANT DISCREPANCIES; LOGISTIC-REGRESSION; MEASUREMENT ERROR; CHILD; THERAPY; PSYCHOTHERAPY; ASSESSMENTS; OUTCOMES; CLIENTS; SYSTEM AB This study explores the relationship between clinician-reported content addressed in sessions, measured with the Session Report Form (SRF), and multi-informant problem alerts stemming from a larger battery of treatment process and progress measures. Multilevel Multinomial Logit Models were conducted with 133 clinicians and 299 youths receiving home-based treatment (N = 3,143 sessions). Results indicate a strong relationship between session content and problems related to youth symptoms and functioning as reported by clinicians in the same session. Session content was related to emotional, family, and friend/peer problems reported by youth and youth behavioral problems reported by caregivers. High-risk problems (alcohol/substance use, harm to self or others) were strongly related to session content regardless of informant. Session content was not related to problem alerts associated with the treatment process, caregiver strain, or client/caregiver strengths. The SRF appears to be a useful measure for assessing common themes addressed in routine mental health settings. C1 [Kelley, Susan Douglas; de Andrade, Ana Regina Vides; Bickman, Leonard] Vanderbilt Univ, Peabody Coll 151, Ctr Evaluat & Program Improvement, Nashville, TN 37203 USA. [Robin, Ashley V.] US Dept Vet Affairs, Washington, DC 20420 USA. RP Kelley, SD (reprint author), Vanderbilt Univ, Peabody Coll 151, Ctr Evaluat & Program Improvement, 230 Appleton Pl, Nashville, TN 37203 USA. EM Susan.D.Kelley@vanderbilt.edu RI Price, Katie/H-1931-2012 OI Bickman, Leonard/0000-0002-0746-3791 FU NIMH NIH HHS [R01 MH068589-02, R01 MH068589, R01 MH087814, R01-MH068589, R01-MH4264600201] NR 39 TC 2 Z9 2 U1 1 U2 4 PU MAIK NAUKA/INTERPERIODICA/SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA SN 0894-587X J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD MAR PY 2012 VL 39 IS 1-2 SI SI BP 133 EP 145 DI 10.1007/s10488-012-0415-y PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 909WT UT WOS:000301597800013 PM 22407564 ER PT J AU Lee, C Klaustermeyer, WB AF Lee, C. Klaustermeyer, W. B. TI Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA LA English DT Article DE Asthma; Cell mediated immunity; Delayed type hypersensitivity skin test; Infection; Inhaled corticosteroids ID BONE-MINERAL DENSITY; FLUTICASONE PROPIONATE; PULMONARY TUBERCULOSIS; HOSPITALIZED-PATIENTS; CHILDREN; THERAPY; BECLOMETHASONE; BUDESONIDE; SUPPRESSION; VOLUNTEERS AB Background: Cell mediated immunity is suppressed by systemic corticosteroids. Inhaled corticosteroids have been shown to affect parameters including bone metabolism, hypothalamus-pituitary adrenal axis, linear growth, and lead to the development of cataracts. However, it is unclear if high dose inhaled corticosteroid therapy affects cell mediated immunity. Study objectives: To evaluate if asthma patients taking high dose inhaled corticosteroids chronically have reduced cell mediated immunity compared to asthma patients not taking inhaled corticosteroids. Methods: Eighteen asthmatic subjects participated in this cross-sectional study. Cell mediated immunity was evaluated in nine patients who had been taking high dose inhaled corticosteroids for >6 months and nine patients not taking inhaled corticosteroids. Cell mediated immunity was evaluated by delayed type hypersensitivity (DTH) skin testing with intradermal placement of candida and tetanus antigens. Results: There was no significant difference in DTH skin test results between the high dose inhaled corticosteroid and no corticosteroid treated asthma group. Conclusion: Patients with asthma taking high dose inhaled corticosteroids chronically (>6 months) did not have significantly greater impaired cell mediated immunity than patients not taking inhaled corticosteroids in this study. (c) 2011 SEICAP. Published by Elsevier Espana, S.L. All rights reserved. C1 [Lee, C.; Klaustermeyer, W. B.] Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Lee, C (reprint author), Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM christina.h.lee@hotmail.com NR 39 TC 2 Z9 3 U1 0 U2 1 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 0301-0546 J9 ALLERGOL IMMUNOPATH JI Allergol. Immunopath. PD MAR-APR PY 2012 VL 40 IS 2 BP 100 EP 103 DI 10.1016/j.aller.2011.11.001 PG 4 WC Allergy; Immunology SC Allergy; Immunology GA 907DR UT WOS:000301398500007 PM 22236734 ER PT J AU Troxel, AB Volpp, KG AF Troxel, Andrea B. Volpp, Kevin G. TI Effectiveness of Financial Incentives for Longer-Term Smoking Cessation: Evidence of Absence or Absence of Evidence? SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article ID CONTROLLED-TRIAL; PROGRAM C1 [Troxel, Andrea B.; Volpp, Kevin G.] Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. [Troxel, Andrea B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Troxel, Andrea B.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Volpp, KG (reprint author), 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu OI Troxel, Andrea/0000-0002-1393-3075 FU NIA NIH HHS [P30 AG034546] NR 12 TC 7 Z9 7 U1 0 U2 7 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD MAR-APR PY 2012 VL 26 IS 4 BP 204 EP 207 DI 10.4278/ajhp.101111-CIT-371 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 908EK UT WOS:000301473000003 PM 22375568 ER PT J AU Separovic, D Breen, P Joseph, N Bielawski, J Pierce, JS Van Buren, E Gudz, TI AF Separovic, Duska Breen, Paul Joseph, Nicholas Bielawski, Jacek Pierce, Jason S. Van Buren, Eric Gudz, Tatyana I. TI Ceramide Synthase 6 Knockdown Suppresses Apoptosis after Photodynamic Therapy in Human Head and Neck Squamous Carcinoma Cells SO ANTICANCER RESEARCH LA English DT Article DE Apoptosis; ceramide; ceramide synthase 6; dihydroceramide; PDT; sphingolipids; head and neck squamous carcinoma; UM-SCC-22A cells ID LONGEVITY ASSURANCE GENE-1; DE-NOVO SPHINGOLIPIDS; PHOTOSENSITIZED CELLS; CANCER-CELLS; DEATH; ACCUMULATION; INHIBITION AB Background: The effectiveness of photodynamic therapy (PDT) for cancer treatment correlates with apoprosis. We observed that suppression of de nova-generated sphingolipids, e.g. ceramide, renders cells resistant to apoptosis post-PDT. Ceramide synthase 6 (CerS6) has been implicated in apoptosis after various stimuli. Aim: To investigate the involvement of down-regulation of CerS6 in apoptosis and its impact on the sphingolipid profile post-PDT with the silicone phthalocyanine Pc 4 in a human head and neck squamous carcinoma cell line. Materials and Methods: Besides siRNA transfections and PDT treatment, immunoblotting for protein expression, mass spectrometry for sphingolipid analysis, spectroflurometry and flow cytometry for apoptotic marker detection, and trypan blue assay for cytotoxicity assessment, were used. Results: CerS6 knockdown led to reduction in PDT-induced DEVDase activation, mitochondrial depolarization, apoptosis and cell death. CerS6 knockdown was associated with selective decreases in ceramides and dihydroceramides, markedly of C18-dihydroceramide, post-PDT. Conclusion: CerS6 might be a novel therapeutic target for regulating apoptotic resistance to PDT. C1 [Separovic, Duska; Breen, Paul; Joseph, Nicholas] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI 48201 USA. [Separovic, Duska; Van Buren, Eric] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA. [Bielawski, Jacek; Pierce, Jason S.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Gudz, Tatyana I.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Separovic, D (reprint author), Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 259 Mack Ave, Detroit, MI 48201 USA. EM dseparovic@wayne.edu FU U.S. Public Health Service; National Cancer Institute, National Institutes of Health [R01 CA77475]; RR&D and BLRD programs; NCI [IPO1CA097132, P30 CA 138313]; NIH/NCRR SC COBRE [P20 RR017677]; NIH; National Center for Research Resources [C06 RR018823] FX This work was supported by U.S. Public Health Service Grant R01 CA77475 from the National Cancer Institute, National Institutes of Health (DS) and the Veterans Administration Merit Awards from RR&D and BLRD programs (TIG). The MS-related work was performed by the Lipidomics Shared Resource (Medical University of South Carolina), supported by NCI grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20 RR017677. Laboratory space for the Lipidomics Shared Resource was supported by the NIH, grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Drs. Besim Ogretmen and Can Ewe Senkal for helpful discussions of the manuscript. NR 29 TC 15 Z9 16 U1 0 U2 3 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 J9 ANTICANCER RES JI Anticancer Res. PD MAR PY 2012 VL 32 IS 3 BP 753 EP 760 PG 8 WC Oncology SC Oncology GA 910EE UT WOS:000301619200006 PM 22399588 ER PT J AU Albrecht, J Werth, VP AF Albrecht, Joerg Werth, Victoria P. TI Improving the Care of Our Patients Who Are Receiving Glucocorticoid Therapy SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material C1 [Werth, Victoria P.] Hosp Univ Penn, Dept Dermatol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA. [Albrecht, Joerg] John H Stroger Jr Hosp Cook Cty, Div Dermatol, Dept Med, Chicago, IL USA. [Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, Perelman Ctr Adv Med, 3400 Civ Ctr Blvd,Ste 1-330S, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24-AR 02207, K24 AR002207] NR 3 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD MAR PY 2012 VL 148 IS 3 BP 314 EP 315 PG 2 WC Dermatology SC Dermatology GA 911BV UT WOS:000301693200005 PM 22431773 ER PT J AU Piette, EW Foering, KP Chang, AY Okawa, J Ten Have, TR Feng, R Werth, VP AF Piette, Evan W. Foering, Kristen P. Chang, Aileen Y. Okawa, Joyce Ten Have, Thomas R. Feng, Rui Werth, Victoria P. TI Impact of Smoking in Cutaneous Lupus Erythematosus SO ARCHIVES OF DERMATOLOGY LA English DT Article ID CIGARETTE-SMOKING; ALCOHOL-CONSUMPTION; TOBACCO-SMOKE; ASSOCIATION; RISK; TUMIDUS; MARKERS; LESIONS AB Objective: To investigate cigarette smoking in cutaneous lupus erythematosus (CLE). Design: Prospective longitudinal cohort study. Setting: Urban cutaneous autoimmune disease clinic. Participants: A total of 218 individuals with CLE or systemic lupus erythematosus and lupus nonspecific skin disease seen between January 5, 2007, and July 30, 2010. Main Outcome Measures: Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores to assess disease severity and response to treatment and Skindex 29+3 scores to assess patient quality of life. Results: Current smokers with lupus erythematosus had higher median CLASI scores (9.5) than did never (7.0) and past (6.0) smokers with CLE (P = .02). Current smokers had higher median scores on all the Skindex 29+3 subsets. Current smokers taking hydroxychloroquine sulfate had higher quinacrine hydrochloride use than did nonsmokers (P = .04). Two to 7 months after enrollment, current smokers (median CLASI change, 3) treated with only antimalarial agents improved more than never (1) and past (0) smokers (P = .02). Eight months or more after enrollment, current smokers (CLASI change, 3.5) treated with antimalarial drugs plus at least 1 additional immunomodulator improved less than never (-1.5) and past (0) smokers (P = .04). Conclusions: Current smokers with lupus erythematosus had worse disease, had worse quality of life, and were more often treated with a combination of hydroxychloroquine and quinacrine than were nonsmokers. Never and past smokers showed greater improvement when treated with antimalarial agents plus at least 1 additional immunomodulator. Current smokers had greater improvement when treated with antimalarial drugs only. C1 [Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA. [Piette, Evan W.; Foering, Kristen P.; Chang, Aileen Y.; Okawa, Joyce; Ten Have, Thomas R.; Feng, Rui; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ten Have, Thomas R.; Feng, Rui; Werth, Victoria P.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Univ Penn, Sch Med, Dept Dermatol, Perelman Ctr Adv Med, Ste 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU National Institutes of Health [K24-AR 18 02207]; Celgene; Amgen FX This study is based on work supported by the National Institutes of Health, including grant K24-AR 18 02207 (Dr Werth).; The copyright for CLASI is owned by the University of Pennsylvania. Dr Werth has served as a consultant to Pfizer, Novartis, Cephalon, Rigel, and Medimmune and has received grant support from Celgene and Amgen. NR 24 TC 28 Z9 28 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD MAR PY 2012 VL 148 IS 3 BP 317 EP 322 DI 10.1001/archdermatol.2011.342 PG 6 WC Dermatology SC Dermatology GA 911BV UT WOS:000301693200006 PM 22105815 ER PT J AU Fett, N AF Fett, Nicole TI Gabapentin Not Shown to Prevent Postherpetic Neuralgia SO ARCHIVES OF DERMATOLOGY LA English DT Letter ID HERPES-ZOSTER; VACCINE C1 [Fett, Nicole] Univ Penn, Dept Dermatol, Sch Med, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA. [Fett, Nicole] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Fett, N (reprint author), Univ Penn, Dept Dermatol, Sch Med, Perelman Ctr Adv Med, 3400 Civ Ctr Blvd,Ste 1-330A, Philadelphia, PA 19104 USA. EM nicole.fett@uphs.upenn.edu NR 5 TC 2 Z9 3 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD MAR PY 2012 VL 148 IS 3 BP 400 EP 401 PG 2 WC Dermatology SC Dermatology GA 911BV UT WOS:000301693200026 PM 22431790 ER PT J AU McKiernan, SH Colman, RJ Aiken, E Evans, TD Beasley, TM Aiken, JM Weindruch, R Anderson, RM AF McKiernan, Susan H. Colman, Ricki J. Aiken, Erik Evans, Trent D. Beasley, T. Mark Aiken, Judd M. Weindruch, Richard Anderson, Rozalyn M. TI Cellular adaptation contributes to calorie restriction-induced preservation of skeletal muscle in aged rhesus monkeys SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE Rhesus monkey; Calorie restriction; Sarcopenia; Aged ID DNA-DELETION MUTATIONS; DIETARY RESTRICTION; MITOCHONDRIAL ABNORMALITIES; FIBER ATROPHY; ADULT MALE; LIFE-SPAN; SARCOPENIA; SIZE; PHENOTYPES; ONSET AB We have previously shown that a 30% reduced calorie intake diet delayed the onset of muscle mass loss in adult monkeys between similar to 16 and similar to 22 years of age and prevented multiple cellular phenotypes of aging. In the present study we show the impact of long term (similar to 17 years) calorie restriction (CR) on muscle aging in very old monkeys (27-33 yrs) compared to age-matched Control monkeys fed ad libitum, and describe these data in the context of the whole longitudinal study. Muscle mass was preserved in very old calorie restricted (CR) monkeys compared to age-matched Controls. Immunohistochemical analysis revealed an age-associated increase in the proportion of Type I fibers in the VL from Control animals that was prevented with CR. The cross sectional area (CSA) of Type II fibers was reduced in old CR animals compared to earlier time points (16-22 years of age); however, the total loss in CSA was only 15% in CR animals compared to 36% in old Controls at similar to 27 years of age. Atrophy was not detected in Type I fibers from either group. Notably, Type I fiber CSA was similar to 1.6 fold greater in VL from CR animals compared to Control animals at similar to 27 years of age. The frequency of VL muscle fibers with defects in mitochondrial electron transport system enzymes (ETSab), the absence of cytochrome c oxidase and hyper-reactive succinate dehydrogenase, were identical between Control and CR. We describe changes in ETSab fiber CSA and determined that CR fibers respond differently to the challenge of mitochondria! deficiency. Fiber counts of intact rectus femoris muscles revealed that muscle fiber density was preserved in old CR animals. We suggest that muscle fibers from CR animals are better poised to endure and adapt to changes in muscle mass than those of Control animals. (C) 2011 Elsevier Inc. All rights reserved. C1 [McKiernan, Susan H.; Aiken, Erik] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. [McKiernan, Susan H.; Colman, Ricki J.] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Evans, Trent D.; Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Beasley, T. Mark] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Aiken, Judd M.] Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2M8, Canada. [Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP McKiernan, SH (reprint author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. EM shmckier@wisc.edu; rmanderson5@wisc.edu FU NIH [P01 AG-11915, P51 RR000167]; Ellison Medical Foundation; Research Facilities Improvement Program [RR15459-01, RR020141-01] FX We acknowledge the efforts of the veterinary staff of the Wisconsin National Primate Research Center. This work was supported by NIH grants P01 AG-11915; P51 RR000167, and the Ellison Medical Foundation Senior Scholar Award (JMA). This research was conducted in part at a facility constructed with support from the Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01. NR 35 TC 15 Z9 15 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD MAR PY 2012 VL 47 IS 3 BP 229 EP 236 DI 10.1016/j.exger.2011.12.009 PG 8 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 911BR UT WOS:000301692800004 PM 22226624 ER PT J AU Bradshaw, AD AF Bradshaw, Amy D. TI Diverse biological functions of the SPARC family of proteins SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Review DE SPL-1; SMOC; Testican; fstl-1; Hevin; SPOCK; Review ID FOLLISTATIN-LIKE PROTEIN-1; THYROGLOBULIN TYPE-1 DOMAIN; CALCIUM-BINDING PROTEIN; INTEGRIN-LINKED KINASE; NULL MICE; MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; MATRICELLULAR PROTEINS; RHEUMATOID-ARTHRITIS; MMP-2 EXPRESSION AB The SPARC family of proteins represents a diverse group of proteins that modulate cell interaction with the extracellular milieu. The eight members of the SPARC protein family are modular in nature. Each shares a follistatin-like domain and an extracellular calcium binding E-F hand motif. In addition, each family member is secreted into the extracellular space. Some of the shared activities of this family include, regulation of extracellular matrix assembly and deposition, counter-adhesion, effects on extracellular protease activity, and modulation of growth factor/cytokine signaling pathways. Recently, several SPARC family members have been implicated in human disease pathogenesis. This review discusses recent advances in the understanding of the functional roles of the SPARC family of proteins in development and disease. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Ralph H Johnson Vet Adm, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA. EM bradshad@musc.edu FU NIH, NIHLB [094517]; Veteran's Administration FX This was supported in part by the NIH, NIHLB through 094517 (ADB), and a Merit Award from the Veteran's Administration to ADB. NR 80 TC 67 Z9 68 U1 3 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PD MAR PY 2012 VL 44 IS 3 BP 480 EP 488 DI 10.1016/j.biocel.2011.12.021 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 913YU UT WOS:000301914100011 PM 22249026 ER PT J AU Maguen, S Luxton, DD Skopp, NA Madden, E AF Maguen, Shira Luxton, David D. Skopp, Nancy A. Madden, Erin TI Gender differences in traumatic experiences and mental health in active duty soldiers redeployed from Iraq and Afghanistan SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Military; Women; Combat; Posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ASSAULT; GULF-WAR; MILITARY; VETERANS; CARE; COMBAT; DEPRESSION; WOMEN; PTSD AB The purpose of this study was to examine gender differences in combat exposure, military sexual trauma (MST), and their associations with mental health screen results among military personnel deployed in support of the wars in Afghanistan and Iraq. Data were collected as part of a pre- and post-deployment screening program at a large Army medical treatment facility. Cases included 7251 active duty soldiers (6697 men and 554 women) who presented for their pre- and post-deployment screening from March 2006 to July 2009. Pre-deployment mental health symptoms were statistically controlled for in our analyses. We found significant gender differences in demographic variables, exposure to combat, and MST. Women reported greater exposure to MST than did men. Although men reported greater exposure to high-intensity combat experiences than women, results indicate that women are experiencing combat at higher rates than observed in prior cohorts. Men were more likely to report problem drinking, and women were more likely to report depression symptoms. There were no gender differences with respect to PTSD symptoms. Although we found few differences between women and men in the impact of combat stressors on mental health, there was a stronger association between injury and PTSD symptoms for women than for men. Our findings indicate that it would be useful for clinicians to be aware of this difference and assess for exposure to a full range of traumatic combat experiences, particularly injury, as not all types of combat experiences may be equally experienced by men and women returning from military deployments. Published by Elsevier Ltd. C1 [Maguen, Shira] San Francisco VA Med Ctr, PTSD Program 116P, San Francisco, CA 94121 USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94122 USA. [Luxton, David D.; Skopp, Nancy A.] OMAMC, Def Ctr Excellence Psychol Hlth, Natl Ctr Telehealtl & Technol, Tacoma, WA 98431 USA. [Luxton, David D.; Skopp, Nancy A.] OMAMC, Def Ctr Traumat Brain Injury, Tacoma, WA 98431 USA. [Luxton, David D.; Skopp, Nancy A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, PTSD Program 116P, 4150 Clement St, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov RI Schueter, nicos/A-3625-2014 FU VA Health Services Research and Development (HSRD) FX This study was funded by a VA Health Services Research and Development (HSR&D) Career Development Award (Maguen). VA HSR&D had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 29 TC 54 Z9 54 U1 2 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD MAR PY 2012 VL 46 IS 3 BP 311 EP 316 DI 10.1016/j.jpsychires.2011.11.007 PG 6 WC Psychiatry SC Psychiatry GA 911YJ UT WOS:000301760300006 PM 22172997 ER PT J AU Rubinsky, AD Sun, H Blough, DK Maynard, C Bryson, CL Harris, AH Hawkins, EJ Beste, LA Henderson, WG Hawn, MT Hughes, G Bishop, MJ Etzioni, R Tonnesen, H Kivlahan, DR Bradley, KA AF Rubinsky, Anna D. Sun, Haili Blough, David K. Maynard, Charles Bryson, Christopher L. Harris, Alex H. Hawkins, Eric J. Beste, Lauren A. Henderson, William G. Hawn, Mary T. Hughes, Grant Bishop, Michael J. Etzioni, Ruth Tonnesen, Hanne Kivlahan, Daniel R. Bradley, Katharine A. TI AUDIT-C Alcohol Screening Results and Postoperative Inpatient Health Care Use SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID LENGTH-OF-STAY; QUALITY IMPROVEMENT PROGRAM; INTENSIVE-CARE; ELECTIVE SURGERY; USE DISORDERS; RISK-FACTORS; MORBIDITY; VETERANS; MEN; COMPLICATIONS AB BACKGROUND: Alcohol screening scores >= 5 on the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) up to a year before surgery have been associated with postoperative complications, but the association with postoperative health care use is unknown. This study evaluated whether AUDIT-C scores in the year before surgery were associated with postoperative hospital length of stay, total ICU days, return to the operating room, and hospital readmission. STUDY DESIGN: This cohort study included male Veterans Affairs patients who completed the AUDIT-C on mailed surveys (October 2003 through September 2006) and were hospitalized for nonemergent noncardiac major operations in the following year. Postoperative health care use was evaluated across 4 AUDIT-C risk groups (scores 0, 1 to 4, 5 to 8, and 9 to 12) using linear or logistic regression models adjusted for sociodemographics, smoking status, surgical category, relative value unit, and time from AUDIT-C to surgery. Patients with AUDIT-C scores indicating low-risk drinking (scores 1 to 4) were the referent group. RESULTS: Adjusted analyses revealed that among eligible surgical patients (n = 5,171), those with the highest AUDIT-C scores (ie, 9 to 12) had longer postoperative hospital length of stay (5.8 [95% CI, 5.0 - 6.7] vs 5.0 [95% CI, 4.7 - 5.3] days), more ICU days (4.5 [95% CI, 3.- - 5.8] vs 2.8 [95% CI, 2.6 - 3.1] days), and increased probability of return to the operating room (10% [95% CI, 6 - 13%] vs 5% [95% CI, 4 - 6%]) in the 30 days after surgery, but not increased hospital readmission within 30 days postdischarge, relative to the low-risk group. CONCLUSIONS: AUDIT-C screening results could be used to identify patients at risk for increased postoperative health care use who might benefit from preoperative alcohol interventions. (J Am Coll Surg 2012; 214: 296-305. c 2012 by the American College of Surgeons) C1 [Rubinsky, Anna D.; Maynard, Charles; Etzioni, Ruth; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bishop, Michael J.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA. [Etzioni, Ruth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Etzioni, Ruth] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Harris, Alex H.] Ctr Hlth Care Evaluat, Dept Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Henderson, William G.; Hughes, Grant] Dept Vet Affairs Eastern Colorado Healthcare Syst, Denver, CO USA. [Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA. [Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, C SMART, Birmingham, W Midlands, England. [Hawn, Mary T.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Tonnesen, Hanne] Bispebjerg Hosp, WHO Collaborating Ctr Evidence Based Hlth Promot, Copenhagen, Denmark. RP Rubinsky, AD (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way,S 152, Seattle, WA 98108 USA. EM Anna.Rubinsky@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development and Health Services Research and Development [IAC 06-021]; Agency for Healthcare Research and Quality Institutional National Research Service through University of Washington [T32 HS 013853] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Health Services Research and Development (IAC 06-021). Ms Rubinsky was also supported by an Agency for Healthcare Research and Quality Institutional National Research Service Award through the University of Washington (T32 HS 013853) when this work was conducted. NR 49 TC 14 Z9 14 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAR PY 2012 VL 214 IS 3 BP 296 EP U69 DI 10.1016/j.jamcollsurg.2011.11.007 PG 11 WC Surgery SC Surgery GA 912BS UT WOS:000301770100008 PM 22244208 ER PT J AU Ben Sassi, S Nabli, F Hentati, E Nahdi, H Trabelsi, M Ben Ayed, H Amouri, R Duda, JE Farrer, MJ Hentati, F AF Ben Sassi, Samia Nabli, Fatma Hentati, Emna Nahdi, Houda Trabelsi, Meriam Ben Ayed, Hela Amouri, Rim Duda, John Eric Farrer, Matthew John Hentati, Faycal TI Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; PARK8; LRRK2 gene; G2019S mutation; Neuropsychological study ID PENETRANCE; MUTATIONS; FAMILIES; GENE AB Background: Cognitive impairment and dementia are frequent and debilitating features associated with idiopathic Parkinson's disease (PD). However the prevalence and the pattern of these complications are lacking for LRRK2 (leucine-rich kinase 2)-associated PD patients. Purpose: The purpose of this study was to assess cognitive function in LRRK2- associated PD patients. Material and methods: 55 patients diagnosed with PD-related LRRK2 G2019S mutation were included in the study and compared to the same number of G2019S non-carriers PD patients. Age, sex, disease duration, the movement disorder society-unified Parkinson's Disease rating scale (MDS-UPDRS), Hoehn and Yahr stage, Schwab and England scale and the 30-item geriatric depression scale (GDS) scores were noted. Cognitive assessment included MMSE (Mini-Mental Examination), MOCA (Montreal Cognitive Assessment) and FAB (Frontal Assessment Battery). Results: MMSE, MOCA and FAB performance in G2019S carriers PD patients was similar to that of non-carriers. In both groups, performance was primarily impaired on visuospatial and executive tasks. Cognitive impairment was associated with older age, lower educational level and increased severity of motor impairment. Conclusion: Cognitive functions were similarly affected in PD patients with and without LRRK2 G2019S mutation with mainly impaired visuospatial and executive abilities. However, these results need to be confirmed by further large and prospective studies. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Ben Sassi, Samia; Nabli, Fatma; Hentati, Emna; Nahdi, Houda; Trabelsi, Meriam; Ben Ayed, Hela; Amouri, Rim; Hentati, Faycal] Natl Inst Neurol, Dept Neurol, Tunis 1007, Tunisia. [Duda, John Eric] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Farrer, Matthew John] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. RP Ben Sassi, S (reprint author), Natl Inst Neurol, Dept Neurol, Tunis 1007, Tunisia. EM bensassisam@yahoo.fr FU Michael J. Fox Foundation FX This study was supported by a grant from the Michael J. Fox Foundation. NR 12 TC 12 Z9 12 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAR PY 2012 VL 18 IS 3 BP 243 EP 246 DI 10.1016/j.parkreldis.2011.10.009 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 912PX UT WOS:000301813200007 PM 22056842 ER PT J AU Heyworth, MF AF Heyworth, Martin F. TI Changing prevalence of human microsporidiosis SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article DE Microsporidiosis; Microsporidia; AIDS; HIV ID ENTEROCYTOZOON-BIENEUSI; ENCEPHALITOZOON-INTESTINALIS AB The frequency of publications about microsporidiosis, indexed in PubMed, was tracked on a yearly basis from 1980 to 2010. Search terms (individual and paired) of various degrees of restrictiveness were used (ranging from least restrictive: 'microsporidia', to most restrictive: 'microsporidiosis/HIV', 'microsporidiosis/AIDS'). The annual number of publications indexed under each search term(s) increased from the early 1980s until the mid 1990s. In subsequent years, there was a decline in numbers of publications retrievable via search terms emphasising human disease. This decline mirrors the declining prevalence of microsporidian infections in the HIV-infected population since the mid to late 1990s. Published by Elsevier Ltd on behalf of Royal Society of Tropical Medicine and Hygiene. C1 [Heyworth, Martin F.] Dept Vet Affairs Med Ctr, Res Serv, Philadelphia, PA 19104 USA. [Heyworth, Martin F.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. RP Heyworth, MF (reprint author), Dept Vet Affairs Med Ctr, Res Serv, Philadelphia, PA 19104 USA. EM martin.heyworth@va.gov NR 10 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0035-9203 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD MAR PY 2012 VL 106 IS 3 BP 202 EP 204 DI 10.1016/j.trstmh.2011.11.005 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 910HD UT WOS:000301626900012 PM 22261187 ER PT J AU Bodnar, RJ Rodgers, ME Wells, A AF Bodnar, R. J. Rodgers, M. E. Wells, A. TI PERICYTE REGULATION OF VASCULAR REMODELING THROUGH THE CXC RECEPTOR 3 SO WOUND REPAIR AND REGENERATION LA English DT Meeting Abstract C1 [Bodnar, R. J.; Rodgers, M. E.; Wells, A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bodnar, R. J.; Wells, A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1067-1927 J9 WOUND REPAIR REGEN JI Wound Repair Regen. PD MAR-APR PY 2012 VL 20 IS 2 BP A16 EP A16 PG 1 WC Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery SC Cell Biology; Dermatology; Research & Experimental Medicine; Surgery GA 901DY UT WOS:000300943100017 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Management of Delayed Postpolypectomy Bleeding: A Decision Analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID COLONOSCOPIC POLYPECTOMY; RISK-FACTORS; HEMORRHAGE AB OBJECTIVES: The benefit of repeat colonoscopy in managing delayed postpolypectomy bleeding is unknown. This study aimed to assess the outcome of repeat colonoscopy to achieve hemostasis. METHODS: Endoscopic management of postpolypectomy bleeding is modeled as a decision tree, measuring the expected overall fraction of patients who benefit from therapeutic hemostasis and the number of patients needed to treat (NNT) in order to achieve one beneficial hemostasis. RESULTS: A repeat colonoscopy to identify and treat postpolypectomy bleeding is beneficial in about 22% of patients, corresponding to an NNT of 4.5 patients. The outcome of the model is sensitive to assumptions underlying the fractions of patients who need treatment and would benefit from successful endoscopic hemostasis. Varying these probabilities over a broad range changes the fraction of patients benefiting from endoscopy between 3% and 33% and the NNT between 28 and 3 patients, respectively. CONCLUSIONS: The expected outcome of repeat colonoscopy justifies the endoscopic attempts at therapeutic hemostasis. The results also suggest that in many patients expectant management aimed at spontaneous resolution of the bleeding remains a valid option. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 18 TC 4 Z9 4 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2012 VL 107 IS 3 BP 339 EP 342 DI 10.1038/ajg.2011.426 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 908NH UT WOS:000301496600002 PM 22388016 ER PT J AU Laine, L Jensen, DM AF Laine, Loren Jensen, Dennis M. TI Management of Patients With Ulcer Bleeding SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID UPPER-GASTROINTESTINAL HEMORRHAGE; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; HELICOBACTER-PYLORI INFECTION; PROTON PUMP INHIBITORS; DOUBLE-BLIND TRIAL; ENDOSCOPIC INJECTION THERAPY; NONBLEEDING VISIBLE VESSELS; CORONARY-ARTERY-DISEASE; UPPER-GI HEMORRHAGE AB This guideline presents recommendations for the step-wise management of patients with overt upper gastrointestinal bleeding. Hemodynamic status is first assessed, and resuscitation initiated as needed. Patients are risk-stratified based on features such as hemodynamic status, comorbidities, age, and laboratory tests. Pre-endoscopic erythromycin is considered to increase diagnostic yield at first endoscopy. Pre-endoscopic proton pump inhibitor (PPI) may be considered to decrease the need for endoscopic therapy but does not improve clinical outcomes. Upper endoscopy is generally performed within 24 h. The endoscopic features of ulcers direct further management. Patients with active bleeding or non-bleeding visible vessels receive endoscopic therapy (e.g., bipolar electrocoagulation, heater probe, sclerosant, clips) and those with an adherent clot may receive endoscopic therapy; these patients then receive intravenous PPI with a bolus followed by continuous infusion. Patients with flat spots or clean-based ulcers do not require endoscopic therapy or intensive PPI therapy. Recurrent bleeding after endoscopic therapy is treated with a second endoscopic treatment; if bleeding persists or recurs, treatment with surgery or interventional radiology is undertaken. Prevention of recurrent bleeding is based on the etiology of the bleeding ulcer. H. pylori is eradicated and after cure is documented anti-ulcer therapy is generally not given. Nonsteroidal anti-inflammatory drugs (NSAIDs) are stopped; if they must be resumed low-dose COX-2-selective NSAID plus PPI is used. Patients with established cardiovascular disease who require aspirin should start PPI and generally re-institute aspirin soon after bleeding ceases (within 7 days and ideally 1-3 days). Patients with idiopathic ulcers receive long-term anti-ulcer therapy. C1 [Laine, Loren] Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06520 USA. [Laine, Loren] VA Connecticut Healthcare Syst, New Haven, CT USA. [Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Jensen, Dennis M.] CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Jensen, Dennis M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Laine, L (reprint author), Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,1080 LMP, New Haven, CT 06520 USA. EM loren.laine@yale.edu FU Boston Scientific; Pentax; Olympus; US Endoscopy; Vascular Technology Inc. FX L. Laine has served as a consultant for AstraZeneca, Eisai, Pfizer, Horizon, and Logical Therapeutics, and has served on Data Safety Monitoring Boards for Bayer, BMS, and Merck. D. Jensen is a consultant for AstraZeneca, Boston Scientific, Merck, and US Endoscopy. D. Jensen has received research grants from Boston Scientific, Pentax, Olympus, US Endoscopy, and Vascular Technology Inc. NR 133 TC 148 Z9 166 U1 3 U2 30 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2012 VL 107 IS 3 BP 345 EP 361 DI 10.1038/ajg.2011.480 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 908NH UT WOS:000301496600003 PM 22310222 ER PT J AU Profit, J Etchegaray, J Petersen, LA Sexton, JB Hysong, SJ Mei, MH Thomas, EJ AF Profit, Jochen Etchegaray, Jason Petersen, Laura A. Sexton, J. Bryan Hysong, Sylvia J. Mei, Minghua Thomas, Eric J. TI The Safety Attitudes Questionnaire as a tool for benchmarking safety culture in the NICU SO ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION LA English DT Article ID NEONATAL INTENSIVE-CARE; COLLABORATIVE QUALITY IMPROVEMENT; PATIENT SAFETY; RANDOMIZED-TRIAL; OF-CARE; CLIMATE; UNITS; TEAMWORK AB Background Neonatal intensive care unit (NICU) safety culture, as measured by the Safety Attitudes Questionnaire (SAQ), varies widely. Associations with clinical outcomes in the adult intensive care unit setting make the SAQ an attractive tool for comparing clinical performance between hospitals. Little information is available on the use of the SAQ for this purpose in the NICU setting. Objectives To determine whether the dimensions of safety culture measured by the SAQ give consistent results when used as a NICU performance measure. Methods Cross-sectional survey of caregivers in 12 NICUs, using the six scales of the SAO: teamwork climate, safety climate, job satisfaction, stress recognition, perceptions of management and working conditions. NICUs were ranked by quantifying their contribution to overall risk-adjusted variation across the scales. Spearman rank correlation coefficients were used to test for consistency in scale performance. The authors then examined whether performance in the top four NICUs in one scale predicted top four performance in others. Results There were 547 respondents in 12 NICUs. Of 15 NICU-level correlations in performance ranking, two were >0.7, seven were between 0.4 and 0.69, and the six remaining were <0.4. The authors found a trend towards significance in comparing the distribution of performance in the top four NICUs across domains with a binomial distribution p=0.051, indicating generally consistent performance across dimensions of safety culture. Conclusion A culture of safety permeates many aspects of patient care and organisational functioning. The SAQ may be a useful tool for comparative performance assessments among NICUs. C1 [Profit, Jochen] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Texas Childrens Hosp, Dept Pediat,Sect Neonatol, Houston, TX 77030 USA. [Profit, Jochen; Petersen, Laura A.; Mei, Minghua] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. [Profit, Jochen; Petersen, Laura A.; Hysong, Sylvia J.; Mei, Minghua] VA Med Ctr, Houston Vet Affairs VA Hlth Serv Res & Dev, Ctr Excellence, Hlth Policy & Qual Program,Michael DeBakey VA Med, Houston, TX USA. [Etchegaray, Jason; Thomas, Eric J.] Univ Texas Houston, Sch Med, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Sexton, J. Bryan] Duke Univ, Dept Psychiat, Sch Med, Duke Univ Hlth Syst, Durham, NC 27706 USA. RP Profit, J (reprint author), Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Texas Childrens Hosp, Dept Pediat,Sect Neonatol, VA HSR&D 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM profit@bcm.edu RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207; Etchegaray, Jason/0000-0002-3427-796X FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [1 K23 HD056298-01, 1 K24 HD053771-01, 1 PO1 HS1154401]; American Heart Association [0540043N]; Veterans Administration Center (VA HSRD CoE) [HFP90-20]; Department of Veterans Affairs Health Services [CD 2-07-0818]; Agency for Healthcare Research and Quality (AHRQ) [1UC1HS014246, 1 K02 HS017145-02]; University of Texas at Houston - Memorial Hermann Center for Quality and Safety FX JP's contribution is supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (#1 K23 HD056298-01, PI: Profit). LAP was a recipient of the American Heart Association Established Investigator Award (#0540043N) at the time that this work was carried out. LAP, SJH and MM also receive support from a Veterans Administration Center Grant (VA HSR&D CoE HFP90-20). SJH's contribution is supported in part by the Department of Veterans Affairs Health Services Research and Development Program (#CD 2-07-0818). EJT's effort is supported in part by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (#1 K24 HD053771-01, PI: Thomas and #1 PO1 HS1154401, PI: Thomas). JBS received support from the Agency for Healthcare Research and Quality (AHRQ) (grant # 1UC1HS014246). JE's effort is supported by a K02 award from AHRQ (#1 K02 HS017145-02) and the University of Texas at Houston - Memorial Hermann Center for Quality and Safety. NR 31 TC 14 Z9 16 U1 3 U2 14 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1359-2998 J9 ARCH DIS CHILD-FETAL JI Arch. Dis. Child.-Fetal Neonatal Ed. PD MAR PY 2012 VL 97 IS 2 BP F127 EP F132 DI 10.1136/archdischild-2011-300612 PG 6 WC Pediatrics SC Pediatrics GA 910JU UT WOS:000301633800010 PM 22337935 ER PT J AU Fried, L AF Fried, Linda TI Albuminuria and Cognitive Impairment SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID GLOMERULAR-FILTRATION-RATE; KIDNEY-FUNCTION; GENERAL-POPULATION; BLOOD-PRESSURE; ALL-CAUSE; DECLINE; ASSOCIATION; MORTALITY; EXCRETION; DEMENTIA C1 [Fried, Linda] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA. [Fried, Linda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15240 USA. [Fried, Linda] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Fried, L (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. EM Linda.Fried@va.gov NR 19 TC 5 Z9 5 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2012 VL 7 IS 3 BP 376 EP 378 DI 10.2215/CJN.00210112 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 904TZ UT WOS:000301222100002 PM 22282483 ER PT J AU Ellison, DH AF Ellison, David H. TI Adaptation in Gitelman Syndrome: "We Just Want to Pump You Up" SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID NA+-CL-COTRANSPORTER; BARTTERS-SYNDROME; HYPOKALEMIC ALKALOSIS; BLOOD-PRESSURE; SALT TRANSPORT; MOUSE MODEL; CHONDROCALCINOSIS; HYPOMAGNESEMIA; MUTATIONS; HYPOCALCIURIA C1 [Ellison, David H.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. RP Ellison, DH (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Suite 262,3314 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X NR 25 TC 4 Z9 5 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2012 VL 7 IS 3 BP 379 EP 382 DI 10.2215/CJN.01060112 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 904TZ UT WOS:000301222100003 PM 22344514 ER PT J AU Sher, L AF Sher, Leo TI Testosterone and suicidal behavior SO EXPERT REVIEW OF NEUROTHERAPEUTICS LA English DT Editorial Material DE aggression; cognition; depression; mood; suicide; testosterone ID VIOLENT OFFENDERS; MEN; DEPRESSION; SUPPLEMENTATION; ASSOCIATION; AGGRESSION; ATTEMPTERS; DISORDERS; MOOD C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM leo.sher@mssm.edu NR 20 TC 6 Z9 6 U1 0 U2 3 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7175 J9 EXPERT REV NEUROTHER JI Expert Rev. Neurother. PD MAR PY 2012 VL 12 IS 3 BP 257 EP 259 DI 10.1586/ERN.12.6 PG 3 WC Clinical Neurology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 907CH UT WOS:000301394900002 PM 22364323 ER PT J AU Boardman, CR Sonnenberg, A AF Boardman, Charles R. Sonnenberg, Amnon TI Are all colon cancers created equal? SO GASTROINTESTINAL ENDOSCOPY LA English DT Letter C1 [Boardman, Charles R.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. RP Boardman, CR (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 8 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2012 VL 75 IS 3 BP 701 EP 702 DI 10.1016/j.gie.2011.11.001 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 906BM UT WOS:000301319900055 PM 22341125 ER PT J AU Srivastava, MK Andersson, A Zhu, L Harris-White, M Lee, JM Dubinett, S Sharma, S AF Srivastava, Minu K. Andersson, Asa Zhu, Li Harris-White, Marni Lee, Jay M. Dubinett, Steven Sharma, Sherven TI Myeloid suppressor cells and immune modulation in lung cancer SO IMMUNOTHERAPY LA English DT Review DE APC; arginase 1; immune suppression; immune therapy; lung cancer; myeloid-derived suppressor cells; nitric oxide synthase; T lymphocytes; tumor genetic signature ID REGULATORY T-CELLS; EPITHELIAL-MESENCHYMAL TRANSITIONS; TUMOR-ASSOCIATED MACROPHAGES; ANTIGEN-PRESENTING CELLS; BONE-MARROW; DENDRITIC CELLS; GROWTH-FACTOR; IN-VIVO; CYCLOOXYGENASE-2-DEPENDENT INVASION; TRANSPLANTATION TOLERANCE AB Many tumors, including lung cancers, promote immune tolerance to escape host immune surveillance and facilitate tumor growth. Tumors utilize numerous pathways to inhibit immune responses, including the elaboration of immune-suppressive mediators such as PGE2, TGF-beta, IL-10, VEGF, GM-CSF, IL-6, S100A8/A9 and SCF, which recruit and/or activate myeloid-derived suppressor cells (MDSCs). MDSCs, a subset of heterogeneous bone marrow-derived hematopoietic cells, are found in the peripheral blood of cancer patients and positively correlate to malignancy. Solid tumors contain MDSCs that maintain an immune-suppressive network in the tumor microenvironment. This review will focus on the interaction of tumors with MDSCs that lead to dysregulation of antigen presentation and T-cell activities in murine tumor models. Specific genetic signatures in lung cancer modulate the activities of MDSCs and impact tumor progression. Targeting MDSCs may have a long-term antitumor benefit and is at the forefront of anticancer therapeutic strategies. C1 [Sharma, Sherven] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. Vet Affairs Greater Los Angeles, Los Angeles, CA USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA. EM ssharma@mednet.ucla.edu FU NCI NIH HHS [R01 CA126944, R01 CA126944-05] NR 128 TC 30 Z9 32 U1 1 U2 19 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1750-743X J9 IMMUNOTHERAPY-UK JI Immunotherapy PD MAR PY 2012 VL 4 IS 3 BP 291 EP 304 DI 10.2217/IMT.11.178 PG 14 WC Immunology SC Immunology GA 906CI UT WOS:000301322100013 PM 22401635 ER PT J AU Ahmed, MI Desai, RV Gaddam, KK Venkatesh, BA Agarwal, S Inusah, S Lloyd, SG Denney, TS Calhoun, D Dell'italia, LJ Gupta, H AF Ahmed, Mustafa I. Desai, Ravi V. Gaddam, Krishna K. Venkatesh, Bharath A. Agarwal, Shilpi Inusah, Seidu Lloyd, Steven G. Denney, Thomas S., Jr. Calhoun, David Dell'italia, Louis J. Gupta, Himanshu TI Relation of Torsion and Myocardial Strains to LV Ejection Fraction in Hypertension SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE hypertension; left ventricular hypertrophy; strain; torsion ID HUMAN LEFT-VENTRICLE; HEART-FAILURE; HYPERTROPHY; WALL; MECHANICS; MOTION; PATTERNS; MODEL; MRI; RECONSTRUCTION AB OBJECTIVES The goal of this study was to define the mechanism of preserved ejection fraction (EF) despite depressed myocardial strains in hypertension (HTN). BACKGROUND Concentric left ventricular (LV) remodeling in HTN may have normal or supranormal EF despite depressed myocardial strains. The reason for such discordance is not clear. The aim of this study was to comprehensively evaluate the LV mechanics in a well-defined HTN population to define underlying reasons for such a paradox. METHODS Sixty-seven patients with resistant HTN and 45 healthy control subjects were studied by cardiac magnetic resonance imaging and tissue tagging with 3-dimensional analysis. Amplitude and directional vector of longitudinal (Ell), circumferential (Ecc), and principal strain for maximal shortening (E3) were computed at basal, mid, and distal LV levels, respectively. LV torsion, defined as the rotation angle of apex relative to base, and LV twist, which accounts for the effects of differential LV remodeling on torsion for comparison among the 2 groups, were also calculated. RESULTS LV mass index and LV mass/LV end-diastolic volume ratio were significantly higher in the HTN group compared with controls, consistent with concentric LV remodeling. Ell and Ecc were significantly decreased in amplitude with altered directional vector in HTN compared with controls. However, the amplitude of E3 was similar in the 2 groups. Torsion and twist were significantly higher in HTN, which was mainly due to increase in apical rotation. The HTN group demonstrated significantly increased LV wall thickening compared with controls that resulted in greater LVEF in the HTN group compared with controls (70% vs. 65%, p < 0.001, respectively). CONCLUSIONS In compensated LV remodeling secondary to HTN, there is increased LV wall thickening with preserved E3 and increased torsion compared with normal controls. This, therefore, contributes to supranormal LVEF in HTN despite depressed longitudinal and circumferential strains. (J Am Coll Cardiol lmg 2012;5:273-81) (C) 2012 by the American College of Cardiology Foundation C1 [Ahmed, Mustafa I.; Desai, Ravi V.; Gaddam, Krishna K.; Agarwal, Shilpi; Lloyd, Steven G.; Calhoun, David; Dell'italia, Louis J.; Gupta, Himanshu] Univ Alabama, Dept Med, Div Cardiovasc Med, Birmingham, AL 35294 USA. [Inusah, Seidu] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Lloyd, Steven G.; Dell'italia, Louis J.; Gupta, Himanshu] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Venkatesh, Bharath A.; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Auburn, AL 36849 USA. RP Gupta, H (reprint author), UAB Med Cardiovasc Dis, CVMRI, BDB 101,1530 3rd Ave S, Birmingham, AL 35294 USA. EM hgupta@uab.edu RI Ambale Venkatesh, Bharath/F-4941-2016 OI Ambale Venkatesh, Bharath/0000-0002-2330-2373 FU National Institutes of Health [NIH P50-HL077100, NIH R01-HL104018] FX Funded by National Institutes of Health grants NIH P50-HL077100 (L.J.D.) and NIH R01-HL104018 (H.G.). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 39 TC 25 Z9 26 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD MAR PY 2012 VL 5 IS 3 BP 273 EP 281 DI 10.1016/j.jcmg.2011.11.013 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 908TC UT WOS:000301513600005 PM 22421172 ER PT J AU Patterson, AL Gritzner, S Resnick, MP Dobscha, SK Turk, DC Morasco, BJ AF Patterson, Alexander L. Gritzner, Susan Resnick, Michael P. Dobscha, Steven K. Turk, Dennis C. Morasco, Benjamin J. TI Smoking Cigarettes as a Coping Strategy for Chronic Pain Is Associated With Greater Pain Intensity and Poorer Pain-Related Function SO JOURNAL OF PAIN LA English DT Article DE Smoking; cigarettes; chronic pain; coping ID LOW-BACK-PAIN; NICOTINE DEPENDENCE; PROSPECTIVE COHORT; POPULATION SAMPLE; FOLLOW-UP; PREDICTORS; INVENTORY; ANXIETY; ADULTS; RISK AB Smoking cigarettes is prevalent among individuals with chronic pain. Some studies indicate nicotine reduces pain and others suggest it may cause or exacerbate pain. Participants in this cross-sectional study were 151 chronic pain patients from a large, urban VA medical center. Patients were divided into 3 groups: 1) nonsmokers; 2) smokers who deny using cigarettes to cope with pain; and 3) smokers who report using cigarettes to cope with pain. Patients who reported smoking as a coping strategy for chronic pain scored significantly worse compared with the other 2 groups on the majority of measures of pain-related outcome. Nonsmokers and smokers who denied smoking to cope did not differ on any variable examined. After controlling for the effects of demographic and clinical factors, smoking cigarettes as a coping strategy for pain was significantly and positively associated with pain intensity (P = .04), pain interference (P = .005), and fear of pain (P = .04). In addition to assessing general smoking status, a more specific assessment of the chronic pain patient's reasons for smoking may be an important consideration as part of interdisciplinary pain treatment. Perspective: This paper describes the relationship between smoking cigarettes as a mechanism to cope with chronic pain and pain-related outcome. Understanding this relationship may illuminate the broader relationship between smoking and chronic pain and provide new directions for effective interdisciplinary pain treatment. C1 [Patterson, Alexander L.; Resnick, Michael P.; Dobscha, Steven K.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Dobscha, Steven K.] Portland VA Med Ctr, Ctr Study Chron Comorbid Med & Psychiat Disorders, Portland, OR USA. [Gritzner, Susan; Resnick, Michael P.; Dobscha, Steven K.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Gritzner, Susan] Univ Pacific, Sch Profess Psychol, Hillsboro, OR USA. [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR USA. EM benjamin.morasco@va.gov FU Portland VA Medical Center; National Institute on Drug Abuse [K23DA023467]; Endo; Johnson Johnson; Philips Respironics; National Institutes of Health; Eli Lilly; Empi; Pfizer; SK LifeScience FX This work was supported with resources and the use of facilities at the Portland VA Medical Center. This study was funded by grant K23DA023467 from the National Institute on Drug Abuse, awarded to Dr. Morasco. Dr. Turk has received research support from Endo, Johnson & Johnson, Philips Respironics, and the National Institutes of Health, and consulting fees from Eli Lilly, Empi, Johnson & Johnson, Pfizer, Philips Respironics, and SK LifeScience. NR 57 TC 30 Z9 30 U1 0 U2 6 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD MAR PY 2012 VL 13 IS 3 BP 285 EP 292 DI 10.1016/j.jpain.2011.11.008 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 910BT UT WOS:000301612900009 PM 22325299 ER PT J AU Goldstein, NE Cohen, LM Arnold, RM Goy, E Arons, S Ganzini, L AF Goldstein, Nathan E. Cohen, Lewis M. Arnold, Robert M. Goy, Elizabeth Arons, Stephen Ganzini, Linda TI Prevalence of Formal Accusations of Murder and Euthanasia against Physicians SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID ASSISTED SUICIDE; UNITED-STATES; PATIENT CHARACTERISTICS; PALLIATIVE CARE; CANCER-PATIENTS; LIFE; END; POPULATION; SURVIVAL; OREGON AB Background: Little is known about how often physicians are formally accused of hastening patient deaths while practicing palliative care. Methods: We conducted an Internet-based survey on a random 50% sample of physician-members of a national hospice and palliative medicine society. Results: The final sample consisted of 663 physicians (response rate 53%). Over half of the respondents had had at least one experience in the last 5 years in which a patient's family, another physician, or another health care professional had characterized palliative treatments as being euthanasia, murder, or killing. One in four stated that at least one friend or family member, or a patient had similarly characterized their treatments. Respondents rated palliative sedation and stopping artificial hydration/nutrition as treatments most likely to be misconstrued as euthanasia. Overall, 25 physicians (4%) had been formally investigated for hastening a patient's death when that had not been their intention-13 while using opiates for symptom relief and six for using medications while discontinuing mechanical ventilation. In eight (32%) cases, another member of the health care team had initiated the charges. At the time of the survey, none had been found guilty, but they reported experiencing substantial anger and worry. Conclusions: Commonly used palliative care practices continue to be misconstrued as euthanasia or murder, despite this not being the intention of the treating physician. Further efforts are needed to explain to the health care community and the public that treatments often used to relieve patient suffering at the end of life are ethical and legal. C1 [Goldstein, Nathan E.] Mt Sinai Med Ctr, Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. [Cohen, Lewis M.] Baystate Med Ctr, Dept Psychiat, Springfield, MA USA. [Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Sch Hlth Sci, Sect Palliat Care & Med Eth, Pittsburgh, PA USA. [Goy, Elizabeth; Ganzini, Linda] Portland VA Med Ctr, Portland, OR USA. [Goy, Elizabeth; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Arons, Stephen] Univ Massachusetts, Dept Legal Studies, Amherst, MA 01003 USA. RP Goldstein, NE (reprint author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, Box 1070,1 Gustave Levy Pl, New York, NY 10029 USA. EM Nathan.Goldstein@mssm.edu FU National Institute on Aging [1K23 AG025933-01A1]; Greenwall Foundation FX The authors would like to thank the physicians who participated in our survey. This work was supported in part by a grant from the Greenwall Foundation. Dr. Goldstein is supported by a Mentored Patient-Oriented Research Career Development Award from the National Institute on Aging (1K23 AG025933-01A1). Drs. Ganzini and Goy received support through the use of resources and facilities at the Portland VAMC. Portions of these data were presented at the Annual Assembly of the American Association of Hospice and Palliative Medicine in Vancouver, BC, in February 2011. Drs. Goldstein, Cohen, Arnold, and Ganzini had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 19 TC 14 Z9 14 U1 0 U2 15 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2012 VL 15 IS 3 BP 334 EP 339 DI 10.1089/jpm.2011.0234 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 906OG UT WOS:000301354800016 PM 22401355 ER PT J AU Nagykaldi, Z Aspy, CB Chou, A Mold, JW AF Nagykaldi, Zsolt Aspy, Cheryl B. Chou, Ann Mold, James W. TI Impact of a Wellness Portal on the Delivery of Patient-Centered Preventive Care SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Community Medicine; Computers; Evidence-Based Medicine; Medical Decision-Making; Patient-Centered Care; Personal Health Records; Practice-Based Research; Primary Health Care; Prevention; Wellness Portal ID ACTIVATION MEASURE; UNITED-STATES; QUALITY; TIME AB Background: The objective of this study was to determine the impact of the Wellness Portal-a novel, web-based patient portal that focuses on wellness, prevention, and longitudinal health-on the delivery of patient-centered preventive care by examining the behavior and experiences of both patients and primary care clinicians and the degree to which recommended services were individualized and provided. Methods: We conducted a 3-year, systematic portal development and testing study, which included a 6-month feasibility and acceptability pilot in 2 primary care practices followed by a 12-month cluster randomized controlled trial in 8 clinician practices (4 in each study group). Descriptive and bivariate analyses were conducted to compare service delivery between intervention and control arms. Results: Ninety percent of patients in the pilot study found the portal easy to use, 83% found it to be a valuable resource, and 80% said that it facilitated their participation in their own care. The cluster randomized controlled trial included 422 adults 40 to 75 years of age and the parents of 116 children 2 to 5 years of age. Seventy three percent of patients used the portal during the study. Both patient activation (measured via the 13-item Patient Activation Measure) and participants' perception of patient-centeredness of care (measured via the Consumer Assessment of Healthcare Providers and Systems instrument) increased significantly in the portal group compared with control (P = .0014 and P = .037, respectively). A greater proportion of portal users received all recommended preventive services (84.4% intervention vs 67.6% control; P < .0001); took low-dose aspirin, if indicated (78.6% intervention vs 52.3% control; P < .0001); and received Pneumovax because of chronic health conditions (82.5% vs 53.9%; P < .0001) and age (86.3% vs 44.6%; P < .0001), despite having fewer visits over the study period compared with those in the control group (average of 2.9 vs 4.3 visits; P < .0001). Children in the intervention group received 95.5% of all recommended immunizations compared with 87.2% in the control group (P = .044). Conclusions: A comprehensive patient portal integrated into the regular process of primary care can increase the patient-centeredness of care, improve patient activation, enhance the delivery of both age- and risk factor-appropriate preventive services, and promote the utilization of web-based personal health records. (J Am Board Fam Med 2012;25:158-167.) C1 [Nagykaldi, Zsolt; Aspy, Cheryl B.; Mold, James W.] Univ Oklahoma, Hlth Sci Ctr, Dept Family & Prevent Med, Oklahoma City, OK 73104 USA. [Chou, Ann] Greater Los Angeles VA Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA USA. RP Nagykaldi, Z (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Family & Prevent Med, 900 NE 10th St, Oklahoma City, OK 73104 USA. EM znagykal@ouhsc.edu FU Agency for Healthcare Research and Quality [1 R18 HS017188-01] FX Support for this study was provided by the Agency for Healthcare Research and Quality grant no. 1 R18 HS017188-01. NR 15 TC 26 Z9 26 U1 2 U2 20 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD MAR-APR PY 2012 VL 25 IS 2 BP 158 EP 167 DI 10.3122/jabfm.2012.02.110130 PG 10 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 905VN UT WOS:000301304300006 PM 22403196 ER PT J AU Wood, KH Hoef, LWV Knight, DC AF Wood, Kimberly H. Hoef, Lawrence W. Ver Knight, David C. TI Neural mechanisms underlying the conditioned diminution of the unconditioned fear response SO NEUROIMAGE LA English DT Article DE fMRI; Learning; Conditioning; Unconditioned response; Amygdala; Prefrontal cortex; Emotion; Fear; Anxiety; Skin conductance ID HUMAN AMYGDALA ACTIVITY; TRAIT ANXIETY; WITHIN-SUBJECT; FUNCTIONAL MRI; EXTINCTION; ACTIVATION; EXPRESSION; FMRI; UNCERTAINTY; EMOTION AB Recognizing cues that predict an aversive event allows one to react more effectively under threatening conditions, and minimizes the reaction to the threat itself. This is demonstrated during Pavlovian fear conditioning when the unconditioned response (UCR) to a predictable unconditioned stimulus (UCS) is diminished compared to the UCR to an unpredictable UCS. The present study investigated the functional magnetic resonance imaging (fMRI) signal response associated with Pavlovian conditioned UCR diminution to better understand the relationship between individual differences in behavior and the neural mechanisms of the threat-related emotional response. Healthy volunteers participated in a fear conditioning study in which trait anxiety, skin conductance response (SCR), UCS expectancy, and the fMRI signal were assessed. During acquisition trials, a tone (CS +) was paired with a white noise UCS and a second tone (CS -) was presented without the UCS. Test trials consisted of the CS + paired with the UCS, CS - paired with the UCS, and presentations of the UCS alone to assess conditioned UCR diminution. UCR diminution was observed within the dorsolateral PFC, dorsomedial PFC, cingulate cortex, inferior parietal lobule (IPL), anterior insula, and amygdala. The threat-related activity within the dorsolateral PFC, dorsomedial PFC, posterior cingulate cortex, and IPL varied with individual differences in trait anxiety. In addition, anticipatory (i.e. CS elicited) activity within the PFC showed an inverse relationship with threat-related (i.e. UCS elicited) activity within the PFC. IPL, and amygdala. Further, the emotional response (indexed via SCR) elicited by the threat was closely linked to amygdala activity. These findings are consistent with the view that the amygdala and PFC support learning-related processes that influence the emotional response evoked by a threat. (C) 2011 Elsevier Inc. All rights reserved. C1 [Wood, Kimberly H.; Knight, David C.] Univ Alabama, Dept Psychol, Civitan Int Res Ctr, Birmingham, AL 35294 USA. [Hoef, Lawrence W. Ver] Univ Alabama, Dept Neurol, Sch Med, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Knight, DC (reprint author), CIRC 235H,1530 3RD AVE S, Birmingham, AL 35294 USA. EM knightdc@uab.edu FU University of Alabama at Birmingham Faculty FX This research was supported by the University of Alabama at Birmingham Faculty Development Grant Program. NR 71 TC 19 Z9 19 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD MAR PY 2012 VL 60 IS 1 BP 787 EP 799 DI 10.1016/j.neuroimage.2011.12.048 PG 13 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 904SR UT WOS:000301218700079 PM 22227141 ER PT J AU Bespalova, IN Angelo, GW Ritter, BP Hunter, J Reyes-Rabanillo, ML Siever, LJ Silverman, JM AF Bespalova, Irina N. Angelo, Gary W. Ritter, Ben P. Hunter, Jason Reyes-Rabanillo, Maria L. Siever, Larry J. Silverman, Jeremy M. TI Genetic Variations in the ADAMTS12 Gene are Associated with Schizophrenia in Puerto Rican Patients of Spanish Descent SO NEUROMOLECULAR MEDICINE LA English DT Article DE ADAMTS12; Association study; Schizophrenia; Case-control sample; Chromosome 5p13 ID THROMBOTIC THROMBOCYTOPENIC PURPURA; MATRIX METALLOPROTEINASES MMPS; ABDOMINAL AORTIC-ANEURYSM; SERIOUS MENTAL-ILLNESS; 409 EUROPEAN-ANCESTRY; LOW-BIRTH-WEIGHT; PATERNAL SCHIZOPHRENIA; POSITIONAL CANDIDATE; SUSCEPTIBILITY LOCI; TISSUE INHIBITORS AB ADAMTS12 belongs to the family of metalloproteinases that mediate a communication between specific cell types and play a key role in the regulation of normal tissue development, remodeling, and degradation. Members of this family have been implicated in neurodegenerative and neuroinflammatory, as well as in muscular-skeletal, cardiovascular, respiratory and renal diseases, and cancer. Several metalloproteinases have been associated with schizophrenia. In our previous study of the pedigree from a genetic isolate of Spanish origin in Puerto Rico, we identified a schizophrenia susceptibility locus on chromosome 5p13 containing ADAMTS12. This gene, therefore, is not only a functional but also a positional candidate gene for susceptibility to the disorder. In order to examine possible involvement of ADAMTS12 in schizophrenia, we performed mutation analysis of the coding, 5'- and 3'-untranslated, and putative promoter regions of the gene in affected members of the pedigree and identified 18 sequence variants segregated with schizophrenia. We then tested these variants in 135 unrelated Puerto Rican schizophrenia patients of Spanish origin and 203 controls and identified the intronic variant rs256792 (P = 0.0035; OR = 1.59; 95% CI = 1.16-2.17) and the two-SNP haplotype rs256603-rs256792 (P = 0.0023; OR = 1.62; 95% CI = 1.19-2.21) associated with the disorder. The association remained significant after correction for multiple testing. Our data support the hypothesis that genetic variations in ADAMTS12 influence the risk of schizophrenia. C1 [Bespalova, Irina N.; Angelo, Gary W.; Ritter, Ben P.; Hunter, Jason; Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Bespalova, Irina N.; Angelo, Gary W.; Ritter, Ben P.; Siever, Larry J.; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Reyes-Rabanillo, Maria L.] San Juan Veteran Affairs Med Ctr, San Juan, PR USA. RP Bespalova, IN (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA. EM irina.bespalova@mssm.edu FU National Alliance for Research on Schizophrenia and Depression (NARSAD); National Institute of Mental Health (NIMH) [MH082134]; Department of Veterans Affairs (VA) FX The authors thank patients and healthy volunteers for their participation in the study. We also thank Enrique Rossy-Fullana and Jose Carrion-Baralt for samples collection and administrative assistance. We thank Martina Durner and James Schmeidler for helpful discussions and Inga Peter for assistance with logistic regression analysis. We are grateful to Andrei Kurochkin and anonymous reviewers for critical reading of the manuscript and useful comments and suggestions. The study was supported by the National Alliance for Research on Schizophrenia and Depression (NARSAD) to INB (Young Investigator Award), the National Institute of Mental Health (NIMH) to INB (RO3 Award MH082134), and The Department of Veterans Affairs (VA) to JMS (Merit Award). The funding sources had no role in study design, analysis and interpretation of the data, and writing the manuscript. NR 101 TC 5 Z9 6 U1 0 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1535-1084 J9 NEUROMOL MED JI Neuromol. Med. PD MAR PY 2012 VL 14 IS 1 BP 53 EP 64 DI 10.1007/s12017-012-8169-y PG 12 WC Neurosciences SC Neurosciences & Neurology GA 909TY UT WOS:000301589200005 PM 22322903 ER PT J AU Golier, JA Caramanica, K Yehuda, R AF Golier, Julia A. Caramanica, Kimberly Yehuda, Rachel TI Neuroendocrine response to CRF stimulation in veterans with and without PTSD in consideration of war zone era SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Medically unexplained illness; Gulf War syndrome; Stress; ACTH; Cortisol; CRF ID POSTTRAUMATIC-STRESS-DISORDER; CORTICOTROPIN-RELEASING HORMONE; SELF-REPORTED SYMPTOMS; GULF-WAR; INCREASED PITUITARY; COMBAT VETERANS; CORTISOL; ENDOCRINE; TRAUMA; BRAIN AB Background: Alterations in hypothalamic-pituitary-adrenal (HPA) axis activity have been observed in Gulf War veterans with posttraumatic stress disorder (PTSD) which differ from those observed in other veteran groups, raising the possibility that there is a unique neuroendocrine profile in this group of veterans. This study seeks to further characterize the effects of PTSD, military cohort (Vietnam, 1991 Gulf War, Operations Enduring Freedom/Iraqi Freedom (OEF/OIF)), and their interaction on the neuroendocrine response to synthetic corticotrophin-releasing factor (CRF) stimulation. Methods: 51 male veterans were studied consisting of 21 from the Vietnam era, 16 from the Gulf War era, and 14 from the OEF/OIF era. 16 of these veterans were deployed to a war zone and had chronic PTSD (PTSD+), 25 were deployed to a war zone and did not have chronic PTSD (PTSD), and 10 were not deployed to a war zone and did not have PTSD (non-exposed). The participants underwent the CRF stimulation test in the afternoon (approximately 2:00 p.m.), which measures the integrity and sensitivity of the pituitary adrenal axis. Plasma cortisol and adrenocorticotropic hormone (ACTH) were measured at baseline and at intervals over a 2 h period following intravenous administration of 1 mu g/kg of ovine CRF (o-CRF, max 100 mu g). In a small subset of participants, dehydroepiandrosterone (DHEA) and cortisol binding globulin (CBG) were also assessed. Results: There was a significant group by era interaction in the response of ACTH to CRF, in addition to a main effect of group (PTSD+, PTSD, non-exposed). The interaction reflected that group differences were only evident in the Gulf War cohort; among Gulf War era veterans, the PTSD+ group had higher elevations in ACTH levels following CRF than the PTSD group and the non-exposed group. Additionally, the peak change in ACTH was associated with a self-reported environmental exposure (pyridostigmine bromide ingestion) which has been found to be linked to the excess morbidity found in Gulf War veterans. Self-reported childhood trauma was greater in veterans of the Gulf War than Vietnam or OEF/OIF, but did not account for the observed differences. There was a significant effect of group on the cortisol response to CRF, reflecting greater responsivity in both of the deployed groups (PTSD+ and PTSD-) compared to the non-exposed group which could be accounted for by baseline differences in cortisol levels; unlike the ACTH response, the cortisol response did not differ by era. There were no effects of group, era, or their interaction on the DHEA and CBG response to CRF. Conclusions: A uniform pattern of PTSD-related alterations in the response to intravenous CRF was not found. Rather, PTSD-related alterations were found only in veterans of the 1991 Gulf War, and were characterized by an enhanced pituitary response to CRF which may reflect increased sensitivity of pituitary corticotrophs or CRF hyposecretion. Together with previous neuroendocrine findings, the data suggest the HPA axis is dysregulated in Gulf War veterans in unique ways which may reflect the long-term effects of environmental exposures in addition to disease effects. Further work is needed to characterize these effects and their impact on long-term psychological and medical outcomes. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Golier, Julia A.; Caramanica, Kimberly; Yehuda, Rachel] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. [Golier, Julia A.; Yehuda, Rachel] Mt Sinai Sch Med, New York, NY USA. RP Golier, JA (reprint author), James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. EM Julia.Golier@va.gov RI Schueter, nicos/A-3625-2014 FU VA MERIT; NIH [5 M01 RR00071] FX Funding for this study was provided by a VA MERIT award to Dr. Golier and by a grant (5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the NIH; the VA and NIH had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 27 TC 6 Z9 6 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD MAR PY 2012 VL 37 IS 3 BP 350 EP 357 DI 10.1016/j.psyneuen.2011.07.004 PG 8 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 904QB UT WOS:000301211900005 PM 21813244 ER PT J AU Cole, SR Hudgens, MG Tien, PC Anastos, K Kingsley, L Chmiel, JS Jacobson, LP AF Cole, Stephen R. Hudgens, Michael G. Tien, Phyllis C. Anastos, Kathryn Kingsley, Lawrence Chmiel, Joan S. Jacobson, Lisa P. TI Marginal Structural Models for Case-Cohort Study Designs to Estimate the Association of Antiretroviral Therapy Initiation With Incident AIDS or Death SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE acquired immunodeficiency syndrome; case-cohort studies; cohort studies; confounding bias; HIV; pharmacoepidemiology; selection bias ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROPENSITY SCORES; SURVIVAL ANALYSIS; CAUSAL INFERENCE; VIRAL LOAD; DISEASE; HIV; INTERVENTIONS; REGRESSION; MORTALITY AB To estimate the association of antiretroviral therapy initiation with incident acquired immunodeficiency syndrome (AIDS) or death while accounting for time-varying confounding in a cost-efficient manner, the authors combined a case-cohort study design with inverse probability-weighted estimation of a marginal structural Cox proportional hazards model. A total of 950 adults who were positive for human immunodeficiency virus type 1 were followed in 2 US cohort studies between 1995 and 2007. In the full cohort, 211 AIDS cases or deaths occurred during 4,456 person-years. In an illustrative 20% random subcohort of 190 participants, 41 AIDS cases or deaths occurred during 861 person-years. Accounting for measured confounders and determinants of dropout by inverse probability weighting, the full cohort hazard ratio was 0.41 (95% confidence interval: 0.26, 0.65) and the case-cohort hazard ratio was 0.47 (95% confidence interval: 0.26, 0.83). Standard multivariable-adjusted hazard ratios were closer to the null, regardless of study design. The precision lost with the case-cohort design was modest given the cost savings. Results from Monte Carlo simulations demonstrated that the proposed approach yields approximately unbiased estimates of the hazard ratio with appropriate confidence interval coverage. Marginal structural model analysis of case-cohort study designs provides a cost-efficient design coupled with an accurate analytic method for research settings in which there is time-varying confounding. C1 [Cole, Stephen R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Hudgens, Michael G.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA. [Tien, Phyllis C.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Anastos, Kathryn] Montefiore Med Ctr, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Kingsley, Lawrence] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA. [Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Jacobson, Lisa P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Cole, SR (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, MacGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA. EM cole@unc.edu FU National Institutes of Health [R01-AA-017594, R01-AI-085073]; National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Cancer Institute [UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131] FX Dr. Stephen Cole was partially supported by National Institutes of Health grant R01-AA-017594. Dr. Michael Hudgens was partially supported by National Institutes of Health grant R01-AI-085073. The Multicenter AIDS Cohort Study is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute (grants UO1-AI-35042, UL1-RR025005 (General Clinical Research Center), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041). The Women's Interagency HIV Study is funded by the National Institute of Allergy and Infectious Diseases (grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant UL1 RR024131). NR 43 TC 5 Z9 5 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 1 PY 2012 VL 175 IS 5 BP 381 EP 390 DI 10.1093/aje/kwr346 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 898GT UT WOS:000300728800005 PM 22302074 ER PT J AU Sinkowitz-Cochran, RL Burkitt, KH Cuerdon, T Harrison, C Gao, SS Obrosky, DS Jain, R Fine, MJ Jernigan, JA AF Sinkowitz-Cochran, Ronda L. Burkitt, Kelly H. Cuerdon, Timothy Harrison, Cassandra Gao, Shasha Obrosky, D. Scott Jain, Rajiv Fine, Michael J. Jernigan, John A. TI The associations between organizational culture and knowledge, attitudes, and practices in a multicenter Veterans Affairs quality improvement initiative to prevent methicillin-resistant Staphylococcus aureus SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Methicillin-resistant Staphylococcus aureus; Organizational culture; Prevention; Quality improvement; Survey ID INTENSIVE-CARE UNITS; HEALTH-CARE; ICU; PERCEPTIONS; INFECTIONS AB Background: Previous research demonstrates that organizational culture (OC) and knowledge, attitudes, and practices of health care personnel are associated with the overall success of infection control programs; however, little attention has been given to the relationships among these factors in contributing to the success of quality improvement programs. Methods: Cross-sectional surveys assessing OC and knowledge, attitudes, and practices related to methicillin-resistant Staphylococcus aureus (MRSA) were distributed to 16 medical centers participating in a Veterans Affairs MRSA prevention initiative in 2 time periods. Factor analysis was performed on the OC survey responses, and factor scores were generated. To assess associations between OC and knowledge, attitudes, and practices of health care personnel, regression analyses were performed overall and then stratified by job type. Results: The final analyzable sample included 2,314 surveys (43% completed by nurses, 9% by physicians, and 48% by other health care personnel). Three OC factors emerged accounting for 53% of the total variance: "Staff Engagement," "Overwhelmed/Stress-Chaos," and "Hospital Leadership." Overall, higher Staff Engagement was associated with greater knowledge scores, better hand hygiene practices, fewer reported barriers, and more positive attitudes. Higher Hospital Leadership scores were associated with better hand hygiene practices, fewer reported barriers, and more positive attitudes. Conversely, higher Overwhelmed/Stress-Chaos scores were associated with poorer reported prevention practices, more barriers, and less positive attitudes. When these associations were stratified by job type, there were significant associations between OC factors and knowledge for nurses only, between OC factors and practice items for nurses and other health care personnel, and between OC factors and the barriers and attitudes items for all job types. OC factors were not associated with knowledge and practices among physicians. Conclusions: Three OC factors-Staff Engagement, Overwhelmed/Stress-Chaos, and Hospital Leadership-were found to be significantly associated with individual health care personnel knowledge, attitudes, and self-reported practices regarding MRSA prevention. When developing a prevention intervention program, health care organizations should not only focus on the link between OC and the knowledge, attitudes, and practices of health care personnel, but also target programs based on health care personnel type to maximize their effectiveness. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Sinkowitz-Cochran, Ronda L.; Harrison, Cassandra; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Burkitt, Kelly H.; Gao, Shasha; Obrosky, D. Scott; Fine, Michael J.] VA Hlth Serv Res & Dev Serv, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Cuerdon, Timothy] VA Cent Off, Off Qual & Performance, Washington, DC USA. [Jain, Rajiv] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Sinkowitz-Cochran, RL (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM RLS7@cdc.gov NR 17 TC 16 Z9 16 U1 1 U2 13 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR PY 2012 VL 40 IS 2 BP 138 EP 143 DI 10.1016/j.ajic.2011.04.332 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 899XK UT WOS:000300849800012 PM 21864944 ER PT J AU Yeo, KK Mahmud, E Armstrong, EJ Bennett, WE Shunk, KA MacGregor, JS Li, ZM Low, RI Rogers, JH AF Yeo, Khung Keong Mahmud, Ehtisham Armstrong, Ehrin J. Bennett, William E. Shunk, Kendrick A. MacGregor, John S. Li, Zhongmin Low, Reginald I. Rogers, Jason H. TI Contemporary clinical characteristics, treatment, and outcomes of angiographically confirmed coronary stent thrombosis: Results from a multicenter California registry SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE stent; coronary intervention; thrombosis ID DRUG-ELUTING STENTS; DEATH MASTER FILE; INTRAVASCULAR ULTRASOUND; MYOCARDIAL-INFARCTION; BARE-METAL; IMPLANTATION; SIROLIMUS; PREDICTORS; RESISTANCE; TRIALS AB Objectives: To describe the contemporary treatment and outcomes for patients with angiographically confirmed (definite) stent thrombosis (ST). Background: Limited data are available on contemporary treatment patterns and outcomes of patients with ST in the United States. Methods: In this multicenter California registry, consecutive cases of definite ST over 5 years were identified. Clinical characteristics, in-hospital outcomes, and long-term survival are reported. Results: One hundred and sixty five consecutive episodes of ST were identified in 153 patients from January 2005 to February 2010. The distribution of acute (=24 hr), subacute (24 hr to 30 days), late (30 days to 1 year), and very late (=1 year) ST was 3.9%, 21.8%, 17.6%, and 50.3%, respectively. Only 41.2% of patients were on dual antiplatelet therapy at the time of presentation, while 22.4% of patients were on none. Of the 61.4% of patients treated with restenting, 71.1% of them received a drug-eluting stent. Procedural success was 88.1%, and in-hospital death, stroke, and CABG occurred in 5.5%, 0.6%, and 6.1% of subjects, respectively. All-cause mortality at 1 year was 14.3%. Although female gender, diabetes mellitus (DM), bifurcation disease, ejection fraction <40%, and cardiogenic shock at the time of presentation were associated with an increased risk of in-hospital mortality, only DM (P = 0.047) and bifurcation disease (P = 0.027) remained independent predictors of in-hospital death. Conclusion: In-hospital mortality from definite ST is lower than previously reported, but long-term mortality remains high. DM and bifurcation disease, but not type of percutaneous therapy, are independently associated with in-hospital mortality. (c) 2011 Wiley Periodicals, Inc. C1 [Yeo, Khung Keong; Li, Zhongmin; Low, Reginald I.; Rogers, Jason H.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. [Mahmud, Ehtisham; Bennett, William E.] Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. [Armstrong, Ehrin J.; Shunk, Kendrick A.] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. [MacGregor, John S.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. RP Rogers, JH (reprint author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. EM jason.rogers@ucdmc.ucdavis.edu FU Boston Scientific; Abbott Vascular; Sanofi Aventis FX Dr Low is on the advisory board of Abbott Vascular and Boston Scientific. Dr Rogers is a consultant for Volcano, Medtronic, Cordis, and Boston Scientific. Dr Mahmud is on the Speakers Bureau for Medtronic and Eli Lilly. He is a consultant for Eli Lilly and has research support from Boston Scientific, Abbott Vascular, and Sanofi Aventis. NR 18 TC 14 Z9 15 U1 1 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAR 1 PY 2012 VL 79 IS 4 BP 550 EP 556 DI 10.1002/ccd.23011 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 897PE UT WOS:000300664300005 PM 21563289 ER PT J AU Chavalitdhamrong, D Jensen, DM Singh, B Kovacs, TOG Han, SH Durazo, F Saab, S Gornbein, JA AF Chavalitdhamrong, Disaya Jensen, Dennis M. Singh, Bhavneet Kovacs, Thomas O. G. Han, Steven H. Durazo, Francisco Saab, Sammy Gornbein, Jeffrey A. TI Capsule Endoscopy Is Not as Accurate as Esophagogastroduodenoscopy in Screening Cirrhotic Patients for Varices SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Detection; Surgery; Esophagus; Cirrhosis; Hepatitis ID ESOPHAGEAL-VARICES; PORTAL-HYPERTENSION; DIAGNOSIS; HEMORRHAGE; EGD AB BACKGROUND & AIMS: Esophagogastroduodenoscopy (EGD) is the standard technique for screening cirrhotic patients for high-risk varices and other significant upper gastrointestinal lesions (HRVLs). We investigated whether esophageal capsule endoscopy (ECE) is as convenient and accurate as EGD for the detection of HRVLs. METHODS: We analyzed data from 65 cirrhotic patients without prior upper gastrointestinal bleeding who were examined for varices and HRVLs by ECE and EGD (both procedures were performed on the same day). EGD was performed by 2 physicians (75% of patients were unsedated) who used standard grading for esophageal and gastric varices, portal hypertensive gastropathy, and HRVLs. Coded capsule tracings were read by 2 investigators, blinded to the EGD findings, using standard grading. RESULTS: The median procedure time for EGD (with or without biopsy collection) was 3 minutes, compared with 20 minutes for ECE. The overall accuracy for diagnosis of esophageal varices was 63.2% +/- 5.9%; for detection of esophageal varices red marks was 68.8% +/- 5.4%; and for diagnosis of other HRVLs was 51.5% +/- 4.2%. The interobserver agreement in the diagnosis of esophageal varices was 90.8%; in the detection of esophageal varices red marks was 86.2%; and in the diagnosis of other HRVLs was 7.3%. CONCLUSIONS: ECE is not as accurate as EGD in the diagnosis of esophageal varices and red markings or in grading esophageal varices. Moreover, ECE had poor accuracy in grading portal hypertensive gastropathy and detecting ulcers, gastric varices, and other significant upper gastrointestinal lesions. It took significantly longer to perform ECE and interpret the results than for EGD. These findings do not support ECE as a preferred tool for screening esophageal varices and HRVLs. C1 [Chavalitdhamrong, Disaya; Jensen, Dennis M.; Singh, Bhavneet; Kovacs, Thomas O. G.] Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Los Angeles, CA USA. [Jensen, Dennis M.; Kovacs, Thomas O. G.; Han, Steven H.; Durazo, Francisco; Saab, Sammy] Univ Calif Los Angeles, Med Ctr, Div Digest Dis, Los Angeles, CA 90024 USA. [Jensen, Dennis M.; Kovacs, Thomas O. G.; Han, Steven H.] Greater Los Angeles VA Healthcare Ctr, Res Sect, Los Angeles, CA USA. [Jensen, Dennis M.; Kovacs, Thomas O. G.; Han, Steven H.] Greater Los Angeles VA Healthcare Ctr, GI Hepatol Sect, Los Angeles, CA USA. [Gornbein, Jeffrey A.] Univ Calif Los Angeles, Biostat Consulting Unit, Los Angeles, CA USA. RP Chavalitdhamrong, D (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM disaya104@gmail.com FU Ethicon Endosurgery, National Institutes of Health [K24-DK002650]; Center for Ulcer Research and Education [P30-DK041301]; Pentax (Montvale, NJ) FX This study was partially supported by research funds from Ethicon Endosurgery, National Institutes of Health grant (K24-DK002650), the Center for Ulcer Research and Education Human Studies Core (P30-DK041301), and an equipment grant from Pentax (Montvale, NJ). NR 14 TC 4 Z9 5 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2012 VL 10 IS 3 BP 254 EP U156 DI 10.1016/j.cgh.2011.11.027 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 904YA UT WOS:000301234100019 PM 22155754 ER PT J AU Strachan, M Gros, DF Yuen, E Ruggiero, KJ Foa, EB Acierno, R AF Strachan, Martha Gros, Daniel F. Yuen, Erica Ruggiero, Kenneth J. Foa, Edna B. Acierno, Ron TI Home-based telehealth to deliver evidence-based psychotherapy in veterans with PTSD SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE PTSD; Prolonged exposure; Psychotherapy; Home-based telehealth ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; IRAQ; AFGHANISTAN; DEPLOYMENT; SERVICES; THERAPY; TRIALS; ISSUES; RISK AB Although medical service delivery via home-based telehealth technology (HBT) is gaining wider acceptance in managing chronic illnesses such as diabetes or chronic obstructive pulmonary disease, few studies have tested HBT applications of psychotherapy. Clinicians, administrators, and researchers question whether delivering psychotherapeutic services to patients in their homes via video-conferencing technology compromises patient safety, potency of treatment, or data security. Despite these concerns. HBT service delivery may increase access to evidence-based psychotherapies for veterans with posttraumatic stress disorder (PTSD), who may be less willing or less able to receive weekly treatment at a VA medical center or outpatient clinic due to symptom severity or other similar barriers to care. Indeed, although combat-exposed service members endorse high rates of psychiatric disorders, few appear to initiate mental health services or receive an adequate dose of treatment. Thus, using HBT technologies to administer evidence-based therapies remains uncharted territory in both the clinical and research arenas. This manuscript describes an ongoing four year randomized controlled trial comparing in-person Prolonged Exposure (PE) - a specialized evidence-based psychotherapy for PTSD - and PE delivered via HBT, with a particular focus on the selection, application, and strengths/weaknesses of HBT procedures. (C) 2011 Elsevier Inc. All rights reserved. C1 [Strachan, Martha; Gros, Daniel F.; Yuen, Erica; Ruggiero, Kenneth J.; Acierno, Ron] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Strachan, Martha; Gros, Daniel F.; Yuen, Erica; Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Foa, Edna B.] Univ Penn, Ctr Treatment & Study Anxiety, Philadelphia, PA 19104 USA. RP Strachan, M (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St,2-S, Charleston, SC 29425 USA. EM stracham@musc.edu RI Schueter, nicos/A-3625-2014 FU Veterans Affairs Health Services Research and Development [NCT01102764]; VAMC [REA08-261] FX This work was supported by a grant from Veterans Affairs Health Services Research and Development awarded to R. Acierno (NCT01102764). In addition, some authors are members of the Ralph H. Johnson VAMC Research Enhancement Award Program (REA08-261; PI: Leonard Egede, M.D.). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. There are no conflicts of interest to disclose. NR 33 TC 20 Z9 20 U1 4 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2012 VL 33 IS 2 BP 402 EP 409 DI 10.1016/j.cct.2011.11.007 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 901JA UT WOS:000300962000020 PM 22101225 ER PT J AU Morone, NE Greco, CM Rollman, BL Moore, CG Lane, B Morrow, L Glynn, NW Delaney, J Albert, SM Weiner, DK AF Morone, Natalia E. Greco, Carol M. Rollman, Bruce L. Moore, Charity G. Lane, Bridget Morrow, Lisa Glynn, Nancy W. Delaney, Jill Albert, Steven M. Weiner, Debra K. TI The design and methods of the aging successfully with pain study SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Low back pain; Older adult; Mindfulness; Meditation; Randomized clinical trial ID LOW-BACK-PAIN; LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE BATTERY; SELF-REPORTED DISABILITY; STRESS REDUCTION PROGRAM; MINDFULNESS MEDITATION; OLDER-ADULTS; PSYCHOMETRIC PROPERTIES; SUBSEQUENT DISABILITY; CANCER OUTPATIENTS AB Chronic low back pain (CLBP) is widespread among older adults (>= 65 years) and is often treated inadequately. With a rapidly growing aging population, CLBP will increase and so will the demand for treatment. We believe that mind-body therapies can help to meet this demand. We present the methodology of a randomized, controlled clinical trial of 300 individuals with CLBP aged 65 years or older. The specific aims are, 1) to determine the effectiveness of a mindfulness meditation program in increasing function and reducing pain among older adults with CLBP, and 2) to evaluate the impact of mindfulness meditation on neuropsychological performance in older adults with CLBP. The intervention program is modeled on the Mindfulness-Based Stress Reduction Program (MBSR) and the control is adapted from the 10 Keys (TM) to Healthy Aging. We will measure self-reported and objectively measured physical function and include a variety of measures to assess pain intensity and pain interference and psychological function. Our primary hypothesis is that the MBSR program will be more effective than the 10 Keys (TM) program in increasing function and decreasing pain. The proposed study represents the first large, well-controlled, comprehensive examination of the effects of a mind-body program on older adults with chronic pain. Published by Elsevier Inc. C1 [Morone, Natalia E.; Rollman, Bruce L.; Moore, Charity G.; Lane, Bridget; Delaney, Jill] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.; Rollman, Bruce L.; Moore, Charity G.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Div Geriatr, Pittsburgh, PA USA. [Greco, Carol M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Ctr Integrat Med,Med Ctr Shadyside, Pittsburgh, PA USA. [Glynn, Nancy W.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Albert, Steven M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15261 USA. RP Morone, NE (reprint author), 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM moronene@upmc.edu OI Albert, Steven/0000-0001-6786-9956; Glynn, Nancy/0000-0003-2265-0162; Moore, Charity/0000-0002-0060-0124 FU National Institute on Aging [R01 AG034078-01] FX This work was supported by a grant from the National Institute on Aging R01 AG034078-01. Clinical trials.gov identifier: NCT01405716. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 51 TC 6 Z9 7 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2012 VL 33 IS 2 BP 417 EP 425 DI 10.1016/j.cct.2011.11.012 PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 901JA UT WOS:000300962000022 PM 22115971 ER PT J AU Zen, AL Whooley, MA Zhao, SJ Cohen, BE AF Zen, Angelica L. Whooley, Mary A. Zhao, Shoujun Cohen, Beth E. TI Post-Traumatic Stress Disorder is Associated With Poor Health Behaviors: Findings From the Heart and Soul Study SO HEALTH PSYCHOLOGY LA English DT Article DE posttraumatic stress disorder; health behaviors; smoking; physical activity; medication adherence ID PHYSICAL-ACTIVITY; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; MEDICATION ADHERENCE; DEPRESSIVE SYMPTOMS; CONSTRUCT-VALIDITY; PROBLEM DRINKING; RISK; NONADHERENCE; VETERANS AB Objective: Posttraumatic stress disorder (PTSD) results in substantial disability, including increased risk of cardiovascular disease (CVD). Poor health behaviors are major risk factors for initial and recurrent CVD events. Therefore, this study investigated whether PTSD is associated with poor health behaviors in patients with CVD. Method: Cross-sectional study of 1,022 men and women with CVD. PTSD was assessed with the Computerized Diagnostic Interview Schedule for DSM-IV. Physical activity, medication adherence and smoking history were determined by self-report questionnaires. Multivariate logistic and linear regression models were used to evaluate the association of PTSD with health behaviors. Results: Of the 1,022 participants, 95 (9%) had PTSD. PTSD was associated with significantly higher rates of physical inactivity in terms of overall exercise (OR 1.6, 95% CI [1.0-2.6]; p = .049), light exercise (OR 1.7, 95% CI [1.0-2.9]; p = .045), and self-rated level of exercise compared to others of their age and sex (OR 1.8, 95% CI [1.0-3.0]; p = .047). Participants with PTSD were more likely to report medication nonadherence, including forgetting medications (OR 1.8, 95% CI [1.0-3.3]; p = .04) or skipping medications (OR 1.7, 95% CI [1.1-2.9]; p = .03). Participants with PTSD also reported a greater smoking history (beta 6.4 pack years, 95% CI [1.8-10.9]; p = .006), which remained significant after adjustment for depression and income. Conclusions: Among patients with heart disease, those with PTSD were more likely to report physical inactivity, medication nonadherence and smoking. The majority of these associations were explained by adjustment for comorbid depression and lower income. C1 [Whooley, Mary A.; Cohen, Beth E.] San Francisco VA Med Ctr, Dept Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Zen, Angelica L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Whooley, Mary A.; Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Zhao, Shoujun] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. RP Cohen, BE (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs Med Ctr, Gen Internal Med Sect, Box 111A1, San Francisco, CA 94121 USA. EM beth.cohen@va.gov RI Schueter, nicos/A-3625-2014 FU NIH/NHLBI [K23 HL 094765-01]; Department of Defense/NCIRE [DAMD17-03-1-0532, W81XWH-05-2-0094]; Irene Perstein Foundation; Department of Veterans Affairs, Washington, DC; National Heart Lung and Blood Institute, Bethesda, MD [R01 HL079235]; American Federation for Aging Research, New York, NY; Robert Wood Johnson Foundation, Princeton, NJ; Ischemia Research and Education Foundation, South San Francisco, CA; Nancy Kirwan Heart Research Fund, San Francisco, CA FX The authors do not have any conflicts of interest. Preliminary data for this article was presented as an abstract at the American Geriatrics Society, 2010 meeting. Dr. Cohen was supported by NIH/NHLBI grant K23 HL 094765-01, Department of Defense/NCIRE grant DAMD17-03-1-0532, W81XWH-05-2-0094, and a grant from the Irene Perstein Foundation. The Heart and Soul Study was funded by the Department of Veterans Affairs, Washington, DC, the National Heart Lung and Blood Institute (R01 HL079235), Bethesda, MD, the American Federation for Aging Research (Paul Beeson Scholars Program), New York, NY, the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, NJ, the Ischemia Research and Education Foundation, South San Francisco, CA, and the Nancy Kirwan Heart Research Fund, San Francisco, CA. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of any of these funding agencies. The funding organizations were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. NR 43 TC 53 Z9 53 U1 2 U2 13 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 J9 HEALTH PSYCHOL JI Health Psychol. PD MAR PY 2012 VL 31 IS 2 BP 194 EP 201 DI 10.1037/a0025989 PG 8 WC Psychology, Clinical; Psychology SC Psychology GA 907BM UT WOS:000301392800009 PM 22023435 ER PT J AU Shi, Y Meeker, WQ AF Shi, Ying Meeker, William Q. TI Bayesian Methods for Accelerated Destructive Degradation Test Planning SO IEEE TRANSACTIONS ON RELIABILITY LA English DT Article DE Compromise plan; general equivalence theorem; large-sample approximation; log-location-scale distribution; optimum plan ID OPTIMAL EXPERIMENTAL-DESIGN AB Accelerated Destructive Degradation Tests (ADDTs) provide timely product reliability information in practical applications. This paper describes Bayesian methods for ADDT planning under a class of nonlinear degradation models with one accelerating variable. We use a Bayesian criterion based on the estimation precision of a specified failure-time distribution quantile at use conditions to find optimum test plans. A large-sample approximation for the posterior distribution provides a useful simplification to the planning criterion. The general equivalence theorem (GET) is used to verify the global optimality of the numerically optimized test plans. Optimum plans usually provide insight for constructing compromise plans which tend to be more robust, and practically useful. We present a numerical example with a log-location-scale distribution to illustrate the Bayesian test planning methods, and to investigate the effects of the prior distribution and sample size on test planning results. C1 [Shi, Ying] San Francisco VA Med Ctr, No Calif Inst Res & Educ, San Francisco, CA 94121 USA. [Meeker, William Q.] Iowa State Univ, Dept Stat, Ames, IA 50011 USA. RP Shi, Y (reprint author), San Francisco VA Med Ctr, No Calif Inst Res & Educ, San Francisco, CA 94121 USA. EM ying.shi2@va.gov; wqmeeker@iastate.edu NR 16 TC 17 Z9 19 U1 3 U2 24 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9529 J9 IEEE T RELIAB JI IEEE Trans. Reliab. PD MAR PY 2012 VL 61 IS 1 BP 245 EP 253 DI 10.1109/TR.2011.2170115 PG 9 WC Computer Science, Hardware & Architecture; Computer Science, Software Engineering; Engineering, Electrical & Electronic SC Computer Science; Engineering GA 904LP UT WOS:000301198500028 ER PT J AU Walsh, J Arora, M Hosenfeld, C Ladabaum, U Kuppermann, M Knight, SJ AF Walsh, Judith Arora, Millie Hosenfeld, Christina Ladabaum, Uri Kuppermann, Miriam Knight, Sara J. TI Preferences for Genetic Testing to Identify Hereditary Colorectal Cancer: Perspectives of High-Risk Patients, Community Members, and Clinicians SO JOURNAL OF CANCER EDUCATION LA English DT Article DE Colorectal cancer screening; Preferences; Focus groups ID BREAST-CANCER; COLON-CANCER; ATTITUDES; KNOWLEDGE; SUSCEPTIBILITY; PERCEPTIONS; WOMEN; INDIVIDUALS; ASSOCIATION; RELATIVES AB The aim of this study was to establish key characteristics that patients, consumers, and health professionals value regarding genetic testing (GT) and personalized medicine using the example of GT for hereditary Lynch syndrome. We conducted a series of focus groups with individuals recruited from a clinic that follows those at high risk for hereditary cancer, individuals recruited from the community, physicians, and genetic counselors. Participants were presented with clinical scenarios about Lynch syndrome testing and asked to identify characteristics that they perceived as important in making decisions about GT. Forty-two participants (19 community members, 8 high-risk and cancer patients, 3 genetic counselors, and 8 physicians) participated. Among community members and patients, the most frequently discussed considerations were the personal impact of GT and family impact, respectively. Among physicians, the most frequently discussed topic was the characteristics of genomic services (e.g., test invasiveness); among genetic counselors, the most frequently discussed topic was evidence and recommendations. A variety of test characteristics were important in decision making about GT. High-risk patients, community members, and health care providers had different priorities. Health care professionals should be aware of differences between their own considerations about GT and those that are important to patients. C1 [Walsh, Judith] UCSF Womens Hlth Clin Res Ctr, San Francisco, CA 94115 USA. [Walsh, Judith; Arora, Millie] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Hosenfeld, Christina] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA. [Ladabaum, Uri] Stanford Univ, Div Gastroenterol, Palo Alto, CA 94304 USA. [Kuppermann, Miriam] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Kuppermann, Miriam] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco, CA USA. RP Walsh, J (reprint author), UCSF Womens Hlth Clin Res Ctr, 1635 Divisadero Suite 600, San Francisco, CA 94115 USA. EM Judith.Walsh@ucsf.edu NR 26 TC 8 Z9 8 U1 3 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-8195 J9 J CANCER EDUC JI J. Cancer Educ. PD MAR PY 2012 VL 27 IS 1 BP 112 EP 119 DI 10.1007/s13187-011-0286-z PG 8 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 895IU UT WOS:000300490600019 PM 22131063 ER PT J AU Pagan, JA Brown, CJ Asch, DA Armstrong, K Bastida, E Guerra, C AF Pagan, Jose A. Brown, Cynthia J. Asch, David A. Armstrong, Katrina Bastida, Elena Guerra, Carmen TI Health Literacy and Breast Cancer Screening among Mexican American Women in South Texas SO JOURNAL OF CANCER EDUCATION LA English DT Article DE Mammography; Mexican American; Health literacy ID HISPANIC WOMEN; MAMMOGRAPHY; DISPARITIES; LATINAS; CARE AB Breast cancer is the main cause of cancer deaths for Hispanic women. This study analyzes the role of functional health literacy on mammography screening behavior and adherence of Hispanic women. Survey data from 722 Mexican American women age 40 and over residing in the Lower Rio Grande Valley of Texas in 2008 were used to estimate logistic regression models to assess the role of functional health literacy on mammography screening behavior and adherence. About 51% of survey respondents had a functional health literacy level deemed as inadequate or marginally functional. After adjusting for other factors, women with adequate health literacy levels were more likely to report to have ever had a mammogram (odds ratio [OR] = 2.92; 95% confidence interval [CI] = 1.62-5.28), to have had a mammogram within the last 2 years (OR = 1.70; 95% CI = 1.14-2.53) or to have had one within the last year (OR = 2.30; 95% CI = 1.54-3.43), compared to women with inadequate or marginally adequate functional health literacy levels. Inadequate/marginal functional health literacy is strongly associated with lower mammography screening. Large improvements in breast cancer control in this population may come from either basic advances in health literacy or by tailored approaches to help women with low literacy navigate local health care systems. C1 [Pagan, Jose A.] Univ N Texas, Hlth Sci Ctr, Sch Publ Hlth, Dept Hlth Management & Policy, Ft Worth, TX 76107 USA. [Pagan, Jose A.; Asch, David A.; Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Brown, Cynthia J.] Univ Texas Pan Amer, Coll Business Adm, Dept Econ & Finance, Edinburg, TX 78541 USA. [Asch, David A.; Armstrong, Katrina; Guerra, Carmen] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bastida, Elena] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Hlth Promot & Dis Prevent, Miami, FL 33199 USA. RP Pagan, JA (reprint author), Univ N Texas, Hlth Sci Ctr, Sch Publ Hlth, Dept Hlth Management & Policy, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM jose.pagan@unthsc.edu OI Asch, David/0000-0002-7970-286X NR 23 TC 13 Z9 13 U1 2 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-8195 J9 J CANCER EDUC JI J. Cancer Educ. PD MAR PY 2012 VL 27 IS 1 BP 132 EP 137 DI 10.1007/s13187-011-0239-6 PG 6 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 895IU UT WOS:000300490600021 PM 21573944 ER PT J AU Lopez-Jimenez, F Kramer, VC Masters, B Stuart, PW Mullooly, C Hinshaw, L Haas, L Warwick, K AF Lopez-Jimenez, Francisco Kramer, Valerie Carroll Masters, Barbara Stuart, Patricia (Mickey) W. Mullooly, Cathy Hinshaw, Ling Haas, Linda Warwick, Kathy TI Recommendations for Managing Patients With Diabetes Mellitus in Cardiopulmonary Rehabilitation AN AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION STATEMENT SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION LA English DT Article DE cardiopulmonary rehabilitation; diabetes mellitus; scientific review; blood glucose monitoring; exercise ID CORONARY-ARTERY-DISEASE; CARDIAC REHABILITATION; GLYCEMIC CONTROL; MYOCARDIAL-INFARCTION; SCIENTIFIC STATEMENT; PREVENTION PROGRAMS; METABOLIC SYNDROME; HEART-ASSOCIATION; BETA-BLOCKER; TASK-FORCE AB Diabetes mellitus is a highly prevalent condition in patients participating in cardiopulmonary rehabilitation. However, research and subsequent guidelines specifically applicable to patients with diabetes, participating in cardiopulmonary rehabilitation, are limited. Recognizing this limitation, the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) initiated this statement, with the goal of developing a template that incorporated recommendations provided in the AACVPR Core Components and the American Association of Diabetes Educators 7 Self-Care Behaviors. This statement describes key processes regarding evaluation, interventions, and expected outcomes in each of the core components for the management of patients with diabetes in a cardiopulmonary rehabilitation program. C1 [Lopez-Jimenez, Francisco; Hinshaw, Ling] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. [Kramer, Valerie Carroll] Northwestern Univ, Evanston Hosp, NorthShore Univ HealthSyst, Evanston, IL 60201 USA. [Masters, Barbara] Protestant Mem Med Ctr, Belleville, IL USA. [Stuart, Patricia (Mickey) W.] Diabet Educ & Etc LLC, Vicksburg, MS USA. [Mullooly, Cathy] Novo Nordisk Inc, Boston, MA USA. [Haas, Linda] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Haas, Linda] VHA Off Nursing Serv, Washington, DC USA. [Warwick, Kathy] Profess Nutr Consultants LLC, Jackson, MS USA. RP Kramer, VC (reprint author), 709 Newgate, Prospect Heights, IL 60070 USA. EM valeriekramer@comcast.net OI Hinshaw, Ling/0000-0002-6103-8294 NR 47 TC 7 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-7501 J9 J CARDIOPULM REHABIL JI J. Cardiopulm. Rehabil. Prev. PD MAR-APR PY 2012 VL 32 IS 2 BP 101 EP 112 DI 10.1097/HCR.0b013e31823be0bc PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 901EG UT WOS:000300943900006 PM 22198371 ER PT J AU Lengerova, M Kocmanova, I Racil, Z Hrncirova, K Pospisilova, S Mayer, J Najvar, LK Wiederhold, NP Kirkpatrick, WR Patterson, TF AF Lengerova, Martina Kocmanova, Iva Racil, Zdenek Hrncirova, Kristyna Pospisilova, Sarka Mayer, Jiri Najvar, Laura K. Wiederhold, Nathan P. Kirkpatrick, William R. Patterson, Thomas F. TI Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)-beta-D-Glucan Detection SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID BRONCHOALVEOLAR LAVAGE FLUID; EXPERIMENTAL MURINE ASPERGILLOSIS; ENZYME-IMMUNOASSAY; FUMIGATUS; DIAGNOSIS; SERUM; DNA; SEQUENCE; RELEASE AB We developed and assessed the diagnostic value of a novel quantitative nested real-time (QNRT) PCR assay targeting the internal transcribed spacer region of ribosomal DNA (rDNA) in a guinea pig model of invasive pulmonary aspergillosis. Groups of 5 immunosuppressed animals that were infected using an aerosol chamber with Aspergillus fumigatus conidia were humanely terminated 1 h postinoculation and at days 3, 5, 7, and 11 postchallenge, and lung tissue, bronchoalveolar lavage (BAL) fluid, whole blood, and serum samples were collected. The QNRT PCR results obtained with the serum and BAL fluid were compared to those achieved with galactomannan and (1 -> 3)-beta-D-glucan assays. High fungal burden levels were detected by QNRT PCR in both lung tissue and BAL fluid in all infected animals at each time point, and the sensitivity of each assay in BAL fluid was 100% by day 3 and remained so through the remainder of the study. The sensitivity of detection of fungi in whole blood and serum samples was significantly lower, and some samples remained negative by all three assays despite the advanced stage of the infection. From these data, we can conclude that this novel QNRT PCR method was highly sensitive for the detection of A. fumigatus from different types of samples in this model. In addition, BAL fluid samples appeared to be the most suitable for the early diagnosis of invasive pulmonary aspergillosis. When testing serum, the use of a combination of available assays may increase the possibility of early detection of this opportunistic mycosis. C1 [Lengerova, Martina; Kocmanova, Iva; Racil, Zdenek; Hrncirova, Kristyna; Pospisilova, Sarka; Mayer, Jiri] Masaryk Univ, Dept Internal Med Hematooncol, Fac Med, Brno, Czech Republic. [Lengerova, Martina; Kocmanova, Iva; Racil, Zdenek; Hrncirova, Kristyna; Pospisilova, Sarka; Mayer, Jiri] Univ Hosp Brno, Brno, Czech Republic. [Lengerova, Martina; Pospisilova, Sarka; Mayer, Jiri] Masaryk Univ, CEITEC Cent European Inst Technol, Brno, Czech Republic. [Najvar, Laura K.; Wiederhold, Nathan P.; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Najvar, Laura K.; Kirkpatrick, William R.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. RP Lengerova, M (reprint author), Masaryk Univ, Dept Internal Med Hematooncol, Fac Med, Brno, Czech Republic. EM mlengerova@fnbrno.cz RI Lengerova, Martina/E-1038-2012; Pospisilova, Sarka/D-7200-2012 FU Ministry of Health of the Czech Republic [NS10442-3/2009, NS10441-3/2009]; Ministry of Industry and Trade of the Czech Republic [FR-TI2/254]; NIH/NIAID [N01-AI-30041] FX This study was supported in part by grants from the Ministry of Health of the Czech Republic (NS10442-3/2009, NS10441-3/2009), the Ministry of Industry and Trade of the Czech Republic (FR-TI2/254), and NIH/NIAID contract N01-AI-30041. NR 28 TC 17 Z9 20 U1 3 U2 20 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2012 VL 50 IS 3 BP 602 EP 608 DI 10.1128/JCM.05356-11 PG 7 WC Microbiology SC Microbiology GA 901WB UT WOS:000300997800011 PM 22189110 ER PT J AU Campbell, JD Lewis, JS McElmeel, ML Fulcher, LC Jorgensen, JH AF Campbell, Jennifer D. Lewis, James S., II McElmeel, M. Leticia Fulcher, Letitia C. Jorgensen, James H. TI Detection of Favorable Oral Cephalosporin-Clavulanate Interactions by In Vitro Disk Approximation Susceptibility Testing of Extended-Spectrum- Beta-Lactamase-Producing Members of the Enterobacteriaceae SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID ESCHERICHIA-COLI; PHARMACOKINETICS; COMBINATION; VOLUNTEERS; ACID; COMMUNITY; EMERGENCE AB Extended-spectrum-beta-lactamase (ESBL)-producing members of the Enterobacteriaceae are often resistant to multiple drug classes, making therapy of urinary infections with oral antibiotics difficult. Previously it was shown that amoxicillin-clavulanate can provide clavulanate inhibition of ESBLs and protect an oral cephalosporin present in combination when tested by broth microdilution. This study has shown that disk approximation testing could detect favorable cephalosporin-clavulanate interactions among a group of 101 previously characterized members of the Enterobacteriaceae with CTX-M, SHV, or TEM ESBLs. C1 [McElmeel, M. Leticia; Fulcher, Letitia C.; Jorgensen, James H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Campbell, Jennifer D.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Campbell, Jennifer D.; Lewis, James S., II] Univ Texas Austin, Coll Pharm, Pharmacotherapy Div, Austin, TX 78712 USA. [Campbell, Jennifer D.; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. [Lewis, James S., II] Univ Hlth Syst, San Antonio, TX USA. RP Jorgensen, JH (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. EM jorgensen@uthscsa.edu NR 18 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2012 VL 50 IS 3 BP 1023 EP 1026 DI 10.1128/JCM.06248-11 PG 4 WC Microbiology SC Microbiology GA 901WB UT WOS:000300997800070 PM 22170910 ER PT J AU Wortzel, HS Strom, LA Anderson, AC Maa, EH Spitz, M AF Wortzel, Hal S. Strom, Laura A. Anderson, Alan C. Maa, Edward H. Spitz, Mark TI Disrobing Associated with Epileptic Seizures and Forensic Implications SO JOURNAL OF FORENSIC SCIENCES LA English DT Article DE forensic science; forensic medicine; forensic psychiatry; seizures; epilepsy; behavioral medicine ID VIOLENCE AB Little is known about the clinical aspects and medico-legal consequences of disrobing in the context of epileptic seizures. Seizure-related disrobing may occur either as an ictal automatism or during the postictal period. Some patients may experience a seizure while already in the unclothed state, engage in ictal wandering, and thereby appear in public in the nude. Two cases involving disrobing associated with seizures captured via video-monitored electroencephalography are offered. An additional case reveals the legal consequences endured by one patient who experienced a nocturnal seizure and began wandering in an unclothed state. Collectively, these cases illustrate the medical reality of seizure-related disrobing and the related adverse effects on patients quality of life. Disrobing associated with epileptic seizures carries the potential for serious legal consequences if not properly identified as an ictal phenomenon. C1 [Wortzel, Hal S.] Denver Vet Hosp, VISN MIRECC 19, Denver, CO 80220 USA. [Wortzel, Hal S.; Anderson, Alan C.] Dept Psychiat, Neurobehav Disorders Program, Aurora, CO 80045 USA. [Strom, Laura A.; Anderson, Alan C.; Maa, Edward H.; Spitz, Mark] Dept Neurol, Aurora, CO 80045 USA. [Strom, Laura A.; Anderson, Alan C.; Maa, Edward H.; Spitz, Mark] Denver Vet Hosp, Div Neurol, Denver, CO 80220 USA. RP Wortzel, HS (reprint author), Denver VA Hosp, VISN MIRECC 19, 1055 Clermont St, Denver, CO 80220 USA. EM hal.wortzel@ucdenver.edu NR 10 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-1198 J9 J FORENSIC SCI JI J. Forensic Sci. PD MAR PY 2012 VL 57 IS 2 BP 550 EP 552 DI 10.1111/j.1556-4029.2011.01995.x PG 3 WC Medicine, Legal SC Legal Medicine GA 897XY UT WOS:000300696400039 PM 22150773 ER PT J AU Madaras-Kelly, KJ Remington, RE Fan, VS Sloan, KL AF Madaras-Kelly, Karl J. Remington, Richard E. Fan, Vincent S. Sloan, Kevin L. TI Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID IN-VITRO ACTIVITY; STAPHYLOCOCCUS-AUREUS; RISK-FACTORS; INFECTION; FLUOROQUINOLONE; SUSCEPTIBILITY; COLONIZATION; GUIDELINES; MANAGEMENT; BACTERIA AB OBJECTIVE: To develop and validate a model to predict resistance to community-acquired pneumonia antibiotics (CAP-resistance) among patients with healthcare-associated pneumonia (HCAP), and to compare the model's predictive performance to a model including only guideline-defined criteria for HCAP. DESIGN: Retrospective cohort study. SETTING: Six Veterans Affairs Medical Centers in the northwestern United States. PATIENTS: Culture-positive inpatients with HCAP. MEASUREMENTS: Patients were identified based upon guideline-defined criteria for HCAP. Relevant cultures obtained within 48 hours of admission were assessed to determine bacteriology and antibiotic susceptibility. Medical records for the year preceding admission were assessed to develop predictive models of CAP-resistance with logistic regression. The predictive performance of cohort-developed and guideline-defined models was compared. RESULTS: CAP-resistant organisms were identified in 118 of 375 culture-positive patients. Of guideline-defined criteria, CAP-resistance was associated (odds ratio (OR) [95% confidence interval (CI)]) with: admission from nursing home (2.6 [1.6-4.4]); recent antibiotic exposure (1.7 [1.0-2.8]); and prior hospitalization (1.6 [1.0-2.6]). In the cohort-developed model, CAP-resistance was associated with: admission from nursing home or recent nursing home discharge (2.3 [1.4-3.8]); positive methicillin-resistant Staphylococcus aureus (MRSA) history within 90 days of admission (6.4 [2.6-17.8]) or 91-365 days (2.3 [0.9-5.9]); cephalosporin exposure (1.8 [1.12.9]); recent infusion therapy (1.9 [1.0-3.5]); diabetes (1.7 [1.0-2.8]); and intensive care unit (ICU) admission (1.6 [1.0-2.6]). Area under the receiver operating characteristic curve (aROC [95% CI]) for the cohort-developed model (0.71 [0.65-0.77]) was significantly higher than for the guideline-defined model (0.63 [0.57-0.69]) (P = 0.01). CONCLUSIONS: Select guideline-defined criteria predicted CAP-resistance. A cohort-developed model based primarily on prior MRSA history, nursing home residence, and specific antibiotic exposures provided improved prediction of CAP-resistant organisms in HCAP. Journal of Hospital Medicine 2012; 7: 195-202 (C) 2011 Society of Hospital Medicine. C1 [Madaras-Kelly, Karl J.] Vet Affairs Med Ctr, Clin Pharm Serv 119A, Boise, ID 83702 USA. [Remington, Richard E.] Vet Affairs Med Ctr, Res Serv, Boise, ID 83702 USA. [Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA. [Madaras-Kelly, Karl J.; Remington, Richard E.] Idaho State Univ, Coll Pharm, Dept Pharm Practice & Adm Sci, Meridian, ID USA. [Fan, Vincent S.] Univ Washington, Sch Med, Dept Pulm & Crit Care Med, Seattle, WA USA. RP Madaras-Kelly, KJ (reprint author), Vet Affairs Med Ctr, Clin Pharm Serv 119A, 500 W Ft St, Boise, ID 83702 USA. EM KMK@pharmacy.isu.edu FU Idaho State University [RO3AI074894-01A2]; Department of Veterans Affairs; National Institutes of Health FX Karl J. Madaras-Kelly is employed full time by Idaho State University. The National Institute of Allergy and Infectious Diseases provided salary support for this study paid through Idaho State University (grant RO3AI074894-01A2). The National Institute of Allergy and Infectious Diseases provided payment for statistical services on this study to Richard E. Remington, sub-contracted through Idaho State University (grant RO3AI074894-01A2). Vincent S. Fan is employed full time by the Department of Veterans Affairs, and receives grant support unrelated to the study from the Department of Veterans Affairs and the National Institutes of Health. He serves as a consultant for Uptake Medical Corporation. Kevin L. Sloan has no conflicts of interest to report. NR 31 TC 15 Z9 16 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2012 VL 7 IS 3 BP 195 EP 202 DI 10.1002/jhm.942 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 901QY UT WOS:000300983100006 PM 22038859 ER PT J AU Freund, K Weckmann, MT Casarett, DJ Swanson, K Brooks, MK Broderick, A AF Freund, Katherine Weckmann, Michelle T. Casarett, David J. Swanson, Kristi Brooks, Mary Kay Broderick, Ann TI Hospice eligibility in patients who died in a tertiary care center SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE communication; palliative care; patient education ID END-OF-LIFE; PALLIATIVE CARE; NURSING-HOMES; NEAR-DEATH; DISCUSSIONS; HEALTH; CANCER; LENGTH; EXPENDITURES; ASSOCIATIONS AB BACKGROUND: Hospice is a service that patients, families, and physicians find beneficial, yet a majority of patients die without receiving hospice care. Little is known about how many hospitalized patients are hospice eligible at the time of hospitalization. METHODS: Retrospective chart review was used to examine all adult deaths (n = 688) at a tertiary care center during 2009. Charts were selected for full review if the death was nontraumatic and the patient had a hospital admission within 12 months of the terminal admission. The charts were examined for hospice eligibility based on medical criteria, evidence of a hospice discussion, and hospice enrollment. RESULTS: Two hundred nine patients had an admission in the year preceding the terminal admission and a nontraumatic death. Sixty percent were hospice eligible during the penultimate admission. Hospice discussions were documented in 14% of the hospice-eligible patients. Patients who were hospice eligible had more subspecialty consults on the penultimate admission compared to those not hospice eligible (P = 0.016), as well as more overall hospitalizations in the 12 months preceding their terminal admission (P = 0.0003), and fewer days between their penultimate admission and death (P = 0.001). CONCLUSION: The majority of terminally ill inpatients did not have a documented discussion of hospice with their care provider. Educating physicians to recognize the stepwise decline of most illnesses and hospice admission criteria will facilitate a more informed decision-making process for patients and their families. A consistent commitment to offer hospice earlier than the terminal admission would increase access to community or home-based care, potentially increasing quality of life. Journal of Hospital Medicine 2012; 7: 218-223. (C) 2011 Society of Hospital Medicine. C1 [Weckmann, Michelle T.; Swanson, Kristi] Univ Iowa, Carver Coll Med, Dept Family Med, Iowa City, IA 52242 USA. [Weckmann, Michelle T.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA. [Casarett, David J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Casarett, David J.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Ctr Bioeth, Inst Aging, Philadelphia, PA USA. [Brooks, Mary Kay] Univ Iowa Hosp & Clin, Off Clin Qual Safety & Performance Improvement, Iowa City, IA 52242 USA. [Broderick, Ann] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA. RP Weckmann, MT (reprint author), Univ Iowa, Carver Coll Med, Dept Family Med, 01102 PFP, Iowa City, IA 52242 USA. EM michelle-weckmann@uiowa.edu FU University of Iowa Carver College of Medicine [NIH 2-T35-HL007485-31] FX Support for this research was provided by the University of Iowa Carver College of Medicine, Medical Student Summer Research Fellowship Program (NIH 2-T35-HL007485-31). None of the authors have any financial conflicts of interest to report. NR 30 TC 10 Z9 10 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2012 VL 7 IS 3 BP 218 EP 223 DI 10.1002/jhm.975 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 901QY UT WOS:000300983100009 PM 22086609 ER PT J AU Hunter, JV Wilde, EA Tong, KA Holshouser, BA AF Hunter, Jill V. Wilde, Elisabeth A. Tong, Karen A. Holshouser, Barbara A. TI Emerging Imaging Tools for Use with Traumatic Brain Injury Research SO JOURNAL OF NEUROTRAUMA LA English DT Article DE adults; children; CT; MRI; neuroimaging; TBI ID DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; PROTON MR SPECTROSCOPY; COMMON DATA ELEMENTS; WHITE-MATTER INJURY; CENTRAL-NERVOUS-SYSTEM; WORKING-MEMORY LOAD; SEVERE HEAD TRAUMA AB This article identifies emerging neuroimaging measures considered by the inter-agency Pediatric Traumatic Brain Injury (TBI) Neuroimaging Workgroup. This article attempts to address some of the potential uses of more advanced forms of imaging in TBI as well as highlight some of the current considerations and unresolved challenges of using them. We summarize emerging elements likely to gain more widespread use in the coming years, because of 1) their utility in diagnosis, prognosis, and understanding the natural course of degeneration or recovery following TBI, and potential for evaluating treatment strategies; 2) the ability of many centers to acquire these data with scanners and equipment that are readily available in existing clinical and research settings; and 3) advances in software that provide more automated, readily available, and cost-effective analysis methods for large scale data image analysis. These include multi-slice CT, volumetric MRI analysis, susceptibility-weighted imaging (SWI), diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), arterial spin tag labeling (ASL), functional MRI (fMRI), including resting state and connectivity MRI, MR spectroscopy (MRS), and hyperpolarization scanning. However, we also include brief introductions to other specialized forms of advanced imaging that currently do require specialized equipment, for example, single photon emission computed tomography (SPECT), positron emission tomography (PET), encephalography (EEG), and magnetoencephalography (MEG)/magnetic source imaging (MSI). Finally, we identify some of the challenges that users of the emerging imaging CDEs may wish to consider, including quality control, performing multi-site and longitudinal imaging studies, and MR scanning in infants and children. C1 [Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA. [Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. [Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med Rehabil & Neurol, Houston, TX 77030 USA. [Wilde, Elisabeth A.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Tong, Karen A.; Holshouser, Barbara A.] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA. RP Hunter, JV (reprint author), Texas Childrens Hosp, Dept Pediat Radiol, 6621 Fannin St,W1120, Houston, TX 77030 USA. EM jhunter@bcm.edu FU National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR); Department of Veterans' Affairs; United States Department of Defense FX This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS), the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR), the Department of Veterans' Affairs, and the United States Department of Defense. NR 196 TC 50 Z9 52 U1 8 U2 39 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR PY 2012 VL 29 IS 4 BP 654 EP 671 DI 10.1089/neu.2011.1906 PG 18 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 901SQ UT WOS:000300987500005 PM 21787167 ER PT J AU McCauley, SR Wilde, EA Anderson, VA Bedell, G Beers, SR Campbell, TF Chapman, SB Ewing-Cobbs, L Gerring, JP Gioia, GA Levin, HS Michaud, LJ Prasad, MR Swaine, BR Turkstra, LS Wade, SL Yeates, KO AF McCauley, Stephen R. Wilde, Elisabeth A. Anderson, Vicki A. Bedell, Gary Beers, Sue R. Campbell, Thomas F. Chapman, Sandra B. Ewing-Cobbs, Linda Gerring, Joan P. Gioia, Gerard A. Levin, Harvey S. Michaud, Linda J. Prasad, Mary R. Swaine, Bonnie R. Turkstra, Lyn S. Wade, Shari L. Yeates, Keith O. TI Recommendations for the Use of Common Outcome Measures in Pediatric Traumatic Brain Injury Research SO JOURNAL OF NEUROTRAUMA LA English DT Article DE children; infants; outcome assessment, TBI ID CLOSED-HEAD-INJURY; VERBAL-LEARNING-TEST; QUALITY-OF-LIFE; TEST-CHILDRENS VERSION; DIFFICULTIES-QUESTIONNAIRE SDQ; MOTOR FUNCTION MEASURE; PORTLAND ADAPTABILITY INVENTORY; FUNCTIONAL INDEPENDENCE MEASURE; BEHAVIOR RATING INVENTORY; POST-CONCUSSIVE SYMPTOMS AB This article addresses the need for age-relevant outcome measures for traumatic brain injury (TBI) research and summarizes the recommendations by the inter-agency Pediatric TBI Outcomes Workgroup. The Pediatric Workgroup's recommendations address primary clinical research objectives including characterizing course of recovery from TBI, prediction of later outcome, measurement of treatment effects, and comparison of outcomes across studies. Consistent with other Common Data Elements (CDE) Workgroups, the Pediatric TBI Outcomes Workgroup adopted the standard three-tier system in its selection of measures. In the first tier, core measures included valid, robust, and widely applicable outcome measures with proven utility in pediatric TBI from each identified domain including academics, adaptive and daily living skills, family and environment, global outcome, health-related quality of life, infant and toddler measures, language and communication, neuropsychological impairment, physical functioning, psychiatric and psychological functioning, recovery of consciousness, social role participation and social competence, social cognition, and TBI-related symptoms. In the second tier, supplemental measures were recommended for consideration in TBI research focusing on specific topics or populations. In the third tier, emerging measures included important instruments currently under development, in the process of validation, or nearing the point of published findings that have significant potential to be superior to measures in the core and supplemental lists and may eventually replace them as evidence for their utility emerges. C1 [McCauley, Stephen R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA. [Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Bedell, Gary] Tufts Univ, Dept Occupat Therapy, Medford, MA 02155 USA. [Beers, Sue R.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Campbell, Thomas F.] Univ Texas Dallas, Callier Ctr Commun Disorders, Commun Disorders Sch Behav & Brain Sci, Dallas, TX 75235 USA. [Chapman, Sandra B.] Univ Texas Dallas, Ctr BrainHlth Behav & Brain Sci, Dallas, TX 75235 USA. [Ewing-Cobbs, Linda; Prasad, Mary R.] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX USA. [Ewing-Cobbs, Linda; Prasad, Mary R.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX USA. [Gerring, Joan P.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. [Gerring, Joan P.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA. [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat, Washington, DC 20052 USA. [Michaud, Linda J.; Wade, Shari L.] Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH USA. [Michaud, Linda J.; Wade, Shari L.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA. [Michaud, Linda J.; Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA. [Swaine, Bonnie R.] Univ Montreal, Ecole Readaptat, Ctr Interdisciplinary Rehabil Res CRIR, Montreal, PQ, Canada. [Turkstra, Lyn S.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [Turkstra, Lyn S.] Univ Wisconsin, Dept Communicat Disorders & Neurol Surg, Madison, WI USA. [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA. RP McCauley, SR (reprint author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200,BCM635, Houston, TX 77030 USA. EM mccauley@bcm.edu OI Yeates, Keith/0000-0001-7680-2892 FU National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR) FX This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS) and the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR). NR 298 TC 61 Z9 61 U1 9 U2 32 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR PY 2012 VL 29 IS 4 BP 678 EP 705 DI 10.1089/neu.2011.1838 PG 28 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA 901SQ UT WOS:000300987500007 PM 21644810 ER PT J AU Subramanian, A Timberlake, M Mittakanti, H Lara, M Brandt, ML AF Subramanian, Anuradha Timberlake, Matthew Mittakanti, Harsha Lara, Michael Brandt, Mary L. TI Novel Educational Approach for Medical Students: Improved Retention Rates Using Interactive Medical Software Compared with Traditional Lecture-Based Format SO JOURNAL OF SURGICAL EDUCATION LA English DT Article DE web-based; surgical education; interactive tool AB BACKGROUND: Mannequin and computer-based simulators are useful for the practice of patient management, physical procedures, and competency. However, they are ineffective in teaching clinical medicine. StepStone Interactive Medical Software (SS) is a web-based medical learning modality that provides the user with a highly focused set of evaluative and interventional tasks to treat memorable virtual patients in a visual case-based format. OBJECTIVE: To determine whether the SS learning modality is superior to traditional lecture format in medical student learning and retention. METHODS: After Institutional Review Board (IRB) approval was obtained and the consents were signed, 30 third-year medical students were assigned randomly to 2 groups of 15 students each: The control group received two 30-minute PowerPoint lectures (Microsoft Corporation, Redmond, Washington) about torsades de pointes (TdP) and pulseless electrical activity (PEA), and the SS group was given 1 hour to review 2 SS cases teaching TdP and PEA. A preintervention test was given to assess their baseline knowledge. An immediate postintervention test was given to both groups. Twenty-two clays later, a long-term retention test was administered. The results were analyzed using a Student t test for continuous variables. RESULTS: The mean scores for the preintervention test in the control and SS groups were 44.9 +/- 3% and 44.1 +/- 2%, respectively (p = 0.41). The mean scores for the postintervention test in the control and SS groups were 61.7 +/- 2% and 86.7 +/- 2%, respectively (p < 0.001). Improvement from baseline knowledge was calculated, and the mean improvement was 16.8 +/- 3% in the control group and 42.5 +/- 2% in the SS group (p < 0.001). The long-term retention test revealed the mean scores of 55.8 +/- 3% in the control group and 70.1 +/- 3% in the SS group (p < 0.001). Long-term improvement from baseline knowledge was calculated and the control group improved by 10.9 +/- 4%, whereas the SS group improved by 26 +/- 3% (p = 0.002). CONCLUSIONS: The SS learning modality demonstrated a significant improvement in student learning retention compared to traditional didactic lecture format. SS is an effective web-based medical education tool. (J Surg 69:253-256. (C) 2012 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.) C1 [Subramanian, Anuradha] Baylor Coll Med, Michael E DeBakey Dept Surg, VA Med Ctr, Houston, TX 77030 USA. RP Subramanian, A (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, VA Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM asubrama@bcm.edu NR 6 TC 13 Z9 13 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-7204 J9 J SURG EDUC JI J. Surg. Educ. PD MAR-APR PY 2012 VL 69 IS 2 BP 253 EP 256 DI 10.1016/j.jsurg.2011.12.007 PG 4 WC Education, Scientific Disciplines; Surgery SC Education & Educational Research; Surgery GA 906AD UT WOS:000301316400023 PM 22365876 ER PT J AU Bechara, CF Barshes, NR Lin, PH Kougias, P AF Bechara, Carlos F. Barshes, Neal R. Lin, Peter H. Kougias, Panagiotis TI Recanalization of flush iliac occlusions with the assistance of a contralateral iliac occlusive balloon SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID RECONSTRUCTION; MANAGEMENT AB Treating flush iliac artery occlusion by endovascular means can be very challenging and is a cause of technical failure requiring open surgical intervention. We describe a simple endovascular technique that can be valuable in increasing technical success and avoiding the use of a re-entry device. The technique involves placing an occlusive contralateral iliac artery balloon to assist in recanalizing a flush iliac artery occlusion. (J Vasc Surg 2012;55:872-4.) C1 Baylor Coll Med, Div Vasc & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Bechara, CF (reprint author), DeBakey VA Med Ctr, 2002 Holcombe Blvd,112, Houston, TX 77030 USA. EM bechara@bcm.edu NR 9 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAR PY 2012 VL 55 IS 3 BP 872 EP 874 DI 10.1016/j.jvs.2011.10.029 PG 3 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 901DE UT WOS:000300941100038 PM 22169670 ER PT J AU Cummings, DE Bloom, SR Rubino, F AF Cummings, David E. Bloom, Stephen R. Rubino, Francesco TI At the heart of the benefits of bariatric surgery SO NATURE MEDICINE LA English DT Editorial Material ID MORTALITY; WEIGHT; OBESE AB Obesity is associated with an increased risk of cardiovascular events, thus weight loss would be expected to have a beneficial effect on cardiovascular disease. This view is supported by a recent paper that used participants from the ongoing Swedish Obese Subjects (SOS) study, a nonrandomized, prospective study to investigate the effects of bariatric surgery on cardiovascular disease(1). Individuals who underwent bariatric surgery had a significantly reduced number of total and fatal cardiovascular events compared with matched obese controls who did not undergo surgery. Surprisingly, the reduction in cardiovascular events was not related to the baseline body mass index (BMI) or the weight loss experienced by the treated patients. We asked three experts how this study affects understanding of the relationship between weight loss, metabolic and cardiovascular disease, as well as how bariatric surgery may mediate its effects on human health. C1 [Cummings, David E.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. [Cummings, David E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Bloom, Stephen R.] Imperial Coll London Hammersmith, London, England. [Rubino, Francesco] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. RP Cummings, DE (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. NR 12 TC 1 Z9 1 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD MAR PY 2012 VL 18 IS 3 BP 358 EP 359 DI 10.1038/nm0312-358 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 905IF UT WOS:000301264800034 PM 22395701 ER PT J AU Rugge, M Fassan, M Graham, DY AF Rugge, Massimo Fassan, Matteo Graham, David Y. TI Secondary prevention of gastric cancer SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY LA English DT Editorial Material ID STOMACH; DIAGNOSIS AB The natural history of 'epidemic' intestinal-type gastric cancer provides consistent data that enable clinicians to design multidisciplinary strategies for secondary prevention. A recent paper by Dinis-Ribeiro et al. reports guidelines for the management of patients with precancerous stomach lesions. C1 [Rugge, Massimo; Fassan, Matteo] Univ Padua, Dept Med, Surg Pathol & Cytopathol Unit, I-35121 Padua, PD, Italy. [Graham, David Y.] Baylor Coll Med, Div Digest Dis, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Rugge, M (reprint author), Univ Padua, Dept Med, Surg Pathol & Cytopathol Unit, Via Aristide Gabelli 61, I-35121 Padua, PD, Italy. EM massimo.rugge@unipd.it RI Fassan, Matteo/F-5152-2012; Rugge, Massimo/K-7525-2016 OI Fassan, Matteo/0000-0001-6515-5482; NR 10 TC 16 Z9 16 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5045 J9 NAT REV GASTRO HEPAT JI Nat. Rev. Gastroenterol. Hepatol. PD MAR PY 2012 VL 9 IS 3 BP 128 EP 129 DI 10.1038/nrgastro.2012.19 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 905PM UT WOS:000301284700002 PM 22330815 ER PT J AU Heffernan-Stroud, LA Helke, KL Jenkins, RW De Costa, AM Hannun, YA Obeid, LM AF Heffernan-Stroud, L. A. Helke, K. L. Jenkins, R. W. De Costa, A-M Hannun, Y. A. Obeid, L. M. TI Defining a role for sphingosine kinase 1 in p53-dependent tumors SO ONCOGENE LA English DT Article DE ceramide; sphingosine-1-phosphate; p53; sphingosine kinase; cancer; senescence ID PROGRAMMED CELL-DEATH; CERAMIDE-INDUCED APOPTOSIS; TANDEM MASS-SPECTROMETRY; BIOACTIVE SPHINGOLIPIDS; QUANTITATIVE-ANALYSIS; GENOTOXIC STRESS; HIGH EXPRESSION; DOWN-REGULATION; MICE DEFICIENT; CYCLE ARREST AB p53 is a crucial tumor suppressor that is mutated or deleted in a majority of cancers. Exactly how p53 prevents tumor progression has proved elusive for many years; however, this information is crucial to define targets for chemotherapeutic development that can effectively restore p53 function. Bioactive sphingolipids have recently emerged as important regulators of proliferative, apoptotic and senescent cellular processes. In this study, we demonstrate that the enzyme sphingosine kinase 1 (SK1), a critical enzyme in the regulation of the key bioactive sphingolipids ceramide, sphingosine and sphingosine-1-phosphate (S1P), serves as a key downstream target for p53 action. Our results show that SK1 is proteolysed in response to genotoxic stress in a p53-dependent manner. p53 null mice display elevation of SK1 levels and a tumor-promoting dysregulation of bioactive sphingolipids in which the anti-growth sphingolipid ceramide is decreased and the pro-growth sphingolipid S1P is increased. Importantly, deletion of SK1 in p53 null mice completely abrogated thymic lymphomas in these mice and prolonged their life span by similar to 30%. Deletion of SK1 also significantly attenuated the formation of other cancers in p53 heterozygote mice. The mechanism of p53 tumor suppression by loss of SK1 is mediated by elevations of sphingosine and ceramide, which in turn were accompanied by increased expression of cell cycle inhibitors and tumor cell senescence. Thus, targeting SK1 may restore sphingolipid homeostasis in p53-dependent tumors and provide insights into novel therapeutic approaches to cancer. Oncogene (2012) 31, 1166-1175; doi:10.1038/onc.2011.302; published online 18 July 2011 C1 [Obeid, L. M.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA. [Heffernan-Stroud, L. A.; Obeid, L. M.] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29403 USA. [Helke, K. L.] Med Univ S Carolina, Dept Comparat Med Lab Anim Resources, Charleston, SC 29403 USA. [Jenkins, R. W.; Hannun, Y. A.; Obeid, L. M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA. [De Costa, A-M] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA. [Obeid, L. M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St, Charleston, SC 29403 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847; Helke, Kris/0000-0001-9746-0764 FU Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX000156]; NIH/NIGMS [R01 GM062887]; NIH/NCI [P01 CA097132-project 3, P01 CA097132-project 1]; American Heart Association [AHA 081509E]; NIH MSTP [GM08716]; MUSC Hollings Cancer Center Abney Foundation; NIH/NIEHS [T32 ES012878, F30ES017379]; NCI [IPO1CA097132, P30 CA 138313]; NIH/NCRR SC COBRE [P20 RR017677]; NIH [C06 RR018823]; National Center for Research Resources FX This work was supported, in part, by Award Number I01BX000156 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development, NIH/NIGMS R01 GM062887, NIH/NCI P01 CA097132-project 3 (to LMO). NIH/NCI P01 CA097132-project 1 (to YAH). American Heart Association Pre-Doctoral Fellowship AHA 081509E (to RWJ), NIH MSTP Training Grant GM08716 (to RWJ, AMDC, LAHS), MUSC Hollings Cancer Center Abney Foundation Scholarship (to RWJ, LAHS), NIH/NIEHS TG T32 ES012878, and NIH/NIEHS National Research Service Award Individual Predoctoral Fellowship F30ES017379 (to LAHS). Liquid chromatography-mass spectrometry analysis of sphingolipids was performed by Lipidomics Shared Resource, MUSC (Methods 2006, 39: 82-91) supported by NCI Grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20 RR017677 as specified in Supplementary Information. Laboratory space in the CRI building of MUSC was supported by the NIH, Grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. Refer to Supplementary Information for individual acknowledgements and the VA disclaimer. NR 72 TC 21 Z9 22 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 EI 1476-5594 J9 ONCOGENE JI Oncogene PD MAR PY 2012 VL 31 IS 9 BP 1166 EP 1175 DI 10.1038/onc.2011.302 PG 10 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 901EW UT WOS:000300945900009 PM 21765468 ER PT J AU Shalaby, A Brumberg, G El-Saed, A Saba, S AF Shalaby, Alaa Brumberg, Genevieve El-Saed, Aiman Saba, Samir TI Mood Disorders and Outcome in Patients Receiving Cardiac Resynchronization Therapy SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE depression; anxiety; cardiac resynchronization therapy; mortality; heart failure ID CHRONIC HEART-FAILURE; DEPRESSIVE SYMPTOMS; CARDIOVERTER-DEFIBRILLATORS; MYOCARDIAL-INFARCTION; RISK; MORTALITY; ANXIETY; PREVALENCE; PREDICTORS; ARRHYTHMIAS AB Background: Mood disorders (MD) have been demonstrated to influence outcome in cardiac disease in general and specifically in chronic heart failure (HF). Little is known about their possible effect on response to cardiac resynchronization therapy (CRT). Objective: To evaluate the influence of MD on CRT response. Methods: We conducted a retrospective chart review of all cardiac CRT-D (CRT defibrillator) recipients (N = 153) at the Veterans Affairs Pittsburgh Healthcare System from beginning of 2004 through end of 2006. All-cause death and HF-related hospitalizations (HFH), individually and combined, were sought through 2009. Results: During a mean follow-up time of 31.4 +/- 14.7 months, there were 48 (31.4%) deaths and 55 (35.9%) HFHs in HF patients having New York Heart Association class of 2.9 +/- 0.3, left ventricular ejection fraction (LVEF) of 25.8 +/- 9.1%, left ventricular end-diastolic diameter (LVEDD) of 61.6 +/- 11.6 mm, and QRS of 152 +/- 30.5 ms. A total of 65 (42.5%) patients had MD (depression, anxiety, or posttraumatic stress disorder). Compared to others, patients in the MD group were at a significantly higher risk of HFH alone (47.7% vs 27.3%, P = 0.009) or when combined with death (58.5% vs 39.8%, P = 0.022) but not death alone (35.4% vs 28.4%, P = 0.36). The significant predictive effect of MD on HFH alone and when combined with death shown in univariate analysis was not attenuated after adjustment for age, ejection fraction, etiology of cardiomyopathy, cumulative number of any shocks, smoking, and evidence of postimplantation echocardiographic improvement. Conclusions: MD in patients with advanced but stable HF receiving CRT-D therapy was a predictor of HFH alone or when combined with death but not mortality alone. (PACE 2012; 35: 294-301) C1 [Shalaby, Alaa; Brumberg, Genevieve; El-Saed, Aiman; Saba, Samir] Univ Pittsburgh, Med Ctr, Vet Affairs Pittsburgh Hlth Syst, Div Cardiol,Cardiovasc Inst, Pittsburgh, PA 15240 USA. RP Shalaby, A (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Div Cardiol, 111C Univ Dr, Pittsburgh, PA 15240 USA. EM Alaa.Shalaby@va.gov NR 39 TC 6 Z9 6 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD MAR PY 2012 VL 35 IS 3 BP 294 EP 301 DI 10.1111/j.1540-8159.2011.03304.x PG 8 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 902PB UT WOS:000301049300015 PM 22229659 ER PT J AU Berry, RB Kushida, CA Kryger, MH Soto-Calderon, H Staley, B Kuna, ST AF Berry, Richard B. Kushida, Clete A. Kryger, Meir H. Soto-Calderon, Haideliza Staley, Bethany Kuna, Samuel T. TI Respiratory Event Detection by a Positive Airway Pressure Device SO SLEEP LA English DT Article DE CPAP; autoCPAP; APAP ID OBSTRUCTIVE SLEEP-APNEA; TREATING ADULT PATIENTS; PRACTICE PARAMETERS; TITRATING PRESSURES; HYPOPNEA SYNDROME; POLYSOMNOGRAPHY; CPAP; DIAGNOSIS; EFFICACY; UPDATE AB Study Objectives: Compare automatic event detection (AED) of respiratory events using a positive airway pressure (PAP) device with manual scoring of polysomnography (PSG) during PAP treatment of obstructive sleep apnea (OSA). Design: Prospective PSGs of patients using a PAP device. Setting: Six academic and private sleep disorders centers. Patients: A total of 148 PSGs from 115 participants with OSA (apnea-hypopnea index [AH I] >= 15 events/hr) were analyzed. Interventions: A signal generated by the PAP device identifying the AED of respiratory events based on airflow was recorded during PSG. Measurements and Results: The PSGs were manually scored without visualization of the AED signal and scoring of a hypopnea required a >= 4% oxygen desaturation. The apnea index (AI), hypopnea index (HI), and AH I by manual score and PAP AED were compared. A customized computer program compared individual events by manual scoring and AED to determine the true positive, false positive, false negative, or true negative events and found a sensitivity of 0.58 and a specificity of 0.98. The AH I, AI, and HI by the two methods were highly correlated. Bland-Altman analysis showed better agreement for AI than HI. Using a manually scored AH I of >= 10 events/hr to denote inadequate treatment, an AED AHI >= 10 events/hr had a sensitivity of 0.58 and a specificity of 0.94. Conclusions: An AHI < 10 events/hr by PAP AED is usually associated with good treatment efficacy. Differences between manually scored and AED events were primarily due to different criteria for hypopnea detection. C1 [Berry, Richard B.] Univ Florida, Dept Med, Gainesville, FL 32610 USA. [Kushida, Clete A.] Stanford Univ, Redwood City, CA USA. [Kryger, Meir H.] Gaylord Sleep Med, Wallingford, CT USA. [Soto-Calderon, Haideliza; Staley, Bethany; Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Soto-Calderon, Haideliza; Staley, Bethany; Kuna, Samuel T.] Univ Penn, Philadelphia, PA 19104 USA. RP Berry, RB (reprint author), Univ Florida, Dept Med, Box 100225 HSC, Gainesville, FL 32610 USA. EM sleep_doc@msn.com FU Philips-Respironics; Ventus Medical; ResMed; Dymedix; Ventus to Gaylord Hospital FX This study was sponsored by Philips-Respironics. Dr. Berry has received research support from Philips-Respironics and Ventus Medical via grant to the University of Florida and ResMed via grant to North Florida Foundation for Research and Education (Gainesville VAMC). Dr. Kushida has received research support from Philips-Respironics and ResMed via grants to Stanford and royalties from patent licensed to Philips-Respironics. Dr. Kryger has received research support from Philips-Respironics, ResMed, Dymedix, and Ventus to Gaylord Hospital. Dr. Kuna has received research support from Philips-Respironics. The other authors have indicated no financial conflicts of interest. NR 14 TC 18 Z9 21 U1 0 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAR 1 PY 2012 VL 35 IS 3 BP 361 EP 367 DI 10.5665/sleep.1696 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 901GG UT WOS:000300950400010 PM 22379242 ER PT J AU Grandner, MA Martin, JL Patel, NP Jackson, NJ Gehrman, PR Pien, G Perlis, ML Xie, DW Sha, DH Weaver, T Gooneratne, NS AF Grandner, Michael A. Martin, Jennifer L. Patel, Nirav P. Jackson, Nicholas J. Gehrman, Philip R. Pien, Grace Perlis, Michael L. Xie, Dawei Sha, Daohang Weaver, Terri Gooneratne, Nalaka S. TI Age and Sleep Disturbances Among American Men And Women: Data From the US Behavioral Risk Factor Surveillance System SO SLEEP LA English DT Article DE Aging; sleep quality; fatigue; epidemiology; depression ID WORK HOURS RECOMMENDATIONS; OLDER-ADULTS; DAYTIME SLEEPINESS; PROSPECTIVE COHORT; HEALTH; INSOMNIA; ADOLESCENT; COMPLAINTS; DISORDERS; POPULATION AB Study Objective: Explore the prevalence of sleep-related complaints across age groups, examining effects of sex, general health, and depressed mood. Design: Cross-sectional analysis of data from the 2006 Behavioral Risk Factor Surveillance System (BRFSS). Setting: Epidemiologic. Participants: Complete-case analysis included 155,877 participants who responded to questions related to Self-Reported Sleep Disturbance (SLEEPDIST) and Self-Reported Tiredness/Lack of Energy (TIREDNESS). Interventions: None. Measurements and Results: Outcomes were self-reported complaints in response to survey questions assessing SLEEPDIST and TIREDNESS, dichotomized as reporting a complaint < 6 versus >= 6 nights or days, respectively, in a 2-wk period. Predictors were age, general health, and depressed mood. All analyses were adjusted for race/ethnicity, income, education, and time since last medical checkup. Across all age groups, women reported more SLEEPDIST and TIREDNESS. Poor general health, mild depressed mood, and moderate/severe depressed mood were associated with SLEEPDIST and TIREDNESS. Both SLEEPDIST and TIREDNESS generally declined across the life span, with fewest endorsements in respondents older than 80 yr. For SLEEPDIST, odds ratios (ORs, reference = 80+) declined from age 18-54 yr, rose slightly, and then declined again after age 59 yr in men. The pattern was similar for women, except a more marked rise was noted from age 40-59 yr. The pattern was similar for TIREDNESS. Conclusions: Advancing age was not associated with increased Self-Reported Sleep Disturbance or Self-Reported Tiredness/Lack of Energy. These results suggest that the often-reported increase in sleep problems with age is a nonlinear phenomenon, mediated by factors other than physiologic aging. C1 [Grandner, Michael A.; Jackson, Nicholas J.; Pien, Grace] Univ Penn, Ctr Sleep & Circadian Neurobiol, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA. [Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Gehrman, Philip R.; Perlis, Michael L.] Univ Penn, Div Pulm & Crit Care Med, Dept Med, Philadelphia, PA 19104 USA. [Pien, Grace] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Xie, Dawei; Sha, Daohang] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Weaver, Terri] Univ Illinois, Chicago Coll Nursing, Biobehav & Hlth Sci Dept, Chicago, IL USA. [Gooneratne, Nalaka S.] Univ Penn, Div Geriatr Med, Dept Med, Philadelphia, PA 19104 USA. RP Grandner, MA (reprint author), Univ Penn, Ctr Sleep & Circadian Neurobiol, Dept Med, Div Sleep Med, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM Grand-ner@upenn.edu FU University of Pennsylvania Center for Sleep and Circadian Neurobiology [T32HL007713, K23AG028452, R21AG31390]; Boehringer Ingelheim; Sanofi-Aventis; Pharma; Actelion; Takeda; Gerson Lehman; Clinical Advisors; LEK; MedaCorp; Respironics Respiratory and Sleep Research Foundation; Cephalon, Inc. FX This work was supported by T32HL007713, K23AG028452 (to Dr. Martin), R21AG31390 (to Dr. Gooneratne) as well as funding for Biostatistical Support from the University of Pennsylvania Center for Sleep and Circadian Neurobiology. The authors thank Allan Pack, MB, ChB, PhD for guidance and other support. Also, the authors thank the BRFSS participants and the Centers for Disease Control and Prevention for collecting these data and making them available.; This was not an industry supported study. Dr. Patel has received research support from Boehringer Ingelheim unrelated to this study. Dr. Pien has the use of equipment on loan from Respironics unrelated to this study. Dr. Perlis has consulted for Gerson Lehrman Group, Clinical Advisors, Meda Corp/Leerink Swann, Actelion, SleepEasily, Sanofi-Aventis, L.E.K. Consulting LLC. He has received research support from Sanofi-Aventis, Pharma, and Cephalon and had speaking honoraria from Sanofi-Aventis, AASM, UR, and Internet Didactic Services. He has received salary and distributions from Actelion, Takeda, Gerson Lehman, Clinical Advisors, LEK, and MedaCorp. Dr. Weaver has received research equipment from Respironics, Inc. and Protech; grant support from Respironics Respiratory and Sleep Research Foundation, Cephalon, Inc. She has consulted for Apnex Medical, Inc., and Cephalon, Inc. and has FOSQ license Agreements with Sanofi-Aventis Pharmaceutical, Merck 7 Co., Inc., Sleep Solutions, N.V. Organon, Apnex Medical, Inc., Ventus medical, GlaxoSmithKline, and Respironics. The other authors have indicated no financial conflicts of interest. NR 54 TC 48 Z9 48 U1 2 U2 17 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAR 1 PY 2012 VL 35 IS 3 BP 395 EP 406 DI 10.5665/sleep.1704 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 901GG UT WOS:000300950400014 PM 22379246 ER PT J AU Turvey, CL Zulman, DM Nazi, KM Wakefield, BJ Woods, SS Hogan, TP Weaver, FM McInnes, K AF Turvey, Carolyn L. Zulman, Donna M. Nazi, Kim M. Wakefield, Bonnie J. Woods, Susan S. Hogan, Timothy P. Weaver, Frances M. McInnes, Keith TI Transfer of Information from Personal Health Records: A Survey of Veterans Using My HealtheVet SO TELEMEDICINE AND E-HEALTH LA English DT Article DE e-health; medical records; telehealth ID RANDOMIZED-TRIAL; MEDICAL-RECORD; SATISFACTION; SERVICES AB Objective: Personal health records provide patients with ownership of their health information and allow them to share information with multiple healthcare providers. However, the usefulness of these records relies on patients understanding and using their records appropriately. My HealtheVet is a Web-based patient portal containing a personal health record administered by the Veterans Health Administration. The goal of this study was to explore veterans' interest and use of My HealtheVet to transfer and share information as well as to identify opportunities to increase veteran use of the My HealtheVet functions. Materials and Methods: Two waves of data were collected in 2010 through an American Customer Satisfaction Index Web-based survey. A random sample of veterans usingMy HealtheVet was invited to participate in the survey conducted on the My HealtheVet portal through a Web-based pop-up browser window. Results: Wave One results (n = 25,898) found that 41% of veterans reported printing information, 21% reported saving information electronically, and only 4% ever sent information from My HealtheVet to another person. In Wave Two (n = 18,471), 30% reported self-entering medication information, with 18% sharing this information with their Veterans Affairs (VA) provider and 9.6% sharing with their non-VA provider. Conclusion: Although veterans are transferring important medical information from their personal health records, increased education and awareness are needed to increase use. Personal health records have the potential to improve continuity of care. However, more research is needed on both the barriers to adoption as well as the actual impact on patient health outcomes and well-being. C1 [Turvey, Carolyn L.; Wakefield, Bonnie J.] Iowa City VA Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat CA, Iowa City, IA 52246 USA. [Turvey, Carolyn L.] Iowa City VA Hlth Care Syst, VA Off Rural Hlth, Vet Rural Hlth Resource Ctr Cent Reg, Iowa City, IA 52246 USA. [Turvey, Carolyn L.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [Zulman, Donna M.] Univ Michigan, Robert Wood Johnson Fdn Clin Scholars Program, Ann Arbor, MI 48109 USA. [Zulman, Donna M.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Washington, DC USA. [Wakefield, Bonnie J.] Univ Missouri, Sinclair Sch Nursing, Columbia, MO USA. [Woods, Susan S.] Portland VA Med Ctr, Portland, OR USA. [Hogan, Timothy P.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Hogan, Timothy P.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Hogan, Timothy P.] Edward Hines Jr VA Hosp, eHlth Qual Enhancement Res Initiat, Hines, IL USA. [Hogan, Timothy P.] Loyola Univ Chicago, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA. [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Dept Med, Chicago, IL 60611 USA. [McInnes, Keith] ENRM Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [McInnes, Keith] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. RP Turvey, CL (reprint author), Iowa City VA Hlth Care Syst, Ctr Comprehens Access & Delivery Res & Evaluat CA, 601 Highway 6 W 152,Suite 40, Iowa City, IA 52246 USA. EM carolyn-turvey@va.gov FU Department of Veteran Affairs, Health Services Research and Development Service through the eHealth QUERI; CADRE Center; Veterans Rural Health Resource Center-Central Region, VA Office of Rural Health FX Dr. Turvey is a Research Health Science Specialist in the Comprehensive Access & Delivery Research and Evaluation (CADRE) Center, Iowa City VA Health Care System. The work reported here was supported by the Department of Veteran Affairs, Health Services Research and Development Service through the eHealth QUERI, the CADRE Center, and the Veterans Rural Health Resource Center-Central Region, VA Office of Rural Health. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 13 TC 9 Z9 9 U1 1 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED E-HEALTH JI Telemed. e-Health PD MAR PY 2012 VL 18 IS 2 BP 109 EP 114 DI 10.1089/tmj.2011.0109 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 902MB UT WOS:000301041200006 PM 22304439 ER PT J AU Prisciandaro, JJ DeSantis, SM Chiuzan, C Brown, DG Brady, KT Tolliver, BK AF Prisciandaro, James J. DeSantis, Stacia M. Chiuzan, Cody Brown, Delisa G. Brady, Kathleen T. Tolliver, Bryan K. TI Impact of Depressive Symptoms on Future Alcohol Use in Patients with Co-Occurring Bipolar Disorder and Alcohol Dependence: A Prospective Analysis in an 8-Week Randomized Controlled Trial of Acamprosate SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Bipolar Disorder; Alcohol; Alcoholism; Comorbidity; Craving; Dependence; Depression; Drinking; Mania; Relapse ID SUBSTANCE USE DISORDERS; TREATMENT ENHANCEMENT PROGRAM; HIDDEN MARKOV-MODELS; ACUTE MANIA; STEP-BD; ABUSE; SCALE; HOSPITALIZATION; PARTICIPANTS; DISTINCTION AB Background: Bipolar disorders and alcohol use disorders commonly co-occur, yet little is known about the proximal impact of bipolar symptoms on alcohol use in patients with this comorbidity. The present study examined the impact of depressive symptoms and alcohol craving on proximal alcohol use in patients with co-occurring bipolar disorder and alcohol dependence. Methods: Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30). Depressive symptoms and alcohol craving were assessed biweekly using the Montgomery Asberg Depression Rating Scale (MADRS) and the Obsessive Compulsive Drinking Scale (OCDS), respectively. Daily alcohol use data were available via administration of the Time-line Follow-back interview at baseline and at subsequent weekly study visits. Correlational analyses and hidden Markov modeling were used to examine the prospective relationships between depressive symptoms, alcohol craving, and alcohol use. Results: Depressive symptoms and alcohol craving were significantly correlated with proximal (i. e., 1 week later) alcohol use across a variety of alcohol consumption summary measures. In hidden Markov models, depressive symptoms (OR = 1.3, 95% credible interval = [1.1, 1.5]) and alcohol craving (OR = 1.6, 95% credible interval = [1.4, 1.9]) significantly predicted transitioning from a light to a heavy drinking state, or remaining in a heavy drinking state. Conclusions: The results from the present study suggest that depressive symptoms and alcohol craving increase proximal risk for alcohol use in individuals with co-occurring bipolar and alcohol use disorders. C1 [Prisciandaro, James J.; Brown, Delisa G.; Brady, Kathleen T.; Tolliver, Bryan K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [DeSantis, Stacia M.; Chiuzan, Cody] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Brady, Kathleen T.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Prisciandaro, JJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St,MSC861, Charleston, SC 29425 USA. EM priscian@musc.edu FU Forest Laboratories, Inc.; NIDA [T32 DA007288] FX This study was funded by an investigator-initiated research grant to BKT from Forest Laboratories, Inc.; Forest Laboratories had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the study for publication. JJP was supported by NIDA T32 DA007288. NR 40 TC 14 Z9 14 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD MAR PY 2012 VL 36 IS 3 BP 490 EP 496 DI 10.1111/j.1530-0277.2011.01645.x PG 7 WC Substance Abuse SC Substance Abuse GA 897PC UT WOS:000300663900012 PM 21933201 ER EF